

NEWS 1 Web Page for STN Seminar Schedule - N. America
 NEWS 2 JAN 02 STN pricing information for 2008 now available
 NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified
 prophetic substances
 NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
 custom IPC display formats
 NEWS 5 JAN 28 MARPAT searching enhanced
 NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days
 of publication
 NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 9 FEB 08 STN Express, Version 8.3, now available
 NEWS 10 FEB 20 PCI now available as a replacement to DPCI
 NEWS 11 FEB 25 IFIREF reloaded with enhancements
 NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
 NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
 U.S. National Patent Classification
 NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
 IPC display formats
 NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental
 spectra
 NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.
 applications updated
 NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
 NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
 NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
 predefined hit display formats
 NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
 NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements
 NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family
 searching
 NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology
 sequence search option
 NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts
 NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents

 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008

=> file caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jun 2008 VOL 148 ISS 24
FILE LAST UPDATED: 10 Jun 2008 (20080610/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> e us2007-599748/apps

E1	1	US2007-599745/AP
E2	1	US2007-599747/AP
E3	0 -->	US2007-599748/AP
E4	0	US2007-599748/PRN
E5	1	US2007-599750/AP
E6	1	US2007-599753/AP
E7	1	US2007-599779/AP
E8	1	US2007-599793/AP
E9	1	US2007-599811/AP
E10	1	US2007-599813/AP
E11	1	US2007-599816/AP
E12	1	US2007-599856/AP

=> e us2006-599748/apps

E1	1	US2006-599741/AP
E2	1	US2006-599744/AP
E3	1 -->	US2006-599748/AP
E4	0	US2006-599748/PRN
E5	1	US2006-599749/AP
E6	1	US2006-599749/PRN
E7	1	US2006-599753/AP
E8	1	US2006-599754/AP
E9	2	US2006-599758/AP
E10	3	US2006-599760/AP
E11	2	US2006-599763/AP
E12	1	US2006-599766/AP

=> s e3

L1	1	US2006-599748/AP
----	---	------------------

=> sel rn l1

E1 THROUGH E162 ASSIGNED

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	3.17	3.38

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2
DICTIONARY FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s el-el62

1 10453-86-8/BI
 (10453-86-8/RN)
1 1072-84-0/BI
 (1072-84-0/RN)
1 115926-52-8/BI
 (115926-52-8/RN)
1 122-04-3/BI
 (122-04-3/RN)
1 129-46-4/BI
 (129-46-4/RN)
1 129318-43-0/BI
 (129318-43-0/RN)
1 130-15-4/BI
 (130-15-4/RN)
1 145-73-3/BI
 (145-73-3/RN)
1 146903-18-6/BI
 (146903-18-6/RN)
1 150560-58-0/BI
 (150560-58-0/RN)
1 15084-51-2/BI
 (15084-51-2/RN)
1 16037-91-5/BI
 (16037-91-5/RN)
1 162086-14-8/BI
 (162086-14-8/RN)
1 1710-98-1/BI
 (1710-98-1/RN)
1 17325-26-7/BI
 (17325-26-7/RN)
1 17630-76-1/BI
 (17630-76-1/RN)

1 1821-12-1/BI
 (1821-12-1/RN)
1 18496-54-3/BI
 (18496-54-3/RN)
1 18711-13-2/BI
 (18711-13-2/RN)
1 2058-74-4/BI
 (2058-74-4/RN)
1 20780-76-1/BI
 (20780-76-1/RN)
1 220965-34-4/BI
 (220965-34-4/RN)
1 2243-83-6/BI
 (2243-83-6/RN)
1 237756-11-5/BI
 (237756-11-5/RN)
1 2632-13-5/BI
 (2632-13-5/RN)
1 2650-44-4/BI
 (2650-44-4/RN)
1 27318-90-7/BI
 (27318-90-7/RN)
1 296771-71-6/BI
 (296771-71-6/RN)
1 296773-88-1/BI
 (296773-88-1/RN)
1 301166-54-1/BI
 (301166-54-1/RN)
1 303092-45-7/BI
 (303092-45-7/RN)
1 303149-87-3/BI
 (303149-87-3/RN)
1 303998-01-8/BI
 (303998-01-8/RN)
1 304883-18-9/BI
 (304883-18-9/RN)
1 311321-81-0/BI
 (311321-81-0/RN)
1 312519-17-8/BI
 (312519-17-8/RN)
1 315671-49-9/BI
 (315671-49-9/RN)
1 339205-70-8/BI
 (339205-70-8/RN)
1 339205-73-1/BI
 (339205-73-1/RN)
1 345630-40-2/BI
 (345630-40-2/RN)
1 345630-42-4/BI
 (345630-42-4/RN)
1 36043-49-9/BI
 (36043-49-9/RN)
1 376383-76-5/BI
 (376383-76-5/RN)
1 39755-95-8/BI
 (39755-95-8/RN)
1 401646-54-6/BI
 (401646-54-6/RN)
1 42494-71-3/BI
 (42494-71-3/RN)
1 42494-73-5/BI

(42494-73-5/RN)
1 43100-25-0/BI
(43100-25-0/RN)
1 43100-38-5/BI
(43100-38-5/RN)
1 443-69-6/BI
(443-69-6/RN)
1 458553-48-5/BI
(458553-48-5/RN)
1 477847-81-7/BI
(477847-81-7/RN)
1 478063-72-8/BI
(478063-72-8/RN)
1 478077-73-5/BI
(478077-73-5/RN)
1 478077-74-6/BI
(478077-74-6/RN)
1 478077-78-0/BI
(478077-78-0/RN)
1 478077-79-1/BI
(478077-79-1/RN)
1 478257-55-5/BI
(478257-55-5/RN)
1 478257-73-7/BI
(478257-73-7/RN)
1 478257-76-0/BI
(478257-76-0/RN)
1 484-17-3/BI
(484-17-3/RN)
1 511518-73-3/BI
(511518-73-3/RN)
1 512796-41-7/BI
(512796-41-7/RN)
1 512796-49-5/BI
(512796-49-5/RN)
1 512796-50-8/BI
(512796-50-8/RN)
1 512796-65-5/BI
(512796-65-5/RN)
1 512796-67-7/BI
(512796-67-7/RN)
1 512796-72-4/BI
(512796-72-4/RN)
1 512796-76-8/BI
(512796-76-8/RN)
1 512796-99-5/BI
(512796-99-5/RN)
1 51630-58-1/BI
(51630-58-1/RN)
1 52315-07-8/BI
(52315-07-8/RN)
1 524-42-5/BI
(524-42-5/RN)
1 52918-63-5/BI
(52918-63-5/RN)
1 5315-25-3/BI
(5315-25-3/RN)
1 547730-75-6/BI
(547730-75-6/RN)
1 5725-96-2/BI
(5725-96-2/RN)

1 585557-83-1/BI
 (585557-83-1/RN)
1 5908-27-0/BI
 (5908-27-0/RN)
1 604-95-5/BI
 (604-95-5/RN)
1 611-09-6/BI
 (611-09-6/RN)
1 650620-84-1/BI
 (650620-84-1/RN)
1 68782-46-7/BI
 (68782-46-7/RN)
1 694-83-7/BI
 (694-83-7/RN)
1 69736-76-1/BI
 (69736-76-1/RN)
1 701-99-5/BI
 (701-99-5/RN)
1 722494-26-0/BI
 (722494-26-0/RN)
1 731831-41-7/BI
 (731831-41-7/RN)
1 7440-62-2/BI
 (7440-62-2/RN)
1 75899-68-2/BI
 (75899-68-2/RN)
1 774184-51-9/BI
 (774184-51-9/RN)
1 79183-26-9/BI
 (79183-26-9/RN)
1 819-83-0/BI
 (819-83-0/RN)
1 827034-63-9/BI
 (827034-63-9/RN)
1 84-11-7/BI
 (84-11-7/RN)
1 847363-06-8/BI
 (847363-06-8/RN)
1 860207-88-1/BI
 (860207-88-1/RN)
1 867339-05-7/BI
 (867339-05-7/RN)
1 867375-71-1/BI
 (867375-71-1/RN)
1 867375-74-4/BI
 (867375-74-4/RN)
1 867375-77-7/BI
 (867375-77-7/RN)
1 867375-78-8/BI
 (867375-78-8/RN)
1 867375-79-9/BI
 (867375-79-9/RN)
1 867375-82-4/BI
 (867375-82-4/RN)
1 867375-88-0/BI
 (867375-88-0/RN)
1 867375-89-1/BI
 (867375-89-1/RN)
1 867375-90-4/BI
 (867375-90-4/RN)
1 867375-91-5/BI

(867375-91-5/RN)
1 867375-92-6/BI
(867375-92-6/RN)
1 867375-93-7/BI
(867375-93-7/RN)
1 867375-94-8/BI
(867375-94-8/RN)
1 867375-96-0/BI
(867375-96-0/RN)
1 867375-97-1/BI
(867375-97-1/RN)
1 867375-99-3/BI
(867375-99-3/RN)
1 867376-00-9/BI
(867376-00-9/RN)
1 867376-01-0/BI
(867376-01-0/RN)
1 867376-02-1/BI
(867376-02-1/RN)
1 867376-03-2/BI
(867376-03-2/RN)
1 867376-04-3/BI
(867376-04-3/RN)
1 867376-05-4/BI
(867376-05-4/RN)
1 867376-06-5/BI
(867376-06-5/RN)
1 867376-07-6/BI
(867376-07-6/RN)
1 867376-08-7/BI
(867376-08-7/RN)
1 867376-10-1/BI
(867376-10-1/RN)
1 867376-11-2/BI
(867376-11-2/RN)
1 867376-12-3/BI
(867376-12-3/RN)
1 867376-13-4/BI
(867376-13-4/RN)
1 867376-14-5/BI
(867376-14-5/RN)
1 867376-15-6/BI
(867376-15-6/RN)
1 867376-16-7/BI
(867376-16-7/RN)
1 867376-17-8/BI
(867376-17-8/RN)
1 867376-18-9/BI
(867376-18-9/RN)
1 867376-19-0/BI
(867376-19-0/RN)
1 867376-20-3/BI
(867376-20-3/RN)
1 867376-27-0/BI
(867376-27-0/RN)
1 867376-28-1/BI
(867376-28-1/RN)
1 867376-29-2/BI
(867376-29-2/RN)
1 867376-33-8/BI
(867376-33-8/RN)

1 867376-34-9/BI
 (867376-34-9/RN)
 1 867376-35-0/BI
 (867376-35-0/RN)
 1 867376-36-1/BI
 (867376-36-1/RN)
 1 867376-37-2/BI
 (867376-37-2/RN)
 1 867376-38-3/BI
 (867376-38-3/RN)
 1 867376-39-4/BI
 (867376-39-4/RN)
 1 867376-46-3/BI
 (867376-46-3/RN)
 1 867376-63-4/BI
 (867376-63-4/RN)
 1 867376-74-7/BI
 (867376-74-7/RN)
 1 867376-75-8/BI
 (867376-75-8/RN)
 1 867376-76-9/BI
 (867376-76-9/RN)
 1 867376-77-0/BI
 (867376-77-0/RN)
 1 867376-80-5/BI
 (867376-80-5/RN)
 1 867376-81-6/BI
 (867376-81-6/RN)
 1 867376-83-8/BI
 (867376-83-8/RN)
 1 867376-85-0/BI
 (867376-85-0/RN)
 1 867376-86-1/BI
 (867376-86-1/RN)
 1 867380-85-6/BI
 (867380-85-6/RN)
 1 87-48-9/BI
 (87-48-9/RN)
 1 91-56-5/BI
 (91-56-5/RN)
 1 939-97-9/BI
 (939-97-9/RN)
 1 98-59-9/BI
 (98-59-9/RN)
 1 98-74-8/BI
 (98-74-8/RN)
 1 99304-37-7/BI
 (99304-37-7/RN)

L2


162 (10453-86-8/BI OR 1072-84-0/BI OR 115926-52-8/BI OR 122-04-3/BI
 OR 129-46-4/BI OR 129318-43-0/BI OR 130-15-4/BI OR 145-73-3/BI
 OR 146903-18-6/BI OR 150560-58-0/BI OR 15084-51-2/BI OR 16037-91
 -5/BI OR 162086-14-8/BI OR 1710-98-1/BI OR 17325-26-7/BI OR 1763
 0-76-1/BI OR 1821-12-1/BI OR 18496-54-3/BI OR 18711-13-2/BI OR
 2058-74-4/BI OR 20780-76-1/BI OR 220965-34-4/BI OR 2243-83-6/BI
 OR 237756-11-5/BI OR 2632-13-5/BI OR 2650-44-4/BI OR 27318-90-7/
 BI OR 296771-71-6/BI OR 296773-88-1/BI OR 301166-54-1/BI OR 3030
 92-45-7/BI OR 303149-87-3/BI OR 303998-01-8/BI OR 304883-18-9/BI
 OR 311321-81-0/BI OR 312519-17-8/BI OR 315671-49-9/BI OR 339205
 -70-8/BI OR 339205-73-1/BI OR 345630-40-2/BI OR 345630-42-4/BI
 OR 36043-49-9/BI OR 376383-76-5/BI OR 39755-95-8/BI OR 401646-54
 -6/BI OR 42494-71-3/BI OR 42494-73-5/BI OR 43100-25-0/BI OR 4310

0-38-5/BI OR 443-69-6/BI OR 458553-48-5/BI OR 477847-81-7/BI OR
478063-72-8/BI OR 478077-73-5/BI OR 478077-74-6/BI OR 478077-78-
0/BI OR 478077-79-1/BI OR 478257

=> s l2 and dione
1031736 DIONE
2 DIONES
1031736 DIONE
(DIONE OR DIONES)
L3 22 L2 AND DIONE

=> d scan l3


L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-2,3-dione, 5-methoxy-
MF C9 H7 N O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):22

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-2,3-dione, 5-bromo-
MF C8 H4 Br N O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-2,3-dione, 4,7-dichloro-
MF C8 H3 Cl2 N O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indole-2,3-dione, 1-[(4-chlorophenyl)methyl]-5-methyl-
 MF C16 H12 Cl N O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 9,10-Phenanthrenedione, 2-nitro-
 MF C14 H7 N O4
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indole-2,3-dione, 5-bromo-1-ethyl-
 MF C10 H8 Br N O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indole-2,3-dione
 MF C8 H5 N O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indole-2,3-dione, 5-iodo-
 MF C8 H4 I N O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indole-2,3-dione, 1-[(4-fluorophenyl)sulfonyl]-
 MF C14 H8 F N O4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-2,3-dione, 5-nitro-
MF C8 H4 N2 O4
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-2,3-dione, 1-[(4-methylphenyl)methyl]-
MF C16 H13 N O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4-Naphthalenedione
MF C10 H6 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,10-Phenanthroline-5,6-dione
MF C12 H6 N2 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 9,10-Phenanthrenedione, 2-[(phenylmethyl)amino]-
MF C21 H15 N O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-2,3-dione, 1-methyl-
MF C9 H7 N O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-2,3-dione, 5-(1-methylethyl)-
MF C11 H11 N O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-2,3-dione, 5-fluoro-
MF C8 H4 F N O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 9,10-Phenanthrenedione, 2-amino-
MF C14 H9 N O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 9,10-Phenanthrenedione
MF C14 H8 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indole-2,3-dione, 5-chloro-
 MF C8 H4 Cl N O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indole-2,3-dione, 1-[(2,4-dichlorophenyl)methyl]-5-nitro-
 MF C15 H8 Cl2 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1,2-Naphthalenedione
 MF C10 H6 O2
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162

L3 22 S L2 AND DIONE

=> s l2 and phenanthroline

5 PHENANTHROLINEDIONE

L4 0 L2 AND PHENANTHROLINEDIONE

=> s l2 and phenanthroline

53251 PHENANTHROLINE

L5 2 L2 AND PHENANTHROLINE


=> d scan l5

L5 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1,10-Phenanthroline-5,6-dione

MF C12 H6 N2 O2

CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L5 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Vanadate(1-), oxodiperoxy(1,10-phenanthroline-κN1,κN10)-,
 potassium, (PB-7-23-111'1'3)- (9CI)
 MF C12 H8 N2 O5 V . K
 CI CCS



● K⁺

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s "substituted phenanthroline"
      902 "SUBSTITUTED"
      53251 "PHENANTHROLINE"
L6      0 "SUBSTITUTED PHENANTHROLINE"
        ("SUBSTITUTED"(W)"PHENANTHROLINE")
```

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

```
L1      1 S E3
        SEL RN L1
```

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

```
L2      162 S E1-E162
L3      22 S L2 AND DIONE
L4      0 S L2 AND PHENANTHROLINEDIONE
L5      2 S L2 AND PHENANTHROLINE
L6      0 S "SUBSTITUTED PHENANTHROLINE"
```

=> file caplus medline embase biosis scisearch
 COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
31.27	34.65

FILE 'CAPLUS' ENTERED AT 09:54:34 ON 11 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:54:34 ON 11 JUN 2008

FILE 'EMBASE' ENTERED AT 09:54:34 ON 11 JUN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 09:54:34 ON 11 JUN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008
Copyright (c) 2008 The Thomson Corporation

=> s l2
L7 224329 L2

=> s l3
L8 13877 L3

=> s l5
L9 406 L5

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008
E US2007-599748/APPS
E US2006-599748/APPS
L1 1 S E3
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008
L2 162 S E1-E162
L3 22 S L2 AND DIONE
L4 0 S L2 AND PHENANTHROLINE DIONE
L5 2 S L2 AND PHENANTHROLINE
L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON
11 JUN 2008
L7 224329 S L2
L8 13877 S L3
L9 406 S L5

=> s l7 or l8 or l9
L10 224329 L7 OR L8 OR L9

=> s l10 and antiangiogenic
L11 3300 10 AND ANTIANGIOGENIC

=> s l11 and ischemia
L12 56 L11 AND ISCHEMIA

=> s l11 and ("heart disease")
L13 28 L11 AND ("HEART DISEASE")

=> s l13 and l12
L14 2 L13 AND L12
=> d l14 1-2 hitstr ibib all

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:143140 CAPLUS
DOCUMENT NUMBER: 140:181449
TITLE: Preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents
INVENTOR(S): Yi, Kyu Yang; Lee, Sun Kyung; Yoo, Sung-eun; Suh, Jee Hee; Kim, Nak Jeong; Hwang, Sun Kyung; Lee, Byung-ho; Seo, Ho Won; Lee, Chong Ock; Choi, Sang-un
PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014898	A1	20040219	WO 2003-KR1534	20030730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2004014023	A	20040214	KR 2002-47189	20020809
CA 2493966	A1	20040219	CA 2003-2493966	20030730
AU 2003247213	A1	20040225	AU 2003-247213	20030730
AU 2003247213	B2	20070405		
EP 1546136	A1	20050629	EP 2003-784665	20030730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675202	A	20050928	CN 2003-819195	20030730
JP 2006509725	T	20060323	JP 2004-527422	20030730
US 20050267188	A1	20051201	US 2005-523015	20050202
US 7279497	B2	20071009		

PRIORITY APPLN. INFO.: KR 2002-47189 A 20020809
WO 2003-KR1534 W 20030730

OTHER SOURCE(S): CASREACT 140:181449; MARPAT 140:181449

AN 2004:143140 CAPLUS
DN 140:181449
ED Entered STN: 22 Feb 2004
TI Preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents
IN Yi, Kyu Yang; Lee, Sun Kyung; Yoo, Sung-eun; Suh, Jee Hee; Kim, Nak Jeong; Hwang, Sun Kyung; Lee, Byung-ho; Seo, Ho Won; Lee, Chong Ock; Choi, Sang-un
PA Korea Research Institute of Chemical Technology, S. Korea
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent

LA English
 IC ICM C07D405-12
 CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 27, 63


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014898	A1	20040219	WO 2003-KR1534	20030730
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	KR 2004014023	A	20040214	KR 2002-47189	20020809
	CA 2493966	A1	20040219	CA 2003-2493966	20030730
	AU 2003247213	A1	20040225	AU 2003-247213	20030730
	AU 2003247213	B2	20070405		
	EP 1546136	A1	20050629	EP 2003-784665	20030730
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1675202	A	20050928	CN 2003-819195	20030730
	JP 2006509725	T	20060323	JP 2004-527422	20030730
	US 20050267188	A1	20051201	US 2005-523015	20050202
	US 7279497	B2	20071009		
PRAI	KR 2002-47189	A	20020809		
	WO 2003-KR1534	W	20030730		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004014898	ICM	C07D405-12
	IPCI	C07D0405-12 [ICM, 7]; C07D0405-00 [ICM, 7, C*]
	IPCR	C07D0405-00 [I, C*]; C07D0405-12 [I, A]
	ECLA	C07D405/12+311C+233
KR 2004014023	IPCI	C07D0405-12 [ICM, 7]; C07D0405-00 [ICM, 7, C*]
	ECLA	C07D405/12+311C+233
CA 2493966	IPCI	C07D0405-12 [ICM, 7]; C07D0405-00 [ICM, 7, C*]
	IPCR	C07D0405-00 [I, C*]; C07D0405-12 [I, A]
	ECLA	C07D405/12+311C+233
AU 2003247213	IPCI	C07D0405-00 [I, C*]; C07D0405-12 [I, A]
	IPCR	C07D0405-00 [I, C*]; C07D0405-12 [I, A]
	ECLA	C07D405/12+311C+233
EP 1546136	IPCI	C07D0405-12 [ICM, 7]; C07D0405-00 [ICM, 7, C*]
	IPCR	C07D0405-00 [I, C*]; C07D0405-12 [I, A]
	ECLA	C07D405/12+311C+233
CN 1675202	IPCI	C07D0405-12 [ICM, 7]; C07D0405-00 [ICM, 7, C*]
	IPCR	C07D0405-00 [I, C*]; C07D0405-12 [I, A]
	ECLA	C07D405/12+311C+233
JP 2006509725	IPCI	C07D0405-12 [I, A]; C07D0405-00 [I, C*]; A61K0031-4178 [I, A]; A61K0031-4164 [I, C*]; A61P0009-00 [I, A]; A61P0009-04 [I, A]; A61P0009-10 [I, A]; A61P0025-02 [I, A]; A61P0025-28 [I, A]; A61P0025-00 [I, C*]; A61P0027-02 [I, A]; A61P0027-06 [I, A]; A61P0027-00 [I, C*]; A61P0029-00 [I, A]; A61P0035-00 [I, A]; A61P0039-06 [I, A]; A61P0039-00 [I, C*]; C07B0061-00 [N, A]
	IPCR	C07D0405-00 [I, C]; C07D0405-12 [I, A]; A61K0031-4164

[I,C]; A61K0031-4178 [I,A]; A61P0009-00 [I,C];
A61P0009-00 [I,A]; A61P0009-04 [I,A]; A61P0009-10
[I,A]; A61P0025-00 [I,C]; A61P0025-02 [I,A];
A61P0025-28 [I,A]; A61P0027-00 [I,C]; A61P0027-02
[I,A]; A61P0027-06 [I,A]; A61P0029-00 [I,C];
A61P0029-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00
[I,A]; A61P0039-00 [I,C]; A61P0039-06 [I,A];
C07B0061-00 [N,C]; C07B0061-00 [N,A]
FTERM 4C063/AA01; 4C063/BB09; 4C063/CC79; 4C063/DD25;
4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03;
4C086/AA04; 4C086/BC82; 4C086/GA02; 4C086/GA07;
4C086/GA16; 4C086/MA01; 4C086/MA04; 4C086/NA14;
4C086/ZA02; 4C086/ZA15; 4C086/ZA20; 4C086/ZA33;
4C086/ZA36; 4C086/ZA45; 4C086/ZB15; 4H039/CA60;
4H039/CA71; 4H039/CB40; 4H039/CF30
US 20050267188 IPCI A61K0031-4164 [I,A]; C07D0233-54 [I,A]; C07D0233-00
[I,C*]
IPCR C07D0405-00 [I,C*]; C07D0405-12 [I,A]
NCL 514/397.000; 548/311.400; 514/385.000; 514/396.000;
548/300.100; 548/311.100
ECLA C07D405/12+311C+233
OS CASREACT 140:181449; MARPAT 140:181449
GI



AB Imidazolylmethylaminobenzopyrans I [R1 = H, CN, NO2, NH2; R2 =
dialkoxymethyl, alkylenedioxymethyl; R3, R4 = H, Cl, Br, F, alkyl, CF3,
OCF3, NO2, (un)substituted OH, CO2H] were prepared for use in the treatment
of cancer, rheumatoid arthritis, and diabetic retinopathies through
anti-angiogenic properties, and in the protection of heart and neuronal
cells against ischemia-reperfusion injury or preserving organs.
Thus, (2S,3R,4R)-3,4-dihydro-2-dimethoxymethyl-3,4-epoxy-2-methyl-6-nitro-
2H-1-benzopyran was treated with N-(4-chlorophenyl)-N-(1H-imidazol-2-
ylmethyl)amine to give (2S,3R,4R)-I [R1 = NO2, R2 = CH(OMe)2, R3 = 4-Cl,
R4 = H] which showed strong inhibition of HUVEC tube formation at
10 μ M.
ST imidazolylmethylaminobenzopyran prepn antiangiogenic
IT Heart, disease
(angina pectoris; preparation of imidazolylmethylaminobenzopyrans as
antiangiogenic agents)
IT Nerve, disease
(diabetic neuropathy; preparation of imidazolylmethylaminobenzopyrans as
antiangiogenic agents)
IT Eye, disease
(diabetic retinopathy; preparation of imidazolylmethylaminobenzopyrans as
antiangiogenic agents)
IT Heart, disease

(failure; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Asphyxia
(infant; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Heart, disease
(infarction; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Angiogenesis
Antiarthritics
Antitumor agents
Atherosclerosis
Glaucoma (disease)
Human
Neoplasm
Rheumatoid arthritis
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Mental and behavioral disorders
(senile psychosis; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Head and Neck, disease
(trauma; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 571141-37-2P 571141-39-4P 660404-73-9P 660404-74-0P 660404-75-1P
660404-76-2P 660404-77-3P 660404-78-4P 660404-80-8P 660404-81-9P
660404-82-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 571141-36-1P 571141-38-3P 571141-47-4P 571141-49-6P 660404-90-0P
660404-91-1P 660404-92-2P 660404-93-3P 660404-94-4P 660404-95-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 106-47-8, 4-Chloroaniline, reactions 10111-08-7, 2-
Imidazolecarboxaldehyde 380912-55-0 380912-56-1 380912-57-2
380912-58-3 660405-19-6 663598-14-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 166096-16-8P 166096-17-9P 660405-04-9P 660405-05-0P 660405-06-1P
660405-07-2P 660405-08-3P 660405-09-4P 660405-10-7P 660405-11-8P
660405-12-9P 660405-13-0P 660405-14-1P 660405-15-2P 660405-16-3P
660405-17-4P 660405-18-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 660404-79-5P 660404-83-1P 660404-84-2P 660404-89-7P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT 660404-85-3P 660404-86-4P 660404-87-5P 660404-88-6P 660404-96-6P
660404-97-7P 660404-98-8P 660404-99-9P 660405-00-5P 660405-01-6P

660405-02-7P 660405-03-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Bristol-Myers Squibb Co; EP 648758 A1 1995 CAPLUS
- (2) Bristol-Myers Squibb Co; US 5629429 A 1997 CAPLUS
- (3) Bristol-Myers Squibb Co; US 5837702 A 1998 CAPLUS
- (4) Ding, C; Journal of Medicinal Chemistry 1999, V42(18), P3711 CAPLUS
- (5) Grover, G; The Journal of Pharmacology and Experimental Therapeutics 2001, V297(3), P1184 CAPLUS
- (6) Merck And Co Inc; US 20020082292 A1 2002
- (7) Rovnyak, G; Journal of Medicinal Chemistry 1997, V40(1), P24 CAPLUS

L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:492385 CAPLUS

DOCUMENT NUMBER: 136:288753

TITLE: Effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44

AUTHOR(S): Wang, Yongmei; Wu, Zonggui; Li, Li; Zhang, Lingzhen; Zhong, Renqian

CORPORATE SOURCE: Department of Cardiovasology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, Peop. Rep. China

SOURCE: Dier Junyi Daxue Xuebao (2001), 22(2), 144-147
CODEN: DJXUE5; ISSN: 0258-879X

PUBLISHER: Dier Junyi Daxue Xuebao Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

AN 2001:492385 CAPLUS

DN 136:288753

ED Entered STN: 09 Jul 2001

TI Effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44

AU Wang, Yongmei; Wu, Zonggui; Li, Li; Zhang, Lingzhen; Zhong, Renqian

CS Department of Cardiovasology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, Peop. Rep. China

SO Dier Junyi Daxue Xuebao (2001), 22(2), 144-147
CODEN: DJXUE5; ISSN: 0258-879X

PB Dier Junyi Daxue Xuebao Bianjibu

DT Journal

LA Chinese

CC 1-8 (Pharmacology)

AB The effects of hyaluronidase (HAase) and hyaluronan (HA) on proliferation of vascular endothelial cells and its mechanism were studied. The cultured aortic endothelial cells (BAEC) were treated with HAase or HA, cell proliferation rate was detected by MTT assay, and expression of CD44 and DNA content of the cells were measured by flow cytometry. The cell proliferation was increased by $(50.10 \pm 1.23)\%$, S phase cell rate was increased, and expression of CD44 was induced by HAase ($50 \mu\text{g mL}^{-1}$). The cell proliferation and expression of CD44 were inhibited by HA ($100 \mu\text{g mL}^{-1}$). The results showed that HAase may degrade antiangiogenic HA of extracellular matrix, which may stimulate proliferation of endothelial cells and enhance the curative effect of growth factors to myocardial ischemia.

ST hyaluronidase hyaluronan angiogenesis vascular endothelium CD44 myocardial ischemia

IT Ischemia

(cardiac; effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT Cardiovascular agents
 Cytoprotective agents
 (cardioprotective agents; effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT Angiogenesis
 Cell cycle
 Cell proliferation
 Extracellular matrix
 (effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT CD44 (antigen)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT Blood vessel
 (endothelium; effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT Heart, disease
 (ischemia; effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT Endothelium
 (vascular; effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT 9004-61-9, Hyaluronan
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

IT 37326-33-3, Hyaluronidase
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44)

=>

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3
 SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162
 L3 22 S L2 AND DIONE
 L4 0 S L2 AND PHENANTHROLINEDIONE
 L5 2 S L2 AND PHENANTHROLINE
 L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008

L7 224329 S L2
 L8 13877 S L3
 L9 406 S L5
 L10 224329 S L7 OR L8 OR L9
 L11 3300 S 10 AND ANTIANGIOGENIC


L12 56 S L11 AND ISCHEMIA
 L13 28 S L11 AND ("HEART DISEASE")
 L14 2 S L13 AND L12

=> s (l3 or l5) and antiangiogenic
 L15 7 (L3 OR L5) AND ANTIANGIOGENIC

=>

=> d l15 1-7 hitstr ibib all

L15 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 91-56-5, Isatin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (isatin and its analog acted on large number of biol. targets and had
 variety of actual and potential pharmacol. action)
 RN 91-56-5 CAPLUS
 CN 1H-Indole-2,3-dione (CA INDEX NAME)



ACCESSION NUMBER: 2008:344354 CAPLUS
 TITLE: Biological targets for isatin and its analogues:
 implications for therapy
 AUTHOR(S): Medvedev, Alexei; Buneeva, Olga; Glover, Vivette
 CORPORATE SOURCE: Institute of Biomedical Chemistry, Russian Academy of
 Medical Sciences, Moscow, Russia
 SOURCE: Biologics: Targets & Therapy (2007), 1(2), 151-162
 CODEN: BTTICT; ISSN: 1177-5475
 PUBLISHER: Dove Medical Press (NZ) Ltd.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AN 2008:344354 CAPLUS
 ED Entered STN: 20 Mar 2008
 TI Biological targets for isatin and its analogues: implications for therapy
 AU Medvedev, Alexei; Buneeva, Olga; Glover, Vivette
 CS Institute of Biomedical Chemistry, Russian Academy of Medical Sciences,
 Moscow, Russia
 SO Biologics: Targets & Therapy (2007), 1(2), 151-162
 CODEN: BTTICT; ISSN: 1177-5475
 PB Dove Medical Press (NZ) Ltd.
 DT Journal; General Review
 LA English
 CC 1-0 (Pharmacology)
 AB A review. Isatin and its metabolites are constituents of many natural
 substances. They are also components of many synthetic compds. exhibiting
 a wide range of effects, including antiviral activity, antitumor and
 antiangiogenic activity, antibacterial, antitubercular,
 antifungal, antiapoptotic, anticonvulsant and anxiolytic activities. Isatin
 itself is an endogenous oxidized indole with a wide spectrum of behavioral
 and metabolic effects. It has a distinct and discontinuous distribution
 in the brain, peripheral tissues and body fluids and isatin binding sites
 are widely distributed also. Its output is increased during stress. Its
 most potent known in vitro actions are as an antagonist of atrial

natriuretic peptide (ANP) function and NO signaling. As we understand more about its function and sites of action we may be able to develop new pharmacol. agents to mimic or counteract its activity. We consider here the most promising biol. targets for various isatin analogs and/or metabolites, which are employed for the development of various groups of therapeutics. It is also possible that the level of endogenous isatin may influence the in vivo pharmacol. activity of compds. possessing the isatin moiety.

ST review isatin analog drug target sensitivity

IT Drug targets

(isatin and its analog acted on large number of biol. targets and had variety of actual and potential pharmacol. action)

IT 91-56-5, Isatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(isatin and its analog acted on large number of biol. targets and had variety of actual and potential pharmacol. action)

L15 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN


IT 87-48-9, 5-Bromo-2,3-indoledione 91-56-5,
2,3-Indoledione 17630-76-1, 5-Chloro-2,3-indoledione

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)


RN 87-48-9 CAPLUS

CN 1H-Indole-2,3-dione, 5-bromo- (CA INDEX NAME)




RN 91-56-5 CAPLUS

CN 1H-Indole-2,3-dione (CA INDEX NAME)



RN 17630-76-1 CAPLUS

CN 1H-Indole-2,3-dione, 5-chloro- (CA INDEX NAME)



ACCESSION NUMBER:

2006:374270 CAPLUS

DOCUMENT NUMBER:

145:62745

TITLE:

Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and

antiangiogenic agents

AUTHOR(S): Abadi, Ashraf H.; Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.; Klein, Christian; Lozach, Olivier; Meijer, Laurent

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt

SOURCE: European Journal of Medicinal Chemistry (2006), 41(3), 296-305
CODEN: EJMCA5; ISSN: 0223-5234

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:62745

AN 2006:374270 CAPLUS

DN 145:62745

ED Entered STN: 25 Apr 2006

TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents

AU Abadi, Ashraf H.; Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.; Klein, Christian; Lozach, Olivier; Meijer, Laurent

CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt

SO European Journal of Medicinal Chemistry (2006), 41(3), 296-305
CODEN: EJMCA5; ISSN: 0223-5234

PB Elsevier B.V.


DT Journal

LA English

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

OS CASREACT 145:62745

GI



AB Several analogs of the 3-substituted-2-oxoindole chemotype were synthesized by condensing isatin or haloisatin with some amino acids or histamine under neutral conditions. All the imino derivs. produced were tested for kinase inhibitory properties against three serine/threonine kinases, namely CDK1/cyclin B, CDK5/p25 and GSK3 α/β . Most of the histidine derivs. showed inhibitory properties to the three kinases in the low micromolar range. The histamine derivs. were less potent against CDK1/cyclin B and CDK5/p25 and totally inactive against GSK3 α/β . So, the management of the carboxyl function may be a tool to impart selectivity in such family of kinases. Docking of

oxindoline I [R = Br] to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3 β , the ligand poses itself in another orientation, and four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate. Also, all the final compds. were tested for their in vitro antitumor properties against MCF7 (breast), NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the synthesized compds. was cytotoxic at 10⁻⁴ molar concentration. Moreover, I [R = H, Br] were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only I [R = Br] showed moderate inhibitory properties to HUVECs proliferation and cord formation while I [R = H] did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases.

ST oxindole prepn kinase neoplasm angiogenesis inhibitor

IT Angiogenesis

Angiogenesis inhibitors

Antitumor agents

Human

Neoplasm

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

IT 9031-44-1, Kinase (phosphorylating)

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

IT 153535-71-8P 167489-36-3P 891192-12-4P 891192-13-5P 891192-14-6P
891192-15-7P 891192-16-8P 891192-17-9P 891192-18-0P 891192-19-1P
891192-20-4P 891192-21-5P 891192-22-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

IT 51-45-6, Histamine, reactions 71-00-1, L-Histidine, reactions 72-18-4, L-Valine, reactions 72-19-5, L-Threonine, reactions 87-48-9, 5-Bromo-2,3-indoledione 91-56-5, 2,3-Indoledione 6341-92-0, 6-Chloroisatin 6344-05-4, 4-Chloroisatin 7477-63-6, 7-Chloroisatin 17630-76-1, 5-Chloro-2,3-indoledione

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aly, M; Tetrahedron 1994, V50, P895 CAPLUS
- (2) Andreani, A; J Med Chem 2002, V45, P2666 CAPLUS
- (3) Belotti, D; Clin, Cancer Res 1996, V2, P1843 CAPLUS
- (4) Borgne, A; J Biol Chem 1996, V271, P27847 CAPLUS
- (5) Bramson, H; J Med Chem 2001, V44, P4339 CAPLUS
- (6) Clark, R; J Soc Dyers Colour 1997, V113, P316 CAPLUS
- (7) Cohen, P; Eur J Biochem 2001, V268, P5001 CAPLUS
- (8) Cohen, P; Nat Rev Drug Discov 2002, V1, P309 CAPLUS
- (9) Cornell, R; Expert Opin, Ther Patents 2003, V13, P738
- (10) De Strooper, B; Nature 2003, V423, P392 CAPLUS
- (11) Delano, W; The PYMOL Molecular Graphics Sysyem, <http://www.pymol.org> 2002
- (12) Folkman, J; J Natl Cancer Inst 1990, V82, P4 MEDLINE
- (13) Fong, T; Cancer Res 1999, V59, P99 CAPLUS
- (14) Ganellini, C; J Med Chem 1973, V16, P610 CAPLUS
- (15) Ganellini, R; J Med Chem 1996, V39, P3806
- (16) GraBman, S; Bioorg Med Chem 2003, V11, P2163
- (17) Greever, M; Semin Oncol 1992, V19, P622

- (18) Ham, N; J Med Chem 1973, V16, P470 CAPLUS
(19) Haspel, H; Microvasc Res 2002, V63, P304 CAPLUS
(20) Hassaan, A; Egypt J Pharm Sci 1992, V33, P679 CAPLUS
(21) Hassaan, A; Egypt J Pharm Sci 1993, V34, P253 CAPLUS
(22) Hassaan, A; Egypt J Pharm Sci 1994, V35, P165 CAPLUS
(23) Hassaan, A; Egypt J Pharm Sci 1995, V36, P309 CAPLUS
(24) Huang, C; Pacific Symposium on Biocomputing 1996, V1, P724
(25) Jianguo, M; J Pharmacol Exp Ther 2003, V305, P833
(26) Knockaert, M; Trends Pharmacol Sci 2002, V23, P417 CAPLUS
(27) Lane, M; Cancer Res 2001, V15, P6170
(28) Leclerc, S; J Biol Chem 2001, V276, P251 CAPLUS
(29) Malumbres, M; Nat Rev Cancer 2001, V1, P222 CAPLUS
(30) Marzola, P; Clin Cancer Res 2004, V15, P739
(31) Meijer, L; Trends Pharmacol Sci 2004, V25, P471 CAPLUS
(32) Milne, G; J Am Chem Soc 1970, V92, P5170 CAPLUS
(33) Mohamadi, F; J Comput Chem 1990, V11, P440 CAPLUS
(34) Monks, A; J Natl Cancer Inst 1991, V83, P757 CAPLUS
(35) Noble, W; Neuron 2003, V38, P555 CAPLUS
(36) Polychronopoulos, P; J Med Chem 2004, V47, P935 CAPLUS
(37) Primot, A; Protein Expr Purif 2000, V20, P394 CAPLUS
(38) Rehn, S; Eur J Org Chem 2004, P413 CAPLUS
(39) Roth, G; DE 10117204 A1 2002 CAPLUS
(40) Roublevskaia, I; Anticancer Res 2000, V20, P3163 CAPLUS
(41) Sridhar, R; Pharm Res 2000, V17, P1345 CAPLUS
(42) Sun, L; J Med Chem 1998, V41, P2588 CAPLUS
(43) Sun, L; J Med Chem 1999, V42, P5120 CAPLUS
(44) Tarabolletti, G; Clin Cancer Res 2002, V8, P1182


L15 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

IT 130-15-4, 1,4-Naphthalenedione

RL: PAC (Pharmacological activity); BIOL (Biological study)
(methylthionaphthoquinone compds., production method, pharmaceutical
compns., and therapeutic use)

RN 130-15-4 CAPLUS

CN 1,4-Naphthalenedione (CA INDEX NAME)



ACCESSION NUMBER: 2005:322408 CAPLUS

DOCUMENT NUMBER: 142:367706

TITLE: 2-Methylthio-1,4-naphthoquinone and derivatives
thereof, method for production thereof, pharmaceutical
compositions, and therapeutic use

INVENTOR(S): Muller, Werner E. G.; Thakur, Narsinh L.; Thakur,
Arachana N.; Schroder, Heinz C.; Lang, Gerhard;
Tsuruta, Hideyuki; Bringmann, Gerhard

PATENT ASSIGNEE(S): Johannes-Gutenberg-Universitat Mainz, Germany;
Julius-Maximilians-Universitat Wurzburg

SOURCE: Ger. Offen., 19 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10343798	A1	20050414	DE 2003-10343798	20030922
WO 2005042442	A2	20050512	WO 2004-EP10465	20040917
WO 2005042442	A3	20050707		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 2003-10343798 A 20030922

OTHER SOURCE(S): MARPAT 142:367706

AN 2005:322408 CAPLUS

DN 142:367706

ED Entered STN: 15 Apr 2005

TI 2-Methylthio-1,4-naphthoquinone and derivatives thereof, method for production thereof, pharmaceutical compositions, and therapeutic use

IN Muller, Werner E. G.; Thakur, Narsinh L.; Thakur, Arachana N.; Schroder, Heinz C.; Lang, Gerhard; Tsuruta, Hideyuki; Bringmann, Gerhard

PA Johannes-Gutenberg-Universitat Mainz, Germany; Julius-Maximilians-Universitat Wurzburg

SO Ger. Offen., 19 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM C07C323-22

ICS C07C319-14

CC 1-12 (Pharmacology)

Section cross-reference(s): 10, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10343798	A1	20050414	DE 2003-10343798	20030922
	WO 2005042442	A2	20050512	WO 2004-EP10465	20040917
	WO 2005042442	A3	20050707		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI DE 2003-10343798 A 20030922

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 10343798	ICM	C07C323-22
	ICS	C07C319-14

IPCI C07C0323-22 [ICM,7]; C07C0323-00 [ICM,7,C*];
 C07C0319-14 [ICS,7]; C07C0319-00 [ICS,7,C*]
 IPCR C07C0323-00 [I,C*]; C07C0323-22 [I,A]; C12P0011-00
 [I,C*]; C12P0011-00 [I,A]
 ECLA C07C323/22; C12P011/00
 WO 2005042442 IPCI C07C [ICM,7]
 IPCR C07C0323-00 [I,C*]; C07C0323-22 [I,A]; C12P0011-00
 [I,C*]; C12P0011-00 [I,A]
 ECLA C07C323/22; C12P011/00
 OS MARPAT 142:367706
 AB 2-Methylthio-1,4-naphthoquinone (MTN) and derivs. thereof are disclosed,
 as are methods for the production and/or isolation thereof. MTN and MTN
 derivs. have antitumor and antiangiogenic properties in cell
 culture models. These compds. also have neointimal proliferation-
 inhibiting properties. The compds. can also be used to treat infections
 by Gram-neg. bacteria.
 ST methylthionaphthoquinone compd prodn antitumor antibacterial; angiogenesis
 inhibitor methylthionaphthoquinone compd; neointimal proliferation
 inhibitor methylthionaphthoquinone compd
 IT Animal cell line
 (PC12; methylthionaphthoquinone compds., production method, pharmaceutical
 compns., and therapeutic use)
 IT HeLa cell
 (S3; methylthionaphthoquinone compds., production method, pharmaceutical
 compns., and therapeutic use)
 IT Proteobacteria
 (alpha group, MBIC3368; methylthionaphthoquinone compds., production
 method, pharmaceutical compns., and therapeutic use)
 IT Infection
 (bacterial; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Drug delivery systems
 (capsules; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Uterus, neoplasm
 (cervix, carcinoma; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Carcinoma
 (cervix; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Drug delivery systems
 (drops; methylthionaphthoquinone compds., production method, pharmaceutical
 compns., and therapeutic use)
 IT Gram-negative bacteria
 (infection; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Drug delivery systems
 (infusions; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Drug delivery systems
 (injections; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Angiogenesis
 Angiogenesis inhibitors
 Antibacterial agents
 Antitumor agents
 Bacillus subtilis
 Chemotherapy
 Combination chemotherapy
 Drug delivery systems
 Dysidea avara

Escherichia coli
 Fermentation
 Human
 Lymphoma
 Neoplasm
 Pheochromocytoma
 (methylthionaphthoquinone compds., production method, pharmaceutical
 compns., and therapeutic use)
 IT Natural products, pharmaceutical
 RL: DEV (Device component use); NPO (Natural product occurrence); PAC
 (Pharmacological activity); PUR (Purification or recovery); THU
 (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP
 (Preparation); USES (Uses)
 (methylthionaphthoquinone compds., production method, pharmaceutical
 compns., and therapeutic use)
 IT Blood vessel
 Cytotoxic agents
 (neointimal proliferation inhibitors; methylthionaphthoquinone compds.,
 production method, pharmaceutical compns., and therapeutic use)
 IT Cell proliferation
 (neointimal; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Drug delivery systems
 (oral; methylthionaphthoquinone compds., production method, pharmaceutical
 compns., and therapeutic use)
 IT Drug delivery systems
 (parenterals; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Drug delivery systems
 (rectal; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Drug delivery systems
 (solns.; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Medical goods
 (stents; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Drug delivery systems
 (suppositories; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Drug delivery systems
 (suspensions; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT Drug delivery systems
 (tablets; methylthionaphthoquinone compds., production method,
 pharmaceutical compns., and therapeutic use)
 IT 26037-60-5P 55699-85-9P
 RL: DEV (Device component use); NPO (Natural product occurrence); PAC
 (Pharmacological activity); PUR (Purification or recovery); THU
 (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP
 (Preparation); USES (Uses)
 (methylthionaphthoquinone compds., production method, pharmaceutical
 compns., and therapeutic use)
 IT 849658-75-9 849658-76-0
 RL: DEV (Device component use); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methylthionaphthoquinone compds., production method, pharmaceutical
 compns., and therapeutic use)
 IT 130-15-4, 1,4-Naphthalenedione
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (methylthionaphthoquinone compds., production method, pharmaceutical

compns., and therapeutic use)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Anon; EP 0863442 A2 CAPLUS
- (2) Coll, G; J Org Chem 1998, V53, P5345
- (3) Kametani, T; J Chem Soc Perkin Trans 1 1977, P386 CAPLUS
- (4) Prakash, G; J Med Chem 1978, V21(4), P369 CAPLUS

L15 ANSWER 4 OF 7 MEDLINE on STN

ACCESSION NUMBER: 2006264196 MEDLINE
DOCUMENT NUMBER: PubMed ID: 16494969
TITLE: Synthesis of 3-substituted-2-oxoindole analogues and their
evaluation as kinase inhibitors, anticancer and
antiangiogenic agents.
AUTHOR: Abadi Ashraf H; Abou-Seri Sahar M; Abdel-Rahman Doaa E;
Klein Christian; Lozach Olivier; Meijer Laurent
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of
Pharmacy, Cairo University, Egypt.. ahabadi@yahoo.com
SOURCE: European journal of medicinal chemistry, (2006 Mar) Vol.
41, No. 3, pp. 296-305. Electronic Publication:
2006-02-21.
Journal code: 0420510. ISSN: 0223-5234.
PUB. COUNTRY: France
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200609
ENTRY DATE: Entered STN: 13 May 2006
Last Updated on STN: 30 Sep 2006
Entered Medline: 29 Sep 2006

AN 2006264196 MEDLINE
DN PubMed ID: 16494969
TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as
kinase inhibitors, anticancer and antiangiogenic agents.
AU Abadi Ashraf H; Abou-Seri Sahar M; Abdel-Rahman Doaa E; Klein Christian;
Lozach Olivier; Meijer Laurent
CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo
University, Egypt.. ahabadi@yahoo.com
SO European journal of medicinal chemistry, (2006 Mar) Vol. 41, No. 3, pp.
296-305. Electronic Publication: 2006-02-21.
Journal code: 0420510. ISSN: 0223-5234.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200609
ED Entered STN: 13 May 2006
Last Updated on STN: 30 Sep 2006
Entered Medline: 29 Sep 2006
AB Several analogues of the 3-substituted-2-oxoindole chemotype were
synthesized by condensing isatin or the appropriate haloisatin with some
amino acids or histamine under neutral conditions. All the imino
derivatives produced were tested for kinase inhibitory properties against
three serine/threonine kinases, namely CDK1/cyclin B, CDK5/p25 and
GSK3alpha/beta. Most of the histidine derivatives showed inhibitory
properties to the three kinases in the low micromolar range. The
histamine derivatives were less potent against CDK1/cyclin B and CDK5/p25
and totally inactive against GSK3alpha/beta. So, the management of the
carboxyl function may be a tool to impart selectivity in such family of

kinases. Docking of 2-[[5-bromo-2-oxoindolin-3-ylidene]amino]-3-(1H-imidazol2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3beta, the ligand poses itself in another orientation, also four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate. Also, all the final compounds were tested for their in vitro antitumor properties against MCF7 (breast), NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the synthesized compounds was cytotoxic at 10(-4) molar concentration. Moreover, compounds 13 and 14 were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only compound 14 showed moderate inhibitory properties to HUVECs proliferation and cord formation while its non-brominated derivative 13 did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases.

CT *Angiogenesis Inhibitors: CS, chemical synthesis
 Angiogenesis Inhibitors: CH, chemistry
 Angiogenesis Inhibitors: PD, pharmacology
 *Antineoplastic Agents: CS, chemical synthesis
 Antineoplastic Agents: CH, chemistry
 Antineoplastic Agents: PD, pharmacology
 Cell Line
 Cell Proliferation: DE, drug effects
 Drug Screening Assays, Antitumor
 Endothelial Cells: DE, drug effects
 Histidine: AA, analogs & derivatives
 Histidine: CS, chemical synthesis
 Histidine: PD, pharmacology
 Humans
 Indoles: CS, chemical synthesis
 *Indoles: CH, chemistry
 *Indoles: PD, pharmacology
 Inhibitory Concentration 50
 Isatin: AA, analogs & derivatives
 Isatin: CH, chemistry
 Models, Molecular
 Molecular Structure
 Protein Kinase Inhibitors: CS, chemical synthesis
 *Protein Kinase Inhibitors: CH, chemistry
 *Protein Kinase Inhibitors: PD, pharmacology
 Umbilical Veins: CY, cytology
 RN 61-71-2 (3-hydroxy-2-oxoindole); 71-00-1 (Histidine); 91-56-5
 (Isatin)
 CN 0 (Angiogenesis Inhibitors); 0 (Antineoplastic Agents); 0 (Indoles); 0
 (Protein Kinase Inhibitors)

L15 ANSWER 5 OF 7 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2006190028 EMBASE
 TITLE: Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
 AUTHOR: Abadi, Ashraf H. (correspondence); Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini street, Cairo, 11562, Egypt. ahabadi@yahoo.com
 AUTHOR: Klein, Christian
 CORPORATE SOURCE: Pharmaceutical and Medicinal Chemistry, Saarland

AUTHOR: University, P.O. Box 151150, D-66041 Saarbrücken, Germany.
 Lozach, Olivier; Meijer, Laurent
 CORPORATE SOURCE: CNRS, Station Biologique, BP 74, 29682 Roscoff cedex,
 France.
 SOURCE: European Journal of Medicinal Chemistry, (Mar 2006) Vol.
 41, No. 3, pp. 296-305.
 Refs: 45
 ISSN: 0223-5234 E-ISSN: 1768-3254 CODEN: EJMCA5
 PUBLISHER IDENT.: S 0223-5234(06)00020-1
 COUNTRY: France
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 6 Jun 2006
 Last Updated on STN: 6 Jun 2006

AN 2006190028 EMBASE
 TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as
 kinase inhibitors, anticancer and antiangiogenic agents.
 AU Abadi, Ashraf H. (correspondence); Abou-Seri, Sahar M.; Abdel-Rahman, Doaa
 E.
 CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo
 University, Kasr El-Aini street, Cairo, 11562, Egypt. ahabadi@yahoo.com
 AU Klein, Christian
 CS Pharmaceutical and Medicinal Chemistry, Saarland University, P.O. Box
 151150, D-66041 Saarbrücken, Germany.
 AU Lozach, Olivier; Meijer, Laurent
 CS CNRS, Station Biologique, BP 74, 29682 Roscoff cedex, France.
 SO European Journal of Medicinal Chemistry, (Mar 2006) Vol. 41, No. 3, pp.
 296-305.
 Refs: 45
 ISSN: 0223-5234 E-ISSN: 1768-3254 CODEN: EJMCA5
 PUI S 0223-5234(06)00020-1
 CY France
 DT Journal; Article
 FS 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 LA English
 SL English
 ED Entered STN: 6 Jun 2006
 Last Updated on STN: 6 Jun 2006

AB Several analogues of the 3-substituted-2-oxoindole chemotype were
 synthesized by condensing isatin or the appropriate haloisatin with some
 amino acids or histamine under neutral conditions. All the imino
 derivatives produced were tested for kinase inhibitory properties against
 three serine/threonine kinases, namely CDK1/cyclin B, CDK5/p25 and
 GSK3 α / β . Most of the histidine derivatives showed inhibitory
 properties to the three kinases in the low micromolar range. The
 histamine derivatives were less potent against CDK1/cyclin B and CDK5/p25
 and totally inactive against GSK3 α / β . So, the management of
 the carboxyl function may be a tool to impart selectivity in such family
 of kinases. Docking of 2-{-5-bromo-2-oxoindolin-3-ylidene}amino-3-(1H-
 imidazol-2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound
 can interact with the enzyme through four hydrogen bonds; for GSK3 β ,
 the ligand poses itself in another orientation, also four hydrogen bonds
 can be formed between the ligand and the receptor, otherwise hydrophobic
 interactions seem to predominate. Also, all the final compounds were
 tested for their in vitro antitumor properties against MCF7 (breast),
 NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the
 synthesized compounds was cytotoxic at 10⁻⁴ molar concentration.

Moreover, compounds 13 and 14 were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only compound 14 showed moderate inhibitory properties to HUVECs proliferation and cord formation while its non-brominated derivative 13 did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases. .COPYRGT. 2006 Elsevier SAS. All rights reserved.

CT Medical Descriptors:

antiangiogenic activity
antineoplastic activity
article
breast cell
bromination
cancer cell culture
cell migration
cell proliferation
central nervous system
concentration (parameters)
controlled study
cytotoxicity
drug synthesis
endothelium cell
enzyme inhibition
human
human cell
hydrogen bond
hydrophobicity
lung alveolus cell
polymerization
protein family
protein protein interaction
umbilical vein

CT Drug Descriptors:

2 [(4 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development
2 [(4 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 hydroxybutanoic acid: DV, drug development
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 hydroxybutanoic acid: PD, pharmacology
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 methylbutanoic acid: DV, drug development
2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 methylbutanoic acid: PD, pharmacology
2 [(5 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development
2 [(5 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology
2 [(6 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development
2 [(6 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology
2 [(7 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development
2 [(7 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic

acid : PD, pharmacology
 3 (1h imidazol 2 yl) 2 [(2 oxoindolin 3 ylidene)amino]propanoic acid: DV, drug development
 3 (1h imidazol 2 yl) 2 [(2 oxoindolin 3 ylidene)amino]propanoic acid: PD, pharmacology
 3 [2 (1h imidazol 4 yl)ethylimino] 5 bromoindolin 2 one: DV, drug development
 3 [2 (1h imidazol 4 yl)ethylimino] 5 bromoindolin 2 one: PD, pharmacology
 3 [2 (1h imidazol 4 yl)ethylimino] 5 chloroindolin 2 one: DV, drug development
 3 [2 (1h imidazol 4 yl)ethylimino] 5 chloroindolin 2 one: PD, pharmacology
 3 [2 (1h imidazol 4 yl)ethylimino]indolin 2 one: DV, drug development
 3 [2 (1h imidazol 4 yl)ethylimino]indolin 2 one: PD, pharmacology
 3 hydroxy 2 [(2 oxoindolin 3 ylidene)amino]butanoic acid: DV, drug development
 3 hydroxy 2 [(2 oxoindolin 3 ylidene)amino]butanoic acid: PD, pharmacology
 3 methyl 2 (2 oxoindolin 3 ylideneamino)butanoic acid: DV, drug development
 3 methyl 2 (2 oxoindolin 3 ylideneamino)butanoic acid: PD, pharmacology
 amino acid
 *angiogenesis inhibitor: DV, drug development
 *angiogenesis inhibitor: PD, pharmacology
 *antineoplastic agent: DV, drug development
 *antineoplastic agent: PD, pharmacology
 carboxyl group
 cyclin B
 cyclin dependent kinase 1
 cyclin dependent kinase 5
 histamine
 histamine derivative
 histidine derivative
 *indole derivative: DV, drug development
 *indole derivative: PD, pharmacology
 isatin
 *phosphotransferase inhibitor: DV, drug development
 *phosphotransferase inhibitor: PD, pharmacology
 propionic acid derivative: DV, drug development
 propionic acid derivative: PD, pharmacology
 protein p25
 protein serine threonine kinase
 unclassified drug
 unindexed drug
 RN (amino acid) 65072-01-7; (histamine) 51-45-6, 56-92-8, 93443-21-1;
 (isatin) 91-56-5

L15 ANSWER 6 OF 7 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
 ACCESSION NUMBER: 2006:437778 BIOSIS
 DOCUMENT NUMBER: PREV200600440686
 TITLE: Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
 AUTHOR(S): Abadi, Ashraf H. [Reprint Author]; Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.; Klein, Christian; Lozach, Olivier; Meijer, Laurent
 CORPORATE SOURCE: Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Kasr El Aini St, Cairo 11562, Egypt
 ahabadi@yahoo.com
 SOURCE: European Journal of Medicinal Chemistry, (MAR 2006) Vol. 41, No. 3, pp. 296-305.
 CODEN: EJMCA5. ISSN: 0223-5234.
 DOCUMENT TYPE: Article

LANGUAGE: English
 ENTRY DATE: Entered STN: 6 Sep 2006
 Last Updated on STN: 6 Sep 2006

AN 2006:437778 BIOSIS
 DN PREV200600440686
 TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as
 kinase inhibitors, anticancer and antiangiogenic agents.
 AU Abadi, Ashraf H. [Reprint Author]; Abou-Seri, Sahar M.; Abdel-Rahman, Doaa
 E.; Klein, Christian; Lozach, Olivier; Meijer, Laurent
 CS Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Kasr El Aini St, Cairo 11562,
 Egypt
 ahabadi@yahoo.com
 SO European Journal of Medicinal Chemistry, (MAR 2006) Vol. 41, No. 3, pp.
 296-305.
 CODEN: EJMCA5. ISSN: 0223-5234.
 DT Article
 LA English
 ED Entered STN: 6 Sep 2006
 Last Updated on STN: 6 Sep 2006

AB Several analogues of the 3-substituted-2-oxoindole chemotype were
 synthesized by condensing isatin or the appropriate haloisatin with some
 amino acids or histamine under neutral conditions. All the imino
 derivatives produced were tested for kinase inhibitory properties against
 three serine/threonine kinases, namely CDKI/cyclin B, CDK5/p25 and GSK
 alpha/beta. Most of the histidine derivatives showed inhibitory
 properties to the three kinases in the low micromolar range. The
 histamine derivatives were less potent against CDKI/cyclin B and CDK5/p25
 and totally inactive against GSU alpha/beta. So, the management of the
 carboxyl function may be a tool to impart selectivity in such family of
 kinases. Docking of 2-{-5bromo-2-oxoindolin-3-ylidene}amino-3-{[H-
 imidazol2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound
 can interact with the enzyme through four hydrogen bonds; for GSK/3 beta,
 the ligand poses itself in another orientation, also four hydrogen bonds
 can be formed between the ligand and the receptor, otherwise hydrophobic
 interactions seem to predominate. Also, all the final compounds were
 tested for their in vitro antitumor properties against MCF7 (breast),
 NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the
 synthesized compounds was cytotoxic at 10(-4) molar concentration.
 Moreover, compounds 13 and 14 were tested for potential
 antiangiogenic properties by testing their ability to inhibit the
 proliferation of human umbilical vein endothelial cells (HUVECs), cord
 formation and migration in response to chemoattractant. Only compound 14
 showed moderate inhibitory properties to HUVECs proliferation and cord
 formation while its non-brominated derivative 13 did not. Thus, the
 antiangiogenesis properties are not apparently caused by inhibition of any
 of the tested kinases. (c) 2006 Elsevier SAS. All rights reserved.

CC Cytology - Human 02508
 Biochemistry studies - Proteins, peptides and amino acids 10064
 Enzymes - General and comparative studies: coenzymes 10802
 Pathology - Therapy 12512
 Respiratory system - Physiology and biochemistry 16004
 Respiratory system - Pathology 16006
 Reproductive system - Physiology and biochemistry 16504
 Reproductive system - Pathology 16506
 Nervous system - Physiology and biochemistry 20504
 Nervous system - Pathology 20506
 Pharmacology - General 22002
 Neoplasms - Pathology, clinical aspects and systemic effects 24004
 Neoplasms - Therapeutic agents and therapy 24008

IT Major Concepts
 Pharmaceuticals (Pharmacology); Enzymology (Biochemistry and Molecular

Biophysics); Tumor Biology

IT Parts, Structures, & Systems of Organisms
breast: reproductive system; lung: respiratory system; glia: nervous system

IT Diseases
glioblastoma: nervous system disease, neoplastic disease
Glioblastoma (MeSH)

IT Diseases
breast cancer: neoplastic disease, reproductive system disease/female
Breast Neoplasms (MeSH)

IT Diseases
lung cancer: respiratory system disease, neoplastic disease
Lung Neoplasms (MeSH)

IT Chemicals & Biochemicals
histidine; isatin; histamine; threonine kinase; serine kinase;
3-substituted-2-oxoindole: synthesis; haloisatin; 2-{-5-bromo-2-oxoindolin-3-ylidene}amino-3-(1H-imidazol-2-yl)propionic acid;
CDK1/cyclin B: antineoplastic-drug; CDK5/p25: antineoplastic-drug;
GSK-3 alpha/beta [glycogen synthase kinase-3 alpha/beta]:
antineoplastic-drug

ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
MCF-7 cell line (cell_line): human breast cancer cells
NCI-H460 cell line (cell_line): human lung cancer cells
SF268 cell line (cell_line): human glioblastoma cells
HUVECs cell line (cell_line): human umbilical vein endothelial cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

RN 4998-57-6 (histidine)
91-56-5 (isatin)
51-45-6 (histamine)
9026-43-1 (serine kinase)

L15 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
ACCESSION NUMBER: 2005:450611 BIOSIS
DOCUMENT NUMBER: PREV200510241116
TITLE: Comparison of the antiinflammatory effects of *Drosera rotundifolia* and *Drosera madagascariensis* in the HET-CAM assay.
AUTHOR(S): Paper, Dietrich H.; Karall, Elisabeth; Kremser, Michaela; Krenn, Liselotte [Reprint Author]
CORPORATE SOURCE: Univ Vienna, Inst Pharmakognosie, Althanstr 14, A-1090 Vienna, Austria
liselotte.krenn@univie.ac.at
SOURCE: PHYTOTHERAPY RESEARCH, (APR 2005) Vol. 19, No. 4, pp. 323-326.
ISSN: 0951-418X.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Nov 2005
Last Updated on STN: 3 Nov 2005

AN 2005:450611 BIOSIS
DN PREV200510241116
TI Comparison of the antiinflammatory effects of *Drosera rotundifolia* and *Drosera madagascariensis* in the HET-CAM assay.
AU Paper, Dietrich H.; Karall, Elisabeth; Kremser, Michaela; Krenn, Liselotte [Reprint Author]
CS Univ Vienna, Inst Pharmakognosie, Althanstr 14, A-1090 Vienna, Austria

liselotte.krenn@univie.ac.at
 SO PHYTOTHERAPY RESEARCH, (APR 2005) Vol. 19, No. 4, pp. 323-326.
 ISSN: 0951-418X.
 DT Article
 LA English
 ED Entered STN: 3 Nov 2005
 Last Updated on STN: 3 Nov 2005
 AB The antinflammatory effects of ethanol and aqueous extracts from *Drosera rotundifolia* and from *Drosera madagascariensis* were compared in vivo in the HET-CAM assay. Both extracts from *D. rotundifolia* and the ethanol extract from *D. madagascariensis* showed remarkable efficacy at doses of 500 µg/pellet. The inhibition of the inflammation by the extracts was stronger than that by 50 µg hydrocortisone/pellet. In contrast, there was only a very weak effect observed at a dose of 500 µg/pellet of the water extract from *D. madagascariensis*. The chemical analyses of the extracts showed that the effect cannot be attributed to naphthoquinones, but might be due to flavonoids. Ellagic acid obviously plays an important role in the antiangiogenic effect of the *Drosera* extracts.
 Copyright (c) 2005 John Wiley & Sons, Ltd.
 CC Biochemistry studies - General 10060
 Pathology - Therapy 12512
 Pharmacology - Connective tissue, bone and collagen-acting drugs 22012
 Pharmacology - Immunological processes and allergy 22018
 Pharmacognosy and pharmaceutical botany 54000
 IT Major Concepts
 Methods and Techniques; Pharmacognosy (Pharmacology)
 IT Chemicals & Biochemicals
 flavonoids; ellagic acid; naphthoquinone; ethanol extract:
 antiinflammatory-drug, immunologic-drug, dosage, crude drug, efficacy,
 inhibition; aqueous extract: antiinflammatory-drug, immunologic-drug,
 dosage, crude drug, efficacy, inhibition
 IT Methods & Equipment
 hen's egg test-chorioallantoic membrane assay: laboratory techniques
 IT Miscellaneous Descriptors
 antiinflammatory effect
 ORGN Classifier
 Droseraceae 25990
 Super Taxa
 Dicotyledones; Angiospermae; Spermatophyta; Plantae
 Organism Name
Drosera madagascariensis (species): medicinal plant
Drosera rotundifolia (species): medicinal plant
 Taxa Notes
 Angiosperms, Dicots, Plants, Spermatophytes, Vascular Plants
 RN 476-66-4 (ellagic acid)
 130-15-4 (naphthoquinone)

=> s 1,1"-Phenanthroline-5,6-dione
 MISMATCHED QUOTE '1,1"-PHENANTHR'
 Quotation marks (or apostrophes) must be used in pairs,
 one before and one after the expression you are setting
 off or masking.

=> s "1,10-Phenanthroline-5,6-dione"
 L16 587 "1,10-PHENANTHROLINE-5,6-DIONE"

=> s l16 and phenanthrene
 L17 4 L16 AND PHENANTHRENE

=> d l17 1-4 hitstr ibib all

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:943703 CAPLUS

DOCUMENT NUMBER: 147:117706

TITLE: Product class 6: phenanthrene-9,10-diones, stilbenequinones, diphenquinones, and related ring assemblies

AUTHOR(S): Echavarren, A. M.; Porcel, S.

CORPORATE SOURCE: Institute of Chemical Research of Catalonia (ICIQ), Tarragona, 43007, Spain

SOURCE: Science of Synthesis (2006), 28, 507-560
CODEN: SSCYJ9

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AN 2006:943703 CAPLUS

DN 147:117706

ED Entered STN: 14 Sep 2006

TI Product class 6: phenanthrene-9,10-diones, stilbenequinones, diphenquinones, and related ring assemblies

AU Echavarren, A. M.; Porcel, S.

CS Institute of Chemical Research of Catalonia (ICIQ), Tarragona, 43007, Spain

SO Science of Synthesis (2006), 28, 507-560
CODEN: SSCYJ9

PB Georg Thieme Verlag

DT Journal; General Review

LA English

CC 21-0 (General Organic Chemistry)

AB A review of methods to prepare phenanthrene-9,10-diones, stilbenequinones, diphenquinones, and related ring assemblies.

ST review phenanthrenedione analog prepn; stilbenequinone analog prepn
review; diphenquinone analog prepn review

IT Quinones

RL: SPN (Synthetic preparation); PREP (Preparation)

(review preparation of phenanthrenedione, stilbenequinones, diphenquinones, and related ring analogs)

IT 141-78-6, Acetic acid ethyl ester, uses 536-80-1

RL: CAT (Catalyst use); USES (Uses)

(review preparation of phenanthrenedione, stilbenequinones, diphenquinones, and related ring analogs)

IT 56-53-1 66-71-7, 1,10-Phenanthroline 67-64-1, 2-Propanone, reactions
78-94-4, 3-Buten-2-one, reactions 85-01-8, Phenanthrene,
reactions 85-02-9, Benzo[f]quinoline 85-97-2 87-65-0 91-10-1
92-88-6, [1,1'-Biphenyl]-4,4'-diol 93-58-3 93-89-0 94-08-6 99-75-2
100-42-5, reactions 110-18-9 128-38-1 128-39-2 129-00-0, Pyrene,
reactions 134-81-6 230-27-3, Benzo[h]quinoline 484-11-7 527-60-6
554-34-7 576-26-1 584-03-2, 1,2-Butanediol 603-35-0, reactions
604-95-5 617-04-9 951-06-4 1068-47-9 1188-33-6 1519-46-6
1576-69-8 1629-58-9, 1-Penten-3-one 1879-09-0 2078-54-8 2219-82-1
2416-98-0 2417-04-1 2432-11-3, [1,1':3',1''-Terphenyl]-2'-ol
2950-01-8 3011-45-8 3697-13-0, 1,7-Phenanthroline-6-ol 4344-45-0
4844-17-1 5398-75-4 5417-63-0 5807-64-7 7693-47-2 13388-73-3
14328-91-7 14970-83-3 15058-36-3 17755-10-1 20185-55-1
21509-95-5 24300-91-2 24415-26-7, 1-Nonen-3-one 24620-40-4
24909-10-2 27018-91-3, 4H-Cyclopenta[def]phenanthrene
-8,9-dione 28622-70-0 28713-50-0 29176-55-4 38256-25-6
40152-05-4 40352-56-5 53622-33-6 54258-41-2, 1,10-Phenanthroline-5-
amine 58245-82-2 65564-60-5 70005-88-8 73049-18-0 74825-06-2
74825-07-3 74825-08-4 74825-09-5 74825-11-9 74825-12-0
74825-13-1 78891-39-1 78939-36-3 80232-65-1 80721-43-3

84405-44-7	85575-93-5	92346-53-7	92599-23-0	95912-03-1
98126-29-5	99248-71-2	100125-12-0	102420-54-2	124974-15-8
127753-94-0	138145-24-1	138145-26-3	138145-28-5	139975-70-5
152660-60-1	153399-67-8	155587-64-7	155587-72-7	155587-84-1
156235-29-9	156235-35-7	156235-36-8	176956-19-7	176956-23-3
176956-24-4	176956-29-9	188677-27-2	188677-28-3	188677-29-4
188677-30-7	190127-31-2	206200-31-9	206200-32-0	216657-09-9
268538-85-8	336184-07-7	682750-08-9	682750-11-4	682750-15-8
682750-26-1	697299-12-0	791637-63-3	791637-64-4	791637-65-5
837421-16-6	855360-67-7	872809-85-3	943126-95-2	

RL: RCT (Reactant); RACT (Reactant or reagent)

(review preparation of phenanthrenedione, stilbenequinones, diphenquinones, and related ring analogs)

IT 84-11-7P, 9,10-Phenanthrenedione 128-37-0P, preparation 809-73-4P
 2607-52-5P 5664-37-9P 6217-22-7P, 4,5-Pyrenedione 6546-78-7P
 60373-53-7P 60373-54-8P 72909-34-3P 74447-88-4P 78939-38-5P
 78939-39-6P 78939-40-9P 92346-54-8P 92346-55-9P 95912-14-4P
 98126-30-8P 99248-72-3P 99248-73-4P 121793-75-7P 139975-66-9P
 142422-23-9P 142422-24-0P 161470-06-0P 190127-32-3P 524746-74-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(review preparation of phenanthrenedione, stilbenequinones, diphenquinones, and related ring analogs)

IT 84-12-8P, 4,7-Phenanthroline-5,6-dione 96-09-3P 110-01-0P 215-58-7P,
 Benzo[b]triphenylene 482-05-3P, [1,1'-Biphenyl]-2,2'-dicarboxylic acid
 493-74-3P 494-72-4P 604-84-2P, 9,10-Phenanthrenediol 1072-43-1P
 1498-99-3P 1516-94-5P 1613-51-0P 1620-98-0P 2178-51-0P
 2179-51-3P 2455-14-3P 3457-53-2P 3550-01-4P 4906-22-3P
 6787-57-1P 13421-38-0P 13693-18-0P 14328-90-6P 14387-17-8P
 17816-26-1P 17816-27-2P 17825-35-3P 20246-79-1P 20851-85-8P
 21736-38-9P 24378-09-4P 27318-90-7P, 1,10-
 Phenanthroline-5,6-dione
 27728-29-6P 35495-11-5P 36909-24-7P 39250-93-6P 54389-66-1P
 54389-67-2P 58856-98-7P 59869-79-3P 60373-56-0P 60566-01-0P
 65938-98-9P, Benzo[h]quinoline-5,6-dione 65938-99-0P,
 Benzo[f]quinoline-5,6-dione 66788-08-7P, Benzo[e]pyrene-4,5-dione
 67080-37-9P 69097-25-2P 73030-04-3P 73049-19-1P 74809-56-6P
 74809-57-7P 74809-58-8P 74809-59-9P 74809-60-2P 74809-61-3P
 74825-14-2P 80721-44-4P 82701-91-5P, 1,7-Phenanthroline-5,6-dione
 84405-38-9P 92599-27-4P 99248-74-5P 99419-91-7P 99420-18-5P
 99520-63-5P, Indeno[1,2,3-cd]pyrene-1,2-dione 102331-54-4P
 102331-58-8P 108744-18-9P 113736-80-4P 117745-54-7P 121793-76-8P
 137936-95-9P 139220-15-8P 139975-73-8P 139975-74-9P 139975-75-0P
 141622-77-7P 142422-22-8P 143255-68-9P, 4H-
 Benzo[b]cyclopenta[jkl]triphenylene 147120-00-1P 153399-73-6P
 153399-74-7P 153399-75-8P 155306-04-0P 155587-66-9P 155587-67-0P
 155587-81-8P 156235-18-6P 156235-19-7P 157488-04-5P 176956-25-5P
 180999-63-7P 180999-65-9P 180999-67-1P 180999-68-2P 188677-34-1P
 188677-35-2P 188677-36-3P 188677-37-4P 190127-36-7P 215674-97-8P
 216656-90-5P 336184-12-4P 337312-91-1P 337312-93-3P 337312-94-4P
 337312-95-5P 337312-96-6P 337312-97-7P 337312-98-8P 379711-32-7P
 602331-25-9P 682749-93-5P 682749-96-8P 682749-99-1P 704860-92-4P
 791637-66-6P 791637-67-7P 791637-69-9P 791637-70-2P 837421-17-7P
 943126-96-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(review preparation of phenanthrenedione, stilbenequinones, diphenquinones, and related ring analogs)

RE.CNT 229 THERE ARE 229 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Abul-Hajj, Y; J Am Chem Soc 1995, V117, P5600 CAPLUS
- (2) Altwicker, E; Chem Rev 1967, V67, P475 CAPLUS

- (3) Amouyal, E; J Chem Soc, Dalton Trans 1990, P1841 CAPLUS
- (4) Andres, J; J Am Chem Soc 1995, V117, P8807 CAPLUS
- (5) Anthony, C; Biochim Biophys Acta 2003, V1647, P18 CAPLUS
- (6) Azuma, J; JP 2003270821 2003 CAPLUS
- (7) Bacon, R; Chem Commun 1967, P977 CAPLUS
- (8) Badesha, S; US 5166016 1992 CAPLUS
- (9) Balog, V; J Org Chem 1971, V36, P1339
- (10) Balogh-Hergovich, E; Synthesis 1982, P731 CAPLUS
- (11) Basavaiah, D; Tetrahedron Lett 2001, V42, P1147 CAPLUS
- (12) Bauer, R; Tetrahedron 1963, V19, P1201 CAPLUS
- (13) Becker, H; J Org Chem 1965, V30, P982 CAPLUS
- (14) Becker, H; J Org Chem 1982, V47, P1095 CAPLUS
- (15) Becker, H; Tetrahedron Lett 1976, P4883 CAPLUS
- (16) Bedell, S; J Am Chem Soc 1985, V107, P7909 CAPLUS
- (17) Benjamin, B; J Org Chem 1978, V43, P2986 CAPLUS
- (18) Bing, Y; Tetrahedron Lett 2004, V45, P6361 CAPLUS
- (19) Bodine, R; J Org Chem 1978, V43, P4025 CAPLUS
- (20) Bolton, J; Chem Res Toxicol 2000, V13, P135 CAPLUS
- (21) Bonhote, P; Synlett 1997, P897 CAPLUS
- (22) Bora, U; Tetrahedron 2001, V57, P2445 CAPLUS
- (23) Braven, J; J Heterocycl Chem 1995, V32, P1051 CAPLUS
- (24) Brink, G; J Org Chem 2001, V66, P2429
- (25) Brooks, H; Biochemistry 1993, V32, P2725 CAPLUS
- (26) Bruce, J; J Chem Soc, Perkin Trans 1 1974, P295 CAPLUS
- (27) Buchi, G; J Am Chem Soc 1985, V107, P5555 CAPLUS
- (28) Byrne, L; J Chem Soc, Perkin Trans 1 1982, P2855 CAPLUS
- (29) Chae, K; Steroids 1998, V63, P149 CAPLUS
- (30) Cho, A; Aerosol Sci Technol 2004, V38(Suppl 1), P68
- (31) Cisek, J; Tetrahedron Lett 2004, V45, P2801
- (32) Cook, C; J Am Chem Soc 1955, V77, P1783 CAPLUS
- (33) Cook, C; J Org Chem 1953, V18, P261 CAPLUS
- (34) Corey, E; J Am Chem Soc 1981, V103, P5599 CAPLUS
- (35) Cosgrove, S; J Chem Soc 1951, P388 CAPLUS
- (36) Cozzi, F; Org Biomol Chem 2003, V1, P157 CAPLUS
- (37) Crivello, J; J Org Chem 1981, V46, P3056 CAPLUS
- (38) DaRooge, M; J Org Chem 1967, V32, P1 CAPLUS
- (39) Davidson, V; Biochem J 1995, V308, P487 CAPLUS
- (40) Davidson, V; Biochemistry 1992, V31, P3385 CAPLUS
- (41) Dekker, R; Eur J Biochem 1982, V125, P69 CAPLUS
- (42) Denes, V; J Prakt Chem 1976, V318, P459 CAPLUS
- (43) Dickeson, G; Aust J Chem 1970, V23, P1023
- (44) Douglas, N; Synlett 1996, P793 CAPLUS
- (45) Druey, J; Helv Chim Acta 1950, V33, P1080 CAPLUS
- (46) Dudley, K; J Org Chem 1967, V32, P3210 CAPLUS
- (47) Duine, J; J Biosci Bioeng 1999, V88, P231 CAPLUS
- (48) Eckert, T; J Am Chem Soc 1983, V105, P4431 CAPLUS
- (49) Edelmann, M; Helv Chim Acta 2002, V85, P2195 CAPLUS
- (50) Edge, M; Polym Degrad Stab 1996, V53, P141 CAPLUS
- (51) Firouzabadi, H; Synthesis 1986, P285 CAPLUS
- (52) Firouzabadi, H; Synthesis 1986, P946 CAPLUS
- (53) Firouzabadi, H; Tetrahedron 1986, V42, P719 CAPLUS
- (54) Flowers-Geary, L; Chem-Biol Interact 1996, V99, P55 CAPLUS
- (55) Foster, E; Chem Commun (Cambridge) 2004, P2052 CAPLUS
- (56) Fouchard, D; J Org Chem 2004, V69, P2626 CAPLUS
- (57) Fujiyama, H; J Catal 1999, V188, P417 CAPLUS
- (58) Fukuzumi, S; J Am Chem Soc 2000, V122, P8435 CAPLUS
- (59) Gainor, J; J Org Chem 1981, V46, P4317 CAPLUS
- (60) Gainor, J; J Org Chem 1982, V47, P2833 CAPLUS
- (61) Garas, A; J Heterocycl Chem 2000, V37, P151 CAPLUS
- (62) Ge, Y; J Org Chem 2000, V65, P8831 CAPLUS
- (63) Goh, S; J Am Chem Soc 1973, V95, P242 CAPLUS

(64) Guo, H; Res Chem Intermed 1992, V17, P137 CAPLUS
(65) Gupta, R; Tetrahedron Lett 2000, V41, P7763 CAPLUS
(66) Hatchard, W; J Am Chem Soc 1958, V80, P3640
(67) Hav, A; US 3210384 1965 CAPLUS
(68) Hebri, H; Synlett 1991, P901 CAPLUS
(69) Hendrickson, J; J Org Chem 1982, V47, P1148 CAPLUS
(70) Hendrickson, J; J Org Chem 1985, V50, P1688 CAPLUS
(71) Hense, A; J Chem Soc, Perkin Trans 1 1997, P2023 CAPLUS
(72) Hewgill, F; J Chem Soc, Perkin Trans 1 1983, P131 CAPLUS
(73) Hewitt, D; J Chem Soc C 1971, P2967 CAPLUS
(74) Higashimura, H; JP 2002030026 2002 CAPLUS
(75) Higuchi, T; J Am Chem Soc 1995, V117, P8879 CAPLUS
(76) Hiort, C; J Am Chem Soc 1993, V115, P3448 CAPLUS
(77) Hirano, M; Bull Chem Soc Jpn 1991, V64, P1434 CAPLUS
(78) Hirao, T; Tetrahedron Lett 1990, V31, P6039 CAPLUS
(79) Horhold, H; Z Chem 1987, V27, P438
(80) Hu, J; J Org Chem 2005, V70, P707 CAPLUS
(81) Husain, M; Biochemistry 1987, V26, P4139 CAPLUS
(82) Hyun, Y; Biochemistry 1995, V34, P816 CAPLUS
(83) Imor, S; Synth Commun 1996, V26, P2197 CAPLUS
(84) Ishida, T; J Am Chem Soc 1989, V111, P6822 CAPLUS
(85) Ishida, T; J Am Chem Soc 1995, V117, P3278 CAPLUS
(86) Itoh, S; J Am Chem Soc 1993, V115, P9960 CAPLUS
(87) Itoh, S; J Am Chem Soc 1997, V119, P439 CAPLUS
(88) Itoh, S; J Chem Soc, Perkin Trans 2 1992, P1245 CAPLUS
(89) Itoh, S; J Org Chem 1992, V57, P2788 CAPLUS
(90) Itoh, S; J Org Chem 1992, V57, P4452 CAPLUS
(91) Itoh, S; J Org Chem 1996, V61, P8967 CAPLUS
(92) Iwai, K; Chem Lett 2003, V32, P58 CAPLUS
(93) Jacob, J; Inorg Chim Acta 1998, V270, P55 CAPLUS
(94) Jagnandan, I; J Pharm Sci 1979, V68, P916 CAPLUS
(95) Jerussi, R; J Org Chem 1970, V35, P2105 CAPLUS
(96) Jeyaraman, R; J Am Chem Soc 1984, V106, P2462 CAPLUS
(97) Jungclaus, G; Environ Sci Technol 1978, V12, P88 CAPLUS
(98) Kaplan, G; WO 2004018401 2004 CAPLUS
(99) Karnes, H; J Am Chem Soc 1968, V90, P458 CAPLUS
(100) Kasahara, T; Nature (London) 2003, V422, P832 CAPLUS
(101) Kawase, M; Tetrahedron 1989, V45, P1653 CAPLUS
(102) Kay, C; J Am Chem Soc 2005, V127, P7974 CAPLUS
(103) Kelly, J; J Org Chem 1986, V51, P4473 CAPLUS
(104) Kessler, H; Tetrahedron Lett 1966, P5257 CAPLUS
(105) Kikuchi, N; JP 9281728 1997 CAPLUS
(106) Kikuchi, N; JP 9281729 1997 CAPLUS
(107) Kikugawa, Y; Tetrahedron Lett 1988, V29, P4297 CAPLUS
(108) Kitahara, Y; Tetrahedron 1997, V53, P6001 CAPLUS
(109) Kitajima, N; J Am Chem Soc 1990, V112, P8833 CAPLUS
(110) Kloc, K; J Prakt Chem 1977, V319, P959 CAPLUS
(111) Komissarov, V; Izv Akad Nauk SSSR, Ser Khim 1991, V5, P1121
(112) Konig, K; Chem Ber 1960, V93, P554 CAPLUS
(113) Kovarova, J; Can J Chem 1995, V73, P1862 CAPLUS
(114) Kuhn, R; Chem Ber 1950, V83, P412
(115) Kumagai, Y; Free Radical Biol Med 1997, V22, P479 CAPLUS
(116) Kuwabata, S; J Am Chem Soc 1994, V116, P5437 CAPLUS
(117) Lantos, I; Tetrahedron Lett 1978, P2761 CAPLUS
(118) Lehr, R; J Org Chem 1978, V43, P3462 CAPLUS
(119) Leventhal, B; Food Sci 1976, V41, P467 CAPLUS
(120) Levin, J; J Org Chem 1984, V49, P4325 CAPLUS
(121) Levin, R; US 6080518 2000 CAPLUS
(122) Li, N; Environ Health Perspect 2003, V111, P455 CAPLUS
(123) Lin, L; US 2004096761 2004 CAPLUS
(124) Linsker, F; J Am Chem Soc 1946, V68, P403 CAPLUS

(125) Lissel, M; Tetrahedron Lett 1992, V33, P1795 CAPLUS
(126) Loy, B; J Org Chem 1966, V31, P2386 CAPLUS
(127) Magnusson, O; J Am Chem Soc 2004, V126, P5342 CAPLUS
(128) Magnusson, R; Acta Chem Scand 1966, V20, P2211 CAPLUS
(129) Mahjoub, A; Tetrahedron Lett 2003, V44, P4555 CAPLUS
(130) Mahoney, L; J Am Chem Soc 1967, V89, P5619 CAPLUS
(131) Margiotta, N; Inorg Chim Acta 2004, V357, P149 CAPLUS
(132) Martin, P; Helv Chim Acta 1994, V77, P100 CAPLUS
(133) Martin, P; Helv Chim Acta 1994, V77, P111 CAPLUS
(134) Matsuse, T; JP 6027693 1994 CAPLUS
(135) McLachlan, J; Steroids 1979, V33, P543 CAPLUS
(136) Meier, H; Eur J Org Chem 2001, P779 CAPLUS
(137) Menger, F; J Org Chem 1985, V50, P3927 CAPLUS
(138) Mervic, M; J Org Chem 1980, V45, P4720 CAPLUS
(139) Mincey, T; Biochemistry 1981, V20, P7502 CAPLUS
(140) Mirifico, M; J Electroanal Chem 2004, V566, P7 CAPLUS
(141) Miyamoto, E; JP 2002148834 2002 CAPLUS
(142) Mohr, B; J Org Chem 1994, V59, P635 CAPLUS
(143) Moore, R; J Chem Soc 1954, P243 CAPLUS
(144) Moriarty, R; Tetrahedron Lett 1975, P2557 CAPLUS
(145) Mure, M; Acc Chem Res 2004, V37, P131 CAPLUS
(146) Musgrave, O; J Chem Soc D 1970, P1461 CAPLUS
(147) Nakamori, H; EP 0591010 1994 CAPLUS
(148) Neureiter, N; J Org Chem 1963, V28, P3486 CAPLUS
(149) Nishino, H; J Chem Soc, Perkin Trans 2 1999, P1919 CAPLUS
(150) Noar, J; J Am Chem Soc 1985, V107, P7198 CAPLUS
(151) Nyquist, E; J Heterocycl Chem 1967, P539 CAPLUS
(152) Obare, S; Inorg Chem 2001, V40, P6080 CAPLUS
(153) Ohkura, K; JP 2000204083 2000 CAPLUS
(154) Okubo, H; J Org Chem 2001, V66, P557 CAPLUS
(155) Omura, K; J Am Oil Chem Soc 1992, V69, P461 CAPLUS
(156) Omura, K; J Am Oil Chem Soc 1995, V72, P1565 CAPLUS
(157) Omura, K; J Org Chem 1984, V49, P3046 CAPLUS
(158) Omura, K; J Org Chem 1991, V56, P921 CAPLUS
(159) Omura, K; J Org Chem 1992, V57, P306 CAPLUS
(160) Oyaizu, K; Chem Lett 2000, P1318 CAPLUS
(161) O'Brien, P; Chem-Biol Interact 1991, V80, P1 CAPLUS
(162) Pandey, G; IN 180089 1989 CAPLUS
(163) Pandey, G; Tetrahedron Lett 1990, V31, P3771 CAPLUS
(164) Paruch, K; J Org Chem 2000, V65, P7602 CAPLUS
(165) Pascal, R; J Am Chem Soc 1987, V109, P4660 CAPLUS
(166) Paw, W; Inorg Chem 1997, V36, P2287 CAPLUS
(167) Pelter, A; Tetrahedron Lett 1988, V29, P677 CAPLUS
(168) Plietker, B; Org Biomol Chem 2004, V2, P1116 CAPLUS
(169) Pospisil, J; Polym Degrad Stab 2002, V78, P251 CAPLUS
(170) Putala, M; Tetrahedron: Asymmetry 2001, V12, P3333
(171) Qian, W; J Am Chem Soc 2000, V122, P8333 CAPLUS
(172) Rabinovitz, M; J Org Chem 1987, V52, P3472
(173) Ranganathan, S; Tetrahedron 1984, V40, P3145 CAPLUS
(174) Ranganathan, S; Tetrahedron Lett 1985, V26, P4955 CAPLUS
(175) Rayne, S; Photochem Photobiol Sci 2005, P876 CAPLUS
(176) Rebelo, S; Chem Commun (Cambridge) 2004, P608 CAPLUS
(177) Rice, J; J Org Chem 1986, V51, P2428 CAPLUS
(178) Rockcliffe, D; J Chem Soc, Chem Commun 1992, P1758 CAPLUS
(179) Rodriguez, C; Chem-Biol Interact 2005, V155, P97 CAPLUS
(180) Rodriguez, E; J Am Chem Soc 1989, V111, P7947 CAPLUS
(181) Rubin, M; J Org Chem 1980, V45, P1847 CAPLUS
(182) Sain, B; Tetrahedron Lett 1994, V35, P5083 CAPLUS
(183) Sakamoto, T; J Org Chem 1994, V59, P6859 CAPLUS
(184) Salisbury, S; Nature (London) 1979, V280, P843 CAPLUS
(185) Schmidt, P; Helv Chim Acta 1957, V40, P350 CAPLUS

(186) Schroeter, S; J Org Chem 1969, V34, P4012 CAPLUS
 (187) Schuetzle, D; Int J Environ Anal Chem 1981, V9, P93 MEDLINE
 (188) Schulte-Frohlinde, D; Justus Liebigs Ann Chem 1964, V671, P92 CAPLUS
 (189) Seiglie, C; Steroids 1984, V43, P529 CAPLUS
 (190) Shimada, H; Chem Res Toxicol 2004, V17, P1145 CAPLUS
 (191) Simandi, L; J Mol Catal A: Chem 1997, V117, P299 CAPLUS
 (192) Sleath, P; J Am Chem Soc 1985, V107, P3328 CAPLUS
 (193) Smith, G; J Org Chem 1947, V12, P781 CAPLUS
 (194) Speck, M; J Chem Soc, Perkin Trans 2 2002, P455 CAPLUS
 (195) Srinivasan, R; Synth Commun 1997, V27, P2057 CAPLUS
 (196) Starnes, W; J Org Chem 1969, V34, P3404 CAPLUS
 (197) Taimr, L; Tetrahedron Lett 1971, P2809 CAPLUS
 (198) Taimr, L; Tetrahedron Lett 1972, P4279 CAPLUS
 (199) Takizawa, Y; J Org Chem 1985, V50, P4383 CAPLUS
 (200) Takuwa, A; J Org Chem 1997, V62, P2658 CAPLUS
 (201) Thomas, R; Carcinogenesis 2004, V25, P787 CAPLUS
 (202) Thomas, R; Int J Mol Med 2001, V7, P389 CAPLUS
 (203) Thomas, R; Oncol Rep 2001, V8, P1035 CAPLUS
 (204) Togashi, D; Synth Commun 1998, V28, P1051 CAPLUS
 (205) Tommasi, L; Inorg Chem 1995, V34, P1514 CAPLUS
 (206) Toshikazu, T; J Org Chem 1983, V48, P4764
 (207) Vakhitova, M; Izv Akad Nauk SSSR, Ser Khim 1987, V8, P1808
 (208) Villemin, D; Synlett 1994, P435
 (209) Vladimir, A; J Am Chem Soc 2001, V123, P5292
 (210) Wan, P; J Chem Soc, Chem Commun 1993, P409
 (211) Wang, X; Tetrahedron Lett 1991, V32, P4883 CAPLUS
 (212) Wang, Z; Angew Chem 2004, V116, P2006
 (213) Wang, Z; Angew Chem Int Ed 2004, V43, P1972 CAPLUS
 (214) Wang, Z; J Am Chem Soc 2004, V126, P7794 CAPLUS
 (215) Warncke, K; J Am Chem Soc 1993, V115, P6464 CAPLUS
 (216) Wenz, G; Makromol Chem, Rapid Commun 1985, V6, P577 CAPLUS
 (217) Wyllie, S; Arch Biochem Biophys 1997, V346, P180 CAPLUS
 (218) Xia, T; Environ Health Perspect 2004, V112, P1347 CAPLUS
 (219) Yamada, M; Bull Chem Soc Jpn 1992, V65, P1006 CAPLUS
 (220) Yamamoto, T; Macromolecules 2003, V36, P6722 CAPLUS
 (221) Yamazaki, S; Tetrahedron Lett 2001, V42, P3355 CAPLUS
 (222) Yang, C; Synlett 1992, P799 CAPLUS
 (223) Yohe, G; J Am Chem Soc 1953, V75, P2688 CAPLUS
 (224) Young, E; J Org Chem 1998, V63, P9995 CAPLUS
 (225) Zabik, M; J Org Chem 1967, V32, P300 CAPLUS
 (226) Zbiral, E; Monatsh Chem 1964, V95, P512 CAPLUS
 (227) Zhang, J; J Org Chem 1998, V63, P8125 CAPLUS
 (228) Zhang, J; Tetrahedron 1999, V55, P625 CAPLUS
 (229) Zhang, Z; Synthesis 1996, P377 CAPLUS

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:695873 CAPLUS

DOCUMENT NUMBER: 143:183097

TITLE: Contact charging type electrophotographic
 photoconductor showing excellent faulty image
 suppression, process cartridge, and
 electrophotographic apparatus

INVENTOR(S): Nagasaka, Hideaki; Sekido, Kunihiro; Sekiya, Michiyo;
 Miki, Nobumichi; Morikawa, Yosuke

PATENT ASSIGNEE(S): Canon Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005208618	A	20050804	JP 2004-373350	20041224
US 20060292469	A1	20061228	US 2005-159307	20050623
PRIORITY APPLN. INFO.:			JP 2003-434017	A 20031226
OTHER SOURCE(S): MARPAT 143:183097				
AN 2005:695873 CAPLUS				
DN 143:183097				
ED Entered STN: 05 Aug 2005				
TI Contact charging type electrophotographic photoconductor showing excellent faulty image suppression, process cartridge, and electrophotographic apparatus				
IN Nagasaka, Hideaki; Sekido, Kunihiro; Sekiya, Michiyo; Miki, Nobumichi; Morikawa, Yosuke				
PA Canon Inc., Japan				
SO Jpn. Kokai Tokkyo Koho, 44 pp.				
CODEN: JKXXAF				
DT Patent				
LA Japanese				
IC ICM G03G005-06				
CC 74-3 (Radiation Chemistry, Photochemistry, and Photographic and Other Reprographic Processes)				
FAN.CNT 2				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005208618	A	20050804	JP 2004-373350	20041224
US 20060292469	A1	20061228	US 2005-159307	20050623
PRAI JP 2003-434017	A	20031226		
CLASS				
PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES		
JP 2005208618	ICM	G03G005-06		
	IPCI	G03G0005-06 [ICM,7]		
	IPCR	G03G0005-06 [I,A]; G03G0005-06 [I,C*]		
	FTERM	2H068/AA14; 2H068/AA19; 2H068/AA34; 2H068/AA35; 2H068/BA39; 2H068/BA63; 2H068/BA64; 2H068/FA27		
US 20060292469	IPCI	G03G0005-047 [I,A]; G03G0005-043 [I,C*]		
	IPCR	G03G0005-043 [I,C]; G03G0005-047 [I,A]		
	NCL	430/059.400; 399/159.000; 430/059.100		
	ECLA	G03G005/06H6; G03G005/05C2D; G03G005/05C4B; G03G005/06B3; G03G005/06B5; G03G005/06B5B; G03G005/06D4B3; G03G005/10C; G03G005/14B		
OS MARPAT 143:183097				
AB The title electrophotog. photoconductor contains an electron transport material dispersed in a binder resin of a charge generation layer. The electron transport material shows a reduction potential between -0.8 and 0 V. The electron transport material may be selected from a specified naphthalenetetracarboxylic diimide compound, a specified phenanthrene compound, a specified phenanthroline compound, and a specified acenaphthoquinone compound. A charge generation material is Ga phthalocyanine, preferably hydroxygallium phthalocyanine.				
ST electrophotog photoconductor electron transport material process cartridge app				
IT Polyvinyl butyrals				
RL: DEV (Device component use); USES (Uses) (binder resin in charge generation layer of contact charging type electrophotog. photoconductor showing excellent faulty image suppression)				
IT Electrophotographic apparatus Electrophotographic photoconductors (photoreceptors)				

(contact charging type electrophotog. photoconductor showing excellent faulty image suppression, process cartridge, and electrophotog. apparatus)

IT 84-65-1, 9,10-Anthracenedione 809-73-4 20725-71-7 27318-90-7, 1,10-Phenanthroline-5,6-dione 27471-02-9 56403-67-9 56403-73-7 56961-98-9 171258-57-4 860806-49-1 860806-50-4
 RL: DEV (Device component use); USES (Uses)
 (electron transport material in charge generation layer of contact charging type electrophotog. photoconductor showing excellent faulty image suppression)

IT 63371-84-6P, Hydroxygallium phthalocyanine
 RL: DEV (Device component use); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of hydroxygallium phthalocyanine charge generation material for contact charging type electrophotog. photoconductor showing excellent faulty image suppression)

IT 91-15-6, 1,2-Benzenedicarbonitrile 13450-90-3, Gallium trichloride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of hydroxygallium phthalocyanine charge generation material for contact charging type electrophotog. photoconductor showing excellent faulty image suppression)

IT 19717-79-4P, Chlorogallium phthalocyanine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hydroxygallium phthalocyanine charge generation material for contact charging type electrophotog. photoconductor showing excellent faulty image suppression)

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:41818 CAPLUS
 DOCUMENT NUMBER: 140:119650
 TITLE: Charge transport compositions and electronic devices made with such compositions
 INVENTOR(S): Lecloux, Daniel David; Guidry, Mark A.; Herron, Norman; Radu, Nora S.; Smith, Eric Maurice; Wang, Ying
 PATENT ASSIGNEE(S): E.I. Du Pont De Nemours and Company, USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004006355	A2	20040115	WO 2003-US21618	20030709
WO 2004006355	A3	20040318		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040066135	A1	20040408	US 2003-612482	20030702
US 7265378	B2	20070904		
US 20040068115	A1	20040408	US 2003-612493	20030702

US 6962995	B2	20051108		
US 20040092687	A1	20040513	US 2003-612237	20030702
US 7074534	B2	20060711		
US 20040097725	A1	20040520	US 2003-612244	20030702
CA 2492692	A1	20040115	CA 2003-2492692	20030709
AU 2003247965	A1	20040123	AU 2003-247965	20030709
EP 1520305	A2	20050406	EP 2003-763463	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1666357	A	20050907	CN 2003-816185	20030709
CN 1666577	A	20050907	CN 2003-816188	20030709
CN 1668703	A	20050914	CN 2003-816415	20030709
CN 1668616	A	20050914	CN 2003-816462	20030709
JP 2005533343	T	20051104	JP 2004-520125	20030709
CN 1726603	A	20060125	CN 2003-816467	20030709
US 20040077860	A1	20040422	US 2003-612704	20031208
US 20050236980	A1	20051027	US 2005-155068	20050617
US 7119204	B2	20061010		
US 20070194698	A1	20070823	US 2007-676401	20070219
US 20070267968	A1	20071122	US 2007-835085	20070807

PRIORITY APPLN. INFO.:

US 2002-394767P	P	20020710
US 2003-458277P	P	20030328
US 2003-612244	B3	20030702
US 2003-612482	A3	20030702
US 2003-612493	A3	20030702
WO 2003-US21618	W	20030709

OTHER SOURCE(S): MARPAT 140:119650

AN 2004:41818 CAPLUS
 DN 140:119650
 ED Entered STN: 18 Jan 2004
 TI Charge transport compositions and electronic devices made with such compositions
 IN Lecloux, Daniel David; Guidry, Mark A.; Herron, Norman; Radu, Nora S.; Smith, Eric Maurice; Wang, Ying
 PA E.I. Du Pont De Nemours and Company, USA
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM H01L051-50
 ICS H01L051-30; C07D471-14; C07D241-46; C07D241-44; C07D241-42; C07D401-14; C07F007-08; C07F015-00; C07D519-00; C07D409-14
 CC 73-11 (Optical, Electron, and Mass Spectroscopy and Other Related Properties)
 Section cross-reference(s): 28, 72, 76

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004006355	A2	20040115	WO 2003-US21618	20030709
	WO 2004006355	A3	20040318		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20040066135	A1	20040408	US 2003-612482	20030702

US 7265378	B2	20070904		
US 20040068115	A1	20040408	US 2003-612493	20030702
US 6962995	B2	20051108		
US 20040092687	A1	20040513	US 2003-612237	20030702
US 7074534	B2	20060711		
US 20040097725	A1	20040520	US 2003-612244	20030702
CA 2492692	A1	20040115	CA 2003-2492692	20030709
AU 2003247965	A1	20040123	AU 2003-247965	20030709
EP 1520305	A2	20050406	EP 2003-763463	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1666357	A	20050907	CN 2003-816185	20030709
CN 1666577	A	20050907	CN 2003-816188	20030709
CN 1668703	A	20050914	CN 2003-816415	20030709
CN 1668616	A	20050914	CN 2003-816462	20030709
JP 2005533343	T	20051104	JP 2004-520125	20030709
CN 1726603	A	20060125	CN 2003-816467	20030709
US 20040077860	A1	20040422	US 2003-612704	20031208
US 20050236980	A1	20051027	US 2005-155068	20050617
US 7119204	B2	20061010		
US 20070194698	A1	20070823	US 2007-676401	20070219
US 20070267968	A1	20071122	US 2007-835085	20070807
PRAI US 2002-394767P	P	20020710		
US 2003-458277P	P	20030328		
US 2003-612244	B3	20030702		
US 2003-612482	A3	20030702		
US 2003-612493	A3	20030702		
WO 2003-US21618	W	20030709		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004006355	ICM	H01L051-50
	ICS	H01L051-30; C07D471-14; C07D241-46; C07D241-44; C07D241-42; C07D401-14; C07F007-08; C07F015-00; C07D519-00; C07D409-14
	IPCI	H01L0051-50 [ICM, 7]; H01L0051-30 [ICS, 7]; H01L0051-05 [ICS, 7, C*]; C07D0471-14 [ICS, 7]; C07D0471-00 [ICS, 7, C*]; C07D0241-46 [ICS, 7]; C07D0241-44 [ICS, 7]; C07D0241-42 [ICS, 7]; C07D0241-00 [ICS, 7, C*]; C07D0401-14 [ICS, 7]; C07D0401-00 [ICS, 7, C*]; C07F0007-08 [ICS, 7]; C07F0007-00 [ICS, 7, C*]; C07F0015-00 [ICS, 7]; C07D0519-00 [ICS, 7]; C07D0409-14 [ICS, 7]; C07D0409-00 [ICS, 7, C*]
	IPCR	H01L0051-50 [I, C*]; H01L0051-50 [I, A]; C07C0211-00 [I, C*]; C07C0211-49 [I, A]; C07C0211-52 [I, A]; C07C0211-54 [I, A]; C07C0215-00 [I, C*]; C07C0215-74 [I, A]; C07C0217-00 [I, C*]; C07C0217-80 [I, A]; C07C0255-00 [I, C*]; C07C0255-58 [I, A]; C07D0209-00 [I, C*]; C07D0209-86 [I, A]; C07D0213-00 [I, C*]; C07D0213-38 [I, A]; C07D0241-00 [I, C*]; C07D0241-38 [I, A]; C07D0241-40 [I, A]; C07D0241-42 [I, A]; C07D0401-00 [I, C*]; C07D0401-14 [I, A]; C07D0409-00 [I, C*]; C07D0409-14 [I, A]; C07D0471-00 [I, C*]; C07D0471-04 [I, A]; C07D0471-14 [I, A]; C07D0487-00 [I, C*]; C07D0487-04 [I, A]; C07D0519-00 [I, C*]; C07D0519-00 [I, A]; C07F0007-00 [I, C*]; C07F0007-21 [I, A]; C07F0015-00 [I, C*]; C07F0015-00 [I, A]; C08G0061-00 [I, C*]; C08G0061-00 [I, A]; C08G0061-12 [I, A]; C08K0005-00 [I, C*]; C08K0005-18 [I, A]; C08L0065-00 [I, C*]; C08L0065-00 [I, A]; C08L0083-00 [I, C*]; C08L0083-08 [I, A]; C09B0011-00 [I, C*];

C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]

US 20040066135 ECLA C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; H01L051/00M6H14; H01L051/00M16; T01L; T01L; T01L; T01L; T01L; T01L; M07D; M07D

US 20040066135 IPCI H01L0051-00 [I,A]

US 20040066135 IPCR H01L0051-00 [N,C*]; H01L0051-00 [N,A]; H01L0051-05 [N,C*]; H01L0051-30 [N,A]; H01L0051-50 [I,C*]; H01L0051-50 [I,A]

NCL 313/503.000; 428/690.000; 257/040.000; 136/263.000; 257/431.000; 257/E51.049; 313/504.000; 313/506.000; 428/917.000

US 20040068115 ECLA H01L051/50E3; H01L051/50G; T01L; T01L

US 20040068115 IPCI C07D0471-04 [ICM,7]; C07D0471-02 [ICS,7]; C07D0471-00 [ICS,7]

US 20040068115 IPCR C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C08G0061-00 [I,C*]; C08G0061-12 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H01L0051-50 [N,C*]; H01L0051-50 [N,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]

NCL 546/088.000; 546/081.000

ECLA C07D209/86; C07D213/38; C08G061/12D; C08G061/12D1B; C08L065/00; H01L051/30D6; H01L051/30H4; H01L051/30H6; H01L051/30H8; H01L051/30S; C09K011/06; C07D471/04+221A+221A; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14

US 20040092687 IPCI G03G0005-04 [I,A]; C07D0241-38 [I,A]; C07D0241-00 [I,C*]; C08F0032-08 [I,A]; C08F0032-00 [I,C*]; C08F0132-08 [I,A]; C08F0132-00 [I,C*]

US 20040092687 IPCR C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C08G0061-00 [I,C*]; C08G0061-12 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H01L0051-50 [N,C*]; H01L0051-50 [N,A]

NCL 526/259.000; 430/076.000; 428/917.000; 430/096.000; 544/349.000; 544/353.000; 548/428.000

ECLA C07D209/86; C07D213/38; C08G061/12D; C08G061/12D1B; C08L065/00; H01L051/30D2; H01L051/30D6; H01L051/30H4; H01L051/30H6; H01L051/30H8; H01L051/30S; H01L051/00M2B; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16

US 20040097725 IPCI C09B0011-04 [ICM,7]; C09B0011-00 [ICM,7,C*]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]

US 20040097725 IPCR C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C08G0061-00 [I,C*]; C08G0061-12 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H01L0051-50 [N,C*]; H01L0051-50 [N,A]

	NCL	540/472.000; 552/101.000
	ECLA	T01L; T01L; T01L
CA 2492692	IPCI	H01L0051-00 [ICM,7]; C07D0519-00 [ICS,7]; C07F0015-00 [ICS,7]; C07F0007-08 [ICS,7]; C07F0007-00 [ICS,7,C*]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; H01L0051-30 [ICS,7]; H01L0051-05 [ICS,7,C*]; C07D0241-42 [ICS,7]; C07D0241-44 [ICS,7]; C07D0241-46 [ICS,7]; C07D0241-00 [ICS,7,C*]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
AU 2003247965	IPCI	C07F0015-00 [ICM,7]; C07D0519-00 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; H01L0051-30 [ICS,7]; H01L0051-05 [ICS,7,C*]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; C07D0241-46 [ICS,7]; C07D0241-44 [ICS,7]; C07D0241-42 [ICS,7]; C07D0241-00 [ICS,7,C*]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07F0007-08 [ICS,7]; C07F0007-00 [ICS,7,C*]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];


		C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
EP 1520305	IPCI	H01L0051-00 [ICM,7]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
CN 1666357	IPCI	H01L0051-30 [ICM,7]; H01L0051-05 [ICM,7,C*]; C08G0061-00 [ICS,7]; C08G0061-12 [ICS,7]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12

		[I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
CN 1666577	IPCI	H05B0033-14 [ICM,7]; H01L0051-30 [ICS,7]; H01L0051-05 [ICS,7,C*]; H01L0027-00 [ICS,7]; C09K0011-06 [ICS,7]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
CN 1668703	IPCI	C09B0011-00 [ICM,7]; C09K0011-06 [ICS,7]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00

		[I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
CN 1668616	IPCI	C07D0471-04 [ICM,7]; C07D0471-00 [ICM,7,C*]; C07F0015-00 [ICS,7]; H01L0051-00 [ICS,7]; C09K0011-06 [ICS,7]
	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	ECLA	C07D241/42; C07C211/49; C07C211/52; C07C211/54; C07C215/74; C07C217/80; C07C255/58; C07D209/86; C07D213/38; C07D241/38B; C07D401/14; C07D401/14R; C07D409/14; C07D471/04+221A+221A; C07D471/14+241A+221A+221A; C07D487/04+241B+239B; C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B; C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
JP 2005533343	IPCI	H05B0033-22 [ICM,7]; H05B0033-14 [ICS,7]; C07D0241-40 [ICS,7]; C07D0241-00 [ICS,7,C*]; C07F0007-21 [ICS,7]; C07F0007-00 [ICS,7,C*]; C07F0015-00 [ICS,7]

	IPCR	H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00 [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A]; C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74 [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A]; C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21 [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A]; C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12 [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00 [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*]; C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
	FTERM	3K007/AB03; 3K007/DB03; 4H049/VN01; 4H049/VP02; 4H049/VQ67; 4H049/VQ78; 4H049/VR23; 4H049/VR41; 4H049/VU29; 4H049/VW02; 4H050/AA03; 4H050/AB91; 4H050/WB11; 4H050/WB14; 4H050/WB21
CN 1726603	IPCI	H01L0051-00 [I,A]; H01L0051-30 [I,A]; H01L0051-05 [I,C*]; C07D0471-14 [I,A]; C07D0471-00 [I,C*]; C07D0241-46 [I,A]; C07D0241-44 [I,A]; C07D0241-42 [I,A]; C07D0241-00 [I,C*]; C07D0401-14 [I,A]; C07D0401-00 [I,C*]; C07F0007-08 [I,A]; C07F0007-00 [I,C*]; C07F0015-00 [I,A]
	IPCR	H01L0051-00 [I,A]; H01L0051-00 [I,C]
US 20040077860	IPCI	A61K0031-498 [ICM,7]; C07D0043-02 [ICS,7]; C07D0241-36 [ICS,7]; C07D0241-00 [ICS,7,C*]
	IPCR	C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38 [I,A]; C07D0241-42 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0403-00 [I,C*]; C07D0403-04 [I,A]; C07D0409-00 [I,C*]; C07D0409-04 [I,A]; C07D0471-00 [I,C*]; C07D0471-16 [I,A]; C07D0475-00 [I,C*]; C07D0475-00 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-08 [I,A]; C08G0061-00 [I,C*]; C08G0061-12 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H01L0051-50 [N,C*]; H01L0051-50 [N,A]
	NCL	544/353.000; 257/E51.051
	ECLA	C07D409/04; C07D209/86; C07D213/38; C07D241/38B; C07D241/42; C07D401/04; C07D403/04; C07D471/16+241B+221B+221B+2; C07D475/00; C07D519/00+471/00+471/00; C07F007/08D4H4F; C08G061/12D; C08G061/12D1B; C08L065/00; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16
US 20050236980	IPCI	C07D0471-02 [I,A]; C07D0471-00 [I,A]
	IPCR	C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C08G0061-00 [I,C*]; C08G0061-12

[I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A];
 C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0051-00
 [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*];
 H01L0051-30 [I,A]; H01L0051-50 [N,C*]; H01L0051-50
 [N,A]; H05B0033-14 [I,C*]; H05B0033-14 [I,A]
 NCL 313/504.000; 546/002.000; 546/088.000; 546/081.000
 ECLA C09K011/06; C07D209/86; C07D213/38;
 C07D471/04+221A+221A; C08G061/12D; C08G061/12D1B;
 C08L065/00; H01L051/00M2F; H01L051/00M6D;
 H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
 US 20070194698 IPCI H01J0001-62 [I,A]; H01J0001-00 [I,C*]; H01J0063-04
 [I,A]; H01J0063-00 [I,C*]; H01L0051-00 [I,A]
 IPCR H01J0001-00 [I,C]; H01J0001-62 [I,A]; C07D0209-00
 [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*];
 C07D0213-38 [I,A]; C08G0061-00 [I,C*]; C08G0061-12
 [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A];
 H01J0063-00 [I,C]; H01J0063-04 [I,A]; H01L0051-00
 [I,C]; H01L0051-00 [I,A]; H01L0051-05 [I,C*];
 H01L0051-30 [I,A]; H01L0051-50 [N,C*]; H01L0051-50
 [N,A]
 NCL 313/504.000; 257/040.000
 ECLA C07D213/38; C07D209/86; C08G061/12D; C08G061/12D1B;
 C08L065/00; H01L051/00M6; H01L051/00M6F;
 H01L051/00M6H14; H01L051/00M16; T01L; T01L; T01L
 US 20070267968 IPCI H01J0063-02 [I,A]; H01J0063-00 [I,C*]
 IPCR H01J0063-00 [I,C]; H01J0063-02 [I,A]; H01L0051-00
 [N,C*]; H01L0051-00 [N,A]; H01L0051-05 [N,C*];
 H01L0051-30 [N,A]; H01L0051-50 [I,C*]; H01L0051-50
 [I,A]
 NCL 313/503.000
 ECLA H01L051/50E3; H01L051/50G; T01L; T01L
 OS MARPAT 140:119650
 GI



- AB Compns. are described which comprise quinoxaline derivs. described by the
 general formula I (R1 and R2 are the same or different at each occurrence
 and are selected from H, F, Cl, Br, alkyl, heteroalkyl, alkenyl, alkynyl,
 aryl, heteroaryl, alkylenearyl, alkenylaryl, alkynylaryl,
 alkyleneheteroaryl, alkenylheteroaryl, alkynylheteroaryl, CnHaFb, OCnHaFb,
 C6HcFd, and OC6HcFd; both R2 together may constitute an arylene or
 heteroarylene group; a, b, c, and d = 0 or an integer such that a+b = 2n +
 1, and c + d = 5; n = an integer; and z = 0-4). Electronic devices (e.g.,
 light-emitting diodes, light-emitting electrochem. cells, or
 photodetectors) comprising ≥ 1 photoactive layer and a second layer
 are also described in which ≥ 1 layer comprises the quinoxaline
 derivs.
 ST quinoxaline deriv compn electronic device; electroluminescent device
 quinoxaline deriv; photodetector quinoxaline deriv; light emitting
 electrochem cell quinoxaline deriv
 IT Electrochemical cells
 (light-emitting; quinoxaline derivative-containing compns. and electronic

devices made using them)

IT Electroluminescent devices
Optical detectors
(quinoxaline derivative-containing compns. and electronic devices made using them)

IT 647375-47-1P
RL: DEV (Device component use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(quinoxaline derivative-containing compns. and electronic devices made using them)

IT 4559-60-8P 17401-62-6P 19802-70-1P 32387-86-3P 36305-56-3P
36305-63-2P 112657-94-0P 205367-28-8P 364067-15-2P 370851-72-2P
410526-67-9P 647375-50-6P 647375-53-9P 647375-59-5P 647375-61-9P
647375-62-0P 647375-63-1P 647375-64-2P 647375-65-3P 647375-66-4P
647375-67-5P 647375-68-6P 647375-69-7P
RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(quinoxaline derivative-containing compns. and electronic devices made using them)

IT 84-11-7, Phenanthrene quinone 95-54-5, 1,2-Phenylenediamine, reactions 128-37-0, 2,6-Di-tert-butyl-p-cresol, reactions 134-81-6, Benzil 492-73-9, 2,2'-Pyridil 496-72-0, 3,4-Diaminotoluene 766-98-3, 4-Fluorophenylacetylene 1226-42-2, 4,4'-Dimethoxybenzil 1746-23-2 1765-93-1, 4-Fluorophenylboronic acid 2050-89-7, [1,1'-Biphenyl]-3,3'-diamine 2627-95-4, 1,3-Divinyltetramethyldisiloxane 2687-25-4, 2,3-Diaminotoluene 3141-27-3 3171-45-7, 4,5-Dimethyl-1,2-phenylenediamine 3363-97-1 4612-26-4 10025-83-9, Iridium trichloride 27318-90-7, 1,10-Phenanthroline-5,6-dione 35578-47-3, 4,4'-Dibromobenzil 36692-49-6, Methyl 3,4-diaminobenzoate 52334-81-3, 2-Chloro-5-trifluoromethylpyridine 647375-45-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(quinoxaline derivative-containing compns. and electronic devices made using them)

IT 370878-58-3P 647375-70-0P 647375-71-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(quinoxaline derivative-containing compns. and electronic devices made using them)

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:628032 CAPLUS

DOCUMENT NUMBER: 138:4578

TITLE: Dramatically enhanced fluorescence of heteroaromatic chromophores upon insertion as spacers into oligo(triacetylene)s

AUTHOR(S): Edelmann, Michael J.; Raimundo, Jean-Manuel; Utesch, Nils F.; Diederich, Francois

CORPORATE SOURCE: Lab. Organische Chemie, ETH-Hoenggerberg, HCI, Zurich, CH-8093, Switz.

SOURCE: Helvetica Chimica Acta (2002), 85(7), 2195-2213
CODEN: HCACAV; ISSN: 0018-019X

PUBLISHER: Verlag Helvetica Chimica Acta

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:4578


AN 2002:628032 CAPLUS

DN 138:4578

ED Entered STN: 21 Aug 2002

TI Dramatically enhanced fluorescence of heteroaromatic chromophores upon insertion as spacers into oligo(triacetylene)s

AU Edelmann, Michael J.; Raimundo, Jean-Manuel; Utesch, Nils F.; Diederich, Francois
 CS Lab. Organische Chemie, ETH-Hoenggerberg, HCI, Zurich, CH-8093, Switz.
 SO Helvetica Chimica Acta (2002), 85(7), 2195-2213
 CODEN: HCACAV; ISSN: 0018-019X
 PB Verlag Helvetica Chimica Acta
 DT Journal
 LA English
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 22, 72, 73, 78
 OS CASREACT 138:4578
 GI



AB In continuation of a previous study on the modulation of π -electron conjugation of oligo(triacetylene)s by insertion of central hetero-spacer fragments between two (E)-hex-3-ene-1,5-diyne ((E)-1,2-diethynylethene, DEE) moieties, trimeric hybrid oligomers (I; A = spacer, R = SiEt₃, SiMe₃) were prepared. Spacers used were both electron-deficient (quinoxaline-based heterocycles, pyridazine) and electron-rich (2,2'-bithiophene, 9,9-dioctyl-9H-fluorene) chromophores. With a dipyrrophenazine spacer, transition metal complexes were synthesized as potential precursors for nanoscale scaffolding based on both covalent acetylenic coupling and supramol. assembly. The UV/visible spectra revealed that the majority of spacers provided heterotrimers featuring extended π -electron delocalization. The new hybrid chromophores show a dramatically enhanced fluorescence compared with the DEE dimer and homo-trimer. This increase in emission intensity appears as a general feature of these systems: even if the spacer mol. is nonfluorescent, the corresponding hetero-trimer may show a strong emission. The redox properties of the new hybrid chromophores were determined by cyclic voltammetry (CV) and rotating disk voltammetry (RDV). In each case, the first 1-electron reduction step in the hetero-trimers appeared anodically shifted compared with DEE dimer and homo-trimer. With larger spacer chromophore extending into two dimensions, the anodic shift (by 240-490 mV) seems to originate from inductive effects of the two strongly electron-accepting DEE substituents rather than from extended π -electron conjugation along the oligomeric backbone, as had previously been observed for DEE substituted porphyrins.

ST hexenediyne benzopyrazine benzothiadiazole phenazine bithiophene pyridazine fluorene prepn fluorescence; benzopyrazine hexenediyne prepn fluorescence electrochem; benzothiadiazole hexenediyne prepn fluorescence electrochem; phenazine hexenediyne prepn fluorescence electrochem; bithiophene hexenediyne prepn fluorescence electrochem; fluorene hexenediyne prepn fluorescence electrochem; transition metal dipyrrophenazine prepn fluorescence electrochem

IT Fluorescence
 Oxidation, electrochemical
 Redox potential

Reduction, electrochemical
 (preparation, electrochem. properties and dramatically enhanced fluorescence
 of compds. consisting of heteroarom. chromophores inserted as spacers
 into oligo(triacetylene)s)

IT Transition metal complexes
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical
 process); PRP (Properties); SPN (Synthetic preparation); PREP
 (Preparation); PROC (Process)
 (preparation, electrochem. properties and dramatically enhanced fluorescence
 of compds. consisting of heteroarom. chromophores inserted as spacers
 into oligo(triacetylene)s)

IT 198277-07-5 198277-13-3
 RL: PRP (Properties)
 (fluorescence and redox potentials)

IT 273-13-2, 2,1,3-Benzothiadiazole
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical
 process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant
 or reagent)
 (fluorescence, electrochem. properties and reactant for preparation of
 compds. having enhanced fluorescence consisting of heteroarom.
 chromophores inserted as spacers into oligo(triacetylene)s)

IT 15155-41-6P 27318-90-7P, 1,10-Phenanthroline
 -5,6-dione 69272-50-0P,
 3,6-Dibromobenzene-1,2-diamine 94544-77-1P 148231-12-3P 200503-12-4P
 285129-85-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate product in preparation of compds. having enhanced fluorescence
 consisting of heteroarom. chromophores inserted as spacers into
 oligo(triacetylene)s)

IT 19535-47-8P, Dipyrido[3,2-a:2',3'-c]phenazine
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and redox potentials)

IT 477293-98-4P 477293-99-5P 477294-00-1P 477294-01-2P 477294-02-3P
 477294-04-5P 477294-06-7P 477294-08-9P 477294-09-0P 477294-10-3P
 477294-11-4P
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical
 process); PRP (Properties); SPN (Synthetic preparation); PREP
 (Preparation); PROC (Process)
 (preparation, electrochem. properties and dramatically enhanced fluorescence
 of compds. consisting of heteroarom. chromophores inserted as spacers
 into oligo(triacetylene)s)

IT 108-31-6, 2,5-Furandione, miscellaneous 111-83-1 123-33-1 141-30-0
 492-97-7, 2,2'-Bithiophene 16433-88-8
 RL: MSC (Miscellaneous)
 (preparation, electrochem. properties and dramatically enhanced fluorescence
 of compds. consisting of heteroarom. chromophores inserted as spacers
 into oligo(triacetylene)s)

IT 66-71-7, 1,10-Phenanthroline 84-11-7, Phenanthrene-9,10-dione
 95-54-5, Benzene-1,2-diamine, reactions 107-22-2, Glyoxal 134-81-6,
 Benzil 3339-80-8, 5,5'-Diiodo-2,2'-bithiophene 20698-04-8,
 3,6-Diiodopyridazine 177500-78-6 198964-46-4, 2,7-Dibromo-9,9-
 dioctylfluorene 309721-72-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant for preparation of compds. having enhanced fluorescence consisting
 of heteroarom. chromophores inserted as spacers into
 oligo(triacetylene)s)

IT 91-19-0, Benzopyrazine 1684-14-6
 RL: PRP (Properties)
 (redox potentials)

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Albota, M; Science 1998, V281, P1653 CAPLUS
- (2) Amouyal, E; J Chem Soc, Dalton Trans 1990, V19, P1841
- (3) Bard, A; ` Electrochemical Methods:Fundamentals and Applications' 1980, P488
- (4) Birckner, E; J Phys Chem A 2001, V105, P10307 CAPLUS
- (5) Chung, S; J Phys Chem B 1999, V103, P10741 CAPLUS
- (6) Diaz, R; Tetrahedron Lett 2001, V42, P6463 CAPLUS
- (7) Dickeson, J; Aust J Chem 1970, V23, P1023 CAPLUS
- (8) Dieck, H; J Organomet Chem 1975, V93, P259 CAPLUS
- (9) Dorr, F; Ber Bunsen-Ges Phys Chem 1963, V67, P193
- (10) Druey, J; Helv Chim Acta 1950, V33, P1080 CAPLUS
- (11) Edelmann, M; Chimia 2001, V55, P132 CAPLUS
- (12) Edelmann, M; Helv Chim Acta 2001, V84, P473 CAPLUS
- (13) Guilbault, G; ` Practical Fluorescence' 1990, P1
- (14) Halkyard, C; Macromolecules 1998, V31, P8655 CAPLUS
- (15) Hay, A; J Org Chem 1962, V27, P3320 CAPLUS
- (16) Huheey, J; ` Anorganische Chemie Prinzipien von Struktur und Reaktivitat' 1988
- (17) Kraft, A; Angew Chem 1998, V110, P416
- (18) Kraft, A; Angew Chem, Int Ed 1998, V37, P402
- (19) Lopez, R; Tetrahedron Lett 1996, V37, P5437
- (20) Martin, R; Chem - Eur J 1997, V3, P1505 CAPLUS
- (21) Martin, R; Chem - Eur J 2000, V6, P3622 CAPLUS
- (22) Martin, R; Helv Chim Acta 1999, V82, P1470 CAPLUS
- (23) Meerholz, K; Electrochim Acta 1996, V41, P1839 CAPLUS
- (24) Miller, L; J Org Chem 1995, V60, P6813 CAPLUS
- (25) Miteva, T; Macromolecules 2000, V33, P652 CAPLUS
- (26) Mizzoni, R; J Am Chem Soc 1951, V73, P1873 CAPLUS
- (27) Moody, C; Tetrahedron 1992, V48, P3589 CAPLUS
- (28) Osipov, V; Teor Eksp Khim 1978, V14, P703 CAPLUS
- (29) Osipov, V; Theor Exp Chem 1978, V14, P549
- (30) Pilgram, K; J Heterocycl Chem 1970, V7, P629 CAPLUS
- (31) Rtishchev, N; Russ J Gen Chem 1999, V69, P1658 CAPLUS
- (32) Rtishchev, N; Zh Obshch Khim 1999, V69, P1731
- (33) Setayesh, S; J Am Chem Soc 2001, V123, P946 CAPLUS
- (34) Setayesh, S; Macromolecules 2000, V33, P2016 CAPLUS
- (35) Shin, M; J Heterocycl Chem 1999, V36, P1135 CAPLUS
- (36) Siemsen, P; Angew Chem 2000, V112, P2740
- (37) Siemsen, P; Angew Chem, Int Ed 2000, V39, P2632 CAPLUS
- (38) Skoog, D; ` Molekulfluoreszenz-, Phosphoreszenz- und Chemilumineszenzspektroskopie' 1996
- (39) Sonogashira, K; ` Metalcatalyzed Cross-coupling Reactions' 1998, P203 CAPLUS
- (40) Takahashi, S; Synthesis 1980, P627 CAPLUS
- (41) Tsubata, Y; J Org Chem 1992, V57, P6749 CAPLUS
- (42) Tykwinski, R; Helv Chim Acta 1996, V79, P2249 CAPLUS
- (43) Wytko, J; Helv Chim Acta 1998, V81, P1964 CAPLUS
- (44) Yamada, M; Bull Chem Soc Jpn 1992, V65, P1006 CAPLUS

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	164.00	198.65
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.20	-7.20

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2
DICTIONARY FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> STR 27318-90-7

:END

L18 STRUCTURE CREATED

=> S L18 FAM SAM

SAMPLE SEARCH INITIATED 10:17:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6 TO 266
PROJECTED ANSWERS: 1 TO 80

L19 1 SEA FAM SAM L18

=>

=> D SCAN

L19 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,10-Phenanthroline-5,6-dione, radical ion(2+) (9CI)
MF C12 H6 N2 O2
CI RIS



ALL ANSWERS HAVE BEEN SCANNED

=> SET SMA OFF

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L15 2

L15 WAS CREATED DURING MULTIFILE PROCESSING AND CANNOT BE USED WHEN CREATING E#S
Enter SET SMARTSELECT ON before using SELECT to create an L-number of
terms extracted from an L-number that contains answers or terms from
more than one file. SET SMARTSELECT ON must be entered before you
execute the SELECT command.

=> SET SMA ON

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L15 2

SmartSELECT INITIATED

New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

NO ANSWERS SELECTED.

THE ANSWER SET WAS CREATED IN FILES 'CAPLUS, MEDLINE, EMBASE, BIOSIS'.
USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILES.
To use the SELECT command, you must be in the same file environment
in which the answer set was created.

=>

=> FIL

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.98	204.63
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-7.20

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

=> SEL RAN.CAPLUS(1) L15 2

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND

command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162
L3 22 S L2 AND DIONE
L4 0 S L2 AND PHENANTHROLINEDIONE
L5 2 S L2 AND PHENANTHROLINE
L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008

L7 224329 S L2
L8 13877 S L3
L9 406 S L5
L10 224329 S L7 OR L8 OR L9
L11 3300 S 10 AND ANTIANGIOGENIC
L12 56 S L11 AND ISCHEMIA
L13 28 S L11 AND ("HEART DISEASE")
L14 2 S L13 AND L12
L15 7 S (L3 OR L5) AND ANTIANGIOGENIC
L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"
L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

L18 STR 27318-90-7
L19 1 S L18 FAM SAM
SET SMA OFF
SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

=> s "1,4-naphthalenedione?"

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file medline caplus embase biosis scisearch

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	205.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.20

FILE 'MEDLINE' ENTERED AT 10:26:36 ON 11 JUN 2008

FILE 'CAPLUS' ENTERED AT 10:26:36 ON 11 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:26:36 ON 11 JUN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:26:36 ON 11 JUN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 10:26:36 ON 11 JUN 2008
Copyright (c) 2008 The Thomson Corporation

=> s ("1,4-naphthalenedione?")
L20 1303 ("1,4-NAPHTHALENEDIONE?")

=> s l20 and (treat or treatment or treating)
L21 129 L20 AND (TREAT OR TREATMENT OR TREATING)

=> s l21 and ("heart attack")
L22 0 L21 AND ("HEART ATTACK")

=> s l21 and ("myocardial infarction")
2 FILES SEARCHED...
L23 0 L21 AND ("MYOCARDIAL INFARCTION")

=> s l21 and ischemia
L24 4 L21 AND ISCHEMIA

=> d scan l24

L24 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 1-8 (Pharmacology)
TI Effect of venotropic drugs on the respiratory activity of isolated mitochondria and in endothelial cells
ST venotropic mitochondrion respiration vascular endothelium hypoxia; venous insufficiency mitochondrion respiration ischemia venotropic; oxidative phosphorylation venotropic ATP mitochondria
IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ADP/ATP carrier; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)
IT Anti-ischemic agents
Hypoxia, animal
Oxidative phosphorylation, biological
(effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)
IT Blood vessel
(endothelium; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)
IT Sweet clover (*Melilotus officinalis*)
(exts.; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)
IT Vein
(insufficiency; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)
IT Respiration, animal
(mitochondrial; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT Procyanidins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (procyanidolic oligomers; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT Mitochondria
 (respiration; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT Cardiovascular agents
 (venotropics; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT 130-15-4, 1,4-Naphthalenedione 153-18-4D, Rutoside, Hydroxyethyl derivs. 372-66-7, Ginkor Fort 520-27-4, Diosmin 6805-41-0, Aescine 31329-57-4, Naftidrofuryl 205886-26-6, Cyclo 3 Fort
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT 56-65-5, 5'-ATP, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L24 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM C07D

CC 1-12 (Pharmacology)

TI Quinone compound cysteine protease inhibitors, and therapeutic use

ST quinone compd cysteine protease inhibitor therapeutic; infectious disease treatment quinone compd cysteine protease inhibitor; caspase inhibitor quinone compd therapeutic

IT Nervous system, disease
 (Huntington's chorea; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Biliary tract, disease
 Inflammation
 (cholangitis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Inflammation
 Intestine, disease
 (colitis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cysteine protease-like, inhibitors; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Nervous system, disease
 (degeneration; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Biological transport
 (drug; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Disease, animal
 (endocerolitis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Allergy
 (hypersensitivity; quinone compound cysteine protease inhibitors, and

therapeutic use)

IT Virus
(immunodeficiency; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Heart, disease
(infarction; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Nerve, disease
Reperfusion
Spinal cord, disease
(injury; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Drug delivery systems
(nasal; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Injury
(neuronal; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Transplant and Transplantation
(organ damage; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Inflammation
Pancreas, disease
(pancreatitis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Alopecia
Alzheimer's disease
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antidiabetic agents
Antiparkinsonian agents
Antiviral agents
Apoptosis
Arthritis
Autoimmune disease
Blood-brain barrier
Cardiovascular agents
Cardiovascular system, disease
Diabetes mellitus
Drug delivery systems
Encephalitis
Hepatitis
Hepatitis virus
Immune disease
Immunodeficiency
Inflammation
Influenza virus
Ischemia
Multiple sclerosis
Nervous system, disease
Nervous system agents
Parkinson's disease
Picornaviridae
QSAR (quantitative structure-activity relationship)
Rhinovirus
Spinal muscular atrophy
(quinone compound cysteine protease inhibitors, and therapeutic use)

IT Injury
(reperfusion; quinone compound cysteine protease inhibitors, and

therapeutic use)

IT Injury
(spinal cord; quinone compound cysteine protease inhibitors, and
therapeutic use)

IT Brain, disease
(stroke; quinone compound cysteine protease inhibitors, and therapeutic
use)

IT Reducing agents
(sulfur reducing agents; quinone compound cysteine protease inhibitors,
and therapeutic use)

IT Multiple sclerosis
(therapeutic agents; quinone compound cysteine protease inhibitors, and
therapeutic use)

IT Infection
(viral; quinone compound cysteine protease inhibitors, and therapeutic
use)

IT 9001-73-4, Papain 9002-07-7, Trypsin 9004-07-3, α -Chymotrypsin
37353-41-6, Cysteine protease 97162-88-4, 3C Protease 169592-56-7,
Caspase 3 186322-81-6, Caspase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(quinone compound cysteine protease inhibitors, and therapeutic use)

IT 58-27-5 70-18-8, Glutathione, biological studies 70-18-8D,
Glutathione, adducts with naphthoquinone derivs. 81-54-9 81-64-1
83-61-4 84-79-7 116-85-8 117-80-6 130-15-4, 1,4-
-Naphthalenedione 130-15-4D, 1,4-
Naphthalenedione, derivs. adducts 389-08-2, Nalidixic acid
389-08-2D, Nalidixic acid, derivs. 475-38-7 480-40-0 481-39-0
481-42-5 517-88-4D, derivs. 517-88-4D, Alkannin, naphthoquinone
derivs. 517-89-5, Shikonin 517-89-5D, derivs. 517-89-5D, Shikonin,
naphthoquinone derivs. 520-36-5 569-77-7 583-63-1D,
3,5-Cyclohexadiene-1,2-dione, derivs. 930-68-7D, 2-Cyclohexen-1-one,
derivs. 1015-62-9D, derivs. 2379-57-9D, derivs. 3483-12-3, DTT
3483-12-3D, DTT, derivs. 3952-78-1 4613-08-5 6041-00-5D, derivs.
6336-72-7 13243-65-7 23444-65-7, Alkannin 33440-64-1 40881-75-2
50614-69-2D, derivs. 59887-87-5 69008-03-3 69016-66-6 70730-92-6
71860-31-6D, derivs. 74839-40-0 75753-48-9 75753-51-4 75753-52-5
78651-40-8D, derivs. 81818-54-4D, derivs. 82789-18-2D, derivs.
85192-90-1 86703-96-0D, derivs. 88818-34-2D, derivs. 92629-07-7
93831-47-1 97136-23-7D, derivs. 100440-78-6 101068-35-3
108772-19-6 117746-18-6D, derivs. 133011-82-2D, derivs. 184529-66-6
187753-94-2D, derivs. 192126-76-4, Mycothiol 192126-76-4D, Mycothiol,
adducts with naphthoquinone derivs. 202350-24-1D, derivs.
208254-19-7D, derivs. 215778-63-5D, derivs. 298208-05-6D, derivs.
304883-59-8 313253-12-2D, derivs. 313471-02-2 313493-32-2D, derivs.
313531-31-6 313549-28-9D, derivs. 313955-32-7D, derivs.
313955-40-7D, derivs. 313957-75-4D, derivs. 313957-76-5D, derivs.
313958-25-7D, derivs. 317337-15-8 324527-07-3D, derivs.
399038-37-0D, derivs. 403496-99-1D, derivs. 464157-05-9D, derivs.
464157-06-0D, derivs. 464157-07-1D, derivs. 464157-08-2D, derivs.
464157-09-3D, derivs. 464157-10-6D, derivs. 464157-11-7D, derivs.
464157-13-9D, derivs. 464157-14-0D, derivs. 464157-15-1D, derivs.
464157-16-2D, derivs. 464157-17-3D, derivs. 464157-18-4D, derivs.
464157-19-5D, derivs. 464157-20-8D, derivs. 464157-21-9D, derivs.
464157-22-0D, derivs. 464157-23-1D, derivs. 464157-24-2D, derivs.
464157-25-3D, derivs. 464157-26-4D, derivs. 464157-27-5D, derivs.
464157-28-6D, derivs. 464157-29-7D, derivs. 464157-30-0D, derivs.
464157-31-1D, derivs. 464157-32-2D, derivs. 464157-33-3D, derivs.
464157-34-4D, derivs. 464157-35-5D, derivs. 464157-36-6D, derivs.
464157-37-7 464157-38-8 464157-39-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(quinone compound cysteine protease inhibitors, and therapeutic use)

L24 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

CC 1-10 (Pharmacology)

Section cross-reference(s): 27, 62, 63

TI Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases

ST naphthoquinone deriv obesity diabetes metabolic syndrome neurodegenerative mitochondria disease; Danshen drug formulation cosmetic naphthoquinone deriv beta lapachone prepn

IT Natural products, pharmaceutical

(Salviae miltiorrhizae radix; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Brain, disease

(cerebrovascular; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Disease, animal

(degenerative; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Eye, disease

(diabetic retinopathy, diabetic; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Hyperlipidemia

Hypertension

(diabetic; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Mitochondria

(disease; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Kidney, disease

(failure, diabetic; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Heart, disease

(infarction; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Cosmetics

(lotions; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Metabolic disorders

(metabolic syndrome X; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Disease, animal

(mitochondrial; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Antidiabetic agents

Antiobesity agents

Arteriosclerosis

Cardiovascular system, disease

Claisen rearrangement

Cyclization
Diabetes mellitus
Diels-Alder reaction
Drug delivery systems
Inflammation
Ischemia
Liver, disease
Obesity
Salvia miltiorrhiza

(pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT Drug delivery systems

(prodrugs; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT 4707-32-8P, β -Lapachone

RL: ADV (Adverse effect, including toxicity); COS (Cosmetic use); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT 33404-57-8P, Dunnione 52436-88-1P 83156-01-8P, α -Dunnione
90149-94-3P 90149-95-4P 90149-97-6P 359762-51-9P 906459-31-2P
906459-32-3P 906459-34-5P 906459-35-6P

RL: ADV (Adverse effect, including toxicity); COS (Cosmetic use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT 130-15-4DP, 1,4-Naphthalenedione, derivs.

15297-93-5P 17112-93-5P 32013-77-7P 52422-61-4P 82420-29-9P
83156-21-2P 90149-96-5P 90149-98-7P 90149-99-8P 104277-62-5P
118949-98-7P 118949-99-8P 195156-60-6P 476213-05-5P 855275-10-4P
906459-29-8P 906459-30-1P 906459-33-4P 906459-36-7P 906459-37-8P

RL: COS (Cosmetic use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT 42164-69-2P

RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases)

IT 78-79-5, 2-Methyl-1,3-butadiene, reactions 83-72-7, 2-Hydroxy-1,4-naphthoquinone 84-58-2 106-51-4, p-Benzoquinone, reactions 115-19-5, 2-Methyl-3-butyn-2-ol 123-91-1, 1,4-Dioxane, reactions 673-84-7, 2,6-Dimethyl-2,4,6-octatriene 869-72-7, 1-Bromo-3-methyl-2-pentene 870-63-3, 1-Bromo-3-methyl-2-butene 932-86-5, 2-Bromo-ethylidenecyclohexane 1000-86-8, 2,4-Dimethyl-1,3-pentadiene 3017-69-4, 1-Bromo-2-methylpropene 4392-24-9, 3-Phenylallyl bromide 6138-90-5, Geranyl bromide 6674-22-2, 1,8-Diazabicyclo[5.4.0]undec-7-ene 8013-00-1, Terpinene 13961-36-9 17173-25-0 21378-06-3, 1-Bromo-3-ethyl-2-pentene 30525-89-4, Paraformaldehyde 58472-21-2, 2-Hydroxy-6-methyl-1,4-naphthoquinone 74237-21-1, 6-Chloro-2-hydroxy-1,4-

naphthoquinone 90149-85-2 114521-72-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (pharmaceutical composition for treatment obesity, diabetes,
 metabolic syndrome, neurodegenerative diseases and mitochondria
 dysfunction diseases)

IT 40432-22-2P, 4,5-Benzofurandione 906459-39-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (pharmaceutical composition for treatment obesity, diabetes,
 metabolic syndrome, neurodegenerative diseases and mitochondria
 dysfunction diseases)

IT 125911-68-4
 RL: PRP (Properties)
 (unclaimed sequence; pharmaceutical composition for the treatment
 or prevention of diseases involving obesity, diabetes, metabolic
 syndrome, neurodegenerative diseases and mitochondria dysfunction
 diseases)

L24 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM C07D223-16
 ICS C07D401-04; C07D403-12; A61K031-55

CC 27-21 (Heterocyclic Compounds (One Hetero Atom))
 Section cross-reference(s): 1, 63

TI 2,5-Dioxo-2,5-dihydro-1H-benz[b]azepines as NMDA receptor antagonists

ST benzazepine prepn NMDA receptor antagonist

IT Nervous system agents
 (benzazepine derivs.)

IT Neurotransmitter antagonists
 (glycinergic, benzazepine derivs.)

IT Brain, disease
 (ischemia, treatment of, benzazepine derivs. for)

IT Neurotransmitter antagonists
 (methyl-D-aspartate, benzazepine derivs.)

IT Brain, disease
 (stroke, treatment of, benzazepine derivs. for)

IT 3984-34-7, 3-(4-Chlorobenzoyl)propionic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Wolff-Kishner reduction of, in preparation of benzazepine NMDA receptor
 antagonists)

IT 74-88-4, Methyl iodide, reactions 100-39-0, Benzyl bromide 2417-72-3,
 Methyl 4-(bromomethyl)benzoate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (alkylation of benzazepinedione derivative by, in preparation of benzazepine
 NMDA receptor antagonists)

IT 51-45-6, 2-(4-Imidazolyl)ethylamine, reactions 62-53-3, Benzenamine,
 reactions 64-04-0, Phenethylamine 74-89-5, Methylamine, reactions
 92-54-6, 1-Phenylpiperazine 100-46-9, Benzylamine, reactions 107-11-9,
 Allylamine 108-00-9, 2-(N,N-Dimethylamino)ethylamine 109-89-7,
 Diethylamine, reactions 110-89-4, Piperidine, reactions 110-91-8,
 Morpholine, reactions 111-42-2, Diethanolamine, reactions 111-49-9,
 Perhydroazepine 123-75-1, Pyrrolidine, reactions 124-40-3,
 Dimethylamine, reactions 141-43-5, reactions 488-43-7, D-Glucamine
 2516-47-4, Cyclopropylmethylamine 2627-86-3, (S)- α -
 Methylbenzylamine 2759-28-6, 1-Benzylpiperazine 3202-33-3,
 4-Phenoxy piperidine 3886-69-9, (R)- α -Methylbenzylamine
 16066-84-5, tert-Butoxycarbonylmethylamine 55536-65-7,
 3,4-Dibenzylloxyphenethylamine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (aminolysis of methoxybenzazepinedione derivative by, in preparation of
 benzazepine NMDA receptor antagonists)

IT 52280-65-6

RL: RCT (Reactant); RACT (Reactant or reagent)
 (ammonolysis and aminolysis of, in preparation of benzazepine NMDA receptor antagonists)

IT 696-59-3, 2,5-Dimethoxytetrahydrofuran
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclocondensation of, with aminobenzazepine derivative, in preparation of benzazepine NMDA receptor antagonists)

IT 55406-29-6P 154314-66-6P 154314-67-7P 154314-68-8P 154314-69-9P
 154314-70-2P 154314-71-3P 154314-72-4P 154314-73-5P 154314-74-6P
 154314-75-7P 154314-76-8P 154314-77-9P 154314-78-0P 154314-79-1P
 154314-80-4P 154314-81-5P 154314-82-6P 154314-83-7P 154314-84-8P
 154314-85-9P 154314-86-0P 154314-87-1P 154314-88-2P 154314-89-3P
 154314-90-6P 154314-91-7P 154314-92-8P 154314-93-9P 154314-94-0P
 154314-95-1P 154314-96-2P 154314-97-3P 154314-98-4P 154314-99-5P
 154315-00-1P 154315-01-2P 154315-02-3P 154315-03-4P 154315-04-5P
 154315-05-6P 154315-06-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as NMDA receptor antagonist)

IT 4619-18-5P, 4-(4-Chlorophenyl)butyric acid 26673-32-5P,
 7-Chloro-1-tetralone 90685-39-5P, 1,4-Naphthalenedione, 7-chloro-2-hydroxy- 90700-78-0P, 1,4-Naphthalenedione, 7-chloro-2-methoxy- 144066-30-8P
 154315-07-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for benzazepine NMDA receptor antagonists)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3
 SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162
 L3 22 S L2 AND DIONE
 L4 0 S L2 AND PHENANTHROLINEDIONE
 L5 2 S L2 AND PHENANTHROLINE
 L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008

L7 224329 S L2
 L8 13877 S L3
 L9 406 S L5
 L10 224329 S L7 OR L8 OR L9
 L11 3300 S 10 AND ANTIANGIOGENIC
 L12 56 S L11 AND ISCHEMIA
 L13 28 S L11 AND ("HEART DISEASE")
 L14 2 S L13 AND L12
 L15 7 S (L3 OR L5) AND ANTIANGIOGENIC
 L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"
 L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

L18 STR 27318-90-7
L19 1 S L18 FAM SAM
SET SMA OFF
SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON 11 JUN 2008

L20 1303 S ("1,4-NAPHTHALENEDIONE?")
L21 129 S L20 AND (TREAT OR TREATMENT OR TREATING)
L22 0 S L21 AND ("HEART ATTACK")
L23 0 S L21 AND ("MYOCARDIAL INFARCTION")
L24 4 S L21 AND ISCHEMIA

=> s l16 and ("myocardial infarction")
2 FILES SEARCHED...

L25 1 L16 AND ("MYOCARDIAL INFARCTION")

=> d scan l25

L25 1 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
IC ICM A61K
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 78
TI Therapeutic delivery of carbon monoxide employing Mn complexes having CO ligands, and additional halogen, monodentate and/or bidentate ligands
ST carbon monoxide manganese complex halogen monodentate bidentate ligand antiinflammatory; manganese complex carbon monoxide ligand neurotransmission vasodilation inflammation hypertension
IT Hyperoxia
(-induced injury; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
IT Respiratory distress syndrome
(adult; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
IT Ligands
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bidentate; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
IT Radiation
(damage; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
IT Ligands
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(halogen, monodentate; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
IT Shock (circulatory collapse)
(hemorrhagic; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
IT Pharmaceutical injections
(i.m. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)
IT Pharmaceutical injections

(i.p. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Pharmaceutical injections
(i.v. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Sexual disorders
(impotence; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Halogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ligands; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Injury
(postischemic; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Pharmaceutical injections
(s.c. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Shock (circulatory collapse)
(septic; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Neurotransmission
(stimulation; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Angina pectoris
Anti-inflammatory agents
Apoptosis
Arteriosclerosis
Cytotoxicity
Dissolution
Hypertension
Inflammation
Inhalation drug delivery systems
Myocardial infarction
Nasal drug delivery systems
Neoplasm
Oral drug delivery systems
Pharmaceutical solutions
Pharmaceutical suppositories
Sepsis
Solubility
Transdermal drug delivery systems
Transplant rejection
Vasodilators
(therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Carbonyl complexes
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate

ligands)

IT 14100-30-2P, Chloropentacarbonylmanganese 14516-54-2P,
Bromopentacarbonylmanganese 14879-42-6P, Pentacarbonyliodomanganese
38173-71-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(therapeutic delivery of carbon monoxide employing manganese complexes
having CO ligands, and addnl. halogen, monodentate and/or bidentate
ligands)

IT 10170-70-4P 14321-60-9P 20480-91-5P 20624-20-8P 52841-89-1P
59893-04-8P 108267-31-8P 115958-82-2P 178935-53-0P 438552-30-8P
1001014-97-6P 1001014-98-7P 1001014-99-8P 1001015-00-4P
1001015-02-6P 1001015-04-8P 1001015-06-0P 1001015-08-2P
1001015-09-3P 1001015-11-7P 1001015-13-9P 1001015-14-0P
1001015-16-2P 1001015-17-3P 1001015-18-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(therapeutic delivery of carbon monoxide employing manganese complexes
having CO ligands, and addnl. halogen, monodentate and/or bidentate
ligands)

IT 630-08-0D, Carbon monoxide, manganese complexes, ligand of 7439-96-5D,
Manganese, complexes
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(therapeutic delivery of carbon monoxide employing manganese complexes
having CO ligands, and addnl. halogen, monodentate and/or bidentate
ligands)

IT 56-23-5, Carbon tetrachloride, reactions 64-19-7, Acetic acid, reactions
65-85-0, Benzoic acid, reactions 67-48-1, Choline chloride 75-09-2,
Methylene chloride, reactions 75-15-0, Carbon disulfide, reactions
75-31-0, Isopropylamine, reactions 75-59-2, Tetramethylammonium
hydroxide 107-22-2, Glyoxal 111-42-2, Diethanolamine, reactions
115-86-6, Triphenyl phosphate 119-91-5, 2,2'-Biquinolyl 121-45-9,
Trimethyl phosphite 127-08-2, Potassium acetate 140-89-6 141-82-2,
Malonic acid, reactions 148-18-5, Sodium diethyldithiocarbamate
366-18-7, 2,2'-Bipyridine 507-09-5, Thioacetic acid, reactions
1310-73-2, Sodium hydroxide (Na(OH)), reactions 2923-28-6, Silver
triflate 7553-56-2, Iodine, reactions 7647-15-6, Sodium bromide
(NaBr), reactions 7726-95-6, Bromine, reactions 10170-69-1,
Decacarbonyldimanganese 11110-52-4, Sodium amalgam 13442-87-0
14104-20-2, Silver fluoroborate (AgBF₄) 15761-38-3 17773-10-3, Choline
iodide 21050-13-5 27318-90-7, 1,10-
Phenanthroline-5,6-dione
33100-27-5, 15-Crown-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(therapeutic delivery of carbon monoxide employing manganese complexes
having CO ligands, and addnl. halogen, monodentate and/or bidentate
ligands)

IT 2801-04-9P, Sodium bis(2-hydroxyethyl)dithiocarbamate 10581-12-1P,
Tetramethylammonium acetate 24764-90-7P 25255-90-7P,
Tetramethylammonium benzoate 33299-53-5P, Tetramethylammonium malonate
62698-51-5P, Tetramethylammonium thioacetate 63321-11-9P 81436-35-3P
89689-95-2P 1001015-19-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(therapeutic delivery of carbon monoxide employing manganese complexes
having CO ligands, and addnl. halogen, monodentate and/or bidentate
ligands)

IT 630-08-0, Carbon monoxide, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic delivery of carbon monoxide employing manganese complexes
having CO ligands, and addnl. halogen, monodentate and/or bidentate
ligands)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162
L3 22 S L2 AND DIONE
L4 0 S L2 AND PHENANTHROLINEDIONE
L5 2 S L2 AND PHENANTHROLINE
L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON
11 JUN 2008

L7 224329 S L2
L8 13877 S L3
L9 406 S L5
L10 224329 S L7 OR L8 OR L9
L11 3300 S 10 AND ANTIANGIOGENIC
L12 56 S L11 AND ISCHEMIA
L13 28 S L11 AND ("HEART DISEASE")
L14 2 S L13 AND L12
L15 7 S (L3 OR L5) AND ANTIANGIOGENIC
L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"
L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

L18 STR 27318-90-7
L19 1 S L18 FAM SAM
SET SMA OFF
SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON
11 JUN 2008

L20 1303 S ("1,4-NAPHTHALENEDIONE?")
L21 129 S L20 AND (TREAT OR TREATMENT OR TREATING)
L22 0 S L21 AND ("HEART ATTACK")
L23 0 S L21 AND ("MYOCARDIAL INFARCTION")
L24 4 S L21 AND ISCHEMIA
L25 1 S L16 AND ("MYOCARDIAL INFARCTION")

=> s l16 and ("angiogenesis inhibitor?")

L26 0 L16 AND ("ANGIOGENESIS INHIBITOR?")

=> s l2 and ("angiogenesis inhibitor?")

L27 552 L2 AND ("ANGIOGENESIS INHIBITOR?")

```
=> s l3 and ("angiogenesis inhibitor?")
L28      24 L3 AND ("ANGIOGENESIS INHIBITOR?")

=> s l5 and ("angiogenesis inhibitor?")
L29      2 L5 AND ("ANGIOGENESIS INHIBITOR?")


=> s (l27 or l28 or l29) aND HEART
L30      53 (L27 OR L28 OR L29) AND HEART

=> S L30 AND ISCHEMIA
L31      24 L30 AND ISCHEMIA

=> S L31 and (treat or treating or treatment)
L32      19 L31 AND (TREAT OR TREATING OR TREATMENT)

=> d l32 1-19 hitstr ibib all

L32  ANSWER 1 OF 19  CAPLUS  COPYRIGHT 2008 ACS on STN
IT   5315-25-3, 2-Bromo-6-methylpyridine
      RL: RCT (Reactant); RACT (Reactant or reagent)
      (preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in
      treatment of diseases)
RN   5315-25-3  CAPLUS
CN   Pyridine, 2-bromo-6-methyl-  (CA INDEX NAME)
```



```
IT   115926-52-8, PI3 kinase
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
      ( $\alpha$  and  $\gamma$  isoforms; preparation of thiazolidinedione derivs. as
      PI3 kinase inhibitors useful in treatment of diseases)
RN   115926-52-8  CAPLUS
CN   Kinase (phosphorylating), phosphatidylinositol 3-  (CA INDEX NAME)
```

```
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
ACCESSION NUMBER:      2008:127697  CAPLUS
DOCUMENT NUMBER:       148:191939
TITLE:                 Preparation of thiazolidinedione derivatives as PI3
                        kinase inhibitors
INVENTOR(S):           Adams, Nicholas D.; Dhanak, Dashyant; Knight, Steven
                        David; Schaller, Lee; Tang, Jun
PATENT ASSIGNEE(S):    Smithkline Beecham Corporation, USA
SOURCE:                PCT Int. Appl., 72pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:         Patent
LANGUAGE:              English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2008014219	A2	20080131	WO 2007-US74155	20070724
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,			

KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-820147P P 20060724
 US 2006-820973P P 20060801

OTHER SOURCE(S): MARPAT 148:191939

AN 2008:127697 CAPLUS

DN 148:191939

ED Entered STN: 01 Feb 2008

TI Preparation of thiazolidinedione derivatives as PI3 kinase inhibitors

IN Adams, Nicholas D.; Dhanak, Dashyant; Knight, Steven David; Schaller, Lee;
 Tang, Jun

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 72pp.

CODEN: PIXXD2

DT Patent

LA English

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008014219	A2	20080131	WO 2007-US74155	20070724
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,				
	CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,				
	GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,				
	KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,				
	MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,				
	PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,				
	TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,				
	GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2006-820147P P 20060724



US 2006-820973P P 20060801

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2008014219	IPCI	A61K0031-519 [I,A]
	IPCR	A61K0031-519 [I,C]; A61K0031-519 [I,A]

OS MARPAT 148:191939

GI



- AB Invented is a method of inhibiting the activity/function of PB kinases using thiazolidinedione derivs. I [R1 = H, alkyl, aryl, etc.; R2, R3 = H, halo, acyl, etc.; n = 0-3; m = 0-2; A, B, D, E and G together form a ring containing from 1 to 2 double bonds and from 1 to 4 N atoms; X, Y, Z = CH, CR3 and N; provided that one and only one of A and B = N]. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivs. I. Twenty-six compds. I were prepared E.g., a multi-step synthesis of II, starting from 2-amino-5-bromopyridine and Et 2-chloro-3-oxopropanoate potassium salt, was described. Exemplified compds. I showed IC50 values from 1 nM to 10 μ M against PI3K α . Pharmaceutical composition comprising compound I is claimed.
- ST thiazolidinedione imidazopyridine prepn phosphatidylinositol PI3 kinase inhibitor antiinflammatory cardiovascular; autoimmune disorder treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; neurodegenerative kidney disease treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; allergy inhibitor treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; pancreatitis multiorgan failure treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; antiasthmatic antitumor immunosuppressant thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; platelet aggregation inhibitor thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase
- IT Nervous system, disease
 (Huntington's chorea; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)
- IT Sarcoma
 (Kaposi's; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)
- IT Microtubule
 (anti-microtubule agents, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)
- IT Antiarteriosclerotics
 (antiatherosclerotics; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)
- IT Cytotoxic agents
 (antimetabolites, codrugs; preparation of thiazolidinedione derivs. as PI3

kinase inhibitors useful in treatment of diseases)

IT Muscle, disease
(atrophy, skeletal muscle; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Infection
(bacterial, acute; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Infection
(bacterial, chronic; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung, disease
(chronic obstructive pulmonary disease; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Alkylating agents, biological
Antibiotics
Antitumor agents
Immunotherapy
(codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Hormones, animal, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease
(degeneration; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Skeletal muscle
(disease, atrophy; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Angiogenesis
(disease; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Sperm motility
(disorder; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Cardiomyocyte
(dysfunction; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung
(epithelium, injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Kidney, disease
(fibrosis, progressive; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Inflammation
Kidney, disease
(glomerulonephritis; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Muscle, disease
(hypertrophy, skeletal muscle; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Brain, disease
(infection; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Respiratory system, disease
(inflammation; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung, disease
(injury, endothelial; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

inhibitors useful in treatment of diseases)

IT Lung, disease
(injury, epithelial; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung, disease
Reperfusion
(injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Neoplasm
(leukocyte recruitment in; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Endothelium
(lung, injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Neoplasm
(metastasis, invasion; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Hypertrophy
(muscular, skeletal muscle; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Angiogenesis inhibitors
(non-receptor tyrosine kinase, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Inflammation
Pancreas, disease
(pancreatitis; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Signal transduction
(pathway inhibitors, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Coordination compounds
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(platinum, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Inflammation
Lung, disease
(pneumonitis; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Allergy
Allergy inhibitors
Alzheimer's disease
Anaphylaxis
Anti-Alzheimer's agents
Anti-infective agents
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Anticoagulants
Antifibrotic agents
Antihypertensives
Antirheumatic agents
Antiviral agents
Asthma
Atherosclerosis
Autoimmune disease
Cardiac hypertrophy
Cardiovascular agents
Cardiovascular system, disease
Central nervous system agents

Combination chemotherapy
 Encephalitis
 Fibrosis
 Glomerulosclerosis
 Heart, disease
 Human
 Hypertension
 Immunosuppressants
 Inflammation
 Inflammatory bowel disease
 Ischemia
 Kidney, disease
 Leukemia
 Mammary gland, neoplasm
 Melanoma
 Meningitis
 Multiple organ failure
 Multiple sclerosis
 Neoplasm
 Nervous system agents
 Neuroprotective agents
 Ovary, neoplasm
 Pancreas, neoplasm
 Pharmaceutical carriers
 Platelet activation
 Platelet aggregation
 Platelet aggregation inhibitors
 Prodrugs
 Prostate gland, neoplasm
 Psoriasis
 Respiratory system agents
 Rheumatoid arthritis
 Sepsis
 Stroke
 Thrombosis
 Transplant rejection
 Vasoconstriction
 Vasodilators

(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Apoptosis

(proapoptotic agents, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Injury

(pulmonary, endothelial; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Injury

(pulmonary, epithelial; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Epithelium

(pulmonary, injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Injury

(pulmonary; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Leukocyte

(recruitment in cancer tissue; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Fibrosis

(renal, progressive; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Injury
(reperfusion; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Inflammation
(respiratory tract; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Cell cycle
(signaling inhibitors, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lupus erythematosus
(systemic; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Central nervous system, disease
(trauma; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Infection
(viral, acute; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Infection
(viral, chronic; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 7440-06-4D, Platinum, complexes
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 142805-56-9, Topoisomerase II 143180-75-0
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 866261-76-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 1004549-86-3P 1004549-93-2P 1004549-94-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 1004549-83-0P 1004549-84-1P 1004549-85-2P 1004549-87-4P
1004549-88-5P 1004549-89-6P 1004549-90-9P 1004549-91-0P
1004549-92-1P 1004549-95-4P 1004549-96-5P 1004549-97-6P
1004549-98-7P 1004549-99-8P 1004550-00-8P 1004550-01-9P
1004550-02-0P 1004550-03-1P 1004550-04-2P 1004550-05-3P
1004550-06-4P 1004550-07-5P 1004550-08-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 109-04-6, 2-Bromopyridine 431-35-6, 3-Bromo-1,1,1-trifluoro-2-propanone
626-55-1, 3-Bromopyridine 816-40-0, 1-Bromo-2-butanone 1072-97-5,
2-Amino-5-bromopyridine 1532-97-4, 4-Bromoisoquinoline 1692-15-5,
Pyridine-4-boronic acid 1694-29-7, 3-Chloroacetylacetone 2295-31-0,
2,4-Thiazolidinedione 5315-25-3, 2-Bromo-6-methylpyridine
5469-26-1, 1-Bromo-3,3-dimethyl-2-butanone 7752-82-1,
2-Amino-5-bromopyrimidine 20503-40-6 29681-44-5, Methyl
5-bromonicotinate 35216-39-8, 3-(Methylsulfonyl)aniline 40235-68-5,
3-Chloro-2-oxopropyl acetate 116355-16-9, Imidazo[1,2-a]pyridine-6-
carboxaldehyde 132213-07-1, Imidazo[1,2-a]pyridine-6-methanol

387350-88-1 1004550-24-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 6188-23-4P 30493-41-5P 138888-98-9P 154877-65-3P 167884-21-1P
372198-69-1P 474706-74-6P 474708-98-0P 865156-68-9P 936638-00-5P
1004550-09-7P 1004550-10-0P 1004550-11-1P 1004550-12-2P
1004550-13-3P 1004550-14-4P 1004550-15-5P 1004550-16-6P
1004550-17-7P 1004550-18-8P 1004550-19-9P 1004550-20-2P
1004550-21-3P 1004550-22-4P 1004550-23-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(α and γ isoforms; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

L32 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 129318-43-0, Fosamax

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

RN 129318-43-0 CAPLUS

CN Phosphonic acid, P,P'-(4-amino-1-hydroxybutylidene)bis-, sodium salt (1:1) (CA INDEX NAME)



● Na

ACCESSION NUMBER: 2008:123834 CAPLUS

DOCUMENT NUMBER: 148:183423

TITLE: Preparation of indole compounds having CRTH2 antagonist activity for treating allergic diseases, asthma, and inflammatory conditions

INVENTOR(S): Armer, Richard Edward; Wynne, Graham Michael

PATENT ASSIGNEE(S): Oxagen Limited, UK

SOURCE: PCT Int. Appl., 68pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2008012511	A1	20080131	WO 2007-GB2761	20070720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,				

GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-14608 A 20060722
 GB 2006-24176 A 20061204

OTHER SOURCE(S): MARPAT 148:183423

AN 2008:123834 CAPLUS

DN 148:183423

ED Entered STN: 31 Jan 2008

TI Preparation of indole compounds having CRTH2 antagonist activity for
 treating allergic diseases, asthma, and inflammatory conditions

IN Armer, Richard Edward; Wynne, Graham Michael

PA Oxagen Limited, UK

SO PCT Int. Appl., 68pp.

CODEN: PIXXD2

DT Patent

LA English

CC 1-7 (Pharmacology)

Section cross-reference(s): 27

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008012511	A1	20080131	WO 2007-GB2761	20070720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI GB 2006-14608 A 20060722



GB 2006-24176 A 20061204

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2008012511	IPCI	C07D0209-10 [I,A]; C07D0209-00 [I,C*]; A61K0031-405 [I,A]; A61K0031-403 [I,C*]
	IPCR	C07D0209-00 [I,C]; C07D0209-10 [I,A]; A61K0031-403 [I,C]; A61K0031-405 [I,A]

OS MARPAT 148:183423

GI



- AB Compds. of general formula I (wherein R is Ph optionally substituted with one or more halo substituents) and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are antagonists at the CRTH2 receptor and are useful in the treatment of conditions mediated by PGD2 or other agonists binding to CRTH2. These include allergic diseases, asthmatic conditions and inflammatory diseases. A process for preparing I was addnl. claimed. Example compound II was prepared by
- measuring reacting 2-(phenylsulfonyl)benzaldehyde with 2-(5-fluoro-2-methyl-1H-indol-1-yl)acetic acid and saponification of the resulting ester. In an assay measuring inhibition of 13,14-dihydro-15-keto-prostaglandin D2 induced blood eosinophilia in rats, II had an ED50 of 0.0025 $\mu\text{g/mL}$.
- ST indole compd prepn CRTH2 antagonist immune inflammatory disease treatment
- IT Bradykinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (B1, antagonists, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Bradykinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (B2, antagonists, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Inflammatory bowel disease
(Crohn's disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Hand
(Dupuytren's disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (FLAP (arachidonate lipoxygenase-activating protein), inhibitors as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Fever and Hyperthermia
(Familial Hibernian fever; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)
- IT Ulcer
(Hunner's ulcer; preparation of indole compds. having CRTH2 antagonist

activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antihistamines
(H4, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Tumor necrosis factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IGs as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgE, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal
(Kikuchi disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Monoamine oxidase inhibitors
(MAOB inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal
(Muckle-Wells syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Muscarinic antagonists
(M1, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Muscarinic antagonists
(M2, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Glutamate antagonists
(NMDA antagonists, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT P2x purinoreceptor antagonists
(P2X7, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Peroxisome proliferators
(PPAR- γ agonists as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal
(Peyronie's; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal
(Sweet's syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal
(Weber-Christian syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Allergy
 Eye, disease
 Inflammation
 (allergic conjunctivitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Transplant rejection
 (allotransplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Edema
 (angioneurotic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
 Spinal column, disease
 (ankylosing spondylitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gout
 (anti-gout drugs, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibodies and Immunoglobulins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-idiotypic, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antiarteriosclerotics
 (antiatherosclerotics; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antitumor agents
 (antibiotic, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Cytotoxic agents
 (antimetabolites, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mitosis
 (antimitotic agents, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibiotics
 (antitumor, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Artery, disease
 (aorta, aortitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Alopecia
 (areata; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal
 (arthropathy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gene therapy
(as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis
(atopic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Autoimmune disease
Inflammation
Thyroid gland, disease
(autoimmune thyroiditis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pain
(back; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Leukotrienes
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(biosynthesis inhibitors as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease
Inflammation
(blepharitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Drug delivery systems
(bronchial; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Bronchi, disease
(bronchiectasis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Bronchi, disease
Inflammation
(bronchitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Fibrosis
(cardiac; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
(cellulitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gallbladder, disease
Inflammation
(cholecystitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease
(choroiditis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung, disease
(chronic obstructive pulmonary disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases,

asthma, inflammatory conditions, and other diseases)

IT Anti-infective agents
 Antiandrogens
 Antiestrogens
 Aromatase inhibitors
 Cytotoxic agents
 Fungicides
 H1-antihistamines
 H2-antihistamines
 β 1-Adrenoceptor agonists
 β 2-Adrenoceptor agonists
 β 3-Adrenoceptor agonists
 (codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Anthracyclines
 Antisense oligonucleotides
 Progestogens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Angiogenesis inhibitors
 Angiotensin AT2 receptor antagonists
 Angiotensin-converting enzyme inhibitors
 Anti-Alzheimer's agents
 Antidepressants
 Antimicrobial agents
 Antiosteoporotic agents
 Antiparkinsonian agents
 Calcium channel blockers
 Central nervous system agents
 Cholinergic antagonists
 Cyclooxygenase 1 inhibitors
 Cyclooxygenase 2 inhibitors
 Dopamine agonists
 Enzyme inhibitors
 HMG-CoA reductase inhibitors
 Hypolipemic agents
 Immunomodulators
 Leukotriene antagonists
 Nicotinic antagonists
 Platelet aggregation inhibitors
 Uricosuric agents
 β -Adrenoceptor antagonists
 (codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Corticosteroids, biological studies
 Fibrates
 Growth hormone secretagogues
 Interferons
 Platelet-derived growth factors
 Transforming growth factor β
 Tumor necrosis factors
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung, disease
(complications of lung transplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Central nervous system, disease
Peripheral nervous system, disease
(complications of malignant, infectious, or autoimmune disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease
Inflammation
(conjunctivitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis
(contact; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eosinophilia
Lymphoma
(cutaneous; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Bladder, disease
Inflammation
(cystitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Neoplasm
(cytokine-transfected tumor cell lines as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Nerve, disease
(degeneration; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mental and behavioral disorders
(dementia; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lupus erythematosus
(discoid; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Penis
(disease, Peyronie's; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Oviduct
(disease, salpingitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Urethra
(disease, urethritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Joint, anatomical
(disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Estrogen receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (down regulators as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal
 (dysplasia; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal
 (eosinophilic paschiitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease
 (epidermolysis bullosa; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Reproductive system, disease
 (epididymitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Esophagus, disease
 Inflammation
 (esophagitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Amyloidosis
 (familial Mediterranean fever; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Fever and Hyperthermia
 (familial Mediterranean; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung, disease
 (farmer's lung; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Heart, disease
 (fibrosis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gene therapy
 (gene-directed enzyme prodrug therapy, as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gingiva, disease
 Inflammation
 (gingivitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
 Kidney, disease
 (glomerulonephritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
 Tongue, disease
 (glossitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis

(herpetiformis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Allergy
Inflammation
Lung, disease
(hypersensitivity pneumonitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Purpura (disease)
(idiopathic thrombocytopenic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Sexual disorders
(impotence; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Growth factor receptors
Growth factors, animal
Urokinase-type plasminogen activator receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Hepatocyte growth factor
Platelet-derived growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Reperfusion
(injury; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pneumonia
(interstitial; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Rheumatoid arthritis
(juvenile; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mouth, disease
Skin, disease
(lichen planus; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Sclerosis
(lichen sclerosis et atrophica; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Transplant and Transplantation
(lung, complications of lung transplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Alopecia

(male pattern; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Interleukin 4
Interleukin 5
RL: BSU (Biological study, unclassified); BIOL (Biological study) (modulators as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (modulators, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (monoclonal, anti-TNF, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Erythema
(multiforme; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
Kidney, disease
(nephritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, neoplasm
(non-melanoma; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pharmacokinetics
(of indole compds.; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Ovary, disease
(oophoritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease
Inflammation
(ophthalmitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
Pancreas, disease
(pancreatitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal
(panniculitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Neoplasm
(paraneoplastic syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease
(pemphigoid; preparation of indole compds. having CRTH2 antagonist activity

for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease
(pemphigus; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
Pericardium
(pericarditis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
Vein, disease
(phlebitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease
(photodermatitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis
(phytodermatitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Rheumatic diseases
(polymyalgia rheumatica; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Nose, neoplasm
(polyp; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT AIDS (disease)
Acne
Addison's disease
Allergy
Allergy inhibitors
Alzheimer's disease
Analgesics
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antifibrotic agents
Antiphospholipid syndrome
Antirheumatic agents
Antitumor agents
Antitussives
Antiulcer agents
Antiviral agents
Asthma
Atherosclerosis
Autoimmune disease
Behcet's syndrome
Bone, disease
Cardiomyopathy
Cardiovascular agents
Celiac disease

Cirrhosis
 Connective tissue, disease
 Cough
 Cystic fibrosis
 Dermatological agents
 Diabetes mellitus
 Drug delivery systems
 Eczema
 Emphysema
 Endocarditis
 Fibrosis
 Food allergy
 Gastrointestinal agents
 Graves' disease
 Hepatitis
 Human
 Inflammatory bowel disease
 Ischemia
 Leprosy
 Mastocytosis
 Multiple sclerosis
 Myasthenia gravis
 Myocarditis
 Myositis
 Nasal drug delivery systems
 Neoplasm
 Nervous system agents
 Oral drug delivery systems
 Osteoarthritis
 Pain
 Parenteral drug delivery systems
 Periodontitis
 Proctitis
 Psoriasis
 Rectal drug delivery systems
 Retinal disease
 Rheumatic fever
 Rheumatoid arthritis
 Sarcoidosis
 Scleroderma
 Seborrhea
 Sezary syndrome
 Sjogren syndrome
 Thrombosis
 Topical drug delivery systems
 Urticaria
 Uveitis
 Vaginal drug delivery systems
 Vascular restenosis
 Vasculitis

(preparation of indole compds. having CRTH2 antagonist activity for
 treating allergic diseases, asthma, inflammatory conditions,
 and other diseases)

IT Wound healing
 Wound healing promoters
 (promotion of healing without fibrotic scarring; preparation of indole
 compds. having CRTH2 antagonist activity for treating
 allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
 Prostate gland, disease
 (prostatitis; preparation of indole compds. having CRTH2 antagonist activity

for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pruritus
(pruritus ani; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis
(psoriatic arthritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antihypertensives
Hypertension
(pulmonary; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease
(pyoderma, pyoderma gangrenosum; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis
(reactive; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Injury
(reperfusion; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
Nose, disease
(rhinitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
(salpingitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease
(sarcoid; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis
(septic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Spinal column, disease
(spondyloarthropathy, undifferentiated spondarthropathy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mast cell
(stabilizers as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis
Synovial membrane, disease
(synovitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lupus erythematosus
(systemic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Erythema
(toxic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Animal cell
(transfected immune cells as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung
(transplant, complications of lung transplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Interleukin 2
Interleukin 4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor cell transfection with interleukins as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Prostanoid receptors
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(type DP2; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Tachykinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type NK1, inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Tachykinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type NK3, inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammatory bowel disease
(ulcerative colitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Colitis
(ulcerative; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation
(urethritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Heart, disease
(valvulitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Drugs
(vascular damaging agents as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung, disease
(vasculitic and thrombotic disorders; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Alkaloids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(vinca, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Infection
(viral; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Vagina, disease
(vulvovaginitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
($\alpha v \beta 3$, inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
($\alpha 4 \beta 1$, antagonists, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β , codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT β -Adrenoceptor agonists
($\beta 4$, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 141579-87-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Abbott 79175, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 65154-06-5, Platelet activating factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 50-07-7, Mitomycin-C 50-18-0, Cyclophosphamide 50-33-9, Phenylbutazone, biological studies 50-76-0, Dactinomycin 50-78-2, Aspirin 51-21-8, 5-Fluorouracil 52-67-5, D-Penicillamine 53-86-1, Indomethacin 55-86-7, Nitrogen mustard 55-98-1, Busulfan 57-22-7, Vincristine 58-55-9, Theophylline, biological studies 59-05-2, Methotrexate 59-42-7, Phenylephrine 61-68-7 90-82-4, Pseudoephedrine 101-40-6, Propylhexedrine 113-92-8 118-42-3, Hydroxychloroquine 127-07-1, Hydroxyurea 147-94-4, Cytosine arabinoside 148-82-3, Melphalan 305-03-3, Chlorambucil 317-34-0, Aminophylline 427-51-0, Cyproterone acetate 446-86-6, Azathioprine 522-48-5, Tetrahydrozoline hydrochloride 550-99-2, Naphazoline hydrochloride 586-06-1, Metaproterenol 595-33-5, Megestrol acetate 865-21-4, Vinblastine 1218-35-5, Xylometazoline hydrochloride 2315-02-8, Oxymetazoline hydrochloride 3198-07-0 5104-49-4, Flurbiprofen 6569-51-3, Borazole 6990-06-3, Fusidic acid 7683-59-2, Isoproterenol 7689-03-4, Camptothecin 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13311-84-7, Flutamide 13539-59-8, Apazone 14838-15-4, Phenylpropanolamine 15307-86-5, Diclofenac 15663-27-1, Cisplatin 15687-27-1, Ibuprofen

15826-37-6, Sodium cromoglycate 17902-23-7, Tegafur 18378-89-7
 18559-94-9, Albuterol 20830-81-3, Daunomycin 22071-15-4, Ketoprofen
 22204-53-1, Naproxen 23031-25-6, Terbutaline 23214-92-8, Doxorubicin
 23593-75-1, Clotrimazole 25316-40-9, Adriamycin 29679-58-1, Fenoprofen
 29767-20-2, Teniposide 30392-41-7, Bitolterol mesylate 30516-87-1, AZT
 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34031-32-8, Auranofin
 36322-90-4, Piroxicam 38194-50-2, Sulindac 38677-81-5, Pirbuterol
 41575-94-4, Carboplatin 51264-14-3, Amsacrine 53123-88-9, Rapamycin
 53643-48-4, Vindesine 53714-56-0, Leuporelin 56420-45-2, Epirubicin
 57982-77-1, Buserelin 58581-89-8, Azelastine 58957-92-9, Idarubicin
 59277-89-3, Acyclovir 59865-13-3, Cyclosporine 63612-50-0, Nilutamide
 63798-73-2, Cyclosporin E 65807-02-5, Goserelin 68844-77-9, Astemizole
 71125-38-7, Meloxicam 71486-22-1, Vinorelbine 73573-87-2, Formoterol
 75706-12-6, Leflunomide 79794-75-5, Loratidine 82413-20-5, Droloxifene
 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 89365-50-4, Salmeterol
 89778-26-7, Toremifene 90357-06-5, Bicalutamide 94055-76-2, Suplatast
 tosylate 95058-81-4, Gemcitabine 98319-26-7, Finasteride 100643-71-8
 104227-87-4 104987-11-3, Tacrolimus 107868-30-4, Exemestane
 112809-51-5, Letrozole 112887-68-0, Raltitrexed 114977-28-5, Taxotere
 116057-75-1 117048-59-6, Combretastatin A4 120511-73-1 123948-87-8,
 Topotecan 126544-47-6, Ciclesonide 129453-61-8, Fulvestrant
 137071-32-0, Pimecrolimus 154039-60-8, Marimastat 159989-65-8,
 Viracept 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 180288-69-1,
 Trastuzumab 181695-72-7, Valdecoxib 202409-33-4, Etoricoxib
 205923-56-4, Cetuximab 242138-07-4, Omalizumab
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(codrug; preparation of indole compds. having CRTH2 antagonist activity for
 treating allergic diseases, asthma, inflammatory conditions,
 and other diseases)

IT 50-24-8, Prednisolone 53-03-2, Prednisone 57-66-9, Probenecid
 57-96-5, Sulfinpyrazone 59-92-7, biological studies 64-86-8,
 Colchicine 76-25-5, Triamcinolone acetonide 315-30-0, Allopurinol
 321-64-2, Tacrine 404-86-4, Capsaicin 2323-36-6, Deprenyl 3385-03-3,
 Flunisolide 3562-84-3, Benzbromarone 5534-09-8, Beclomethasone
 dipropionate 7440-57-5D, Gold, compds. 9004-08-4, Cathepsin
 9004-61-9, Synvisc 9067-32-7, Hyalgan 14611-51-9, Selegiline
 22254-24-6, Ipratropium bromide 28797-61-7, Pirenzepine 30286-75-0,
 Oxitropium bromide 51333-22-3, Budesonide 55242-55-2, Propentofylline
 62031-54-3, Fibroblast growth factor 79617-96-2, Sertraline
 80474-14-2, Fluticasone propionate 80880-90-6, Telenzepine 83869-56-1,
 Colony-stimulating factor 2 83919-23-7, Mometasone furoate 84088-42-6,
 Linomide 84449-90-1 91374-20-8, Requip 93211-49-5, L-651392
 96566-25-5, Ablukast 103177-37-3, Pranlukast 103475-41-8, Tepoxalin
 106096-93-9, Basic fibroblast growth factor 107753-78-6, Zafirlukast
 111406-87-2, Zileuton 118414-82-7, MK-886 120014-06-4, Donepezil
 120128-20-3, RG-12525 120443-16-5, Verlukast 122320-73-4,
 Rosiglitazone 128312-51-6, Ro-24-5913 129318-43-0, Fosamax
 134308-13-7, Tasmar 136236-51-6, Rasagiline 136310-93-5, Tiotropium
 bromide 140841-32-3, ZD2138 141579-54-6, Fenleuton 143538-27-6, BAY
 x 7195 147030-01-1, MK-591 147398-01-4, CGS-25019c 147432-77-7,
 Ontazolast 151581-24-7, Iralkast 153259-65-5, Cilomilast
 154355-76-7, ABT-761 158930-07-5, L-739010 158966-92-8, Montelukast
 162750-10-9, SB-210661 168154-07-2, L-746530 171964-73-1, ZD-0892
 174636-32-9, Talnetant 180916-16-9, Lasofoxifene 183321-74-6,
 Erlotinib 184475-35-2, Gefitinib 188039-54-5, Palivizumab
 191217-81-9, Mirapex 204974-93-6, BIIL 284/260 216974-75-3,
 Bevacizumab 257892-34-5, D-4418 289499-45-2, CI 1033 350610-64-9,
 NKP 608C 446023-33-2, UT 77

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 1004293-19-9P, 2-[5-Fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1H-indol-1-yl]acetic acid 1004293-21-3P, 2-[3-[2-(4-Chlorophenylsulfonyl)benzyl]-5-fluoro-2-methyl-1H-indol-1-yl]acetic acid 1004293-24-6P, 2-[5-Fluoro-3-[2-(4-fluorophenylsulfonyl)benzyl]-2-methyl-1H-indol-1-yl]acetic acid
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 9025-82-5, Phosphodiesterase 9026-43-1 9036-21-9, PDE4 62229-50-9, Epidermal growth factor 79079-06-4, EGF receptor tyrosine kinase 80449-02-1 131384-38-8, Farnesyl transferase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 9004-06-2, Elastase 9081-34-9, 5 α Reductase 80449-01-0, Topoisomerase 80619-02-9, 5-Lipoxygenase 81669-70-7 86090-08-6, Angiostatin 151769-16-3, TACE 501433-35-8, INOS 506430-87-1, Neuronal nitric oxide synthase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 9001-66-5 9012-25-3, Catechol methyltransferase 141907-41-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 9039-48-9, Aromatase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 9001-40-5, Glucose-6-phosphate dehydrogenase 9002-17-9, Xanthine oxidase 9015-82-1 9028-35-7 9028-93-7, Inosine monophosphate dehydrogenase 97501-93-4, Tryptase 122191-40-6, Interleukin converting enzyme 142243-02-5 329900-75-6 329967-85-3
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 67763-96-6, Insulin-like growth factor I
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mimetics as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 9034-40-6, Luteinizing hormone-releasing factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (modulators as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 41598-07-6, Prostaglandin D2
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 371-42-6, 4-Fluorobenzenethiol 446-52-6, 2-Fluorobenzaldehyde 873-55-2, Benzenesulfinic acid sodium salt 107572-07-6, 2-(4-Chlorophenylthio)benzaldehyde 646515-46-0, 2-(5-Fluoro-2-methyl-1H-indol-1-yl)acetic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 126076-76-4P, 2-(Phenylsulfonyl)benzaldehyde 643763-14-8P, 2-(4-Fluorophenylthio)benzaldehyde 1004293-20-2P 1004293-22-4P, 2-(4-Chlorophenylsulfonyl)benzaldehyde 1004293-23-5P, Ethyl 2-[3-[[2-(4-chlorophenylsulfonyl)phenyl]methyl]-5-fluoro-2-methyl-1H-indol-1-yl]acetate 1004293-25-7P 1004293-26-8P, 1-(Dimethoxymethyl)-2-(4-fluorophenylsulfonyl)benzene 1004293-27-9P, 2-(4-Fluorophenylsulfonyl)benzaldehyde 1004293-28-0P, Ethyl 2-[5-fluoro-3-[[2-(4-fluorophenylsulfonyl)phenyl]methyl]-2-methyl-1H-indol-1-yl]acetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT 51-61-6, Dopamine, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (reuptake inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)


RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Bach Nicholas J; US 5641800 A 1997 CAPLUS
 (2) Boyd; WO 2005044260 A 2005 CAPLUS
 (3) Shionogi & Co; EP 1505061 A1 2005 CAPLUS

L32 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 129318-43-0, Fosamax
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (integrin-binding small mols. for treatment of diseases and combination with other agents)

RN 129318-43-0 CAPLUS

CN Phosphonic acid, P,P'-(4-amino-1-hydroxybutylidene)bis-, sodium salt (1:1)
 (CA INDEX NAME)



● Na

ACCESSION NUMBER: 2007:563324 CAPLUS
 DOCUMENT NUMBER: 147:2055
 TITLE: Integrin-binding small molecules

INVENTOR(S): Neamati, Nouri; Dayam, Raveendra
 PATENT ASSIGNEE(S): University of Southern California, USA
 SOURCE: PCT Int. Appl., 112pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007059195	A1	20070524	WO 2006-US44305	20061114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

US 20070155750 A1 20070705 US 2006-559857 20061114
 PRIORITY APPLN. INFO.: US 2005-736780P P 20051114

OTHER SOURCE(S): MARPAT 147:2055

AN 2007:563324 CAPLUS

DN 147:2055

ED Entered STN: 24 May 2007

TI Integrin-binding small molecules

IN Neamati, Nouri; Dayam, Raveendra

PA University of Southern California, USA

SO PCT Int. Appl., 112pp.

CODEN: PIXXD2

DT Patent

LA English

CC 1-12 (Pharmacology)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007059195	A1	20070524	WO 2006-US44305	20061114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

US 20070155750 A1 20070705 US 2006-559857 20061114

PRAI US 2005-736780P P 20051114

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007059195	IPCI	A61K0031-52 [I,A]; A61K0031-519 [I,C*]; A61K0031-517 [I,A]

IPCR A61K0031-519 [I,C]; A61K0031-52 [I,A]; A61K0031-517
 [I,C]; A61K0031-517 [I,A]
 US 20070155750 IPCI A61K0031-519 [I,A]; A61K0031-525 [I,A]
 IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61K0031-525
 [I,A]
 NCL 514/249.000; 514/251.000; 514/264.100
 OS MARPAT 147:2055
 AB The present invention relates in general to integrin-binding small mols.
 More specifically, the invention provides novel compns. and methods of
 using these compns. for treating various diseases. Accordingly,
 in one aspect, the invention features a composition comprising a compound, or a
 pharmaceutically or cosmeceutically acceptable salt, solvate, or hydrate
 thereof, wherein the compound comprises one H-bond donor (HBD), one H-bond
 acceptor (HBA), two hydrophobic aromatic groups (HAR1 and HAR2), and one neg.
 ionizable group (NI).
 ST integrin binding mol disease treatment
 IT Inflammatory bowel disease
 (Crohn's disease; integrin-binding small mols. for treatment
 of diseases and combination with other agents)
 IT Bone, disease
 (Paget's; integrin-binding small mols. for treatment of
 diseases and combination with other agents)
 IT Blood vessel, disease
 (adhesion; integrin-binding small mols. for treatment of
 diseases and combination with other agents)
 IT Respiratory distress syndrome
 (adult; integrin-binding small mols. for treatment of
 diseases and combination with other agents)
 IT Retinal disease
 (age-related macular degeneration; integrin-binding small mols. for
 treatment of diseases and combination with other agents)
 IT Thrombosis
 (arterial; integrin-binding small mols. for treatment of
 diseases and combination with other agents)
 IT Disease, animal
 (arthropathy, hemophilic; integrin-binding small mols. for
 treatment of diseases and combination with other agents)
 IT Dermatitis
 (atopic; integrin-binding small mols. for treatment of
 diseases and combination with other agents)
 IT Cardiovascular system
 Immune system
 Inflammation
 Vascular endothelium
 (cells, integrins of; integrin-binding small mols. for
 treatment of diseases and combination with other agents)
 IT Thrombosis
 (cerebral artery; integrin-binding small mols. for treatment
 of diseases and combination with other agents)
 IT Ischemia
 (cerebral; integrin-binding small mols. for treatment of
 diseases and combination with other agents)
 IT Gastroenteritis
 (chronic; integrin-binding small mols. for treatment of
 diseases and combination with other agents)
 IT Estrogens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (conjugated, Premarin; integrin-binding small mols. for
 treatment of diseases and combination with other agents)
 IT Dermatitis

(contact; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Transplant and Transplantation
(cornea, neovascularization; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Eye
(cornea, transplant, neovascularization; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Radiation
(damage, dermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Dermatitis
(dermatitis exfoliativa neonatorum; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Cosmetics and personal care products
IR radiation
Ionizing radiation
UV radiation
(dermatitis from; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Toxicity
(dermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Retinal disease
(diabetic retinopathy, proliferative; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Joint, anatomical
(disease, hemophilic; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Mucous membrane
(disease, inflammation; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Lung, disease
(embolism; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Hyperplasia
(endometrial; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Uterus, disease
(endometriosis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Uterus, disease
(endometrium, hyperplasia; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Skin, disease
(erythematosquamous dermatosis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Gingiva, disease
Inflammation
(gingivitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Wound
(granulation; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Uterus, disease
(hemorrhage; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Dermatitis
(herpetiformis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Muscle, disease

(idiopathic inflammatory myopathy; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Blood vessel
 (imaging agents for; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Radionuclides, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (imaging agents; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Platelet activation
 (inappropriate; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Adenoviridae
 Bunyaviridae
 Foot-and-mouth disease virus
 Hantavirus
 Human coxsackievirus
 Human echovirus
 Human immunodeficiency virus 1
 Human parechovirus
 Picornaviridae
 Reoviridae
 Retroviridae
 Rotavirus
 (infection, integrins in; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Vascular restenosis
 (inhibitors; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Adhesion, biological
 Allergy
 Allergy inhibitors
 Angiogenesis
 Angiogenesis inhibitors
 Angioplasty
 Animalia
 Animals
 Anti-inflammatory agents
 Anti-ischemic agents
 Antiartherosclerotics
 Antiarthritics
 Antiasthmatics
 Anticoagulants
 Antiosteoporotic agents
 Antirheumatic agents
 Antitumor agents
 Arterial occlusion
 Arteriosclerosis
 Asthma
 Atherectionomy
 Autoimmune disease
 Blood vessel, disease
 Combination chemotherapy
 Coronary artery disease
 Coronary bypass surgery
 Coronary thrombosis
 Cosmetics and personal care products
 Dermatitis
 Dermatomyositis
 Drug screening

Duodenitis
 Eczema
 Embolism
 Erythema
 Eye, neoplasm
 Gastritis
 Hemangioma
 Hematopoietic neoplasm
 Hodgkin's disease
 Human
 Imaging agents
 Immune disease
 Inflammation
 Inflammatory bowel disease
 Ischemia
 Keloid
 Leukemia
 Mucosal drug delivery systems
 Multiple myeloma
 Multiple sclerosis
 Myeloproliferative disorders
 Myocardial infarction
 Myocardial ischemia
 Neoplasm
 Non-Hodgkin lymphoma
 Oral drug delivery systems
 Osteoporosis
 Parenteral drug delivery systems
 Pharmaceutical carriers
 Preeclampsia
 Psoriasis
 Radiopharmaceuticals
 Rectal drug delivery systems
 Rheumatoid arthritis
 Seborrhea
 Stroke
 Sunburn
 Telangiectasia
 Thrombosis
 Transdermal drug delivery systems
 Transplant rejection
 Uveitis
 Wart

(integrin-binding small mols. for treatment of diseases and
 combination with other agents)

IT Integrins

RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
 unclassified); BIOL (Biological study)

(integrin-binding small mols. for treatment of diseases and
 combination with other agents)

IT Thrombospondins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(integrin-binding small mols. for treatment of diseases and
 combination with other agents)

IT Tumor necrosis factors

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(integrin-binding small mols. for treatment of diseases and
 combination with other agents)

IT Structure-activity relationship

(integrin-binding; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Animal cell

Dendritic cell

Leukocyte

Macrophage

Osteoclast

Stromal cell

Vascular smooth muscle

(integrins of; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Erythema

(intertrigo; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Drug delivery systems

(intradermal; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Eye, disease

(iris erythema; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Brain, disease

(ischemia, transient; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Brain, disease

Lung, disease

(ischemia; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Hemophilia

(joint disease; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Dermatitis

(juvenile; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Skin, disease

(lichen planus; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Retinal disease

(macular degeneration; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Bone, neoplasm

(metastasis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Inflammation

(mucous membrane; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Erythema

(multiforme; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Myeloproliferative disorders

(myelofibrosis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Eye, disease

(neovascularization, choroidal and iris; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Angiogenesis

(neovascularization, eye, choroidal and iris; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Angiogenesis

(neovascularization, heart; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Heart, disease
(neovascularization; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Dermatitis
(neurodermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Eye, disease
Inflammation
(ophthalmitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Keratosis
(parakeratosis, variegate; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Bone, disease
(pathol. resorption; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Allergy
(photoallergic contact dermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Dermatitis
(photoallergic contact; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Myositis
(polymyositis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Retinal disease
(prematurity-associated; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Arthritis
(psoriatic arthritis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Embolism
Ischemia
(pulmonary; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Granuloma
(pyogenic; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Skin, disease
(rosacea; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Pharmaceutical injections
(s.c. injections; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Connective tissue, disease
(s.c., inflammation; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Neoplasm
(solid; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Skin, disease
(staphylococcal scalded-skin syndrome; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Medical goods
(stents, placement; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Skin, disease
(subcorneal pustular dermatosis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Surgery
(thrombosis in; integrin-binding small mols. for treatment of

diseases and combination with other agents)

IT Ischemia
(transient cerebral; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Blood vessel, disease
(transplant vasculopathy; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Inflammatory bowel disease
(ulcerative colitis; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Colitis
(ulcerative; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Angina pectoris
(unstable; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Adhesion, biological
(vascular; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Thrombosis
(venous; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Infection
(viral, integrins in; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Granulation
(wound; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT Integrins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
($\alpha v \beta 3$; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT 9002-64-6, Parathormone
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(hypercalcemia mediated by; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT 7440-70-2, Calcium, biological studies
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(hypercalcemia, parathormone-mediated; integrin-binding small mols. for treatment of diseases and combination with other agents)

IT 50-18-0, Cyclophosphamide 50-28-2, Climara, biological studies
50-35-1, Thalidomide 57-22-7, Vincristine 362-07-2, 2-Methoxyestradiol
1084-65-7, Arresten 3275-78-3 4323-02-8 7414-83-7, Didronel
8015-12-1, Femhrt 9007-12-9, Calcitonin 10098-06-3 15663-27-1,
Cisplatin 23214-92-8, Doxorubicin 24045-19-0 33069-62-4, Paclitaxel
47931-85-1, Miacalcin 57248-88-1, Aredia 77728-33-7, Combipatch
82640-04-8, Evista 82855-09-2, Combretastatin 86090-08-6, Angiostatin
115436-72-1, Actonel 123948-87-8, Topotecan 129318-43-0,
Fosamax 134461-48-6, Prefest 135843-32-2, Prempro 181427-78-1, NM-3
187888-07-9, Endostatin 216974-75-3, Bevacizumab 232927-14-9
292034-65-2 309732-80-7 309949-29-9 311795-57-0 312747-18-5
326906-42-7 328130-39-8 353774-36-4 354125-43-2 354144-06-2
364623-94-9 385398-46-9 425664-72-8 439946-76-6 442150-15-4
443876-79-7 500261-75-6 500577-98-0 501108-10-7 501347-80-4
593274-97-6 642000-26-8 670240-89-8 675168-61-3 850544-78-4,
Tumstatin 851717-89-0 892553-42-3, Vitaxin 905811-52-1
906449-76-1, Canstatin 937237-42-8 937237-43-9 937237-44-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(integrin-binding small mols. for treatment of diseases and
combination with other agents)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Baell; Journal of Computer-Aided Molecular Design 2002, V16, P245 CAPLUS
- (2) Genentech Inc; WO 9845331 A2 1998 CAPLUS
- (3) Lee; Journal of Medicinal Chemistry 1974, V17(3), P326 CAPLUS

L32 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 301166-54-1, Protein, PTEN

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

RN 301166-54-1 CAPLUS

CN Phosphatase, gene PTEN (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

ACCESSION NUMBER: 2007:357681 CAPLUS

DOCUMENT NUMBER: 146:357244

TITLE: Dual variable domain immunoglobulins and multispecific
derivatives for treating acute and chronic
inflammation, cancer and other diseases

INVENTOR(S): Wu, Chengbin; Ghayur, Tariq; Dixon, Richard W.;
Salfeld, Jochen G.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 126pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070071675	A1	20070329	US 2006-507050	20060818
WO 2008024188	A2	20080228	WO 2007-US17340	20070803
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:
US 2005-709911P P 20050819
US 2005-732892P P 20051102
US 2006-507050 A 20060818

AN 2007:357681 CAPLUS

DN 146:357244

ED Entered STN: 30 Mar 2007

TI Dual variable domain immunoglobulins and multispecific derivatives for
treating acute and chronic inflammation, cancer and other diseases

IN Wu, Chengbin; Ghayur, Tariq; Dixon, Richard W.; Salfeld, Jochen G.

PA USA

SO U.S. Pat. Appl. Publ., 126pp.

CODEN: USXXCO

DT Patent

LA English

INCL 424001490; 530388800; 530391100; 530388220; 424155100; 424178100;
435069100; 435326000; 435252300; 435254210

CC 15-3 (Immunochemistry)

Section cross-reference(s): 1, 2, 3, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070071675	A1	20070329	US 2006-507050	20060818
	WO 2008024188	A2	20080228	WO 2007-US17340	20070803
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-709911P	P	20050819		
	US 2005-732892P	P	20051102		
	US 2006-507050	A	20060818		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20070071675	INCL	424001490; 530388800; 530391100; 530388220; 424155100; 424178100; 435069100; 435326000; 435252300; 435254210
	IPCI	A61K0051-00 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]; C12P0021-06 [I,A]; C12N0001-21 [I,A]; C12N0001-18 [I,A]; C12N0005-06 [I,A]
	IPCR	A61K0051-00 [I,C]; A61K0051-00 [I,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A]; C12N0001-18 [I,C]; C12N0001-18 [I,A]; C12N0001-21 [I,C]; C12N0001-21 [I,A]; C12N0005-06 [I,C]; C12N0005-06 [I,A]; C12P0021-06 [I,C]; C12P0021-06 [I,A]
	NCL	424/001.490; 424/155.100; 424/178.100; 435/069.100; 435/252.300; 435/254.210; 435/326.000; 435/348.000; 530/388.220; 530/388.800; 530/391.100; 536/023.530
	ECLA	K61K; M07K; M07K; M07K
WO 2008024188	IPCI	A61K0051-00 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]; C12P0021-06 [I,A]; C12N0001-21 [I,A]; C12N0001-18 [I,A]; C12N0005-06 [I,A]
	IPCR	A61K0051-00 [I,C]; A61K0051-00 [I,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A]; C12N0001-18 [I,C]; C12N0001-18 [I,A]; C12N0001-21 [I,C]; C12N0001-21 [I,A]; C12N0005-06 [I,C]; C12N0005-06 [I,A]; C12P0021-06 [I,C]; C12P0021-06 [I,A]

AB The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

ST dual variable domain humanized chimeric multispecific antibody inflammation cancer

IT Gram-negative bacteria

(-caused sepsis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and

other diseases)

IT Drugs
 (-induced interstitial lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (-mediated cytotoxicity; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (12; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Glycoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (130; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (18; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins
 Keratins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (19; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Keratins
 Syndecans
 Thrombospondins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (20; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (21; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (22 α ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (22; dual variable domain Igs and multispecific derivs. for treating

acute and chronic inflammation, cancer and other diseases)

IT Interleukin receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (22 α 2; dual variable domain Igs and multispecific derivs
 . for treating acute and chronic inflammation, cancer and
 other diseases)

IT Interleukins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (25; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Interleukins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (26; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Interleukins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (27; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Interleukins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (27w; C19orf10; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Interleukins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (28B; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Interleukins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (28 α ; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Interleukins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (29; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Thrombospondins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Keratins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2A; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Interleukins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (30; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Metallothioneins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (3; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Thrombospondins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (4; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (5; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Insulin-like growth factor-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cyclins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (A1CDA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 10 receptors
 Interleukin 11 receptors
 Interleukin 12
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ABCF1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ACVR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ACVR1B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ACVR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ACVR2B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ACVRL1; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ADAM8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ADORA2A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AGR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AIF1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AIG1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AKAP1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AKAP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AMH; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AMHR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ANGPT1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ANGPT2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ANGPTL3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ANGPTL4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ANPEP; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Interleukin 1 receptors
 Interleukin 18 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (AP; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Interleukin 1 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (APL1; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (APL2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (APOC1; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (AR; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Glycoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (AZGP1; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Interleukin 12 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (B1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and
 other diseases)

IT Interleukin 12 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (B2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Interleukin 10 receptors
 Interleukin 12
 Interleukin 17
 Lipophilins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (B; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Cytokines
 Cytokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (BAFF; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Bcl2-associated athanogene proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (BAG-1; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(BAI1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BCA-1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BLNK (B-cell linker); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BLR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 18
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BRAX; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BRCA1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BTNO2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Bad; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Bcl-2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (BlyS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study) (C-X-C, GCP-2 (granulocyte chemotactic protein 2); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (C/EBP- β (CCAAT box/enhancer element-binding protein β); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other

diseases)

IT Complement receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (C5R1; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CANT1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CAP (catabolite gene activator protein); dual variable domain Igs
 and multispecific derivs. for treating acute and
 chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CAV1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and
 other diseases)

IT Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCBP2 (chemokine-binding protein 2); dual variable domain Igs and
 multispecific derivs. for treating acute and
 chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCBP2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and
 other diseases)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCL1 (C-C motif ligand 1); dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation,
 cancer and other diseases)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCL16 (C-C motif ligand 16); dual variable domain Igs and
 multispecific derivs. for treating acute and
 chronic inflammation, cancer and other diseases)

IT Chemokines
 Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCL17 (C-C motif ligand 17); dual variable domain Igs and
 multispecific derivs. for treating acute and
 chronic inflammation, cancer and other diseases)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCL25 (C-C motif ligand 25); dual variable domain Igs and
 multispecific derivs. for treating acute and
 chronic inflammation, cancer and other diseases)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCL27 (C-C motif ligand 27); dual variable domain Igs and
 multispecific derivs. for treating acute and
 chronic inflammation, cancer and other diseases)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCL28 (C-C motif ligand 28); dual variable domain Igs and
 multispecific derivs. for treating acute and chronic
 inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCNA2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and
 other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCND1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and
 other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCNE1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and
 other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCNE2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and
 other diseases)

IT Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCR1; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors
 Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCR2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCR3; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCR4; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors
 Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCR5; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other
 diseases)

IT Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCR6; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCR8; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCR; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(CCRL1 (chemokine (C-C motif) receptor-like 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCRL2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD164; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD1 (antigen)
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD1c; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD200; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD24; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD27; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD30 ligand; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD31; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD37; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Glycoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD40-L (antigen CD40 ligand); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD52; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD70; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(CD72; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CD79a; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CD83; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDKN1A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDKN1B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 Proteins
 Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDKN2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDKN3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CER1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CHGA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CHGB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal cell line
 (CHO; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CHST10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CKLFSF2; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CL25; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CLN3 (ceroid-lipofuscinosis, neuronal 3); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CMKLR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CMKOR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CNR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (COL18A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(COL1A1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(COL4A3; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(COL6A1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Animal cell line
(COS; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and
other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CSPG; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CX3CR1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXCL16; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXCR1; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXCR2; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and
other diseases)

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXCR3; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXCR4; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXCR6; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CYB5; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and
other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CYC1; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CYSLTR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Cln3 (cyclinlike 3); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease
Prion diseases
(Creutzfeldt-Jakob; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Cripto; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammatory bowel disease
(Crohn's disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DAB21P; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DARC (Duffy antigen receptor for chemokines); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DES; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DKFZp451J0118; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DNCL1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (DPP4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (E2F1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Sphingosine-1-phosphate receptors

Sphingosine-1-phosphate receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-1; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer
and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EFNA1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EFNA3; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and
other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EFNB2; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ENA-78; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ENG; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ENO1; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ENO2; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ENO3; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EREG; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ERK8; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ESR1; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ESR2; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT EphB receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EphB4; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other

diseases)

IT Interleukin 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F10; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Interleukin 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F5; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Interleukin 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F6; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Interleukin 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F7; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Interleukin 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F8; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Interleukin 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F9; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Prostaglandins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FADD (Fas-associated death domain protein); dual variable domain Igs and
multispecific derivs. for treating acute and chronic
inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FASN; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FCER1A; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FCER2; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FCGR3A; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (FIL1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (FLJ12584; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (FLJ25530; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (FRA-1 (fos-related antigen 1); dual variable domain Igs and
 multispecific derivs. for treating acute and chronic
 inflammation, cancer and other diseases)

IT Nervous system, disease
 (Friedreich's ataxia; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT GABA receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GABAA; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GAGEB1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GAGEC1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GALNAC4S-6ST; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GATA-1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GATA-3; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GF-11; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(GGT1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GNAS1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GNRH1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRCC10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP (glucose-regulated protein); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP31; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP44; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP81; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GSTP1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease
(Goodpasture's syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (H1F1A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (HAVCR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

diseases)

IT Keratins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HB6; hair-specific type II; dual variable domain Igs and multispecific
derivs. for treating acute and chronic inflammation, cancer
and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HDAC4; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HDAC5; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HDAC7A; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HDAC9; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HIP1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HLA-A; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HLA-DR, A; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HM74; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HMOX1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Heat-shock proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HSP 75; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HUMCYT2A; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Interleukin 1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (HY1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Brain, disease
 (Hallervorden-Spatz disease; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Purpura (disease)
 (Henoch-Schoenlein; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Heart
 (His bundle, arrhythmia; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Nervous system, disease
 (Huntington's chorea; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (I-TAC; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ICE-BERG; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ICOS (inducible co-stimulator), ligand; dual variable domain Igs and
 multispecific derivs. for treating acute and chronic
 inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ID2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IF-3; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IGBP1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Insulin-like growth factor-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IGFBP-2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Insulin-like growth factor-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IGFBP-3; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Interleukin 17
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IL-17C; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ILK; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (INHA; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (INHBA; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (INSL3; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (INSL4; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Antibodies and Immunoglobulins
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
 unclassified); BIOL (Biological study)
 (IgA, disease; linear; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (JAG1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Jun, protein product; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (KITLG; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (KLF5; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (KLF6 (Kruppel-like factor 6); dual variable domain Igs and
 multispecific derivs. for treating acute and chronic
 inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK12; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK14; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK15; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Sarcoma
(Kaposi's; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (L1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(L2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (LAMA5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Lingo-Troy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Lingo-p75; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MDC (macrophage-derived chemokine); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MDK; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MIB1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MIF; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MS4A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MSMB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MTSS1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (MUC1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Mig (monokine induced by interferon- γ); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (MyD88 (myeloid differentiation primary response protein 88); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (N; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NCK, 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NFKB1 (nuclear factor of κ light chain gene enhancer in B-cells, 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NFKB2 (nuclear factor of κ light chain gene enhancer in B-cells, 2); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NME1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease
 (NOS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NOX5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NPPB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR0B1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR0B2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(NR1D1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1D2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1H2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1H3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1H4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1I2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1I3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2C1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2C2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2E1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2E3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2F1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2F2; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2F6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR3C1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR3C2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR4A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR4A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR4A3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR5A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR5A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR6A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NT5E; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NTN4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (NgR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Nogo, A; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Nogo, NgR-Lingo; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer and other
diseases)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Nogo, NgR-Troy; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Nogo, NgR-nogo66; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer and other
diseases)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Nogo, NgR-p75; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ODZ1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(OMGP (oligodendrocyte myelin glycoprotein), p; dual variable domain
Igs and multispecific derivs. for treating acute and chronic
inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(OPRD1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(P2RX7; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PAP (pancreatitis-associated protein); dual variable domain Igs and
multispecific derivs. for treating acute and chronic
inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PART1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PATE; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PAWR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PCA3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PECAM-1 (platelet-endothelial cell adhesion mol. 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PED2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PF4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PGR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PIAS2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PIK3CG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PLG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PLXDC1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal
(POEMS syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PPID; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(PR-1 (pathogenesis-related, 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PRKCQ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PRKD1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PROC; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PROK2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PSAP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PSCA (prostate stem cell antigen); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PTAFR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RARB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGM A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGS (regulator of G protein signaling), 13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGS-1 (regulator of G protein signaling 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGS-3 (regulator of G protein signaling 3); dual variable domain Igs

and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNF110; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (ROBO (Roundabout), 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis
(Reiter's syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (S100A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SBP (sex steroid-binding protein); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mammaglobins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCGB2A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mammaglobins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCGB2A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCYE1; endothelial monocyte-activating; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SDF-1 (stromal-derived factor-1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal cell line
(SF9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SLA (swine leukocyte antigen), class II; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
Chemokines
Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SLC (secondary lymphoid tissue chemokine); dual variable domain Igs and multispecific derivs. for treating acute and chronic

inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SLC2A2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SLC33A1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SLC43A1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Lung, disease
 (SLE-associated; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SLIT2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SPP1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SPRR1B; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SPRR2A (small proline-rich protein 2A); dual variable domain Igs and
 multispecific derivs. for treating acute and chronic
 inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SPRR2B; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ST6GAL1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (STAB1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Transcription factor STAT
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (STAT6; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(STEAP2; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(STEAP; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(STRL33; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Autoimmune disease
(Schmidt's syndrome; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TAC2; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TAPA-1 (target of antiproliferative antibody, 1); dual variable domain
Igs and multispecific derivs. for treating acute and chronic
inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TB4R2; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TBX21; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TCP10; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TGFA; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TGFB111; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TGFB11; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TGFB1; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TH1L; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (THP0; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TIMP3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Toll-like receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

diseases)

IT Toll-like receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TLR-7; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Toll-like receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TLR-8; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Toll-like receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TLR-9; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TNFAIP2 (tumor necrosis factor α -induced protein 2); dual
variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TNFAIP3 (tumor necrosis factor α -induced protein 3); dual
variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TNFRSF21; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Tumor necrosis factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TNFRSF5; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Tumor necrosis factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TNFRSF8; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Tumor necrosis factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TNFRSF9; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TNFSF7 (tumor necrosis factor superfamily member 7); dual variable
domain Igs and multispecific derivs. for treating acute and
chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TOLLIP; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TPM1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TPM2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TRADD (tumor necrosis factor receptor 1-associated death domain); dual
 variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factor receptor-associated factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TRAF1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Tumor necrosis factor receptor-associated factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TRAF2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Tumor necrosis factor receptor-associated factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TRAF3; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Tumor necrosis factor receptor-associated factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TRAF4; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Tumor necrosis factor receptor-associated factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TRAF5; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Tumor necrosis factor receptor-associated factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TRAF6; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TRAIL (tumor necrosis factor-related apoptosis-inducing ligand); dual
 variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TREM1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TREM2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TRPC6; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TSLP; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TWEAK; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Blood vessel, disease
(Takayasu's disease; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Te38; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Tyrosine kinase receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Tie-1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Tyrosine kinase receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Tie-2; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VHL C5; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Granulomatous disease
(Wegener's granulomatosis; dual variable domain Igs and multispecific
derivs. for treating acute and chronic inflammation, cancer
and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(XCR1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ZFPM2; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Hyperlipoproteinemia
(abeta-; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Skin, disease
(acanthosis nigricans; dual variable domain Igs and multispecific
derivs. for treating acute and chronic inflammation, cancer
and other diseases)

IT Antibodies and Immunoglobulins
(acquired hypogammaglobulinemia; dual variable domain Igs and
multispecific derivs. for treating acute and chronic
inflammation, cancer and other diseases)

IT Pain
(acute and chronic; dual variable domain Igs and multispecific derivs.

for treating acute and chronic inflammation, cancer and other diseases)

IT Immune disease
(acute or chronic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation
Pancreas, disease
(acute pancreatitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Liver, disease
Rheumatic fever
(acute; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Carcinoma
(adenocarcinoma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Endocrine system
(adrenal-hypothalamus-pituitary; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Respiratory distress syndrome
(adult; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Gonadotropin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonist; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cirrhosis
(alc.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy
(allergic asthma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy
Eye, disease
Inflammation
(allergic conjunctivitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy
(allergic contact dermatitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Dermatitis
(allergic contact; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy
Inflammation
Nose, disease
(allergic rhinitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Asthma
(allergic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant rejection
(allotransplant; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hormones, animal, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anabolic steroids; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation
Spinal column, disease
(ankylosing spondylitis, lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Spinal cord
(anterior horn, cell degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Psoriasis
(anti-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytotoxicity
(antibody-mediated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytotoxic agents
(antimetabolites; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Artery
(aorta, dissection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Artery, disease
(aorta, occlusion; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation
(aorta; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Aneurysm
(aortic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Alopecia
(areata; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal
(arthropathy, seroneg.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chlamydia
Disease, animal

Salmonella
Yersinia
(arthropathy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal
(asthenia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease
Spinal column, disease
(ataxia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy
(atopy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hypothyroidism
(atrophic autoimmune; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Anemia (disease)
Autoimmune disease
(autoimmune hemolytic anemia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease
(autoimmune thrombocytopenia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease
Inflammation
Thyroid gland, disease
(autoimmune thyroiditis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hypoglycemia
Thyroid gland, disease
(autoimmune; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Sperm
(autoimmunity; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Infection
(bacterial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain
(basal ganglia, disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Luminescent substances
(bioluminescent; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)
(bispecific; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Oral drug delivery systems
(bolus drug delivery systems; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation
(bone marrow, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation
(bone, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Bronchi, disease
(bronchiolitis obliterans syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease
(bullous, autoimmune; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Heart, disease
(bundle branch block; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-jun; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Pancreas, neoplasm
(carcinoma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Neoplasm
(cardiac; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Shock (circulatory collapse)
(cardiogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation
(cardiopulmonary bypass; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Aves
Birds
Insecta
Protista
(cell; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain
(cerebellar cortex, degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease

(cerebellar; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease
(cerebellum, degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tachycardia
(chaotic or multifocal atrial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Biliary tract, disease
(cholestasis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease
(chorea, senile; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Viral hepatitis
(chronic active; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fatigue, biological
Fatigue, biological
(chronic fatigue syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Newborn
(chronic lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Candidiasis
(chronic mucocutaneous; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease
(chronic obstructive pulmonary disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease
(chronic, neonatal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Liver, disease
(chronic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Claudins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(claudin-3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Claudins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(claudin-7; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(co-stimulation mol.; dual variable domain Igs and multispecific
derivs. for treating acute and chronic inflammation, cancer
and other diseases)

IT Intestine, neoplasm
(colon; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Intestine, neoplasm
(colorectal carcinoma; dual variable domain Igs and multispecific
derivs. for treating acute and chronic inflammation, cancer
and other diseases)

IT Carcinoma
(colorectal; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(conjugates; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(conjugates; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Eye, disease
Inflammation
(conjunctivitis; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Dermatitis
(contact; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Heart, disease
(cor pulmonale; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Nervous system
(corticospinal tract, disease; dual variable domain Igs and
multispecific derivs. for treating acute and chronic
inflammation, cancer and other diseases)

IT Autoimmune hepatitis
(cryptogenic; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(crystallized; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Sepsis

(culture-neg.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal
(cyanosis, acro-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease
(degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal
(degenerative, multi-system; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mental and behavioral disorders
(dementia, AIDS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mental and behavioral disorders
(dementia, pugilistica; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nerve, disease
(demyelination; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Infection
(dengue; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mental and behavioral disorders
(depression; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arteriosclerosis
(diabetic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mental and behavioral disorders
(diffuse Lewy body disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cardiomyopathy
(dilated congestive; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cardiomyopathy
(dilated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lupus erythematosus
(discoid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Platelet (blood)
(disease, autoimmune thrombocytopenia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Reticuloendothelial system
(disease, histiocytosis, malignant; dual variable domain Igs and

multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mitochondria
(disease, multi-system; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Joint, anatomical
(disease, seroneg.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Platelet (blood)
(disease, thrombocytopenia, idiopathic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemotherapy
Joint, anatomical
(disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Dopamine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Blood coagulation disorders
(disseminated intravascular coagulation; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT AIDS (disease)
Acute lymphocytic leukemia
Acute myeloid leukemia
Addison's disease
Alkylating agents, biological
Allergy
Alopecia
Alzheimer's disease
Analgesics
Anaphylaxis
Anemia (disease)
Anesthetics
Angina pectoris
Angiogenesis inhibitors
Animal cell
Antiasthmatics
Antibiotics
Antimicrobial agents
Antiphospholipid syndrome
Antirheumatic agents
Arterial occlusion
Arteriosclerosis
Arteriosclerosis
Asthma
Asthma
Atherosclerosis
Atherosclerosis
Atrial fibrillation
Atrial flutter
B-cell lymphoma
Bladder, neoplasm
Buccal drug delivery systems
Burkitt lymphoma

Burn
Cachexia
Cardiac arrhythmia
Cardiac arrhythmia
Cardiomyopathy
Cardiopulmonary bypass
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Connective tissue, disease
Controlled-release drug delivery systems
Coronary artery disease
Cystic fibrosis
Cytotoxic agents
DNA sequences
Dermatitis
Dermatitis
Diabetes mellitus
Dissociation constant
Down's syndrome
Drug delivery systems
Drugs
Eczema
Encephalomyelitis
Endocarditis
Endocrine system, disease
Escherichia coli
Eukaryota
Fibrosis
Fungi
Genetic vectors
Gout
Granuloma
Graves' disease
Hairy cell leukemia
Hay fever
 Heart block
 Heart failure
 Heart failure
Hematopoietic neoplasm
Hemochromatosis
Hemodialysis
Hemorrhage
Hemorrhage
Hepatitis
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis C
Hodgkin's disease
Human
Human immunodeficiency virus
Hypertension
Hypertension
Hyperthyroidism
Hypnotics and Sedatives
Hypoparathyroidism
Imaging agents
Immunosuppressants
Indicators
Infection
Inflammatory bowel disease

Influenza
Inhalation drug delivery systems
Intestine, disease
Intragastric drug delivery systems
Ischemia
Kawasaki disease
Kidney, disease
Legionella
Leprosy
Leukemia
Leukemia
Linking agents
Lung, neoplasm
Lyme disease
Lymphoma
Malaria
Mammary gland, neoplasm
Melanoma
Meningitis
Mental and behavioral disorders
Metabolic disorders
Molecular cloning
Mouse
Movement disorders
Multiple myeloma
Multiple sclerosis
Mus musculus
Muscle relaxants
Myasthenia gravis
Mycobacterium avium
Mycobacterium tuberculosis
Mycosis
Myelodysplastic syndromes
Myocardial infarction
Myocardial ischemia
Narcotics
Neoplasm
Nervous system stimulants
Neuromuscular blocking agents
Non-Hodgkin lymphoma
Nonsteroidal anti-inflammatory drugs
Osteoarthritis
Osteoarthritis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Parasite
Parkinson's disease
Pharmaceutical carriers
Plant cell
Preeclampsia
Prokaryota
Prostate gland, neoplasm
Protein sequences
Radiotherapy
Raynaud disease
Refsum disease
Rheumatoid arthritis
Rodentia
Saccharomyces cerevisiae
Sarcoidosis

Sarcoma
 Schizophrenia
 Scleroderma
 Scleroderma
 Sepsis
 Shock (circulatory collapse)
 Sick cell anemia
 Skin, disease
 Stomach, neoplasm
 Streptococcus group B
 Stroke
 Stroke
 Sublingual drug delivery systems
 Surface plasmon resonance
 Syphilis
 Telangiectasia
 Transdermal drug delivery systems
 Transplant rejection
 Urticaria
 Uveitis
 Vaccines
 Vaginal drug delivery systems
 Valvular heart disease
 Varicose vein
 Vasculitis
 Vein, disease
 Ventricular fibrillation
 Vitiligo
 Wernicke-Korsakoff syndrome
 Wilson's disease
 Yeast

β -Adrenoceptor agonists
 (dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Antibodies and Immunoglobulins

Nucleic acids

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT APC protein

Aggrecans

Antigens

Bone morphogenetic protein 1

Bone morphogenetic protein 2

Bone morphogenetic protein 4

Bone morphogenetic protein 6

Bone morphogenetic protein 8

Brain-derived neurotrophic factors

CD19 (antigen)

CD20 (antigen)

CD22 (antigen)

CD28 (antigen)

CD3 (antigen)

CD38 (antigen)

CD4 (antigen)

CD40 (antigen)

CD44 (antigen)

CD45RB (antigen)
CD69 (antigen)
CD8 (antigen)
CD80 (antigen)
CD80 (antigen)
CD86 (antigen)
CD86 (antigen)
CTLA-4 (antigen)
Cell adhesion molecules
Chemokines
Clusterin
Clusterin
Cytokines
Enzymes, biological studies
Eotaxin 1
Eotaxin 2
Eotaxin 3
Epidermal growth factor receptors
Fas antigen
Fas ligand
Fibronectins
Gelsolin
Hepatocyte growth factor
Histamine receptors
Insulin-like growth factor I receptors
Integrins
Interleukin 1
Interleukin 10
Interleukin 11
Interleukin 12
Interleukin 13
Interleukin 14
Interleukin 15
Interleukin 16
Interleukin 17
Interleukin 17 receptors
Interleukin 18
Interleukin 18 receptors
Interleukin 19
Interleukin 1 α
Interleukin 1 β
Interleukin 2
Interleukin 20
Interleukin 22
Interleukin 23
Interleukin 24
Interleukin 3
Interleukin 4
Interleukin 5
Interleukin 6
Interleukin 6 receptors
Interleukin 7
Interleukin 8
Interleukin 9
Interleukin 9 receptors
Invariant chain (class II antigen)
Ki-67 antigen
Lipopolysaccharides
Lymphokine receptors
Lymphokines
Lymphotoxin

Macrophage inflammatory protein 2
 Macrophage inflammatory protein 2 α
 Macrophage inflammatory protein 2 β
 Macrophage inflammatory protein 3 α
 Macrophage inflammatory protein 3 β
 Macrophage inflammatory protein 4
 Macrophage inflammatory protein 5
 Melanoma growth-stimulating activity- α
 Midkines
 Monocyte chemoattractant protein-1
 Monocyte chemoattractant protein-2
 Monocyte chemoattractant protein-3
 Monocyte chemoattractant protein-4
 Monokines
 Nerve growth factor receptors
 Neutrophil-activating peptide-2
 Proliferating cell nuclear antigen
 RANTES (chemokine)
 Receptors
 Toll-like receptors
 Transforming growth factor β
 Tumor necrosis factors
 Tumor necrosis factors
 Versicans
 neu (receptor)
 neu (receptor)
 p53 (protein)

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Anthracyclines
 Growth factors, animal
 Radionuclides, biological studies
 Toxins

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Corticosteroids, biological studies
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT CD3 (antigen)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (e; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Lung, disease
 (eosinophilia; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Epididymis
 (epididymitis; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Respiratory system, disease
 (epiglottitis; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal
(erythromelalgia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease
(extrapyramidal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease
(failure, acute; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease
Ovary, disease
(failure; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal
(familial hemophagocytic lymphohistiocytosis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fertility disorders
(female; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Embryo, animal
(fetus, thymus implant rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease
(fibrosis, cryptogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease
Radiation
(fibrosis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal
(fistula, arteriovenous; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fos; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fractalkines; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD3 (antigen)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (g; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Necrosis
 (gas gangrene; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Ulcer
 (gastric; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene B29; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene BCL6; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene ELAC2; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Glycoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene KAI1; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Arteritis
 (giant cell; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Inflammation
 Inflammation
 Kidney, disease
 Kidney, disease
 (glomerulonephritis; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Transplant and Transplantation
 (graft-vs.-host reaction; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Transplant and Transplantation
 (heart; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Antibodies and Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (heavy chain; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Anemia (disease)
 (hemolytic, Coombs-pos.; dual variable domain Igs and multispecific

derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Kidney, disease
 (hemolytic-uremic syndrome; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Anemia (disease)
 (hemolytic; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Injury
 (hepatic, alc.-induced; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Disease, animal
 (histiocytosis, malignant; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Antibodies and Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (humanized; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Allergy
 (hypersensitivity; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Pharmaceutical injections
 (i.m. injections; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Pharmaceutical injections
 (i.p. injections; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Pharmaceutical injections
 (i.v. injections; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Blood, disease
 (idiopathic thrombocytopenia; dual variable domain Igs and
 multispecific derivs. for treating acute and chronic
 inflammation, cancer and other diseases)

IT Leukocytopenia
 (idiopathic; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (immunoadhesins; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Thymus gland
 (implant rejection; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Human herpesvirus 4
 Neisseria meningitidis
 (infection; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Apoptosis
Mitosis
(inhibitors; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Liver, disease
(injury, alc.-induced; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Reperfusion
(injury; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease
(insulin-dependent diabetes mellitus; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Diabetes mellitus
(insulin-dependent; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interferon γ -inducible protein-10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation
Lung, disease
(interstitial pneumonitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease
(interstitial, connective tissue disease-associated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease
(interstitial, post-inflammatory; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease
(interstitial, rheumatoid arthritis-associated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nasal drug delivery systems
Rectal drug delivery systems
(intra-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intraabdominal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intraarticular; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intrabronchial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

diseases)

IT Drug delivery systems
(intracapsular; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intracartilaginous; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intracavitary; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intracelial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intracerebellar; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intracerebroventricular; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intracervical; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intracolic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intrahepatic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intramyocardial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intraosteal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intrapelvic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intrapleural; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intraprostatic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intrapulmonary; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intrarenal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intraretinal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intraspinal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intrasynovial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intrathoracic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intrauterine; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(intravesical; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Eye, disease
Inflammation
(iridocyclitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Rheumatoid arthritis
Rheumatoid arthritis
Rheumatoid arthritis
(juvenile; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(k6HF; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation
(kidney, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fluorescent substances
Luminescent substances
Magnetic materials
(label; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(labeled; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Infection
(leishmaniasis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Leukotriene receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(leukotriene B4, LTB4R2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Leukotriene receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(leukotriene B4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(linker; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation
(liver, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Anesthetics
(local; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Sjogren syndrome
(lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Edema
(lymph-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease
(lymphocytic infiltrative; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lymphotactin, XCL2 or SCM-1b; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lymphotactin; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fertility disorders
(male; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lymphoma
(malignant; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal cell
(mammalian; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease
(microscopic vasculitis of; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Vasculitis
(microscopic; of kidney; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Headache
(migraine; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal
(mitochondrial, multi-system; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Connective tissue, disease
(mixed connective tissue disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monoclonal gammopathy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, therapy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monokine; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(myc; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation
Spinal cord, disease
(myelitis, acute transverse; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Edema
 Hypothyroidism
 (myxedema; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Carcinoma
 (nasopharyngeal; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Pharynx, neoplasm
 (nasopharynx, carcinoma; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Heart, disease
 (neoplasm; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Inflammation
 Kidney, disease
 (nephritis; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and
 other diseases)

IT Kidney, disease
 (nephrotic syndrome; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Proteoglycans, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neurocan; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Muscular dystrophy
 (neurogenic I; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Nerve, disease
 (neuropathy, HIV; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Agranulocytosis
 (neutropenia, autoimmune; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Fever and Hyperthermia
 (neutropenic; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Steatohepatitis
 (nonalc.; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Eye, disease
 (ophthalmia, sympathetic; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Inflammation
 Nerve, disease
 (optic neuritis; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer
 and other diseases)

IT Inflammation

Testis, disease
 (orchitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Immune disease
 (organ transplant-associated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal
 (organomegaly; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cyclin dependent kinase inhibitors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (p57KIP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors
 (pBJ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors
 (pBV; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors
 (pEF6TOP0; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors
 (pEFBOS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors
 (pJV; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors
 (pTT3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors
 (pTT; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation
 (pancreas, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Carcinoma
 (pancreatic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Neoplasm
 (paraneoplastic syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors
 (pcDNA3.1TOP0; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors
 (pcDNA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Body, anatomical
 (pelvis, inflammation; dual variable domain Igs and

multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease
(pemphigoid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease
(pemphigus foliaceus; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease
(pemphigus vulgaris; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Artery, disease
Inflammation
(periarteritis nodosa, pulmonary manifestation; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
(pericardiac; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal organ
(pericardial, disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation
Peritoneum, disease
(peritonitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Anemia (disease)
(pernicious anemia, acquired or juvenile; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Uveitis
(phacogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(phosphacan; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(plectins; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease
Endocrine system, disease
(polyglandular syndrome, type I and II deficiency; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hormone receptors
Hormones, animal, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polypeptide; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Infection
(postinfectious interstitial lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Ovary, disease
(premature failure; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Biliary tract, disease
(primary biliary cirrhosis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hepatitis
(primary sclerosing; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Paralysis
(pseudobulbar, progressive; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis
(psoriatic arthritis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fibrosis
(pulmonary, cryptogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fibrosis
Hypertension
(pulmonary; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis
(reactive; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Intestine, neoplasm
(rectum; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Injury
(reperfusion; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation
Nose, disease
(rhinitis, perenial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Pharmaceutical injections
(s.c. injections; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Biliary tract, disease
Inflammation
(sclerosing cholangitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis
Shock (circulatory collapse)

(septic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (sialomucin MUC-24; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation
(skin, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation
(small intestine, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation
Spinal column, disease
(spondylitis, rheumatoid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Spinal column, disease
Spinal column, disease
(spondyloarthropathy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Myositis
(streptococcal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Encephalitis
(subacute sclerosing; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 11; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 12; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 14; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 18; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(superfamily 4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (surface; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease
 (syncope; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis
 Synovial membrane, disease
 (synovitis, enteropathic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lupus erythematosus
 (systemic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokines
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapy-associated disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Thrombosis
 (thromboangiitis obliterans; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Purpura (disease)
 (thrombocytopenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease
 (thyroid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation
 Thyroid gland, disease
 (thyroiditis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Shock (circulatory collapse)
 (toxic shock syndrome; dual variable domain Igs and multispecific

derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cartilage
 Parathyroid gland
 (transplant rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Bone
 Bone marrow
 Kidney
 Liver
 Pancreas
 Skin
 Small intestine
 (transplant, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Heart
 (transplant; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Injury
 (trauma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Psoriasis
 (type 1 and 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type 1, TNFRSFB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Complement receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fibroblast growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type 3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune hepatitis
 (type I and II; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Spinal muscular atrophy
 (type I; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 1 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type I; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Bone morphogenetic protein receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type IA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Bone morphogenetic protein receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type IB; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other diseases)

IT Bone morphogenetic protein receptors
 Interleukin 1 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type II; dual variable domain Igs and
 multispecific derivs. for treating acute and chronic inflammation,
 cancer and other diseases)

IT Spinal muscular atrophy
 (type III; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other diseases)

IT Vascular endothelial growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type VEGFR-1; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer and other
 diseases)

IT Vascular endothelial growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type VEGFR-2; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer and other
 diseases)

IT Stomach, disease
 (ulcer; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammatory bowel disease
 (ulcerative colitis, arthropathy; dual variable domain Igs
 and multispecific derivs. for treating acute and chronic inflammation,
 cancer and other diseases)

IT Inflammatory bowel disease
 (ulcerative colitis; dual variable domain Igs and
 multispecific derivs. for treating acute and chronic inflammation,
 cancer and other diseases)

IT Colitis
 (ulcerative, arthropathy; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic inflammation, cancer
 and other diseases)

IT Colitis
 (ulcerative; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT Sepsis
 (uro-; dual variable domain Igs and multispecific derivs. for treating
 acute and chronic inflammation, cancer and other diseases)

IT Growth inhibitors, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (vascular endothelial growth inhibitor; dual variable domain Igs
 and multispecific derivs. for treating acute and chronic
 inflammation, cancer and other diseases)

IT Lung, disease
 (vasculitic diffuse; dual variable domain Igs and multispecific derivs.
 for treating acute and chronic inflammation, cancer and other
 diseases)

IT Surgery
 Vas deferens
 (vasectomy, orchitis; dual variable domain Igs and multispecific
 derivs. for treating acute and chronic
 inflammation, cancer and other diseases)

IT Thrombosis
 (venous; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Infection
(viral; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation
(xenotransplant, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD3 (antigen)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(z; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 2 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α , 4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α , 5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α , 6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α , 7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Amyotrophic lateral sclerosis
(α 1-antitrypsin-deficient; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons
Interleukin 13 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons
Interleukin 13 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons
Interleukin 15 receptors
Interleukin 3 receptors
Interleukin 4 receptors
Interleukin 5 receptors
Interleukin 7 receptors

Interleukin 8 receptors

Platelet-derived growth factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α ; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer
and other diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α v; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 1, ITGA1; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer and other
diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 2, ITGA2; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer and other
diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 3, ITGA3; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer and other
diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 4 β 1; dual variable domain Igs and multispecific
derivs. for treating acute and chronic inflammation, cancer and
other diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 6, ITGA6; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer and other
diseases)

IT Interleukin 2 receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β chain; dual variable domain Igs and multispecific
derivs. for treating acute and chronic inflammation, cancer and
other diseases)

IT Catenins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β -; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Interferons

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 1; dual variable domain Igs and multispecific derivs. for
treating acute and chronic inflammation, cancer and other
diseases)

IT Interleukin 8 receptors

Lymphotoxin

Platelet-derived growth factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β ; dual variable domain Igs and multispecific derivs.
for treating acute and chronic inflammation, cancer
and other diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 3; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\beta 4$; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 2 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (γ chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study) (γ ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study) (ω , 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 203874-76-4, Fibroblast growth factor 12
RL: BSU (Biological study, unclassified); BIOL (Biological study) (B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 37205-61-1, Proteinase inhibitor
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SERPIN F 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 930324-46-2P 930324-47-3P 930324-48-4P 930324-49-5P 930324-50-8P
930324-51-9P 930324-52-0P 930324-53-1P 930324-54-2P 930324-55-3P
930324-56-4P 930324-57-5P 930324-58-6P 930324-59-7P 930324-60-0P
930324-61-1P 930324-62-2P 930324-63-3P 930324-64-4P 930324-65-5P
930324-66-6P 930324-67-7P 930324-68-8P 930324-69-9P 930324-70-2P
930324-71-3P 930324-72-4P 930324-73-5P 930324-74-6P 930324-75-7P
930324-76-8P 930324-77-9P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (amino acid sequence; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 69-72-7, Salicylic acid, biological studies
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study) (chronic intoxication; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 51-43-4D, Epinephrine, analogs 51-45-6, Histamine, biological studies
9001-06-3, Chitinase 9001-92-7, Protease 9002-07-7, PTN 9002-62-4, PRL, biological studies 9035-58-9, Blood-coagulation factor III
9041-92-3, SERPIN A 1 9047-22-7, Cathepsin B 9061-61-4, NGF
11096-26-7, EPO 62031-54-3, FGF 62229-50-9, EGF 67763-96-6, IGF-1
67763-97-7, IGF-2 80295-41-6, Complement C3 80295-49-4, Complement C4a
80295-53-0, Complement C5 81627-83-0, M-CSF 83869-56-1, GM-CSF
88232-92-2, SDF 2 106096-92-8, FGF 1 106096-93-9, FGF 2 122191-40-6, CASP-1 123584-45-2, FGF 4 127464-60-2, VEGF 129653-64-1, FGF 5
130939-41-2, FGF 6 140208-23-7, SERPIN E 1 141176-92-3, SERPIN A 3

141349-86-2, CDK-2 kinase 143011-72-7, G-CSF 146480-35-5, Mmp 2
 146480-36-6, Mmp 9 147014-96-8, CDK-5 kinase 147014-97-9, CDK-4 kinase
 148348-14-5, FGF 3 148348-15-6, FGF 7 151185-16-9, FGF 9
 152478-56-3, JAK1 kinase 153190-71-7, CDK-3 kinase 157482-36-5, JAK3
 kinase 157857-21-1, SERPIN B 5 164003-41-2, FGF 8 167397-96-8,
 IRAK-1 kinase 169494-85-3, Leptin 171758-70-6, Fibroblast growth
 factor 10 182762-08-9, CASP-4 182938-13-2, CDK-9 kinase 185915-21-3,
 FGF 11 185915-22-4, FGF 13 185915-23-5, Fibroblast growth factor 14
 188417-84-7, VEGFC 192662-83-2, Vascular endothelial growth factor B
 193363-12-1, VEGFD 193830-08-9, GDF-5 200578-48-9, IRAK-2 kinase
 204719-95-9, Fibroblast growth factor 16 214210-47-6, Neuropilin 1
 223121-69-5, Fibroblast growth factor 19 227018-38-4, Neuropilin 2
 245480-69-7, Fibroblast growth factor 20 271597-13-8, GDF-10
 301166-54-1, Protein, PTEN 303014-92-8, CDK-6 kinase
 314026-96-5, Fibroblast growth factor 23 322637-17-2, Fibroblast growth
 factor 17 322637-18-3, FGF 18 329900-75-6, Cox-2 330197-29-0, CDK-7
 kinase 335217-23-7, Fibroblast growth factor 22 341970-61-4,
 Fibroblast growth factor 21 372092-80-3, Protein kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT 58-85-5, Biotin
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
 (dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT 59-05-2, Methotrexate 10028-17-8, Hydrogen-3, biological studies
 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90,
 biological studies 13967-65-2, Holmium-166, biological studies
 14133-76-7, Technetium-99, biological studies 14158-31-7, Iodine-125,
 biological studies 14265-75-9, Lutetium-177, biological studies
 14762-75-5, Carbon-14, biological studies 15117-53-0, Sulfur-35,
 biological studies 15750-15-9, Indium-111, biological studies
 15766-00-4, Samarium-153, biological studies 53123-88-9, Rapamycin
 79217-60-0, Cyclosporin 104987-11-3, FK 506
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT 7439-89-6, Iron, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hemosiderosis, lung disease; dual variable domain Igs and
 multispecific derivs. for treating acute and chronic
 inflammation, cancer and other diseases)

IT 122024-47-9 500995-49-3 500995-50-6 532391-75-6 669774-82-7
 865864-24-0 865864-26-2 923954-87-4 930288-78-1 930288-80-5
 930288-82-7 930288-91-8 930288-96-3 930289-05-7 930289-14-8
 930289-22-8 930289-25-1 930289-43-3
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (linker; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)

IT 930324-92-8 930324-93-9 930324-94-0 930324-95-1 930324-96-2
 930324-97-3 930324-98-4 930324-99-5 930325-00-1 930325-01-2
 930325-02-3 930325-03-4 930325-04-5 930325-05-6 930325-06-7
 930325-07-8 930325-08-9 930325-09-0 930325-10-3 930325-11-4
 930325-14-7 930325-15-8 930325-16-9 930325-17-0 930325-18-1

930325-19-2 930325-20-5 930325-21-6 930325-22-7 930325-23-8
930325-24-9 930325-25-0 930325-26-1 930325-27-2 930325-28-3
930325-29-4 930325-30-7 930325-31-8 930325-32-9 930325-33-0
930325-34-1

RL: PRP (Properties)

(unclaimed nucleotide sequence; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 930324-80-4 930324-81-5 930324-82-6 930324-83-7 930324-84-8
930324-85-9 930324-86-0 930324-87-1 930324-88-2 930324-89-3
930324-90-6 930324-91-7 930325-12-5 930325-13-6 930325-35-2
930325-36-3 930325-37-4 930325-38-5 930325-39-6 930325-40-9
930325-41-0 930325-42-1 930325-43-2 930325-44-3 930325-45-4
930325-46-5 930325-47-6 930325-48-7 930325-49-8 930325-50-1
930325-51-2 930325-52-3

RL: PRP (Properties)

(unclaimed protein sequence; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 362526-53-2 609338-75-2 930288-59-8 930288-63-4 930288-65-6
930288-67-8 930288-69-0 930288-71-4 930288-73-6 930288-75-8

RL: PRP (Properties)

(unclaimed sequence; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT 142805-56-9

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(α , α ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

L32 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, Phosphoinositide-3-kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

ACCESSION NUMBER: 2007:284115 CAPLUS

DOCUMENT NUMBER: 146:352574

TITLE: Double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases

INVENTOR(S): Chajut, Ayelet; Pinner, Elhanan

PATENT ASSIGNEE(S): Quark Biotech, Inc., USA

SOURCE: PCT Int. Appl., 145pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007029249	A2	20070315	WO 2006-IL1036	20060906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,			

RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-715414P P 20050909
 US 2005-732188P P 20051031

AN 2007:284115 CAPLUS
 DN 146:352574
 ED Entered STN: 16 Mar 2007
 TI Double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases
 IN Chajut, Ayelet; Pinner, Elhanan
 PA Quark Biotech, Inc., USA
 SO PCT Int. Appl., 145pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 CC 3-1 (Biochemical Genetics)
 Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007029249	A2	20070315	WO 2006-IL1036	20060906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-715414P	P	20050909		
US 2005-732188P	P	20051031		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007029249	IPCI	A61K0048-00 [I,A]; C07H0021-02 [I,A]; C07H0021-00 [I,C*]
	IPCR	A61K0048-00 [I,C]; A61K0048-00 [I,A]; C07H0021-00 [I,C]; C07H0021-02 [I,A]

AB The invention relates to a double-stranded compound, such as siRNAs, which down-regulates the expression of one or more cardiovascular-related gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a cardiovascular disorder or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically ED so as to thereby treat the patient.

ST siRNA cardiovascular disease treatment

IT Hemoglobins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ζ; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Heat-shock proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (105kDa/110kDa, 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (13; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Cadherins
 Keratins
 Kinesins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (14; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (162; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Keratins
 Nexins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (17; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Keratins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (18; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Keratins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (19; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Ankyrins
 Calmodulins
 Calponin
 Fibrillins
 Thrombospondins
 Tropomyosins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (1; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Kinesins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (1B; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Metallothioneins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (1K; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Nexins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (24; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Heat-shock proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (27kDa protein 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Heat-shock proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (27kDa protein 3; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Calmodulins

Fibrillins
 Kinesins
 Presenilins
 Tropomyosins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Metallothioneins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2A; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Cyclin dependent kinase inhibitors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2B; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Ankyrins
 Calponin
 Nexins
 Synaptobrevins
 Tropomyosins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (3; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Splicing factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (3a, subunit 3, 60kDa; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Splicing factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (3b, subunit 2, 145kDa; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Connexins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (43, 43kDa; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Syndecans
 Tropomyosins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (4; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (5; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Kinesins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (5B; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Heat-shock proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (70kDa protein 14; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Heat-shock proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (70kDa protein 4; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Heat-shock proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (70kDa protein 5; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Keratins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Heat-shock proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(90kDa protein 1, alpha; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Heat-shock proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(90kDa protein 1, beta; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription elongation factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(A-like 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(A/B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(A3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ADF (actin-depolymerizing factor); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ADP-ribosylation factor-like 2 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ADP-ribosylation factor-like 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ADP-ribosylation factor-like 6 interacting protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ADP-ribosylation-like factor 6 interacting protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(A11-associated protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Clathrin adaptor proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AP-1 (adaptor protein complex 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(APC (anaphase-promoting complex); double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases
)

IT ADP ribosylation factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ARF-3; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT ADP ribosylation factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ARF-4; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT ADP ribosylation factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ARF-5; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ASK interacting protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (AT2 domain containing 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ATF-3 (activating transcription factor 3); double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ATF-4 (activating transcription factor 4); double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Phosphoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Anp32b (acidic nuclear phosphoprotein 32 family member B);
 double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Phosphoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Anp32e (acidic nuclear phosphoprotein 32 family member E);
 double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Actin-related proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Arp2; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Actin-related proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Arp3; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Small nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (B and B1; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Cyclins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (B1; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Cyclins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (B2; double-stranded RNAs and their use for downregulating genes and

treating cardiovascular diseases)

IT Nexins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (B; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (BF1 interacting corepressor; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (BP-like protein 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (BPAG1 (bullous pemphigoid antigen 1); double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (C/EBP (CCAAT box/enhancer element-binding protein); double-stranded
 RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CBL; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CD151; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CD24; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CD31; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CD56; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CD63; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CD72; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CD9; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Cell cycle regulatory proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDC20; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Cell cycle regulatory proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDC2; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDC42 effector protein 3; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT G proteins (guanine nucleotide-binding proteins)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDC42; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDC44; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDC45 cell division cycle 45-like; double-stranded RNAs and their use
for downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDK2-associated protein 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDK2-associated protein 2; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDK5 regulatory subunit associated protein 1; double-stranded RNAs and
their use for downregulating genes and treating
cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDK5 regulatory subunit associated protein 3; double-stranded RNAs and
their use for downregulating genes and treating
cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CENP-E (centromere protein E); double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CL2-antagonist of cell death; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CL2-associated X protein; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CL2-related protein A1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CL2/adenovirus E1B 19kDa interacting protein 2; double-stranded RNAs

and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CL2/adenovirus E1B 19kDa interacting protein 3-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (COMM domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (COMM domain containing 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CR4-NOT transcription complex, subunit 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cellular retinol-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CRBP-I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collapsin response mediator proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CRMP-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Colony stimulating factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CSF2RB; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CXXC finger 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Cbp/p300-interacting transactivator 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chloride channels
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ClC-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chloride channels
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ClC-4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Cripto; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (D-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cyclins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (D1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Small nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (D2, 165kDa; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (D2-associated; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Cyclins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (D2; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Small nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (D3, 18kDa; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Cyclins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (D3; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DAZ associated protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DEAD box protein 17; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DEAD box protein 39; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DEAD box protein 41; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DEAD box protein 47; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DEAD box protein 48; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DEAD box protein 51; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DEAD box protein 5; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DEAD box protein 6; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular

diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DEAH box protein 30; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DEAH box protein 9; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DNA fragmentation factor DFF35; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DNA helicase, homolog; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DNA methyltransferase 1 associated protein 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DNase I-like 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DP (docking protein); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DRP (dystrophin-related protein); double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DTW domain containing 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DiGeorge syndrome critical region gene 6-like; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Molecular chaperones
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DnaJ, homolog; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Down syndrome cell adhesion mol. like 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Down syndrome critical region gene 1-like 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Down syndrome critical region gene 5; double-stranded RNAs and their use
for downregulating genes and treating
cardiovascular diseases)

IT Cyclins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Sphingosine-1-phosphate receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-1; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Lysophosphatidic acid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-7; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Translation elongation factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EF-1γ; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT Translation elongation factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EF-Tu; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EF-hand domain family, member D2; double-stranded RNAs and their use
for downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EGF-like-domain, multiple 7; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ES130-related protein; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Egr-1; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT EphB receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EphB3; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F-box protein 16; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F-box protein 21; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F-box protein 30; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F-box protein 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F-box protein FBX29; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FABP3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FBP-interacting repressor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FERM domain containing 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FK506 binding protein 10, 65 kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FK506 binding protein 1A, 12kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FK506 binding protein 2, 13kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FK506 binding protein 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FK506 binding protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FK506 binding protein 9, 63 kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FKRP (fukutin-related protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FLYWCH-type zinc finger 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (FOXM1 (forkhead box M1); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (FP291; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (FX1D domain containing ion transport regulator 5; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Fanconi anemia, complementation group L; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Fas apoptotic inhibitory mol. 2; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (G protein pathway suppressor 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (G protein $\beta 1/\gamma 2$ subunit-interacting factor 3;
 double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (G protein-coupled receptor kinase interactor 1; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Cyclins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (G1; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Cyclins
 Small nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (G; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GAB1 (GRB2-associated binder 1); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GADD153; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GAS6 (growth arrest-specific 6); double-stranded RNAs and their use
 for downregulating genes and treating
 cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GATA-1; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GATA-2; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GATA-2A; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GATA-6; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GC-rich promoter binding protein 1; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GDI-1 (GDP dissociation inhibitor-1); double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GDI-2 (GDP dissociation inhibitor-2); double-stranded RNAs and their use
 for downregulating genes and treating
 cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GEM, associated protein 7; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GKLF (gut-enriched Kruppel-like factor); double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GLI pathogenesis-related 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GTP cyclohydrolase I feedback regulator; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Gi (adenylate cyclase-inhibiting); double-stranded RNAs and their
 use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (H-rev0107-like protein 5; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HCLS1 associated protein X-1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HIRA interacting protein 5; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HIV-1 enhancer binding protein 1; double-stranded RNAs and their use
for downregulating genes and treating
cardiovascular diseases)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HLA-A; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HLA-B associated transcript 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HLA-B; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HLA-C; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HLA-DRB1; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HMG-box transcription factor 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular
diseases)

IT High-mobility group proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HMG14; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HMG2 like; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HMP19; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HOXB9; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HSPC038; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HSPC244; double-stranded RNAs and their use for downregulating genes

and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (HT-1080; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Huntingtin interacting protein K; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Fibronectins
 Profilins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (I; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Insulin-like growth factor-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IGFBP-4; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Insulin-like growth factor-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IGFBP-5; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Insulin-like growth factor-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IGFBP-7; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Annexins
 Profilins
 Secretogranins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (II; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IQ motif containing F3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IQ motif containing GTPase activating protein 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ISGF-2 (interferon-stimulated gene factor 2); double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Myosins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IXB; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Voltage-gated potassium channels
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Isk-related family, member 1; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Molecular chaperones
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (J-type co-chaperone HSC20; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (JAB1; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Jagged 1; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Jumonji AT rich interactive domain 1B; double-stranded RNAs and their
 use for downregulating genes and treating
 cardiovascular diseases)

IT Blood-group substances
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (K (Kell); double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (KDEL endoplasmic reticulum protein retention, receptor 2;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (KLF2 (Kruppel-like factor 2); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (KLF3 (Kruppel-like factor 3); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (KLF9 (Kruppel-like factor 9); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Heterogeneous nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (L; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LIM and senescent cell antigen-like domains 2; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LIM domain binding 3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LIM domain-containing; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LMO4 (LIM domain only 4); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LSM3 homolog, U6 small nuclear RNA associated; double-stranded RNAs and
 their use for downregulating genes and treating

cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LSM4 homolog, U6 small nuclear RNA associated; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LSM5 homolog, U6 small nuclear RNA associated; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LSM7 homolog, U6 small nuclear RNA associated; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LTBP2 (latent transforming growth factor β -binding protein 2);
 double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MAD2L1 binding protein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Microtubule-associated proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MAP1, light chain 3 α ; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Microtubule-associated proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MAP1B; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MARCKS-like 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MASL1; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MBC3205; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MCM6 (minichromosome maintenance deficient 6); double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MDC9 (metalloprotease-disintegrin-cysteine-rich); double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT P-glycoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MDR3; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MID1 interacting protein 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MLAA-37; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MLAA-3; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MMSA-10; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Phosphoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MPP4; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MSH6; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MTERF domain containing 2; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Meisl, myeloid ecotropic viral integration site 1 homolog;
double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MovO10, Moloney leukemia virus 10, homolog; double-stranded RNAs and
their use for downregulating genes and treating
cardiovascular diseases)

IT Ionotropic glutamate receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(N-Me D-aspartate-like 1A; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(N-acylsphingosine amidohydrolase 3-like; double-stranded RNAs and
their use for downregulating genes and treating
cardiovascular diseases)

IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NAD(P) dependent steroid dehydrogenase-like; double-stranded RNAs and
their use for downregulating genes and treating
cardiovascular diseases)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NCAM (neural cell adhesion mol.); double-stranded RNAs and their use
for downregulating genes and treating
cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NDRG2 (N-myc downstream-regulated gene 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NECAP endocytosis associated I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NFκB-interacting Ras-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NOL1/NOP2/Sun domain family 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Atrial natriuretic peptide receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NPR-A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NS5ATP13TP2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Voltage-gated sodium channels
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Nav1.1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Nedd4 family interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Ninjurin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(OAZ1 (ornithine decarboxylase antizyme 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(P381P; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PA1-1 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PAK1 interacting protein I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PBX/knotted 1 homeobox 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PCOLCE (procollagen C-proteinase enhancer); double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PDGFA associated protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PDZ and LIM domain 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PDZ and LIM domain 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PDZ and LIM domain 7; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Cell adhesion molecules
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PECAM-1 (platelet-endothelial cell adhesion mol. 1); double-stranded
 RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PED; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PEST-containing nuclear protein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PHD finger protein 5A; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PIN2-interacting protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PKCq-interacting protein PICOT; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PPAR binding protein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PRA1 domain family 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(PRP19PSO4 pre-mRNA processing factor 19 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PRP39 pre-mRNA processing factor 39 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PSF (PTB-associated splicing factor); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PTK9L protein tyrosine kinase 9-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PWP2 periodic tryptophan protein homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PWHP domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Quiescin Q6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (R; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAB18; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAB1A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAB3A-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAB7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RABII family interacting protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAD23 homolog B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAD9 homolog A; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAG-1 (recombination-activating gene, 1); double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAG-2 (recombination-activating gene, 2); double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAN binding protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAN binding protein 5; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAN; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RATS1; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RAVER; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (REX2, RNA exonuclease 2 homolog; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Translation termination factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RF-1 (release factor 1); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RFP (ret finger protein); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RI3 binding protein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RING1 and YY1 binding protein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA binding motif protein 12; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA binding motif protein 8A; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA binding protein, autoantigenic; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA helicase DDX3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA-binding region containing 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA-binding, 1,; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA-binding, S1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA-binding, cold shock domain containing E1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA-binding, poly(A) binding protein, C1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA-binding, poly(A) binding protein, nuclear 1; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA-binding, poly(rC) binding protein 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNA-binding, synaptotagmin-binding; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RP42 homolog; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Microtubule-associated proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RPEB family, member 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RRN3, homolog; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(RUN and SH3 domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RUNX2 (runt-related transcription factor 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RWD domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Rab acceptor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Rac; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Ras association domain family 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Ras-GTPase activating protein SH3 domain-binding protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Ras-related GTP binding C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RasGEF domain family 1B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RelA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Rho-GDI α (Rho-specific GDP dissociation inhibitor α); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Rho-GDI γ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Rho-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT GTPase-activating protein
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RhoGAP (Rho GTPase-activating protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT GTPase-activating protein
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RhoGAP 22 (Rho GTPase-activating protein 22); double-stranded RNAs and

their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Rtf1, Paf1/RNA polymerase II complex component, homolog;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT S-100 proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (S-100A10; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT S-100 proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (S-100C; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SAA1 (serum amyloid A1); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SAM and SH3 domain containing 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SAM domain and HD domain 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SCP65 (synaptonemal complex protein 65); double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SCP2 (sterol carrier protein 2); double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SEC31-like 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SECIS-binding protein 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SFRP1 (secreted frizzled-related protein 1); double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SG2NA; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SH2 domain binding protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SH3 domain binding glutamic acid-rich; double-stranded RNAs and their

use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SIN3 homolog B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SM-11044 binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SMT3 suppressor of mif two 3 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Nexins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SNX22; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SOCS-2 (suppressor of cytokine signaling-2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SRP14 (signal recognition particle 14 kDa); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SRP9 (signal recognition particle 9 kDa); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SRY-box 11; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SRY-box 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins, specific or class
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SSB (single-stranded DNA-binding), 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(STAT3-interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factor STAT
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(STAT5A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factor STAT
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(STAT5B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(STEAP family member 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SUB1 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SUMO-1 activating; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Sec61; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Sip1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Sjogren syndrome B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Spl1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (T-rich interactive domain 5B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TACC3 (transforming acidic coiled-coil 3); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TAF9 RNA polymerase II, TATA box binding protein-associated factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TAPA-1 (target of antiproliferative antibody, 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TAR; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TBC1 domain family, member 8; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TCF-4 (T-cell factor 4); double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TEA domain family member I; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TERA; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TFIIIC (transcription factor IIIC), polypeptide 3, 102kDa;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TGF- β induced apoptosis protein 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TGF β -induced factor; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TGF β -inducible nuclear protein 1; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Transforming growth factor β
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TGF β 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (THAP domain containing 7; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (THRSP (thyroid hormone-responsive protein); double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TIP47; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TM2 domain containing 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TNF receptor-associated factor 7; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TNF receptor-associated protein 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TPMsk3; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TPRDI; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT DNA-binding proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TRF1 (telomeric repeat-binding factor 1); double-stranded RNAs and
their use for downregulating genes and treating
cardiovascular diseases)

IT Transient receptor potential cation channels
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TRPM7; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Proteins
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TSC22 domain family, member 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TSPY-like 4; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Tax1 binding protein 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Tax1 binding protein 3; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(U2 small nuclear RNA auxiliary factor 2; double-stranded RNAs and
their use for downregulating genes and treating
cardiovascular diseases)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(U2 small nuclear RNA-associated; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(UBX domain containing 5; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Annexins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(V; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Voltage-dependent anion channels
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VDAC1; double-stranded RNAs and their use for downregulating genes and
treating cardiovascular diseases)

IT Voltage-dependent anion channels
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VDAC2; double-stranded RNAs and their use for downregulating genes and

treating cardiovascular diseases)

IT Voltage-dependent anion channels
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (VDAC3; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (WD repeat domain 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (WD repeat domain 26; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (WNT1 inducible signaling pathway protein 2; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (WW domain binding protein 5; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Williams-Beuren syndrome chromosome region 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Wilms tumor 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (X-ray repair complementing defective repair in Chinese hamster cells
 1; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (XPA binding protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Y box binding protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (YEATS domain containing 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (YP1; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Zic family member 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (abhydrolase domain containing 11; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(abhydrolase domain containing 6; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Transforming proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(acidic coiled-coil containing protein 1; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(actin filament-associated; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(actin-capping, gelsolin-like; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(actin-capping, muscle Z-line, $\alpha 1$; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(actin-capping, muscle Z-line, $\alpha 2$; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(actin-capping, muscle Z-line, β ; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(actin-like 6A; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(actin-related protein 23; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(acyl-CoA binding domain containing 5; double-stranded RNAs and their use
for downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(adenylate cyclase-associated protein 1; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(adhesion regulating mol. 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(adiponectin, 1; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(adipophilin; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (afamin; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (alanine-glyoxylate aminotransferase 2-like 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (amphiphysin; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (amyloid beta precursor protein binding protein 2; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (amyloid beta precursor-like protein 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (angiopoietin-like 7; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ankyrin repeat and SOCS box-containing 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ankyrin repeat and SOCS box-containing 4; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ankyrin repeat domain 13; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ankyrin repeat domain 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ankyrin repeat domain 37; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ankyrin repeat, family A, 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (anterior pharynx defective 1 homolog A; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antioxidant protein ATX1 homolog; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(aquarius homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(arginine-glutamic acid dipeptide repeats; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(arginine-rich, mutated in early stage tumors; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(arginine/serine-rich 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(arginine/serine-rich 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(arginine/serine-rich 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(arginine/serine-rich 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(arginine/serine-rich coiled-coil 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(arrestin domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(astrotactin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ataxin 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ataxin 2-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(autoantigens, NOR-90; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (autoantigens, SjogrenNULLs syndrome nuclear autoantigen 1;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (autoantigens, calcium binding atopy-related autoantigen 1;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (autophagy 12-like protein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (autophagy 7-like protein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (baculoviral IAP repeat-containing 6; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (barren homolog; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (barrier to autointegration factor 1; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (basic leucine zipper and W2 domains 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (basic leucine zipper nuclear factor 1; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (basic leucine zipper transcription factor 2; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (basic transcription factor 3-like 4; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (brain abundant, membrane attached signal protein 1; double-stranded
 RNAs and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (brain expressed, X-linked 1; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (brain protein 13; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (brain protein 44-like; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (brain protein 44; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (brain-specific angiogenesis inhibitor 2;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (brain-specific; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (breast carcinoma-associated, isoform I; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (brix domain containing 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (bromodomain and WD repeat domain containing 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (bromodomain containing 3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (bromodomain containing 8; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Growth factors, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (c-fos induced; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cAMP responsive element binding protein-like 1; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cAMP responsive element binding protein-like 2; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Chloride channels
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (calcium activated, family member 3; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calcyclin binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Calcium-binding proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calcyclins; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calsenilin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calsyntenin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(carbon catabolite repression 4-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Troponin T
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cardiac, TNNT2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(carnitine deficiency-associated, expressed in ventricle 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(catenins $\alpha 1$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cell cycle regulatory proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cell division cycle 2-like 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cell cycle regulatory proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cell division cycle associated 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(centaurin, $\gamma 3$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(contractin α ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(contractin β ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(centrosome-associated protein 350; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cereblon; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cervical cancer oncogene 9; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromatin accessibility complex 1; double-stranded RNAs and their use
for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromatin modifying 2A; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromobox homolog 3; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromobox homolog 5; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromodomain helicase DNA binding 9; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromosome 1 open reading frame 106; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromosome 1 open reading frame 119; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromosome 1 open reading frame 122; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromosome 1 open reading frame 58; double-stranded RNAs and their use
for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromosome 1 open reading frame 75; double-stranded RNAs and their use
for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chromosome 1 open reading frame 8; double-stranded RNAs and their use
for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(chromosome 1 open reading frame 91; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 1 open reading frame 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 10 open reading frame 119; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 10 open reading frame 56; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 10 open reading frame 88; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 11 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 11 open reading frame 31; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 12 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 12 open reading frame 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 13 open reading frame 12; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 14 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 14 open reading frame 111; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 14 open reading frame 166; double-stranded RNAs and their

use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 16 open reading frame 53; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 17 open reading frame 25; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 17 open reading frame 35; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 17 open reading frame 37; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 18 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 19 open reading frame 27; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 2 open reading frame 18; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 20 open reading frame 111; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 20 open reading frame 116; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 20 open reading frame 149; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 20 open reading frame 31; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 20 open reading frame 47; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 20 open reading frame 67; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 22 open reading frame 13; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 22 open reading frame 16; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 22 open reading frame 9; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 4 open reading frame 9; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 6 open reading frame 106; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 6 open reading frame 111; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 6 open reading frame 62; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 6 open reading frame 82; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 6 open reading frame 85; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 6 open reading frame 93; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 7 open reading frame 21; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular

diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 7 open reading frame 30; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 9 open reading frame 10; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 9 open reading frame 24; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 9 open reading frame 58; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 9 open reading frame 88; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (chromosome 9 open reading frame 89; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cingulin-like 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cingulins; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Claudins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (claudin-15; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Claudins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (claudin-7; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cleavage stimulation factor; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coated vesicle membrane protein; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coatamer, subunit alpha; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coatomer, subunit beta; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coatomer, subunit zeta 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coenzyme Q7 homolog, ubiquinone; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cofilin, 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cofilin, 2; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coiled-coil domain containing 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coiled-coil domain containing 80; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coiled-coil-helix domain containing 1; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coiled-coil-helix domain containing 2; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coiled-coil-helix domain containing 3; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cold shock domain protein A; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Molecular chaperones
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (containing TCP1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (copine I; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (copine III; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (copper metabolism domain containing 1; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cornichon homolog 4; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coronin, actin binding protein, 1B; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coronin, actin binding protein, 1C; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coronin, actin binding protein, 2B; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cortactins; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cross-immune reaction antigen PCIA1; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cyclin D-binding myb-like, 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cysteine and glycine-rich protein 1; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cysteine and glycine-rich protein 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cysteine and glycine-rich protein 3; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cysteine-rich, angiogenic inducer, 61; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cytoglobin; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cytokine induced apoptosis inhibitor 1; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cytoskeleton-associated protein 4; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(damage-specific, 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Guanine nucleotide exchange factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(deafness locus-associated; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(death-associated; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(defender against cell death 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dendritic cell; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dermokine; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dickkopf homolog 3; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(differential display and activated by p53; double-stranded RNAs and
their use for downregulating genes and treating
cardiovascular diseases)

IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dihydropyrimidinase-like 3; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dihydrouridine synthase 1-like; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(disintegrin and metalloproteinase, domain 32; double-stranded RNAs and
their use for downregulating genes and treating
cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(disks large homolog-associated protein 4; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(dispatched homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (disrupted in renal carcinoma 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (docking protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cardiac arrest
 Cardiac arrhythmia
 Cardiovascular system, disease
 Coronary artery disease
 Coronary thrombosis
 DNA sequences
 Human
 Myocardial infarction
 Myocardial ischemia
 Stroke
 Valvular heart disease
 cDNA sequences
 (double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Agglutinins and Lectins
 Albumins, biological studies
 Amyloid precursor proteins
 Benzodiazepine receptors
 Biglycans
 Bone morphogenetic protein 1
 Bone morphogenetic protein 2
 Bone morphogenetic protein 4
 C-reactive protein
 CD19 (antigen)
 CD3 (antigen)
 CD34 (antigen)
 CD4 (antigen)
 Caldesmon
 Calnexin
 Calreticulin
 Clusterin
 DNA formation factors
 DNA-binding proteins
 Decorins
 Desmins
 Desmoplakins
 Endothelin ETA receptors
 Ephrin-A2
 Ephrin-B1
 Ephrin-B3
 Epidermal growth factor receptors
 Erythropoietin receptors
 Ferritins
 Fibromodulins
 Filamin
 G protein-coupled receptors
 G proteins (guanine nucleotide-binding proteins)
 Gelsolin
 Glypicans
 Heat-shock proteins
 Insulin-like growth factor II receptors

Interleukin 7 receptors
 Leptin receptors
 Leukemia inhibitory factor receptors
 Lumicans
 Macrophage inflammatory protein 1 β
 Macrophage migration inhibitory factor
 Mdm2 protein
 Midkines
 Monocyte chemoattractant protein-5
 Nicotinic receptors
 Osteonectin
 Platelet-derived growth factor receptors
 Pleiotrophins
 Prion proteins
 Protamines
 Proteins
 Proteins
 Signal sequence receptors
 Stem cell factor
 Synaptophysin
 Thrombomodulin
 Thyroid hormone receptors
 Transferrin receptors
 Transferrins
 Translation initiation factors
 Troponin C
 Troponin I
 Troponin I
 Troponin T
 Vimentins
 Vinculin
 Vitronectin
 p53 (protein)
 α -Actins
 β -Actins
 β 1-Adrenoceptors
 β 2-Adrenoceptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (down-regulated by Ctnnbl; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (down-regulator of transcription 1, TBP-binding; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (dpy-30-like; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (dysferlin; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (dystonin; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Translation elongation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eEF-1 α ; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Translation elongation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eEF-2; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-1A; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-2B; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-3; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-4A; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-4B; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-4E-BP1 (eIF-4E-binding protein 1); double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-4E; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-4G; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-5; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-5A; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Translation initiation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (eIF-5B; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (echinoderm microtubule associated protein like 4; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (egl nine homolog 2; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (elastin microfibril interfacer 1; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (elastin microfibril interfacer 2; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Flavoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (electron transfer flavoprotein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (emopamil binding protein-like; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (enabled, homolog; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (endophilin, B1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (endothelial differentiation-related factor 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (endozepine-like protein type 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (enhancer of rudimentary, homolog; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (epithelial membrane protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (epithelial membrane protein 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (epithelial membrane protein 3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (erythrocyte membrane protein band 41-like 2; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(essential meiotic endonuclease 1 homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(eukaryotic initiation factor-2-associated, p67; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Organelle
(exosome (exonuclease complex), components 5 and 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(far upstream element binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fascin homolog 1, actin-bundling protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fibrinogen-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fibulin, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fibulin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(filamin A interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(flightless I homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(follistatin-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(forty-two-three domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(four and a half LIM domains 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fracture callus 1 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (fragile X mental retardation, autosomal homolog 1; double-stranded
 RNAs and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (frizzled homolog 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (frizzled homolog 4; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (frizzled homolog 6; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (fumarylacetoacetate hydrolase domain containing 2A; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Agglutinins and Lectins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (galactose-binding, soluble, 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Agglutinins and Lectins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (galactose-binding, soluble, 3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Agglutinins and Lectins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (galactose-binding, soluble, 4; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Agglutinins and Lectins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (galactose-binding, soluble, 8; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Agglutinins and Lectins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (galectin-3; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gap junction-specific, $\alpha 7$, 45kDa; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene B29; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene HGFL; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Glycoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene KAI1; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(gene RAB10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene RAB14; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene RAB20; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene RAB22A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene RAB40C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene RAB4A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene RAB5C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene RAB8A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene RAB9A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene SCL; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (glioma tumor suppressor candidate region gene 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (glycerophosphodiester phosphodiesterase domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (glycine cleavage system protein H; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (glycosyltransferase 25 domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (golgi complex, 6; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (golgi complex, 8; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (golgi reassembly stacking protein 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (growth arrest and DNA-damage-inducible, gamma; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (growth arrest-specific 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (growth factor receptor-bound protein 10; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (growth factor receptor-bound protein 14; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (growth factor receptor-bound protein 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (heart and neural crest derivs. expressed 1; double-stranded
 RNAs and their use for downregulating genes and treating
 cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (heat shock, 2; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Myosins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (heavy chain 11, smooth muscle; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Clathrin
 Dyneins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (heavy chain; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hematopoietic stem progenitor cells 176; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteoglycans, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (heparitin sulfate-containing; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Growth factors, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hepatoma-derived; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT High-mobility group proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (high mobility group AT-hook 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT High-mobility group proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (high-mobility group box 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT High-mobility group proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (high-mobility group box 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT High-mobility group proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (high-mobility group nucleosomal binding domain 2; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (high-risk human papilloma viruses E6 oncoproteins targeted protein
 E6TP1 α ; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hnRNP A1; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hnRNP A2/B1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hnRNP C; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hnRNP F; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hnRNP H; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hnRNP K; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hnRNP U; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (homeodomain-containing, iroquois homeobox protein 3; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(homeodomain-containing, iroquois homeobox protein 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (homeodomain-containing, msh homeo box homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (homeodomain-containing, msh homeo box homolog 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Ras proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (huntingtin interacting protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hypoxia up-regulated 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (immature colon carcinoma transcript 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (immediate early response 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (influenza virus NSIA binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor of DNA binding 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor of DNA binding 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor of growth family, member 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (insulin-induced gene 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (integrin β 1 binding protein 1; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (integrin β 1 binding protein 2; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (integrin β 1 binding protein 3; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (integrin β 4 binding protein; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Post-transcriptional processing
 (interference; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (interferon-induced transmembrane protein 2; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (interferon-induced transmembrane protein 3; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (interferon-related developmental regulator 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (interferon-stimulated transcription factor 3, γ 48kDa;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (interleukin 6 signal transducer; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Dyneins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (intermediate chain; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (intersectin 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (jagunal homolog 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(jumonji, AT-rich interactive domain 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(junB; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(junD; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(kelch domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(keratin associated protein 6-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(keratinocyte associated protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(kinase anchor protein 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(kinase anchor protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(kinase anchor protein 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(kinase insert domain receptor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lamin AC; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Calcium-activated potassium channels
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(large-conductance, subfamily M, beta member 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(late cornified envelope 1B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(latent transforming growth factor β binding protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(latrophilin, 3; double-stranded RNAs and their use for downregulating

genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (leucine rich repeat containing 10; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (leucine rich repeat containing 45; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (leucine rich repeat containing 8B; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (leucine zipper protein 5; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (leucine-rich PPR-motif containing; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (leucine-rich repeats and Ig-like domains 3; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (leukocyte Ig-like receptor, subfamily A, member 2; double-stranded
 RNAs and their use for downregulating genes and treating
 cardiovascular diseases)

IT Myosins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (light chain, 1 slow a; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Clathrin
 Dyneins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (light chain; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (low d. lipoprotein receptor adaptor protein 1; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (lymphocyte cytosolic protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (lymphocyte-specific protein 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (lysyl oxidase-like 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (lysyl oxidase-like 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (major facilitator superfamily domain containing 1; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (major nuclear matrix protein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (major vault protein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (makorin, ring finger protein, 1; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (male-enhanced antigen 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Mannose receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mannose 6-phosphate; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mannose phosphate-dolichol utilization defect 1; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Agglutinins and Lectins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mannose-binding, 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (melanoma antigen family D, 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (melanoma antigen family D, 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (membrane, 2A; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (membrane, integral membrane protein 1; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (membrane, integral membrane protein 2B; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (membrane, lysosomal-associated membrane protein 1; double-stranded RNAs
 and their use for downregulating genes and treating

cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (membrane, lysosomal-associated membrane protein 2; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (membrane, lysosomal-associated protein transmembrane 4 α ;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (membrane, palmitoylated 1, 55kDa; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (membrane, vesicle-associated, 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (membrane, vesicle-associated, 8; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (membrane-associated ring finger 7; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mesoderm specific transcript homolog; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (metaxin 1; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (metaxin 2; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (meteorin-like; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (meteorin; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (methyl-CpG binding domain protein 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (microfibrillar-associated protein 2; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(microfibrillar-associated protein 3-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (microfibrillar-associated protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (midnolin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (milk fat globule-EGF factor 8 protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (modulator of estrogen induced transcription; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (monocyte to macrophage differentiation-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mortality factor 4 like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mucolipin 1, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mucolipin 1, 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (muscleblind-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (myc target 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (myelin gene expression factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (myelin protein zero-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (myeloblastosis viral oncogene homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (myeloid leukemia factor 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (myeloid-associated differentiation marker-like; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (myeloid/lymphoid or mixed-lineage leukemia; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (myogenic factor 3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (myotubularin related protein 9; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (myristoylated alanine-rich protein kinase C substrate; double-stranded
 RNAs and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nasal embryonic LHRH factor; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nasopharyngeal carcinoma-related; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (necdin, homolog; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nerve growth factor receptor-associated protein 1; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neural precursor cell expressed, developmentally down-regulated
 4-like; double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neural precursor cell expressed, developmentally down-regulated 4;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neural precursor cell expressed, developmentally down-regulated 8;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neural proliferation, differentiation and control, 1; double-stranded
 RNAs and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neuralized-like 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neuroblastoma RAS viral oncogene homolog; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neurofibromin 2; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Cytoskeleton

(neurofilament, light polypeptide 68kDa; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Cytoskeleton

(neurofilament; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neuroligin 3; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neuronatin; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neurotrimin; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neutrophil cytosolic factor 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nexilin; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nidogen 1; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear VCP-like; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear casein kinase and cyclin-dependent kinase substrate 1;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear factor I; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear factor of activated T-cells 5, tonicity-responsive;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear factor, interleukin 3 regulated; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear factor-like 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear protein E3-3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Nuclear receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear receptor subfamily 1, group D, member 1; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Nuclear receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear receptor subfamily 1, group H, member 2; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Nuclear receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear receptor subfamily 2, group F, member 2; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nucleic acid-binding, polypyrimidine tract binding protein 1;
 double-stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nucleobindin 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nucleolar complex associated 2, homolog; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nucleolar protein 11; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nucleolar protein 5A; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nucleolar protein family A, member 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nucleolar protein family A, member 3; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nucleolar protein with MIF4G domain 1; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nucleophosmin; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nucleoporin, 54 and 205kDa; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nucleosome assembly protein 1-like 1; double-stranded RNAs and their
use for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nucleotide binding protein 2; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(olfactomedin-like 3; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(optic atrophy 3; double-stranded RNAs and their use for downregulating
genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(outer dense fiber of sperm tails 1; double-stranded RNAs and their use
for downregulating genes and treating cardiovascular
diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oxidase assembly 1-like; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Cyclin dependent kinase inhibitors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p19INK4D; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Cyclin dependent kinase inhibitors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p21CIP1; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Cyclin dependent kinase inhibitors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p27KIP1; double-stranded RNAs and their use for downregulating genes
and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p53 and DNA damage regulated 1; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(p53-inducible nuclear protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (p53-inducible nuclear protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cyclin dependent kinase inhibitors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (p57KIP2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (paired box gene 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (partitioning defective 6 homolog alpha; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (patatin-like phospholipase domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pentatricopeptide repeat domain 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (peptide/histidine transporter 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (peripheral myelin protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pern-like domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Peroxins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (peroxin 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (peroxisomal membrane protein 2, 22kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (peroxisome biogenesis factor 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pescadillo homolog 1, containing BRCT domain; double-stranded RNAs and

their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (phosphatidylinositol transfer protein, alpha; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Glycophospholipids
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (phosphatidylinositol-containing; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (phosphofurin acidic cluster sorting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (phospholemman; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pim-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pinin, desmosome associated protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pleckstrin homol. domain containing, family B member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pleckstrin homol. domain containing, family C, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pleckstrin homol.-like domain, family A, member 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pleckstrin homol.-like domain, family B, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (plectins, intermediate filament binding protein 500kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (poly binding protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (poly polymerase family, member 6; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polycomb group ring finger 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(popeye domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(popeye domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(postsynaptic protein CRIPT; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pre-B-cell leukemia transcription factor interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prefoldin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prefoldin 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prefoldin 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(programmed cell death 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(programmed cell death 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proliferation-associated 2G4, 38kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proline-, glutamic acid-, leucine-rich protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prosaposins; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prostaglandin F2 receptor neg. regulator; double-stranded RNAs and their use for downregulating genes and treating

cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (prostateins; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protein inhibitor of activated STAT, 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protein regulator of cytokinesis I; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protein tyrosine phosphatase domain containing 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (proteolipid protein 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily A, 10; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily A, 11; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily A, 12; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily A, 1; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily A, 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily A, 3; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily A, 4; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(protocadherin, gamma subfamily A, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily A, 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily A, 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily B, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily B, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily B, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily B, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins
 Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily B, 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily C, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (protocadherin, gamma subfamily C, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Gene
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pseudogene, UBBP4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Gene
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pseudogene, UOX; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Gene
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pseudogene, cytochrome c processed; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

diseases)

IT Gene
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pseudogene, thioredoxin 1 pseudogene 5; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pxl9-like protein; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (quaking homolog, KH domain RNA binding; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (rap1B; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ras homolog gene family, member A; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ras homolog gene family, member J; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ras-related C3 botulinum toxin substrate 1; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ras-related C3 botulinum toxin substrate 2; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (regulator of chromosome condensation 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT DNA formation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (replication factor C 2, 40kDa; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular diseases)

IT DNA formation factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (replication protein A3, 14kDa; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (restin; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (reticulocalbin 3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (reticulon 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (reticulon 3; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (reticulon 4a; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (retinitis pigmentosa GTPase regulator interacting protein 1;
 double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (retinoblastoma binding protein 2 homolog 1; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (retinoblastoma binding protein 4; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (retinoblastoma binding protein 7; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular
 diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (retinoblastoma-like 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (retinoblastoma-like 2; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (retinol binding protein 4; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ribophorin I; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ribophorin II; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ring finger protein 128; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ring finger protein 149; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(ring finger protein 185; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ring finger protein CKBBP1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(runt-related transcription factor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sarcolemma-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sarcoma antigen NY-SAR-77; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selenium-binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selenium-containing, K; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selenium-containing, P, plasma, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selenium-containing, X, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selenium-containing; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selenocysteine-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(septin 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(septins, 11; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(septins, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(septins, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(serine/arginine repetitive matrix 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (serine/arginine repetitive matrix I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (serine/threonine kinase receptor-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (seven in absentia homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (sex comb on midleg homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (shroom; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (sialomucin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (signal transducing adaptor mol. 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (sin3-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
Proteins, specific or class
RL: BSU (Biological study, unclassified); BIOL (Biological study) (single-stranded DNA-binding, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (small EDRK-rich factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (small acidic; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Double stranded RNA
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small interfering; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (small muscle, X-linked; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (small nuclear RNA auxiliary factor 1-like 2; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Ribonucleoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (snoRNP (small nucleolar ribonucleoprotein), UTP1-like, U3;
 double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (soc-2 suppressor of clear homolog; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 12, member 7; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 16, member 1; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 2, member 1; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 2, member 3; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 20, member 1; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 22, member 3; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 23, member 1; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 24, member 5; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 25, member 13; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 35, member A4; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 36, member 1; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 36, member 2; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 37, member 2; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 39, member 13; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 39, member 6; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 6, member 8; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (solute carrier family 9, isoform 1; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (sortilin-related VPS10 domain-containing receptor 3; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (sparc osteonectin; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (spen homolog; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (sperm associated antigen 7; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (spermatogenesis associated 16; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (spermatogenesis associated 21; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (spinster; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (split handfoot malformation type 1; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (sprouty-related, EVH1 domain containing 2; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stabilin 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stannin; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stathmin-like 2; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stathmin; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (steroid 5 alpha-reductase 2-like; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (steroid sensitive gene 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (sterol regulatory element binding, 2; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (sterol-C4-Me oxidase-like; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stomatin-like 1; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(stress-induced, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stromal cell derived factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stromal cell derived factor 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (structure-specific recognition protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Voltage-gated potassium channels
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (subfamily H, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (suppressor of *S. cerevisiae* gcr2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (suppressor of Ty 16 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (surfeit 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (sushi domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (synaptopodin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (synaptoporin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (synaptotagmin IV; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (syncoilin, intermediate filament 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (syndecan-binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (syntaxin 16; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(t-complex-associated-testis-expressed 1-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(t-complex-associated-testis-expressed 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tafazzin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(talin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tankyrase 1 binding protein 1, 182kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(taxilin α ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tensin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(testis-expressed sequence 261; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tetraspan NET-4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tetratricopeptide repeat domain 7B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(thioredoxin domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(thioredoxin-like 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(thyroid hormone receptor interactor 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(thyroid hormone receptor interactor 12; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (thyroid hormone receptor interactor 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (thyrotrophic embryonic factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (tight junction protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (timeless-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (toll-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (torsin, family 1, member A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (trafficking protein particle complex 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transcript release factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transformer-2 α ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transforming growth factor β -induced; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transforming growth factor β 1-induced transcript 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transgelin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transgelin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(translocation protein-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane trafficking; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane, 30A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane, 38A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane, 49; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane, 64; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane, BAX inhibitor motif containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane, channel-like 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane, emp24 protein transport domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane, emp24 protein transport domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane, growth hormone-inducible; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transmembrane, prostate androgen-induced; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transportin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (tribbles homolog 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(tripartite motif-containing 23; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tripartite motif-containing 28; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tripartite motif-containing 41; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tripartite motif-containing 55; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tripartite motif-containing 65; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tripartite motif-containing 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(triple functional domain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tristetraprolin, C3H type, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tristetraprolin, C3H type-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(trophoblast; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Molecular chaperones
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tubulin-specific, a; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tubulointerstitial nephritis antigen-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tumor necrosis factor receptor superfamily, member 12A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tumor necrosis factor receptor superfamily, member 5 isoform 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(tumor necrosis factor α -induced, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor necrosis factor α -induced, 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor protein D52; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor protein, translationally-controlled 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor rejection antigen 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor suppressor candidate 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor susceptibility gene 101; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Prostanoid receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (type FP; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (type I, $\alpha 1(I)$ -chain, collagens, $\alpha 1(I)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Bone morphogenetic protein receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (type IA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Activin receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (type IIA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Voltage-gated sodium channels
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (type III; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Voltage-gated sodium channels
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (type IX, α subunit; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (tyrosine ligase-like family, member 4; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular
 diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ubiquitin; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ubiquinol-cytochrome c reductase binding protein; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ubiquitin-activating; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ubiquitin-conjugating; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ubiquitin-like 3; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (unc-5 homolog B; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (unc-93 homolog B1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Angina pectoris
 (unstable; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (upregulated during skeletal muscle growth 5; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (upstream transcription factor 2, c-fos interacting; double-stranded
 RNAs and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2;
 double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (v-fos FBJ murine osteosarcoma viral oncogene homolog; double-stranded
 RNAs and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (v-jun sarcoma virus 17 oncogene homolog; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;
 double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (v-myb myeloblastosis viral oncogene homolog; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (v-raf-1 murine leukemia viral oncogene homolog 1; double-
 stranded RNAs and their use for downregulating genes and
 treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (v-ral simian leukemia viral oncogene homolog B; double-stranded RNAs
 and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (vacuolar protein sorting 25; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (vacuolar protein sorting 29; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (vacuolar protein sorting 4A; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (wingless-type MMTV integration site family, member 7B; double-stranded
 RNAs and their use for downregulating genes and treating
 cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (yeast INO80 protein homolog; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (yrdC domain-containing; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 11B; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 161; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 205; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 23; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 336; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 445; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 574; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 605; double-stranded RNAs and their
 use for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 662; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 670; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 91, homolog; double-stranded RNAs and their use
 for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, 9; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, BTB domain containing 16; double-stranded
 RNAs and their use for downregulating genes and treating cardiovascular
 diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, CCCH-type containing 11A; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, CCHC domain containing 9; double-stranded
 RNAs and their use for downregulating genes and treating
 cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, CSL-type containing 2; double-stranded RNAs and
 their use for downregulating genes and treating
 cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, Chk2-interacting; double-stranded RNAs and
 their use for downregulating genes and treating cardiovascular
 diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, FYVE domain containing 9; double-stranded
 RNAs and their use for downregulating genes and treating

cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, GLIS family zinc finger 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zinc finger proteins, matrin type 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (zyxin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (κ -chain, VJ region; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Laminins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α subunit, $\alpha 1$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Karyopherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α , $\alpha 3$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Spectrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α -, SPTAN1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Spectrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α -, non-erythrocytic 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Hemoglobins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 ($\alpha 2$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Tubulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Actinins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α -actinin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Actinins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α -actinin 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 ($\alpha 1$ (III); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 ($\alpha 1$ (IV); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

($\alpha 1(V)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 1(VIII)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 1(XII)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 1(XV)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 1(XVIII)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT α -Actins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 1$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 2(I)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 2(IV)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 2(V)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 2(VI)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT α -Actins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 2$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collagens, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 3(VI)$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Platelet-derived growth factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (α ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Crystallins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (αB -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Microglobulins
 Tubulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) ($\alpha 1$ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Macroglobulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

($\alpha 2$ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Fibrinogens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β chain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Karyopherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β , $\beta 1$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Spectrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β -, non-erythrocytic 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Spectrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β -, non-erythrocytic 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Tubulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β -chimaerin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β -galactosidase protective protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Catenins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β -like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Catenins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 ($\beta 1$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 ($\beta 1$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 ($\beta 5$; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Fibrinogens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (γ chain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Catenins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (γ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT γ -Actins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 ($\gamma 1$ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Laminins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(γ 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT γ -Actins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (γ 2-; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Hemoglobins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ϵ -1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Crystallins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (μ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 71427-00-4, Ribonuclease P
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (14kDa subunit; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 37205-61-1, Proteinase inhibitor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (16; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9026-23-7, Carbamoyl-phosphate synthetase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9025-77-8, Phosphatidic acid phosphatase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 433940-25-1, MRNA splicing endonuclease
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (34 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 109136-49-4, Ubiquitin specific protease
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 95076-93-0, Peptidylprolyl isomerase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (A, B and C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9024-52-6 9054-75-5, Guanylate cyclase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9032-58-0, Farnesyltransferase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CAAX box, β -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9013-93-8, Phospholipase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (D3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9082-72-8, Branched-chain keto acid dehydrogenase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (E1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9000-83-3, ATPase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (H⁺, Ca²⁺, or Na⁺/K⁺-transporting; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases)

IT 9014-24-8
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (I, II and III; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9001-85-8, Lysophospholipase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (II or 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 80449-02-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Ig-like and EGF-like domains-containing, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 866261-76-9
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MX; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9068-67-1, Sulfatase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (SULF-2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9031-98-5, Carboxypeptidase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (X; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 96282-35-8, Serpin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (clade A, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 139691-92-2, Serine proteinase inhibitor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (clade G member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9025-42-7
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (class 2A, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9000-86-6, Glutamic-pyruvate transaminase 9000-95-7, Ectonucleoside triphosphate diphosphohydrolase 9000-96-8, Arginase 9001-15-4, Creatine kinase 9001-16-5, Cytochrome c oxidase 9001-26-7, Coagulation factor II 9001-42-7, α -Glucosidase 9001-52-9, Fructose-1,6-bisphosphatase 9001-58-5, Isocitrate dehydrogenase 9001-59-6, Pyruvate kinase 9001-60-9, Lactate dehydrogenase 9001-62-1, Lipase A 9001-63-2, Lysozyme 9001-64-3, Malate dehydrogenase 9001-77-8, Acid phosphatase 9001-78-9, Alkaline phosphatase 9001-80-3, Phosphofructokinase 9001-82-5, Phosphogluconate dehydrogenase 9001-88-1, Phosphorylase kinase 9004-02-8, Lipoprotein lipase 9012-34-4, Acylphosphatase 9012-42-4, Adenylate cyclase 9012-49-1, Aspartate transcarbamylase 9012-52-6, Methionine adenosyltransferase 9013-02-9, Adenylate kinase 9013-10-9, Glucosamine-6-phosphate deaminase 9013-18-7, Acyl-CoA synthetase 9013-66-5, Glutathione peroxidase 9014-08-8, Enolase 9014-20-4, Pyruvate dehydrogenase 9014-34-0, Fatty acid desaturase 9016-12-0, Hypoxanthine phosphoribosyltransferase 9023-44-3, Tryptophanyl-tRNA synthetase 9023-47-6, Valyl-tRNA synthetase 9023-53-4, Phosphoribosylaminoimidazole synthetase 9023-58-9, Argininosuccinate synthetase 9023-66-9, Formyltetrahydrofolate synthetase 9023-70-5, Glutamate-ammonia ligase 9023-78-3, Triosephosphate isomerase 9023-93-2, Acetyl-Coenzyme A carboxylase 9024-25-3, Aconitase 9024-60-6, Ornithine decarboxylase 9024-93-5,

Dihydroorotase 9025-26-7, Cathepsin D 9025-32-5 9025-54-1,
 S-Adenosylhomocysteine hydrolase 9025-83-6, 3'(2'),5'-Bisphosphate
 nucleotidase 9026-39-5, Uridine-cytidine kinase 9026-43-1 9026-46-4,
 Phosphomevalonate kinase 9026-59-9, Guanylate kinase 9027-03-6,
 Ubiquinol-cytochrome c reductase 9027-13-8, Enoyl Coenzyme A hydratase
 9027-33-2 9027-63-8, Sterol acyltransferase 9027-80-9, Adenine
 phosphoribosyltransferase 9027-81-0, Adenylosuccinate lyase 9027-95-6,
 ATP citrate lyase 9027-97-8, Methenyltetrahydrofolate cyclohydrolase
 9028-04-0, NADH dehydrogenase 9028-06-2 9028-39-1,
 3-Hydroxyisobutyrate dehydrogenase 9028-40-4, 3-Hydroxyacyl-Coenzyme A
 dehydrogenase 9028-86-8, Aldehyde dehydrogenase 9028-93-7, IMP
 dehydrogenase 9029-12-3, Glutamate dehydrogenase 1 9029-14-5,
 Methylenetetrahydrofolate dehydrogenase 9029-32-7, Guanosine
 monophosphate reductase 9029-72-5, p-Hydroxyphenylpyruvate dioxygenase
 9029-73-6, Phenylalanine hydroxylase 9029-78-1, Betaine-homocysteine
 methyltransferase 9030-08-4, UDP glucuronosyltransferase 9030-66-4,
 Glycerol kinase 9030-96-0, Isoleucine-tRNA synthetase 9031-19-0,
 Saccharopine dehydrogenase 9031-26-9, Lysyl-tRNA synthetase 9031-37-2,
 Ceruloplasmin 9031-50-9, Nucleotidyltransferase 9031-68-9,
 Galactosyltransferase 9031-71-4, Alanine-tRNA synthetase 9031-82-7,
 Phosphoribosyl pyrophosphate amidotransferase 9031-86-1, Aspartoacylase
 9031-99-6, Dipeptidase 9032-01-3 9032-02-4, Phosphoribosylglycinamide
 formyltransferase 9032-25-1, Cytochrome b5 reductase 9032-59-1,
 Fumarylacetoacetate hydrolase 9032-62-6, Phosphoglycerate mutase
 9032-68-2, Cathepsin C 9032-95-5 9033-53-8, Retinol dehydrogenase
 9033-55-0, Saccharopine dehydrogenase 9036-20-8, Adenosylmethionine
 decarboxylase 9036-37-7, δ -Aminolevulinate dehydratase
 9037-14-3, δ -Aminolevulinate synthase 9037-42-7, DNA
 methyltransferase 9037-62-1, Glycyl-tRNA synthetase 9037-65-4,
 α -L-Fucosidase 9046-67-7, Serine carboxypeptidase 9047-22-7,
 Cathepsin B 9048-63-9, Epoxide hydrolase 9054-44-8,
 Acetylgalactosaminyltransferase 9054-89-1, Superoxide dismutase
 9055-65-6, Prostaglandin synthase 9055-67-8, Tankyrase 9055-72-5,
 Pyridoxine-5'-phosphate oxidase 9059-22-7, Heme oxygenase 9059-25-0,
 Lysyl oxidase 9073-96-5, Saccharopine dehydrogenase 9074-01-5,
 Pyruvate dehydrogenase kinase 9074-14-0, Thioredoxin reductase
 9074-83-3, Aspartyl aminopeptidase 9074-87-7, Glutamate carboxypeptidase
 9075-21-2, Pyroglutamyl-peptidase I 9075-29-0, Phosphoglycerate
 dehydrogenase 9075-59-6, Glutamyl-tRNA synthetase 9075-64-3,
 Prolylcarboxypeptidase 9077-14-9, Farnesyl diphosphate
 farnesyltransferase 9080-21-1, 7-Dehydrocholesterol reductase
 37228-72-1, Glycine N-methyltransferase 37256-26-1, Saccharopine
 dehydrogenase 37256-59-0, Cysteine dioxygenase 37256-73-8,
 Flavin-containing monooxygenase 37270-94-3, Platelet factor 4
 37278-25-4, Ribonuclease T2 37288-40-7, N-Acetyl- α -glucosaminidase
 37289-06-8, N-Acylsphingosine amidohydrolase 37318-49-3, Protein
 disulfide isomerase 37341-57-4 39391-18-9, Prostaglandin-endoperoxide
 synthase 50812-36-7, Farnesyl diphosphate synthase 50812-37-8,
 Glutathione S-transferase 52227-79-9, Prostaglandin E synthase
 52660-18-1, Casein kinase 1 53096-17-6, Bleomycin hydrolase
 55963-40-1, Vitamin K epoxide reductase 55976-95-9 60382-71-0,
 Diacylglycerol kinase 60571-91-7, Hydroxysteroid dehydrogenase 7
 60748-73-4, Cathepsin H 62213-44-9, Dolichyl-phosphate
 mannosyltransferase 62213-50-7, Serine palmitoyltransferase
 65979-36-4, Signal peptidase 67763-97-7, IGF-II 71124-51-1,
 β -Galactoside α -2,3-sialyltransferase 71965-46-3, Cathepsin S
 74506-58-4, Heparan 2-O-sulfotransferase 74812-43-4, Spermine synthase
 74812-49-0, E3 Ubiquitin protein ligase 76901-00-3, Platelet-activating
 factor acetylhydrolase 77114-08-0, Serine racemase 77642-24-1,
 Thymosin β 4 78689-77-7, 6-Phosphofructo-2-kinase 80146-85-6,
 Transglutaminase 80295-41-6, Complement C3 80295-50-7, Complement C4b

81611-75-8, Fructose-2,6-bisphosphatase 81627-83-0, Colony-stimulating factor 1 83268-44-4 83380-83-0 86480-67-3, Ubiquitin carboxyl-terminal hydrolase 87397-91-9, Thymosin β 10 89964-14-7, Prothymosin, alpha 90597-47-0, Peptidylglycine α -amidating monooxygenase 95328-48-6, Parathymosin 98668-52-1, ADP ribosylarginine hydrolase 106283-10-7, Inositol 1,4,5-trisphosphate 3-kinase 106640-75-9, Aldo-keto reductase 108658-39-5, Myosin phosphatase 109319-16-6, Von Willebrand factor 115926-52-8, Phosphoinositide-3-kinase 116283-83-1, Elongation factor-2 kinase 117444-13-0, tRNA splicing endonuclease 120178-12-3, Telomerase reverse transcriptase 124861-55-8 127464-60-2, Vascular endothelial growth factor 130731-20-3, Prenylcysteine carboxymethyltransferase 137632-07-6, Protein kinase ERK1 137632-08-7, Mitogen-activated protein kinase 1 139316-54-4, Epithelin 141349-86-2, Cyclin-dependent kinase 2 141436-78-4, Protein kinase C 142008-29-5, CAMP-dependent protein kinase 143375-65-9, CDC2 protein 145809-21-8, Tissue inhibitor of metalloproteinase 3 146480-35-5, Matrix metalloproteinase 2 146480-36-6, Matrix metalloproteinase 9 146702-84-3, Mitogen-activated protein kinase kinase kinase 147014-97-9, Cyclin-dependent kinase 4 149371-18-6, Legumain 149885-84-7 151125-25-6, Selenophosphate synthetase 151662-36-1, Tripeptidyl peptidase I 151821-61-3, Ubiquitin B 151821-62-4, Ubiquitin C 152478-57-4, Janus kinase 2 153190-63-7, AXL receptor tyrosine kinase 154531-34-7, Heparin-binding EGF-like growth factor 156681-44-6, α -Methylacyl-CoA racemase 165245-96-5, Mitogen-activated protein kinase 14 167397-96-8, Interleukin-1 receptor-associated kinase 1 169277-44-5, Sphingosine-1-phosphate phosphatase 171715-12-1, Cathepsin Z 172308-13-3, Mitogen-activated protein kinase kinase kinase 3 178037-70-2, Serum- and glucocorticoid-regulated protein kinase 180189-96-2, Caspase 9 183257-54-7, Heparan sulfate 3-O-sulfotransferase 186270-49-5, Angiopoietin 1 186359-58-0, Protein kinase ZAK 189460-40-0, Connective tissue growth factor 190396-38-4, Carboxypeptidase Z 192140-83-3, p21-Activated kinase 2 192662-83-2, Vascular endothelial growth factor B 204719-95-9, Fibroblast growth factor 16 207137-51-7, Peroxiredoxin 207137-52-8, Nemo like kinase 214210-47-6, Neuropilin 1 220983-94-8, Sorbitol dehydrogenase 252901-98-7, Tousled-like kinase 1 271597-11-6, Growth differentiation factor 3 271597-13-8, Growth differentiation factor 10 300855-77-0, Protein tyrosine phosphatase, non-receptor type 6 300857-36-7, Protein tyrosine phosphatase, receptor type, D 302355-25-5, Receptor protein tyrosine phosphatase N 302355-88-0 336874-97-6, Cytochrome P 450 3A5 353498-78-9, Mitogen-activated protein kinase 6 370088-29-2, Mitogen-activated protein kinase kinase kinase kinase 4 372092-80-3, Protein kinase 372170-33-7, Apelin 400653-73-8, Dual specificity phosphatase 5 403648-87-3, Protein kinase Cdc28 403652-37-9, Cyclin-dependent kinase 8 423124-77-0, Inter- α trypsin inhibitor 4 438496-81-2, Sirtuin 443900-95-6, Glycogen synthase kinase 3 β 644991-16-2, Peroxiredoxin 6 676145-27-0, Protein tyrosine phosphatase, non-receptor type 18

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 689772-77-8, Calpain 7 710319-61-2, Sestrin 2 859235-38-4, WNK kinase 905848-61-5, Cytochrome P 450 20A1

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929740-27-2	929740-28-3	929740-29-4	929740-30-7	929740-31-8
	929740-32-9	929740-33-0	929740-34-1	929740-35-2	929740-36-3
	929740-37-4	929740-38-5	929740-39-6	929740-40-9	929740-41-0
	929740-42-1	929740-43-2	929740-44-3	929740-45-4	929740-46-5
	929740-47-6	929740-48-7	929740-49-8	929740-50-1	929740-51-2

929740-52-3	929740-53-4	929740-54-5	929740-55-6	929740-56-7
929740-57-8	929740-58-9	929740-59-0	929740-60-3	929740-61-4
929740-62-5	929740-63-6	929740-64-7	929740-65-8	929740-66-9
929740-67-0	929740-68-1	929740-69-2	929740-70-5	929740-71-6
929740-72-7	929740-73-8	929740-74-9	929740-75-0	929740-76-1
929740-77-2	929740-78-3	929740-79-4	929740-80-7	929740-81-8
929740-82-9	929740-83-0	929740-84-1	929740-85-2	929740-86-3
929740-87-4	929740-88-5	929740-89-6	929740-90-9	929740-91-0
929740-92-1	929740-93-2	929740-94-3	929740-95-4	929740-96-5
929740-97-6	929740-98-7	929740-99-8	929741-00-4	929741-01-5
929741-02-6	929741-03-7	929741-04-8	929741-05-9	929741-06-0
929741-07-1	929741-08-2	929741-09-3	929741-10-6	929741-11-7
929741-12-8	929741-13-9	929741-14-0	929741-15-1	929741-16-2
929741-17-3	929741-18-4	929741-19-5	929741-20-8	929741-21-9
929741-22-0	929741-23-1	929741-24-2	929741-25-3	929741-26-4
929741-27-5	929741-28-6	929741-29-7	929741-30-0	929741-31-1
929741-32-2	929741-33-3	929741-34-4	929741-35-5	929741-36-6
929741-37-7	929741-38-8	929741-39-9	929741-40-2	929741-41-3
929741-42-4	929741-43-5	929741-44-6	929741-45-7	929741-46-8
929741-47-9	929741-48-0	929741-49-1	929741-50-4	929741-51-5
929741-52-6	929741-53-7	929741-54-8	929741-55-9	929741-56-0
929741-57-1	929741-58-2	929741-59-3	929741-60-6	929741-61-7
929741-62-8	929741-63-9	929741-64-0	929741-65-1	929741-66-2
929741-67-3	929741-68-4	929741-69-5	929741-70-8	929741-71-9
929741-72-0	929741-73-1	929741-74-2	929741-75-3	929741-76-4
929741-77-5	929741-78-6	929741-79-7	929741-80-0	929741-81-1
929741-82-2	929741-83-3	929741-84-4	929741-85-5	929741-86-6
929741-87-7	929741-88-8	929741-89-9	929741-90-2	929741-91-3
929741-92-4	929741-93-5	929741-94-6	929741-95-7	929741-96-8
929741-97-9	929741-98-0	929741-99-1	929742-00-7	929742-01-8
929742-02-9	929742-03-0	929742-04-1	929742-05-2	929742-06-3
929742-07-4	929742-08-5	929742-09-6	929742-10-9	929742-11-0
929742-12-1	929742-13-2	929742-14-3	929742-15-4	929742-16-5
929742-17-6	929742-18-7	929742-19-8	929742-20-1	929742-21-2
929742-22-3	929742-23-4	929742-24-5	929742-25-6	929742-26-7
929742-27-8	929742-28-9	929742-29-0	929742-30-3	929742-31-4
929742-32-5	929742-33-6	929742-34-7	929742-35-8	929742-36-9
929742-37-0	929742-38-1	929742-39-2	929742-40-5	929742-41-6
929742-42-7	929742-43-8	929742-44-9	929742-45-0	929742-46-1
929742-47-2	929742-48-3	929742-49-4	929742-50-7	929742-51-8
929742-52-9	929742-53-0	929742-54-1	929742-55-2	929742-56-3
929742-57-4	929742-58-5	929742-59-6	929742-60-9	929742-61-0
929742-62-1				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene CTTN-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929742-63-2	929742-64-3	929742-65-4	929742-66-5	929742-67-6
	929742-68-7	929742-69-8	929742-70-1	929742-71-2	929742-72-3
	929742-73-4	929742-74-5	929742-75-6	929742-76-7	929742-77-8
	929742-78-9	929742-79-0	929742-80-3	929742-81-4	929742-82-5
	929742-83-6	929742-84-7	929742-85-8	929742-86-9	929742-87-0
	929742-88-1	929742-89-2	929742-90-5	929742-91-6	929742-92-7
	929742-93-8	929742-94-9	929742-95-0	929742-96-1	929742-97-2
	929742-98-3	929742-99-4	929743-00-0	929743-01-1	929743-02-2
	929743-03-3	929743-04-4	929743-05-5	929743-06-6	929743-07-7
	929743-08-8	929743-09-9	929743-10-2	929743-11-3	929743-12-4
	929743-13-5	929743-14-6	929743-15-7	929743-16-8	929743-17-9
	929743-18-0	929743-19-1	929743-20-4	929743-21-5	929743-22-6
	929743-23-7	929743-24-8	929743-25-9	929743-26-0	929743-27-1
	929743-28-2	929743-29-3	929743-30-6	929743-31-7	929743-32-8

929743-33-9	929743-34-0	929743-35-1	929743-36-2	929743-37-3
929743-38-4	929743-39-5	929743-40-8	929743-41-9	929743-42-0
929743-43-1	929743-44-2	929743-45-3	929743-46-4	929743-47-5
929743-48-6	929743-49-7	929743-50-0	929743-51-1	929743-52-2
929743-53-3	929743-54-4	929743-55-5	929743-56-6	929743-57-7
929743-58-8	929743-59-9	929743-60-2	929743-61-3	929743-62-4
929743-63-5	929743-64-6	929743-65-7	929743-66-8	929743-67-9
929743-68-0				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene CTTN-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929743-69-1	929743-70-4	929743-71-5	929743-72-6	929743-73-7
	929743-74-8	929743-75-9	929743-76-0	929743-77-1	929743-78-2
	929743-79-3	929743-80-6	929743-81-7	929743-82-8	929743-83-9
	929743-84-0	929743-85-1	929743-86-2	929743-87-3	929743-88-4
	929743-89-5	929743-90-8	929743-91-9	929743-92-0	929743-93-1
	929743-94-2	929743-95-3	929743-96-4	929743-97-5	929743-98-6
	929743-99-7	929744-00-3	929744-01-4	929744-02-5	929744-03-6
	929744-04-7	929744-05-8	929744-06-9	929744-07-0	929744-08-1
	929744-09-2	929744-10-5	929744-11-6	929744-12-7	929744-13-8
	929744-14-9	929744-15-0	929744-16-1	929744-17-2	929744-18-3
	929744-19-4	929744-20-7	929744-21-8	929744-22-9	929744-23-0
	929744-24-1	929744-25-2	929744-26-3	929744-27-4	929744-28-5
	929744-29-6	929744-30-9	929744-31-0	929744-32-1	929744-33-2
	929744-34-3	929744-35-4	929744-36-5	929744-37-6	929744-38-7
	929744-39-8	929744-40-1	929744-41-2	929744-42-3	929744-43-4
	929744-44-5	929744-45-6	929744-46-7	929744-47-8	929744-48-9
	929744-49-0	929744-50-3	929744-51-4	929744-52-5	929744-53-6
	929744-54-7	929744-55-8	929744-56-9	929744-57-0	929744-58-1
	929744-59-2	929744-60-5	929744-61-6	929744-62-7	929744-63-8
	929744-64-9	929744-65-0	929744-66-1	929744-67-2	929744-68-3
	929744-69-4	929744-70-7	929744-71-8	929744-72-9	929744-73-0
	929744-74-1	929744-75-2	929744-76-3	929744-77-4	929744-78-5
	929744-79-6	929744-80-9	929744-81-0	929744-82-1	929744-83-2
	929744-84-3	929744-85-4	929744-86-5	929744-87-6	929744-88-7
	929744-89-8	929744-90-1	929744-91-2	929744-92-3	929744-93-4
	929744-94-5	929744-95-6	929744-96-7	929744-97-8	929744-98-9
	929744-99-0	929745-00-6	929745-01-7	929745-02-8	929745-03-9
	929745-04-0	929745-05-1	929745-06-2	929745-07-3	929745-08-4
	929745-09-5	929745-10-8	929745-11-9	929745-12-0	929745-13-1
	929745-14-2	929745-15-3	929745-16-4	929745-17-5	929745-18-6
	929745-19-7	929745-20-0	929745-21-1	929745-22-2	929745-23-3
	929745-24-4	929745-25-5	929745-26-6	929745-27-7	929745-28-8
	929745-29-9	929745-30-2	929745-31-3	929745-32-4	929745-33-5
	929745-34-6	929745-35-7	929745-36-8	929745-37-9	929745-38-0
	929745-39-1	929745-40-4	929745-41-5	929745-42-6	929745-43-7
	929745-44-8	929745-45-9	929745-46-0	929745-47-1	929745-48-2
	929745-49-3	929745-50-6	929745-51-7	929745-52-8	929745-53-9
	929745-54-0	929745-55-1	929745-56-2	929745-57-3	929745-58-4
	929745-59-5	929745-60-8	929745-61-9	929745-62-0	929745-63-1
	929745-64-2	929745-65-3	929745-66-4	929745-67-5	929745-68-6

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene FXVD5-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929745-69-7	929745-70-0	929745-71-1	929745-72-2	929745-73-3
	929745-74-4	929745-75-5	929745-76-6	929745-77-7	929745-78-8
	929745-79-9	929745-80-2	929745-81-3	929745-82-4	929745-83-5
	929745-84-6	929745-85-7	929745-86-8	929745-87-9	929745-88-0
	929745-89-1	929745-90-4	929745-91-5	929745-92-6	929745-93-7

929745-94-8	929745-95-9	929745-96-0	929745-97-1	929745-98-2
929745-99-3	929746-00-9	929746-01-0	929746-02-1	929746-03-2
929746-04-3	929746-05-4	929746-06-5	929746-07-6	929746-08-7
929746-09-8	929746-10-1	929746-11-2	929746-12-3	929746-13-4
929746-14-5	929746-15-6	929746-16-7	929746-17-8	929746-18-9
929746-19-0	929746-20-3	929746-21-4	929746-22-5	929746-23-6
929746-24-7	929746-25-8	929746-26-9	929746-27-0	929746-28-1
929746-29-2	929746-30-5	929746-31-6	929746-32-7	929746-33-8
929746-34-9	929746-35-0	929746-36-1	929746-37-2	929746-38-3
929746-39-4	929746-40-7	929746-41-8	929746-42-9	929746-43-0
929746-44-1	929746-45-2	929746-46-3	929746-47-4	929746-48-5
929746-49-6	929746-50-9	929746-51-0	929746-52-1	929746-53-2
929746-54-3	929746-55-4	929746-56-5	929746-57-6	929746-58-7
929746-59-8	929746-60-1	929746-61-2	929746-62-3	929746-63-4
929746-64-5	929746-65-6	929746-66-7	929746-67-8	929746-68-9
929746-69-0	929746-70-3	929746-71-4	929746-72-5	929746-73-6
929746-74-7	929746-75-8	929746-76-9	929746-77-0	929746-78-1
929746-79-2	929746-80-5	929746-81-6	929746-82-7	929746-83-8
929746-84-9	929746-85-0	929746-86-1	929746-87-2	929746-88-3
929746-89-4	929746-90-7	929746-91-8	929746-92-9	929746-93-0
929746-94-1	929746-95-2	929746-96-3	929746-97-4	929746-98-5
929746-99-6	929747-00-2	929747-01-3	929747-02-4	929747-03-5
929747-04-6	929747-05-7	929747-06-8	929747-07-9	929747-08-0
929747-09-1	929747-10-4	929747-11-5	929747-12-6	929747-13-7
929747-14-8	929747-15-9	929747-16-0	929747-17-1	929747-18-2
929747-19-3	929747-20-6	929747-21-7	929747-22-8	929747-23-9
929747-24-0	929747-25-1	929747-26-2	929747-27-3	929747-28-4
929747-29-5	929747-30-8	929747-31-9	929747-32-0	929747-33-1
929747-34-2	929747-35-3	929747-36-4	929747-37-5	929747-38-6
929747-39-7	929747-40-0	929747-41-1	929747-42-2	929747-43-3
929747-44-4	929747-45-5	929747-46-6	929747-47-7	929747-48-8
929747-49-9	929747-50-2	929747-51-3	929747-52-4	929747-53-5
929747-54-6	929747-55-7	929747-56-8	929747-57-9	929747-58-0
929747-59-1	929747-60-4	929747-61-5	929747-62-6	929747-63-7
929747-64-8	929747-65-9	929747-66-0	929747-67-1	929747-68-2
929747-69-3	929747-70-6	929747-71-7	929747-72-8	929747-73-9
929747-74-0	929747-75-1	929747-76-2	929747-77-3	929747-78-4
929747-79-5	929747-80-8	929747-81-9	929747-82-0	929747-83-1
929747-84-2	929747-85-3	929747-86-4	929747-87-5	929747-88-6
929747-89-7	929747-90-0	929747-91-1	929747-92-2	929747-93-3

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene HBEGF-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929747-94-4	929747-95-5	929747-96-6	929747-97-7	929747-98-8
	929747-99-9	929748-00-5	929748-01-6	929748-02-7	929748-03-8
	929748-04-9	929748-05-0	929748-06-1	929748-07-2	929748-08-3
	929748-09-4	929748-10-7	929748-11-8	929748-12-9	929748-13-0
	929748-14-1	929748-15-2	929748-16-3	929748-17-4	929748-18-5
	929748-19-6	929748-20-9	929748-21-0	929748-22-1	929748-23-2
	929748-24-3	929748-25-4	929748-26-5	929748-27-6	929748-28-7
	929748-29-8	929748-30-1	929748-31-2	929748-32-3	929748-33-4
	929748-34-5	929748-35-6	929748-36-7	929748-37-8	929748-38-9
	929748-39-0	929748-40-3	929748-41-4	929748-42-5	929748-43-6
	929748-44-7	929748-45-8	929748-46-9	929748-47-0	929748-48-1
	929748-49-2	929748-50-5	929748-51-6	929748-52-7	929748-53-8
	929748-54-9	929748-55-0	929748-56-1	929748-57-2	929748-58-3
	929748-59-4	929748-60-7	929748-61-8	929748-62-9	929748-63-0
	929748-64-1	929748-65-2	929748-66-3	929748-67-4	929748-68-5
	929748-69-6	929748-70-9	929748-71-0	929748-72-1	929748-73-2
	929748-74-3	929748-75-4	929748-76-5	929748-77-6	929748-78-7

929748-79-8	929748-80-1	929748-81-2	929748-82-3	929748-83-4
929748-84-5	929748-85-6	929748-86-7	929748-87-8	929748-88-9
929748-89-0	929748-90-3	929748-91-4	929748-92-5	929748-93-6
929748-94-7	929748-95-8	929748-96-9	929748-97-0	929748-98-1
929748-99-2	929749-00-8	929749-01-9	929749-02-0	929749-03-1
929749-04-2	929749-05-3	929749-06-4	929749-07-5	929749-08-6
929749-09-7	929749-10-0	929749-11-1	929749-12-2	929749-13-3
929749-14-4	929749-15-5	929749-16-6	929749-17-7	929749-18-8
929749-19-9	929749-20-2	929749-21-3	929749-22-4	929749-23-5
929749-24-6	929749-25-7	929749-26-8	929749-27-9	929749-28-0
929749-29-1	929749-30-4	929749-31-5	929749-32-6	929749-33-7
929749-34-8	929749-35-9	929749-36-0	929749-37-1	929749-38-2
929749-39-3	929749-40-6	929749-41-7	929749-42-8	929749-43-9
929749-44-0	929749-45-1	929749-46-2	929749-47-3	929749-48-4
929749-49-5	929749-50-8	929749-51-9	929749-52-0	929749-53-1
929749-54-2	929749-55-3	929749-56-4	929749-57-5	929749-58-6
929749-59-7	929749-60-0	929749-61-1	929749-62-2	929749-63-3
929749-64-4	929749-65-5	929749-66-6	929749-67-7	929749-68-8
929749-69-9	929749-70-2	929749-71-3	929749-72-4	929749-73-5
929749-74-6	929749-75-7	929749-76-8	929749-77-9	929749-78-0
929749-79-1	929749-80-4	929749-81-5	929749-82-6	929749-83-7
929749-84-8	929749-85-9	929749-86-0	929749-87-1	929749-88-2
929749-89-3	929749-90-6	929749-91-7	929749-92-8	929749-93-9
929749-94-0	929749-95-1	929749-96-2	929749-97-3	929749-98-4
929749-99-5	929750-00-5	929750-01-6	929750-02-7	929750-03-8
929750-04-9	929750-05-0	929750-06-1	929750-07-2	929750-08-3
929750-09-4	929750-10-7	929750-11-8	929750-12-9	929750-13-0
929750-14-1	929750-15-2	929750-16-3	929750-17-4	929750-18-5
929750-19-6	929750-20-9	929750-21-0	929750-22-1	929750-23-2
929750-24-3	929750-25-4	929750-26-5	929750-27-6	929750-28-7
929750-29-8				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene IQGAP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929750-30-1	929750-31-2	929750-32-3	929750-33-4	929750-34-5
	929750-35-6	929750-36-7	929750-37-8	929750-38-9	929750-39-0
	929750-40-3	929750-41-4	929750-42-5	929750-43-6	929750-44-7
	929750-45-8	929750-46-9	929750-47-0	929750-48-1	929750-49-2
	929750-50-5	929750-51-6	929750-52-7	929750-53-8	929750-54-9
	929750-55-0	929750-56-1	929750-57-2	929750-58-3	929750-59-4
	929750-60-7	929750-61-8	929750-62-9	929750-63-0	929750-64-1
	929750-65-2	929750-66-3	929750-67-4	929750-68-5	929750-69-6
	929750-70-9	929750-71-0	929750-72-1	929750-73-2	929750-74-3
	929750-75-4	929750-76-5	929750-77-6	929750-78-7	929750-79-8
	929750-80-1	929750-81-2	929750-82-3	929750-83-4	929750-84-5
	929750-85-6	929750-86-7	929750-87-8	929750-88-9	929750-89-0
	929750-90-3	929750-91-4	929750-92-5	929750-93-6	929750-94-7
	929750-95-8	929750-96-9	929750-97-0	929750-98-1	929750-99-2
	929751-00-8	929751-01-9	929751-02-0	929751-03-1	929751-04-2
	929751-05-3	929751-06-4	929751-07-5	929751-08-6	929751-09-7
	929751-10-0	929751-11-1	929751-12-2	929751-13-3	929751-14-4
	929751-15-5	929751-16-6	929751-17-7	929751-18-8	929751-19-9
	929751-20-2	929751-21-3	929751-22-4	929751-23-5	929751-24-6
	929751-25-7	929751-26-8	929751-27-9	929751-28-0	929751-29-1
	929751-30-4	929751-31-5	929751-32-6	929751-33-7	929751-34-8
	929751-35-9	929751-36-0	929751-37-1	929751-38-2	929751-39-3
	929751-40-6	929751-41-7	929751-42-8	929751-43-9	929751-44-0
	929751-45-1	929751-46-2	929751-47-3	929751-48-4	929751-49-5
	929751-50-8	929751-51-9	929751-52-0	929751-53-1	929751-54-2
	929751-55-3	929751-56-4	929751-57-5	929751-58-6	929751-59-7

929751-60-0	929751-61-1	929751-62-2	929751-63-3	929751-64-4
929751-65-5	929751-66-6	929751-67-7	929751-68-8	929751-69-9
929751-70-2	929751-71-3	929751-72-4	929751-73-5	929751-74-6
929751-75-7	929751-76-8	929751-77-9	929751-78-0	929751-79-1
929751-80-4	929751-81-5	929751-82-6	929751-83-7	929751-84-8
929751-85-9	929751-86-0	929751-87-1	929751-88-2	929751-89-3
929751-90-6	929751-91-7	929751-92-8	929751-93-9	929751-94-0
929751-95-1	929751-96-2	929751-97-3	929751-98-4	929751-99-5
929752-00-1	929752-01-2	929752-02-3	929752-03-4	929752-04-5
929752-05-6	929752-06-7	929752-07-8	929752-08-9	929752-09-0
929752-10-3	929752-11-4	929752-12-5	929752-13-6	929752-14-7
929752-15-8	929752-16-9	929752-17-0	929752-18-1	929752-19-2
929752-20-5	929752-21-6	929752-22-7	929752-23-8	929752-24-9
929752-25-0	929752-26-1	929752-27-2	929752-28-3	929752-29-4
929752-30-7	929752-31-8	929752-32-9	929752-33-0	929752-34-1
929752-35-2	929752-36-3	929752-37-4	929752-38-5	929752-39-6
929752-40-9	929752-41-0	929752-42-1	929752-43-2	929752-44-3
929752-45-4	929752-46-5	929752-47-6	929752-48-7	929752-49-8
929752-50-1	929752-51-2	929752-52-3	929752-53-4	929752-54-5
929752-55-6	929752-56-7	929752-57-8	929752-58-9	929752-59-0
929752-60-3	929752-61-4	929752-62-5	929752-63-6	929752-64-7
929752-65-8				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene IQGAP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929752-66-9	929752-67-0	929752-68-1	929752-69-2	929752-70-5
	929752-71-6	929752-72-7	929752-73-8	929752-74-9	929752-75-0
	929752-76-1	929752-77-2	929752-78-3	929752-79-4	929752-80-7
	929752-81-8	929752-82-9	929752-83-0	929752-84-1	929752-85-2
	929752-86-3	929752-87-4	929752-88-5	929752-89-6	929752-90-9
	929752-91-0	929752-92-1	929752-93-2	929752-94-3	929752-95-4
	929752-96-5	929752-97-6	929752-98-7	929752-99-8	929753-00-4
	929753-01-5	929753-02-6	929753-03-7	929753-04-8	929753-05-9

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene IQGAP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929753-06-0	929753-07-1	929753-08-2	929753-09-3	929753-10-6
	929753-11-7	929753-12-8	929753-13-9	929753-14-0	929753-15-1
	929753-16-2	929753-17-3	929753-18-4	929753-19-5	929753-20-8
	929753-21-9	929753-22-0	929753-23-1	929753-24-2	929753-25-3
	929753-26-4	929753-27-5	929753-28-6	929753-29-7	929753-30-0
	929753-31-1	929753-32-2	929753-33-3	929753-34-4	929753-35-5
	929753-36-6	929753-37-7	929753-38-8	929753-39-9	929753-40-2
	929753-41-3	929753-42-4	929753-43-5	929753-44-6	929753-45-7
	929753-46-8	929753-47-9	929753-48-0	929753-49-1	929753-50-4
	929753-51-5	929753-52-6	929753-53-7	929753-54-8	929753-55-9
	929753-56-0	929753-57-1	929753-58-2	929753-59-3	929753-60-6
	929753-61-7	929753-62-8	929753-63-9	929753-64-0	929753-65-1
	929753-66-2	929753-67-3	929753-68-4	929753-69-5	929753-70-8
	929753-71-9	929753-72-0	929753-73-1	929753-74-2	929753-75-3
	929753-76-4	929753-77-5	929753-78-6	929753-79-7	929753-80-0
	929753-81-1	929753-82-2	929753-83-3	929753-84-4	929753-85-5
	929753-86-6	929753-87-7	929753-88-8	929753-89-9	929753-90-2
	929753-91-3	929753-92-4	929753-93-5	929753-94-6	929753-95-7
	929753-96-8	929753-97-9	929753-98-0	929753-99-1	929754-00-7
	929754-01-8	929754-02-9	929754-03-0	929754-04-1	929754-05-2
	929754-06-3	929754-07-4	929754-08-5	929754-09-6	929754-10-9
	929754-11-0	929754-12-1	929754-13-2	929754-14-3	929754-15-4
	929754-16-5	929754-17-6	929754-18-7	929754-19-8	929754-20-1

929754-21-2	929754-22-3	929754-23-4	929754-24-5	929754-25-6
929754-26-7	929754-27-8	929754-28-9	929754-29-0	929754-30-3
929754-31-4	929754-32-5	929754-33-6	929754-34-7	929754-35-8
929754-36-9	929754-37-0	929754-38-1	929754-39-2	929754-40-5
929754-41-6	929754-42-7	929754-43-8	929754-44-9	929754-45-0
929754-46-1	929754-47-2	929754-48-3	929754-49-4	929754-50-7
929754-51-8	929754-52-9	929754-53-0	929754-54-1	929754-55-2
929754-56-3	929754-57-4	929754-58-5	929754-59-6	929754-60-9
929754-61-0	929754-62-1	929754-63-2	929754-64-3	929754-65-4
929754-66-5	929754-67-6	929754-68-7	929754-69-8	929754-70-1
929754-71-2	929754-72-3	929754-73-4	929754-74-5	929754-75-6
929754-76-7	929754-77-8	929754-78-9	929754-79-0	929754-80-3
929754-81-4	929754-82-5	929754-83-6	929754-84-7	929754-85-8
929754-86-9	929754-87-0	929754-88-1	929754-89-2	929754-90-5
929754-91-6	929754-92-7	929754-93-8	929754-94-9	929754-95-0
929754-96-1	929754-97-2	929754-98-3	929754-99-4	929755-00-0
929755-01-1	929755-02-2	929755-03-3	929755-04-4	929755-05-5
929755-06-6	929755-07-7	929755-08-8	929755-09-9	929755-10-2
929755-11-3	929755-12-4	929755-13-5	929755-14-6	929755-15-7
929755-16-8	929755-17-9	929755-18-0	929755-19-1	929755-20-4
929755-21-5	929755-22-6	929755-23-7	929755-24-8	929755-25-9
929755-26-0	929755-27-1	929755-28-2	929755-29-3	929755-30-6
929755-31-7	929755-32-8	929755-33-9	929755-34-0	929755-35-1
929755-36-2	929755-37-3	929755-38-4	929755-39-5	929755-40-8
929755-41-9				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene ODC1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929755-42-0	929755-43-1	929755-44-2	929755-45-3	929755-46-4
	929755-47-5	929755-48-6	929755-49-7	929755-50-0	929755-51-1
	929755-52-2	929755-53-3	929755-54-4	929755-55-5	929755-56-6
	929755-57-7	929755-58-8	929755-59-9	929755-60-2	929755-61-3
	929755-62-4	929755-63-5	929755-64-6	929755-65-7	929755-66-8
	929755-67-9	929755-68-0	929755-69-1	929755-70-4	929755-71-5
	929755-72-6	929755-73-7	929755-74-8	929755-75-9	929755-76-0
	929755-77-1	929755-78-2	929755-79-3	929755-80-6	929755-81-7
	929755-82-8	929755-83-9	929755-84-0	929755-85-1	929755-86-2
	929755-87-3	929755-88-4	929755-89-5		

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene ODC1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929755-90-8	929755-91-9	929755-92-0	929755-93-1	929755-94-2
	929755-95-3	929755-96-4	929755-97-5	929755-98-6	929755-99-7
	929756-00-3	929756-01-4	929756-02-5	929756-03-6	929756-04-7
	929756-05-8	929756-06-9	929756-07-0	929756-08-1	929756-09-2
	929756-10-5	929756-11-6	929756-12-7	929756-13-8	929756-14-9
	929756-15-0	929756-16-1	929756-17-2	929756-18-3	929756-19-4
	929756-20-7	929756-21-8	929756-22-9	929756-23-0	929756-24-1
	929756-25-2	929756-26-3	929756-27-4	929756-28-5	929756-29-6
	929756-30-9	929756-31-0	929756-32-1	929756-33-2	929756-34-3
	929756-35-4	929756-36-5	929756-37-6	929756-38-7	929756-39-8
	929756-40-1	929756-41-2	929756-42-3	929756-43-4	929756-44-5
	929756-45-6	929756-46-7	929756-47-8	929756-48-9	929756-49-0
	929756-50-3	929756-51-4	929756-52-5	929756-53-6	929756-54-7
	929756-55-8	929756-56-9	929756-57-0	929756-58-1	929756-59-2
	929756-60-5	929756-61-6	929756-62-7	929756-63-8	929756-64-9
	929756-65-0	929756-66-1	929756-67-2	929756-68-3	929756-69-4
	929756-70-7	929756-71-8	929756-72-9	929756-73-0	929756-74-1
	929756-75-2	929756-76-3	929756-77-4	929756-78-5	929756-79-6

929756-80-9	929756-81-0	929756-82-1	929756-83-2	929756-84-3
929756-85-4	929756-86-5	929756-87-6	929756-88-7	929756-89-8
929756-90-1	929756-91-2	929756-92-3	929756-93-4	929756-94-5
929756-95-6	929756-96-7	929756-97-8	929756-98-9	929756-99-0
929757-00-6	929757-01-7	929757-02-8	929757-03-9	929757-04-0
929757-05-1	929757-06-2	929757-07-3	929757-08-4	929757-09-5
929757-10-8	929757-11-9	929757-12-0	929757-13-1	929757-14-2
929757-15-3	929757-16-4	929757-17-5	929757-18-6	929757-19-7
929757-20-0	929757-21-1	929757-22-2	929757-23-3	929757-24-4
929757-25-5	929757-26-6	929757-27-7	929757-28-8	929757-29-9
929757-30-2	929757-31-3	929757-32-4	929757-33-5	929757-34-6
929757-35-7	929757-36-8	929757-37-9	929757-38-0	929757-39-1
929757-40-4	929757-41-5	929757-42-6	929757-43-7	929757-44-8
929757-45-9	929757-46-0	929757-47-1	929757-48-2	929757-49-3
929757-50-6	929757-51-7	929757-52-8	929757-53-9	929757-54-0
929757-55-1	929757-56-2	929757-57-3	929757-58-4	929757-59-5
929757-60-8	929757-61-9	929757-62-0	929757-63-1	929757-64-2
929757-65-3	929757-66-4	929757-67-5	929757-68-6	929757-69-7
929757-70-0	929757-71-1	929757-72-2	929757-73-3	929757-74-4
929757-75-5	929757-76-6	929757-77-7	929757-78-8	929757-79-9
929757-80-2	929757-81-3	929757-82-4	929757-83-5	929757-84-6
929757-85-7	929757-86-8	929757-87-9	929945-16-4	929945-17-5
929945-18-6	929945-19-7	929945-20-0	929945-21-1	929945-22-2
929945-23-3	929945-24-4	929945-25-5	929945-26-6	929945-27-7
929945-28-8	929945-29-9	929945-30-2	929945-31-3	929945-32-4
929945-33-5	929945-34-6	929945-35-7	929945-36-8	929945-37-9
929945-38-0	929945-39-1	929945-40-4	929945-41-5	

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene PIM1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929757-88-0	929757-89-1	929757-90-4	929757-91-5	929757-92-6
	929757-93-7	929757-94-8	929757-95-9	929757-96-0	929757-97-1
	929757-98-2	929757-99-3	929758-00-9	929758-01-0	929758-02-1
	929758-03-2	929758-04-3	929758-05-4	929758-06-5	929758-07-6
	929758-08-7	929758-09-8	929758-10-1	929758-11-2	929758-12-3
	929758-13-4	929758-14-5	929758-15-6	929758-16-7	929758-17-8
	929758-18-9	929758-19-0	929758-20-3	929758-21-4	929758-22-5
	929758-23-6	929758-24-7	929758-25-8	929758-26-9	929758-27-0
	929758-28-1	929758-29-2	929758-30-5	929758-31-6	929758-32-7
	929758-33-8	929758-34-9	929758-35-0	929758-36-1	929758-37-2
	929758-38-3	929758-39-4	929758-40-7	929758-41-8	929758-42-9
	929758-43-0	929758-44-1	929758-45-2	929758-46-3	929758-47-4
	929758-48-5	929758-49-6	929758-50-9	929758-51-0	929758-52-1
	929758-53-2	929758-54-3	929758-55-4	929758-56-5	929758-57-6
	929758-58-7	929758-59-8	929758-60-1	929758-61-2	929758-62-3
	929758-63-4	929758-64-5	929758-65-6	929758-66-7	929758-67-8
	929758-68-9	929758-69-0	929758-70-3	929758-71-4	929758-72-5
	929758-73-6	929758-74-7	929758-75-8	929758-76-9	929758-77-0
	929758-78-1	929758-79-2	929758-80-5	929758-81-6	929758-82-7
	929758-83-8	929758-84-9	929758-85-0	929758-86-1	929758-87-2
	929758-88-3	929758-89-4	929758-90-7	929758-91-8	929758-92-9
	929758-93-0	929758-94-1	929758-95-2	929758-96-3	929758-97-4
	929758-98-5	929758-99-6	929759-00-2	929759-01-3	929759-02-4
	929759-03-5	929759-04-6	929759-05-7	929759-06-8	929759-07-9
	929759-08-0	929759-09-1	929759-10-4	929759-11-5	929759-12-6
	929759-13-7	929759-14-8	929759-15-9	929759-16-0	929759-17-1
	929759-18-2	929759-19-3	929759-20-6	929759-21-7	929759-22-8
	929759-23-9	929759-24-0	929759-25-1	929759-26-2	929759-27-3
	929759-28-4	929759-29-5	929759-30-8	929759-31-9	929759-32-0
	929759-33-1	929759-34-2	929759-35-3	929759-36-4	929759-37-5

929759-38-6	929759-39-7	929759-40-0	929759-41-1	929759-42-2
929759-43-3	929759-44-4	929759-45-5	929759-46-6	929759-47-7
929759-48-8	929759-49-9	929759-50-2	929759-51-3	929759-52-4
929759-53-5	929759-54-6	929759-55-7	929759-56-8	929759-57-9
929759-58-0	929759-59-1	929759-60-4	929759-61-5	929759-62-6
929759-63-7	929759-64-8	929759-65-9	929759-66-0	929759-67-1
929759-68-2	929759-69-3	929759-70-6	929759-71-7	929759-72-8
929759-73-9	929759-74-0	929759-75-1	929759-76-2	929759-77-3
929759-78-4	929759-79-5	929759-80-8	929759-81-9	929759-82-0
929759-83-1	929759-84-2	929759-85-3	929759-86-4	929759-87-5
929759-88-6	929759-89-7	929759-90-0	929759-91-1	929759-92-2
929759-93-3	929759-94-4	929759-95-5	929759-96-6	929759-97-7
929759-98-8	929759-99-9	929760-00-9	929760-01-0	929760-02-1
929760-03-2	929760-04-3	929760-05-4	929760-06-5	929760-07-6
929760-08-7	929760-09-8	929760-10-1	929760-11-2	929760-12-3
929760-13-4	929760-14-5	929760-15-6	929760-16-7	929760-17-8
929760-18-9	929760-19-0	929760-20-3	929760-21-4	929760-22-5
929760-23-6				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SGPP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929760-24-7	929760-25-8	929760-26-9	929760-27-0	929760-28-1
	929760-29-2	929760-30-5	929760-31-6	929760-32-7	929760-33-8
	929760-34-9	929760-35-0	929760-36-1	929760-37-2	929760-38-3
	929760-39-4	929760-40-7	929760-41-8	929760-42-9	929760-43-0
	929760-44-1	929760-45-2	929760-46-3	929760-47-4	929760-48-5
	929760-49-6	929760-50-9	929760-51-0	929760-52-1	929760-53-2
	929760-54-3	929760-55-4	929760-56-5	929760-57-6	929760-58-7
	929760-59-8	929760-60-1	929760-61-2	929760-62-3	929760-63-4
	929760-64-5				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SGPP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929760-65-6	929760-66-7	929760-67-8	929760-68-9	929760-69-0
	929760-70-3	929760-71-4	929760-72-5	929760-73-6	929760-74-7
	929760-75-8	929760-76-9	929760-77-0	929760-78-1	929760-79-2
	929760-80-5	929760-81-6	929760-82-7	929760-83-8	929760-84-9
	929760-85-0	929760-86-1	929760-87-2	929760-88-3	929760-89-4
	929760-90-7	929760-91-8	929760-92-9	929760-93-0	929760-94-1
	929760-95-2	929760-96-3	929760-97-4	929760-98-5	929760-99-6
	929761-00-2	929761-01-3	929761-02-4	929761-03-5	929761-04-6
	929761-05-7	929761-06-8	929761-07-9	929761-08-0	929761-09-1
	929761-10-4	929761-11-5	929761-12-6	929761-13-7	929761-14-8
	929761-15-9	929761-16-0	929761-17-1	929761-18-2	929761-19-3
	929761-20-6	929761-21-7	929761-22-8	929761-23-9	929761-24-0
	929761-25-1	929761-26-2	929761-27-3	929761-28-4	929761-29-5
	929761-30-8	929761-31-9	929761-32-0	929761-33-1	929761-34-2
	929761-35-3	929761-36-4	929761-37-5	929761-38-6	929761-39-7
	929761-40-0	929761-41-1	929761-42-2	929761-43-3	929761-44-4
	929761-45-5	929761-46-6	929761-47-7	929761-48-8	929761-49-9
	929761-50-2	929761-51-3	929761-52-4	929761-53-5	929761-54-6
	929761-55-7	929761-56-8	929761-57-9	929761-58-0	929761-59-1
	929761-60-4	929761-61-5	929761-62-6	929761-63-7	929761-64-8
	929761-65-9	929761-66-0	929761-67-1	929761-68-2	929761-69-3
	929761-70-6	929761-71-7	929761-72-8	929761-73-9	929761-74-0
	929761-75-1	929761-76-2	929761-77-3	929761-78-4	929761-79-5
	929761-80-8	929761-81-9	929761-82-0	929761-83-1	929761-84-2
	929761-85-3	929761-86-4	929761-87-5	929761-88-6	929761-89-7
	929761-90-0	929761-91-1	929761-92-2	929761-93-3	929761-94-4

929761-95-5	929761-96-6	929761-97-7	929761-98-8	929761-99-9
929762-00-5	929762-01-6	929762-02-7	929762-03-8	929762-04-9
929762-05-0	929762-06-1	929762-07-2	929762-08-3	929762-09-4
929762-10-7	929762-11-8	929762-12-9	929762-13-0	929762-14-1
929762-15-2	929762-16-3	929762-17-4	929762-18-5	929762-19-6
929762-20-9	929762-21-0	929762-22-1	929762-23-2	929762-24-3
929762-25-4	929762-26-5	929762-27-6	929762-28-7	929762-29-8
929762-30-1	929762-31-2	929762-32-3	929762-33-4	929762-34-5
929762-35-6	929762-36-7	929762-37-8	929762-38-9	929762-39-0
929762-40-3	929762-41-4	929762-42-5	929762-43-6	929762-44-7
929762-45-8	929762-46-9	929762-47-0	929762-48-1	929762-49-2
929762-50-5	929762-51-6	929762-52-7	929762-53-8	929762-54-9
929762-55-0	929762-56-1	929762-57-2	929762-58-3	929762-59-4
929762-60-7	929762-61-8	929762-62-9	929762-63-0	929762-64-1
929762-65-2	929762-66-3	929762-67-4	929762-68-5	929762-69-6
929762-70-9	929762-71-0	929762-72-1	929762-73-2	929762-74-3
929762-75-4	929762-76-5	929762-77-6	929762-78-7	929762-79-8
929762-80-1	929762-81-2	929762-82-3	929762-83-4	929762-84-5
929762-85-6	929762-86-7	929762-87-8	929762-88-9	929762-89-0
929762-90-3	929762-91-4	929762-92-5	929762-93-6	929762-94-7
929762-95-8	929762-96-9	929762-97-0	929762-98-1	929762-99-2
929763-00-8				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SPTLC2-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929763-01-9	929763-02-0	929763-03-1	929763-04-2	929763-05-3
	929763-06-4	929763-07-5	929763-08-6	929763-09-7	929763-10-0
	929763-11-1	929763-12-2	929763-13-3	929763-14-4	929763-15-5
	929763-16-6	929763-17-7	929763-18-8	929763-19-9	929763-20-2
	929763-21-3	929763-22-4	929763-23-5	929763-24-6	929763-25-7
	929763-26-8	929763-27-9	929763-28-0	929763-29-1	929763-30-4
	929763-31-5	929763-32-6	929763-33-7	929763-34-8	929763-35-9
	929763-36-0	929763-37-1	929763-38-2	929763-39-3	929763-40-6
	929763-41-7	929763-42-8	929763-43-9	929763-44-0	929763-45-1
	929763-46-2	929763-47-3	929763-48-4	929763-49-5	929763-50-8
	929763-51-9	929763-52-0	929763-53-1	929763-54-2	929763-55-3
	929763-56-4	929763-57-5	929763-58-6	929763-59-7	929763-60-0
	929763-61-1	929763-62-2	929763-63-3	929763-64-4	929763-65-5
	929763-66-6	929763-67-7	929763-68-8	929763-69-9	929763-70-2
	929763-71-3	929763-72-4	929763-73-5	929763-74-6	929763-75-7
	929763-76-8	929763-77-9	929763-78-0	929763-79-1	929763-80-4
	929763-81-5	929763-82-6	929763-83-7	929763-84-8	929763-85-9
	929763-86-0	929763-87-1	929763-88-2	929763-89-3	929763-90-6
	929763-91-7	929763-92-8	929763-93-9	929763-94-0	929763-95-1
	929763-96-2	929763-97-3	929763-98-4	929763-99-5	929764-00-1
	929764-01-2	929764-02-3	929764-03-4	929764-04-5	929764-05-6
	929764-06-7	929764-07-8	929764-08-9	929764-09-0	929764-10-3
	929764-11-4	929764-12-5	929764-13-6	929764-14-7	929764-15-8
	929764-16-9	929764-17-0	929764-18-1	929764-19-2	929764-20-5
	929764-21-6	929764-22-7	929764-23-8	929764-24-9	929764-25-0
	929764-26-1	929764-27-2	929764-28-3	929764-29-4	929764-30-7
	929764-31-8	929764-32-9	929764-33-0	929764-34-1	

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SPTLC2-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929764-35-2	929764-36-3	929764-37-4	929764-38-5	929764-39-6
	929764-40-9	929764-41-0	929764-42-1	929764-43-2	929764-44-3
	929764-45-4	929764-46-5	929764-47-6	929764-48-7	929764-49-8
	929764-50-1	929764-51-2	929764-52-3	929764-53-4	929764-54-5

929764-55-6	929764-56-7	929764-57-8	929764-58-9	929764-59-0
929764-60-3	929764-61-4	929764-62-5	929764-63-6	929764-64-7
929764-65-8	929764-66-9	929764-67-0	929764-74-9	929764-75-0
929764-76-1	929764-77-2	929764-78-3	929764-79-4	929764-80-7
929764-81-8	929764-82-9	929764-83-0	929764-84-1	929764-85-2
929764-86-3	929764-87-4	929764-88-5	929764-89-6	929764-90-9
929764-91-0	929764-92-1	929764-93-2	929764-94-3	929764-95-4
929764-96-5	929764-97-6	929764-98-7	929764-99-8	929765-00-4
929765-01-5	929765-02-6	929765-03-7	929765-04-8	929765-05-9
929765-06-0	929765-07-1	929765-08-2	929765-09-3	929765-10-6
929765-11-7	929765-12-8	929765-13-9	929765-14-0	929765-15-1
929765-16-2	929765-17-3	929765-18-4	929765-19-5	929765-20-8
929765-21-9	929765-22-0	929765-23-1	929765-24-2	929765-25-3
929765-26-4	929765-27-5	929765-28-6	929765-29-7	929765-30-0
929765-31-1	929765-32-2	929765-33-3	929765-34-4	929765-36-6
929765-37-7	929765-38-8	929765-39-9	929765-40-2	929765-41-3
929765-42-4	929765-43-5	929765-44-6	929765-46-8	929765-47-9
929765-48-0	929765-49-1	929765-50-4	929765-51-5	929765-52-6
929765-53-7	929765-54-8	929765-55-9	929765-56-0	929765-57-1
929765-58-2	929765-59-3	929765-60-6	929765-61-7	929765-62-8
929765-63-9	929765-64-0	929765-65-1	929765-66-2	929765-67-3
929765-68-4	929765-69-5	929765-70-8	929765-71-9	929765-72-0
929765-73-1	929765-74-2	929765-75-3	929765-76-4	929765-78-6
929765-79-7	929765-80-0	929765-81-1	929765-82-2	929765-83-3
929765-84-4	929765-85-5	929765-86-6	929765-87-7	929765-88-8
929765-89-9	929765-90-2	929765-92-4	929765-93-5	929765-94-6
929765-95-7	929765-96-8	929765-97-9	929765-98-0	929765-99-1
929766-00-7	929766-01-8	929766-02-9	929766-03-0	929766-05-2
929766-06-3	929766-07-4	929766-08-5	929766-09-6	929766-10-9
929766-11-0	929766-12-1	929766-13-2	929766-14-3	929766-15-4
929766-16-5	929766-17-6	929766-19-8	929766-20-1	929766-21-2
929766-22-3	929766-23-4	929766-24-5	929766-25-6	929766-26-7
929766-27-8	929766-28-9	929766-29-0	929766-31-4	929766-32-5
929766-33-6	929766-34-7	929766-35-8	929766-36-9	929766-37-0
929766-38-1	929766-39-2	929766-41-6	929766-42-7	929766-43-8
929766-44-9	929766-45-0	929766-46-1	929766-47-2	929766-48-3
929766-49-4	929766-50-7	929766-52-9	929766-53-0	929766-54-1
929766-55-2	929766-56-3	929766-57-4	929766-58-5	929766-59-6
929766-60-9	929766-61-0	929766-63-2	929766-64-3	929766-65-4
929766-66-5	929766-67-6	929766-68-7	929766-69-8	929766-70-1
929766-71-2	929766-72-3	929766-73-4	929766-74-5	929766-75-6
929766-76-7	929766-77-8	929766-78-9	929766-79-0	929766-80-3
929766-81-4	929766-82-5	929766-83-6	929766-84-7	929766-85-8
929766-86-9				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SSAT-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929766-87-0	929766-88-1	929766-89-2	929766-90-5	929766-91-6
	929766-92-7	929766-93-8	929766-94-9	929766-95-0	929766-96-1
	929766-97-2	929766-98-3	929766-99-4	929767-00-0	929767-01-1
	929767-02-2	929767-03-3	929767-04-4	929767-05-5	929767-06-6
	929767-07-7	929767-08-8	929767-09-9	929767-10-2	929767-11-3
	929767-12-4	929767-13-5	929767-14-6	929767-15-7	929767-16-8
	929767-17-9	929767-18-0	929767-19-1	929767-20-4	929767-21-5
	929767-22-6	929767-23-7	929767-24-8	929767-25-9	929767-26-0
	929767-27-1	929767-28-2	929767-29-3	929767-30-6	929767-31-7
	929767-32-8	929767-33-9	929767-34-0	929767-35-1	929767-36-2
	929767-37-3	929767-38-4	929767-39-5	929767-40-8	929767-41-9
	929767-43-1	929767-44-2	929767-45-3	929767-46-4	929767-47-5
	929767-48-6	929767-49-7	929767-50-0	929767-51-1	929767-52-2

929767-53-3	929767-54-4	929767-55-5	929767-56-6	929767-57-7
929767-58-8	929767-59-9	929767-61-3	929767-62-4	929767-63-5
929767-64-6	929767-65-7	929767-66-8	929767-67-9	929767-68-0
929767-69-1	929767-71-5	929767-72-6	929767-73-7	929767-74-8
929767-75-9	929767-76-0	929767-77-1	929767-78-2	929767-80-6
929767-81-7	929767-82-8	929767-83-9	929767-84-0	929767-85-1
929767-86-2	929767-87-3	929767-89-5	929767-90-8	929767-91-9
929767-92-0	929767-93-1	929767-94-2	929767-95-3	929767-96-4
929767-97-5	929767-99-7	929768-00-3	929768-01-4	929768-02-5
929768-03-6	929768-04-7	929768-05-8	929768-06-9	929768-07-0
929768-08-1	929768-09-2	929768-10-5	929768-12-7	929768-13-8

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SSAT-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT	929768-14-9	929768-15-0	929768-16-1	929768-17-2	929768-18-3
	929768-19-4	929768-20-7	929768-21-8	929768-22-9	929768-24-1
	929768-25-2	929768-26-3	929768-27-4	929768-28-5	929768-29-6
	929768-30-9	929768-31-0	929768-32-1	929768-33-2	929768-35-4
	929768-36-5	929768-37-6	929768-38-7	929768-39-8	929768-40-1
	929768-41-2	929768-42-3	929768-44-5	929768-45-6	929768-46-7
	929768-47-8	929768-48-9	929768-49-0	929768-50-3	929768-51-4
	929768-52-5	929768-54-7	929768-55-8	929768-56-9	929768-57-0
	929768-58-1	929768-59-2	929768-60-5	929768-61-6	929768-62-7
	929768-63-8	929768-65-0	929768-66-1	929768-67-2	929768-68-3
	929768-69-4	929768-70-7	929768-71-8	929768-72-9	929768-73-0
	929768-74-1	929768-76-3	929768-77-4	929768-78-5	929768-79-6
	929768-80-9	929768-81-0	929768-82-1	929768-83-2	929768-84-3
	929768-85-4	929768-86-5	929768-88-7	929768-89-8	929768-90-1
	929768-91-2	929768-92-3	929768-93-4	929768-94-5	929768-95-6
	929768-96-7	929768-97-8	929768-99-0	929769-00-6	929769-01-7
	929769-02-8	929769-03-9	929769-04-0	929769-05-1	929769-06-2
	929769-07-3	929769-08-4	929769-09-5	929769-11-9	929769-12-0
	929769-13-1	929769-14-2	929769-15-3	929769-16-4	929769-17-5
	929769-18-6	929769-20-0	929769-21-1	929769-22-2	929769-23-3
	929769-24-4	929769-25-5	929769-26-6	929769-27-7	929769-28-8
	929769-29-9	929769-30-2	929769-31-3	929769-32-4	929769-33-5
	929769-34-6	929769-35-7	929769-36-8	929769-37-9	929769-38-0
	929769-39-1	929769-40-4	929769-42-6	929769-43-7	929769-44-8
	929769-45-9	929769-46-0	929769-47-1	929769-48-2	929769-49-3
	929769-51-7	929769-52-8	929769-53-9	929769-54-0	929769-55-1
	929769-56-2	929769-57-3	929769-58-4	929769-59-5	929769-60-8
	929769-61-9	929769-62-0	929769-63-1	929769-64-2	929769-65-3
	929769-66-4	929769-67-5	929769-68-6	929769-69-7	929769-70-0
	929769-72-2	929769-73-3	929769-74-4	929769-75-5	929769-76-6
	929769-77-7	929769-78-8	929769-79-9	929769-80-2	929769-81-3
	929769-83-5	929769-84-6	929769-85-7	929769-86-8	929769-87-9
	929769-88-0	929769-89-1	929769-90-4	929769-91-5	929769-92-6
	929769-93-7	929769-95-9	929769-96-0	929769-97-1	929769-98-2
	929769-99-3	929770-00-3	929770-01-4	929770-02-5	929770-03-6
	929770-04-7	929770-05-8	929770-06-9	929770-07-0	929770-08-1
	929770-09-2	929770-10-5	929770-11-6	929770-12-7	929770-13-8
	929770-14-9	929770-15-0	929770-16-1	929770-17-2	929770-18-3
	929770-19-4	929770-20-7	929770-21-8	929770-22-9	929770-23-0
	929770-24-1	929770-25-2	929770-26-3	929770-27-4	929770-28-5
	929770-29-6	929770-30-9	929770-31-0	929770-32-1	929770-33-2
	929770-34-3	929770-35-4	929770-36-5	929770-37-6	929770-38-7
	929770-39-8	929770-40-1	929770-41-2	929770-42-3	929770-43-4
	929770-44-5	929770-45-6	929770-46-7	929770-47-8	929770-48-9
	929770-49-0	929770-50-3	929770-51-4	929770-52-5	929770-53-6
	929770-54-7	929770-55-8	929770-56-9	929770-57-0	929770-58-1

929770-59-2 929770-60-5 929770-61-6 929770-62-7 929770-63-8
929770-64-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(gene SSG1-targeting siRNA; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT	929770-65-0	929770-66-1	929770-67-2	929770-68-3	929770-69-4
	929770-70-7	929770-71-8	929770-72-9	929770-73-0	929770-74-1
	929770-75-2	929770-76-3	929770-77-4	929770-78-5	929770-79-6
	929770-80-9	929770-81-0	929770-82-1	929770-83-2	929770-84-3
	929770-85-4	929770-86-5	929770-87-6	929770-88-7	929770-89-8
	929770-90-1	929770-91-2	929770-92-3	929770-93-4	929770-94-5
	929770-95-6	929770-96-7	929770-97-8	929770-98-9	929770-99-0
	929771-00-6	929771-01-7	929771-02-8	929771-03-9	929771-04-0
	929771-05-1	929771-06-2	929771-07-3	929771-08-4	929771-09-5
	929771-10-8	929771-11-9	929771-12-0	929771-13-1	929771-14-2
	929771-15-3	929771-16-4	929771-17-5	929771-18-6	929771-19-7
	929771-20-0	929771-21-1	929771-22-2	929771-23-3	929771-24-4

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(gene SSG1-targeting siRNA; double-stranded RNAs and their use for
downregulating genes and treating cardiovascular diseases)

IT	929771-25-5	929771-26-6	929771-27-7	929771-28-8	929771-29-9
	929771-30-2	929771-31-3	929771-32-4	929771-33-5	929771-34-6
	929771-35-7	929771-36-8	929771-37-9	929771-38-0	929771-39-1
	929771-40-4	929771-41-5	929771-42-6	929771-43-7	929771-44-8
	929771-45-9	929771-46-0	929771-47-1	929771-48-2	929771-49-3
	929771-50-6	929771-51-7	929771-52-8	929771-53-9	929771-54-0
	929771-55-1	929771-56-2	929771-57-3	929771-58-4	929771-59-5
	929771-60-8	929771-61-9	929771-62-0	929771-63-1	929771-64-2
	929771-65-3	929771-66-4	929771-67-5	929771-68-6	929771-69-7
	929771-70-0	929771-71-1	929771-72-2	929771-73-3	929771-74-4
	929771-75-5	929771-76-6	929771-77-7	929771-78-8	929771-79-9
	929771-80-2	929771-81-3	929771-82-4	929771-83-5	929771-84-6
	929771-85-7	929771-86-8	929771-87-9	929771-88-0	929771-89-1
	929771-90-4	929771-91-5	929771-92-6	929771-93-7	929771-94-8
	929771-95-9	929771-96-0	929771-97-1	929771-98-2	929771-99-3
	929772-00-9	929772-01-0	929772-02-1	929772-03-2	929772-04-3
	929772-05-4	929772-06-5	929772-07-6	929772-08-7	929772-09-8
	929772-10-1	929772-11-2	929772-12-3	929772-13-4	929772-14-5
	929772-15-6	929772-16-7	929772-17-8	929772-18-9	929772-19-0
	929772-20-3	929772-21-4	929772-22-5	929772-23-6	929772-24-7
	929772-25-8	929772-26-9	929772-27-0	929772-28-1	929772-29-2
	929772-30-5	929772-31-6	929772-32-7	929772-33-8	929772-34-9
	929772-35-0	929772-36-1	929772-37-2	929772-38-3	929772-39-4
	929772-40-7	929772-41-8	929772-42-9	929772-43-0	929772-44-1
	929772-45-2	929772-46-3	929772-47-4	929772-48-5	929772-49-6
	929772-50-9	929772-51-0	929772-52-1	929772-53-2	929772-54-3
	929772-55-4	929772-56-5	929772-57-6	929772-58-7	929772-59-8
	929772-60-1	929772-61-2	929772-62-3	929772-63-4	929772-64-5
	929772-65-6	929772-66-7	929772-67-8	929772-68-9	929772-69-0
	929772-70-3	929772-71-4	929772-72-5	929772-73-6	929772-74-7
	929772-75-8	929772-76-9	929772-77-0	929772-78-1	929772-79-2
	929772-80-5	929772-81-6	929772-82-7	929772-83-8	929772-84-9
	929772-85-0	929772-86-1	929772-87-2	929772-88-3	929772-89-4
	929772-90-7	929772-91-8	929772-92-9	929772-93-0	929772-94-1
	929772-95-2	929772-96-3	929772-97-4	929772-98-5	929772-99-6
	929773-00-2	929773-01-3	929773-02-4	929773-03-5	929773-04-6
	929773-05-7	929773-06-8	929773-07-9	929773-08-0	929773-09-1
	929773-10-4	929773-11-5	929773-12-6	929773-13-7	929773-14-8
	929773-15-9	929773-16-0	929773-17-1	929773-18-2	929773-19-3

929773-20-6	929773-21-7	929773-22-8	929773-23-9	929773-24-0
929773-25-1	929773-26-2	929773-27-3	929773-28-4	929773-29-5
929773-30-8	929773-31-9	929773-32-0	929773-33-1	929773-34-2
929773-35-3	929773-36-4	929773-37-5	929773-38-6	929773-39-7
929773-40-0	929773-41-1	929773-42-2	929773-43-3	929773-44-4
929773-45-5	929773-46-6	929773-47-7	929773-48-8	929773-49-9
929773-50-2	929773-51-3	929773-52-4	929773-53-5	929773-54-6
929773-55-7	929773-56-8	929773-57-9	929773-58-0	929773-59-1
929773-60-4				

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SYNPO2L-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 929773-61-5

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene SYNPO2L-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 97002-67-0, Mak3 N-acetyltransferase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 301167-57-7, Protein tyrosine phosphatase, type IVA

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 139805-02-0, GenBank M22878 139811-39-5, DNA (human clone 137.)
 139812-87-6, GenBank X07499 139841-85-3, DNA (human clone 5 gene flg cDNA) 145405-49-8 150835-03-3, DNA (human cell line CEPH 134702)
 150946-39-7 151315-20-7, DNA (human gene CSF1 cDNA) 156132-00-2
 161072-70-4 161073-44-5 161784-22-1 164244-73-9 170178-96-8
 170896-07-8 172247-21-1, DNA (human myosin isoform IXb cDNA)
 174518-29-7 177308-82-6 183100-56-3 183818-28-2 184892-27-1
 185082-45-5 190047-47-3 191307-27-4, DNA (human clone 22QTEL001)
 191307-34-3 197840-86-1 199496-62-3 200768-39-4 204565-11-7
 206630-64-0 209999-07-5 210466-21-0 213076-75-6 216296-73-0
 220500-43-6 226540-81-4, DNA (human gene P38IP cDNA) 227447-51-0
 228685-95-8, DNA (human gene PIF1 cDNA) 241463-12-7 253570-31-9, DNA (human gene FIR cDNA) 256189-00-1 256630-24-7, DNA (human clone ADKA01901 cDNA) 259479-03-3 261330-04-5, DNA (human clone LCHN cDNA)
 266667-92-9 268185-97-3 273904-51-1 274670-41-6 280739-08-4
 283089-44-1 288708-52-1, DNA (human reticulon 4a) 292553-67-4, DNA (human clone HRC10233 cDNA) 292555-59-0, DNA (human clone HSI07791 cDNA)
 292558-35-1 292564-53-5, DNA (human clone LNG09301 cDNA) 312679-19-9, DNA (human DC44 cDNA) 326661-72-7 326664-67-9 326673-49-8
 326682-96-6 329305-57-9 336774-53-9 336774-78-8 344977-30-6
 346015-95-0, DNA (human clone IMAGE:3544244 cDNA) 346026-13-9
 350730-14-2 354192-22-6 355890-95-8 361976-35-4, DNA (human gene MDM2 cDNA) 362583-35-5 364650-10-2 366408-13-1 366422-30-2
 366425-45-8 366426-57-5 366429-37-0, DNA (human clone PLACE5000058 cDNA) 366431-18-7, DNA (human clone PROST2003563 cDNA) 366434-69-7, DNA (human clone TESTI1000131 cDNA) 366435-27-0, DNA (human clone TESTI2001099 cDNA) 366437-44-7, DNA (human clone TESTI2007951 cDNA)
 366442-40-2, DNA (human clone STM06043 cDNA) 375317-70-7 375323-40-3, DNA (human clone IMAGE:4500659 cDNA) 378180-53-1 381471-54-1, DNA (Hepatitis B virus gene OG23) 381982-42-9, GenBank AF456479
 381987-16-2 384432-32-0 384455-81-6 384515-64-4 384569-79-3, DNA (human gene APRF cDNA) 384599-49-9 384749-58-0 384976-50-5
 385263-69-4 385727-26-4, DNA (human gene FBX29 cDNA) 385733-36-8
 386194-13-4 389180-82-9 389184-31-0 389184-37-6 389185-71-1, GenBank M30496 389203-01-4, DNA (human binding protein cDNA)

390095-19-9 390125-31-2 390129-38-1, DNA (human cell line U937 gene G16 cDNA) 390136-69-3, DNA (human gene G7b cDNA) 390250-30-3
 390259-86-6 390329-02-9, DNA (human clone PLACE1005876 cDNA)
 390330-80-0, DNA (human clone PLACE2000216 cDNA) 390333-13-8
 390632-01-6 390636-37-0, DNA (human clone HEMBB1002600 cDNA)
 391532-75-5 391542-33-9, DNA (human PLC alfa cDNA) 391542-59-9
 391552-32-2 391812-63-8 391831-71-3 391831-89-3, DNA (human gene HTP-1 cDNA) 391837-44-8, DNA (human myosin I beta cDNA) 391849-15-3
 392039-63-3 392049-86-4 392053-57-5 392059-27-7 392065-27-9
 392074-84-9 392079-85-5, DNA (human gene RBBP2H1 cDNA) 392084-92-3
 392093-04-8 392111-57-8 398399-18-3, DNA (human clone IMAGE:3508235 cDNA) 398425-79-1, GenBank M15841 407526-89-0, DNA (human gene TPM3 cDNA) 411873-71-7, DNA (human clone IMAGE:4339438 cDNA) 417979-99-8
 418524-58-0 423687-63-2, DNA (human pseudogene Uox exon 8) 424470-24-6
 427276-40-2 427276-44-6 438080-29-6 438080-63-8 439658-66-9
 439774-65-9, DNA (human clone DKFZp451C066 cDNA) 439778-78-6, DNA (human clone DKFZp686I1727 cDNA) 439779-47-2 439779-78-9 439781-74-5
 439787-71-0, DNA (human clone DKFZp667K0520 cDNA) 440393-98-6
 441606-54-8, DNA (human clone KIDNE2008403 cDNA) 441626-81-9, DNA (human clone TRACH2015243 cDNA) 441628-70-2, DNA (human clone ADRGL2006124 cDNA) 441633-37-0, DNA (human clone BRAMY2010441 cDNA) 441642-14-4, DNA (human clone D9OST2001433 cDNA) 441642-50-8, DNA (human clone FCBBF1000053 cDNA) 441646-38-4, DNA (human clone HCHON2003642 cDNA) 441646-90-8, DNA (human clone HEART2006195 cDNA) 441650-05-1
 441654-43-9, DNA (human clone PEBLM2006049 cDNA) 441655-85-2, DNA (human clone PROST2017617 cDNA) 441657-18-7, DNA (human clone SMINT2003386 cDNA) 441658-14-6, DNA (human clone SMINT2016313 cDNA) 441664-41-1, DNA (human clone TESTI2034718 cDNA) 441665-98-1, DNA (human clone TESTI2046786 cDNA) 441668-54-8, DNA (human clone TRACH2005210 cDNA) 441669-68-7, DNA (human clone UTERU2001024 cDNA) 444477-92-3
 450510-87-9 453089-64-0, DNA (human clone PLACE1005539 cDNA)
 453090-79-4, DNA (human clone THYRO1001457 cDNA) 453091-04-8
 455220-38-9, DNA (human clone IMAGE:5263531 cDNA) 456953-20-1, DNA (human clone IMAGE:5241630 cDNA) 456954-22-6, DNA (human clone IMAGE:5288990 cDNA) 492991-19-2 493096-18-7, DNA (human clone IMAGE:5787152 cDNA) 493356-90-4, DNA (human clone IMAGE:4400215 cDNA) 494346-55-3 494365-08-1 494455-40-2 494509-13-6, DNA (human clone IMAGE:5277710 cDNA) 494509-88-5 495663-69-9 495690-84-1, DNA (human clone IMAGE:4820027 cDNA) 496323-48-9, DNA (human clone CS0DF038Y005 cDNA) 496401-61-7 496417-48-2, DNA (human clone CS0DF007YN24 cDNA) 503763-48-2 503986-53-6 505903-25-3 514986-90-4 520897-62-5
 520900-32-7 520902-26-5 528328-40-7 537435-71-5, DNA (human clone DKFZp779B0244 cDNA) 552534-13-1 556761-35-4 577611-74-6
 577612-50-1, DNA (human clone DKFZp686O10247 cDNA) 577668-65-6, DNA (human clone DKFZp686K02111 cDNA) 577675-09-3, DNA (human clone DKFZp686N2252 cDNA) 577678-62-7, DNA (human clone DKFZp686I16170 cDNA) 577679-80-2, DNA (human clone DKFZp686C20269 cDNA) 577679-94-8, DNA (human clone DKFZp686K17155 cDNA) 577680-64-9 577683-33-1, DNA (human clone DKFZp686A06190 cDNA) 577686-80-7 581048-25-1 582931-34-8, DNA (human clone TLIVE2007016 cDNA) 582934-76-7, DNA (human clone SYNOV4009298 cDNA) 582935-07-7, DNA (human clone TESTI4014553 cDNA) 582935-98-6, DNA (human clone ASTRO1000009 cDNA) 582954-59-4, DNA (human clone BRACE3002508 cDNA) 582957-67-3, DNA (human clone BRAWH3004530 cDNA) 582958-06-3, DNA (human clone BRCAN2002562 cDNA) 582964-77-0 582965-11-5 582967-69-9, DNA (human clone PLACE6015211 cDNA) 582968-81-8, DNA (human clone SPLEN2016480 cDNA) 582972-11-0, DNA (human clone TESTI4006407 cDNA) 582972-75-6, DNA (human clone TESTI4009457 cDNA) 582979-35-9, DNA (human clone TRACH3008902 cDNA) 582981-36-0, DNA (human clone UTERU3005205 cDNA) 582986-75-2, DNA (human clone BRAMY3015549 cDNA) 582987-73-3, DNA (human clone BRAWH3011623 cDNA) 582990-54-3, DNA (human clone BRCAN2006051 cDNA) 583000-39-9, DNA (human

clone PLACE7000266 cDNA) 583004-17-5, DNA (human clone TESTI4010979 cDNA) 583879-62-3, GenBank AY225123 626095-42-9 633183-54-7, DNA (human FP291 cDNA)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 633234-90-9, DNA (human LP4947 cDNA) 635266-00-1 638122-93-7
645887-63-4, GenBank AY288946 645888-06-8, GenBank AY288979
663533-87-7, DNA (human unknown cDNA) 664946-03-6 668088-69-5, DNA (human clone IMAGE:30343220 cDNA) 673849-79-1, DNA (human clone IMAGE:5193590 cDNA) 680961-30-2, DNA (human clone CTONG2004000 cDNA) 680965-75-7, DNA (human clone TESTI4029528 cDNA) 686696-63-9
689699-30-7 695137-68-9 700666-63-3 700734-94-7 716907-04-9, DNA (human clone CS0CAP003YE18 cDNA) 716907-58-3, DNA (human clone CS0DI002YD21 cDNA) 716918-63-7, DNA (human clone CS0DI086YE21 cDNA) 716923-06-7, DNA (human clone CS0DI063YH06 cDNA) 716924-53-7, DNA (human clone CS0DI085YB07 cDNA) 716926-59-9, DNA (human clone CS0DI076YG17 cDNA) 716926-73-7, DNA (human clone CS0DC026YC15 cDNA) 716931-74-7, DNA (human clone CS0DF037YF09 cDNA) 716937-10-9, DNA (human clone CS0DI031YC12 cDNA) 716938-18-0, DNA (human clone CS0DI011YP01 cDNA) 716952-87-3, DNA (human clone CS0DI045YB05 cDNA) 716957-76-5, DNA (human clone CS0DF005YK21 cDNA) 716959-00-1, DNA (human clone CS0DK001YM17 cDNA) 716963-73-4, DNA (human clone CS0DF005YM18 cDNA) 716965-60-5, DNA (human clone CS0DI044YL08 cDNA) 716967-17-8, DNA (human clone CS0DD007YL12 cDNA) 716967-57-6, DNA (human clone CS0DH004YL21 cDNA) 716970-46-6, DNA (human clone CS0DI066YB16 cDNA) 716973-09-0, DNA (human clone CS0DI022YG21 cDNA) 716975-10-9, DNA (human clone CL0BA005ZG04 cDNA) 716979-70-3, DNA (human clone CS0DC001YH18 cDNA) 716983-78-7, DNA (human clone CS0DI084YG07 cDNA) 716993-15-6, DNA (human clone CS0DF036YG02 cDNA) 716994-30-8, DNA (human clone CS0DK008YI13 cDNA) 717004-61-0, DNA (human clone CS0DM011YK19 cDNA) 717007-19-7, DNA (human clone CS0DI053YB05 cDNA) 717018-01-4, DNA (human clone CS0DI057YM10 cDNA) 717025-51-9, DNA (human clone CS0DE006YB21 cDNA) 717028-42-7, DNA (human clone CS0DF006YB20 cDNA) 717028-86-9, DNA (human clone CL0BA006ZC10 cDNA) 717029-38-4, DNA (human clone CS0DB001YD10 cDNA) 717035-20-6, DNA (human clone CS0DL006YG09 cDNA) 717035-58-0, DNA (human clone CS0DJ005YD11 cDNA) 717035-87-5, DNA (human clone CS0DC017YA10 cDNA) 717042-47-2, DNA (human clone CS0DA010YE20 cDNA) 717043-26-0, DNA (human clone CS0DH001YN15 cDNA) 717053-08-2, DNA (human clone CS0DF018YJ11 cDNA) 717053-16-2, DNA (human clone CS0DI027YE21 cDNA) 717054-62-1, DNA (human clone CS0DI036YF07 cDNA) 717059-74-0, DNA (human clone CS0DC005YH06 cDNA) 717064-83-0, DNA (human clone CS0DF032YB12 cDNA) 717071-34-6, DNA (human clone CS0DF018YK19 cDNA) 717073-42-2, DNA (human clone CS0DI010YH14 cDNA) 717077-18-4, DNA (human clone CS0DL011YN12 cDNA) 717077-35-5, DNA (human clone CS0DK007YF11 cDNA) 717080-53-0, DNA (human clone CS0DB001YA17 cDNA) 717081-00-0, DNA (human clone CS0DI031YE19 cDNA) 717085-18-2, DNA (human clone CS0DM007YI10 cDNA) 717086-07-2, DNA (human clone CS0DD007YD16 cDNA) 717613-14-4, DNA (human clone CS0DI034YG17 cDNA) 717614-74-9, DNA (human clone CS0DJ015YL04 cDNA) 717615-19-5, DNA (human clone CS0DI020YO04 cDNA) 717617-67-9, DNA (human clone CS0DF028YO07 cDNA) 717619-51-7, DNA (human clone CS0DI016YM08 cDNA) 717622-23-6, DNA (human clone CS0DI059YF19 cDNA) 717623-43-3, DNA (human clone CS0CAP007YI09 cDNA) 717624-10-7, DNA (human clone CL0BA012ZA08 cDNA) 717627-50-4, DNA (human clone CS0DI060YJ19 cDNA) 717632-37-6, DNA (human clone CS0DJ002YN19 cDNA) 717632-77-4, DNA (human clone CS0DI019YI14 cDNA) 717644-46-7, DNA (human clone CS0DB004YO23 cDNA) 717650-67-4, DNA (human clone CS0DI013YH09 cDNA) 717653-98-0, DNA (human clone CS0DG007YD04 cDNA) 717658-48-5, DNA (human clone CS0DF008YL18 cDNA) 717661-22-8, DNA (human clone CS0DE002YP03 cDNA) 717670-75-2, DNA (human clone CS0DJ001YD15 cDNA)

717679-39-5, DNA (human clone CL0BA009ZC04 cDNA) 717680-82-5, DNA (human clone CS0DB008YA09 cDNA) 717682-06-9, DNA (human clone CS0DC007YC01 cDNA) 717685-75-1, DNA (human clone CS0DC017YN21 cDNA) 717686-17-4, DNA (human clone CS0DI077YN15 cDNA) 717691-81-1, DNA (human clone CS0DC004YN01 cDNA) 717693-04-4, DNA (human clone CS0DE003YE04 cDNA) 717695-93-7, DNA (human clone CS0DC023YC13 cDNA) 717704-82-0, DNA (human clone CS0DF011YP12 cDNA) 717711-45-0, DNA (human clone CS0DI081YB23 cDNA) 717717-03-8, DNA (human clone CS0DK012YC18 cDNA) 717719-05-6, DNA (human clone CS0DC014YC18 cDNA) 717732-34-8, DNA (human clone CS0DI056YJ24 cDNA) 717734-75-3, DNA (human clone CS0DL011YM05 cDNA) 717735-42-7, DNA (human clone CS0DC003YK02 cDNA) 717741-89-4, DNA (human clone CS0DL004YL07 cDNA) 717747-53-0, DNA (human clone CS0DB006YN23 cDNA) 717752-64-2, DNA (human clone CS0DJ009YD01 cDNA) 717752-98-2, DNA (human clone CS0DI044YP06 cDNA) 717755-07-2, DNA (human clone CS0DJ006YC05 cDNA) 717755-58-3, DNA (human clone CS0DF022YL07 cDNA) 717756-80-4, DNA (human clone CS0DI019YM04 cDNA) 717758-31-1, DNA (human clone CS0DH006YI09 cDNA) 717771-77-2, DNA (human clone CS0DB002YC13 cDNA) 717775-74-1, DNA (human clone CL0BB019ZH12 cDNA) 717786-50-0, DNA (human clone CS0DI036YF21 cDNA) 717794-26-8, DNA (human clone CS0DF010YL22 cDNA) 717795-17-0, DNA (human clone CS0DF002YP14 cDNA) 717796-45-7, DNA (human clone CS0DF034YK23 cDNA) 717798-79-3, DNA (human clone CS0DE009YF20 cDNA) 721296-60-2, GenBank AY044853 757860-59-6 770642-77-8 838051-94-8, DNA (human clone DKFZp686M208 cDNA) 838052-91-8, DNA (human clone DKFZp686G0883 cDNA) 838053-45-5, DNA (human clone DKFZp686P12164 cDNA) 929579-52-2 929579-54-4 929579-56-6 929579-58-8 929579-60-2, GenBank AY954500 929579-61-3 929579-63-5 929579-65-7 929579-67-9 929579-69-1 929579-71-5 929579-73-7 929579-75-9 929579-77-1 929579-79-3 929579-81-7 929579-83-9 929579-85-1 929579-87-3 929579-89-5 929579-91-9, DNA (human gene SMAP2 cDNA) 929579-93-1 929579-97-5 929579-99-7 929580-00-7 929580-02-9, DNA (human clone IMAGE:30529503 cDNA) 929580-03-0 929580-05-2 929871-85-2, GenBank F87463

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 929739-88-8 929739-89-9 929739-90-2 929739-91-3 929739-92-4
 929739-93-5 929739-94-6 929739-95-7 929739-96-8 929739-97-9
 929739-98-0 929739-99-1 929740-00-1 929740-01-2 929740-02-3
 929740-03-4 929740-04-5 929740-05-6 929740-06-7 929740-07-8
 929740-08-9 929740-09-0 929740-10-3 929740-11-4 929740-12-5
 929740-13-6 929740-14-7 929740-15-8 929740-16-9 929740-17-0
 929740-18-1 929740-19-2 929740-20-5 929740-21-6 929740-22-7
 929740-23-8 929740-24-9 929740-25-0 929740-26-1

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9002-02-2, Succinate dehydrogenase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(subunit B, iron sulfur; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 140879-24-9, 26S Proteasome 172522-01-9, AMP-activated protein kinase
 362479-32-1, Protein phosphatase 1 362674-81-5, Protein phosphatase 2
 364367-46-4, Protein phosphatase 4

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(subunits; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9013-05-2, Phosphatase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(tensin-like C1 domain containing; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT 104645-76-3, Phosphatidylinositol-4-phosphate 5-kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type II, alpha; double-stranded RNAs and their use for downregulating
 genes and treating cardiovascular diseases)

IT 9001-86-9, Phospholipase C
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α and γ 1; double-stranded RNAs and their use for
 downregulating genes and treating cardiovascular diseases)

IT 9026-30-6, Poly(A) polymerase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α ; double-stranded RNAs and their use for downregulating genes
 and treating cardiovascular diseases)

L32 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, Phosphoinositide 3-kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of pyrazine derivs. as PI3K inhibitors useful in
 treatment and prophylaxis of diseases)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

ACCESSION NUMBER: 2007:220269 CAPLUS

DOCUMENT NUMBER: 146:295955

TITLE: Preparation of pyrazine derivatives, particularly
 N-[3-(oxyphenylamino)quinoxalin-2-yl]sulfonamides, as
 PI3K inhibitors

INVENTOR(S): Gaillard, Pascale; Quattropiani, Anna; Pomel, Vincent;
 Rueckle, Thomas; Klicic, Jasna; Church, Dennis

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.
 Antilles

SOURCE: PCT Int. Appl., 170pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007023186	A1	20070301	WO 2006-EP65688	20060825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006283846	A1	20070301	AU 2006-283846	20060825
CA 2618479	A1	20070301	CA 2006-2618479	20060825
EP 1917252	A1	20080507	EP 2006-793019	20060825
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
KR 2008049767	A	20080604	KR 2008-707158	20080325

PRIORITY APPLN. INFO.:	EP 2005-107838	A 20050826
	US 2005-711873P	P 20050826
	WO 2006-EP65688	W 20060825

OTHER SOURCE(S): MARPAT 146:295955

AN 2007:220269 CAPLUS

DN 146:295955

ED Entered STN: 01 Mar 2007

TI Preparation of pyrazine derivatives, particularly N-[3-(oxyphenylamino)quinoxalin-2-yl]sulfonamides, as PI3K inhibitors

IN Gaillard, Pascale; Quattropiani, Anna; Pomel, Vincent; Rueckle, Thomas; Klicic, Jasna; Church, Dennis

PA Applied Research Systems Ars Holding N.V., Neth. Antilles

SO PCT Int. Appl., 170pp.

CODEN: PIXXD2

DT Patent

LA English

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007023186	A1	20070301	WO 2006-EP65688	20060825
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006283846	A1	20070301	AU 2006-283846	20060825
	CA 2618479	A1	20070301	CA 2006-2618479	20060825
	EP 1917252	A1	20080507	EP 2006-793019	20060825
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
	KR 2008049767	A	20080604	KR 2008-707158	20080325
PRAI	EP 2005-107838	A	20050826		
	US 2005-711873P	P	20050826		
	WO 2006-EP65688	W	20060825		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007023186	IPCI	C07D0241-44 [I,A]; C07D0241-00 [I,C*]; C07D0401-12 [I,A]; C07D0401-00 [I,C*]; C07D0403-12 [I,A]; C07D0403-00 [I,C*]; C07D0405-12 [I,A]; C07D0405-00 [I,C*]; C07D0409-12 [I,A]; C07D0409-00 [I,C*]; C07D0417-12 [I,A]; C07D0417-00 [I,C*]; A61K0031-498 [I,A]; A61P0035-00 [I,A]
	IPCR	C07D0241-00 [I,C]; C07D0241-44 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07D0401-00 [I,C]; C07D0401-12 [I,A]; C07D0403-00 [I,C]; C07D0403-12 [I,A]; C07D0405-00 [I,C]; C07D0405-12 [I,A]; C07D0409-00 [I,C]; C07D0409-12 [I,A]; C07D0417-00 [I,C]; C07D0417-12 [I,A]
	ECLA	C07D241/44; C07D401/12; C07D403/12; C07D405/12;

			C07D409/12; C07D413/12; C07D417/12
AU 2006283846	IPCI		C07D0241-00 [I,C]; C07D0241-44 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07D0401-00 [I,C]; C07D0401-12 [I,A]; C07D0403-00 [I,C]; C07D0403-12 [I,A]; C07D0405-00 [I,C]; C07D0405-12 [I,A]; C07D0409-00 [I,C]; C07D0409-12 [I,A]; C07D0417-00 [I,C]; C07D0417-12 [I,A]
	ECLA		C07D241/44; C07D401/12; C07D403/12; C07D405/12; C07D409/12; C07D413/12; C07D417/12
CA 2618479	IPCI		A61K0031-498 [I,A]; A61P0035-00 [I,A]; C07D0241-44 [I,A]; C07D0241-00 [I,C*]; C07D0401-12 [I,A]; C07D0401-00 [I,C*]; C07D0403-12 [I,A]; C07D0403-00 [I,C*]; C07D0405-12 [I,A]; C07D0405-00 [I,C*]; C07D0409-12 [I,A]; C07D0409-00 [I,C*]; C07D0417-12 [I,A]; C07D0417-00 [I,C*]
EP 1917252	IPCI		C07D0241-44 [I,A]; C07D0241-00 [I,C*]; C07D0401-12 [I,A]; C07D0401-00 [I,C*]; C07D0403-12 [I,A]; C07D0403-00 [I,C*]; C07D0405-12 [I,A]; C07D0405-00 [I,C*]; C07D0409-12 [I,A]; C07D0409-00 [I,C*]; C07D0417-12 [I,A]; C07D0417-00 [I,C*]; A61K0031-498 [I,A]; A61P0035-00 [I,A]
KR 2008049767	IPCI		C07D0241-44 [I,A]; C07D0241-00 [I,C*]; C07D0405-12 [I,A]; C07D0405-00 [I,C*]; A61K0031-498 [I,A]; A61P0035-00 [I,A]
OS	MARPAT	146:295955	
GI			



AB Title compds. I [A, B, D, E = independently C, N, such that the ring R is an aromatic ring; R1 = H, halo, NO₂, alk(en/yn)yl; R2 = H, alk(en/yn)yl; R3 = H, halo, alk(en/yn)yl, alkoxy, aryl, heteroaryl; R4 = alk(en/yn)yl, aryl, heteroaryl, arylalkenyl, cycloalkylalkyl, etc.; n = 0-4; and their geometrical isomers, their optically active forms as enantiomers,

diastereomers, tautomers, racemates, and their pharmaceutically acceptable salts] were prepared as phosphoinositide 3-kinase (PI3K) inhibitors for use as a drug. Thus, treatment of 2,3-dichloroquinoxaline with ammonium carbonate in DMF, amination of the chloride with 2,5-dimethoxyaniline, and reaction of the amine 1-methylimidazole-4-sulfonyl chloride gave quinoxaline II. II inhibited PI3K induced-lipid phosphorylation with $IC_{50} = 0.08 \mu M$. II inhibited IgM-induced Akt phosphorylation with $IC_{50} = 0.03 \mu M$. Selected I inhibited stem cell factor-induced PKB/Akt phosphorylation in mast cells with IC_{50} ranging from $0.09 \mu M$ to $1.22 \mu M$. I are useful for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

- ST pyrazine quinoxaline oxyphenylamino sulfonamide prepn phosphoinositide kinase PIK3K inhibitor; pyridopyrazine pyrazine quinoxaline prepn PIK3K inhibitor
- IT Nervous system, disease
(Huntington's chorea; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Sarcoma
(Kaposi's; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Lung, disease
(airway inflammation; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Antiarteriosclerotics
(antiatherosclerotics; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Muscle, disease
(atrophy, skeletal; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Infection
(bacterial, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Infection
(bacterial, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Infection
(bacterial; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Lung, disease
(chronic obstructive pulmonary disease; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Nervous system, disease
(degeneration; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Erythrocyte
(disease, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Sperm motility
(diseases; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Blood vessel, disease
(endothelium injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Lung
(epithelium, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Blood, disease

(erythrocyte, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Kidney, disease
(fibrosis, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation
Kidney, disease
(glomerulonephritis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Muscle, disease
(hypertrophy; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Brain, disease
(infection; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease
Reperfusion
(injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Neoplasm
(metastasis, invasion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Hypertrophy
(muscular; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation
Pancreas, disease
(pancreatitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Skin, disease
(passive cutaneous anaphylaxis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation
Lung, disease
(pneumonitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Allergy
Allergy inhibitors
Alzheimer's disease
Anaphylaxis
Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Antibacterial agents
Antifibrotic agents
Antihypertensives
Antirheumatic agents
Antitumor agents
Antiviral agents
Asthma
Atherosclerosis
Autoimmune disease
B cell (lymphocyte)
Bone marrow
Cardiac hypertrophy
Cardiovascular agents
Cardiovascular system, disease
Central nervous system agents

Encephalitis
 Fibrosis
 Glomerulosclerosis
 Heart, disease
 Human
 Hypertension
 Immunomodulators
 Immunosuppressants
 Inflammation
 Inflammatory bowel disease
 Ischemia
 Kidney, disease
 Mast cell
 Melanoma
 Meningitis
 Multiple organ failure
 Multiple sclerosis
 Neoplasm
 Neuroprotective agents
 Pharmaceutical carriers
 Pharmaceutical excipients
 Platelet activation
 Platelet aggregation
 Platelet aggregation inhibitors
 Prophylaxis
 Psoriasis
 Rheumatoid arthritis
 Sepsis
 Stroke
 Thrombolytics
 Thrombosis
 Transplant and Transplantation
 Transplant rejection
 Vasoconstriction
 Vasodilators

 (preparation of pyrazine derivs. as PI3K inhibitors useful in
 treatment and prophylaxis of diseases)

- IT Epithelium
 - (pulmonary, injury; preparation of pyrazine derivs. as PI3K inhibitors
 useful in treatment and prophylaxis of diseases)
- IT Injury
 - (pulmonary; preparation of pyrazine derivs. as PI3K inhibitors useful in
 treatment and prophylaxis of diseases)
- IT Leukocyte
 - (recruitment in cancer tissue; preparation of pyrazine derivs. as PI3K
 inhibitors useful in treatment and prophylaxis of diseases)
- IT Fibrosis
 - (renal, progressive; preparation of pyrazine derivs. as PI3K inhibitors
 useful in treatment and prophylaxis of diseases)
- IT Injury
 - (reperfusion; preparation of pyrazine derivs. as PI3K inhibitors useful in
 treatment and prophylaxis of diseases)
- IT Lupus erythematosus
 - (systemic; preparation of pyrazine derivs. as PI3K inhibitors useful in
 treatment and prophylaxis of diseases)
- IT Central nervous system, disease
 - (trauma; preparation of pyrazine derivs. as PI3K inhibitors useful in
 treatment and prophylaxis of diseases)
- IT Injury
 - (vascular endothelial; preparation of pyrazine derivs. as PI3K inhibitors
 useful in treatment and prophylaxis of diseases)

IT Endothelium
(vascular, disease, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection
(viral, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection
(viral, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection
(viral; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 328039-48-1P, 4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 331723-61-6P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 371958-49-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 372090-78-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 372091-52-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide 424804-76-2P, 4-Chloro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 432007-91-5P, 4-Bromo-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 577998-70-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 585560-01-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide 713083-87-5P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714245-33-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 714257-01-9P, 4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714282-93-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 714916-66-2P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 714917-87-0P, 4-Fluoro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714932-70-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 714932-98-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methoxybenzenesulfonamide 843630-52-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928139-93-9P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928139-97-3P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928140-00-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(hydroxymethyl)pyridine-3-sulfonamide 928140-31-2P, Methyl 3-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylate 928140-32-3P, Methyl 3-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylate 928140-36-7P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-38-9P, Methyl 3-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-39-0P, Methyl 3-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-43-6P, 4-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-50-5P, Methyl 4-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-51-6P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-52-7P, Methyl 4-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoate 928140-53-8P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoate 928140-71-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928140-73-2P, 4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-

yl]benzenesulfonamide 928140-75-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-77-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-79-8P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-83-4P, 4-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-85-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(trifluoromethyl)Benzenesulfonamide 928140-87-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide 928140-90-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide 928140-92-5P, 4,5-Dichloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 928140-95-8P, 4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-96-9P, Methyl 3-[4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]propanoate 928140-98-1P, 5-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928141-00-8P, 5-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928141-04-2P, 5-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 928141-06-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide 928141-11-1P, N-[7-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-13-3P, Methyl 5-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-carboxylate 928141-14-4P, 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928141-15-5P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928141-18-8P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-20-2P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-22-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-24-6P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-26-8P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-28-0P, 6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-30-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(dimethylamino)pyridine-3-sulfonamide 928141-32-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide 928141-35-9P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-4-cyanobenzenesulfonamide 928141-37-1P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-39-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxypyridine-3-sulfonamide 928141-42-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-47-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluoro-2-methylbenzenesulfonamide 928141-51-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-53-1P, 4-Cyano-N-[3-[(5-methoxy-2-methylphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-56-4P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-58-6P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-59-7P, Methyl 5-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]pyridine-2-carboxylate 928141-62-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide 928141-75-7P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]pyridine-2-carboxylic acid 928141-78-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide

928141-81-5P, 4-(Aminomethyl)-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-84-8P, 3-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-88-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-yl)methyl]benzenesulfonamide 928141-90-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide 928141-91-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide 928141-93-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(dimethylamino)methyl]benzenesulfonamide 928141-95-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(dimethylamino)methyl]benzenesulfonamide 928142-00-1P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-(dimethylamino)propyl]benzamide 928142-02-3P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-(dimethylamino)propyl]benzamide 928142-07-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide 928142-12-5P, 5-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 714244-38-9P, 3-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714924-49-9P, 3-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-02-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylsulfonylbenzenesulfonamide 928140-03-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide 928140-04-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(morpholin-4-yl)pyridine-3-sulfonamide 928140-07-2P, N-[3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]acetamide 928140-08-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-(methylsulfonyl)benzenesulfonamide 928140-09-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-(methylsulfonyl)benzenesulfonamide 928140-10-7P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,3-dihydro-1,4-benzodioxine-6-sulfonamide 928140-11-8P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(pyrrolidin-1-yl)sulfonyl]benzenesulfonamide 928140-12-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide 928140-13-0P, 2-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-14-1P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-15-2P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methoxybenzenesulfonamide 928140-16-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928140-17-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-fluorobenzenesulfonamide 928140-18-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-fluorobenzenesulfonamide 928140-19-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(methylsulfonyl)benzenesulfonamide 928140-20-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(pyrrolidin-1-yl)sulfonyl]benzenesulfonamide 928140-21-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-(methylsulfonyl)benzenesulfonamide 928140-22-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,1,3-benzothiadiazole-4-sulfonamide 928140-23-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928140-24-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,1,3-benzoxadiazole-4-sulfonamide 928140-25-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-2-yl)methanesulfonamide

928140-26-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-2-yl)methanesulfonamide 928140-27-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-3-yl)methanesulfonamide 928140-29-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-3-yl)methanesulfonamide 928140-30-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1,2-dimethyl-1H-imidazole-5-sulfonamide 928140-33-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide 928140-34-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide 928140-35-6P, 2-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-37-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methoxybenzenesulfonamide 928140-40-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-fluorobenzenesulfonamide 928140-41-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-fluorobenzenesulfonamide 928140-42-5P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-44-7P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-45-8P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-sulfonamide 928140-46-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-sulfonamide 928140-47-0P, N-[3-[[5-Methoxy-2-(1H-pyrrol-1-yl)phenyl]amino]quinoxalin-2-yl]benzenesulfonamide 928140-48-1P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-49-2P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-55-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-56-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide potassium salt 928140-59-4P, 4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-60-7P, 4-Fluoro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-61-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928140-62-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methoxybenzenesulfonamide potassium salt 928140-63-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide potassium salt 928140-64-1P, 4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-65-2P, 4-Chloro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-66-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-67-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928140-68-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-69-6P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-70-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928140-72-1P, 4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-74-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-76-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-78-7P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-80-1P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-81-2P, 4-Bromo-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-82-3P, 4-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-84-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(trifluoromethyl)Benzenesulfonami

de potassium salt 928140-86-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide potassium salt 928140-88-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide potassium salt 928140-91-4P, 4,5-Dichloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928140-93-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-94-7P, 4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-97-0P, 5-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide potassium salt 928140-99-2P, 5-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide potassium salt 928141-01-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide potassium salt 928141-02-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide potassium salt 928141-03-1P, 5-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928141-05-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide potassium salt 928141-07-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide 928141-08-6P, N-[2-[(2,5-Dimethoxyphenyl)amino]pyrido[3,4-b]pyrazin-3-yl]benzenesulfonamide 928141-09-7P, N-[7-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928141-12-2P 928141-16-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928141-17-7P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-19-9P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-21-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-23-5P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-25-7P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-27-9P, 6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-29-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(dimethylamino)pyridine-3-sulfonamide potassium salt 928141-31-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide hydrochloride 928141-33-7P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-34-8P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-4-cyanobenzenesulfonamide potassium salt 928141-36-0P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-38-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxypyridine-3-sulfonamide potassium salt 928141-40-6P 928141-41-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-44-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluoro-2-methylbenzenesulfonamide potassium salt 928141-49-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-55-3P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-57-5P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-60-0P, N-[3-[(2-Bromo-5-methoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928141-61-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide potassium salt 928141-63-3P, 3-[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-

yl)sulfamoyl]benzoic acid 928141-65-5P, 4-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid
 928141-66-6P, 4-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoic acid 928141-67-7P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoic acid
 928141-68-8P, 3-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylic acid 928141-69-9P,
 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylic acid 928141-70-2P,
 3-[4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]propanoic acid 928141-71-3P,
 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-carboxylic acid 928141-72-4P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-carboxylic acid
 928141-73-5P, 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium salt 928141-74-6P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium salt
 928141-76-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-yl)methyl]benzenesulfonamide 928141-77-9P,
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide dihydrochloride 928141-80-4P
 928141-82-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-(hydroxymethyl)benzenesulfonamide 928141-83-7P, 3-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide hydrochloride 928141-85-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(hydroxymethyl)benzenesulfonamide 928141-87-1P,
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-yl)methyl]benzenesulfonamide hydrochloride 928141-89-3P,
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide dihydrochloride 928141-92-8P,
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(dimethylamino)methyl]benzenesulfonamide hydrochloride 928141-94-0P,
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(dimethylamino)methyl]benzenesulfonamide hydrochloride 928141-96-2P,
 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzamide sodium salt 928141-97-3P,
 4-[[[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzamide sodium salt 928141-98-4P,
 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-(3-methoxypropyl)benzamide 928141-99-5P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-(dimethylamino)propyl]benzamide hydrochloride 928142-01-2P
 928142-03-4P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-dimethylpyridine-2-carboxamide 928142-04-5P,
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide potassium salt 928142-05-6P,
 N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(morpholin-4-yl)carbonyl]pyridine-3-sulfonamide 928142-06-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide potassium salt 928142-08-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(4-methylpiperazin-1-yl)methyl]pyridine-3-sulfonamide
 928142-09-0P 928142-14-7P, N-[6-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928142-15-8P,
 N-[3-[[[2,3-Dihydro-1,4-benzodioxin-5-yl)methyl]amino]quinoxalin-2-yl]benzenesulfonamide 928142-16-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]-6-nitroquinoxalin-2-yl]benzenesulfonamide 928142-17-0P,
 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid 928142-18-1P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid 928142-19-2P, 4-[[[3-[(3,5-

Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzamide
928142-20-5P, 4-[[[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 98-10-2P, Benzenesulfonamide 636-76-0P, 3-(Aminosulfonyl)benzoic acid 825-86-5P, 4-Iodobenzenesulfonamide 1565-17-9P, 4-Acetylbenzenesulfonamide 1899-94-1P, 3-Methylbenzenesulfonamide 2067-84-7P, 1,4-Dihydropyrido[2,3-b]pyrazine-2,3-dione 2922-45-4P, 3-Pyridinesulfonamide 4029-41-8P, N-(3-Chloroquinoxalin-2-yl)-4-methylbenzenesulfonamide 4029-43-0P, 4-Bromo-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 6339-87-3P, 2-Thiophenesulfonamide 6684-39-5P, 6-Chloropyridine-3-sulfonyl chloride 22808-73-7P, Methyl 4-(aminosulfonyl)benzoate 24243-71-8P, 1-Propanesulfonamide 25710-18-3P, 2,3-Dichloropyrido[2,3-b]pyrazine 32947-34-5P, Methyl 5-(aminosulfonyl)pyridine-2-carboxylate 34082-13-8P, 6-Methylpyridine-3-sulfonamide 34117-90-3P, 3-Chloroquinoxalin-2-amine 35251-84-4P, 1,4-Dihydropyrido[3,4-b]pyrazine-2,3-dione 35251-99-1P, 2,3-Dichloropyrido[3,4-b]pyrazine 40741-46-6P, 6-Chloropyridine-3-sulfonamide 53595-65-6P, 5-Bromothiophene-2-sulfonamide 59777-67-2P, Methyl 3-(aminosulfonyl)benzoate 63555-50-0P, Methyl 3-(chlorosulfonyl)benzoate 69156-30-5P, 2-Chloro-4-fluorobenzenesulfonamide 88398-46-3P, 5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonamide 165058-49-1P, N-(3-Methoxyphenyl)quinoxaline-2,3-diamine 166271-34-7P, N-(3-Chloro-2-quinoxalinyl)benzenesulfonamide 199590-78-8P, 6-(Dimethylamino)pyridine-3-sulfonamide 256353-34-1P, 4,5-Dichlorothiophene-2-sulfonamide 478264-00-5P, 6-Methylpyridine-3-sulfonyl chloride 488744-02-1P, N-(3-Chloroquinoxalin-2-yl)-4-fluorobenzenesulfonamide 522628-95-1P, 4-Chloro-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 565172-05-6P, N-(3-Chloroquinoxalin-2-yl)-3-methylbenzenesulfonamide 743444-94-2P, 3-Chloro-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 847985-15-3P, 2-Chloro-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide 848052-87-9P, N-(3-Chloroquinoxalin-2-yl)thiophene-2-sulfonamide 856955-32-3P, 6-Methoxypyridine-3-sulfonamide 859491-30-8P, 5-[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-2-sulfonamide 883057-32-7P, 5-(Aminosulfonyl)-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928139-26-8P, N-(3,5-Dimethoxyphenyl)quinoxaline-2,3-diamine 928139-27-9P, N-(2,5-Dimethoxyphenyl)quinoxaline-2,3-diamine 928139-28-0P, Methyl 3-[4-(aminosulfonyl)phenyl]propanoate 928139-29-1P, Methyl 5-(aminosulfonyl)-4-methylthiophene-2-carboxylate 928139-30-4P, 3-Cyano-4-fluorobenzenesulfonamide 928139-31-5P, 6-Cyanopyridine-3-sulfonyl chloride 928139-32-6P, 6-Cyanopyridine-3-sulfonamide 928139-33-7P, 3-[(Morpholin-4-yl)carbonyl]benzenesulfonamide 928139-34-8P, 6-[(3-Methoxypropyl)amino]pyridine-3-sulfonamide 928139-35-9P, N-(3-Chloroquinoxalin-2-yl)-3-fluorobenzenesulfonamide 928139-36-0P, N-(3-Chloroquinoxalin-2-yl)propane-1-sulfonamide 928139-37-1P, Methyl 4-[[[3-chloroquinoxalin-2-yl)amino]sulfonyl]butanoate 928139-39-3P, Methyl 4-[[[3-chloroquinoxalin-2-yl)amino]sulfonyl]benzoate 928139-44-0P, N-(3-Chloroquinoxalin-2-yl)-4-methoxybenzenesulfonamide 928139-48-4P, N-(3-Chloroquinoxalin-2-yl)pyridine-3-sulfonamide 928139-50-8P, N-(3-Chloroquinoxalin-2-yl)-4-cyanobenzenesulfonamide 928139-52-0P, N-(3-Chloroquinoxalin-2-yl)methanesulfonamide 928139-54-2P, N-(3-Chloroquinoxalin-2-yl)-4-(trifluoromethyl)benzenesulfonamide 928139-56-4P, N-(3-Chloroquinoxalin-2-yl)-4-iodobenzenesulfonamide 928139-58-6P, 4,5-Dichloro-N-(3-chloroquinoxalin-2-yl)thiophene-2-sulfonamide 928139-60-0P, 5-Chloro-N-(3-chloroquinoxalin-2-yl)-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928139-62-2P, 4-Acetyl-N-(3-

chloroquinoxalin-2-yl)benzenesulfonamide 928139-63-3P, Methyl
 3-[4-[[3-chloroquinoxalin-2-yl)amino]sulfonyl]phenyl]propanoate
 928139-64-4P, 5-Bromo-N-(3-chloroquinoxalin-2-yl)thiophene-2-sulfonamide
 928139-66-6P, N-(3,6-Dichloroquinoxalin-2-yl)benzenesulfonamide
 928139-67-7P, Methyl 5-[[3-chloroquinoxalin-2-yl)amino]sulfonyl]-4-
 methylthiophene-2-carboxylate 928139-70-2P, 5-[[3-Chloroquinoxalin-2-
 yl)amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester
 928139-72-4P, 2-Chloro-N-(3-chloroquinoxalin-2-yl)-4-
 fluorobenzenesulfonamide 928139-74-6P, N-(3-Chloroquinoxalin-2-yl)-5-
 [(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-2-sulfonamide
 928139-76-8P, N-(3-Chloroquinoxalin-2-yl)-3-cyano-4-
 fluorobenzenesulfonamide 928139-78-0P, 6-Chloro-N-(3-chloroquinoxalin-2-
 yl)pyridine-3-sulfonamide 928139-79-1P, N-(3-Chloroquinoxalin-2-yl)-6-
 (dimethylamino)pyridine-3-sulfonamide 928139-81-5P, N-(3-
 Chloroquinoxalin-2-yl)-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide
 928139-83-7P, N-(3-Chloroquinoxalin-2-yl)-6-methoxypyridine-3-sulfonamide
 928139-85-9P, N-(3-Chloroquinoxalin-2-yl)-6-methylpyridine-3-sulfonamide
 928139-87-1P, Methyl 5-[[3-chloroquinoxalin-2-yl)amino]sulfonyl]pyridine-
 2-carboxylate 928139-88-2P, N-(3-Chloroquinoxalin-2-yl)-3-[(morpholin-4-
 yl)carbonyl]benzenesulfonamide 928139-89-3P, N-(3-Chloroquinoxalin-2-yl)-
 1-methyl-1H-imidazole-4-sulfonamide 928139-90-6P, N-(2-Chloropyrido[3,4-
 b]pyrazin-3-yl)benzenesulfonamide 928139-91-7P, N-(3-Chloropyrido[2,3-
 b]pyrazin-2-yl)benzenesulfonamide 928139-92-8P, N-[3-[(3,5-
 Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-
 yl)carbonyl]benzenesulfonamide 928139-94-0P, N-[3-[(3,5-
 Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-
 yl)carbonyl]benzenesulfonamide 928139-95-1P, 4-[[3-[(3,5-
 Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-
 dimethylbenzamide 928139-96-2P, 3-[[3-[(3,5-
 Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-
 dimethylbenzamide 928139-98-4P, 6-(Chloromethyl)-N-[3-[(3,5-
 dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide
 928140-01-6P, Methyl 5-[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
 yl]amino]sulfonyl]-4-methylthiophene-2-carboxylate 928142-21-6P,
 N-(5-Methoxy-2-methylphenyl)quinoxaline-2,3-diamine 928142-22-7P,
 N-[5-Methoxy-2-(pyrrol-1-yl)phenyl]quinoxaline-2,3-diamine 928142-23-8P,
 N-(5-Methoxy-2-chlorophenyl)quinoxaline-2,3-diamine 928142-24-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of pyrazine derivs. as PI3K inhibitors useful in
 treatment and prophylaxis of diseases)

IT 115926-52-8, Phosphoinositide 3-kinase 148640-14-6, Akt kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of pyrazine derivs. as PI3K inhibitors useful in
 treatment and prophylaxis of diseases)

IT 928142-13-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
 yl]benzenesulfonamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazine derivs. as PI3K inhibitors useful in
 treatment and prophylaxis of diseases)

IT 54-96-6, 3,4-Diaminopyridine 70-55-3, p-Toluenesulfonamide 98-09-9,
 Benzenesulfonyl chloride 98-61-3, Pipsyl chloride 98-64-6,
 4-Chlorobenzenesulfonamide 102-56-7, 2,5-Dimethoxyaniline 109-01-3,
 1-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 138-41-0,
 4-(Aminosulfonyl)benzoic acid 402-46-0, 4-Fluorobenzenesulfonamide
 452-58-4, 2,3-Diaminopyridine 536-90-3, m-Anisidine 701-34-8,
 4-Bromobenzenesulfonamide 830-43-3, 4-(Trifluoromethyl)benzenesulfonamid
 e 1129-26-6, 4-Methoxybenzenesulfonamide 1524-40-9,
 3-Fluorobenzenesulfonamide 1788-10-9, 4-Acetylbenzenesulfonyl chloride

1899-93-0, m-Toluenesulfonyl chloride 2213-63-0, 2,3-Dichloroquinoxaline
 2401-24-3, 2-Chloro-5-methoxyaniline 2905-21-7, 2-Fluorobenzenesulfonyl
 chloride 2958-87-4, 2,3,6-Trichloroquinoxaline 3119-02-6,
 4-Cyanobenzenesulfonamide 3430-14-6, 3-Amino-6-methylpyridine
 4025-64-3, 3-(Chlorosulfonyl)benzoic acid 4808-69-9,
 6-Methylpyridine-3-sulfonic acid 5332-73-0, 3-Methoxypropylamine
 5335-40-0, 3-(Methylsulfonyl)benzenesulfonyl chloride 5350-93-6,
 5-Amino-2-chloropyridine 6961-82-6, 2-Chlorobenzenesulfonamide
 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1,
 1-Propanesulfonyl chloride 10272-07-8, 3,5-Dimethoxyaniline
 16133-25-8, 3-Pyridinesulfonyl chloride 16629-19-9, 2-Thiophenesulfonyl
 chloride 17260-71-8, 3-Chlorobenzenesulfonamide 23905-46-6,
 3-Acetylaminobenzenesulfonyl chloride 50868-72-9, 5-Methoxy-2-
 methylaniline 51175-71-4, 3-Thiophenesulfonyl chloride 55338-73-3,
 5-Amino-2-cyanopyridine 55854-46-1, 5-Bromothiophene-2-sulfonyl chloride
 56542-67-7, 3-Cyanobenzenesulfonyl chloride 59194-26-2,
 5-Methoxy-2-(1H-pyrrol-1-yl)aniline 59337-92-7, Methyl
 3-(chlorosulfonyl)thiophene-2-carboxylate 59557-92-5,
 2-Bromo-5-methoxyaniline 63758-12-3 69360-26-5, 2-Cyanobenzenesulfonyl
 chloride 73713-79-8 82964-91-8, 4-(Methylsulfonyl)benzenesulfonyl
 chloride 85958-57-2, 2-Chloro-4-fluorobenzenesulfonyl chloride
 88398-93-0, 5-Chloro-1,3-dimethylpyrazole-4-sulfonyl chloride
 89265-35-0, 2-(Methylsulfonyl)benzenesulfonyl chloride 111124-90-4,
 1-Methyl-1H-imidazole-4-sulfonamide 114322-14-4, 2,1,3-Benzoxadiazole-4-
 sulfonyl chloride 126714-85-0, 2,3-Dichlorothiophene-5-sulfonyl chloride
 137049-00-4, 1-Methylimidazole-4-sulfonyl chloride 165669-32-9,
 4-[(Pyrrolidin-1-yl)sulfonyl]benzenesulfonyl chloride 175476-51-4,
 Methyl 4-(aminosulfonyl)butanoate 306936-62-9, 5-(Aminosulfonyl)-1-
 methyl-1H-pyrrole-2-carboxylic acid 312300-42-8, 6-Methoxypyridine-3-
 sulfonyl chloride 332361-07-6, 5-[(1,3-Dioxo-1,3-dihydroisoindol-2-
 yl)methyl]thiophene-2-sulfonyl chloride 337508-68-6 351003-23-1,
 4-Fluoro-3-cyanobenzenesulfonyl chloride 374537-95-8, Methyl
 3-(4-chlorosulfonylphenyl)propionate 423768-46-1, Methyl
 5-(chlorosulfonyl)-4-methyl-2-thiophenecarboxylate 847744-22-3,
 N-(3-Chloroquinoxalin-2-yl)-4-fluoro-2-methylbenzenesulfonamide
 849351-92-4, 1,2-Dimethyl-1H-imidazole-5-sulfonyl chloride 878682-97-4,
 3-Methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonyl chloride
 882564-09-2 928140-28-7 928141-10-0, N-(3,7-Dichloroquinoxalin-2-
 yl)benzenesulfonamide 928142-10-3, N-[3-[(3,5-
 Dimethoxyphenyl)amino]quinoxalin-2-yl]-5-[(1,3-dioxo-1,3-dihydro-2H-
 isoindol-2-yl)methyl]thiophene-2-sulfonamide

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazine derivs. as PI3K inhibitors useful in
 treatment and prophylaxis of diseases)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; Ambinter Stock Screening Collection 2005

(2) Anon; DATABASE CHEMCATS 2005

(3) Icos Corporation; WO 03035075 A 2003

L32 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 98-59-9, 4-Methylphenylsulfonyl chloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase
 inhibitors useful in treatment of diseases)

RN 98-59-9 CAPLUS

CN Benzenesulfonyl chloride, 4-methyl- (CA INDEX NAME)



ACCESSION NUMBER: 2007:11341 CAPLUS
 DOCUMENT NUMBER: 146:121941
 TITLE: Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
 INVENTOR(S): Ibrahim, Prabha N.; Artis, Dean R.; Bremer, Ryan; Habets, Gaston; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Zuckerman, Rebecca; West, Brian; Suzuki, Yoshihisa; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxian; Zhu, Hongyao; Shi, Shenghua
 PATENT ASSIGNEE(S): Plexxikon, Inc., USA
 SOURCE: PCT Int. Appl., 631 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002433	A1	20070104	WO 2006-US24524	20060621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006261993	A1	20070104	AU 2006-261993	20060621
CA 2613015	A1	20070104	CA 2006-2613015	20060621
EP 1893612	A1	20080305	EP 2006-773861	20060621
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, YU				
PRIORITY APPLN. INFO.:			US 2005-692960P	P 20050622
			US 2005-731528P	P 20051028
			WO 2006-US24524	W 20060621

OTHER SOURCE(S): MARPAT 146:121941
 AN 2007:11341 CAPLUS
 DN 146:121941
 ED Entered STN: 04 Jan 2007
 TI Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
 IN Ibrahim, Prabha N.; Artis, Dean R.; Bremer, Ryan; Habets, Gaston; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang;

Zuckerman, Rebecca; West, Brian; Suzuki, Yoshihisa; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxian; Zhu, Hongyao; Shi, Shenghua

PA Plexxikon, Inc., USA

SO PCT Int. Appl., 631 pp.

CODEN: PIXXD2

DT Patent

LA English

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63


FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007002433	A1	20070104	WO 2006-US24524	20060621
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006261993	A1	20070104	AU 2006-261993	20060621
	CA 2613015	A1	20070104	CA 2006-2613015	20060621
	EP 1893612	A1	20080305	EP 2006-773861	20060621
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, YU			
PRAI	US 2005-692960P	P	20050622		
	US 2005-731528P	P	20051028		
	WO 2006-US24524	W	20060621		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007002433	IPCI	C07D0471-04 [I,A]; C07D0471-00 [I,C*]; A61K0031-435 [I,A]; C07C0049-517 [I,A]; C07C0049-00 [I,C*]; A61P0035-00 [I,A]
	IPCR	C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]
	ECLA	C07C037/62; C07C039/27; C07C045/00+47/565; C07C045/67C+47/575; C07C045/71+47/575; C07C047/565; C07C047/575; C07D209/08; C07D471/04+221B+209B; M07D
AU 2006261993	IPCI	C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]
	IPCR	C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]
	ECLA	C07C037/62; C07C039/27; C07C045/00+47/565; C07C045/67C+47/575; C07C045/71+47/575; C07C047/565; C07C047/575; C07D209/08; C07D471/04+221B+209B; M07D
CA 2613015	IPCI	A61K0031-435 [I,A]; A61P0035-00 [I,A]; C07C0049-517 [I,A]; C07C0049-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-00 [I,C*]

IPCR C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]
 EP 1893612 IPCI C07D0471-04 [I,A]; C07D0471-00 [I,C*]; A61K0031-435 [I,A]; C07C0049-517 [I,A]; C07C0049-00 [I,C*]; A61P0035-00 [I,A]
 IPCR C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]
 ECLA C07C037/62; C07C039/27; C07C045/00+47/565; C07C045/67C+47/575; C07C045/71+47/575; C07C047/565; C07C047/575; C07D209/08; C07D471/04+221B+209B; M07D
 OS MARPAT 146:121941
 GI



AB Comps. of formula I which are active on protein kinases are described, as well as methods of using such comps. to treat diseases and conditions associated with aberrant activity of protein kinases. Comps. of formula I wherein Q is (un)substituted aryl, (un)substituted indole, (un)substituted heteroaryl, etc.; A is O, S, (un)substituted methylene, NH and derivs., CO, CS, SO and SO₂; R⁴ - R⁶ is H, halo, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted alkynyl, (un)substituted (hetero)cycloalkyl, and (un)substituted (hetero)aryl; and their pharmaceutically acceptable salts, prodrugs, tautomers, and isomers thereof, are claimed. Example compound II was prepared by carboxylation of 2,4-difluoroaniline with benzyl chloroformate; the resulting benzyl 3-amino-2,6-difluorobenzoate underwent sulfonylation with propane-1-sulfonyl chloride to give benzyl 2,6-difluoro-3-(propylsulfonylamino)benzoate, which underwent hydrogenation to give the corresponding benzoic acid, which underwent chlorination, to give the corresponding acid chloride, which underwent reaction with 5-bromo-7-azaindole to give compound II. All the invention comps. were evaluated for their protein kinase inhibitory activity. Several of the tested comps. exhibited good protein kinase inhibitory activity against several kinases.

ST pyrrolopyridine prepn protein kinase inhibitory activity

IT Diabetes mellitus

(-associated renal complication, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus

(-associated renal hypertrophy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation

(CNS, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(Costello, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammatory bowel disease
(Crohn's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, disease
Teratogenesis
(Crouzon craniofacial dysostosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphA receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EphA1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphA receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EphA2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphB receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EphB2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphB receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EphB4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Intestine, disease
(Hirschsprung's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease
(Huntington's chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(Jackson-Weiss, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(MEN2, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(MEN2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(Noonan syndrome, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(Pfeiffer's, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Granulomatous disease
(Wegener's granulomatosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Antibodies and Immunoglobulins
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (X-linked infantile hypogammaglobulinemia; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
 (acrocephalosyndactylia type I, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain
 Respiratory distress syndrome
 (acute, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Retinal disease
 (age-related macular degeneration, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Allergy
 Inflammation
 Nose, disease
 (allergic rhinitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Antiarteriosclerotics
 (antiatherosclerotics; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neuroglia, neoplasm
 (astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Dermatitis
 (atopic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Autoimmune disease
 Inflammation
 Thyroid gland, disease
 (autoimmune thyroiditis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Infection
 (bacterial, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Prostate gland, disease
 (benign hyperplasia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Hyperplasia
 (benign prostatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bronchi, disease
 Inflammation
 (bronchitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm
 Mammary gland, neoplasm
 Pancreas, neoplasm
 (carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
 (cardio-faciocutaneous, treatment of; preparation of

pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia
(cerebrovascular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Hypoxia
(chemotherapy-induced, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease
(chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease
(chronic obstructive pulmonary disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain
(chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Intestine, neoplasm
(colon, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
Intestine, neoplasm
(colon, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neoplasm
(complications, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders
(dementia, multi-infarct, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders
(dementia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Skin, disease
(dermal scarring, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Retinal disease
(diabetic retinopathy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, disease
(endometriosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, neoplasm
(endometrium, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(faciocutaneoskeletal, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease
(failure, chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of

diseases)

IT Reproductive system
(female, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease
(fibrosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, disease
(fracture, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene ALK5; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(genetic, developmental, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neuroglia, neoplasm
(glioblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation
Kidney, disease
(glomerulonephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant and Transplantation
(graft-vs.-host reaction, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Injury
(head and neck, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia
(hepatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(hepatocellular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Liver, neoplasm
(hepatoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lymphoma
(histiocytic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sexual disorders
(impotence, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(in situ, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Helicobacter pylori pylori
Influenza virus
(infection, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain
(inflammatory pain, treatment of; preparation of pyrrolopyridine

derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Head and Neck, disease
 Reperfusion
 Spinal cord, disease
 (injury, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Autoimmune disease
 (insulin-dependent diabetes mellitus, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Diabetes mellitus
 (insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Inflammation
 Kidney, disease
 (interstitial nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Liver, disease
 (ischemia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Myoma
 Sarcoma
 (leiomyosarcoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Disease, animal
 (leopard, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Inflammation
 Kidney, disease
 (lupus nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Edema
 (lympho-, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Carcinoma
 (mammary, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Metabolic disorders
 (metabolic syndrome X, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Bone, neoplasm
 (metastasis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Blood vessel, disease
 (microangiopathy, thrombotic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Headache
 (migraine, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)
 IT Bone formation
 (mineralization, diseases, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Oviduct
(neoplasm, adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Astrocyte
(neoplasm, astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Schwann cell
(neoplasm, schwannoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation
Kidney, disease
(nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease
(nephrosclerosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(neural crest, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nerve, neoplasm
(neuroblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain
(neuropathic pain, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus
(non-insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm
(non-small-cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sarcoma
(of neuro-ectodermal origin, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant rejection
(organ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(oviduct adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(pancreatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation
Pancreas, disease
(pancreatitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease
(polycystic, treatment of; preparation of pyrrolopyridine derivs.

as protein kinase inhibitors useful in treatment of diseases)

IT Allergy inhibitors

Analgesics

Angiogenesis inhibitors

Anti-Alzheimer's agents

Anti-infective agents

Anti-inflammatory agents

Anti-ischemic agents

Antiarthritics

Antiasthmatics

Antibacterial agents

Antidiabetic agents

Antifibrotic agents

Antimigraine agents

Antiobesity agents

Antiosteoporotic agents

Antiparkinsonian agents

Antipyretics

Antirheumatic agents

Antitumor agents

Antiviral agents

Canidae

Cardiovascular agents

Combination chemotherapy

Human

Immunostimulants

Immunosuppressants

Lipolysis

Nervous system agents

Pharmaceutical carriers

Prodrugs

Respiratory system agents

Thrombolytics

Transplant and Transplantation

(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT c-Kit (protein)

neu (receptor)

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(pulmonary non-small-cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(pulmonary small-cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

Fibrosis

(pulmonary, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, neoplasm

(renal cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(renal cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Injury

(reperfusion, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, neoplasm
(schwannoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT T lymphocyte
(selective defect of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Immunodeficiency
(severe combined, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm
(small-cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Injury
(spinal cord, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(squamous cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Digestive tract, neoplasm
(stroma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lupus erythematosus
(systemic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(tissue scarring, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Acute lymphocytic leukemia
Acute myeloid leukemia
Aging, animal
Allergy
Alopecia
Alzheimer's disease
Amyotrophic lateral sclerosis
Asthma
Atherosclerosis
Bladder, neoplasm
Bone, disease
Bone, neoplasm
Brain, neoplasm
Cardiac hypertrophy
Cardiovascular system, disease
Central nervous system, neoplasm
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Diabetic nephropathy
Digestive tract, neoplasm
Emphysema
Endocrine system, disease
Eosinophilia
Fever and Hyperthermia
Fibrosis
Graves' disease
Hair, disease
Heart failure

Hepatic steatosis
 Hepatitis
 Hyperglycemia
 Immunodeficiency
 Infection
 Inflammation
 Inflammatory bowel disease
 Intestine, disease
 Ischemia
 Kidney, disease
 Leukemia
 Liver, neoplasm
 Lung, disease
 Lung, neoplasm
 Lymphoma
 Mammary gland, neoplasm
 Mastocytoma
 Mastocytosis
 Melanoma
 Multiple myeloma
 Multiple sclerosis
 Mutation
 Myasthenia gravis
 Myelodysplastic syndromes
 Neoplasm
 Neurofibromatosis 1
 Neuroglia, neoplasm
 Non-Hodgkin lymphoma
 Obesity
 Osteoarthritis
 Osteoporosis
 Ovary, neoplasm
 Pancreas, neoplasm
 Parkinson's disease
 Prostate gland, disease
 Prostate gland, neoplasm
 Psoriasis
 Rheumatoid arthritis
 Sarcoma
 Scleroderma
 Sepsis
 Sjogren syndrome
 Skeleton, disease
 Skin, disease
 Skin, neoplasm
 Stroke
 Systemic mastocytosis
 Testis, neoplasm
 Thrombosis
 Thyroid gland, neoplasm
 Tuberous sclerosis
 Vascular restenosis

(treatment of; preparation of pyrrolopyridine derivs. as protein
 kinase inhibitors useful in treatment of diseases)

IT Necrosis

(tubular, treatment of; preparation of pyrrolopyridine derivs. as
 protein kinase inhibitors useful in treatment of diseases)

IT Angiogenesis

(tumor, treatment of; preparation of pyrrolopyridine derivs. as
 protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type 1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
 useful in treatment of diseases)

IT Fibroblast growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type 2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
 useful in treatment of diseases)

IT Fibroblast growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type 3; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
 useful in treatment of diseases)

IT Fibroblast growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type 4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
 useful in treatment of diseases)

IT Inflammatory bowel disease
 (ulcerative colitis, treatment of; preparation of pyrrolopyridine
 derivs. as protein kinase inhibitors useful in treatment of
 diseases)

IT Colitis
 (ulcerative, treatment of; preparation of pyrrolopyridine derivs.
 as protein kinase inhibitors useful in treatment of diseases)

IT Infection
 (viral, treatment of; preparation of pyrrolopyridine derivs. as
 protein kinase inhibitors useful in treatment of diseases)

IT Platelet-derived growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α ; preparation of pyrrolopyridine derivs. as protein kinase
 inhibitors useful in treatment of diseases)

IT Platelet-derived growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
 useful in treatment of diseases)

IT 142805-58-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
 useful in treatment of diseases)

IT 50-99-7, D-Glucose, biological studies
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
 unclassified); BIOL (Biological study)
 (blood; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
 useful in treatment of diseases)

IT 858118-20-4P 918504-27-5P 918506-28-2P 918506-62-4P 918507-15-0P
 918507-82-1P 918507-83-2P 918507-84-3P 918507-86-5P 918507-89-8P
 918508-05-1P 918508-18-6P 918508-21-1P 918508-33-5P 918509-12-3P
 918509-57-6P 918509-58-7P 918509-59-8P 918510-12-0P 918510-89-1P
 918510-93-7P 918510-98-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of pyrrolopyridine derivs. as
 protein kinase inhibitors useful in treatment of diseases)

IT 4649-09-6P 55052-24-9P 55052-28-3P 74420-15-8P 183208-35-7P
 611204-98-9P 611205-38-0P 757978-25-9P 849067-96-5P 849068-05-9P
 858116-85-5P 858118-15-7P 866319-00-8P 866546-07-8P 918504-28-6P
 918504-29-7P 918504-31-1P 918504-32-2P 918504-33-3P 918504-36-6P
 918504-37-7P 918504-38-8P 918504-39-9P 918505-66-5P 918505-72-3P
 918506-47-5P 918506-48-6P 918506-97-5P 918507-50-3P 918507-53-6P
 918507-54-7P 918507-55-8P 918507-56-9P 918507-67-2P 918510-14-2P
 918510-28-8P 918510-95-9P 918511-92-9P 918512-43-3P 918514-97-3P
 918516-12-8P 918516-27-5P 918517-04-1P 918519-14-9P 918519-37-6P

918519-69-4P 918520-82-8P 918521-31-0P 918522-25-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 23612-48-8P 23616-63-9P 27663-72-5P 27663-73-6P 65623-46-3P
74420-00-1P, 1H-Pyrrolo[2,3-b]pyridin-4-amine 116168-44-6P
122379-64-0P 145934-58-3P 151098-60-1P 161225-76-9P 183208-54-0P
226085-70-7P 344327-11-3P, 1H-Pyrrolo[2,3-b]pyridine-4-carbonitrile
344454-28-0P 348640-06-2P 348640-54-0P 351438-96-5P 351439-00-4P
351439-01-5P 394223-03-1P 460053-58-1P 479552-75-5P 611204-94-5P
611205-04-0P 611205-10-8P 611205-12-0P 611205-16-4P 611205-18-6P
611205-34-6P 633303-87-4P 633303-90-9P 675840-52-5P 754214-42-1P
850014-39-0P 850014-40-3P 858116-60-6P 858116-61-7P 858116-65-1P
858116-68-4P 858116-69-5P 858116-70-8P 858116-73-1P 858116-74-2P
858116-75-3P 858116-76-4P 858116-77-5P 858116-78-6P 858116-82-2P
858116-87-7P 858116-89-9P 858116-90-2P 858116-91-3P 858116-93-5P
858116-97-9P 858116-98-0P 858116-99-1P 858117-01-8P 858117-07-4P
858117-12-1P 858117-13-2P 858117-14-3P 858117-15-4P 858117-16-5P
858117-19-8P 858117-20-1P 858117-21-2P 858117-22-3P 858117-23-4P
858117-24-5P 858117-25-6P 858117-26-7P 858117-27-8P 858117-28-9P
858117-29-0P 858117-30-3P 858117-33-6P 858117-34-7P 858117-35-8P
858117-36-9P 858117-37-0P 858117-38-1P 858117-39-2P 858117-40-5P
858117-41-6P 858117-42-7P 858117-43-8P 858117-44-9P 858117-45-0P
858117-46-1P 858117-47-2P 858117-48-3P 858117-49-4P 858117-50-7P
858117-51-8P 858117-52-9P 858117-53-0P 858117-54-1P 858117-55-2P
858117-56-3P 858117-57-4P 858117-58-5P 858117-59-6P 858117-60-9P
858117-61-0P 858117-62-1P 858117-63-2P 858117-64-3P 858117-65-4P
858117-66-5P 858117-67-6P 858117-68-7P 858117-69-8P 858117-70-1P
858117-71-2P 858117-72-3P 858117-73-4P 858117-74-5P 858117-76-7P
858117-77-8P 858117-78-9P 858117-79-0P 858117-80-3P 858117-81-4P
858117-82-5P 858117-83-6P 858117-84-7P 858117-85-8P 858117-86-9P
858117-87-0P 858117-88-1P 858117-89-2P 858117-90-5P 858117-91-6P
858117-92-7P 858117-93-8P 858117-94-9P 858117-95-0P 858117-96-1P
858117-97-2P 858117-98-3P 858117-99-4P 858118-00-0P 858118-01-1P
858118-02-2P 858118-03-3P 858118-04-4P 858118-05-5P 858118-06-6P
858118-07-7P 858118-08-8P 858118-09-9P 858118-10-2P 858118-11-3P
858118-12-4P 858118-13-5P 858118-14-6P 858118-17-9P 858118-18-0P
858118-19-1P 858118-21-5P 858118-22-6P 858118-23-7P 858118-24-8P
858118-25-9P 858118-26-0P 858118-27-1P 858118-28-2P 858118-29-3P
858118-30-6P 858118-31-7P 858118-32-8P 858118-33-9P 858118-34-0P
858118-35-1P 858118-36-2P 858118-37-3P 858118-38-4P 858118-39-5P
858118-40-8P 858118-41-9P 858118-42-0P 858118-43-1P 858118-44-2P
858118-45-3P 858118-46-4P 858118-47-5P 858118-48-6P 858118-49-7P
858118-50-0P 858118-51-1P 858118-52-2P 858118-53-3P 858118-54-4P
858118-55-5P 858118-56-6P 858118-57-7P 858118-58-8P 858118-59-9P
858118-60-2P 858118-61-3P 858118-62-4P 858118-63-5P 858118-64-6P
858118-65-7P 858118-66-8P 858118-67-9P 858118-68-0P 858118-69-1P
858118-70-4P 858118-71-5P 858118-72-6P 858118-73-7P 858118-74-8P
858118-75-9P 858118-76-0P 858118-77-1P 858118-78-2P 858118-79-3P
858118-80-6P 858118-81-7P 858118-82-8P 858118-83-9P 858118-84-0P
858118-85-1P 858118-86-2P 858118-87-3P 858118-88-4P 858118-89-5P
858118-90-8P 858118-91-9P 858118-92-0P 858118-93-1P 858118-94-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 858118-95-3P 858118-96-4P 858118-97-5P 858118-98-6P 858118-99-7P
858119-00-3P 858119-01-4P 858119-02-5P 858119-03-6P 858119-04-7P

858119-05-8P	858119-06-9P	858119-07-0P	858119-08-1P	858119-09-2P
858119-10-5P	858119-11-6P	858119-12-7P	858119-13-8P	858119-14-9P
858119-15-0P	858119-16-1P	858119-17-2P	858119-18-3P	858119-19-4P
858119-20-7P	858119-21-8P	858119-22-9P	858119-23-0P	858119-24-1P
858119-25-2P	858119-26-3P	858119-27-4P	858119-28-5P	858119-29-6P
858119-30-9P	858119-31-0P	858119-32-1P	858119-33-2P	858119-34-3P
858119-35-4P	858119-36-5P	858119-37-6P	858119-38-7P	858119-39-8P
866545-86-0P	866545-87-1P	873786-06-2P	873786-08-4P	873786-10-8P
873786-11-9P	873786-12-0P	873786-16-4P	873786-17-5P	873786-19-7P
880770-36-5P	880770-84-3P	880770-85-4P	880770-86-5P	880771-30-2P
880771-31-3P	880771-32-4P	880771-34-6P	880771-35-7P	916172-49-1P
916173-07-4P	916173-12-1P	916173-13-2P	916173-16-5P	916173-34-7P
916174-24-8P	916174-48-6P	916174-49-7P	918504-30-0P	918504-34-4P
918504-35-5P	918504-40-2P	918504-41-3P	918504-42-4P	918504-43-5P
918504-44-6P	918504-45-7P	918504-46-8P	918504-47-9P	918504-48-0P
918504-49-1P	918504-50-4P	918504-51-5P	918504-52-6P	918504-53-7P
918504-54-8P	918504-55-9P	918504-56-0P	918504-57-1P	918504-58-2P
918504-59-3P	918504-60-6P	918504-61-7P	918504-62-8P	918504-63-9P
918504-64-0P	918504-65-1P	918504-66-2P	918504-67-3P	918504-68-4P
918504-69-5P	918504-70-8P	918504-71-9P	918504-72-0P	918504-73-1P
918504-74-2P	918504-75-3P	918504-76-4P	918504-77-5P	918504-78-6P
918504-79-7P	918504-80-0P	918504-81-1P	918504-82-2P	918504-83-3P
918504-84-4P	918504-85-5P	918504-86-6P	918504-87-7P	918504-88-8P
918504-89-9P	918504-90-2P	918504-91-3P	918504-92-4P	918504-93-5P
918504-94-6P	918504-95-7P	918504-96-8P	918504-97-9P	918504-98-0P
918504-99-1P	918505-00-7P	918505-01-8P	918505-02-9P	918505-03-0P
918505-04-1P	918505-05-2P	918505-07-4P	918505-08-5P	918505-09-6P
918505-10-9P	918505-11-0P	918505-12-1P	918505-13-2P	918505-14-3P
918505-15-4P	918505-16-5P	918505-17-6P	918505-18-7P	918505-19-8P
918505-20-1P	918505-21-2P	918505-22-3P	918505-23-4P	918505-24-5P
918505-25-6P	918505-26-7P	918505-27-8P	918505-28-9P	918505-29-0P
918505-30-3P	918505-31-4P	918505-32-5P	918505-33-6P	918505-34-7P
918505-35-8P	918505-36-9P	918505-37-0P	918505-38-1P	918505-39-2P
918505-40-5P	918505-41-6P	918505-42-7P	918505-43-8P	918505-44-9P
918505-45-0P	918505-46-1P	918505-47-2P	918505-48-3P	918505-49-4P
918505-50-7P	918505-51-8P	918505-52-9P	918505-53-0P	918505-54-1P
918505-55-2P	918505-56-3P	918505-57-4P	918505-58-5P	918505-59-6P
918505-60-9P	918505-61-0P	918505-62-1P	918505-63-2P	918505-64-3P
918505-65-4P	918505-67-6P	918505-68-7P	918505-69-8P	918505-70-1P
918505-71-2P	918505-73-4P	918505-74-5P	918505-75-6P	918505-76-7P
918505-77-8P	918505-78-9P	918505-79-0P	918505-80-3P	918505-81-4P
918505-82-5P	918505-83-6P	918505-84-7P	918505-85-8P	918505-86-9P
918505-87-0P	918505-88-1P	918505-89-2P	918505-90-5P	918505-91-6P
918505-92-7P	918505-93-8P	918505-94-9P	918505-95-0P	918505-96-1P
918505-97-2P	918505-98-3P	918505-99-4P	918506-00-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
inhibitors useful in treatment of diseases)

IT	918506-01-1P	918506-02-2P	918506-03-3P	918506-04-4P	918506-05-5P
	918506-06-6P	918506-07-7P	918506-08-8P	918506-09-9P	918506-10-2P
	918506-11-3P	918506-12-4P	918506-13-5P	918506-14-6P	918506-15-7P
	918506-16-8P	918506-17-9P	918506-18-0P	918506-19-1P	918506-20-4P
	918506-21-5P	918506-22-6P	918506-23-7P	918506-24-8P	918506-25-9P
	918506-26-0P	918506-27-1P	918506-29-3P	918506-30-6P	918506-31-7P
	918506-32-8P	918506-33-9P	918506-34-0P	918506-35-1P	918506-36-2P
	918506-37-3P	918506-38-4P	918506-39-5P	918506-40-8P	918506-41-9P
	918506-42-0P	918506-43-1P	918506-44-2P	918506-45-3P	918506-46-4P
	918506-49-7P	918506-50-0P	918506-51-1P	918506-52-2P	918506-53-3P
	918506-54-4P	918506-55-5P	918506-56-6P	918506-57-7P	918506-58-8P

918506-59-9P	918506-60-2P	918506-61-3P	918506-63-5P	918506-64-6P
918506-65-7P	918506-66-8P	918506-67-9P	918506-68-0P	918506-69-1P
918506-70-4P	918506-71-5P	918506-72-6P	918506-73-7P	918506-74-8P
918506-75-9P	918506-76-0P	918506-77-1P	918506-78-2P	918506-79-3P
918506-80-6P	918506-81-7P	918506-82-8P	918506-83-9P	918506-84-0P
918506-85-1P	918506-86-2P	918506-87-3P	918506-88-4P	918506-89-5P
918506-90-8P	918506-91-9P	918506-92-0P	918506-93-1P	918506-94-2P
918506-95-3P	918506-96-4P	918506-98-6P	918506-99-7P	918507-00-3P
918507-01-4P	918507-02-5P	918507-03-6P	918507-04-7P	918507-05-8P
918507-06-9P	918507-07-0P	918507-08-1P	918507-09-2P	918507-10-5P
918507-11-6P	918507-12-7P	918507-13-8P	918507-14-9P	918507-16-1P
918507-17-2P	918507-18-3P	918507-19-4P	918507-20-7P	918507-21-8P
918507-22-9P	918507-23-0P	918507-24-1P	918507-25-2P	918507-26-3P
918507-27-4P	918507-28-5P	918507-29-6P	918507-30-9P	918507-31-0P
918507-32-1P	918507-33-2P	918507-34-3P	918507-35-4P	918507-36-5P
918507-37-6P	918507-38-7P	918507-40-1P	918507-47-8P	918507-49-0P
918507-51-4P	918507-52-5P	918507-57-0P	918507-58-1P	918507-59-2P
918507-60-5P	918507-61-6P	918507-62-7P	918507-63-8P	918507-64-9P
918507-65-0P	918507-66-1P	918507-68-3P	918507-70-7P	918507-71-8P
918507-72-9P	918507-73-0P	918507-74-1P	918507-75-2P	918507-76-3P
918507-77-4P	918507-78-5P	918507-79-6P	918507-80-9P	918507-81-0P
918507-85-4P	918507-87-6P	918507-88-7P	918507-90-1P	918507-91-2P
918507-92-3P	918507-93-4P	918507-94-5P	918507-95-6P	918507-96-7P
918507-97-8P	918507-98-9P	918507-99-0P	918508-00-6P	918508-01-7P
918508-02-8P	918508-03-9P	918508-04-0P	918508-06-2P	918508-07-3P
918508-08-4P	918508-09-5P	918508-10-8P	918508-11-9P	918508-12-0P
918508-13-1P	918508-14-2P	918508-15-3P	918508-16-4P	918508-17-5P
918508-19-7P	918508-20-0P	918508-22-2P	918508-23-3P	918508-24-4P
918508-25-5P	918508-26-6P	918508-27-7P	918508-28-8P	918508-29-9P
918508-30-2P	918508-31-3P	918508-32-4P	918508-34-6P	918508-35-7P
918508-36-8P	918508-37-9P	918508-38-0P	918508-39-1P	918508-40-4P
918508-41-5P	918508-42-6P	918508-43-7P	918508-44-8P	918508-45-9P
918508-46-0P	918508-47-1P	918508-48-2P	918508-49-3P	918508-50-6P
918508-51-7P	918508-52-8P	918508-53-9P	918508-54-0P	918508-55-1P
918508-56-2P	918508-57-3P	918508-58-4P	918508-59-5P	918508-60-8P
918508-61-9P	918508-62-0P	918508-63-1P	918508-64-2P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT	918508-65-3P	918508-66-4P	918508-67-5P	918508-68-6P	918508-69-7P
	918508-70-0P	918508-71-1P	918508-72-2P	918508-73-3P	918508-74-4P
	918508-75-5P	918508-76-6P	918508-77-7P	918508-78-8P	918508-79-9P
	918508-80-2P	918508-81-3P	918508-82-4P	918508-83-5P	918508-84-6P
	918508-85-7P	918508-86-8P	918508-87-9P	918508-88-0P	918508-89-1P
	918508-90-4P	918508-91-5P	918508-92-6P	918508-93-7P	918508-94-8P
	918508-95-9P	918508-96-0P	918508-97-1P	918508-98-2P	918508-99-3P
	918509-00-9P	918509-01-0P	918509-02-1P	918509-03-2P	918509-04-3P
	918509-05-4P	918509-06-5P	918509-07-6P	918509-08-7P	918509-09-8P
	918509-10-1P	918509-11-2P	918509-13-4P	918509-14-5P	918509-15-6P
	918509-16-7P	918509-17-8P	918509-18-9P	918509-19-0P	918509-20-3P
	918509-21-4P	918509-22-5P	918509-23-6P	918509-24-7P	918509-25-8P
	918509-26-9P	918509-27-0P	918509-28-1P	918509-29-2P	918509-30-5P
	918509-31-6P	918509-32-7P	918509-33-8P	918509-34-9P	918509-35-0P
	918509-36-1P	918509-37-2P	918509-38-3P	918509-39-4P	918509-40-7P
	918509-41-8P	918509-42-9P	918509-43-0P	918509-44-1P	918509-45-2P
	918509-46-3P	918509-47-4P	918509-48-5P	918509-49-6P	918509-50-9P
	918509-51-0P	918509-52-1P	918509-53-2P	918509-54-3P	918509-55-4P
	918509-56-5P	918509-60-1P	918509-61-2P	918509-62-3P	918509-63-4P
	918509-64-5P	918509-65-6P	918509-66-7P	918509-67-8P	918509-68-9P

918509-69-0P	918509-70-3P	918509-71-4P	918509-72-5P	918509-73-6P
918509-74-7P	918509-75-8P	918509-76-9P	918509-77-0P	918509-78-1P
918509-79-2P	918509-80-5P	918509-81-6P	918509-82-7P	918509-83-8P
918509-84-9P	918509-85-0P	918509-86-1P	918509-87-2P	918509-88-3P
918509-89-4P	918509-90-7P	918509-91-8P	918509-92-9P	918509-93-0P
918509-94-1P	918509-95-2P	918509-96-3P	918509-97-4P	918509-98-5P
918509-99-6P	918510-00-6P	918510-01-7P	918510-02-8P	918510-03-9P
918510-04-0P	918510-05-1P	918510-06-2P	918510-07-3P	918510-08-4P
918510-09-5P	918510-10-8P	918510-11-9P	918510-13-1P	918510-15-3P
918510-16-4P	918510-17-5P	918510-18-6P	918510-19-7P	918510-20-0P
918510-21-1P	918510-22-2P	918510-23-3P	918510-24-4P	918510-25-5P
918510-26-6P	918510-27-7P	918510-29-9P	918510-30-2P	918510-31-3P
918510-32-4P	918510-33-5P	918510-34-6P	918510-36-8P	918510-38-0P
918510-40-4P	918510-41-5P	918510-42-6P	918510-44-8P	918510-46-0P
918510-48-2P	918510-50-6P	918510-52-8P	918510-53-9P	918510-54-0P
918510-55-1P	918510-56-2P	918510-57-3P	918510-58-4P	918510-59-5P
918510-60-8P	918510-61-9P	918510-62-0P	918510-63-1P	918510-64-2P
918510-65-3P	918510-66-4P	918510-67-5P	918510-68-6P	918510-69-7P
918510-70-0P	918510-71-1P	918510-72-2P	918510-73-3P	918510-74-4P
918510-75-5P	918510-76-6P	918510-77-7P	918510-78-8P	918510-79-9P
918510-80-2P	918510-81-3P	918510-82-4P	918510-83-5P	918510-84-6P
918510-85-7P	918510-86-8P	918510-87-9P	918510-88-0P	918510-90-4P
918510-91-5P	918510-92-6P	918510-94-8P	918510-96-0P	918510-97-1P
918510-99-3P	918511-00-9P	918511-01-0P	918511-02-1P	918511-03-2P
918511-04-3P	918511-05-4P	918511-06-5P	918511-07-6P	918511-08-7P
918511-09-8P	918511-10-1P	918511-11-2P	918511-12-3P	918511-13-4P
918511-14-5P	918511-15-6P	918511-16-7P	918511-17-8P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT	918511-18-9P	918511-19-0P	918511-20-3P	918511-21-4P	918511-22-5P
	918511-23-6P	918511-24-7P	918511-25-8P	918511-26-9P	918511-27-0P
	918511-28-1P	918511-29-2P	918511-30-5P	918511-31-6P	918511-32-7P
	918511-33-8P	918511-34-9P	918511-35-0P	918511-36-1P	918511-37-2P
	918511-38-3P	918511-39-4P	918511-40-7P	918511-41-8P	918511-42-9P
	918511-43-0P	918511-44-1P	918511-45-2P	918511-46-3P	918511-47-4P
	918511-48-5P	918511-49-6P	918511-50-9P	918511-51-0P	918511-52-1P
	918511-53-2P	918511-54-3P	918511-55-4P	918511-56-5P	918511-57-6P
	918511-58-7P	918511-59-8P	918511-60-1P	918511-61-2P	918511-62-3P
	918511-63-4P	918511-64-5P	918511-65-6P	918511-66-7P	918511-67-8P
	918511-68-9P	918511-69-0P	918511-70-3P	918511-71-4P	918511-72-5P
	918511-73-6P	918511-74-7P	918511-75-8P	918511-76-9P	918511-77-0P
	918511-78-1P	918511-79-2P	918511-80-5P	918511-81-6P	918511-82-7P
	918511-83-8P	918511-84-9P	918511-85-0P	918511-86-1P	918511-87-2P
	918511-88-3P	918511-89-4P	918511-90-7P	918511-91-8P	918511-93-0P
	918511-94-1P	918511-95-2P	918511-96-3P	918511-97-4P	918511-98-5P
	918511-99-6P	918512-00-2P	918512-01-3P	918512-03-5P	918512-04-6P
	918512-05-7P	918512-06-8P	918512-07-9P	918512-08-0P	918512-09-1P
	918512-10-4P	918512-11-5P	918512-12-6P	918512-13-7P	918512-14-8P
	918512-15-9P	918512-16-0P	918512-17-1P	918512-18-2P	918512-19-3P
	918512-20-6P	918512-21-7P	918512-22-8P	918512-23-9P	918512-24-0P
	918512-25-1P	918512-26-2P	918512-27-3P	918512-28-4P	918512-29-5P
	918512-30-8P	918512-31-9P	918512-32-0P	918512-33-1P	918512-34-2P
	918512-35-3P	918512-36-4P	918512-37-5P	918512-38-6P	918512-39-7P
	918512-40-0P	918512-41-1P	918512-42-2P	918512-44-4P	918512-45-5P
	918512-46-6P	918512-47-7P	918512-48-8P	918512-49-9P	918512-50-2P
	918512-51-3P	918512-52-4P	918512-53-5P	918512-54-6P	918512-55-7P
	918512-56-8P	918512-57-9P	918512-58-0P	918512-59-1P	918512-60-4P
	918512-61-5P	918512-62-6P	918512-63-7P	918512-64-8P	918512-65-9P

918512-66-0P	918512-67-1P	918512-68-2P	918512-69-3P	918512-70-6P
918512-71-7P	918512-72-8P	918512-73-9P	918512-74-0P	918512-75-1P
918512-76-2P	918512-77-3P	918512-78-4P	918512-79-5P	918512-80-8P
918512-81-9P	918512-82-0P	918512-83-1P	918512-84-2P	918512-85-3P
918512-86-4P	918512-87-5P	918512-88-6P	918512-89-7P	918512-90-0P
918512-91-1P	918512-92-2P	918512-93-3P	918512-94-4P	918512-95-5P
918512-96-6P	918512-97-7P	918512-98-8P	918512-99-9P	918513-00-5P
918513-01-6P	918513-02-7P	918513-03-8P	918513-04-9P	918513-05-0P
918513-06-1P	918513-07-2P	918513-08-3P	918513-09-4P	918513-10-7P
918513-11-8P	918513-12-9P	918513-13-0P	918513-14-1P	918513-15-2P
918513-16-3P	918513-17-4P	918513-18-5P	918513-19-6P	918513-20-9P
918513-21-0P	918513-22-1P	918513-23-2P	918513-24-3P	918513-25-4P
918513-26-5P	918513-27-6P	918513-28-7P	918513-29-8P	918513-30-1P
918513-31-2P	918513-32-3P	918513-33-4P	918513-34-5P	918513-35-6P
918513-36-7P	918513-37-8P	918513-38-9P	918513-39-0P	918513-40-3P
918513-41-4P	918513-42-5P	918513-43-6P	918513-44-7P	918513-45-8P
918513-46-9P	918513-47-0P	918513-48-1P	918513-49-2P	918513-50-5P
918513-51-6P	918513-52-7P	918513-53-8P	918513-54-9P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
inhibitors useful in treatment of diseases)

IT	918513-55-0P	918513-56-1P	918513-57-2P	918513-58-3P	918513-59-4P
	918513-60-7P	918513-61-8P	918513-62-9P	918513-63-0P	918513-64-1P
	918513-65-2P	918513-66-3P	918513-67-4P	918513-68-5P	918513-69-6P
	918513-70-9P	918513-71-0P	918513-72-1P	918513-73-2P	918513-74-3P
	918513-75-4P	918513-76-5P	918513-77-6P	918513-78-7P	918513-79-8P
	918513-80-1P	918513-81-2P	918513-82-3P	918513-83-4P	918513-84-5P
	918513-85-6P	918513-86-7P	918513-87-8P	918513-88-9P	918513-89-0P
	918513-90-3P	918513-91-4P	918513-92-5P	918513-93-6P	918513-94-7P
	918513-95-8P	918513-96-9P	918513-97-0P	918513-98-1P	918513-99-2P
	918514-00-8P	918514-01-9P	918514-02-0P	918514-03-1P	918514-04-2P
	918514-05-3P	918514-06-4P	918514-07-5P	918514-08-6P	918514-09-7P
	918514-10-0P	918514-11-1P	918514-12-2P	918514-13-3P	918514-14-4P
	918514-15-5P	918514-16-6P	918514-17-7P	918514-18-8P	918514-19-9P
	918514-20-2P	918514-21-3P	918514-22-4P	918514-23-5P	918514-24-6P
	918514-25-7P	918514-26-8P	918514-27-9P	918514-28-0P	918514-29-1P
	918514-30-4P	918514-31-5P	918514-32-6P	918514-33-7P	918514-34-8P
	918514-35-9P	918514-36-0P	918514-37-1P	918514-38-2P	918514-39-3P
	918514-40-6P	918514-41-7P	918514-42-8P	918514-43-9P	918514-44-0P
	918514-45-1P	918514-46-2P	918514-47-3P	918514-48-4P	918514-49-5P
	918514-50-8P	918514-51-9P	918514-52-0P	918514-53-1P	918514-54-2P
	918514-55-3P	918514-56-4P	918514-57-5P	918514-58-6P	918514-59-7P
	918514-60-0P	918514-61-1P	918514-62-2P	918514-63-3P	918514-64-4P
	918514-65-5P	918514-66-6P	918514-67-7P	918514-68-8P	918514-69-9P
	918514-70-2P	918514-71-3P	918514-72-4P	918514-73-5P	918514-74-6P
	918514-75-7P	918514-76-8P	918514-77-9P	918514-78-0P	918514-79-1P
	918514-80-4P	918514-81-5P	918514-82-6P	918514-83-7P	918514-84-8P
	918514-85-9P	918514-86-0P	918514-87-1P	918514-88-2P	918514-89-3P
	918514-90-6P	918514-91-7P	918514-92-8P	918514-93-9P	918514-94-0P
	918514-95-1P	918514-96-2P	918514-98-4P	918514-99-5P	918515-00-1P
	918515-01-2P	918515-02-3P	918515-03-4P	918515-04-5P	918515-05-6P
	918515-06-7P	918515-07-8P	918515-08-9P	918515-09-0P	918515-10-3P
	918515-11-4P	918515-12-5P	918515-13-6P	918515-14-7P	918515-15-8P
	918515-16-9P	918515-17-0P	918515-18-1P	918515-19-2P	918515-20-5P
	918515-21-6P	918515-22-7P	918515-23-8P	918515-24-9P	918515-25-0P
	918515-26-1P	918515-27-2P	918515-28-3P	918515-29-4P	918515-30-7P
	918515-31-8P	918515-32-9P	918515-33-0P	918515-34-1P	918515-35-2P
	918515-36-3P	918515-37-4P	918515-38-5P	918515-39-6P	918515-40-9P
	918515-41-0P	918515-42-1P	918515-43-2P	918515-44-3P	918515-45-4P

918515-46-5P	918515-47-6P	918515-48-7P	918515-49-8P	918515-50-1P
918515-51-2P	918515-52-3P	918515-53-4P	918515-54-5P	918515-55-6P
918515-56-7P	918515-57-8P	918515-58-9P	918515-59-0P	918515-60-3P
918515-61-4P	918515-62-5P	918515-63-6P	918515-64-7P	918515-65-8P
918515-66-9P	918515-67-0P	918515-68-1P	918515-69-2P	918515-70-5P
918515-71-6P	918515-72-7P	918515-73-8P	918515-74-9P	918515-75-0P
918515-76-1P	918515-77-2P	918515-78-3P	918515-79-4P	918515-80-7P
918515-81-8P	918515-82-9P	918515-83-0P	918515-84-1P	918515-85-2P
918515-86-3P	918515-87-4P	918515-88-5P	918515-89-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
inhibitors useful in treatment of diseases)

IT	918515-90-9P	918515-91-0P	918515-92-1P	918515-93-2P	918515-94-3P
	918515-95-4P	918515-96-5P	918515-97-6P	918515-98-7P	918515-99-8P
	918516-00-4P	918516-01-5P	918516-02-6P	918516-03-7P	918516-04-8P
	918516-05-9P	918516-06-0P	918516-07-1P	918516-08-2P	918516-09-3P
	918516-10-6P	918516-11-7P	918516-13-9P	918516-14-0P	918516-15-1P
	918516-16-2P	918516-17-3P	918516-18-4P	918516-19-5P	918516-20-8P
	918516-21-9P	918516-22-0P	918516-23-1P	918516-24-2P	918516-25-3P
	918516-26-4P	918516-28-6P	918516-29-7P	918516-30-0P	918516-31-1P
	918516-32-2P	918516-33-3P	918516-34-4P	918516-35-5P	918516-36-6P
	918516-37-7P	918516-38-8P	918516-39-9P	918516-40-2P	918516-41-3P
	918516-42-4P	918516-43-5P	918516-44-6P	918516-45-7P	918516-46-8P
	918516-47-9P	918516-48-0P	918516-49-1P	918516-50-4P	918516-51-5P
	918516-52-6P	918516-53-7P	918516-54-8P	918516-55-9P	918516-56-0P
	918516-57-1P	918516-58-2P	918516-59-3P	918516-60-6P	918516-61-7P
	918516-62-8P	918516-63-9P	918516-64-0P	918516-65-1P	918516-66-2P
	918516-67-3P	918516-68-4P	918516-69-5P	918516-70-8P	918516-71-9P
	918516-72-0P	918516-73-1P	918516-74-2P	918516-75-3P	918516-76-4P
	918516-77-5P	918516-78-6P	918516-79-7P	918516-80-0P	918516-81-1P
	918516-82-2P	918516-83-3P	918516-84-4P	918516-85-5P	918516-86-6P
	918516-87-7P	918516-88-8P	918516-89-9P	918516-90-2P	918516-91-3P
	918516-92-4P	918516-93-5P	918516-94-6P	918516-95-7P	918516-96-8P
	918516-97-9P	918516-98-0P	918516-99-1P	918517-00-7P	918517-01-8P
	918517-02-9P	918517-06-3P	918517-08-5P	918517-10-9P	918517-12-1P
	918517-14-3P	918517-16-5P	918517-18-7P	918517-20-1P	918517-22-3P
	918517-24-5P	918517-26-7P	918517-28-9P	918517-29-0P	918517-31-4P
	918517-33-6P	918517-35-8P	918517-37-0P	918517-39-2P	918517-41-6P
	918517-43-8P	918517-45-0P	918517-47-2P	918517-49-4P	918517-51-8P
	918517-53-0P	918517-55-2P	918517-57-4P	918517-59-6P	918517-61-0P
	918517-63-2P	918517-65-4P	918517-67-6P	918517-71-2P	918517-73-4P
	918517-75-6P	918517-77-8P	918517-79-0P	918517-82-5P	918517-84-7P
	918517-86-9P	918517-88-1P	918517-90-5P	918517-92-7P	918517-94-9P
	918517-96-1P	918517-98-3P	918518-00-0P	918518-02-2P	918518-04-4P
	918518-07-7P	918518-09-9P	918518-14-6P	918518-16-8P	918518-19-1P
	918518-21-5P	918518-23-7P	918518-25-9P	918518-27-1P	918518-30-6P
	918518-32-8P	918518-34-0P	918518-39-5P	918518-42-0P	918518-45-3P
	918518-48-6P	918518-50-0P	918518-53-3P	918518-55-5P	918518-57-7P
	918518-59-9P	918518-61-3P	918518-63-5P	918518-65-7P	918518-67-9P
	918518-69-1P	918518-71-5P	918518-73-7P	918518-75-9P	918518-77-1P
	918518-78-2P	918518-80-6P	918518-82-8P	918518-84-0P	918518-85-1P
	918518-86-2P	918518-87-3P	918518-88-4P	918518-90-8P	918518-92-0P
	918518-93-1P	918518-96-4P	918518-98-6P	918519-01-4P	918519-04-7P
	918519-05-8P	918519-06-9P	918519-26-3P	918519-32-1P	918519-33-2P
	918519-35-4P	918519-40-1P	918519-42-3P	918519-44-5P	918519-46-7P
	918519-47-8P	918519-48-9P	918519-50-3P	918519-51-4P	918519-52-5P
	918519-53-6P	918519-54-7P	918519-55-8P	918519-56-9P	918519-57-0P
	918519-58-1P	918519-59-2P	918519-60-5P	918519-61-6P	918519-62-7P
	918519-63-8P	918519-64-9P	918519-65-0P	918519-66-1P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
inhibitors useful in treatment of diseases)

IT	918519-67-2P	918519-68-3P	918519-70-7P	918519-71-8P	918519-72-9P
	918519-73-0P	918519-74-1P	918519-75-2P	918519-76-3P	918519-77-4P
	918519-79-6P	918519-80-9P	918519-81-0P	918519-82-1P	918519-83-2P
	918519-84-3P	918519-85-4P	918519-86-5P	918519-87-6P	918519-88-7P
	918519-89-8P	918519-90-1P	918519-91-2P	918519-92-3P	918519-93-4P
	918519-94-5P	918519-95-6P	918519-96-7P	918519-97-8P	918519-98-9P
	918519-99-0P	918520-00-0P	918520-01-1P	918520-02-2P	918520-03-3P
	918520-04-4P	918520-05-5P	918520-06-6P	918520-07-7P	918520-08-8P
	918520-09-9P	918520-10-2P	918520-11-3P	918520-12-4P	918520-13-5P
	918520-14-6P	918520-15-7P	918520-16-8P	918520-17-9P	918520-18-0P
	918520-19-1P	918520-20-4P	918520-21-5P	918520-22-6P	918520-23-7P
	918520-24-8P	918520-25-9P	918520-26-0P	918520-27-1P	918520-28-2P
	918520-29-3P	918520-30-6P	918520-31-7P	918520-32-8P	918520-33-9P
	918520-34-0P	918520-35-1P	918520-36-2P	918520-37-3P	918520-38-4P
	918520-39-5P	918520-40-8P	918520-41-9P	918520-42-0P	918520-43-1P
	918520-44-2P	918520-45-3P	918520-46-4P	918520-47-5P	918520-48-6P
	918520-49-7P	918520-50-0P	918520-51-1P	918520-52-2P	918520-53-3P
	918520-54-4P	918520-55-5P	918520-56-6P	918520-57-7P	918520-58-8P
	918520-59-9P	918520-60-2P	918520-61-3P	918520-62-4P	918520-63-5P
	918520-64-6P	918520-65-7P	918520-66-8P	918520-67-9P	918520-68-0P
	918520-69-1P	918520-70-4P	918520-71-5P	918520-72-6P	918520-73-7P
	918520-74-8P	918520-75-9P	918520-76-0P	918520-77-1P	918520-78-2P
	918520-79-3P	918520-80-6P	918520-81-7P	918520-83-9P	918520-84-0P
	918520-85-1P	918520-86-2P	918520-87-3P	918520-88-4P	918520-89-5P
	918520-90-8P	918520-91-9P	918520-92-0P	918520-93-1P	918520-94-2P
	918520-95-3P	918520-96-4P	918520-97-5P	918520-98-6P	918520-99-7P
	918521-00-3P	918521-01-4P	918521-02-5P	918521-03-6P	918521-04-7P
	918521-05-8P	918521-06-9P	918521-07-0P	918521-08-1P	918521-09-2P
	918521-10-5P	918521-11-6P	918521-12-7P	918521-13-8P	918521-14-9P
	918521-15-0P	918521-16-1P	918521-17-2P	918521-18-3P	918521-19-4P
	918521-20-7P	918521-21-8P	918521-22-9P	918521-23-0P	918521-24-1P
	918521-25-2P	918521-26-3P	918521-27-4P	918521-28-5P	918521-29-6P
	918521-30-9P	918521-32-1P	918521-33-2P	918521-34-3P	918521-35-4P
	918521-36-5P	918521-37-6P	918521-38-7P	918521-39-8P	918521-40-1P
	918521-41-2P	918521-42-3P	918521-43-4P	918521-44-5P	918521-45-6P
	918521-46-7P	918521-47-8P	918521-48-9P	918521-49-0P	918521-50-3P
	918521-51-4P	918521-52-5P	918521-53-6P	918521-54-7P	918521-55-8P
	918521-56-9P	918521-57-0P	918521-58-1P	918521-59-2P	918521-60-5P
	918521-61-6P	918521-62-7P	918521-63-8P	918521-64-9P	918521-65-0P
	918521-66-1P	918521-67-2P	918521-68-3P	918521-69-4P	918521-70-7P
	918521-71-8P	918521-72-9P	918521-73-0P	918521-74-1P	918521-75-2P
	918521-76-3P	918521-77-4P	918521-78-5P	918521-79-6P	918521-80-9P
	918521-81-0P	918521-82-1P	918521-83-2P	918521-84-3P	918521-85-4P
	918521-86-5P	918521-87-6P	918521-88-7P	918521-89-8P	918521-90-1P
	918521-91-2P	918521-92-3P	918521-93-4P	918521-94-5P	918521-95-6P
	918521-96-7P	918521-97-8P	918521-98-9P	918521-99-0P	918522-00-6P
	918522-01-7P	918522-02-8P	918522-03-9P	918522-04-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
inhibitors useful in treatment of diseases)

IT	918522-05-1P	918522-06-2P	918522-07-3P	918522-08-4P	918522-09-5P
	918522-10-8P	918522-11-9P	918522-12-0P	918522-13-1P	918522-14-2P
	918522-15-3P	918522-16-4P	918522-17-5P	918522-18-6P	918522-19-7P
	918522-20-0P	918522-21-1P	918522-22-2P	918522-23-3P	918522-24-4P

918522-26-6P	918522-27-7P	918522-28-8P	918522-29-9P	918522-30-2P
918522-31-3P	918522-32-4P	918522-33-5P	918522-34-6P	918522-35-7P
918522-36-8P	918522-37-9P	918522-38-0P	918522-39-1P	918522-40-4P
918522-41-5P	918522-43-7P	918522-45-9P	918522-46-0P	918522-48-2P
918522-49-3P	918522-51-7P	918522-53-9P	918522-55-1P	918522-56-2P
918522-57-3P	918522-59-5P	918522-61-9P	918522-63-1P	918522-65-3P
918522-67-5P	918522-69-7P	918522-71-1P	918522-73-3P	918522-75-5P
918522-77-7P	918522-79-9P	918522-81-3P	918522-83-5P	918522-85-7P
918522-87-9P	918522-89-1P	918522-91-5P	918522-93-7P	918522-95-9P
918522-97-1P	918522-99-3P	918523-01-0P	918523-02-1P	918523-03-2P
918523-05-4P	918523-06-5P	918523-07-6P	918523-08-7P	918523-09-8P
918523-10-1P	918523-11-2P	918523-12-3P	918523-13-4P	918523-14-5P
918523-15-6P	918523-16-7P	918523-17-8P	918523-18-9P	918523-19-0P
918523-20-3P	918523-21-4P	918523-22-5P	918523-23-6P	918523-24-7P
918523-25-8P	918523-26-9P	918523-27-0P	918523-28-1P	918523-29-2P
918523-30-5P	918523-31-6P	918523-32-7P	918523-33-8P	918523-34-9P
918523-35-0P	918523-36-1P	918523-37-2P	918523-38-3P	918523-39-4P
918523-40-7P	918523-41-8P	918523-42-9P	918523-43-0P	918523-50-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
inhibitors useful in treatment of diseases)

IT 7440-70-2, Calcium, biological studies

RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
unclassified); BIOL (Biological study)

(hypercalcemia; preparation of pyrrolopyridine derivs. as protein kinase
inhibitors useful in treatment of diseases)

IT 824-52-2P	5654-92-2P	39255-23-7P	56741-33-4P	70205-04-8P
76588-84-6P	79418-72-7P	79418-77-2P	112434-18-1P	132303-32-3P
143468-13-7P	152434-86-1P	152434-87-2P	152434-88-3P	183208-36-8P
208986-50-9P	269072-20-0P	443124-79-6P	486424-36-6P	849409-81-0P
849409-82-1P	858116-59-3P	858116-66-2P	858116-86-6P	858117-08-5P
901238-24-2P	902458-30-4P	913983-25-2P	918523-44-1P	918523-45-2P
918523-46-3P	918523-47-4P	918523-48-5P	918523-49-6P	918523-51-0P
918523-52-1P	918523-53-2P	918523-54-3P	918523-55-4P	918523-56-5P
918523-57-6P	918523-58-7P	918523-59-8P	918523-60-1P	918523-61-2P
918523-62-3P	918523-63-4P	918523-64-5P	918523-65-6P	918523-66-7P
918523-67-8P	918523-68-9P	918523-69-0P	918523-70-3P	918523-71-4P
918523-72-5P	918523-73-6P	918523-74-7P	918523-75-8P	918523-76-9P
918523-77-0P	918523-78-1P	918523-79-2P	918523-80-5P	918523-81-6P
918523-82-7P	918523-83-8P	918523-84-9P	918523-85-0P	918523-86-1P
918523-87-2P	918523-88-3P	918523-89-4P	918523-90-7P	918523-91-8P
918523-92-9P	918523-93-0P	918523-94-1P	918523-95-2P	918523-96-3P
918523-97-4P	918523-98-5P	918523-99-6P	918524-00-2P	918524-01-3P
918524-02-4P	918524-03-5P	918524-04-6P	918524-05-7P	918524-06-8P
918524-07-9P	918524-08-0P	918524-09-1P	918524-10-4P	918524-11-5P
918524-12-6P	918524-13-7P	918524-14-8P	918524-15-9P	918524-16-0P
918524-17-1P	918524-18-2P	918524-19-3P	918524-20-6P	918524-21-7P
918524-22-8P	918524-23-9P	918524-24-0P	918524-25-1P	918524-26-2P
918524-27-3P	918524-28-4P	918524-29-5P	918524-30-8P	918524-31-9P
918524-32-0P	918524-33-1P	918524-34-2P	918524-35-3P	918524-36-4P
918524-37-5P	918524-38-6P	918524-39-7P	918524-40-0P	918524-41-1P
918524-42-2P	918524-43-3P	918524-44-4P	918524-45-5P	918524-46-6P
918524-47-7P	918524-48-8P	918524-49-9P	918524-50-2P	918524-51-3P
918524-52-4P	918524-53-5P	918524-54-6P	918524-55-7P	918524-56-8P
918524-57-9P	918524-58-0P	918524-59-1P	918524-60-4P	918524-61-5P
918524-62-6P				

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(intermediate; preparation of pyrrolopyridine derivs. as protein kinase

inhibitors useful in treatment of diseases)

IT 7782-44-7, Oxygen, biological studies
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 79079-06-4, EGFR kinase 98037-52-6, Abl protein kinase 103843-29-4, IGF1R kinase 108891-60-7 111694-09-8 114051-78-4, LCK kinase 136396-12-8 137632-03-2, Met kinase 137632-06-5, Csk kinase 137632-08-7, Erk2 kinase 137632-09-8, Erbb2 kinase 138359-29-2, c-KIT kinase 138674-26-7, Protein kinase Syk 139691-76-2, c-Raf-1 141349-86-2, Cdk2 kinase 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes protein kinase 141350-03-0, Flt1 kinase 141436-78-4, Protein kinase C β 144114-16-9, Fak kinase 144376-45-4, Pim1 kinase 144638-77-7, Flt4 kinase 144697-16-5, B-Raf kinase 145539-86-2, HCK kinase 146279-92-7, Ret kinase 146838-30-4, MAPKAPK2 147014-96-8, CDK5 kinase 147014-97-9, CDK4 kinase 147230-71-5, Flt3 kinase 148047-29-4, Tie 2 kinase 148047-34-1, Protein kinase Zap70 148640-14-6, Akt 1 kinase 149147-12-6, Btk kinase 150027-21-7 150316-14-6, Mitogen-activated protein kinase 2 150977-45-0, Kdr kinase 151662-26-9, Itk kinase 152478-56-3, Jak1 kinase 152478-57-4, Jak2 kinase 152743-99-2, Her4 kinase 152787-58-1, Protein kinase TrkA 154907-65-0, CHK1 kinase 157482-36-5, Jak3 kinase 165245-96-5, p38 Kinase 165245-99-8, Polo like kinase 1 166433-56-3, Anaplastic lymphoma kinase 170780-46-8, Pyk2 kinase 176023-60-2, Akt2 kinase 182238-33-1, Gene Ron protein kinase 182938-07-4, Protein kinase ROCK1 182938-08-5, Protein kinase ROCK2 191359-13-4, Mnk1 kinase 191808-15-8, 3-Phosphoinositide dependent protein kinase-1 205265-41-4, Akt3 kinase 250649-03-7, Protein kinase MLK1 270086-00-5, Pim3 kinase 289898-51-7, Jnk1 kinase 289899-93-0, Jnk2 kinase 291756-39-3, Jnk3 kinase 303014-92-8, CDK6 kinase 362517-43-9, IKK- β kinase 370088-29-2, Mitogen-activated protein kinase kinase kinase kinase 4 372092-80-3 420790-04-1, Pim2 kinase 428817-87-2, Irak4 kinase 443900-95-6, Glycogen synthase kinase 3 β 458560-40-2, Protein kinase Stk6 553648-93-4, Glycogen synthase kinase 3 α

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 9004-10-8, Insulin, biological studies
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 62-53-3, Aniline, reactions 83-38-5, 2,6-Dichlorobenzaldehyde 89-97-4, 2-Chlorobenzylamine 90-04-0, 2-Methoxyaniline 94-99-5, 2,4-Dichlorobenzyl chloride 95-51-2, 2-Chloroaniline 96-32-2, Methyl bromoacetate 96-33-3, Methyl acrylate 98-09-9, Benzenesulfonyl chloride 98-16-8, 3-Trifluoromethylaniline 98-18-0, 3-Aminobenzenesulfonamide 98-31-7, 3,4-Dichlorophenylsulfonyl chloride 98-59-9, 4-Methylphenylsulfonyl chloride 98-60-2, 4-Chlorophenylsulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-80-6, Phenylboronic acid 99-61-6, 3-Nitrobenzaldehyde 99-98-9, 4-Dimethylaminoaniline 100-07-2, 4-Methoxybenzoic acid chloride 100-37-8, 2-(Diethylamino)ethanol 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-55-0, 3-Pyridinemethanol 100-61-8, N-Methylaniline, reactions 100-81-2, 3-Methylbenzylamine 103-71-9, Phenyl isocyanate, reactions 104-12-1, 4-Chlorophenyl isocyanate 104-84-7, 4-Methylbenzylamine 104-86-9, 4-Chlorobenzylamine 104-94-9, 4-Methoxyaniline 106-41-2, 4-Bromophenol 106-47-8, 4-Chloroaniline, reactions 106-49-0, 4-Methylaniline, reactions 107-10-8,

1-Propanamine, reactions 108-42-9, 3-Chloroaniline 108-91-8,
Aminocyclohexane, reactions 109-01-3 109-73-9, 1-Butanamine, reactions
109-86-4, 2-Methoxyethanol 110-68-9, N-Methyl-1-butanamine 110-91-8,
Morpholine, reactions 111-36-4, Butyl isocyanate 121-32-4,
3-Ethoxy-4-hydroxybenzaldehyde 121-33-5, 4-Hydroxy-3-methoxybenzaldehyde
121-51-7, 3-Nitrobenzenesulfonyl chloride 121-60-8, 4-
(Acetylamino)benzenesulfonyl chloride 123-08-0, 4-Hydroxybenzaldehyde
133-59-5, 2-Methylbenzenesulfonyl chloride 139-59-3, 4-Phenoxyaniline
140-75-0, 4-Fluorobenzylamine 271-63-6, 7-Azaindole 303-38-8,
2,3-Dihydroxybenzoic acid 327-78-6, 4-Chloro-3-trifluoromethylphenyl
isocyanate 349-88-2, 4-Fluorophenylsulfonyl chloride 367-25-9,
2,4-Difluoroaniline 367-27-1, 2,4-Difluorophenol 371-40-4,
4-Fluoroaniline 399-95-1, 2-Fluoro-4-hydroxyaniline 404-71-7,
3-Fluorophenyl isocyanate 405-05-0, 3-Fluoro-4-hydroxybenzaldehyde
437-81-0, 2,6-Difluorobenzaldehyde 445-05-6, 5-Fluoro-2-
methylbenzenesulfonyl chloride 445-26-1, 1-(2-Fluorophenyl)ethanol
446-31-1, 4-Amino-2-fluorobenzoic acid 446-51-5, 2-Fluorobenzyl alcohol
454-89-7, 3-Trifluoromethylbenzaldehyde 459-59-6, N-Methyl-4-
fluoroaniline 461-82-5, 4-Trifluoromethoxyaniline 462-08-8,
3-Aminopyridine 501-30-4 501-53-1, Benzyl chloroformate 536-90-3,
3-Methoxyaniline 582-33-2, Ethyl 3-aminobenzoate 586-95-8,
4-Pyridinemethanol 586-98-1, 2-Pyridinemethanol 589-87-7,
1-Bromo-4-iodobenzene 603-80-5, 3-Hydroxy-2-methylbenzoic acid
614-68-6, 2-Methylphenyl isocyanate 621-29-4, 3-Methylphenyl isocyanate
621-59-0, 3-Hydroxy-4-methoxybenzaldehyde 622-40-2, N-(2-
Hydroxyethyl)morpholine 622-58-2, 4-Methylphenyl isocyanate 622-95-7,
4-Chlorobenzyl bromide 623-24-5, 1,4-Bis(bromomethyl)benzene 626-43-7,
3,5-Dichloroaniline 626-58-4, 4-Methylpiperidine 656-42-8,
3,4-(Difluoromethylenedioxy)benzaldehyde 696-44-6 701-27-9,
3-Fluorobenzenesulfonyl chloride 701-34-8, 4-Bromobenzenesulfonamide
766-00-7, 2-Cyclopentylethanol 766-80-3, 3-Chlorobenzyl bromide
767-05-5, 3-Cyclopentylpropanol 768-35-4, 3-Fluorophenylboronic acid
777-44-6, 3-Trifluoromethylbenzenesulfonyl chloride 824-94-2,
4-Methoxybenzyl chloride 932-96-7, N-Methyl-4-chloroaniline 1003-03-8,
Aminocyclopentane 1072-67-9, 3-Amino-5-methylisoxazole 1074-86-8,
4-Indolecarboxaldehyde 1122-71-0, 6-Methylpyridine-2-methanol
1123-56-4, 2,6-Dimethylbenzaldehyde 1138-56-3, 4-Butoxyphenylsulfonyl
chloride 1195-45-5, 4-Fluorophenyl isocyanate 1423-26-3,
3-Trifluoromethylphenylboronic acid 1483-28-9, 2,5-
Dimethoxybenzenesulfonyl chloride 1535-73-5, 3-Trifluoromethoxyaniline
1548-13-6, 4-Trifluoromethylphenyl isocyanate 1679-18-1,
4-Chlorophenylboronic acid 1692-15-5, Pyridin-4-ylboronic acid
1692-25-7, Pyridin-3-ylboronic acid 1765-93-1, 4-Fluorophenylboronic
acid 1777-82-8, 2,4-Dichlorobenzyl alcohol 1899-93-0,
3-Methylbenzenesulfonyl chloride 1978-37-6, N-Methyl-3-fluoroaniline
1996-41-4, 2-Chloro-4-fluorophenol 2038-03-1, N-(2-Aminoethyl)morpholine
2124-55-2, 4-Indolecarboxylic acid 2359-60-6, 4-(Piperidin-1-yl)aniline
2386-60-9, 1-Butanesulfonyl chloride 2393-23-9, 4-Methoxybenzylamine
2420-16-8, 3-Chloro-4-hydroxybenzaldehyde 2426-87-1,
4-Benzyloxy-3-methoxybenzaldehyde 2516-47-4, Cyclopropylmethylamine
2524-67-6, 4-(Morpholin-4-yl)aniline 2688-84-8, 2-Phenoxyaniline
2713-31-7, 2,5-Difluorophenol 2740-83-2, 3-Trifluoromethylbenzylamine
2836-04-6, 3-Dimethylaminoaniline 2905-21-7, 2-Fluorobenzenesulfonyl
chloride 2909-38-8, 3-Chlorophenyl isocyanate 2987-49-7,
2-Methylsulfonylaniline 2991-42-6, 4-Trifluoromethylphenylsulfonyl
chloride 3048-01-9, 2-Trifluoromethylbenzylamine 3173-56-6, Benzyl
isocyanate 3218-02-8, Cyclohexanemethanamine 3300-51-4,
4-Trifluoromethylbenzylamine 3355-28-0, 1-Bromo-2-butyne 3445-11-2,
N-(2-Hydroxyethyl)pyrrolidin-2-one 3586-12-7, 3-Phenoxyaniline
3587-60-8, Benzyloxymethyl chloride 3731-51-9, Pyridine-2-methylamine
3731-52-0, 3-Pyridinemethanamine 3954-13-0, Pentyl isocyanate

4152-90-3, 3-Chlorobenzylamine 4393-16-2, 4-Methylsulfonylbenzylamine
 4441-30-9, N-(3-Hydroxypropyl)morpholine 4595-59-9, 5-Bromopyrimidine
 5071-96-5, 3-Methoxybenzylamine 5180-79-0 5345-54-0,
 3-Chloro-4-methoxyaniline 5369-19-7, 3-tert-Butylaniline 5416-93-3,
 4-Methoxyphenyl isocyanate 5470-49-5, 4-Methylsulfonylaniline
 5585-33-1, 2-Morpholinoaniline 5720-07-0, 4-Methoxyphenylboronic acid
 5779-95-3, 3,5-Dimethylbenzaldehyde 5961-59-1, N-Methyl-4-methoxyaniline
 6165-68-0, Thiophene-2-boronic acid 6482-24-2, 1-Bromo-2-methoxyethane
 7006-52-2, N-Methyl-3-chloroaniline 7304-32-7, 2-Fluoro-5-nitrobenzoic
 acid 10130-74-2, 3-Methoxyphenylsulfonyl chloride 10147-36-1,
 1-Propanesulfonyl chloride 10147-37-2, 2-Propanesulfonyl chloride
 10203-08-4, 3,5-Dichlorobenzaldehyde 10272-07-8, 3,5-Dimethoxyaniline
 10365-98-7, 3-Methoxyphenylboronic acid 10541-83-0, 4-Methylaminobenzoic
 acid 13358-73-1, Dibutyl carbamoyl chloride 13360-63-9,
 N-Ethyl-1-butanamine 13918-92-8, 2,4-Difluorobenzenesulfonyl chloride
 13952-84-6, 2-Butanamine 14318-66-2, N-Methyl-3-methoxyaniline
 15268-31-2, 3-Isocyanatopyridine 15854-87-2, 4-Iodopyridine
 16315-59-6, 4-Dimethylaminophenyl isocyanate 16629-19-9,
 2-Thiophenesulfonyl chloride 16712-69-9, 4-Ethylphenylsulfonyl chloride
 17334-08-6, 1-Methylimidazole-2-methanol 18278-34-7,
 4-Hydroxy-2-methoxybenzaldehyde 18908-07-1, 3-Methoxyphenyl isocyanate
 20012-63-9, 2-Benzyloxyaniline 20443-98-5, 2,6-Dichlorobenzyl bromide
 20984-81-0, 3-(Diethylamino)pyrrolidine 21626-70-0 22184-97-0
 23095-31-0, 3,4-Dimethoxyphenylsulfonyl chloride 23616-57-1
 26153-38-8, 3,5-Dihydroxybenzaldehyde 27086-19-7, Dipropylcarbamoyl
 chloride 28439-86-3, 4-Butoxyphenyl isocyanate 28611-39-4,
 4-Dimethylaminophenylboronic acid 29668-44-8, 3,4-Ethylenedioxybenzaldehyde
 30418-59-8, 3-Aminophenylboronic acid 35216-39-8, 3-Methylsulfonylaniline
 35856-62-3, 1-Piperidinesulfonyl chloride 37045-73-1 37527-66-5, 3,4-Dimethoxyphenyl isocyanate
 38041-19-9, 4-Amino-tetrahydropyran 38070-73-4 39893-50-0,
 3-Chloro-4-trifluoromethylphenyl isocyanate 39989-43-0,
 3,5-Dichlorobenzylamine 40750-59-2, N-Methyl-3,4-dichloroaniline
 41419-59-4, N-Methyl-4-trifluoromethoxyaniline 41483-74-3 41838-46-4,
 4-Amino-1-methylpiperidine 42170-95-6, 2-Methoxyethyl isocyanate
 42601-04-7, 3,4-Difluorophenyl isocyanate 49584-26-1,
 4-Cyanophenylsulfonyl chloride 50382-32-6, 2,4-Dimethylthiazole-5-methanol
 50528-86-4, 2-Chloro-5-trifluoromethylphenyl isocyanate 51175-71-4,
 3-Thiophenesulfonyl chloride 51488-22-3, 2-Chloro-4-trifluoromethylphenyl isocyanate
 52130-17-3, 3-Amino-2-methylbenzoic acid 52771-21-8, 3-Trifluoromethoxybenzaldehyde
 53104-95-3, 4-Hydroxy-3-trifluoromethoxybenzaldehyde 54751-01-8,
 4-Bromomethylpyridine 54997-90-9, 4-Isopropylbenzenesulfonyl chloride
 56456-47-4, 2,4-Difluorobenzylalcohol 56456-49-6, 4-Chloro-2-fluorobenzyl alcohol
 56542-67-7, 3-Cyanobenzenesulfonyl chloride 56962-11-9, 2-Chloro-4-hydroxybenzaldehyde
 57012-20-1 57678-46-3, 3-Dimethylaminobenzylamine 57946-56-2, 4-Chloro-2-fluoroaniline
 61424-26-8, 3-Benzylaniline 61672-75-1, Isoxazol-3-yl isocyanate 63503-60-6,
 3-Chlorophenylboronic acid 63624-28-2 63758-12-3 69360-26-5, 2-Cyanobenzenesulfonyl chloride
 69816-05-3 70067-45-7 71189-18-9 71916-82-0, 4-Chloro-2-fluorobenzyl bromide 71924-62-4
 72975-46-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 78887-39-5, 3-(Acetylamino)phenylboronic acid 79418-78-3,
 3-Fluoro-4-hydroxy-5-methoxybenzaldehyde 80466-80-4 85345-76-2,
 3-Chloro-2-fluorobenzoyl chloride 85684-61-3, 3-Difluoromethoxybenzaldehyde
 86718-08-3 89599-01-9, 3-Bromobenzenesulfonamide 90001-64-2, Benzothiophene-2-sulfonyl chloride
 90260-13-2, 3-Fluoro-4-methylbenzenesulfonyl chloride 93071-75-1,

3-Trifluoromethoxybenzylamine 93919-56-3, 4-Trifluoromethoxybenzylamine
 97272-04-3, 2,5-Dimethylthiophene-3-sulfonyl chloride 98437-24-2,
 2-Benzofuranboronic acid 103438-86-4 103438-88-6, 2-Fluoro-3-
 methoxybenzaldehyde 104451-70-9, 2,3,6-Trifluorobenzaldehyde
 108679-71-6, 3-Amino-2-chlorobenzoic acid 109299-78-7,
 Pyrimidine-5-boronic acid 119895-68-0 123088-59-5,
 4-(Aminocarbonyl)phenylboronic acid 126747-14-6, 4-Cyanophenylboronic
 acid 128796-39-4, 4-Trifluoromethylphenylboronic acid 137049-02-6
 137654-20-7, 2-Fluoro-3-methoxybenzoic acid 138564-16-6,
 N-Methyl-2,4-difluoroaniline 148355-75-3, 3-
 (Methylsulfonylamino)phenylboronic acid 151411-98-2,
 2,4,6-Trifluorobenzyl bromide 151858-64-9, 5-(2-Pyridinyl)thiophene-2-
 sulfonyl chloride 153912-60-8, 1,5-Dimethyl-1H-pyrazole-3-methanol
 156545-07-2, 3,5-Difluorophenylboronic acid 163105-89-3,
 2-Methoxypyridin-5-ylboronic acid 166964-26-7, 2,5-Dimethylfuran-3-
 sulfonyl chloride 167678-46-8, Acetic acid 3-chlorocarbonyl-2-
 methylphenyl ester 168899-43-2 175205-64-8, 2-
 Trifluoromethoxybenzylamine 179113-90-7, 3-Trifluoromethoxyphenylboronic
 acid 180200-86-6 181124-40-3, 6-Benzothiazolesulfonyl chloride
 188815-30-7, 3-Fluoro-5-trifluoromethylbenzaldehyde 190774-52-8,
 2-Fluoro-3-trifluoromethylphenyl isocyanate 197239-49-9,
 2-Fluoro-4-trifluoromethylbenzyl alcohol 208186-84-9,
 2-Chloro-4-fluorobenzyl alcohol 210532-25-5, 3,5-Difluorobenzenesulfonyl
 chloride 216144-91-1 252928-74-8 306936-35-6 321309-40-4
 337508-66-4, 4-(Oxazol-5-yl)benzenesulfonyl chloride 351003-34-4,
 4-Difluoromethoxybenzenesulfonyl chloride 351422-73-6,
 3-(Aminocarbonyl)phenylboronic acid 364794-80-9 373384-18-0,
 3-(Methylsulfonyl)phenylboronic acid 380430-52-4 386704-04-7
 388088-73-1 389621-84-5 405520-68-5 423151-49-9 445264-61-9
 485799-04-0 532967-21-8, 2,6-Difluoro-4-hydroxybenzaldehyde
 551930-53-1 628692-15-9 690632-68-9 701269-22-9 754214-56-7
 761446-44-0 785785-59-3 852180-61-1 852227-95-3 858116-95-7
 909501-40-2 911210-53-2, 4-Cyano-3,5-dimethylphenylboronic acid
 918524-63-7 918524-64-8 918524-65-9 918524-66-0 918524-67-1
 918524-68-2 918524-69-3 918524-70-6 918524-71-7 918524-72-8
 918524-73-9 918524-74-0 918524-75-1 918524-76-2 918524-77-3
 918524-78-4 918524-80-8 918524-83-1 918524-85-3 918524-86-4
 918524-87-5 918524-88-6 918524-89-7 918524-90-0 918524-91-1
 918524-92-2 918524-93-3 918524-94-4 918524-95-5 918524-96-6
 918524-97-7 918524-98-8 918524-99-9 918525-00-5 918525-01-6
 918525-02-7 918525-03-8 918525-04-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase
 inhibitors useful in treatment of diseases)

IT 918724-49-9 918724-53-5 918724-54-6 918724-55-7 918724-56-8
 918724-57-9 918724-58-0 918724-59-1 918724-61-5 918724-62-6
 918724-63-7

RL: PRP (Properties)

(unclaimed nucleotide sequence; pyrrolo[2,3-b]pyridine derivs. as
 protein kinase inhibitors and their preparation, pharmaceutical compns. and
 use in the treatment of diseases)

IT 918724-60-4 918724-64-8

RL: PRP (Properties)

(unclaimed protein sequence; pyrrolo[2,3-b]pyridine derivs. as protein
 kinase inhibitors and their preparation, pharmaceutical compns. and use in
 the treatment of diseases)

IT 918724-35-3 918724-36-4 918724-37-5 918724-38-6 918724-39-7
 918724-40-0 918724-41-1 918724-42-2 918724-43-3 918724-44-4
 918724-45-5 918724-46-6 918724-47-7 918724-48-8 918724-50-2
 918724-51-3 918724-52-4 918724-65-9 918724-66-0 918724-67-1
 918724-68-2 918724-69-3 918724-70-6 918724-71-7 918724-72-8

918724-73-9	918724-74-0	918724-75-1	918724-76-2	918724-77-3
918724-78-4	918724-79-5	918724-80-8	918724-81-9	918724-82-0
918724-83-1	918724-84-2	918724-85-3	918724-86-4	918724-87-5
918724-88-6	918724-89-7	918724-90-0	918724-91-1	918724-92-2
918724-93-3	918724-94-4	918724-95-5	918724-96-6	918724-97-7
918724-98-8	918724-99-9	918725-00-5	918725-01-6	918725-02-7
918725-03-8	918725-04-9	918725-05-0	918725-06-1	918725-07-2
918725-08-3	918725-09-4	918725-10-7	918725-11-8	918725-12-9
918725-13-0	918725-14-1	918725-15-2	918725-16-3	918725-17-4
918725-18-5	918725-19-6	918725-20-9	918725-21-0	918725-22-1
918725-23-2	918725-24-3	918725-25-4	918725-26-5	918725-27-6
918725-28-7	918725-29-8	918725-30-1	918725-31-2	918725-32-3
918725-33-4	918725-34-5	918725-35-6	918725-36-7	918725-37-8
918725-38-9	918725-39-0	918725-40-3	918725-41-4	918725-42-5
918725-43-6	918725-44-7	918725-45-8	918725-46-9	918725-47-0
918725-48-1	918725-49-2	918725-50-5	918725-51-6	918725-52-7
918725-53-8	918725-54-9	918725-55-0	918725-56-1	918725-57-2
918725-58-3				

RL: PRP (Properties)

(unclaimed sequence; pyrrolo[2,3-b]pyridine derivs. as protein kinase inhibitors and their preparation, pharmaceutical compns. and use in the treatment of diseases)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aadal, N; WO 2004016610 A 2004 CAPLUS
- (2) Barton; TETRAHEDRON 1987, V43(2), P323 CAPLUS
- (3) Bayer Ag; DE 2413258 A1 1975 CAPLUS
- (4) Curtin; J MED CHEM 1998, V41, P74 CAPLUS
- (5) Heacock; J AM CHEM SOC 1960, V82, P3460 CAPLUS
- (6) Langham; J AM CHEM SOC 1941, V63, P545 CAPLUS
- (7) Normington, J; US 2234705 A 1941 CAPLUS
- (8) Pierce; J AM CHEM SOC 1942, V64, P1691

L32 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 98-59-9, 4-Methylbenzenesulfonyl chloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

RN 98-59-9 CAPLUS

CN Benzenesulfonyl chloride, 4-methyl- (CA INDEX NAME)



ACCESSION NUMBER:

2007:11300 CAPLUS

DOCUMENT NUMBER:

146:142627

TITLE:

Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S):

Ibrahim, Prahbha N.; Artis, Dean R.; Bremer, Ryan; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxiam; Zhu, Hongyao;

PATENT ASSIGNEE(S): Shi, Shenghua
 SOURCE: Plexxikon, Inc., USA
 PCT Int. Appl., 291 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002325	A1	20070104	WO 2006-US24361	20060621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KR 2008030619	A	20080404	KR 2008-701659	20080121
PRIORITY APPLN. INFO.:			US 2005-692960P	P 20050622
			US 2005-731528P	P 20051028
			WO 2006-US24361	W 20060621

OTHER SOURCE(S): MARPAT 146:142627

AN 2007:11300 CAPLUS
 DN 146:142627
 ED Entered STN: 04 Jan 2007
 TI Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their
 preparation, pharmaceutical compositions and use in the treatment
 of diseases
 IN Ibrahim, Prahbha N.; Artis, Dean R.; Bremer, Ryan; Mamo, Shumeye; Nespi,
 Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Tsai, James; Hirth,
 Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel
 J.; Wu, Guoxiam; Zhu, Hongyao; Shi, Shenghua
 PA Plexxikon, Inc., USA
 SO PCT Int. Appl., 291 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 FAN.CNT 3


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002325	A1	20070104	WO 2006-US24361	20060621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM
KR 2008030619 A 20080404 KR 2008-701659 20080121
PRAI US 2005-692960P P 20050622
US 2005-731528P P 20051028
WO 2006-US24361 W 20060621

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007002325	IPCI	C07D0471-04 [I,A]; C07D0471-00 [I,C*]; A61K0031-435 [I,A]; C07C0049-517 [I,A]; C07C0049-00 [I,C*]; A61P0035-00 [I,A]
	IPCR	C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]
	ECLA	C07C037/62; C07C039/27; C07C045/00+47/565; C07C045/67C+47/575; C07C045/71+47/575; C07C047/565; C07C047/575; C07D209/08; C07D471/04+221B+209B; M07D
KR 2008030619	IPCI	C07D0471-04 [I,A]; C07D0471-00 [I,C*]; A61K0031-435 [I,A]

OS MARPAT 146:142627
GI



AB Compds. of formula I which are active on protein kinases are described, as well as methods of using such compds. to treat diseases and conditions associated with aberrant activity of protein kinases. Compds. of formula I wherein Q is (un)substituted (hetero)aryl, and (un)substituted indole; A is O, S, (un)substituted methylene, NH and derivs., CO, CS, SO and SO₂; R₄ - R₆ are independently H, halo, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted lower alkynyl, (un)substituted (hetero)cycloalkyl, (un)substituted (hetero)aryl, etc.; and their pharmaceutically acceptable salts, prodrugs, tautomer, and isomers thereof, are claimed. Example compound II was prepared by carboxylation of 2,4-difluoroaniline with benzyl chloroformate; the resulting benzyl 3-amino-2,6-difluorobenzoate underwent sulfonylation with propane-1-sulfonyl chloride to give benzyl 2,6-difluoro-3-(propylsulfonylamino)benzoate, which underwent hydrolysis to give the corresponding benzoic acid, which underwent chlorination and coupling with 5-bromo-7-azaindole to give compound II. All the invention compds. were evaluated for their protein kinase inhibitory activity. Several of the invention compds. exhibited good inhibitory activity against various protein kinases.

ST pyrrolopyridine prepn protein kinase inhibitor

IT Diabetes mellitus

(-associated renal complication, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus
 (-associated renal hypertrophy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation
 (CNS, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
 (Costello, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammatory bowel disease
 (Crohn's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, disease
 Teratogenesis
 (Crouzon craniofacial dysostosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphA receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EphA1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphA receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EphA2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphB receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EphB2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT EphB receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EphB4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Intestine, disease
 (Hirschsprung's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease
 (Huntington's chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
 (Jackson-Weiss, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
 (MEN2, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (MEN2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
 (Noonan syndrome, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
 (Pfeiffer's, treatment of; preparation of pyrrolopyridine derivs.

as protein kinase inhibitors useful in treatment of diseases)

IT Granulomatous disease
(Wegener's granulomatosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Antibodies and Immunoglobulins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(X-linked infantile hypogammaglobulinemia; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(acrocephalosyndactylia type I, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain
Respiratory distress syndrome
(acute, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Retinal disease
(age-related macular degeneration, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Allergy
Inflammation
Nose, disease
(allergic rhinitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neuroglia, neoplasm
(astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Dermatitis
(atopic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Autoimmune disease
Inflammation
Thyroid gland, disease
(autoimmune thyroiditis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Infection
(bacterial, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Prostate gland, disease
(benign hyperplasia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Hyperplasia
(benign prostatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bronchi, disease
Inflammation
(bronchitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm
Mammary gland, neoplasm

Pancreas, neoplasm
(carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(cardio-faciocutaneous, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia
(cerebrovascular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Hypoxia
(chemotherapy-induced, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease
(chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease
(chronic obstructive pulmonary disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain
(chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Intestine, neoplasm
(colon, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
Intestine, neoplasm
(colon, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neoplasm
(complications, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders
(dementia, multi-infarct, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders
(dementia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Skin, disease
(dermal scarring, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Retinal disease
(diabetic retinopathy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, disease
(endometriosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, neoplasm
(endometrium, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(faciocutaneoskeletal, treatment of; preparation of

pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease
(failure, chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Reproductive system
(female, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease
(fibrosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, disease
(fracture, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene ALK5; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(genetic, developmental, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neuroglia, neoplasm
(glioblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation
Kidney, disease
(glomerulonephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant and Transplantation
(graft-vs.-host reaction, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Injury
(head and neck, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia
(hepatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(hepatocellular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Liver, neoplasm
(hepatoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lymphoma
(histiocytic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sexual disorders
(impotence, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(in situ, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Helicobacter pylori pylori

Influenza virus
 (infection, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain
 (inflammatory pain, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Head and Neck, disease
 Reperfusion
 Spinal cord, disease
 (injury, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Autoimmune disease
 (insulin-dependent diabetes mellitus, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus
 (insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation
 Kidney, disease
 (interstitial nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Liver, disease
 (ischemia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Myoma
 Sarcoma
 (leiomyosarcoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
 (leopard, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation
 Kidney, disease
 (lupus nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Edema
 (lympho-, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
 (mammary, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Metabolic disorders
 (metabolic syndrome X, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, neoplasm
 (metastasis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Blood vessel, disease
 (microangiopathy, thrombotic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Headache
 (migraine, treatment of; preparation of pyrrolopyridine derivs. as

protein kinase inhibitors useful in treatment of diseases)

IT Bone formation
(mineralization, diseases, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Oviduct
(neoplasm, adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Astrocyte
(neoplasm, astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Schwann cell
(neoplasm, schwannoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation
Kidney, disease
(nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease
(nephrosclerosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(neural crest, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nerve, neoplasm
(neuroblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain
(neuropathic pain, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus
(non-insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm
(non-small-cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sarcoma
(of neuro-ectodermal origin, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant rejection
(organ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(oviduct adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(pancreatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation
Pancreas, disease

(pancreatitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease
(polycystic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Allergy inhibitors

Analgesics

Angiogenesis inhibitors

Anti-Alzheimer's agents

Anti-infective agents

Anti-inflammatory agents

Anti-ischemic agents

Antiarthritics

Antiasthmatics

Antibacterial agents

Antidiabetic agents

Antifibrotic agents

Antimigraine agents

Antiobesity agents

Antiosteoporotic agents

Antiparkinsonian agents

Antipyretics

Antirheumatic agents

Antitumor agents

Antiviral agents

Canidae

Cardiovascular agents

Combination chemotherapy

Human

Immunostimulants

Immunosuppressants

Lipolysis

Nervous system agents

Pharmaceutical carriers

Prodrugs

Respiratory system agents

Thrombolytics

Transplant and Transplantation
(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT c-Kit (protein)
neu (receptor)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(pulmonary non-small-cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(pulmonary small-cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

Fibrosis
(pulmonary, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, neoplasm
(renal cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in

treatment of diseases)

IT Carcinoma
(renal cell, treatment of; preparation of pyrrolopyridine derivs.
as protein kinase inhibitors useful in treatment of diseases)

IT Injury
(reperfusion, treatment of; preparation of pyrrolopyridine derivs.
as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, neoplasm
(schwannoma, treatment of; preparation of pyrrolopyridine derivs.
as protein kinase inhibitors useful in treatment of diseases)

IT T lymphocyte
(selective defect of; preparation of pyrrolopyridine derivs. as protein
kinase inhibitors useful in treatment of diseases)

IT Immunodeficiency
(severe combined, treatment of; preparation of pyrrolopyridine
derivs. as protein kinase inhibitors useful in treatment of
diseases)

IT Lung, neoplasm
(small-cell carcinoma, treatment of; preparation of
pyrrolopyridine derivs. as protein kinase inhibitors useful in
treatment of diseases)

IT Injury
(spinal cord, treatment of; preparation of pyrrolopyridine derivs.
as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma
(squamous cell, treatment of; preparation of pyrrolopyridine
derivs. as protein kinase inhibitors useful in treatment of
diseases)

IT Digestive tract, neoplasm
(stroma, treatment of; preparation of pyrrolopyridine derivs. as
protein kinase inhibitors useful in treatment of diseases)

IT Lupus erythematosus
(systemic, treatment of; preparation of pyrrolopyridine derivs. as
protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal
(tissue scarring, treatment of; preparation of pyrrolopyridine
derivs. as protein kinase inhibitors useful in treatment of
diseases)

IT Acute lymphocytic leukemia
Acute myeloid leukemia
Aging, animal
Allergy
Alopecia
Alzheimer's disease
Amyotrophic lateral sclerosis
Asthma
Atherosclerosis
Bladder, neoplasm
Bone, disease
Bone, neoplasm
Brain, neoplasm
Cardiac hypertrophy
Cardiovascular system, disease
Central nervous system, neoplasm
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Diabetic nephropathy
Digestive tract, neoplasm
Emphysema
Endocrine system, disease
Eosinophilia

Fever and Hyperthermia
Fibrosis
Graves' disease
Hair, disease
 Heart failure
Hepatic steatosis
Hepatitis
Hyperglycemia
Immunodeficiency
Infection
Inflammation
Inflammatory bowel disease
Intestine, disease
 Ischemia
Kidney, disease
Leukemia
Liver, neoplasm
Lung, disease
Lung, neoplasm
Lymphoma
Mammary gland, neoplasm
Mastocytoma
Mastocytosis
Melanoma
Multiple myeloma
Multiple sclerosis
Mutation
Myasthenia gravis
Myelodysplastic syndromes
Neoplasm
Neurofibromatosis 1
Neuroglia, neoplasm
Non-Hodgkin lymphoma
Obesity
Osteoarthritis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Parkinson's disease
Prostate gland, disease
Prostate gland, neoplasm
Psoriasis
Rheumatoid arthritis
Sarcoma
Scleroderma
Sepsis
Sjogren syndrome
Skeleton, disease
Skin, disease
Skin, neoplasm
Stroke
Systemic mastocytosis
Testis, neoplasm
Thrombosis
Thyroid gland, neoplasm
Tuberous sclerosis
Vascular restenosis

(treatment of; preparation of pyrrolopyridine derivs. as protein
kinase inhibitors useful in treatment of diseases)

IT Necrosis

(tubular, treatment of; preparation of pyrrolopyridine derivs. as

protein kinase inhibitors useful in treatment of diseases)

IT Angiogenesis
(tumor, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type 1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type 2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type 3; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type 4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammatory bowel disease
(ulcerative colitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Colitis
(ulcerative, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Infection
(viral, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Platelet-derived growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Platelet-derived growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 142805-58-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 50-99-7, D-Glucose, biological studies
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(blood; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918504-27-5P 918506-28-2P 918507-15-0P 918507-82-1P 918507-83-2P
918507-84-3P 918507-88-7P 918508-05-1P 918508-21-1P 918508-33-5P
918509-12-3P 918509-57-6P 918509-58-7P 918509-59-8P 918510-89-1P
918511-00-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918504-32-2P 918504-33-3P 918504-39-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase

	inhibitors useful in treatment of diseases)				
IT	918504-31-1P	918504-34-4P	918504-35-5P	918504-40-2P	918504-41-3P
	918504-42-4P	918504-43-5P	918504-61-7P	918504-62-8P	918504-63-9P
	918504-64-0P	918504-65-1P	918504-66-2P	918504-67-3P	918504-68-4P
	918504-69-5P	918504-70-8P	918504-71-9P	918504-72-0P	918504-75-3P
	918504-76-4P	918504-77-5P	918504-78-6P	918504-79-7P	918504-80-0P
	918504-81-1P	918504-82-2P	918504-83-3P	918504-84-4P	918504-85-5P
	918504-86-6P	918504-87-7P	918504-88-8P	918504-89-9P	918504-90-2P
	918504-91-3P	918504-92-4P	918504-93-5P	918504-94-6P	918504-95-7P
	918504-96-8P	918504-97-9P	918505-58-5P	918505-61-0P	918505-62-1P
	918505-63-2P	918505-69-8P	918505-70-1P	918505-71-2P	918505-73-4P
	918505-74-5P	918505-75-6P	918505-76-7P	918505-77-8P	918505-78-9P
	918505-79-0P	918505-80-3P	918505-81-4P	918505-82-5P	918505-83-6P
	918505-84-7P	918505-85-8P	918505-86-9P	918505-87-0P	918505-88-1P
	918505-90-5P	918505-91-6P	918505-92-7P	918505-93-8P	918505-94-9P
	918505-95-0P	918505-96-1P	918505-97-2P	918505-98-3P	918505-99-4P
	918506-00-0P	918506-01-1P	918506-02-2P	918506-03-3P	918506-04-4P
	918506-05-5P	918506-06-6P	918506-07-7P	918506-08-8P	918506-09-9P
	918506-10-2P	918506-11-3P	918506-12-4P	918506-13-5P	918506-14-6P
	918506-15-7P	918506-16-8P	918506-17-9P	918506-18-0P	918506-19-1P
	918506-20-4P	918506-21-5P	918506-26-0P	918506-27-1P	918506-29-3P
	918506-35-1P	918506-36-2P	918506-37-3P	918506-38-4P	918506-39-5P
	918506-40-8P	918506-42-0P	918506-43-1P	918506-44-2P	918506-45-3P
	918506-49-7P	918506-50-0P	918506-51-1P	918506-52-2P	918506-53-3P
	918506-54-4P	918506-55-5P	918506-56-6P	918506-57-7P	918506-58-8P
	918506-59-9P	918506-60-2P	918506-61-3P	918506-62-4P	918506-63-5P
	918506-64-6P	918506-65-7P	918506-66-8P	918506-67-9P	918506-68-0P
	918506-70-4P	918506-71-5P	918506-72-6P	918506-73-7P	918506-74-8P
	918506-75-9P	918506-76-0P	918506-77-1P	918506-78-2P	918506-79-3P
	918506-80-6P	918506-81-7P	918506-82-8P	918506-83-9P	918506-84-0P
	918506-85-1P	918506-86-2P	918506-87-3P	918506-88-4P	918506-89-5P
	918506-90-8P	918506-92-0P	918506-93-1P	918506-94-2P	918506-95-3P
	918506-96-4P	918506-97-5P	918506-98-6P	918506-99-7P	918507-00-3P
	918507-01-4P	918507-02-5P	918507-03-6P	918507-04-7P	918507-05-8P
	918507-06-9P	918507-07-0P	918507-08-1P	918507-09-2P	918507-10-5P
	918507-11-6P	918507-12-7P	918507-13-8P	918507-14-9P	918507-16-1P
	918507-17-2P	918507-20-7P	918507-21-8P	918507-22-9P	918507-23-0P
	918507-24-1P	918507-28-5P	918507-29-6P	918507-30-9P	918507-31-0P
	918507-32-1P	918507-33-2P	918507-34-3P	918507-38-7P	918507-40-1P
	918507-47-8P	918507-49-0P	918507-51-4P	918507-57-0P	918507-58-1P
	918507-59-2P	918507-60-5P	918507-61-6P	918507-62-7P	918507-63-8P
	918507-64-9P	918507-65-0P	918507-66-1P	918507-67-2P	918507-68-3P
	918507-78-5P	918507-79-6P	918507-85-4P	918507-86-5P	918507-87-6P
	918507-89-8P	918507-90-1P	918507-91-2P	918507-92-3P	918507-93-4P
	918507-94-5P	918507-95-6P	918507-96-7P	918507-97-8P	918507-98-9P
	918507-99-0P	918508-00-6P	918508-01-7P	918508-02-8P	918508-03-9P
	918508-04-0P	918508-06-2P	918508-07-3P	918508-08-4P	918508-09-5P
	918508-10-8P	918508-11-9P	918508-12-0P	918508-13-1P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

	(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)				
IT	918508-14-2P	918508-15-3P	918508-16-4P	918508-17-5P	918508-18-6P
	918508-19-7P	918508-20-0P	918508-22-2P	918508-23-3P	918508-25-5P
	918508-26-6P	918508-27-7P	918508-28-8P	918508-29-9P	918508-30-2P
	918508-31-3P	918508-32-4P	918508-34-6P	918508-35-7P	918508-36-8P
	918508-37-9P	918508-38-0P	918508-39-1P	918508-40-4P	918508-41-5P
	918508-42-6P	918508-43-7P	918508-44-8P	918508-45-9P	918508-46-0P
	918508-47-1P	918508-48-2P	918508-49-3P	918508-50-6P	918508-51-7P
	918508-52-8P	918508-53-9P	918508-54-0P	918508-55-1P	918508-56-2P

918508-57-3P	918508-58-4P	918508-59-5P	918508-60-8P	918508-61-9P
918508-62-0P	918508-63-1P	918508-64-2P	918508-65-3P	918508-66-4P
918508-67-5P	918508-68-6P	918508-69-7P	918508-70-0P	918508-71-1P
918508-72-2P	918508-73-3P	918508-74-4P	918508-75-5P	918508-76-6P
918508-77-7P	918508-78-8P	918508-79-9P	918508-80-2P	918508-81-3P
918508-82-4P	918508-83-5P	918508-84-6P	918508-85-7P	918508-86-8P
918508-87-9P	918508-88-0P	918508-89-1P	918508-90-4P	918508-91-5P
918508-92-6P	918508-93-7P	918508-94-8P	918508-95-9P	918508-96-0P
918508-97-1P	918508-98-2P	918508-99-3P	918509-00-9P	918509-01-0P
918509-02-1P	918509-03-2P	918509-04-3P	918509-05-4P	918509-06-5P
918509-07-6P	918509-08-7P	918509-09-8P	918509-10-1P	918509-11-2P
918509-13-4P	918509-14-5P	918509-15-6P	918509-16-7P	918509-17-8P
918509-18-9P	918509-19-0P	918509-20-3P	918509-21-4P	918509-22-5P
918509-23-6P	918509-24-7P	918509-25-8P	918509-26-9P	918509-27-0P
918509-28-1P	918509-29-2P	918509-30-5P	918509-31-6P	918509-32-7P
918509-33-8P	918509-34-9P	918509-35-0P	918509-36-1P	918509-37-2P
918509-38-3P	918509-39-4P	918509-41-8P	918509-42-9P	918509-43-0P
918509-44-1P	918509-45-2P	918509-46-3P	918509-47-4P	918509-48-5P
918509-49-6P	918509-50-9P	918509-51-0P	918509-52-1P	918509-53-2P
918509-54-3P	918509-55-4P	918509-56-5P	918509-60-1P	918509-61-2P
918509-62-3P	918509-63-4P	918509-64-5P	918509-65-6P	918509-66-7P
918509-67-8P	918509-68-9P	918509-69-0P	918509-70-3P	918509-71-4P
918509-72-5P	918509-73-6P	918509-74-7P	918509-75-8P	918509-76-9P
918509-77-0P	918509-78-1P	918509-79-2P	918509-80-5P	918509-81-6P
918509-82-7P	918509-83-8P	918509-84-9P	918509-85-0P	918509-86-1P
918509-87-2P	918509-88-3P	918509-89-4P	918509-90-7P	918509-91-8P
918509-92-9P	918509-93-0P	918509-94-1P	918509-95-2P	918509-96-3P
918509-97-4P	918509-98-5P	918509-99-6P	918510-00-6P	918510-01-7P
918510-02-8P	918510-03-9P	918510-04-0P	918510-05-1P	918510-06-2P
918510-07-3P	918510-08-4P	918510-09-5P	918510-10-8P	918510-11-9P
918510-90-4P	918510-91-5P	918510-92-6P	918511-01-0P	918511-33-8P
918511-34-9P	918511-35-0P	918511-36-1P	918511-89-4P	918511-94-1P
918512-65-9P	918513-93-6P	918515-13-6P	918516-21-9P	918516-54-8P
918517-29-0P	918517-39-2P	918517-41-6P	918518-09-9P	918519-06-9P
918520-58-8P	918520-62-4P	918520-75-9P	918520-76-0P	918520-85-1P
918521-03-6P	918521-04-7P	918521-05-8P	918521-06-9P	918521-09-2P
918521-38-7P	918521-56-9P	918521-57-0P	918521-58-1P	918521-59-2P
918521-68-3P	918521-73-0P	918521-74-1P	918521-87-6P	918521-92-3P
918521-93-4P	918521-94-5P	918521-95-6P	918521-99-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918522-00-6P 918522-24-4P 918522-27-7P 918522-83-5P 918522-97-1P
918803-06-2P 918803-08-4P 918803-09-5P 918803-10-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 7440-70-2, Calcium, biological studies

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(hypercalcemia; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918517-04-1P 918520-82-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate, drug candidate; preparation of pyrrolopyridine derivs. as

protein kinase inhibitors useful in treatment of diseases)

IT 824-52-2P 4649-09-6P 39255-23-7P 79418-72-7P 112434-18-1P
152434-86-1P 152434-87-2P 183208-36-8P 208986-50-9P 269072-20-0P
443124-79-6P 486424-36-6P, 4-Bromo-2,5-difluorophenol 611204-98-9P
611205-38-0P 849067-96-5P 849068-05-9P 849409-81-0P 849409-82-1P
858116-66-2P 858116-85-5P 858116-86-6P 858117-08-5P 866319-00-8P
866546-07-8P 901238-24-2P 913983-25-2P 918507-52-5P 918511-92-9P
918516-27-5P 918519-14-9P 918519-37-6P 918522-25-5P 918523-44-1P
918523-45-2P 918523-46-3P 918523-47-4P 918523-48-5P 918523-49-6P
918523-51-0P 918523-52-1P 918523-53-2P 918523-54-3P 918523-56-5P
918523-57-6P 918523-58-7P 918523-59-8P 918523-60-1P 918523-61-2P
918523-62-3P 918523-63-4P 918523-64-5P 918523-65-6P 918523-66-7P
918523-67-8P 918523-68-9P 918523-70-3P 918523-71-4P 918523-72-5P
918523-73-6P 918523-76-9P 918523-77-0P 918523-78-1P 918523-79-2P
918523-80-5P 918523-81-6P 918523-82-7P 918523-83-8P 918523-84-9P
918523-85-0P 918523-86-1P 918523-87-2P 918523-88-3P 918523-89-4P
918523-90-7P 918523-91-8P 918523-92-9P 918523-93-0P 918523-94-1P
918523-95-2P 918523-96-3P 918523-98-5P 918523-99-6P 918524-01-3P
918524-02-4P 918524-03-5P 918524-04-6P 918524-05-7P 918524-06-8P
918524-07-9P 918524-08-0P 918524-09-1P 918524-11-5P 918524-12-6P
918524-13-7P 918524-14-8P 918524-15-9P 918524-16-0P 918524-17-1P
918524-18-2P 918524-19-3P 918524-20-6P 918524-21-7P 918524-22-8P
918524-23-9P 918524-24-0P 918524-25-1P 918524-26-2P 918524-27-3P
918524-28-4P 918524-31-9P 918524-32-0P 918524-33-1P 918524-37-5P
918524-44-4P 918524-45-5P 918524-46-6P 918524-50-2P 918524-52-4P
918524-53-5P 918524-54-6P 918524-55-7P 918524-56-8P 918524-57-9P
918524-58-0P 918524-59-1P 918524-60-4P 918524-61-5P 918524-62-6P
918803-34-6P 918803-35-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 7782-44-7, Oxygen, biological studies

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 79079-06-4, EGFR kinase 98037-52-6, Abl protein kinase 103843-29-4, IGF1R kinase 108891-60-7 111694-09-8 114051-78-4, LCK kinase 136396-12-8 137632-03-2, Met kinase 137632-06-5, Csk kinase 137632-08-7, Erk2 kinase 138359-29-2, c-KIT kinase 138674-26-7, Protein kinase Syk 139691-76-2, c-Raf-1 141349-86-2, Cdk2 kinase 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes protein kinase 141350-03-0, Flt1 kinase 141436-78-4, Protein kinase C β 144114-16-9, Fak kinase 144376-45-4, Pim1 kinase 144638-77-7, Flt4 kinase 144697-16-5, B-Raf kinase 145539-86-2, HCK kinase 146279-92-7, Ret kinase 146838-30-4, MAPKAPK2 147014-96-8, CDK5 kinase 147014-97-9, CDK4 kinase 147230-71-5, Flt3 kinase 148047-29-4, Tie 2 kinase 148047-34-1, Protein kinase Zap70 148640-14-6, Akt 1 kinase 149147-12-6, Btk kinase 150027-21-7 150316-14-6, Mitogen-activated protein kinase kinase 2 150977-45-0, Kdr kinase 151662-26-9, Itk kinase 152478-56-3, Jak1 kinase 152478-57-4, Jak2 kinase 152743-99-2, Her4 kinase 152787-58-1, Protein kinase TrkA 154907-65-0, CHK1 kinase 157482-36-5, Jak3 kinase 165245-96-5, p38 Kinase 165245-99-8, Polo like kinase 1 166433-56-3, Anaplastic lymphoma kinase 170780-46-8, Pyk2 kinase 176023-60-2, Akt2 kinase 182238-33-1, Gene Ron protein kinase 182938-07-4, Protein kinase ROCK1 182938-08-5, Protein kinase ROCK2 191359-13-4, Mnk1 kinase 191808-15-8, 3-Phosphoinositide dependent protein kinase-1 205265-41-4, Akt3 kinase 250649-03-7, Protein kinase MLK1 270086-00-5, Pim3 kinase 289898-51-7, Jnk1 kinase 289899-93-0, Jnk2 kinase 291756-39-3, Jnk3

kinase 303014-92-8, CDK6 kinase 362517-43-9, IKK- β kinase
370088-29-2, Mitogen-activated protein kinase kinase kinase 4
372092-80-3 420790-04-1, Pim2 kinase 428817-87-2, Irak4 kinase
443900-95-6, Glycogen synthase kinase 3 β 458560-40-2, Protein
kinase Stk6 553648-93-4, Glycogen synthase kinase 3 α

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful
in treatment of diseases)

IT 348-62-9, 4-Chloro-2-fluorophenol 13358-73-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful
in treatment of diseases)

IT 9004-10-8, Insulin, biological studies

RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
unclassified); BIOL (Biological study)

(resistance; preparation of pyrrolopyridine derivs. as protein kinase
inhibitors useful in treatment of diseases)

IT 918505-72-3P 918511-37-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)

(starting material, drug candidate; preparation of pyrrolopyridine derivs.
as protein kinase inhibitors useful in treatment of diseases)

IT 56741-33-4P 70205-04-8P 79418-77-2P 918523-55-4P 918523-69-0P
918523-74-7P 918523-75-8P 918523-97-4P 918524-00-2P 918524-30-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(starting material, intermediate; preparation of pyrrolopyridine derivs. as
protein kinase inhibitors useful in treatment of diseases)

IT 62-53-3, Aniline, reactions 94-99-5, 2,4-Dichlorobenzyl chloride
96-33-3, Methyl acrylate 98-09-9, Benzenesulfonyl chloride 98-31-7,
3,4-Dichlorobenzenesulfonyl chloride 98-59-9,
4-Methylbenzenesulfonyl chloride 98-60-2, 4-Chlorobenzenesulfonyl
chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-80-6,
Phenylboronic acid 99-61-6, 3-Nitrobenzaldehyde 100-37-8,
2-(Diethylamino)ethanol 100-39-0, Benzyl bromide 100-46-9,
Benzylamine, reactions 100-55-0, 3-Pyridinemethanol 103-71-9, Phenyl
isocyanate, reactions 104-12-1, 4-Chlorophenyl isocyanate 106-41-2,
4-Bromophenol 107-10-8, 1-Propanamine, reactions 109-01-3 109-73-9,
1-Butanamine, reactions 109-85-3, 2-Methoxyethylamine 109-86-4,
2-Methoxyethanol 110-68-9, N-Methylbutanamine 110-91-8, Morpholine,
reactions 111-36-4, Butyl isocyanate 120-83-2, 2,4-Dichlorophenol
121-32-4, 3-Ethoxy-4-hydroxybenzaldehyde 121-33-5, 4-Hydroxy-3-
methoxybenzaldehyde 121-60-8, 4-(Acetylamino)phenylsulfonyl chloride
123-08-0, 4-Hydroxybenzaldehyde 133-59-5, 2-Methylbenzenesulfonyl
chloride 140-75-0, 4-Fluorobenzylamine 271-63-6, 7-Azaindole
327-78-6, 4-Chloro-3-trifluoromethylphenyl isocyanate 329-01-1,
3-Trifluoromethylphenyl isocyanate 349-88-2, 4-Fluorobenzenesulfonyl
chloride 367-25-9, 2,4-Difluoroaniline 367-27-1, 2,4-Difluorophenol
371-40-4, 4-Fluoroaniline 402-49-3, 1-Bromomethyl-4-
(trifluoromethyl)benzene 404-71-7, 3-Fluorophenyl isocyanate 405-05-0,
3-Fluoro-4-hydroxybenzaldehyde 444-30-4, 2-(Trifluoromethyl)phenol
445-05-6, 5-Fluoro-2-methylbenzenesulfonyl chloride 445-26-1,
1-(2-Fluorophenyl)ethanol 446-51-5, 2-Fluorobenzyl alcohol 501-30-4
501-53-1, Benzyl chloroformate 541-41-3, Ethyl chloroformate 582-33-2,
Ethyl 3-aminobenzoate 586-95-8, 4-Pyridinemethanol 586-98-1,
2-Pyridinemethanol 603-80-5, 3-Hydroxy-2-methylbenzoic acid 614-68-6,
2-Methylphenyl isocyanate 621-29-4, 3-Methylphenyl isocyanate
622-40-2, N-(2-Hydroxyethyl)morpholine 622-58-2, 4-Methylphenyl
isocyanate 622-95-7 623-24-5, 1,4-Bis(bromomethyl)benzene 626-58-4,
4-Methylpiperidine 701-27-9, 3-Fluorobenzenesulfonyl chloride

701-34-8, 4-Bromobenzenesulfonamide 766-00-7, 2-Cyclopentylethanol
 766-80-3, 3-Chlorobenzyl bromide 767-05-5, 3-Cyclopentylpropanol
 768-35-4, 3-Fluorophenylboronic acid 777-44-6, 3-Trifluoromethylphenylsulfonyl chloride 824-94-2, 4-Methoxybenzyl chloride 1003-03-8, Aminocyclopentane 1074-86-8, Indole-4-carboxaldehyde 1122-71-0, 6-Methylpyridine-2-methanol 1138-56-3, 4-Butoxybenzenesulfonyl chloride 1195-45-5, 4-Fluorophenylisocyanate 1483-28-9, 2,5-Dimethoxybenzenesulfonyl chloride 1548-13-6, 4-Trifluoromethylphenyl isocyanate 1679-18-1, 4-Chlorophenylboronic acid 1692-15-5, Pyridine-4-boronic acid 1692-25-7, Pyridine-3-boronic acid 1765-93-1, 4-Fluorophenylboronic acid 1777-82-8, 2,4-Dichlorobenzyl alcohol 1899-93-0, 3-Methylbenzenesulfonyl chloride 1996-41-4, 2-Chloro-4-fluorophenol 2038-03-1, N-(2-Aminoethyl)morpholine 2124-55-2, Indole-4-carboxylic acid 2386-60-9, Butanesulfonyl chloride 2420-16-8, 3-Chloro-4-hydroxybenzaldehyde 2426-87-1, 4-Benzyloxy-3-methoxybenzaldehyde 2516-47-4, Cyclopropylmethylamine 2713-31-7, 2,5-Difluorophenol 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2909-38-8, 3-Chlorophenyl isocyanate 2991-42-6, 4-Trifluoromethylbenzenesulfonyl chloride 3173-56-6, Benzyl isocyanate 3391-10-4, 1-(4-Chlorophenyl)ethanol 3445-11-2, N-(2-Hydroxyethyl)pyrrolidin-2-one 3954-13-0, Pentyl isocyanate 4441-30-9, N-(3-Hydroxypropyl)morpholine 4595-59-9, 5-Bromopyrimidine 4747-71-1, Isocyanatocyclopentane 4857-04-9, 2-Chloromethyl-1H-benzimidazole 5180-79-0, 3-Isocyanatobenzoyl chloride 5345-54-0, 3-Chloro-4-methoxyaniline 5416-93-3, 4-Methoxyphenyl isocyanate 5720-07-0, 4-Methoxyphenylboronic acid 6482-24-2, 1-Bromo-2-methoxyethane 7304-32-7, 2-Fluoro-5-nitrobenzoic acid 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1, 1-Propanesulfonyl chloride 10147-37-2, 2-Propanesulfonyl chloride 10365-98-7, 3-Methoxyphenylboronic acid 13360-63-9, N-Ethylbutanamine 13918-92-8, 2,4-Difluorobenzenesulfonyl chloride 13952-84-6, 2-Butanamine 15268-31-2, Pyridin-3-yl isocyanate 15854-87-2, 4-Iodopyridine 16315-59-6, 4-Dimethylaminophenyl isocyanate 16629-19-9, 2-Thiophenesulfonyl chloride 16712-69-9, 4-Ethylbenzenesulfonyl chloride 17334-08-6, 1-Methylimidazole-2-methanol 17739-45-6, 2-(2-Bromoethoxy)tetrahydropyran 18278-34-7, 4-Hydroxy-2-methoxybenzaldehyde 18908-07-1, 3-Methoxyphenyl isocyanate 19463-48-0, 3-Chloro-4-hydroxy-5-methoxybenzaldehyde 20443-98-5, 2,6-Dichlorobenzyl bromide 20984-81-0, 3-(Diethylamino)pyrrolidine 23095-31-0, 3,4-Dimethoxybenzenesulfonyl chloride 23616-57-1, 3-Iodo-7-azaindole 24677-78-9, 2,3-Dihydroxybenzaldehyde 27086-19-7, Dipropyl carbamoyl chloride 28439-86-3, 4-Butoxyphenyl isocyanate 28611-39-4, 4-Dimethylaminophenylboronic acid 35856-62-3, 1-Piperidinesulfonyl chloride 37527-66-5, 3,4-Dimethoxyphenyl isocyanate 38070-73-4, 39893-50-0, 3-Chloro-4-trifluoromethylphenyl isocyanate 42170-95-6, 2-Methoxyethyl isocyanate 42601-04-7, 3,4-Difluorophenyl isocyanate 49584-26-1, 4-Cyanophenylsulfonyl chloride 50382-32-6, 2,4-Dimethylthiazole-5-methanol 50528-86-4, 2-Chloro-5-trifluoromethylphenyl isocyanate 50824-04-9, 4-Bromo-2-(trifluoromethyl)phenol 51175-71-4, 3-Thiophenesulfonyl chloride 51488-22-3, 2-Chloro-4-trifluoromethylphenyl isocyanate 52130-17-3, 3-Amino-2-methylbenzoic acid 53104-95-3, 4-Hydroxy-3-(trifluoromethoxy)benzaldehyde 54751-01-8, 4-Bromomethylpyridine 54997-90-9, 4-Isopropylbenzenesulfonyl chloride 55052-28-3, 4-Chloro-7-azaindole 56456-47-4, 2,4-Difluorobenzyl alcohol 56456-49-6, 4-Chloro-2-fluorobenzyl alcohol 56542-67-7, 3-Cyanobenzenesulfonyl chloride 56962-11-9, 2-Chloro-4-hydroxybenzaldehyde 57012-20-1 57946-56-2, 4-Chloro-2-fluoroaniline 61672-75-1 63503-60-6, 3-Chlorophenylboronic acid 63624-28-2, 2,4-Dimethoxybenzenesulfonyl chloride 63758-12-3 69360-26-5, 2-Cyanobenzenesulfonyl chloride 69816-05-3 70067-45-7 71189-18-9

71916-82-0, 4-Chloro-2-fluorobenzyl bromide 71924-62-4 72975-46-3
 79418-78-3, 3-Fluoro-4-hydroxy-5-methoxybenzaldehyde 80466-80-4
 86718-08-3 89599-01-9, 3-Bromobenzenesulfonamide 90001-64-2,
 Benzothiophene-2-sulfonyl chloride 90260-13-2, 3-Fluoro-4-
 methylbenzenesulfonyl chloride 97272-04-3, 2,5-Dimethylthiophene-3-
 sulfonyl chloride 108679-71-6, 3-Amino-2-chlorobenzoic acid
 123088-59-5, 4-Aminocarbonylphenylboronic acid 128796-39-4,
 4-Trifluoromethylphenylboronic acid 137049-02-6 151411-98-2,
 2,4,6-Trifluorobenzyl bromide 151858-64-9 152434-88-3 153912-60-8,
 1,5-Dimethylpyrazole-3-methanol 163105-89-3, 2-Methoxypyridine-5-boronic
 acid 166964-26-7, 2,5-Dimethylfuran-3-sulfonyl chloride 168899-43-2
 179113-90-7, 3-Trifluoromethoxyphenylboronic acid 180200-86-6
 181124-40-3, 6-Benzothiazolesulfonyl chloride 183208-35-7,
 5-Bromo-7-azaindole 190774-52-8, 2-Fluoro-3-trifluoromethylphenyl
 isocyanate 197239-49-9, 2-Fluoro-4-trifluoromethylbenzyl alcohol
 208186-84-9, 2-Chloro-4-fluorobenzyl alcohol 210532-25-5,
 3,5-Difluorobenzenesulfonyl chloride 306936-35-6 321309-40-4
 337508-66-4 351003-34-4, 4-Difluoromethoxybenzenesulfonyl chloride
 351422-73-6, 3-Aminocarbonylphenylboronic acid 364794-80-9
 373384-18-0, 3-(Methylsulfonyl)phenylboronic acid 380430-52-4
 386704-04-7 388088-73-1 389621-84-5 405520-68-5 423151-49-9
 445264-61-9 485799-04-0 551930-53-1 628692-15-9 690632-68-9
 754214-56-7 757978-25-9 761446-44-0 785785-59-3 852180-61-1
 852227-95-3 858116-95-7 909501-40-2 911210-53-2,
 4-Cyano-3,5-dimethylphenylboronic acid 918519-69-4 918523-07-6
 918524-34-2 918524-63-7 918524-64-8 918524-65-9 918524-70-6
 918524-71-7 918524-72-8 918524-73-9 918524-74-0 918524-75-1
 918524-76-2 918524-77-3 918524-78-4 918524-83-1 918524-85-3
 918524-86-4 918524-87-5 918524-88-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918524-89-7 918524-90-0 918524-91-1 918524-92-2 918524-93-3,
 4-Benzyloxy-2,6-difluorobenzaldehyde 918524-94-4 918524-95-5
 918524-96-6 918524-97-7 918524-99-9 918525-00-5 918525-01-6
 918525-03-8 918525-04-9 918803-36-8 918803-37-9 918803-38-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT 918919-61-6 918919-62-7 918919-63-8 918919-64-9 918919-65-0
 918919-66-1 918919-67-2 918919-68-3 918919-69-4 918919-70-7
 918919-71-8 918919-72-9 918919-73-0 918919-74-1 918919-75-2
 918919-76-3 918919-77-4 918919-78-5 918919-79-6 918919-80-9
 918919-81-0 918919-82-1 918919-83-2 918919-84-3 918919-85-4
 918919-86-5 918919-87-6 918919-88-7 918919-89-8 918919-90-1
 918919-91-2 918919-92-3 918919-93-4 918919-94-5 918919-95-6
 918919-96-7 918919-97-8 918919-98-9 918919-99-0 918920-00-0
 918920-01-1 918920-02-2 918920-03-3 918920-04-4 918920-05-5
 918920-06-6 918920-07-7 918920-08-8 918920-09-9 918920-10-2
 918920-11-3 918920-12-4 918920-13-5 918920-14-6 918920-15-7
 918920-16-8 918920-17-9 918920-18-0 918920-19-1 918920-20-4
 918920-21-5 918920-22-6 918920-23-7 918920-24-8 918920-25-9
 918920-26-0 918920-27-1 918920-28-2 918920-29-3 918920-30-6
 918920-31-7 918920-32-8 918920-33-9

RL: PRP (Properties)

(unclaimed sequence; pyrrolo[2,3-b]pyridine derivs. as protein kinase inhibitors and their preparation, pharmaceutical compns. and use in the treatment of diseases)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aadal, N; WO 2004016610 A 2004 CAPLUS

(2) Barton; TETRAHEDRON 1987, V43(2), P323 CAPLUS
 (3) Bayer Ag; DE 2413258 A1 1975 CAPLUS
 (4) Curtin; J MED CHEM 1998, V41, P74 CAPLUS
 (5) Heacock; J AM CHEM SOC 1960, V82, P3460 CAPLUS
 (6) Langham; J AM CHEM SOC 1941, V63, P545 CAPLUS
 (7) Normington, J; US 2234705 A 1941 CAPLUS
 (8) Pierce; J AM CHEM SOC 1942, V64, P1691

L32 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
 derivs. as PI3 kinase inhibitors with therapeutic uses)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

ACCESSION NUMBER: 2006:1252615 CAPLUS

DOCUMENT NUMBER: 146:7952

TITLE: Preparation of 4,5'-bithiazole and
 4-(oxazol-5-yl)thiazole derivatives as
 phosphoinositide-3 kinase inhibitors with therapeutic
 uses

INVENTOR(S): Quattropiani, Anna; Dorbais, Jerome; Covini, David;
 Desforges, Gwenaelle; Rueckle, Thomas

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N. V., Neth.
 Antilles

SOURCE: PCT Int. Appl., 149pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125805	A1	20061130	WO 2006-EP62595	20060524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006251159	A1	20061130	AU 2006-251159	20060524
CA 2607385	A1	20061130	CA 2006-2607385	20060524
EP 1888546	A1	20080220	EP 2006-777240	20060524
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
MX 200714883	A	20080215	MX 2007-14883	20071126
NO 2007006557	A	20071219	NO 2007-6557	20071219
KR 2008015119	A	20080218	KR 2007-729932	20071221
PRIORITY APPLN. INFO.:			EP 2005-104394	A 20050524
			US 2005-686270P	P 20050601
			WO 2006-EP62595	W 20060524

OTHER SOURCE(S): MARPAT 146:7952
 AN 2006:1252615 CAPLUS
 DN 146:7952
 ED Entered STN: 01 Dec 2006
 TI Preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivatives as phosphoinositide-3 kinase inhibitors with therapeutic uses
 IN Quattropiani, Anna; Dorbais, Jerome; Covini, David; Desforges, Gwenaelle; Rueckle, Thomas
 PA Applied Research Systems Ars Holding N. V., Neth. Antilles
 SO PCT Int. Appl., 149pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006125805	A1	20061130	WO 2006-EP62595	20060524
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006251159	A1	20061130	AU 2006-251159	20060524
	CA 2607385	A1	20061130	CA 2006-2607385	20060524
	EP 1888546	A1	20080220	EP 2006-777240	20060524
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	MX 200714883	A	20080215	MX 2007-14883	20071126
	NO 2007006557	A	20071219	NO 2007-6557	20071219
	KR 2008015119	A	20080218	KR 2007-729932	20071221
PRAI	EP 2005-104394	A	20050524		
	US 2005-686270P	P	20050601		
	WO 2006-EP62595	W	20060524		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2006125805	IPCI	C07D0277-46 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; C07D0491-10 [I,A]; C07D0491-00 [I,C*]; C07D0493-08 [I,A]; C07D0493-00 [I,C*]; A61K0031-427 [I,A]; A61K0031-433 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-496 [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-553 [I,A]; A61P0009-00 [I,A]; A61P0025-00 [I,A]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-433 [I,A]; A61K0031-433 [I,C]; A61K0031-454 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C];

		A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C]; C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
	ECLA	C07D277/46; C07D277/48; C07D417/14; C07D491/10+317B+221B; C07D498/04+317C+265C
AU 2006251159	IPCI	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C]; A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C]; A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C]; C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C]; A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C]; A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C]; C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
	ECLA	C07D277/46; C07D277/48; C07D417/14; C07D491/10+317B+221B; C07D498/04+317C+265C
CA 2607385	IPCI	A61K0031-427 [I,A]; A61K0031-433 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-496 [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-553 [I,A]; A61P0009-00 [I,A]; A61P0025-00 [I,A]; C07D0277-46 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; C07D0491-10 [I,A]; C07D0491-00 [I,C*]; C07D0493-08 [I,A]; C07D0493-00 [I,C*]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C]; A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C]; A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C]; C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
EP 1888546	IPCI	C07D0277-46 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; C07D0491-10 [I,A]; C07D0491-00 [I,C*]; C07D0493-08 [I,A]; C07D0493-00 [I,C*]; A61K0031-427 [I,A]; A61K0031-433 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-496 [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-553 [I,A]; A61P0009-00 [I,A]; A61P0025-00 [I,A]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427

[I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C];
 A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454
 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A];
 A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375
 [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C];
 A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00
 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];
 C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00
 [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C];
 C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
 MX 200714883 IPCI C07D0277-46 [I,A]; A61K0031-427 [I,A]; A61K0031-433
 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C*];
 A61K0031-496 [I,A]; A61K0031-497 [I,A]; A61K0031-4965
 [I,C*]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*];
 A61K0031-553 [I,A]; A61P0025-00 [I,A]; A61P0009-00
 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A];
 C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00
 [I,C*]; C07D0491-10 [I,A]; C07D0491-00 [I,C*];
 C07D0493-08 [I,A]; C07D0493-00 [I,C*]
 NO 2007006557 IPCI C07D0277-00 [I,C]; C07D0277-46 [I,A]
 IPCR C07D0277-00 [I,C]; C07D0277-46 [I,A]
 ECLA C07D277/46; C07D277/48; C07D417/14;
 C07D491/10+317B+221B; C07D498/04+317C+265C
 KR 2008015119 IPCI C07D0417-04 [I,A]; C07D0417-14 [I,A]; C07D0417-00
 [I,C*]; C07D0491-10 [I,A]; C07D0491-00 [I,C*]
 OS MARPAT 146:7952
 GI



AB The present invention is related to thiazole derivs. (shown as I;
 variables defined below; e.g. Et 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-
 thiazole-2-carboxylate) as well as geometrical isomers, optically active
 forms as enantiomers, diastereomers and its racemate forms, as well as
 pharmaceutically acceptable salts thereof, in particular for the
 treatment and/or prophylaxis of autoimmune disorders and/or
 inflammatory diseases, cardiovascular diseases, neurodegenerative
 diseases, bacterial or viral infections, kidney diseases, platelet
 aggregation, cancer, transplantation, graft rejection or lung injuries (no
 data). Although the methods of preparation are not claimed, preps. and/or
 characterization data for .apprx.80 examples of I are included. For
 example, Et 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate
 was prepared in 46 % yield by cyclizing N-[5-(bromoacetyl)-4-methyl-1,3-
 thiazol-2-yl]acetamide (preparation given) with Et thiooxamate in dioxane. For
 I: R1 = -C(O)R5, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl
 C1-C6-alkyl, heteroaryl C1-C6-alkyl, C3-C8 cycloalkyl C1-C6-alkyl and
 heterocycloalkyl C1-C6-alkyl; R2 = H, halogen, C1-C6-alkyl, C2-C6-alkenyl
 and C2-C6-alkynyl; R3 = H, halogen, C1-C6-alkyl, C2-C6-alkenyl and
 C2-C6-alkynyl; R4 = -C(O)R6, aryl, heteroaryl, heterocycloalkyl and C3-C8
 cycloalkyl; R5 = H, hydroxy, alkoxy, amino, aryl, heteroaryl, C3-C8
 cycloalkyl and heterocycloalkyl; R6 = H, C1-C6-alkyl, C2-C6-alkenyl,

C2-C6-alkynyl, aryl C1-C6-alkyl, heteroaryl C1-C6-alkyl and amino; X = S and O. IC50 values for inhibition of PI3K γ -induced lipid and/or PI3K-induced Akt/PKB phosphorylation are tabulated for 12 examples of I.

ST thiazole deriv prepn PI3 kinase inhibitor therapeutic use; bithiazole oxazolylthiazole prepn PI3 kinase inhibitor therapeutic use

IT Nervous system, disease
(Huntington's chorea; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Sarcoma
(Kaposi's; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PI3 kinase γ , inhibitors; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Fibrosis
(anaphylactic shock; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Muscle, disease
(atrophy; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Infection
(bacterial; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Lung, disease
(chronic obstructive pulmonary disease; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Nervous system, disease
(degeneration; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Nervous system agents
(degenerative; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Erythrocyte
(disease, deficiency; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Lung, disease
(endothelial and epithelial injuries; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Blood, disease
(erythrocyte, deficiency; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Kidney, disease
(fibrosis, progressive; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Inflammation
Kidney, disease
(glomerulonephritis; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Muscle, disease

(hypertrophy; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Brain, disease
(infection; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Lung, disease
Reperfusion
(injury; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Neoplasm
(metastasis; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Hypertrophy
(muscular; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Heart, disease
(myocyte dysfunction; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Inflammation
Lung, disease
(pneumonitis; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Allergy
Allergy inhibitors
Alzheimer's disease
Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Antibacterial agents
Antifibrotic agents
Antihypertensives
Antirheumatic agents
Antitumor agents
Antiviral agents
Asthma
Atherosclerosis
Autoimmune disease
Cardiac hypertrophy
Cardiovascular agents
Cardiovascular system, disease
Encephalitis
Glomerulosclerosis
Human
Hypertension
Immunomodulators
Inflammation
Inflammatory bowel disease
Ischemia
Kidney, disease
Melanoma
Meningitis
Multiple sclerosis
Neoplasm
Platelet aggregation
Platelet aggregation inhibitors
Psoriasis
Respiratory system, disease

Respiratory system agents

Rheumatoid arthritis

Sepsis

Stroke

Thrombolytics

Thrombosis

Transplant and Transplantation

Transplant rejection

Vasoconstriction

(preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Injury

(pulmonary; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Fibrosis

(renal, progressive; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Injury

(reperfusion; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Lupus erythematosus

(systemic; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Central nervous system, disease

(trauma; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT Infection

(viral; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT 915702-31-7P, Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate 915702-33-9P, N-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-34-0P, 2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylic acid 915702-64-6P, 5-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]carbonyl]amino]-2-hydroxybenzoic acid 915702-68-0P, 2'-(Acetylamino)-4'-methyl-N-[4-(1H-tetrazol-5-yl)phenyl]-4,5'-bi-1,3-thiazole-2-carboxamide 915702-70-4P, N-[4'-Methyl-2-[(2H-tetrazol-5-yl)methyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-74-8P, 1-[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]carbonyl]piperidine-4-carboxylic acid 915702-88-4P, 2'-(Acetylamino)-N-(1H-1,2,3-benzotriazol-5-yl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-92-0P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]carbonyl]amino]-2-hydroxybenzoic acid 915702-94-2P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]carbonyl]amino]-2-fluorobenzoic acid 915702-96-4P, 2'-(Acetylamino)-N-[3-(5-hydroxy-1,3,4-oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-98-6P, 2'-(Acetylamino)-N-[4-(5-hydroxy-1,3,4-oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915703-28-5P, tert-Butyl 4-[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-4-oxobutanoate 915703-29-6P, Methyl 5-[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-5-oxopentanoate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT 915702-32-8P, 2'-(Acetylamino)-N-allyl-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-35-1P, 2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylic acid potassium salt 915702-36-2P, 2'-(Acetylamino)-N-(2-methoxyethyl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-37-3P, 2'-(Acetylamino)-4'-methyl-N-(tetrahydrofuran-

2-ylmethyl)-4,5'-bi-1,3-thiazole-2-carboxamide 915702-38-4P,
 2'-(Acetylamino)-N-[2-(dimethylamino)ethyl]-4'-methyl-4,5'-bi-1,3-thiazole-
 2-carboxamide 915702-39-5P, N-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-
 4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-40-8P, N-[4'-Methyl-2-[(4-
 methylpiperazin-1-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide
 915702-41-9P, N-[4'-Methyl-2-[(4-methylpiperazin-1-yl)carbonyl]-4,5'-bi-
 1,3-thiazol-2'-yl]acetamide mono(trifluoroacetate) 915702-42-0P,
 2'-(Acetylamino)-N-[3-(dimethylamino)propyl]-4'-methyl-4,5'-bi-1,3-
 thiazole-2-carboxamide 915702-43-1P, 2'-(Acetylamino)-N-[3-
 (dimethylamino)propyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide
 mono(trifluoroacetate) 915702-44-2P, 2'-(Acetylamino)-N-(2-hydroxyethyl)-
 4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-45-3P,
 2'-(Acetylamino)-N-(2-cyanoethyl)-4'-methyl-4,5'-bi-1,3-thiazole-2-
 carboxamide 915702-46-4P, 2'-(Acetylamino)-4'-methyl-N-(1H-tetrazol-5-
 yl)-4,5'-bi-1,3-thiazole-2-carboxamide potassium salt 915702-48-6P,
 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-
 yl]carbonyl]amino]benzoic acid potassium salt 915702-49-7P,
 3-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-
 yl]carbonyl]amino]benzoic acid potassium salt 915702-50-0P,
 2'-(Acetylamino)-4'-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-4,5'-bi-1,3-
 thiazole-2-carboxamide potassium salt 915702-51-1P, 2'-(Acetylamino)-N-
 benzyl-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-52-2P,
 2'-(Acetylamino)-4'-methyl-N-propyl-4,5'-bi-1,3-thiazole-2-carboxamide
 915702-53-3P, 2'-(Acetylamino)-4'-methyl-N-[4-(1H-tetrazol-5-yl)phenyl]-
 4,5'-bi-1,3-thiazole-2-carboxamide potassium salt 915702-56-6P,
 3-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-
 hydroxybenzoic acid potassium salt 915702-58-8P, 1-[[2'-(Acetylamino)-4'-
 methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]piperidine-3-carboxylic acid
 915702-60-2P, 5-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-
 yl]carbonyl]amino]-2-hydroxybenzoic acid potassium salt 915702-66-8P,
 N-[4'-Methyl-2-[(2H-tetrazol-5-yl)methyl]-4,5'-bi-1,3-thiazol-2'-
 yl]acetamide potassium salt 915702-72-6P, 1-[[2'-(Acetylamino)-4'-methyl-
 4,5'-bi-1,3-thiazol-2-yl]carbonyl]piperidine-4-carboxylic acid potassium
 salt 915702-76-0P, 2'-(Acetylamino)-N-[3-(5-amino-1,3,4-thiadiazol-2-
 yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-78-2P,
 N-[2-[(3-Hydroxypiperidin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
 yl]acetamide 915702-80-6P, N-[2-[[4-(Hydroxymethyl)piperidin-1-
 yl]carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-82-8P,
 N-[2-[[4-(2-Hydroxyethyl)piperidin-1-yl]carbonyl]-4'-methyl-4,5'-bi-1,3-
 thiazol-2'-yl]acetamide 915702-84-0P, N-[2-[(4-Hydroxypiperidin-1-
 yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915702-86-2P,
 2'-(Acetylamino)-N-(1H-1,2,3-benzotriazol-5-yl)-4'-methyl-4,5'-bi-1,3-
 thiazole-2-carboxamide potassium salt 915702-90-8P, 4-[[[2'-
 (Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-
 hydroxybenzoic acid potassium salt 915702-93-1P, 4-[[[2'-(Acetylamino)-
 4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-fluorobenzoic acid
 potassium salt 915702-95-3P, 2'-(Acetylamino)-N-[3-(5-hydroxy-1,3,4-
 oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide
 potassium salt 915702-97-5P, 2'-(Acetylamino)-N-[4-(5-hydroxy-1,3,4-
 oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide
 potassium salt 915702-99-7P, N-[2-(Hydroxymethyl)-4'-methyl-4,5'-bi-1,3-
 thiazol-2'-yl]acetamide 915703-00-3P, 1-(2-Methoxyethyl)-3-[4'-methyl-2-
 [(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]urea 915703-02-5P,
 Ethyl N-[[[4'-methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-
 yl]amino]carbonyl]-β-alaninate 915703-03-6P, N-[2-[(1,4-Dioxo-8-
 azaspiro[4.5]decan-8-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
 yl]acetamide 915703-04-7P, 2'-(Acetylamino)-N-(2,3-dihydroxypropyl)-4'-
 methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915703-05-8P,
 1-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]urea
 915703-06-9P, N-[4'-Methyl-2-[(3-oxopiperazin-1-yl)carbonyl]-4,5'-bi-1,3-
 thiazol-2'-yl]acetamide 915703-07-0P, N-[4'-Methyl-2-[(4-oxopiperidin-1-

yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-08-1P,
 N-[2-[(3-Hydroxypyrrolidin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
 yl]acetamide 915703-09-2P, 2'-(Acetylamino)-4'-methyl-N-(2-propyn-1-yl)-
 4,5'-bi-1,3-thiazole-2-carboxamide 915703-10-5P, N-[2-[(4-
 Acetyl)piperazin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
 yl]acetamide 915703-11-6P, N,N-Dimethyl-N'-[[[4'-methyl-2-[(morpholin-4-
 yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]glycinamide
 915703-12-7P, N-[[[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-
 thiazol-2'-yl]amino]carbonyl]-β-alanine 915703-13-8P,
 N-[2-[(4-Fluoropiperidin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
 yl]acetamide 915703-14-9P, N-[2-[[[1S,5S,7S]-7-(Hydroxymethyl)-6,8-dioxa-
 3-azabicyclo[3.2.1]oct-3-yl]carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
 yl]acetamide 915703-15-0P, Ethyl N-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-
 1,3-thiazol-2'-yl]amino]carbonyl]-β-alaninate 915703-17-2P,
 N-[2-[[[1R,5R,7R]-7-(Hydroxymethyl)-6,8-dioxa-3-azabicyclo[3.2.1]oct-3-
 yl]carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-19-4P,
 tert-Butyl N-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-
 yl]amino]carbonyl]-β-alaninate 915703-20-7P, [4'-Methyl-2'-
 [(pyrazin-2-yl)amino]-4,5'-bi-1,3-thiazol-2-yl]acetonitrile
 915703-22-9P, Ethyl 4'-methyl-2'-[(pyrazin-2-yl)amino]-4,5'-bi-1,3-
 thiazole-2-carboxylate 915703-23-0P, [4'-Methyl-2'-[(1H-pyrazol-3-
 yl)amino]-4,5'-bi-1,3-thiazol-2-yl]acetonitrile 915703-25-2P,
 N-[4'-Methyl-2-[2-(morpholin-4-yl)-2-oxoethyl]-4,5'-bi-1,3-thiazol-2'-
 yl]acetamide 915703-27-4P 915703-30-9P, Methyl 6-[[2-(cyanomethyl)-4'-
 methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-6-oxohexanoate 915703-31-0P,
 2'-(Acetylamino)-N,N,4'-trimethyl-4,5'-bi-1,3-thiazole-2-carboxamide
 915703-32-1P, 2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-
 carboxamide 915703-33-2P, 4-[[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-
 thiazol-2'-yl]amino]-4-oxobutanoic acid 915703-34-3P,
 5-[[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-5-
 oxopentanoic acid 915703-35-4P, tert-Butyl N-[[[2-(cyanomethyl)-4'-
 methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]glycinate 915703-36-5P,
 tert-Butyl 4-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-
 yl]amino]carbonyl]amino]butanoate 915703-37-6P, N'-[[[2-(Cyanomethyl)-4'-
 methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-N,N-dimethylglycinamide
 915703-38-7P, tert-Butyl N-[[[4'-methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-
 bi-1,3-thiazol-2'-yl]amino]carbonyl]-β-alaninate 915703-39-8P,
 1-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-
 (morpholin-4-yl)-2-oxoethyl]urea 915703-40-1P, 1-[2-(Cyanomethyl)-4'-
 methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-(morpholin-4-yl)-2-oxoethyl]urea
 915703-41-2P, Methyl N-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-
 yl]amino]carbonyl]-β-alaninate 915703-42-3P, N'-[[[2-(Cyanomethyl)-
 4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-N,N-diisopropyl-β-
 alaninamide 915703-43-4P, N'-[[[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-
 thiazol-2'-yl]amino]carbonyl]-N-(2-hydroxy-1,1-dimethylethyl)-β-
 alaninamide 915703-44-5P, N-(tert-Butyl)-N'-[[[2-(cyanomethyl)-4'-methyl-
 4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-β-alaninamide
 915703-45-6P, 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-
 (2,2-dimethyl-1,3-thiazolidin-3-yl)-3-oxopropyl]urea 915703-46-7P,
 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-
 1,3-oxazolidin-3-yl)-3-oxopropyl]urea 915703-47-8P, N'-[[[2-
 (Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-N-(2,2-
 dimethylpropyl)glycinamide 915703-50-3P, 1-[3-(Azocan-1-yl)-3-oxopropyl]-
 3-[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]urea
 915703-52-5P, 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-
 (1-isopropyl-1H-imidazol-4-yl)ethyl]urea 915703-54-7P,
 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-(1-ethyl-1H-
 imidazol-4-yl)ethyl]urea 915703-55-8P, 1-[2-(5-tert-Butyl-1,2,4-
 oxadiazol-3-yl)ethyl]-3-[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-
 yl]urea 915703-56-9P, 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-
 2'-yl]-3-[2-(5-isopropyl-1,2,4-oxadiazol-3-yl)ethyl]urea 915703-57-0P,

N-[4'-Methyl-2-[[5-(1-methylpiperidin-4-yl)-1,2,4-oxadiazol-3-yl]methyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-58-1P, 2'-(Acetylamino)-4'-methyl-N-(1H-tetrazol-5-yl)-4,5'-bi-1,3-thiazole-2-carboxamide 915703-59-2P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]benzoic acid 915703-60-5P, 3-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]benzoic acid 915703-61-6P, 2'-(Acetylamino)-4'-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-4,5'-bi-1,3-thiazole-2-carboxamide 915703-62-7P, 3-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-hydroxybenzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

IT 51-45-6, 2-(1H-Imidazol-4-yl)ethanamine, reactions 62-23-7, 4-Nitrobenzoic acid 75-30-9, 2-Iodopropane 75-64-9, tert-Butylamine, reactions 96-97-9, 2-Hydroxy-5-nitrobenzoic acid 97-72-3, Isobutyric anhydride 99-05-8, 3-Aminobenzoic acid 100-46-9, Benzylamine, reactions 107-10-8, N-Propylamine, reactions 107-11-9, Allylamine 107-95-9, β -Alanine 108-00-9, 2-Dimethylaminoethylamine 108-18-9, Diisopropylamine 109-01-3, 1-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 109-85-3, 2-Methoxyethylamine 110-91-8, Morpholine, reactions 121-92-6, 3-Nitrobenzoic acid 124-68-5, 2-Amino-2-methyl-1-propanol 133-10-8, Sodium p-aminosalicylate 150-13-0, 4-Aminobenzoic acid 151-18-8, N-(2-Cyanoethyl)amine 177-11-7, 1,4-Dioxo-8-azaspiro[4.5]decane 446-31-1, 4-Amino-2-fluorobenzoic acid 498-94-2, Isonipecotic acid 498-95-3, Nipecotic acid 501-53-1, Benzyl chloroformate 570-23-0, 3-Aminosalicylic acid 622-26-4, 4-Piperidineethanol 627-91-8 1121-92-2, Heptamethylenimine 1501-27-5 1694-29-7, 3-Chloro-2,4-pentanedione 1820-80-0, 3-Aminopyrazole 2237-30-1, 3-Aminobenzonitrile 2450-71-7, Propargylamine 3196-73-4 3282-30-2, Trimethylacetyl chloride 3303-84-2, N-Boc- β -alanine 3325-11-9, 5-Aminobenzotriazole 4418-61-5, 5-Aminotetrazole 4530-20-5, Boc-glycine 4795-29-3, Tetrahydrofurfurylamine 5049-61-6, 2-Aminopyrazine 5100-34-5, Ethyl 3-isocyanatopropionate 5382-16-1, 4-Hydroxypiperidine 5625-67-2, Piperazin-2-one 5813-64-9, Neopentylamine 6456-74-2 6457-49-4, 4-(Hydroxymethyl)piperidine 6859-99-0, 3-Hydroxypiperidine 7357-70-2, 2-Cyanothioacetamide 13794-28-0, Ethyl 2-isocyanatopropionate 13889-98-0, 1-Acetyl piperazine 15026-17-2, Succinic acid mono-tert-butyl ester 16982-21-1, Ethyl thiooxamate 19351-18-9, 2,2-Dimethylthiazolidine 22195-47-7, 2,2-Dimethyl-1,3-dioxolane-4-methanamine 30748-47-1, 5-Acetyl-2-amino-4-methylthiazole 40499-83-0, 3-Pyrrolidinol 41979-39-9, 4-Piperidone hydrochloride 51200-87-4, 4,4-Dimethyloxazolidine 53588-95-7, tert-Butyl N-(2-cyanoethyl)carbamate 56414-96-1, 2-Amino-1-(morpholin-4-yl)ethanone 58620-93-2, β -Alanine tert-butyl ester hydrochloride 58640-01-0, tert-Butyl 4-aminobutanoate hydrochloride 68947-43-3, N-Methyl-4-piperidinecarboxylic acid 72410-06-1, 2-Thiocarbamoylacetamide 73732-51-1, 5-(3-Aminophenyl)tetrazole 78197-27-0, 4-Fluoropiperidine 200634-33-9, Glycine dimethylamide acetate 250137-96-3, ((1S,5S,7S)-6,8-Dioxo-3-azabicyclo[3.2.1]oct-7-yl)methanol 915702-54-4, 4-(2H-Tetrazol-5-yl)aniline hydrochloride 915703-18-3, ((1R,5R,7R)-6,8-Dioxo-3-azabicyclo[3.2.1]oct-7-yl)methanol 915703-26-3, 3-(Morpholin-4-yl)-3-thioxopropionamide

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3

kinase inhibitors with therapeutic uses)

IT 618-94-0P, 3-Nitrobenzohydrazide 618-95-1P, Methyl 3-nitrobenzoate
619-50-1P, Methyl 4-nitrobenzoate 636-97-5P, 4-Nitrobenzohydrazide
6935-15-5P, 4-[[(Benzyloxy)carbonyl]amino]-2-hydroxybenzoic acid
14509-66-1P, 7,8-Dihydroimidazo[1,5-c]pyrimidin-5(6H)-one 31437-04-4P,
N-[[(Pyrazin-2-yl)amino]carbonothioyl]benzamide 31437-05-5P,
1-(Pyrazin-2-yl)thiourea 32519-74-7P, N-[5-(Bromoacetyl)-4-methyl-1,3-
thiazol-2-yl]acetamide 32519-75-8P, N-[5-(Bromoacetyl)-4-methyl-1,3-
thiazol-2-yl]acetamide hydrobromide 34683-41-5P, N-[[(1H-Pyrazol-3-
yl)amino]carbonothioyl]benzamide 39884-12-3P, N-(5-Acetyl-4-methyl-1,3-
thiazol-2-yl)acetamide 41125-77-3P, 5-(4-Nitrophenyl)-1,3,4-oxadiazol-2-
ol 71274-46-9P, N,N-Diisopropyl- β -alaninamide 83725-80-8P,
5-(3-Nitrophenyl)-1,3,4-oxadiazol-2-ol 94284-80-7P, 1-(2-Amino-4-methyl-
1,3-thiazol-5-yl)-2-bromoethanone hydrobromide 98804-62-7P,
7-(N-Cbz-amino)-2,2-dimethyl-4H-1,3-benzodioxin-4-one 113118-47-1P,
5-(4-Aminophenyl)-1,3,4-oxadiazol-2-ol 115082-05-8P,
5-(3-Aminophenyl)-1,3,4-oxadiazol-2-ol 209467-48-1P,
N-(tert-Butyl)- β -alaninamide 299171-15-6P, (2'-Amino-4'-methyl-4,5'-
bi-1,3-thiazol-2-yl)acetonitrile 299441-33-1P, 5-(3-Aminophenyl)-1,3,4-
thiadiazol-2-amine 479408-49-6P, 2-(1-Ethyl-1H-imidazol-4-yl)ethanamine
479408-51-0P, 2-(1-Isopropyl-1H-imidazol-4-yl)ethanamine 758715-91-2P,
1-(1H-Pyrazol-3-yl)thiourea 842137-44-4P, 7-Amino-2,2-dimethyl-4H-1,3-
benzodioxin-4-one 842137-46-6P, 6-Amino-2,2-dimethyl-4H-1,3-benzodioxin-
4-one 847789-44-0P, N'-(tert-Butoxycarbonyl)-N-(tert-butyl)- β -
alaninamide 915702-00-0P, 2-Bromo-1-[4-methyl-2-[(pyrazin-2-yl)amino]-
1,3-thiazol-5-yl]ethanone hydrobromide 915702-01-1P,
1-[4-Methyl-2-[(pyrazin-2-yl)amino]-1,3-thiazol-5-yl]ethanone
hydrochloride 915702-02-2P, N-(5-Acetyl-4-methyl-1,3-thiazol-2-yl)-N-
(pyrazin-2-yl)acetamide 915702-03-3P, 1-[2-[(1-Acetyl-1H-pyrazol-3-
yl)amino]-4-methyl-1,3-thiazol-5-yl]-2-bromoethanone hydrobromide
915702-04-4P, 1-[4-Methyl-2-[(1H-pyrazol-3-yl)amino]-1,3-thiazol-5-
yl]ethanone 915702-05-5P, N-(5-Acetyl-4-methyl-1,3-thiazol-2-yl)-N-(1-
acetyl-1H-pyrazol-3-yl)acetamide 915702-06-6P,
N-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-1H-imidazole-1-
carboxamide 915702-07-7P, N-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-
bi-1,3-thiazol-2'-yl]-1H-imidazole-1-carboxamide 915702-08-8P, Ethyl
2'-amino-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate 915702-10-2P,
4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-amine
mono(trifluoroacetate) 915702-11-3P, 6-[Hydroxy(oxido)amino]-2,2-
dimethyl-4H-1,3-benzodioxin-4-one 915702-14-6P, N3-(tert-Butoxycarbonyl)-
N1,N1-diisopropyl- β -alaninamide 915702-15-7P, N1-(2-Hydroxy-1,1-
dimethylethyl)- β -alaninamide 915702-16-8P, N3-(tert-Butoxycarbonyl)-
N1-(2-hydroxy-1,1-dimethylethyl)- β -alaninamide 915702-17-9P,
3-(2,2-Dimethyl-1,3-thiazolidin-3-yl)-3-oxopropan-1-amine 915702-18-0P,
tert-Butyl [3-(2,2-dimethyl-1,3-thiazolidin-3-yl)-3-oxopropyl]carbamate
915702-19-1P, 3-(4,4-Dimethyl-1,3-oxazolidin-3-yl)-3-oxopropan-1-amine
915702-20-4P, tert-Butyl [3-(4,4-dimethyl-1,3-oxazolidin-3-yl)-3-
oxopropyl]carbamate 915702-21-5P, N-(2,2-Dimethylpropyl)glycinamide
915702-22-6P, tert-Butyl [2-[(2,2-dimethylpropyl)amino]-2-
oxoethyl]carbamate 915702-23-7P, 3-(Azocan-1-yl)-3-oxopropan-1-amine
915702-24-8P, tert-Butyl [3-(azocan-1-yl)-3-oxopropyl]carbamate
915702-25-9P, 2-Isopropyl-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidin-
2-ium iodide 915702-26-0P, 2-Ethyl-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-
c]pyrimidin-2-ium bromide 915702-27-1P, 2-(5-tert-Butyl-1,2,4-oxadiazol-
3-yl)ethanamine 915702-28-2P, tert-Butyl [2-(5-tert-butyl-1,2,4-
oxadiazol-3-yl)ethyl]carbamate 915702-29-3P, 2-(5-Isopropyl-1,2,4-
oxadiazol-3-yl)ethanamine 915702-30-6P, tert-Butyl [2-(5-isopropyl-1,2,4-
oxadiazol-3-yl)ethyl]carbamate 915702-47-5P, 2'-(Acetylamino)-4'-methyl-
4,5'-bithiazole-2-carbonyl chloride 915702-62-4P, 2'-(Acetylamino)-N-
(2,2-dimethyl-4-oxo-4H-1,3-benzodioxin-6-yl)-4'-methyl-4,5'-bi-1,3-
thiazole-2-carboxamide 915702-91-9P, 2'-(Acetylamino)-N-(2,2-dimethyl-4-

oxo-4H-1,3-benzodioxin-7-yl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide
915703-01-4P, Ethyl 2'-amino-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate
monohydrobromide 915703-21-8P, 2-Bromo-1-[4-methyl-2-[(pyrazin-2-
yl)amino]-1,3-thiazol-5-yl]ethanone 915703-24-1P, 1-[2-[(1-Acetyl-1H-
pyrazol-3-yl)amino]-4-methyl-1,3-thiazol-5-yl]-2-bromoethanone
915710-94-0P, tert-Butyl [(3E)-3-amino-3-(hydroxyimino)propyl]carbamate
915710-95-1P, tert-Butyl [(3Z)-3-amino-3-[[2,2-
dimethylpropanoyl]oxy]imino]propyl]carbamate 915710-96-2P,
N-[2-[(2E)-2-Amino-2-(hydroxyimino)ethyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
yl]acetamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3
kinase inhibitors with therapeutic uses)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Agouron Pharmaceuticals Inc; WO 0075120 A 2000 CAPLUS
- (2) Bloomfield, G; WO 2004078754 A 2004 CAPLUS
- (3) Bruce, I; WO 03072557 A 2003 CAPLUS
- (4) Bruce, I; WO 2004096797 A 2004 CAPLUS
- (5) Fujisawa Pharmaceutical Co Ltd; EP 0117082 A 1984 CAPLUS
- (6) Sawhney, S; INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC, INCL
MEDICINAL, PUBLICATIONS & INFORMATIONS DIRECTORATE 1976, V14B(7), P552
CAPLUS

L32 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, Phosphoinositide-3-kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of vasculostatic agents and use for treatment of
disorders associated with compromised vasculostasis)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 91-56-5, Isatin

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of vasculostatic agents and use for
treatment of disorders associated with compromised vasculostasis)

RN 91-56-5 CAPLUS

CN 1H-Indole-2,3-dione (CA INDEX NAME)



ACCESSION NUMBER: 2005:1335074 CAPLUS

DOCUMENT NUMBER: 144:69859

TITLE: Indoles, pteridines, pyridopyrazines, and
benzotriazines as vasculostatic agents, their
preparation, pharmaceutical compositions and use in
therapy

INVENTOR(S): Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor;
Noronha, Glenn; Hood, John D.; Dneprovskaja, Elena;
Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning

PATENT ASSIGNEE(S): Targen, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S.
Ser. No. 679,209.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050282814	A1	20051222	US 2005-105845	20050413
US 20040167198	A1	20040826	US 2003-679209	20031002
US 7208493	B2	20070424		
ZA 2005002328	A	20060927	ZA 2005-2328	20050318
US 20070208019	A1	20070906	US 2007-653190	20070111

PRIORITY APPLN. INFO.:
US 2002-415981P P 20021003
US 2003-440234P P 20030114
US 2003-443752P P 20030129
US 2003-463818P P 20030417
US 2003-466983P P 20030430
US 2003-479295P P 20030617
US 2003-679209 A2 20031002

OTHER SOURCE(S): CASREACT 144:69859; MARPAT 144:69859
AN 2005:1335074 CAPLUS
DN 144:69859
ED Entered STN: 23 Dec 2005
TI Indoles, pteridines, pyridopyrazines, and benzotriazines as vasculostatic agents, their preparation, pharmaceutical compositions and use in therapy
IN Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor; Noronha, Glenn; Hood, John D.; Dneprovskaja, Elena; Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning
PA Targen, Inc., USA
SO U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S. Ser. No. 679,209.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-525
ICS A61K031-724
INCL 514251000; 514058000
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63



FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050282814	A1	20051222	US 2005-105845	20050413
	US 20040167198	A1	20040826	US 2003-679209	20031002
	US 7208493	B2	20070424		
	ZA 2005002328	A	20060927	ZA 2005-2328	20050318
	US 20070208019	A1	20070906	US 2007-653190	20070111
PRAI	US 2002-415981P	P	20021003		
	US 2003-440234P	P	20030114		
	US 2003-443752P	P	20030129		
	US 2003-463818P	P	20030417		
	US 2003-466983P	P	20030430		
	US 2003-479295P	P	20030617		
	US 2003-679209	A2	20031002		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20050282814	ICM	A61K031-525
	ICS	A61K031-724
	INCL	514251000; 514058000
	IPCI	A61K0031-525 [ICM, 7]; A61K0031-519 [ICM, 7, C*];

A61K0031-724 [ICS,7]; A61K0031-716 [ICS,7,C*]
 IPCR A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519
 [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*];
 A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02
 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A];
 C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
 C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00
 [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*];
 C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12
 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A];
 C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04
 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
 C07D0519-00 [I,C*]; C07D0519-00 [I,A]
 NCL 514/251.000; 514/058.000
 US 20040167198 IPCI A61K0031-4985 [I,A]; C07D0471-02 [I,A]; C07D0471-00
 [I,C*]
 IPCR A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519
 [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*];
 A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02
 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A];
 C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
 C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00
 [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*];
 C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12
 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A];
 C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04
 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
 C07D0519-00 [I,C*]; C07D0519-00 [I,A]
 NCL 514/414.000; 514/415.000; 548/465.000; 548/511.000;
 514/249.000; 544/256.000
 ZA 2005002328 IPCI A61K [N,S]; C07D [N,S]
 US 20070208019 IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-525
 [I,A]; A61K0031-519 [I,C*]; A61K0039-395 [I,A];
 A61K0031-704 [I,A]; A61K0031-7028 [I,C*]; A61K0031-7048
 [I,A]; A61K0031-7042 [I,C*]; A61K0031-337 [I,A];
 A61K0031-404 [I,A]; A61K0031-403 [I,C*]
 IPCR A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-337
 [I,C]; A61K0031-337 [I,A]; A61K0031-403 [I,C];
 A61K0031-404 [I,A]; A61K0031-519 [I,C]; A61K0031-525
 [I,A]; A61K0031-7028 [I,C]; A61K0031-704 [I,A];
 A61K0031-7042 [I,C]; A61K0031-7048 [I,A]; A61K0039-395
 [I,C]; A61K0039-395 [I,A]
 NCL 514/234.500; 424/155.100; 424/649.000; 514/027.000;
 514/034.000; 514/251.000; 514/414.000; 514/449.000;
 514/492.000
 OS CASREACT 144:69859; MARPAT 144:69859
 GI



- AB The invention relates to nitrogen heterocyclic compds. of formula I, which are useful for treating disorders associated with compromised vasculostasis. In compds. I, each of A, B, W, X, Y, and Z is independently selected from C, C(O), N, and NR₃, where R₃ is H or (un)substituted alkyl; each R₁ is independently halo, OR₄, N(R₄)₂, or SR₄, where R₄ is H, lower alkyl, aryl, heteroaryl, etc.; each R₂ is independently halo, OR₅, N(R₅)₂, SR₅, OPO₃H₂, (un)substituted alkyl, (un)substituted aryl, (un)substituted heteroaryl, where R₅ is H, lower alkyl, aryl, heteroaryl, etc.; and each of m and n is independently an integer from 1 to 4. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of a variety of disorders including stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like. Cyclocondensation of 3,3'-dihydroxybenzil with 2,4,5,6-tetraaminopyrimidine sulfate results in the formation of diaminopteridine II. Compound II expresses an IC₅₀ value of 83 nM in an assay for the inhibition of the human p120 γ subunit of PI3 kinase and results in 65% reduction of myocardial infarction in rats.
- ST indolyl phenyl carboxamide prepn vasculostatic; pteridine prepn vasculostatic; pyridopyrazine prepn vasculostatic; quinazoline prepn vasculostatic; benzotriazine prepn vasculostatic
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HER2; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Respiratory distress syndrome
(acute; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Respiratory distress syndrome
(adult; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Antibiotics
(anthracycline; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Cytotoxic agents
(antimetabolites; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Disease, animal
 (arthropathy; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Disease, animal
 (associated with compromised vasculostasis; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Antibiotics
 (bleomycin-type; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Muscle, disease
 (cancer; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Drug delivery systems
 (carriers; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Intestine, neoplasm
 (colon; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT DNA
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (crosslinking agents; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Joint, anatomical
 (disease; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Heart, disease
 (failure; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Heart, disease
 (infarction; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Drug delivery systems
 (injections; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Reperfusion
 (injury; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Capillary vessel, disease
 (leakage syndrome; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Eye, disease
 (macula, degeneration; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Lung, neoplasm
 (metastasis; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Antibiotics
 (mitomycin-type; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Blood vessel
 (permeability; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Biological transport
 (permeation, vascular; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Alkylating agents, biological
 Angiogenesis
 Angiogenesis inhibitors
 Anti-inflammatory agents

- Anti-ischemic agents
- Antiarthritics
- Antitumor agents
- Arthritis
- Autoimmune disease
- Bladder, neoplasm
- Bone, neoplasm
- Brain, neoplasm
- Burn
- Cardiovascular agents
- Combination chemotherapy
- Digestive tract, neoplasm
- Edema
- Human
- Immunomodulators
- Inflammation
- Kidney, neoplasm
- Leukemia
- Liver, neoplasm
- Lung, neoplasm
- Lymphoma
- Mammary gland, neoplasm
- Melanoma
- Microtubule
- Neoplasm
- Ovary, neoplasm
- Prostate gland, neoplasm
- Skin, neoplasm
- Spleen
- T cell (lymphocyte)
- Transplant rejection
 - (preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Growth factor receptors
 - Growth factors, animal
 - Integrins
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Interleukin 2
 - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Injury
 - (reperfusion; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Eye, disease
 - (retinopathy, vitreo-; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Eye, disease
 - (retinopathy; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Brain, disease
 - (stroke; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Drug interactions
 - (synergistic; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)
- IT Antibodies and Immunoglobulins
 - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
 (therapeutic; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Cardiovascular agents
 (vasculostatics; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Alkaloids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vinca; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Eye
 (vitreous humor, vitreoretinal disease; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 677297-15-3P, N-[2-(1H-Indol-2-yl)-phenyl]-2-(2-methoxyphenyl)acetamide
 677297-25-5P, N-[2-(1H-Indol-2-yl)-phenyl]phthalamic acid 677297-30-2P,
 6,7-Bis(4-hydroxyphenyl)pteridin-4-ylamine 677297-48-2P,
 4-(4-Aminopteridin-7-yl)-phenol 677297-51-7P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4,-diamine 677297-58-4P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine 677297-61-9P, 6,7-Bis(4-hydroxyphenyl)pteridin-4-ylamine sulfate 677297-63-1P,
 6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diamine dihydrochloride 677297-65-3P, 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine 677297-75-5P 677297-77-7P 677297-90-4P, 7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-ylamine 677298-01-0P,
 N-(7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)-phenylamine 677298-27-0P,
 6-Bromo-3-(3-hydroxypropionyl)-3H-quinazolin-4-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 14892-98-9P 102704-20-1P, N-[2-(1H-Indol-2-yl)-phenyl]-2-phenylacetamide
 128076-13-1P, 6-Phenylpteridin-4-ylamine 278799-97-6P,
 6-(Benzylaminomethyl)-2,4-pteridinediamine 677297-11-9P,
 2-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]acetamide 677297-12-0P,
 4-Hydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide 677297-13-1P,
 3,4-Dihydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide 677297-14-2P,
 2-Hydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide 677297-16-4P,
 2-(2-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]acetamide 677297-17-5P,
 2-(3,4-Dihydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]acetamide 677297-18-6P, 2-[1,3-Benzodioxol-5-yl]-N-[2-(1H-indol-2-yl)-phenyl]-acetamide 677297-19-7P, N-[2-(1H-Indol-2-yl)-phenyl]-3-phenylpropionamide 677297-20-0P, 3-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]propionamide 677297-21-1P, N-[2-(1H-Indol-2-yl)-phenyl]-3-(2-methoxyphenyl)propionamide 677297-22-2P, 3-(3,4-Dihydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]propionamide 677297-23-3P, 2-(4-Hydroxyphenoxy)-N-[2-(1H-indol-2-yl)-phenyl]acetamide 677297-26-6P, 2-[2-(1H-Indol-2-yl)-phenyl]carbamoyl]nicotinic acid 677297-27-7P, 3,4,5-Trihydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide 677297-28-8P 677297-29-9P,
 6,7-Bis-(4-hydroxyphenyl)pteridin-4-yl-(3-(morpholin-4-yl)propyl)amine hydrochloride 677297-31-3P, Acetic acid 4-[7-(4-acetoxyphenyl)-4-aminopteridin-6-yl]-phenyl ester 677297-32-4P, Acetic acid 4-[2-(4-acetoxyphenyl)-6-aminopyrido[2,3-b]pyrazin-3-yl]-phenyl ester 677297-35-7P, (3,4-Dimethoxyphenyl)-(6-phenylpteridin-4-yl)-amine 677297-36-8P, (3-Chloro-4,6-dimethoxyphenyl)-(6-phenylpteridin-4-yl)-amine 677297-37-9P, (3-Hydroxy-4-methoxyphenyl)-(6-phenylpteridin-4-yl)-amine 677297-38-0P, (4-Hydroxyphenyl)-(6-phenylpteridin-4-yl)-amine 677297-39-1P, (2,5-Dimethyl-4-hydroxyphenyl)-(6-phenylpteridin-4-yl)-amine 677297-40-4P, 2-Hydroxy-5-(6-phenylpteridin-4-ylamino)benzenesulfonic acid

677297-41-5P, 2-Diethylaminomethyl-4-(6-phenylpteridin-4-ylamino)phenol
 677297-44-8P, Benzyl-(6-phenylpteridin-4-yl)-amine 677297-45-9P,
 4-[(6-Phenylpteridin-4-ylamino)methyl]benzene-1,2-diol 677297-46-0P,
 Indan-2-yl-(6-phenylpteridin-4-yl)-amine 677297-47-1P,
 2-(3,4-Dimethoxyphenyl)ethyl]-(6-phenylpteridin-4-yl)-amine
 677297-49-3P, 4-(4-Benzylaminopteridin-7-yl)-phenol 677297-53-9P,
 6-Pyridin-2-yl-7-pyridin-3-ylpteridin-4-amine sulfate 677297-54-0P,
 6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diol 677297-55-1P,
 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine dihydrochloride
 677297-56-2P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine
 methanesulfonate 677297-57-3P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-
 diamine dihydrobromide 677297-59-5P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-
 ylamine hydrochloride 677297-60-8P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-
 ylamine methanesulfonate 677297-62-0P, 6,7-Bis(3,4-
 dihydroxyphenyl)pteridine-2,4-diamine 677297-64-2P, 6,7-Bis(3,4-
 dihydroxyphenyl)pteridin-4-ylamine hydrochloride 677297-66-4P,
 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine methanesulfonate
 677297-67-5P, 4-(2,4-Diaminopteridin-6-yl)phenol 677297-68-6P,
 2,3-Diphenylpyrido[3,4-b]pyrazin-8-ylamine hydrochloride 677297-69-7P,
 2,3-Bis(4-hydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine hydrochloride
 677297-70-0P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine
 hydrochloride 677297-71-1P, 2,3-Bis(3-hydroxyphenyl)pyrido[3,4-b]pyrazin-
 8-ylamine hydrochloride 677297-72-2P, 2,3-Bis(3-hydroxyphenyl)pyrido[2,3-
 b]pyrazin-6-ylamine dihydrochloride 677297-73-3P, 2,3-Bis(4-
 hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride
 677297-76-6P 677297-78-8P 677297-79-9P, 4-(4-Aminopteridin-7-yl)-
 benzene-1,2-diol 677297-80-2P, 4-(2,4-Diaminopteridin-7-yl)-benzene-1,2-
 diol 677297-81-3P, 4-(2,4-Diaminopteridin-7-yl)-phenol 677297-82-4P,
 4-[2-(6-Phenylpteridin-4-ylamino)ethyl]benzene-1,2-diol 677297-83-5P,
 2,3-Bis(3,4-dihydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride
 677297-84-6P, 2,3-Bis(3-hydroxyphenyl)quinoxalin-6-ylamine dihydrochloride
 677297-85-7P, 2,3-Bis(4-hydroxyphenyl)quinoxalin-6-ylamine dihydrochloride
 677297-86-8P, 2,3-Bis(3,4-dihydroxyphenyl)quinoxalin-6-ylamine
 dihydrochloride 677297-89-1P, [7-(1,3-Benzodioxol-5-
 yl)benzo[1,2,4]triazin-3-yl]amine 677297-91-5P, 7-(4-
 Phenoxyphenyl)benzo[1,2,4]triazin-3-ylamine 677297-92-6P,
 7-(2,6-Dimethoxyphenyl)benzo[1,2,4]triazin-3-ylamine 677297-93-7P,
 7-(4-tert-Butylphenyl)benzo[1,2,4]triazin-3-ylamine 677297-94-8P,
 7-(2-Trifluoromethylphenyl)benzo[1,2,4]triazin-3-ylamine 677297-95-9P,
 7-Biphenyl-4-ylbenzo[1,2,4]triazin-3-ylamine 677297-96-0P,
 7-Benzofuran-2-ylbenzo[1,2,4]triazin-3-ylamine 677297-97-1P,
 7-Dibenzofuran-4-ylbenzo[1,2,4]triazin-3-ylamine 677297-98-2P,
 7-Naphthalen-1-ylbenzo[1,2,4]triazin-3-ylamine 677297-99-3P,
 3-(3-Aminobenzo[1,2,4]triazin-7-yl)-phenol 677298-00-9P,
 N-[7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-yl]-phenylamine
 677298-02-1P, (7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)-[3-(4-
 methylpiperazin-1-yl)-propyl]amine 677298-03-2P, N-[5-Methyl-7-(2,4,6-
 trimethylphenyl)benzo[1,2,4]triazin-3-yl]-phenylamine 677298-04-3P,
 N-[7-(2-Fluoro-6-methoxyphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-
 phenylamine 677298-05-4P, N-[7-(2,6-Dimethoxyphenyl)-5-
 methylbenzo[1,2,4]triazin-3-yl]-phenylamine 677298-06-5P,
 N-[7-(2,6-Dimethylphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-phenylamine
 677298-07-6P, 7-Naphthalen-2-ylbenzo[1,2,4]triazin-3-ylamine-1-oxide
 677298-08-7P, 2-[(2,4-Diaminopteridin-6-ylmethyl)amino]-3-(4-
 hydroxyphenyl)propionic acid tert-butyl ester 677298-09-8P,
 6-[[(Pyridin-2-ylmethyl)amino]methyl]-2,4-pteridinediamine 677298-10-1P,
 6-[[(Naphthalen-1-ylmethyl)amino]methyl]-2,4-pteridinediamine
 677298-11-2P, 6-[[(Adamantan-1-ylmethyl)amino]methyl]-2,4-pteridinediamine
 677298-13-4P, 6-[2,2-Dimethylpropylamino]methyl]-2,4-pteridinediamine
 677298-14-5P, 6-[[2-(3,4-Dimethoxyphenyl)ethylamino]methyl]-2,4-
 pteridinediamine 677298-15-6P, 6-[[2-(3,4-Dihydroxyphenyl)ethylamino]met

hyl]-2,4-pteridinediamine 677298-16-7P, 4-[2-[Di(2,4-diaminopteridin-6-ylmethyl)amino]ethyl]benzene-1,2-diol 677298-17-8P 677298-18-9P, 3-(4-tert-Butoxyphenyl)-2-[(2,4-diaminopteridin-6-ylmethyl)amino]propionic acid tert-butyl ester 677298-19-0P, 1-[[[Bis-(2,4-Diaminopteridin-6-ylmethyl)]-amino]methyl]naphthalene 677298-20-3P, 6-(2,6-Dimethylphenyl)-3H-quinazolin-4-one 677298-21-4P, 6-(2,6-Dimethoxyphenyl)-3H-quinazolin-4-one 677298-22-5P, 6-(2-Chloro-6-methoxyphenyl)-3H-quinazolin-4-one 677298-23-6P, 6-(2,4,6-Trimethylphenyl)-3H-quinazolin-4-one 677298-24-7P, 6-(Naphthalen-1-yl)-3H-quinazolin-4-one 677298-25-8P, 6-(Naphthalen-2-yl)-3H-quinazolin-4-one 677298-26-9P, 6-(4-Phenoxyphenyl)-3H-quinazolin-4-one 677298-28-1P, 6-(2,6-Dimethylphenyl)-3-(3-hydroxypropionyl)-3H-quinazolin-4-one 677298-29-2P, 6-(2-Chloro-6-methoxyphenyl)-3-(3-hydroxypropionyl)-3H-quinazolin-4-one 677298-31-6P, 8-Bromo-4-[3-(4-methylpiperazin-1-yl)-propylamino]-6-nitroquinazolin-2-ol 677298-32-7P, (6,7-Diphenylpteridin-4-yl)-[3-(4-methylpiperazin-1-yl)-propyl]amine 677298-33-8P 677298-34-9P 871590-51-1P, (S)-2-Acetyl-amino-3-(4-hydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]propionamide 871590-52-2P, 5-(6-Phenylpteridin-4-ylamino)quinolin-8-ol hydrochloride 871590-53-3P, 6-((3,4-Dimethoxybenzylamino)methyl)-2,4-pteridinediamine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 6298-38-0P, 7-Bromobenzo[1,2,4]triazin-3-ylamine-1-oxide 32084-59-6P, 6-Bromo-3H-quinazolin-4-one 52853-40-4P, 6-Bromomethyl-2,4-pteridinediamine hydrobromide 59368-16-0P, 6-Bromomethyl-2,4-pteridinediamine 677297-74-4P 677297-87-9P 677297-88-0P, [7-(1,3-Benzodioxol-5-yl)-1-oxo-benzo[1,2,4]triazin-3-yl]amine 677298-30-5P, 4-Amino-8-bromo-6-nitroquinazolin-2-ol
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 115926-52-8, Phosphoinositide-3-kinase 127464-60-2, VEGF 141349-89-5, Src kinase 141349-91-9, Yes kinase 143180-75-0 144114-16-9, Protein tyrosine kinase 2 148640-14-6, Akt kinase 372092-80-3, Protein kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 50-76-0, Dactinomycin 59-05-2, Methotrexate 64-86-8, Colchicine 477-30-5, Demecolcine 1605-68-1, Taxane 7585-39-9, β -Cyclodextrin 12619-70-4, Cyclodextrin 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 33069-62-4, Taxol 33419-42-0, Etoposide 41575-94-4, Carboplatin 42077-25-8, Adriamycin-14-octanoate 50935-04-1 56420-45-2, Epirubicin 58957-92-9, Idarubicin 59367-03-2, Adriamycin-14-benzoate 64161-91-7, Adriamycin-14-naphthaleneacetate 65271-80-9, Mitoxantrone 79466-09-4, 13-Deoxydaunorubicin 84325-15-5, 11-Deoxydaunorubicin 114977-28-5, Taxotere 154447-36-6, LY294002 180288-69-1, Trastuzumab 183319-69-9, OSI-774 194615-04-8, Captisol 216974-75-3, Bevacizumab 677298-35-0, 6,7-Bis-(3-hydroxyphenyl)pteridine-2,4-diamine sulfate 892553-42-3, Vitaxin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 77-92-9, Citric acid, biological studies 1404-00-8, Mitomycin 11056-06-7, Bleomycin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT 51-61-6, 2-(3,4-Dihydroxyphenyl)ethylamine, reactions 62-31-7, 3-Hydroxytyramine hydrochloride 62-53-3, Aniline, reactions 69-72-7, Salicylic acid, reactions 85-44-9, Phthalic anhydride 91-56-5, Isatin 93-25-4, 2-Methoxyphenylacetic acid 97-50-7, (3-Chloro-4,6-dimethoxyphenyl)amine 99-50-3, 3,4-Dihydroxybenzoic acid 99-96-7, 4-Hydroxybenzoic acid, reactions 100-46-9, Benzylamine, reactions 102-32-9, 3,4-Dihydroxyphenylacetic acid 103-82-2, Phenylacetic acid, reactions 118-31-0, 1-Aminomethylnaphthalene 118-70-7, 4,5,6-Triaminopyrimidine 120-20-7, 2-(3,4-Dimethoxyphenyl)ethylamine 123-00-2, N-(3-Aminopropyl)morpholine 123-30-8, (4-Hydroxyphenyl)amine 134-81-6, Benzil 149-91-7, Gallic acid, reactions 156-38-7, 4-Hydroxyphenylacetic acid 501-52-0, Hydrocinnamic acid 501-97-3, 3-(4-Hydroxyphenyl)propionic acid 537-55-3, N-Acetyl-L-tyrosine 615-47-4 635-85-8, 2-(3,4-Dimethoxyphenyl)ethylamine hydrochloride 699-98-9, 2,3-Pyridinedicarboxylic anhydride 814-68-6, Acryloyl chloride 875-51-4, 4-Bromo-2-nitrophenylamine 1004-74-6, 2,4,5,6-Tetraaminopyrimidine 1078-61-1, 3,4-Dihydroxyhydrocinnamic acid 1124-40-9, 3,4-Dihydroxybenzylamine hydrochloride 1423-27-4, 2-Trifluoromethyl phenylboronic acid 1687-53-2, (3-Hydroxy-4-methoxyphenyl)amine 1878-84-8, (4-Hydroxyphenoxy)acetic acid 2835-04-3, 2-Hydroxy-5-aminobenzenesulfonic acid 2861-28-1, 3,4-(Methylenedioxy)phenylacetic acid 2975-41-9, Indan-2-ylamine 3096-71-7, (2,5-Dimethyl-4-hydroxyphenyl)amine 3731-51-9, 2-(Aminomethyl)pyridine 4572-03-6, 3-(4-Methylpiperazin-1-yl)-propylamine 5122-94-1, 4-Biphenylboronic acid 5763-61-1, 3,4-Dimethoxybenzylamine 5794-88-7, 2-Amino-5-Bromobenzoic acid 5813-64-9, 2,2-Dimethylpropylamine 5980-97-2, 2,4,6-Trimethylphenylboronic acid 5993-91-9, 2-Aminomethylbenzimidazole dihydrochloride 6309-15-5, 3,3',4,4'-Tetrahydroxybenzil 6315-89-5, (3,4-Dimethoxyphenyl)amine 6342-77-4, 3-(2-Methoxyphenyl)propionic acid 13207-66-4, 5-(Amino)quinolin-8-ol 13922-41-3, 1-Naphthylboronic acid 16290-26-9, 3,4-Dihydroxybenzylamine hydrobromide 17601-94-4, 2-Amino-3-bromo-5-nitrobenzonitrile 17768-41-1, 1-Aminomethyl adamantane 20284-90-6, 2,3,6-Triaminopyridine dihydrochloride 21454-19-3, 23112-96-1, 2,6-Dimethoxyphenylboronic acid 24645-80-5, 4-Hydroxyphenylglyoxal 24850-02-0, 6,7-Diphenylpteridin-4-ylamine 29477-55-2, 3,4-Dihydroxyphenylglyoxal 32316-92-0, 2-Naphthylboronic acid 32566-01-1, 2-(2-Aminophenyl)indole 33288-79-8, 4,4'-Dihydroxybenzil 37491-68-2, 4-[(Amino)methyl]benzene-1,2-diol 42965-55-9, 5,6-Diamino-2,4-dihydropyrimidine sulfate 49647-58-7, 2,4,5,6-Tetraaminopyrimidine sulfate 49721-45-1, 4,5,6-Triaminopyrimidine sulfate 51067-38-0, 4-Phenoxyphenylboronic acid 51387-92-9, 2-Diethylaminomethyl-4-(amino)phenol 63192-57-4, 3,3'-Dihydroxybenzil 76145-91-0, (2,4-Diaminopteridin-6-yl)-methanol hydrobromide 77712-97-1, 3,4,5-Triaminopyridine hydrochloride 77811-44-0, 4-Bromo-2-methyl-6-nitrophenylamine 78495-63-3, 2-Fluoro-6-methoxyphenylboronic acid 87199-18-6, 3-Hydroxyphenylboronic acid 88878-78-8, 2-Amino-3-(4-hydroxyphenyl)propionic acid tert-butyl ester 94839-07-3, 3,4-(Methylenedioxy)phenylboronic acid 95195-43-0, 2,3'-Pyridil 98437-24-2, 2-Benzofuranboronic acid 100124-06-9, 4-Dibenzofuranboronic acid 100379-00-8, 2,6-Dimethylphenylboronic acid 123324-71-0, 4-tert-Butylphenylboronic acid 385370-80-9, 2-Chloro-6-methoxyphenylboronic acid 545390-26-9, 2-Amino-3-(4-tert-butoxyphenyl)propionic acid tert-butyl ester hydrochloride 677297-33-5, 2,3-Bis(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine 677297-34-6, N'-(3-Cyano-5-phenylpyrazin-2-yl)-N,N-dimethylformamidine

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

L32 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 115926-52-8
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of thiazole derivs. as modulators of the phosphoinositide
 3-kinases (PI3Ks))
 RN 115926-52-8 CAPLUS
 CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

ACCESSION NUMBER: 2005:673279 CAPLUS
 DOCUMENT NUMBER: 143:172865
 TITLE: Preparation of thiazole derivatives as modulators of
 the phosphoinositide 3-kinases (PI3Ks)
 INVENTOR(S): Quattropani, Anna; Rueckle, Thomas; Schwarz, Matthias;
 Dorbais, Jerome; Sauer, Wolfgang; Cleva, Christophe;
 Desforages, Gwenaelle
 PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N. V., Neth.
 Antilles
 SOURCE: PCT Int. Appl., 212 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068444	A2	20050728	WO 2005-EP50102	20050111
WO 2005068444	A3	20050909		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005205201	A1	20050728	AU 2005-205201	20050111
CA 2551415	A1	20050728	CA 2005-2551415	20050111
EP 1709019	A2	20061011	EP 2005-701490	20050111
EP 1709019	B1	20070808		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
CN 1926121	A	20070307	CN 2005-80006639	20050111
BR 2005006749	A	20070522	BR 2005-6749	20050111
JP 2007517835	T	20070705	JP 2006-548315	20050111
AT 369349	T	20070815	AT 2005-701490	20050111
ES 2287896	T3	20071216	ES 2005-701490	20050111
IN 2006DN03731	A	20070420	IN 2006-DN3731	20060629
MX 2006PA07934	A	20060914	MX 2006-PA7934	20060711
NO 2006003606	A	20061012	NO 2006-3606	20060809
PRIORITY APPLN. INFO.:			EP 2004-100083	A 20040112
			WO 2005-EP50102	W 20050111
OTHER SOURCE(S):	CASREACT 143:172865; MARPAT 143:172865			
AN 2005:673279	CAPLUS			
DN 143:172865				

ED Entered STN: 29 Jul 2005
 TI Preparation of thiazole derivatives as modulators of the phosphoinositide
 3-kinases (PI3Ks)
 IN Quattropiani, Anna; Rueckle, Thomas; Schwarz, Matthias; Dorbais, Jerome;
 Sauer, Wolfgang; Cleva, Christophe; Desforges, Gwenaelle
 PA Applied Research Systems ARS Holding N. V., Neth. Antilles
 SO PCT Int. Appl., 212 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D277-46
 CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005068444	A2	20050728	WO 2005-EP50102	20050111
	WO 2005068444	A3	20050909		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005205201	A1	20050728	AU 2005-205201	20050111
	CA 2551415	A1	20050728	CA 2005-2551415	20050111
	EP 1709019	A2	20061011	EP 2005-701490	20050111
	EP 1709019	B1	20070808		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
	CN 1926121	A	20070307	CN 2005-80006639	20050111
	BR 2005006749	A	20070522	BR 2005-6749	20050111
	JP 2007517835	T	20070705	JP 2006-548315	20050111
	AT 369349	T	20070815	AT 2005-701490	20050111
	ES 2287896	T3	20071216	ES 2005-701490	20050111
	IN 2006DN03731	A	20070420	IN 2006-DN3731	20060629
	MX 2006PA07934	A	20060914	MX 2006-PA7934	20060711
	NO 2006003606	A	20061012	NO 2006-3606	20060809
PRAI	EP 2004-100083	A	20040112		
	WO 2005-EP50102	W	20050111		



CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005068444	ICM	C07D277-46
	IPCI	C07D0277-46 [ICM, 7]; C07D0277-00 [ICM, 7, C*]
	IPCR	C07D0277-00 [I, C*]; C07D0277-46 [I, A]; C07D0417-00 [I, C*]; C07D0417-14 [I, A]
	ECLA	C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
AU 2005205201	IPCI	C07D0277-00 [I, C*]; C07D0417-00 [I, C*]; C07D0277-46 [I, A]; C07D0417-14 [I, A]
CA 2551415	IPCI	A61K0031-427 [I, A]; C07D0277-46 [I, A]; C07D0277-00 [I, C*]; C07D0417-14 [I, A]; C07D0417-00 [I, C*]

	ECLA	C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
EP 1709019	IPCI	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
CN 1926121	IPCI	C07D0277-46 [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; A61K0031-427 [I,A]
	IPCR	C07D0277-00 [I,C]; C07D0277-46 [I,A]; C07D0417-00 [I,C*]; C07D0417-14 [I,A]
	ECLA	C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
BR 2005006749	IPCI	C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
	ECLA	C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
JP 2007517835	IPCI	C07D0277-20 [I,A]; C07D0277-46 [I,A]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; C07D0277-48 [I,A]; C07D0277-00 [I,C*]; A61K0031-427 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0031-496 [I,A]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-433 [I,A]; A61K0031-4709 [I,A]; A61P0025-28 [I,A]; A61P0025-14 [I,A]; A61P0025-00 [I,A]; A61P0043-00 [I,A]; A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0017-06 [I,A]; A61P0017-00 [I,C*]; A61P0019-02 [I,A]; A61P0019-00 [I,C*]; A61P0037-02 [I,A]; A61P0001-04 [I,A]; A61P0001-00 [I,C*]; A61P0011-00 [I,A]; A61P0007-02 [I,A]; A61P0007-00 [I,C*]; A61P0031-00 [I,A]; A61P0029-00 [I,A]; A61P0009-12 [I,A]; A61P0009-08 [I,A]; A61P0037-08 [I,A]; A61P0011-06 [I,A]; A61P0021-02 [I,A]; A61P0021-00 [I,C*]; A61P0035-00 [I,A]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0037-06 [I,A]; A61P0037-00 [I,C*]; A61P0013-12 [I,A]; A61P0013-00 [I,C*]; A61P0015-08 [I,A]; A61P0015-00 [I,C*]
	IPCR	C07D0277-00 [I,C]; C07D0277-20 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C]; A61K0031-433 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0009-08 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C]; A61P0013-12 [I,A]; A61P0015-00 [I,C]; A61P0015-08 [I,A]; A61P0017-00 [I,C]; A61P0017-06 [I,A]; A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0021-00 [I,C]; A61P0021-02 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];

A61P0025-14 [I,A]; A61P0025-28 [I,A]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C]; A61P0031-00 [I,A]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; A61P0037-00 [I,C]; A61P0037-02 [I,A]; A61P0037-06 [I,A]; A61P0037-08 [I,A]; A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D0277-46 [I,A]; C07D0277-48 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
 ECLA C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
 FTERM 4C033/AD04; 4C033/AD07; 4C033/AD15; 4C033/AD16; 4C033/AD17; 4C033/AD20; 4C063/AA03; 4C063/BB02; 4C063/BB07; 4C063/BB09; 4C063/CC62; 4C063/CC67; 4C063/CC73; 4C063/CC76; 4C063/CC94; 4C063/DD03; 4C063/DD04; 4C063/DD10; 4C063/DD12; 4C063/DD14; 4C063/DD47; 4C063/DD51; 4C063/DD52; 4C063/DD58; 4C063/DD62; 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BC82; 4C086/GA02; 4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA09; 4C086/GA10; 4C086/GA12; 4C086/MA01; 4C086/MA02; 4C086/MA04; 4C086/MA05; 4C086/NA14; 4C086/NA15; 4C086/ZA02; 4C086/ZA16; 4C086/ZA22; 4C086/ZA23; 4C086/ZA36; 4C086/ZA39; 4C086/ZA42; 4C086/ZA45; 4C086/ZA54; 4C086/ZA59; 4C086/ZA66; 4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB05; 4C086/ZB08; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB21; 4C086/ZB26; 4C086/ZB32; 4C086/ZB33; 4C086/ZB35; 4C086/ZC19; 4C086/ZC20
 AT 369349 IPCI C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
 IPCR C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
 ECLA C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
 ES 2287896 IPCI C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
 IPCR C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
 ECLA C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
 IN 2006DN03731 IPCI C07D0277-46 [ICM,7]; C07D0277-00 [ICM,7,C*]
 MX 2006PA07934 IPCI A61K0031-427 [ICM,7]; C07D0277-46 [ICS,7]; C07D0277-00 [ICS,7,C*]; C07D0417-14 [ICS,7]; C07D0417-00 [ICS,7,C*]
 NO 2006003606 IPCI C07D0277-00 [I,C]; C07D0277-46 [I,A]
 IPCR C07D0277-00 [I,C]; C07D0277-46 [I,A]; C07D0417-00 [I,C*]; C07D0417-14 [I,A]
 ECLA C07D277/46; C07D417/14+277B+263B+207; C07D417/14+277B+277B+207; C07D417/14+277B+277B+211; C07D417/14+277B+277B+213; C07D417/14+307+277B+277B; C07D417/14+307B+277B+277B
 OS CASREACT 143:172865; MARPAT 143:172865

GI



- AB The title compds. I [R1 = NR5R6; R2, R3, R5 = H, alkyl, alkenyl, alkynyl; R4 = H, alkyl, alkenyl, alkynyl, NR8R9 (wherein R8, R9 = H, alkyl, alkenyl, etc.); R6 = alkyl, aryl, heteroaryl, etc.], useful in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries, were prepared and formulated. Thus, reacting 3-[(aminocarbonothioyl)amino]benzoic acid with N-[5-(bromoacetyl)-4-methyl-1,3-thiazol-2-yl]acetamide (preparation given) afforded II.HBr which showed IC50 of 10 nM against PI3K γ .
- ST thiazole prepn phosphoinositide 3 kinase PI3K gamma modulator
- IT Nervous system, disease
(Huntington's chorea, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Sarcoma
(Kaposi's, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Antiarteriosclerotics
(antiatherosclerotics; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Muscle, disease
(atrophy, treating or preventing skeletal muscle atrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Infection
(bacterial, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Muscle
(cardiac, treating or preventing cardiac myocyte dysfunction; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Hypertrophy
(cardiac, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Lung, disease

(chronic obstructive pulmonary disease, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Nervous system, disease
(degeneration, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Kidney, disease
(fibrosis, treating or preventing progressive renal fibrosis; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Inflammation
Kidney, disease
(glomerulonephritis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Kidney, disease
(glomerulosclerosis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle, disease
(hypertrophy, treating or preventing skeletal muscle atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Heart, disease
(hypertrophy, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Brain, disease
(infection, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Intestine, disease
(inflammatory, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Lung, disease
Reperfusion
(injury, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Neoplasm
(metastasis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Hypertrophy
(muscular, treating or preventing skeletal muscle atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Heart
(myocardium, treating or preventing cardiac myocyte dysfunction; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Inflammation
Lung, disease
(pneumonitis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Allergy inhibitors
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Antibacterial agents
Anticoagulants
Antihypertensives
Antirheumatic agents

- Antitumor agents
- Antiviral agents
- Cardiovascular agents
- Human
- Immunosuppressants
- Platelet aggregation inhibitors
 - (preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Injury
 - (pulmonary, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Fibrosis
 - (renal, treating or preventing progressive renal fibrosis; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Injury
 - (reperfusion, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Brain, disease
 - (stroke, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Lupus erythematosus
 - (systemic, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Central nervous system, disease
 - (trauma, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Leukocyte
 - (treating or preventing leukocyte recruitment in cancer tissue; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Allergy
- Alzheimer's disease
- Anaphylaxis
- Angiogenesis
- Asthma
- Atherosclerosis
- Autoimmune disease
- Cardiovascular system, disease
- Encephalitis
- Fibrosis
- Hypertension
- Inflammation
- Ischemia
- Kidney, disease
- Melanoma
- Meningitis
- Multiple sclerosis
- Neoplasm
- Platelet aggregation
- Psoriasis
- Rheumatoid arthritis
- Sepsis
- Thrombosis
- Transplant and Transplantation
- Transplant rejection
- Vasoconstriction
 - (treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
- IT Infection
 - (viral, treating or preventing; preparation of thiazole derivs. as

modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 115926-52-8
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of thiazole derivs. as modulators of the phosphoinositide
 3-kinases (PI3Ks))

IT 860619-22-3P 860619-39-2P 860619-58-5P 860619-75-6P 860620-37-7P
 860620-38-8P 860620-39-9P 860620-40-2P 860620-42-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of thiazole derivs. as modulators of the phosphoinositide
 3-kinases (PI3Ks))

IT 32558-17-1P 307343-36-8P 315704-54-2P 315705-71-6P 315705-72-7P
 315705-74-9P 315705-75-0P 315705-76-1P 315705-77-2P 315705-78-3P
 315705-79-4P 315705-80-7P 315705-81-8P 315705-82-9P 315705-83-0P
 315705-86-3P 315705-87-4P 315705-90-9P 315705-91-0P 315705-92-1P
 333746-84-2P 412919-76-7P 421580-61-2P 428836-20-8P 443747-65-7P
 472980-88-4P 860619-23-4P 860619-24-5P 860619-25-6P 860619-26-7P
 860619-27-8P 860619-28-9P 860619-29-0P 860619-30-3P 860619-31-4P
 860619-32-5P 860619-33-6P 860619-34-7P 860619-35-8P 860619-36-9P
 860619-37-0P 860619-38-1P 860619-40-5P 860619-41-6P 860619-42-7P
 860619-43-8P 860619-44-9P 860619-45-0P 860619-46-1P 860619-47-2P
 860619-48-3P 860619-49-4P 860619-50-7P 860619-51-8P 860619-52-9P
 860619-53-0P 860619-54-1P 860619-55-2P 860619-56-3P 860619-57-4P
 860619-59-6P 860619-60-9P 860619-61-0P 860619-62-1P 860619-63-2P
 860619-64-3P 860619-65-4P 860619-66-5P 860619-67-6P 860619-68-7P
 860619-69-8P 860619-70-1P 860619-71-2P 860619-72-3P 860619-73-4P
 860619-74-5P 860619-76-7P 860619-77-8P 860619-78-9P 860619-79-0P
 860619-80-3P 860619-81-4P 860619-82-5P 860619-83-6P 860619-84-7P
 860619-85-8P 860619-86-9P 860619-87-0P 860619-88-1P 860619-89-2P
 860619-90-5P 860619-91-6P 860619-92-7P 860619-93-8P 860619-94-9P
 860619-95-0P 860619-96-1P 860619-98-3P 860620-00-4P 860620-02-6P
 860620-03-7P 860620-04-8P 860620-05-9P 860620-06-0P 860620-07-1P
 860620-08-2P 860620-09-3P 860620-10-6P 860620-11-7P 860620-12-8P
 860620-13-9P 860620-14-0P 860620-15-1P 860620-16-2P 860620-17-3P
 860620-18-4P 860620-19-5P 860620-20-8P 860620-21-9P 860620-22-0P
 860620-23-1P 860620-24-2P 860620-25-3P 860620-26-4P 860620-27-5P
 860620-28-6P 860620-29-7P 860620-30-0P 860620-31-1P 860620-32-2P
 860620-33-3P 860620-34-4P 860620-35-5P 860620-36-6P 860620-41-3P
 860620-43-5P 860620-44-6P 860620-45-7P 860620-46-8P 860620-47-9P
 860620-48-0P 860620-49-1P 860620-50-4P 860620-51-5P 860620-52-6P
 860620-53-7P 860620-70-8P 860620-75-3P 860620-76-4P 860620-77-5P
 860620-78-6P 860620-83-3P 860620-84-4P 860620-86-6P 860620-87-7P
 860620-88-8P 860620-89-9P 860621-18-7P 860621-19-8P 860621-20-1P
 860621-21-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of thiazole derivs. as modulators of the phosphoinositide
 3-kinases (PI3Ks))

IT 79-19-6, Thiosemicarbazide 103-85-5, N-Phenylthiourea 107-95-9,
 β -Alanine 109-57-9, N-Allylthiourea 109-94-4, Ethyl formate
 121-92-6, 3-Nitrobenzoic acid 123-54-6, 2,4-Pentanedione, reactions
 367-57-7, 1,1,1-Trifluoropentane-2,4-dione 621-83-0, N-Benzylthiourea
 709-72-8 1516-33-2, N-Isobutylthiourea 1516-37-6, N-(2-
 Methoxyphenyl)thiourea 1520-26-9 1520-27-0, N-(4-
 Hydroxyphenyl)thiourea 2237-30-1, 3-Aminobenzonitrile 2293-07-4,
 N-(4-Methoxyphenyl)thiourea 2295-31-0, 2,4-Thiazolidinedione
 3394-05-6, N-(3-Hydroxyphenyl)thiourea 3460-55-7, N-(4-
 Cyanophenyl)thiourea 3696-22-8, N-(4-Nitrophenyl)thiourea 3696-23-9,

N-(4-Chlorophenyl)thiourea 4947-89-1, N-(3-Chlorophenyl)thiourea
 5055-72-1, N-Cyclohexylthiourea 5100-34-5, Ethyl 3-isocyanatopropionate
 5344-82-1, N-(2-Chlorophenyl)thiourea 5657-42-1 6814-99-9,
 N-(sec-Butyl)thiourea 6815-00-5, N-(2-Phenylethyl)thiourea 7204-48-0,
 N-(tert-Butyl)thiourea 7366-56-5 14294-09-8, 1-
 Piperidinecarbothioamide 14294-10-1, 4-Morpholinecarbothioamide
 14294-11-2, N-Pyridin-2-ylthiourea 20602-45-3 25343-29-7,
 N-(2,2-Dimethylpropyl)thiourea 25433-09-4 29146-81-4 30162-37-9,
 N-Pyridin-3-ylthiourea 30162-39-1 30381-21-6, N-(2-Cyanoethyl)thiourea
 30748-47-1, 5-Acetyl-2-amino-4-methylthiazole 33860-28-5,
 4-Methylpiperazine-1-carbothioamide 37014-08-7 37182-75-5
 40398-36-5, 1-Pyrrolidinecarbothioamide 51039-84-0 52992-37-7
 55130-40-0 56541-14-1, N-Cyclopropylthiourea 61451-94-3,
 N-(2,3-Dihydro-1H-inden-2-yl)thiourea 63467-61-8, N-(2,2-
 Diethoxyethyl)thiourea 66892-01-1 66892-25-9, N-(Tetrahydrofuran-2-
 ylmethyl)thiourea 72806-58-7 73161-70-3, N-(Pyridin-3-
 ylmethyl)thiourea 73434-75-0, N-(2-Hydroxy-2-phenylethyl)thiourea
 74764-61-7 86114-63-8 99115-47-6 102353-42-4, N-(2-
 Methoxyethyl)thiourea 102936-57-2, N-Cyclopentylthiourea 111538-46-6,
 N-(3-(Morpholin-4-yl)propyl)thiourea 122641-10-5, N-(2-(Morpholin-4-
 yl)ethyl)thiourea 125117-97-7, N-(6-Chloropyridin-3-yl)thiourea
 140899-50-9 171874-49-0, N-[2-(2-Hydroxyethyl)phenyl]thiourea
 179927-28-7 196809-80-0 206761-87-7, N-(2-(Piperidin-1-
 yl)ethyl)thiourea 227932-43-6 237385-80-7, N-[3-
 (Hydroxymethyl)phenyl]thiourea 282715-65-5, N-(Pyridin-4-
 ylmethyl)thiourea 342626-46-4 420130-44-5, N-(6-Methoxypyridin-3-
 yl)thiourea 473706-96-6 473706-97-7 500865-55-4 572889-33-9,
 N-Cyclobutylthiourea 618913-44-3, N-(Cyclopropylmethyl)thiourea
 659741-74-9 659741-75-0 763887-70-3 850164-09-9,
 N-(3-Cyanophenyl)thiourea 859786-81-5 860615-45-8,
 N-(Benzofuran-5-yl)thiourea 860617-18-1, N-(2-Chloropyridin-4-
 yl)thiourea 860620-65-1 860620-66-2 860620-67-3 860620-68-4,
 3-Hydroxypyrrolidine-1-carbothioamide 860620-69-5, N-(2-Fluoropyridin-3-
 yl)thiourea 860620-71-9, N-(3,3-Diethoxypropyl)thiourea 860620-72-0,
 N-(2-Chloropyridin-3-yl)thiourea 860620-73-1, N-[3-(1,3-Oxazol-5-
 yl)phenyl]thiourea 860620-74-2, N-[3-(1H-Tetrazol-5-yl)phenyl]thiourea
 860620-79-7, N-[3-(5-Hydroxy-1,3,4-oxadiazol-2-yl)phenyl]thiourea
 860620-80-0, N-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]thiourea
 860620-91-3 860620-92-4, N-[4-(2-Hydroxyethyl)phenyl]thiourea
 860620-93-5, N-[3-[(2-Hydroxyethyl)sulfonyl]phenyl]thiourea 860620-94-6
 860620-95-7 860620-96-8 860620-97-9 860620-98-0 860620-99-1
 860621-00-7 860621-01-8 860621-02-9 860621-03-0 860621-04-1
 860621-05-2, N-(4-Hydroxybutyl)thiourea 860621-06-3 860621-07-4
 860621-08-5 860621-09-6 860621-10-9 860621-11-0 860621-12-1
 860621-13-2 860621-14-3 860621-15-4 860621-16-5 860621-17-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiazole derivs. as modulators of the phosphoinositide
 3-kinases (PI3Ks))

IT 618-95-1P, Methyl 3-nitrobenzoate 926-59-0P 3043-28-5P,
 3-Bromo-2,4-pentanedione 4138-35-6P, Methyl 3-aminopropanoate
 14062-34-1P 32519-72-5P 32519-75-8P 39884-12-3P 53159-71-0P,
 1-(2-Amino-1,3-thiazol-5-yl)ethanone 83725-80-8P, 5-(3-Nitrophenyl)-
 1,3,4-oxadiazol-2-ol 87005-15-0P 94284-63-6P, Ethyl
 5-acetyl-2-amino-1,3-thiazole-4-carboxylate 115082-05-8P 167405-28-9P,
 1-[2-Amino-4-(trifluoromethyl)-1,3-thiazol-5-yl]ethanone 191399-17-4P,
 1-(2-Amino-4-methyl-1,3-oxazol-5-yl)ethanone 299441-33-1P,
 5-(3-Aminophenyl)-1,3,4-thiadiazol-2-amine 440087-89-8P 696629-98-8P
 860615-87-8P 860620-54-8P 860620-55-9P, N-(5-Acetyl-4-methyl-1,3-
 oxazol-2-yl)acetamide 860620-56-0P 860620-57-1P, N-(5-Acetyl-1,3-
 thiazol-2-yl)acetamide 860620-58-2P 860620-59-3P, N-[5-Acetyl-4-
 (trifluoromethyl)-1,3-thiazol-2-yl]acetamide 860620-60-6P

860620-61-7P, Ethyl 5-acetyl-2-(acetylamino)-1,3-thiazole-4-carboxylate
 860620-62-8P 860620-63-9P 860620-64-0P, N-[3-(5-Amino-
 [1,3,4]thiadiazol-2-yl)phenyl]-2,2,2-trifluoro-acetamide 860620-81-1P
 860620-82-2P 860620-85-5P 860620-90-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of thiazole derivs. as modulators of the phosphoinositide
 3-kinases (PI3Ks))

L32 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 115926-52-8, PI3 kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; VEGF receptor inhibitor combination with other agents for
 therapeutic use)
 RN 115926-52-8 CAPLUS
 CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 ACCESSION NUMBER: 2005:283364 CAPLUS
 DOCUMENT NUMBER: 142:349102
 TITLE: Combinations of a VEGF receptor inhibitor with other
 agents for therapeutic use
 INVENTOR(S): Bold, Guido; Brueggen, Josef Bernhard; Huang, Jerry
 Min-Jian; Kinder, Frederick Ray; Lane, Heidi; Latour,
 Elisabeth Jeanne; Manley, Paul William; Wood, Jeanette
 Marjorie
 PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027973	A2	20050331	WO 2004-EP10701	20040923
WO 2005027973	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004273619	A1	20050331	AU 2004-273619	20040923
CA 2539230	A1	20050331	CA 2004-2539230	20040923
EP 1667721	A2	20060614	EP 2004-765555	20040923
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1856326	A	20061101	CN 2004-80027535	20040923
BR 2004014604	A	20061107	BR 2004-14604	20040923
JP 2007505939	T	20070315	JP 2006-527355	20040923
MX 2006PA03164	A	20060605	MX 2006-PA3164	20060320
PRIORITY APPLN. INFO.:			US 2003-505255P	P 20030923
			WO 2004-EP10701	W 20040923
OTHER SOURCE(S):	MARPAT	142:349102		

AN 2005:283364 CAPLUS
 DN 142:349102
 ED Entered STN: 01 Apr 2005
 TI Combinations of a VEGF receptor inhibitor with other agents for
 therapeutic use
 IN Bold, Guido; Brueggen, Josef Bernhard; Huang, Jerry Min-Jian; Kinder,
 Frederick Ray; Lane, Heidi; Latour, Elisabeth Jeanne; Manley, Paul
 William; Wood, Jeanette Marjorie
 PA Novartis Ag, Switz.; Novartis Pharma GmbH
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K045-06
 ICS A61P035-00; A61P027-00; A61P009-00; A61P003-00
 CC 1-12 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005027973	A2	20050331	WO 2004-EP10701	20040923
	WO 2005027973	A3	20050909		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, BY, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BH, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004273619	A1	20050331	AU 2004-273619	20040923
	CA 2539230	A1	20050331	CA 2004-2539230	20040923
	EP 1667721	A2	20060614	EP 2004-765555	20040923
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	CN 1856326	A	20061101	CN 2004-80027535	20040923
	BR 2004014604	A	20061107	BR 2004-14604	20040923
	JP 2007505939	T	20070315	JP 2006-527355	20040923
	MX 2006PA03164	A	20060605	MX 2006-PA3164	20060320
PRAI	US 2003-505255P	P	20030923		
	WO 2004-EP10701	W	20040923		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005027973	ICM	A61K045-06
	ICS	A61P035-00; A61P027-00; A61P009-00; A61P003-00
	IPCI	A61K0045-06 [ICM, 7]; A61K0045-00 [ICM, 7, C*]; A61P0035-00 [ICS, 7]; A61P0027-00 [ICS, 7]; A61P0009-00 [ICS, 7]; A61P0003-00 [ICS, 7]
	IPCR	A61K0045-00 [I, C*]; A61K0045-06 [I, A]; A61P0003-00 [I, C*]; A61P0003-00 [I, A]; A61P0009-00 [I, C*]; A61P0009-00 [I, A]; A61P0027-00 [I, C*]; A61P0027-00 [I, A]; A61P0035-00 [I, C*]; A61P0035-00 [I, A]
	ECLA	A61K045/06
AU 2004273619	IPCI	A61K0045-00 [I, C]; A61P0003-00 [I, C]; A61P0009-00 [I, C]; A61P0027-00 [I, C]; A61P0035-00 [I, C]; A61K0045-06 [I, A]; A61P0003-00 [I, A]; A61P0009-00 [I, A]; A61P0027-00 [I, A]; A61P0035-00 [I, A]
	IPCR	A61K0045-00 [I, C]; A61K0045-06 [I, A]; A61P0003-00

		[I,C]; A61P0003-00 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0027-00 [I,C]; A61P0027-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]
CA 2539230	IPCI	A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61P0003-00 [I,A]; A61P0009-00 [I,A]; A61P0027-00 [I,A]; A61P0035-00 [I,A]
	IPCR	A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0003-00 [I,C]; A61P0003-00 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0027-00 [I,C]; A61P0027-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]
	ECLA	A61K045/06
EP 1667721	IPCI	A61K0045-06 [ICM,7]; A61K0045-00 [ICM,7,C*]; A61P0035-00 [ICS,7]; A61P0027-00 [ICS,7]; A61P0009-00 [ICS,7]; A61P0003-00 [ICS,7]
	IPCR	A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0009-00 [I,C*]; A61P0009-00 [I,A]; A61P0027-00 [I,C*]; A61P0027-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]
	ECLA	A61K045/06
CN 1856326	IPCI	A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61P0035-00 [I,A]; A61P0027-00 [I,A]; A61P0009-00 [I,A]; A61P0003-00 [I,A]
	IPCR	A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0009-00 [I,C*]; A61P0009-00 [I,A]; A61P0027-00 [I,C*]; A61P0027-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]
	ECLA	A61K045/06
BR 2004014604	IPCI	A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61P0003-00 [ICS,7]; A61P0009-00 [ICS,7]; A61P0027-00 [ICS,7]; A61P0035-00 [ICS,7]
	IPCR	A61K0045-00 [I,C*]; A61P0003-00 [I,C*]; A61P0009-00 [I,C*]; A61P0027-00 [I,C*]; A61P0035-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,A]; A61P0009-00 [I,A]; A61P0027-00 [I,A]; A61P0035-00 [I,A]
	ECLA	A61K045/06
JP 2007505939	IPCI	A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61K0031-502 [I,A]; A61P0017-06 [I,A]; A61P0009-10 [I,A]; A61P0015-00 [I,A]; A61P0001-04 [I,A]; A61P0019-02 [I,A]; A61P0019-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,A]; A61P0009-14 [I,A]; A61P0009-00 [I,C*]; A61P0027-02 [I,A]; A61P0003-10 [I,A]; A61P0003-00 [I,C*]; A61P0027-06 [I,A]; A61P0041-00 [I,A]; A61P0027-10 [I,A]; A61P0027-00 [I,C*]; A61P0013-12 [I,A]; A61P0013-00 [I,C*]; A61P0007-02 [I,A]; A61P0007-00 [I,C*]; A61P0037-06 [I,A]; A61P0037-00 [I,C*]; A61P0001-16 [I,A]; A61P0001-00 [I,C*]; A61P0025-00 [I,A]; A61P0017-00 [I,A]; A61P0017-02 [I,A]; A61P0011-06 [I,A]; A61P0011-00 [I,A]; A61P0043-00 [I,A]; C07D0401-06 [N,A]; C07D0401-00 [N,C*]
	IPCR	A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61K0031-502 [I,C]; A61K0031-502 [I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0001-16 [I,A]; A61P0003-00 [I,C]; A61P0003-00 [I,A]; A61P0003-10 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0009-14 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C]; A61P0013-12 [I,A]; A61P0015-00 [I,C]; A61P0015-00 [I,A]; A61P0017-00 [I,C]; A61P0017-00 [I,A]; A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00

[I,C]; A61P0019-02 [I,A]; A61P0025-00 [I,C];
 A61P0025-00 [I,A]; A61P0027-00 [I,C]; A61P0027-00
 [I,A]; A61P0027-02 [I,A]; A61P0027-06 [I,A];
 A61P0027-10 [I,A]; A61P0029-00 [I,C]; A61P0029-00
 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A];
 A61P0037-00 [I,C]; A61P0037-06 [I,A]; A61P0041-00
 [I,C]; A61P0041-00 [I,A]; A61P0043-00 [I,C];
 A61P0043-00 [I,A]; C07D0401-00 [N,C]; C07D0401-06 [N,A]
 FTERM 4C063/AA01; 4C063/BB03; 4C063/CC28; 4C063/DD12;
 4C063/EE01; 4C084/AA19; 4C084/AA20; 4C084/MA02;
 4C084/NA05; 4C084/NA14; 4C084/ZA011; 4C084/ZA331;
 4C084/ZA361; 4C084/ZA441; 4C084/ZA451; 4C084/ZA541;
 4C084/ZA591; 4C084/ZA661; 4C084/ZA681; 4C084/ZA751;
 4C084/ZA811; 4C084/ZA891; 4C084/ZA961; 4C084/ZB071;
 4C084/ZB081; 4C084/ZB111; 4C084/ZB151; 4C084/ZB261;
 4C084/ZC021; 4C084/ZC351; 4C084/ZC751; 4C086/AA01;
 4C086/AA02; 4C086/BC41; 4C086/MA02; 4C086/MA04;
 4C086/NA05; 4C086/NA14; 4C086/ZA01; 4C086/ZA33;
 4C086/ZA36; 4C086/ZA44; 4C086/ZA45; 4C086/ZA54;
 4C086/ZA59; 4C086/ZA66; 4C086/ZA68; 4C086/ZA75;
 4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB07;
 4C086/ZB08; 4C086/ZB11; 4C086/ZB15; 4C086/ZB26;
 4C086/ZC02; 4C086/ZC35; 4C086/ZC75
 MX 2006PA03164 IPCI A61K0045-06 [ICM,7]; A61K0045-00 [ICM,7,C*];
 A61P0027-00 [ICS,7]; A61P0003-00 [ICS,7]; A61P0035-00
 [ICS,7]; A61P0009-00 [ICS,7]
 ECLA A61K045/06
 OS MARPAT 142:349102
 AB The invention discloses a combination therapy for treating
 patients suffering from diseases characterized by cell proliferation and
 infiltration of inflammatory cells, coronary diseases, hypertension, renal
 diseases, diabetes, or ocular diseases and conditions. The patient is
 treated with a combination of a VEGF inhibitor compound and one or more
 second therapeutic agents selected from angiostatic steroids,
 photosensitizers, implants containing corticosteroids, AT1 receptor
 antagonists, ACE inhibitors, cyclooxygenase inhibitors, IGF-IR inhibitors,
 mTOR kinase inhibitors, somatostatin receptor antagonists, P13K
 inhibitors, Raf kinase inhibitors, PKC inhibitors; xiii. integrin
 antagonists, endogenous anti-angiogenic mols., and PEDF (pigment
 epithelium-derived factor) and analogs.
 ST VEGF receptor inhibitor combination therapeutic; cell proliferation
 inflammatory cell infiltration VEGF receptor inhibitor combination;
 coronary renal disease hypertension VEGF receptor inhibitor combination
 therapeutic; diabetes eye disease VEGF receptor inhibitor combination
 therapeutic
 IT Inflammation
 (Crohn's disease; VEGF receptor inhibitor combination with other agents
 for therapeutic use)
 IT Intestine, disease
 (Crohn's; VEGF receptor inhibitor combination with other agents for
 therapeutic use)
 IT Angiogenesis inhibitors
 Anti-inflammatory agents
 Anti-ischemic agents
 Antiarteriosclerotics
 Antiarthritics
 Antiasthmatics
 Anticoagulants
 Antidiabetic agents
 Antiglaucoma agents
 Antihypertensives

- Antirheumatic agents
- Antitumor agents
- Arteriosclerosis
- Arthritis
- Asthma
- Cardiovascular agents
- Cell proliferation
- Cirrhosis
- Combination chemotherapy
- Cytotoxic agents
- Diabetes mellitus
- Drug delivery systems
- Eye, disease
- Fibrosis
- Gastrointestinal agents
 - Heart, disease
- Human
- Hypertension
- Immunosuppressants
- Inflammation
- Kidney, disease
- Nervous system agents
- Photosensitizers, pharmaceutical
- Prophylaxis
- Rheumatoid arthritis
- Thrombosis
- Transplant rejection
- Wound
- Wound healing promoters

- (VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Vascular endothelial growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Corticosteroids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Aging, animal
 (age spots; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, neoplasm
 (angiofibroma; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Steroids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (angiostatic; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angiotensin AT1 receptors
 Integrins
 Somatostatin receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel
 (artificial; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Bronchi, disease

Inflammation
(chronic bronchitis; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Dermatitis
(contact; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Transplant and Transplantation
(cornea, after-effects; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye
(cornea, neovascularization; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye
(cornea, transplant, after-effects; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease
(cystoid macular edema; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease
(diabetic macular edema; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney, disease
(diabetic nephropathy; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease
(diabetic retinopathy; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Uterus, disease
(endometriosis; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Inflammation
Kidney, disease
(glomerulonephritis; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney, disease
(glomerulus; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, neoplasm
(hemangioma; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Drug delivery systems
(implants, corticosteroid-containing; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Insulin-like growth factor I receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Nerve, disease
(injury; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye
(iris, neovascularization; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Ischemia
(ischemic retinopathy; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Transplant and Transplantation
(kidney; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease
(macula, senile degeneration; VEGF receptor inhibitor combination with

other agents for therapeutic use)

IT Eye, disease
(macular edema; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Medical goods
(mech. devices for holding vessels open; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney
(mesangium, proliferative disease; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, disease
(microangiopathy, thrombotic microangiopathic syndrome; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Vision disorders
(myopia, pathol.; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Glaucoma (disease)
(neovascular; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angiogenesis
(neovascularization, ocular; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angiogenesis
(neovascularization, retinal; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney, disease
(nephrosclerosis, malignant; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Injury
(neuronal; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Vein, disease
(occlusion, central vein occlusion; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, disease
(occlusion, re-occlusion after balloon catheter treatment; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Histoplasma capsulatum
(ocular; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Disease, animal
(proliferative; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angioplasty
(re-occlusion after; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Artery, disease
(restenosis, stent-induced; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease
(retina, neovascularization; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease
(retinopathy, ischemic; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease
(retrolental fibroplasia; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Wound healing
(scar-free; VEGF receptor inhibitor combination with other agents for

therapeutic use)

IT Medical goods
(stents, restenosis induced by; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney
(transplant; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT 127464-60-2, VEGF 386705-49-3, Vascular endothelial growth factor receptor kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VEGF receptor inhibitor combination with other agents for therapeutic use)

IT 50-02-2, Dexamethasone 124-94-7, Triamcinolone 807-38-5, Fluocinolone 7753-60-8, Anecortave 83150-76-9, Octreotide 86541-75-5, Benazepril 129497-78-5, BPD-MA 137862-53-4, Valsartan 159351-69-6, Everolimus 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 197980-93-1, Pigment epithelium-derived factor 197980-93-1D, Pigment epithelium-derived factor, analogs 212141-54-3 220991-20-8, Lumiracoxib 396091-73-9, SOM230
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(VEGF receptor inhibitor combination with other agents for therapeutic use)


IT 9015-82-1 39391-18-9, Cyclooxygenase 103843-29-4, IGF-1 receptor tyrosine kinase 115926-52-8, PI3 kinase 139691-76-2, Raf kinase 141436-78-4, Protein kinase C 171715-28-9, MTOR kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; VEGF receptor inhibitor combination with other agents for therapeutic use)

L32 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 39755-95-8, 5-Methoxy isatin
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

RN 39755-95-8 CAPLUS

CN 1H-Indole-2,3-dione, 5-methoxy- (CA INDEX NAME)



ACCESSION NUMBER: 2005:238947 CAPLUS

DOCUMENT NUMBER: 142:316831

TITLE: Preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors for the treatment of inflammatory diseases

INVENTOR(S): Boman, Erik; Ceide, Susana C.; Dahl, Russell; Delaet, Nancy G. J.; Ernst, Justin; Montalban, Antonio G.; Kahl, Jeffrey D.; Larson, Christopher; Miller, Stephen; Nakanishi, Hiroshi; Roberts, Edward; Saiah, Eddine; Sullivan, Robert; Wang, Zhijun

PATENT ASSIGNEE(S): Kemia, Inc., USA

SOURCE: PCT Int. Appl., 316 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023761	A2	20050317	WO 2004-US29372	20040910
WO 2005023761	A3	20050714		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004270733	A1	20050317	AU 2004-270733	20040910
CA 2538820	A1	20050317	CA 2004-2538820	20040910
US 20050107399	A1	20050519	US 2004-939324	20040910
EP 1670787	A2	20060621	EP 2004-809707	20040910
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004014313	A	20061107	BR 2004-14313	20040910
CN 1878769	A	20061213	CN 2004-80033055	20040910
JP 2007505127	T	20070308	JP 2006-526272	20040910
KR 2007020370	A	20070221	KR 2006-705055	20060310
MX 2006PA02853	A	20060614	MX 2006-PA2853	20060313
IN 2006KN00791	A	20080215	IN 2006-KN791	20060331
PRIORITY APPLN. INFO.:			US 2003-502569P	P 20030911
			US 2003-531234P	P 20031218
			US 2004-575704P	P 20040528
			US 2004-585012P	P 20040702
			WO 2004-US29372	W 20040910

OTHER SOURCE(S): CASREACT 142:316831; MARPAT 142:316831

AN 2005:238947 CAPLUS

DN 142:316831

ED Entered STN: 18 Mar 2005

TI Preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors for the treatment of inflammatory diseases

IN Boman, Erik; Ceide, Susana C.; Dahl, Russell; Delaet, Nancy G. J.; Ernst, Justin; Montalban, Antonio G.; Kahl, Jeffrey D.; Larson, Christopher; Miller, Stephen; Nakanishi, Hiroshi; Roberts, Edward; Saiah, Eddine; Sullivan, Robert; Wang, Zhijun

PA Kemia, Inc., USA

SO PCT Int. Appl., 316 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005023761	A2	20050317	WO 2004-US29372	20040910
WO 2005023761	A3	20050714		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,			

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

AU 2004270733	A1	20050317	AU 2004-270733	20040910
CA 2538820	A1	20050317	CA 2004-2538820	20040910
US 20050107399	A1	20050519	US 2004-939324	20040910
EP 1670787	A2	20060621	EP 2004-809707	20040910
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004014313	A	20061107	BR 2004-14313	20040910
CN 1878769	A	20061213	CN 2004-80033055	20040910
JP 2007505127	T	20070308	JP 2006-526272	20040910
KR 2007020370	A	20070221	KR 2006-705055	20060310
MX 2006PA02853	A	20060614	MX 2006-PA2853	20060313
IN 2006KN00791	A	20080215	IN 2006-KN791	20060331
PRAI US 2003-502569P	P	20030911		
US 2003-531234P	P	20031218		
US 2004-575704P	P	20040528		
US 2004-585012P	P	20040702		
WO 2004-US29372	W	20040910		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005023761	ICM	C07D
	IPCI	C07D [ICM, 7]
	IPCR	A61K0031-416 [I,C*]; A61K0031-416 [I,A]; C07D [I,S]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]
AU 2004270733	IPCI	C07D0403-00 [I,C*]; A61K0031-416 [I,C*]; C07D0403-12 [I,A]; A61K0031-416 [I,A]
	IPCR	C07D0403-00 [I,C*]; C07D0403-12 [I,A]; A61K0031-416 [I,C*]; A61K0031-416 [I,A]; C07D [I,S]
CA 2538820	IPCI	A61K0031-416 [I,A]; C07D0403-12 [I,A]; C07D0403-00 [I,C*]
	IPCR	C07D0403-00 [I,C]; C07D0403-12 [I,A]; A61K0031-416 [I,C]; A61K0031-416 [I,A]; C07D [I,S]
US 20050107399	IPCI	A61K0031-4965 [ICM, 7]
	IPCR	A61K0031-4965 [I,C*]; A61K0031-4965 [I,A]
	NCL	514/255.060; 514/356.000; 514/617.000
EP 1670787	IPCI	C07D0403-12 [ICM, 7]; C07D0403-00 [ICM, 7,C*]; A61K0031-416 [ICS, 7]
	IPCR	A61K0031-416 [I,C*]; A61K0031-416 [I,A]; C07D [I,S]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]
BR 2004014313	IPCI	C07D0403-12 [ICS, 7]; C07D0403-00 [ICS, 7,C*]; A61K0031-416 [ICS, 7]
	IPCR	A61K0031-416 [I,C*]; C07D0403-00 [I,C*]; A61K0031-416 [I,A]; C07D0403-12 [I,A]
CN 1878769	IPCI	C07D0403-12 [I,A]; C07D0403-00 [I,C*]; A61K0031-416 [I,A]
	IPCR	C07D0403-00 [I,C]; C07D0403-12 [I,A]
JP 2007505127	IPCI	C07D0207-40 [I,A]; C07D0207-00 [I,C*]; C07D0231-38 [I,A]; C07D0231-00 [I,C*]; C07D0239-47 [I,A]; C07D0239-00 [I,C*]; C07D0249-12 [I,A]; C07D0249-00 [I,C*]; C07D0253-06 [I,A]; C07D0253-00 [I,C*]; C07D0295-08 [I,A]; C07D0295-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-00 [I,C*]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]; A61K0031-415 [I,A]; A61K0031-437

[I,A]; A61K0031-4353 [I,C*]; A61K0031-5375 [I,A];
A61K0031-5377 [I,A]; A61P0001-02 [I,A]; A61P0001-04
[I,A]; A61P0001-14 [I,A]; A61P0001-18 [I,A];
A61P0001-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04
[I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];
A61P0005-48 [I,A]; A61P0005-00 [I,C*]; A61P0007-00
[I,A]; A61P0007-02 [I,A]; A61P0009-00 [I,A];
A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0009-14
[I,A]; A61P0011-00 [I,A]; A61P0011-02 [I,A];
A61P0011-06 [I,A]; A61P0011-10 [I,A]; A61P0013-02
[I,A]; A61P0013-12 [I,A]; A61P0013-00 [I,C*];
A61P0015-00 [I,A]; A61P0017-00 [I,A]; A61P0017-02
[I,A]; A61P0017-06 [I,A]; A61P0017-10 [I,A];
A61P0019-02 [I,A]; A61P0019-06 [I,A]; A61P0019-10
[I,A]; A61P0019-00 [I,C*]; A61P0021-00 [I,A];
A61P0025-00 [I,A]; A61P0025-04 [I,A]; A61P0025-08
[I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A];
A61P0025-18 [I,A]; A61P0025-22 [I,A]; A61P0025-24
[I,A]; A61P0025-28 [I,A]; A61P0025-30 [I,A];
A61P0027-02 [I,A]; A61P0027-06 [I,A]; A61P0027-14
[I,A]; A61P0027-00 [I,C*]; A61P0029-00 [I,A];
A61P0031-04 [I,A]; A61P0031-08 [I,A]; A61P0031-12
[I,A]; A61P0031-18 [I,A]; A61P0031-00 [I,C*];
A61P0033-06 [I,A]; A61P0033-00 [I,C*]; A61P0035-00
[I,A]; A61P0037-00 [I,A]; A61P0037-02 [I,A];
A61P0039-00 [I,A]; A61P0043-00 [I,A]
IPCR C07D0207-00 [I,C]; C07D0207-40 [I,A]; A61K0031-415
[I,C]; A61K0031-415 [I,A]; A61K0031-416 [I,C*];
A61K0031-416 [I,A]; A61K0031-4353 [I,C]; A61K0031-437
[I,A]; A61K0031-5375 [I,C]; A61K0031-5375 [I,A];
A61K0031-5377 [I,A]; A61P0001-00 [I,C]; A61P0001-02
[I,A]; A61P0001-04 [I,A]; A61P0001-14 [I,A];
A61P0001-18 [I,A]; A61P0003-00 [I,C]; A61P0003-00
[I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A];
A61P0003-10 [I,A]; A61P0005-00 [I,C]; A61P0005-48
[I,A]; A61P0007-00 [I,C]; A61P0007-00 [I,A];
A61P0007-02 [I,A]; A61P0009-00 [I,C]; A61P0009-00
[I,A]; A61P0009-04 [I,A]; A61P0009-10 [I,A];
A61P0009-14 [I,A]; A61P0011-00 [I,C]; A61P0011-00
[I,A]; A61P0011-02 [I,A]; A61P0011-06 [I,A];
A61P0011-10 [I,A]; A61P0013-00 [I,C]; A61P0013-02
[I,A]; A61P0013-12 [I,A]; A61P0015-00 [I,C];
A61P0015-00 [I,A]; A61P0017-00 [I,C]; A61P0017-00
[I,A]; A61P0017-02 [I,A]; A61P0017-06 [I,A];
A61P0017-10 [I,A]; A61P0019-00 [I,C]; A61P0019-02
[I,A]; A61P0019-06 [I,A]; A61P0019-10 [I,A];
A61P0021-00 [I,C]; A61P0021-00 [I,A]; A61P0025-00
[I,C]; A61P0025-00 [I,A]; A61P0025-04 [I,A];
A61P0025-08 [I,A]; A61P0025-14 [I,A]; A61P0025-16
[I,A]; A61P0025-18 [I,A]; A61P0025-22 [I,A];
A61P0025-24 [I,A]; A61P0025-28 [I,A]; A61P0025-30
[I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A];
A61P0027-06 [I,A]; A61P0027-14 [I,A]; A61P0029-00
[I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C];
A61P0031-04 [I,A]; A61P0031-08 [I,A]; A61P0031-12
[I,A]; A61P0031-18 [I,A]; A61P0033-00 [I,C];
A61P0033-06 [I,A]; A61P0035-00 [I,C]; A61P0035-00
[I,A]; A61P0037-00 [I,C]; A61P0037-00 [I,A];
A61P0037-02 [I,A]; A61P0039-00 [I,C]; A61P0039-00
[I,A]; A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D
[I,S]; C07D0231-00 [I,C]; C07D0231-38 [I,A];

C07D0239-00 [I,C]; C07D0239-47 [I,A]; C07D0249-00 [I,C]; C07D0249-12 [I,A]; C07D0253-00 [I,C]; C07D0253-06 [I,A]; C07D0295-00 [I,C]; C07D0295-08 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A]; C07D0487-00 [I,C]; C07D0487-04 [I,A]

FTERM 4C050/AA01; 4C050/BB05; 4C050/CC05; 4C050/EE04; 4C050/FF02; 4C050/FF05; 4C050/GG01; 4C050/HH04; 4C065/AA04; 4C065/BB06; 4C065/CC01; 4C065/DD03; 4C065/EE02; 4C065/HH01; 4C065/JJ07; 4C065/KK09; 4C065/LL04; 4C065/PP03; 4C065/PP04; 4C069/AC32; 4C069/BB08; 4C069/BB16; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BC36; 4C086/BC73; 4C086/CB03; 4C086/CB05; 4C086/GA07; 4C086/GA12; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA02; 4C086/ZA06; 4C086/ZA08; 4C086/ZA12; 4C086/ZA16; 4C086/ZA18; 4C086/ZA21; 4C086/ZA22; 4C086/ZA29; 4C086/ZA33; 4C086/ZA34; 4C086/ZA36; 4C086/ZA44; 4C086/ZA45; 4C086/ZA51; 4C086/ZA54; 4C086/ZA59; 4C086/ZA63; 4C086/ZA66; 4C086/ZA68; 4C086/ZA69; 4C086/ZA70; 4C086/ZA75; 4C086/ZA81; 4C086/ZA89; 4C086/ZA94; 4C086/ZA96; 4C086/ZA97; 4C086/ZB01; 4C086/ZB07; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB21; 4C086/ZB26; 4C086/ZB33; 4C086/ZB35; 4C086/ZB37; 4C086/ZC01; 4C086/ZC31; 4C086/ZC33; 4C086/ZC35; 4C086/ZC37; 4C086/ZC39; 4C086/ZC41; 4C086/ZC54; 4C086/ZC55




KR 2007020370 IPCI A61K0031-416 [I,A]; C07D0403-12 [I,A]; C07D0403-00 [I,C*]; A61K0031-4965 [I,A]

MX 2006PA02853 IPCI A61K0031-416 [ICM,7]; C07D0403-12 [ICS,7]; C07D0403-00 [ICS,7,C*]

IN 2006KN00791 IPCI C07D0403-12 [ICM,7]; C07D0403-00 [ICM,7,C*]; A61K0031-416 [ICS,7]

OS CASREACT 142:316831; MARPAT 142:316831

GI



AB Title compds., such as I and II (four Markush structures are claimed), wherein X = C(O), C(S) or CH₂; G = (un)substituted carbocyclyl or heterocyclyl; Ar = indazolyl, indolyl, pyrazolyl, alkyl, etc.; L = covalent bond or (un)substituted carbon chain; Q = H, (un)substituted amino, cycloalkyl, heterocyclyl, alkoxy or sulfonyl; with some limitations and exclusions, and stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, were prepared as cytokine inhibitors. For instance, cyclization of p-tolylhydrazine hydrochloride with 4,4-dimethyl-3-oxopentanenitrile to the corresponding pyrazolamine

(92% yield) followed by EDC-mediated coupling with indazole-3-carboxylic acid gave indazolopyrazole III (40% yield). I were found to have activity in the TNF α ELISA assay, with some compds. having IC₅₀ < 10 μ M. Therefore, I and their pharmaceutical compns. are useful in preventing or treating conditions mediated by cytokines, such as arthritis and inflammatory diseases.

- ST pyrazolamine aniline amide prepn cytokine TNF inhibitor antiinflammatory agent
- IT AIDS (disease)
 - (AIDS dementia complex, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Mental and behavioral disorders
 - (AIDS dementia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Lymph node, disease
 - (Castleman's, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Inflammation
 - (Crohn's disease, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Intestine, disease
 - (Crohn's, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Selectins
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (E-, compns. comprising of inhibitors of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Brain, disease
 - (Gilles de la Tourette syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Nervous system, disease
 - (Guillain-Barre syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Nervous system, disease
 - (Huntington's chorea, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Brain, disease
 - (MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes), treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Muscle, disease
 - (MERRF (myoclonic epilepsy associated with ragged-red muscle fibers), treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Arthritis
 - (Reiter's syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Brain, disease
 - (Rett syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Anti-infective agents
 - (SARS; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Pain
 - (acute, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Respiratory distress syndrome
 - (adult, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)
- IT Allergy

Eye, disease
 Inflammation
 (allergic conjunctivitis, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Allergy
 Inflammation
 Nose, disease
 (allergic rhinitis, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Transplant rejection
 (allotransplant; preparation of amides of pyrazolamines and anilines as well
 as analogs as cytokine inhibitors)

IT Nervous system, disease
 (amyotrophic lateral sclerosis, treatment of; preparation of
 amides of pyrazolamines and anilines as well as analogs as cytokine
 inhibitors)

IT Nervous system agents
 (amyotrophic lateral sclerosis; preparation of amides of pyrazolamines and
 anilines as well as analogs as cytokine inhibitors)

IT Antiarteriosclerotics
 (antiatherosclerotics; preparation of amides of pyrazolamines and anilines
 as well as analogs as cytokine inhibitors)

IT Artery, disease
 Inflammation
 (arteritis, Takayasu, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Disease, animal
 (arthropathy, bursitis, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Animal tissue
 (artificial, phantom, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Infection
 (aseptic meningitis, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Meningitis
 (aseptic, treatment of; preparation of amides of pyrazolamines and
 anilines as well as analogs as cytokine inhibitors)

IT Dermatitis
 (atopic, treatment of; preparation of amides of pyrazolamines and
 anilines as well as analogs as cytokine inhibitors)

IT Meningitis
 (bacterial, treatment of; preparation of amides of pyrazolamines
 and anilines as well as analogs as cytokine inhibitors)

IT Bronchi, disease
 Inflammation
 (bronchitis, treatment of; preparation of amides of pyrazolamines
 and anilines as well as analogs as cytokine inhibitors)

IT Medical goods
 (cannulas; preparation of amides of pyrazolamines and anilines as well as
 analogs as cytokine inhibitors)

IT Ischemia
 (cardiac, treatment of; preparation of amides of pyrazolamines and
 anilines as well as analogs as cytokine inhibitors)

IT Heart, disease
 (cardiomyopathy, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation
 (carditis, treatment of; preparation of amides of pyrazolamines
 and anilines as well as analogs as cytokine inhibitors)

IT Lung, disease

(chronic obstructive pulmonary disease, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation
Lung, disease
(chronic pneumonitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Pain
(chronic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Headache
(cluster, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Intestine, neoplasm
(colon, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Adhesion, biological
(compsns. comprising of inhibitors; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Angiogenesis inhibitors
Anticoagulants
Cytotoxic agents
Immunomodulators
Immunosuppressants
(compsns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT CTLA-4 (antigen)
Glucocorticoids
Interleukin 1 receptor antagonist
LFA-1 (antigen)
Macrolides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compsns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Dermatitis
(contact, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Artery, disease
(coronary, occlusion, acute, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Artery, disease
(coronary, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Ulcer
(cutaneous, varicose ulcers, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease
(decreased cardiac output, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Muscle, disease
(degeneration, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nerve, disease
(demyelination, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Mental and behavioral disorders
(depression, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Kidney, disease

(diabetic nephropathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease
(diabetic retinopathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lung, disease
(diminished lung compliance, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Toxins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diphtheria, DAB389, compns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Joint, anatomical
(disease, bursitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Viscera
(disease, pain, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Tendon
(disease, tendinitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Tendon
(disease, tenosynovitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Platelet (blood)
(disease, thrombocytopenia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Blood coagulation disorders
(disseminated intravascular coagulation, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Thrombosis
(during pregnancy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lung, disease
(embolism, massive, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lung, disease
(embolism, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Uterus, disease
(endometriosis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease
Kidney, disease
(failure, chronic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease
(failure, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Muscle, disease
(fibromyalgia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Kidney, disease
(fibrosis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Meningitis
(fulminant meningococemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation

Kidney, disease
 (glomerulonephritis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Transplant and Transplantation
 (graft-vs.-host reaction; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Brain, disease
 (hepatic encephalopathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease
 (hereditary optic atrophy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inborn errors of metabolism
 (homocysteinuria, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Metabolic disorders
 (hydroxybutyric aminoaciduria, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inborn errors of metabolism
 (hyperhomocysteinuria, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Metabolic disorders
 (hyperprolinemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Mucus
 (hypersecretion, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease
 (infarction, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Arthritis
 (infectious, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Respiratory system, disease
 (inflammation, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Intestine, disease
 (inflammatory, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease
 (injury, laser induced, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Reperfusion
 Spinal cord, disease
 (injury, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Spinal column, disease
 (intervertebral disk syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Intestine, disease
 (irritable bowel syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease
 (ischemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Brain, disease
(lead, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Infection
(leishmaniasis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Headache
(migraine, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease

Inflammation
(myocarditis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Skin, disease
(necrosis, hemorrhagic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nerve, disease

Pain
(neuralgia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation

Nerve, disease
(neuritis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nerve, disease
(neuropathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lymphoma
(nodular, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lymphoma
(non-Hodgkin's, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation
(non-articular, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Metabolic disorders
(nonketotic hyperglycinemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Anti-inflammatory agents
(nonsteroidal, compns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Artery, disease
(occlusion, acute peripheral, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Injury
(ocular, laser induced, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Pain
(osteo-traumatic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation

Pancreas, disease
(pancreatitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease
(periretinal proliferation, trauma-induced, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nerve, disease
 (polyneuropathy, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Allergy inhibitors

Analgesics

Anti-AIDS agents

Anti-Alzheimer's agents

Anti-inflammatory agents

Antiarthritics

Antiasthmatics

Anticonvulsants

Antidepressants

Antidiabetic agents

Antiglaucoma agents

Antimalarials

Antimigraine agents

Antiobesity agents

Antiparkinsonian agents

Antipsychotics

Antirheumatic agents

Antitumor agents

Anxiolytics

Drug tolerance

Fibrinolytics

Hematopoietic precursor cell

Human

Parturition

Rheumatoid arthritis

Surgery

Vascular resistance
 (preparation of amides of pyrazolamines and anilines as well as analogs as
 cytokine inhibitors)

IT Arthritis
 (psoriatic arthritis, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Embolism
 (pulmonary, massive, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Embolism
 (pulmonary, treatment of; preparation of amides of pyrazolamines
 and anilines as well as analogs as cytokine inhibitors)

IT Nervous system, disease
 (reflex sympathetic dystrophy, treatment of; preparation of amides
 of pyrazolamines and anilines as well as analogs as cytokine
 inhibitors)

IT Fibrosis
 (renal, treatment of; preparation of amides of pyrazolamines and
 anilines as well as analogs as cytokine inhibitors)

IT Injury
 (reperfusion, treatment of; preparation of amides of pyrazolamines
 and anilines as well as analogs as cytokine inhibitors)

IT Bone, disease
 (resorption, treatment of; preparation of amides of pyrazolamines
 and anilines as well as analogs as cytokine inhibitors)

IT Inflammation
 (respiratory tract, treatment of; preparation of amides of
 pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Artery, disease
 (restenosis, treatment of; preparation of amides of pyrazolamines
 and anilines as well as analogs as cytokine inhibitors)

IT Cardiovascular agents

(restenosis; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease
(retinal ischemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Ischemia
(retinal, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Disease, animal
(sciatica, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Necrosis
(skin, hemorrhagic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Injury
(spinal cord, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nervous system, disease
(spinocerebellar ataxia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Arthritis
(spondylarthritis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation
Spinal column, disease
(spondylitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Brain, disease
(stroke, acute thrombotic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Brain, disease
(stroke, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Arthritis
Synovial membrane, disease
(synovitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lupus erythematosus
(systemic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation
(tendinitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation
(tenosynovitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Blood, disease
(thrombocytopenia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Shock (circulatory collapse)
(toxic shock syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Central nervous system, disease
Injury
(trauma, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Arthritis
(traumatic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Hepatitis C virus

Human immunodeficiency virus
(treatment of infection from; preparation of amides of
pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT AIDS (disease)

Acne

Acute myeloid leukemia

Alcoholism

Alzheimer's disease

Aneurysm

Angiogenesis

Anorexia

Anxiety

Asthma

Atherosclerosis

Blood coagulation

Bulimia

Cachexia

Convulsion

Diabetes insipidus

Diabetes mellitus

Drug dependence

Drug resistance

Eczema

Emphysema

Endotoxemia

Epilepsy

Familial hypercholesterolemia

Fibrinolytic disorders

Glaucoma (disease)

Gout

Hypercholesterolemia

Hypotension

Infection

Leprosy

Leukocytopenia

Lung, neoplasm

Lyme disease

Malaria

Mammary gland, neoplasm

Multiple myeloma

Multiple sclerosis

Musculoskeletal diseases

Myelodysplastic syndromes

Neoplasm

Obesity

Osteoarthritis

Osteoporosis

Pain

Parkinson's disease

Prostate gland, neoplasm

Psoriasis

Rubella

Schizophrenia

Seizures

Sepsis

Silicosis

Thrombosis

Thrombus

Wernicke-Korsakoff syndrome
(treatment of; preparation of amides of pyrazolamines and anilines
as well as analogs as cytokine inhibitors)

IT Skin, disease
 (ulcer, varicose ulcers, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation
 Intestine, disease
 (ulcerative colitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Eye, disease
 Inflammation
 (uveitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease
 (valve, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Blood vessel, disease
 Inflammation
 (vasculitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Liver, disease
 (venoocclusive, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Thrombosis
 (venous, axillary, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Thrombosis
 (venous, massive iliofemoral, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Thrombosis
 (venous, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Disease, animal
 (visceral pain, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Pain
 (visceral, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Interferons
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (α , compns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 80449-02-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (compns. comprising of inhibitors of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 127464-60-2, VEGF
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (compns. comprising of inhibitors; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 50-02-2, Dexamethasone 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-35-1, Thalidomide 50-78-2, Aspirin 52-67-5, D-Penicillamine 53-86-1, Indomethacin 54-21-7, Sodium salicylate 58-32-2, Dipyridamole 59-05-2, Methotrexate 61-68-7, Mefenamic acid 67-73-2, Fluocinolone acetonide 67-97-0, Vitamin D3 76-25-5, Triamcinolone acetonide 77-86-1, Tromethamine 80-08-0, Dapsone 83-43-2, Methylprednisolone 89-57-6, 5-ASA 91-64-5, Coumarin 103-90-2, Acetaminophen 118-42-3, Hydroxychloroquine 127-07-1, Hydroxyurea 154-42-7, 6-Thioguanine 305-03-3, Chlorambucil 356-12-7, Fluocinonide 378-44-9, Betamethasone 446-86-6, Azathioprine 552-94-3, Salsalate 599-79-1, Sulfasalazine 2016-36-6, Choline salicylate 2607-06-9, Diflucortolone 3615-24-5, Ramifenazone

5104-49-4, Flurbiprofen 6385-02-0, Meclofenamate sodium 6493-05-6
 9002-01-1, Streptokinase 9005-49-6, Heparin, biological studies
 9039-53-6, Urokinase 10118-90-8, Minocycline 12244-57-4, Gold sodium
 thiomalate 14484-47-0, Deflazacort 15307-86-5, Diclofenac
 15687-27-1, Ibuprofen 18917-89-0, Magnesium salicylate 21256-18-8,
 Oxaprozin 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4,
 Diflunisal 23187-87-3, Choline magnesium salicylate 26171-23-3,
 Tolmetin 31441-78-8, Mercaptopurine 31842-01-0, Indoprofen
 32222-06-3, 1 α ,25-Dihydroxyvitamin D3 33005-95-7, Tiaprofenic acid
 33069-62-4, Taxol 34031-32-8, Auranofin 34597-40-5, Fenoprofen calcium
 36322-90-4, Piroxicam 38194-50-2, Sulindac 41340-25-4, Etodolac
 42924-53-8, Nabumetone 51333-22-3, Budesonide 51803-78-2, Nimesulide
 53123-88-9, Sirolimus 53716-49-7, Carprofen 54063-32-0, Clobetasone
 55142-85-3, Ticlopidine 57333-96-7, Tacalcitol 59865-13-3,
 Cyclosporine A 63798-73-2, Cyclosporine 70374-27-5, Lomoxicam
 70374-39-9, Lornoxicam 71125-38-7, Meloxicam 74103-06-3, Ketorolac
 75706-12-6, Leflunomide 80937-31-1, Flosulide 82657-92-9, Pro-UK
 87653-67-6, Aggrenox 90566-53-3, Fluticasone 98651-66-2, Halobetasol
 103370-86-1, Parathyroid hormone-related peptide 103909-75-7,
 Maxacalcitol 104987-11-3, Tacrolimus 104987-12-4, Ascomycin
 105102-22-5, Mometasone 105913-11-9, Plasminogen activator
 106362-32-7, Peptide T 112965-21-6, Calcipotriol 113665-84-2,
 Clopidogrel 128794-94-5, Mycophenolate mofetil 137071-32-0,
 Pimecrolimus 143090-92-0, Anakinra 143653-53-6, Abciximab
 144494-65-5, Aggrestat 145155-23-3, Interferon beta-1B 152923-56-3,
 Daclizumab 162011-90-7, Rofecoxib 169590-42-5, Celecoxib
 170277-31-3, Infliximab 173146-27-5, DAB389 IL-2 179045-86-4,
 Basiliximab 181695-72-7, Valdecoxib 185243-69-0, Etanercept
 188627-80-7, Integrilin 202409-33-4, Etoricoxib 214745-43-4,
 Efalizumab 222535-22-0, Alefacept 331731-18-1, Adalimumab
 679809-58-6, Enoxaparin sodium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. comprising of; preparation of amides of pyrazolamines and anilines
 as well as analogs as cytokine inhibitors)

IT 9029-38-3, Sulfite oxidase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (deficiency, treatment of; preparation of amides of pyrazolamines
 and anilines as well as analogs as cytokine inhibitors)

IT 848144-15-0P 848144-45-6P 848144-49-0P 848144-84-3P 848144-85-4P
 848145-00-6P 848145-02-8P 848150-50-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (inhibitor; preparation of amides of pyrazolamines and anilines as well as
 analogs as cytokine inhibitors)

IT 105438-50-4P 763089-51-6P 848144-05-8P 848144-09-2P 848144-12-7P
 848144-14-9P 848144-21-8P 848144-26-3P 848144-31-0P 848144-32-1P
 848144-34-3P 848144-35-4P 848144-39-8P 848144-42-3P 848144-47-8P
 848144-48-9P 848144-50-3P 848144-64-9P 848144-77-4P 848144-78-5P
 848144-89-8P 848144-90-1P 848144-91-2P 848144-92-3P 848144-94-5P
 848144-96-7P 848144-98-9P 848145-01-7P 848145-05-1P 848145-07-3P
 848145-08-4P 848145-09-5P 848145-10-8P 848145-11-9P 848145-12-0P
 848145-13-1P 848145-14-2P 848145-15-3P 848145-16-4P 848145-17-5P
 848145-18-6P 848145-19-7P 848145-20-0P 848145-21-1P 848145-22-2P
 848145-23-3P 848145-24-4P 848145-25-5P 848145-26-6P 848145-27-7P
 848145-28-8P 848145-29-9P 848145-30-2P 848145-31-3P 848145-32-4P
 848145-33-5P 848145-34-6P 848145-35-7P 848145-36-8P 848145-37-9P
 848145-38-0P 848145-39-1P 848145-40-4P 848145-41-5P 848145-42-6P
 848145-43-7P 848145-44-8P 848145-45-9P 848145-46-0P 848145-47-1P
 848145-48-2P 848145-49-3P 848145-50-6P 848145-51-7P 848145-52-8P
 848145-53-9P 848145-54-0P 848145-55-1P 848145-56-2P 848145-57-3P

848145-58-4P	848145-59-5P	848145-60-8P	848145-61-9P	848145-62-0P
848145-63-1P	848145-64-2P	848145-65-3P	848145-66-4P	848145-67-5P
848145-68-6P	848145-69-7P	848145-71-1P	848145-72-2P	848145-73-3P
848145-74-4P	848145-75-5P	848145-76-6P	848145-77-7P	848145-78-8P
848145-79-9P	848145-80-2P	848145-81-3P	848145-82-4P	848145-83-5P
848145-84-6P	848145-85-7P	848145-86-8P	848145-87-9P	848145-88-0P
848145-89-1P	848145-90-4P	848145-91-5P	848145-92-6P	848145-93-7P
848145-94-8P	848145-95-9P	848145-96-0P	848145-97-1P	848145-98-2P
848145-99-3P	848146-00-9P	848146-01-0P	848146-02-1P	848146-03-2P
848146-04-3P	848146-05-4P	848146-06-5P	848146-07-6P	848146-08-7P
848146-09-8P	848146-10-1P	848146-11-2P	848146-12-3P	848146-13-4P
848146-14-5P	848146-15-6P	848146-16-7P	848146-17-8P	848146-18-9P
848146-19-0P	848146-20-3P	848146-21-4P	848146-22-5P	848146-23-6P
848146-24-7P	848146-25-8P	848146-26-9P	848146-27-0P	848146-28-1P
848146-29-2P	848146-30-5P	848146-31-6P	848146-32-7P	848146-33-8P
848146-34-9P	848146-35-0P	848146-36-1P	848146-37-2P	848146-38-3P
848146-39-4P	848146-40-7P	848146-41-8P	848146-42-9P	848146-43-0P
848146-44-1P	848146-45-2P	848146-46-3P	848146-47-4P	848146-48-5P
848146-49-6P	848146-50-9P	848146-51-0P	848146-52-1P	848146-53-2P
848146-54-3P	848146-55-4P	848146-56-5P	848146-57-6P	848146-58-7P
848146-59-8P	848146-60-1P	848146-61-2P	848146-62-3P	848146-63-4P
848146-64-5P	848146-65-6P	848146-66-7P	848146-67-8P	848146-68-9P
848146-69-0P	848146-70-3P	848146-71-4P	848146-72-5P	848146-73-6P
848146-75-8P	848146-77-0P	848146-79-2P	848146-81-6P	848146-82-7P
848146-83-8P	848146-84-9P	848146-85-0P	848146-86-1P	848146-87-2P
848146-88-3P	848146-89-4P	848146-90-7P	848146-91-8P	848146-92-9P
848146-93-0P	848146-94-1P	848146-95-2P	848146-96-3P	848146-97-4P
848146-98-5P	848146-99-6P	848147-00-2P	848147-01-3P	848147-02-4P
848147-03-5P	848147-04-6P	848147-05-7P	848147-06-8P	848147-07-9P
848147-08-0P	848147-09-1P	848147-10-4P	848147-11-5P	848147-12-6P
848147-13-7P	848147-14-8P	848147-15-9P	848147-16-0P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(inhibitor; preparation of amides of pyrazolamines and anilines as well as
analogs as cytokine inhibitors)

IT	848147-17-1P	848147-18-2P	848147-19-3P	848147-20-6P	848147-21-7P
	848147-22-8P	848147-23-9P	848147-24-0P	848147-25-1P	848147-26-2P
	848147-27-3P	848147-28-4P	848147-29-5P	848147-30-8P	848147-31-9P
	848147-32-0P	848147-33-1P	848147-34-2P	848147-35-3P	848147-36-4P
	848147-37-5P	848147-38-6P	848147-39-7P	848147-40-0P	848147-41-1P
	848147-42-2P	848147-43-3P	848147-44-4P	848147-45-5P	848147-46-6P
	848147-47-7P	848147-48-8P	848147-49-9P	848147-50-2P	848147-51-3P
	848147-52-4P	848147-53-5P	848147-54-6P	848147-55-7P	848147-56-8P
	848147-57-9P	848147-58-0P	848147-59-1P	848147-60-4P	848147-61-5P
	848147-62-6P	848147-63-7P	848147-64-8P	848147-65-9P	848147-66-0P
	848147-67-1P	848147-68-2P	848147-69-3P	848147-70-6P	848147-71-7P
	848147-72-8P	848147-73-9P	848147-74-0P	848147-75-1P	848147-76-2P
	848147-77-3P	848147-78-4P	848147-79-5P	848147-80-8P	848147-81-9P
	848147-82-0P	848147-83-1P	848147-84-2P	848147-85-3P	848147-86-4P
	848147-87-5P	848147-88-6P	848147-89-7P	848147-90-0P	848147-91-1P
	848147-92-2P	848147-93-3P	848147-94-4P	848147-95-5P	848147-96-6P
	848147-97-7P	848147-99-9P	848148-00-5P	848148-01-6P	848148-02-7P
	848148-03-8P	848148-04-9P	848148-05-0P	848148-06-1P	848148-07-2P
	848148-08-3P	848148-09-4P	848148-10-7P	848148-11-8P	848148-12-9P
	848148-13-0P	848148-14-1P	848148-15-2P	848148-16-3P	848148-17-4P
	848148-18-5P	848148-19-6P	848148-20-9P	848148-21-0P	848148-22-1P
	848148-23-2P	848148-24-3P	848148-25-4P	848148-26-5P	848148-27-6P
	848148-28-7P	848148-29-8P	848148-30-1P	848148-31-2P	848148-32-3P
	848148-33-4P	848148-34-5P	848148-35-6P	848148-36-7P	848148-37-8P
	848148-38-9P	848148-39-0P	848148-40-3P	848148-41-4P	848148-42-5P

848148-43-6P	848148-44-7P	848148-45-8P	848148-46-9P	848148-47-0P
848148-48-1P	848148-49-2P	848148-50-5P	848148-51-6P	848148-52-7P
848148-53-8P	848148-54-9P	848148-55-0P	848148-56-1P	848148-57-2P
848148-58-3P	848148-59-4P	848148-60-7P	848148-61-8P	848148-62-9P
848148-63-0P	848148-64-1P	848148-65-2P	848148-66-3P	848148-67-4P
848148-68-5P	848148-69-6P	848148-70-9P	848148-71-0P	848148-72-1P
848148-73-2P	848148-74-3P	848148-75-4P	848148-76-5P	848148-77-6P
848148-78-7P	848148-79-8P	848148-80-1P	848148-81-2P	848148-82-3P
848148-83-4P	848148-84-5P	848148-85-6P	848148-86-7P	848148-87-8P
848148-88-9P	848148-89-0P	848148-91-4P	848148-92-5P	848148-93-6P
848148-94-7P	848148-95-8P	848148-96-9P	848148-97-0P	848148-98-1P
848148-99-2P	848149-00-8P	848149-01-9P	848149-02-0P	848149-03-1P
848149-04-2P	848149-05-3P	848149-06-4P	848149-07-5P	848149-08-6P
848149-09-7P	848149-10-0P	848149-11-1P	848149-12-2P	848149-13-3P
848149-14-4P	848149-15-5P	848149-16-6P	848149-17-7P	848149-18-8P
848149-19-9P	848149-20-2P	848149-21-3P	848149-22-4P	848149-23-5P
848149-24-6P	848149-25-7P	848149-26-8P	848149-27-9P	848149-28-0P
848149-29-1P	848149-30-4P	848149-31-5P	848149-32-6P	848149-33-7P
848149-34-8P	848149-35-9P	848149-36-0P	848149-37-1P	848149-38-2P
848149-39-3P	848149-40-6P	848149-42-8P	848149-44-0P	848149-46-2P
848149-48-4P	848149-50-8P	848149-51-9P	848149-52-0P	848149-53-1P
848149-55-3P	848149-56-4P	848149-57-5P	848149-58-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT	848149-59-7P	848149-60-0P	848149-61-1P	848149-62-2P	848149-63-3P
	848149-64-4P	848149-65-5P	848149-66-6P	848149-67-7P	848149-68-8P
	848149-69-9P	848149-70-2P	848149-71-3P	848149-72-4P	848149-73-5P
	848149-74-6P	848149-75-7P	848149-76-8P	848149-77-9P	848149-78-0P
	848149-79-1P	848149-80-4P	848149-81-5P	848149-82-6P	848149-83-7P
	848149-84-8P	848149-85-9P	848149-86-0P	848149-87-1P	848149-88-2P
	848149-89-3P	848149-90-6P	848149-91-7P	848149-92-8P	848149-93-9P
	848149-94-0P	848149-95-1P	848149-96-2P	848149-97-3P	848149-98-4P
	848149-99-5P	848150-00-5P	848150-01-6P	848150-02-7P	848150-03-8P
	848150-04-9P	848150-05-0P	848150-06-1P	848150-07-2P	848150-08-3P
	848150-09-4P	848150-10-7P	848150-11-8P	848150-12-9P	848150-13-0P
	848150-14-1P	848150-15-2P	848150-16-3P	848150-17-4P	848150-18-5P
	848150-19-6P	848150-20-9P	848150-21-0P	848150-22-1P	848150-23-2P
	848150-24-3P	848150-25-4P	848150-26-5P	848150-27-6P	848150-28-7P
	848150-29-8P	848150-30-1P	848150-31-2P	848150-32-3P	848150-33-4P
	848150-34-5P	848150-35-6P	848150-36-7P	848150-37-8P	848150-38-9P
	848150-39-0P	848150-40-3P	848150-41-4P	848150-42-5P	848150-43-6P
	848150-44-7P	848150-45-8P	848150-46-9P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT	848150-47-0P
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT	9004-10-8, Insulin, biological studies
----	--

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(insulinitis; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT	3993-78-0P, 4-Chloro-2-pyrimidinamine	848144-76-3P	848144-86-5P
	RL: BYP (Byproduct); PREP (Preparation)		

(preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 62-53-3, Aniline, reactions 90-11-9, 1-Bromonaphthalene 90-15-3, 1-Naphthalenol 98-09-9, Benzenesulfonyl chloride 98-27-1, 4-tert-Butyl-2-methylphenol 98-54-4, 4-tert-Butylphenol 106-49-0, (p-Methylphenyl)amine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 134-32-7, 1-Naphthylamine 135-19-3, 2-Hydroxynaphthalene, reactions 444-30-4, 2-Trifluoromethylphenol 637-60-5, p-Tolylhydrazine hydrochloride 765-30-0, Cyclopropylamine 1774-47-6, Trimethylsulfoxonium iodide 2534-77-2, exo-2-Bromonorbornane 2605-67-6 3240-94-6, 4-(2-Chloroethyl)morpholine 3279-07-0, 4-tert-Butyl-2-nitrophenol 3647-69-6, N-(2-Chloroethyl)morpholine hydrochloride 3934-20-1, 2,4-Dichloropyrimidine 4114-31-2, Ethyl hydrazinecarboxylate 4498-67-3, Indazole-3-carboxylic acid 5369-19-7, 3-tert-Butylaniline 5720-05-8, (p-Methylphenyl)boronic acid 5781-53-3, Methyl chloroglyoxylate 7677-24-9, Trimethylsilyl cyanide 7770-45-8, 4-Hydroxy-1-naphthaldehyde 16013-85-7, 2,6-Dichloro-3-nitropyridine 16640-68-9, (Triphenylphosphoranylidene)acetonitrile 23056-36-2, 2-Chloro-4-nitropyridine 23894-12-4, 6-Amino-1-naphthalenol 26867-21-0 36082-50-5, 5-Bromo-2,4-dichloropyrimidine 39755-95-8, 5-Methoxy isatin 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 73469-54-2, 5-tert-Butyl-2-methoxybenzoic acid 74124-79-1 82560-12-1, (5-tert-Butyl-1H-pyrazol-3-yl)amine 83405-70-3 88139-91-7, (5-Bromopyridin-2-yl)methanol 118430-73-2 175137-04-9 285984-25-0 285984-50-1 306937-27-9, 3-tert-Butylphenylhydrazine hydrochloride 317806-90-9 473269-70-4, 5-tert-Butyl-2-methoxybenzene-1,3-diamine 725686-47-5 848144-33-2 848144-81-0, 2,6-Dichloro-3-nitropyrimidine 848144-88-7 848144-99-0 855304-89-1 929011-97-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT 98-28-2P, 4-tert-Butyl-2-chlorophenol 7461-50-9P, 2-Chloro-4-pyrimidinamine 14593-28-3P, 4-tert-Butyl-2-chloro-6-nitrophenol 18215-94-6P, [2-(Morpholin-4-yl)pyrimidin-4-yl]amine 20294-44-4P, 4-tert-Butyl-2-methyl-6-nitrophenol 21660-76-4P, N-Naphthalen-1-yloxalamic acid 26867-13-0P 32569-82-7P 33353-61-6P 33353-66-1P 35980-77-9P, [2-(Morpholin-4-yl)pyridin-4-yl]amine 55304-16-0P 57477-80-2P, 4-tert-Butyl-2-trifluoromethylphenol 90417-53-1P, 5-Methoxy-1H-indazole-3-carboxylic acid 157130-34-2P 254751-07-0P 294851-95-9P, 4-(5-Bromopyridin-2-ylmethyl)morpholine 294851-97-1P 404010-35-1P, N-(3-Amino-5-tert-butyl-2-methoxyphenyl)methanesulfonamide 848144-06-9P 848144-07-0P 848144-08-1P 848144-10-5P 848144-11-6P 848144-13-8P 848144-16-1P 848144-17-2P 848144-18-3P 848144-19-4P 848144-20-7P 848144-22-9P 848144-23-0P 848144-24-1P 848144-25-2P 848144-27-4P, 4-(4-Nitropyridin-2-yl)morpholine 848144-28-5P 848144-29-6P 848144-30-9P 848144-36-5P 848144-37-6P 848144-38-7P 848144-40-1P 848144-41-2P 848144-43-4P 848144-44-5P 848144-46-7P 848144-51-4P 848144-52-5P 848144-54-7P 848144-56-9P 848144-59-2P 848144-61-6P 848144-68-3P 848144-69-4P 848144-70-7P 848144-71-8P, 6-(Boc-amino)naphthalen-1-ol 848144-72-9P 848144-73-0P 848144-74-1P 848144-75-2P 848144-79-6P 848144-80-9P 848144-82-1P 848144-83-2P 848144-87-6P 848144-93-4P 848144-95-6P 848144-97-8P 848145-03-9P 848145-04-0P 848145-06-2P 848150-48-1P 848150-49-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

L32 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

ACCESSION NUMBER: 2005:120737 CAPLUS

DOCUMENT NUMBER: 142:219270

TITLE: Preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors
INVENTOR(S): Rueckle, Thomas; Shaw, Jeffrey; Church, Denis; Covini, David

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011686	A1	20050210	WO 2004-EP51625	20040727
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004260836	A1	20050210	AU 2004-260836	20040727
CA 2531140	A1	20050210	CA 2004-2531140	20040727
EP 1648452	A1	20060426	EP 2004-766335	20040727
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007500171	T	20070111	JP 2006-521581	20040727
US 20070021447	A1	20070125	US 2004-565976	20040727
NO 2006000573	A	20060203	NO 2006-573	20060203
PRIORITY APPLN. INFO.:			EP 2003-102313	A 20030728
			WO 2004-EP51625	W 20040727

OTHER SOURCE(S): CASREACT 142:219270; MARPAT 142:219270

AN 2005:120737 CAPLUS

DN 142:219270

ED Entered STN: 11 Feb 2005

TI Preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors

IN Rueckle, Thomas; Shaw, Jeffrey; Church, Denis; Covini, David

PA Applied Research Systems Ars Holding N.V., Neth.

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-427

ICS A61P037-00; A61P029-00; C07D417-06; C07D417-14

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005011686	A1	20050210	WO 2004-EP51625	20040727
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004260836	A1	20050210	AU 2004-260836	20040727
	CA 2531140	A1	20050210	CA 2004-2531140	20040727
	EP 1648452	A1	20060426	EP 2004-766335	20040727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007500171	T	20070111	JP 2006-521581	20040727
	US 20070021447	A1	20070125	US 2004-565976	20040727
	NO 2006000573	A	20060203	NO 2006-573	20060203
PRAI	EP 2003-102313	A	20030728		
	WO 2004-EP51625	W	20040727		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005011686	ICM	A61K031-427
	ICS	A61P037-00; A61P029-00; C07D417-06; C07D417-14
	IPCI	A61K0031-427 [ICM,7]; A61P0037-00 [ICS,7]; A61P0029-00 [ICS,7]; C07D0417-06 [ICS,7]; C07D0417-14 [ICS,7]; C07D0417-00 [ICS,7,C*]
	IPCR	A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-00 [I,A]; C07D0417-00 [I,C*]; C07D0417-06 [I,A]; C07D0417-14 [I,A]
	ECLA	C07D417/06+277B+215; C07D417/06+277B+239; C07D417/06+277B+241; C07D417/06+317+277B; C07D417/14+317+277B+213; C07D417/14+317+277B+215; C07D417/14+317+277B+231; C07D417/14+333B+277B+215; C07D417/14+333B+317+277B
AU 2004260836	IPCI	A61K0031-427 [I,C]; A61P0029-00 [I,C]; A61P0037-00 [I,C]; C07D0417-00 [I,C]; A61K0031-427 [I,A]; A61P0029-00 [I,A]; A61P0037-00 [I,A]; C07D0417-06 [I,A]; C07D0417-14 [I,A]
	IPCR	A61K0031-427 [I,A]; A61K0031-427 [I,C]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0037-00 [I,C]; A61P0037-00 [I,A]; C07D0417-00 [I,C]; C07D0417-06 [I,A]; C07D0417-14 [I,A]
CA 2531140	IPCI	A61K0031-427 [I,A]; A61P0029-00 [I,A]; A61P0037-00 [I,A]; C07D0417-06 [I,A]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]
	IPCR	A61K0031-427 [I,A]; A61K0031-427 [I,C]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0037-00 [I,C]; A61P0037-00 [I,A]; C07D0417-00 [I,C]; C07D0417-06 [I,A]; C07D0417-14 [I,A]
	ECLA	C07D417/06+277B+215; C07D417/06+277B+239; C07D417/06+277B+241; C07D417/06+317+277B; C07D417/14+317+277B+213; C07D417/14+317+277B+215; C07D417/14+317+277B+231; C07D417/14+333B+277B+215; C07D417/14+333B+317+277B
EP 1648452	IPCI	A61K0031-427 [ICM,7]; A61P0037-00 [ICS,7]; A61P0029-00

		[ICS,7]; C07D0417-06 [ICS,7]; C07D0417-14 [ICS,7]; C07D0417-00 [ICS,7,C*]
JP 2007500171	IPCI	C07D0417-06 [I,A]; A61K0031-427 [I,A]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4709 [I,A]; A61K0031-498 [I,A]; A61K0031-517 [I,A]; A61P0037-06 [I,A]; A61P0037-00 [I,C*]; A61P0029-00 [I,A]; A61P0009-00 [I,A]; A61P0025-00 [I,A]; A61P0007-02 [I,A]; A61P0007-00 [I,C*]; A61P0035-00 [I,A]; A61P0011-00 [I,A]; C07B0061-00 [N,A]
	IPCR	C07D0417-00 [I,C]; C07D0417-06 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A]; A61K0031-517 [I,C]; A61K0031-517 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; A61P0037-00 [I,C]; A61P0037-00 [I,A]; A61P0037-06 [I,A]; C07B0061-00 [N,C]; C07B0061-00 [N,A]; C07D0417-14 [I,A]
	FTERM	4C063/AA01; 4C063/AA03; 4C063/BB03; 4C063/BB08; 4C063/CC81; 4C063/CC92; 4C063/DD14; 4C063/DD31; 4C063/DD34; 4C063/DD62; 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/BC82; 4C086/GA02; 4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA10; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA02; 4C086/ZA36; 4C086/ZA54; 4C086/ZA59; 4C086/ZB08; 4C086/ZB11; 4C086/ZB26; 4H039/CA80; 4H039/CD20
US 20070021447	IPCI	A61K0031-517 [I,A]; A61K0031-4709 [I,A]; A61K0031-427 [I,A]; A61K0031-422 [I,A]; A61K0031-4178 [I,A]; A61K0031-4164 [I,C*]; C07D0417-02 [I,A]; C07D0417-00 [I,C*]; C07D0413-02 [I,A]; C07D0413-00 [I,C*]
	NCL	514/266.230; 514/317.000; 514/369.000; 514/376.000; 514/388.000; 544/284.000; 546/159.000; 548/181.000; 548/225.000; 548/311.100
	ECLA	C07D417/06+277B+215; C07D417/06+277B+239; C07D417/06+277B+241; C07D417/06+317+277B; C07D417/14+317+277B+213; C07D417/14+317+277B+215; C07D417/14+317+277B+231; C07D417/14+333B+277B+215; C07D417/14+333B+317+277B
NO 2006000573	IPCI	C07D0413-00 [I,C]; A61K0031-427 [I,C]; C07D0413-06 [I,A]; A61K0031-427 [I,A]
	IPCR	C07D0413-00 [I,C]; C07D0413-06 [I,A]; A61K0031-427 [I,C]; A61K0031-427 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-00 [I,A]; C07D0417-00 [I,C*]; C07D0417-06 [I,A]; C07D0417-14 [I,A]
	ECLA	C07D417/06+277B+215; C07D417/06+277B+239; C07D417/06+277B+241; C07D417/06+317+277B; C07D417/14+317+277B+213; C07D417/14+317+277B+215; C07D417/14+317+277B+231; C07D417/14+333B+277B+215; C07D417/14+333B+317+277B
OS	CASREACT 142:219270; MARPAT 142:219270	
GI		



- AB The title compds. I [A = 5-8 membered heterocyclic or carbocyclic group which may be fused with an aryl, heteroaryl, cycloalkyl or heterocycloalkyl; X = S, O, NR₃, Y = S, O; R₁ = H, CN, CO₂H, acyl, etc.; R₂ = H, halo, acyl, NH₂, etc.; G = alkoxy, alkyl, CN, etc.; R₃ = H, alkyl; with provisos], useful in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries, were prepared and formulated. Thus, reacting 5-benzo[1,3]dioxol-5-ylmethylene-2-iminothiazolidin-4-one (preparation given) with 2-chlorobenzenesulfonyl chloride afforded 17% II. The tested compds. I showed IC₅₀ of < 10 μM with regard to PI3Kγ.
- ST iminothioxopolycyclovinyllazoline prepn PI3 kinase inhibitor; thiazolidine benzodioxolylmethylene quinoxalinyllmethylene quinolinyllmethylene prepn PI3 kinase inhibitor
- IT Nervous system, disease
(Huntington's chorea, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Sarcoma
(Kaposi's, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Antiarteriosclerotics
(antiatherosclerotics; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Muscle, disease
(atrophy, treating skeletal muscle atrophy/hypertrophy; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Muscle
(cardiac, treating cardiac myocyte dysfunction; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Hypertrophy
(cardiac, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Lung, disease
(chronic obstructive pulmonary disease, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)
- IT Nervous system, disease
(degeneration, treating; preparation of 2-imino-4-(thio)oxo-5-

polycyclovinyllazolines as PI3 kinase inhibitors)

IT Kidney, disease
(fibrosis, treating progressive renal fibrosis; preparation of
2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Inflammation
Kidney, disease
(glomerulonephritis, treating; preparation of 2-imino-4-(thio)oxo-
5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Kidney, disease
(glomerulosclerosis, treating; preparation of 2-imino-4-(thio)oxo-
5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Muscle, disease
(hypertrophy, treating skeletal muscle atrophy/hypertrophy;
preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase
inhibitors)

IT Heart, disease
(hypertrophy, treating; preparation of 2-imino-4-(thio)oxo-5-
polycyclovinyllazolines as PI3 kinase inhibitors)

IT Intestine, disease
(inflammatory, treating; preparation of 2-imino-4-(thio)oxo-5-
polycyclovinyllazolines as PI3 kinase inhibitors)

IT Lung, disease
Reperfusion
(injury, treating; preparation of 2-imino-4-(thio)oxo-5-
polycyclovinyllazolines as PI3 kinase inhibitors)

IT Leukocyte
(leukocyte recruitment in cancer tissue; preparation of 2-imino-4-(thio)oxo-
5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Neoplasm
(metastasis, treating; preparation of 2-imino-4-(thio)oxo-5-
polycyclovinyllazolines as PI3 kinase inhibitors)

IT Hypertrophy
(muscular, treating skeletal muscle atrophy/hypertrophy;
preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase
inhibitors)

IT Heart
(myocardium, treating cardiac myocyte dysfunction; preparation of
2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Inflammation
Lung, disease
(pneumonitis, treatment; preparation of 2-imino-4-(thio)oxo-5-
polycyclovinyllazolines as PI3 kinase inhibitors)

IT Allergy inhibitors
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Anticoagulants
Antihypertensives
Antirheumatic agents
Antitumor agents
Cardiovascular agents
Human
Immunomodulators
Immunosuppressants
Nervous system agents
Platelet aggregation inhibitors
(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase
inhibitors)

IT Injury

(pulmonary, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Fibrosis
(renal, treating progressive renal fibrosis; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Injury
(reperfusion, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Brain, disease
(stroke, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Lupus erythematosus
(systemic, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Central nervous system, disease
(trauma, treating CNS trauma; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Brain, disease
Encephalitis
Meningitis
(treating brain infection/inflammation; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT Allergy
Alzheimer's disease
Anaphylaxis
Angiogenesis
Asthma
Atherosclerosis
Autoimmune disease
Cardiovascular system, disease
Hypertension
Inflammation
Ischemia
Kidney, disease
Melanoma
Multiple sclerosis
Neoplasm
Platelet aggregation
Psoriasis
Rheumatoid arthritis
Sepsis
Thrombosis
Transplant rejection
(treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT 115926-52-8, PI3 kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT 843641-13-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT 176529-68-3P 326093-91-8P 419552-35-5P 843641-09-8P 843641-10-1P
843641-11-2P 843641-12-3P 843641-14-5P 843641-15-6P 843641-16-7P
843641-17-8P 843641-18-9P 843641-19-0P 843641-20-3P 843641-21-4P
843641-22-5P 843641-23-6P 843641-24-7P 843641-25-8P 843641-26-9P
843641-27-0P 843641-28-1P 843641-29-2P 843641-30-5P 888948-67-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT 100-46-9, Benzylamine, reactions 120-57-0, Piperonal 656-42-8, 2,2-Difluoro-1,3-benzodioxole-5-carboxaldehyde 2688-90-6, [1,1'-Biphenyl]-2-sulfonyl chloride 2905-23-9, 2-Chlorobenzenesulfonyl chloride 3113-71-1, 3-Methyl-4-nitrobenzoic acid 4113-04-6, 6-Quinolinecarboxaldehyde 130345-50-5, 6-Quinoxalinecarboxaldehyde 412311-41-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

IT 4315-09-7P 28824-66-0P 33890-03-8P 33986-75-3P 152536-17-9P 152536-21-5P 300829-97-4P 304645-61-2P 648449-05-2P 648449-06-3P 648449-09-6P 648449-81-4P 648450-30-0P 719286-35-8P 843641-32-7P 843641-33-8P 843641-34-9P 843641-35-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyllazolines as PI3 kinase inhibitors)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Fujimoto Pharmaceutical Co Ltd; EP 0697410 A 1996 CAPLUS

(2) Roue, N; TETRAHEDRON 1999, V55(51), P14729 CAPLUS

L32 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 91-56-5, Isatin

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of vasculostatic agents and methods of use)

RN 91-56-5 CAPLUS

CN 1H-Indole-2,3-dione (CA INDEX NAME)



ACCESSION NUMBER: 2004:308364 CAPLUS

DOCUMENT NUMBER: 140:321386

TITLE: Preparation of vasculostatic agents and methods of use

INVENTOR(S): Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor; Noronha, Glenn; Hood, John D.; Dneprovskaja, Elena; Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning

PATENT ASSIGNEE(S): Targen, Inc., USA

SOURCE: PCT Int. Appl., 230 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030635	A2	20040415	WO 2003-US31721	20031002
WO 2004030635	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2500727 A1 20040415 CA 2003-2500727 20031002
 AU 2003282726 A1 20040423 AU 2003-282726 20031002
 EP 1549614 A2 20050706 EP 2003-774610 20031002
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003015053 A 20050809 BR 2003-15053 20031002
 CN 1720224 A 20060111 CN 2003-80104711 20031002
 JP 2006515317 T 20060525 JP 2005-500378 20031002
 IN 2005DN01020 A 20070316 IN 2005-DN1020 20050316
 ZA 2005002328 A 20060927 ZA 2005-2328 20050318
 MX 2005PA03477 A 20050722 MX 2005-PA3477 20050401

PRIORITY APPLN. INFO.:

US 2002-415981P P 20021003
 US 2003-440234P P 20030114
 US 2003-443752P P 20030129
 US 2003-463818P P 20030417
 US 2003-466983P P 20030430
 US 2003-479295P P 20030617
 WO 2003-US31721 W 20031002

OTHER SOURCE(S): MARPAT 140:321386

AN 2004:308364 CAPLUS
 DN 140:321386
 ED Entered STN: 15 Apr 2004
 TI Preparation of vasculostatic agents and methods of use
 IN Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor; Noronha, Glenn; Hood,
 John D.; Dneprovskaja, Elena; Gong, Xianchang; Splittgerber, Ute; Zhao,
 Ningning
 PA Targegen, Inc., USA
 SO PCT Int. Appl., 230 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030635	A2	20040415	WO 2003-US31721	20031002
WO 2004030635	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500727	A1	20040415	CA 2003-2500727	20031002
AU 2003282726	A1	20040423	AU 2003-282726	20031002
EP 1549614	A2	20050706	EP 2003-774610	20031002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
BR	2003015053	A	20050809
CN	1720224	A	20060111
JP	2006515317	T	20060525
IN	2005DN01020	A	20070316
ZA	2005002328	A	20060927
MX	2005PA03477	A	20050722
PRAI	US 2002-415981P	P	20021003
	US 2003-440234P	P	20030114
	US 2003-443752P	P	20030129
	US 2003-463818P	P	20030417
	US 2003-466983P	P	20030430
	US 2003-479295P	P	20030617
	WO 2003-US31721	W	20031002

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004030635	ICM	A61K
	IPCI	A61K [ICM]
	IPCR	A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*]; A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00 [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90; C07D239/95; C07D241/42; C07D253/08C; C07D401/12; C07D403/12; C07D405/04; C07D405/12; C07D471/04+241B+221B; C07D487/04+241B+239B; C07D519/00+487/00+487/00; M07D; M07D
CA 2500727	IPCI	C07D0209-04 [ICM,7]; C07D0209-00 [ICM,7,C*]; A61K0031-404 [ICS,7]; A61K0031-403 [ICS,7,C*]; A61K0031-495 [ICS,7]
	IPCR	A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*]; A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00 [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90; C07D239/95; C07D241/42; C07D253/08C; C07D401/12; C07D403/12; C07D405/04; C07D405/12; C07D471/04+241B+221B; C07D487/04+241B+239B; C07D519/00+487/00+487/00
AU 2003282726	IPCI	C07D0209-04 [ICM,7]; C07D0209-00 [ICM,7,C*]; A61K0031-404 [ICS,7]; A61K0031-403 [ICS,7,C*]; A61K0031-495 [ICS,7]

EP 1549614	IPCR	A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*]; A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00 [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	IPCI	C07D0209-04 [ICM,7]; C07D0209-00 [ICM,7,C*]; A61K0031-404 [ICS,7]; A61K0031-403 [ICS,7,C*]; A61K0031-495 [ICS,7]
	IPCR	C07D0209-00 [I,C]; C07D0209-14 [I,A]; A61K0031-403 [I,C]; A61K0031-404 [I,A]; A61K0031-405 [I,A]; A61K0031-495 [I,C]; A61K0031-495 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*]; A61K0031-724 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00 [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
BR 2003015053	ECLA	C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90; C07D239/95; C07D241/42; C07D253/08C; C07D401/12; C07D403/12; C07D405/04; C07D405/12; C07D471/04+241B+221B; C07D487/04+241B+239B; C07D519/00+487/00+487/00; M07D; M07D
	IPCI	C07D0209-04 [ICM,7]; C07D0209-00 [ICM,7,C*]; A61K0031-404 [ICS,7]; A61K0031-403 [ICS,7,C*]; A61K0031-495 [ICS,7]
	IPCR	A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*]; A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A]; C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A]; C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00 [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
CN 1720224	ECLA	C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90; C07D239/95; C07D241/42; C07D253/08C; C07D401/12; C07D403/12; C07D405/04; C07D405/12; C07D471/04+241B+221B; C07D487/04+241B+239B; C07D519/00+487/00+487/00
	IPCI	C07D0209-04 [I,A]; C07D0209-00 [I,C*]; A61K0031-404 [I,A]; A61K0031-403 [I,C*]; A61K0031-495 [I,A]
	IPCR	C07D0209-00 [I,C]; C07D0209-04 [I,A]
JP 2006515317	IPCI	C07D0209-14 [I,A]; A61K0031-404 [I,A]; A61K0031-403

[I,C*]; C07D0209-48 [I,A]; C07D0209-00 [I,C*];
 A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; C07D0475-08
 [I,A]; C07D0519-00 [I,A]; C07D0471-04 [I,A];
 C07D0471-00 [I,C*]; A61K0031-4985 [I,A]; C07D0253-08
 [I,A]; C07D0253-00 [I,C*]; A61K0031-53 [I,A];
 C07D0487-04 [I,A]; C07D0487-00 [I,C*]; C07D0475-02
 [I,A]; C07D0475-06 [I,A]; C07D0475-00 [I,C*];
 A61K0031-519 [I,A]; C07D0241-44 [I,A]; C07D0241-00
 [I,C*]; A61K0031-498 [I,A]; A61P0009-00 [I,A];
 A61P0009-10 [I,A]; A61P0035-00 [I,A]; A61P0019-02
 [I,A]; A61P0019-00 [I,C*]; A61P0027-02 [I,A];
 A61P0027-00 [I,C*]; A61P0037-06 [I,A]; A61P0037-00
 [I,C*]; A61P0029-00 [I,A]; A61P0017-02 [I,A];
 A61P0017-00 [I,C*]; A61P0011-00 [I,A]; A61P0043-00
 [I,A]; A61K0031-704 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-337 [I,A]; A61K0038-00 [I,A]; A61K0039-395
 [I,A]; A61K0031-661 [I,A]; C07D0405-04 [I,A];
 A61J0001-05 [I,A]; A61J0003-00 [I,A]; A61K0031-5377
 [I,A]; A61K0031-5375 [I,C*]; C07D0405-12 [I,A];
 C07D0405-00 [I,C*]
 IPCR C07D0209-00 [I,C]; C07D0209-14 [I,A]; A61J0001-05
 [I,C]; A61J0001-05 [I,A]; A61J0003-00 [I,C];
 A61J0003-00 [I,A]; A61K0031-337 [I,C]; A61K0031-337
 [I,A]; A61K0031-403 [I,C]; A61K0031-404 [I,A];
 A61K0031-405 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439
 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A];
 A61K0031-4985 [I,C]; A61K0031-4985 [I,A]; A61K0031-519
 [I,C]; A61K0031-519 [I,A]; A61K0031-525 [I,A];
 A61K0031-53 [I,C]; A61K0031-53 [I,A]; A61K0031-5375
 [I,C]; A61K0031-5377 [I,A]; A61K0031-661 [I,C];
 A61K0031-661 [I,A]; A61K0031-7028 [I,C]; A61K0031-704
 [I,A]; A61K0031-716 [I,C*]; A61K0031-724 [I,A];
 A61K0038-00 [I,C]; A61K0038-00 [I,A]; A61K0039-395
 [I,C]; A61K0039-395 [I,A]; A61P0009-00 [I,C];
 A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0011-00
 [I,C]; A61P0011-00 [I,A]; A61P0017-00 [I,C];
 A61P0017-02 [I,A]; A61P0019-00 [I,C]; A61P0019-02
 [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A];
 A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0035-00
 [I,C]; A61P0035-00 [I,A]; A61P0037-00 [I,C];
 A61P0037-06 [I,A]; A61P0043-00 [I,C]; A61P0043-00
 [I,A]; C07D0209-02 [I,A]; C07D0209-04 [I,A];
 C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
 [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
 C07D0241-00 [I,C]; C07D0241-42 [I,A]; C07D0241-44
 [I,A]; C07D0253-00 [I,C]; C07D0253-08 [I,A];
 C07D0253-10 [I,A]; C07D0401-00 [I,C*]; C07D0401-12
 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A];
 C07D0405-00 [I,C]; C07D0405-04 [I,A]; C07D0405-12
 [I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A];
 C07D0475-00 [I,C]; C07D0475-02 [I,A]; C07D0475-06
 [I,A]; C07D0475-08 [I,A]; C07D0487-00 [I,C];
 C07D0487-04 [I,A]; C07D0519-00 [I,C]; C07D0519-00 [I,A]
 FTERM 4C050/AA01; 4C050/BB08; 4C050/CC12; 4C050/EE04;
 4C050/FF05; 4C050/GG04; 4C050/HH01; 4C063/AA01;
 4C063/BB01; 4C063/BB09; 4C063/CC12; 4C063/CC76;
 4C063/CC81; 4C063/DD06; 4C063/DD44; 4C063/EE01;
 4C065/AA04; 4C065/BB12; 4C065/CC01; 4C065/DD03;
 4C065/EE02; 4C065/HH01; 4C065/JJ07; 4C065/KK04;
 4C065/LL01; 4C065/PP03; 4C072/MM02; 4C084/AA02;
 4C084/BA44; 4C084/DB52; 4C084/MA02; 4C084/NA05;

4C084/NA14; 4C084/ZA331; 4C084/ZA332; 4C084/ZA361;
 4C084/ZA362; 4C084/ZA891; 4C084/ZA892; 4C084/ZA961;
 4C084/ZA962; 4C084/ZB081; 4C084/ZB082; 4C084/ZB111;
 4C084/ZB112; 4C084/ZB261; 4C084/ZB262; 4C084/ZC751;
 4C085/AA13; 4C085/EE03; 4C086/AA01; 4C086/AA02;
 4C086/AA03; 4C086/BA02; 4C086/BC13; 4C086/BC17;
 4C086/BC52; 4C086/BC64; 4C086/CB09; 4C086/CB14;
 4C086/DA34; 4C086/EA10; 4C086/GA02; 4C086/GA07;
 4C086/GA08; 4C086/MA01; 4C086/MA02; 4C086/MA04;
 4C086/NA05; 4C086/NA14; 4C086/ZA33; 4C086/ZA36;
 4C086/ZA89; 4C086/ZA96; 4C086/ZB08; 4C086/ZB11;
 4C086/ZB26; 4C086/ZC75; 4C204/BB01; 4C204/CB03;
 4C204/CB04; 4C204/DB03; 4C204/DB30; 4C204/EB02;
 4C204/EB03; 4C204/FB01; 4C204/FB16; 4C204/GB01
 IN 2005DN01020 IPCI C07D0209-04 [ICM,7]; C07D0209-00 [ICM,7,C*]
 ZA 2005002328 IPCI A61K [N,S]; C07D [N,S]
 MX 2005PA03477 IPCI A61K [ICM,7]; A61K0031-404 [ICS,7]; A61K0031-403
 [ICS,7,C*]; A61K0031-495 [ICS,7]; C07D0209-04 [ICS,7];
 C07D0209-00 [ICS,7,C*]
 OS MARPAT 140:321386
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. (2 Markush structures shown as I and II; others are described in the claims and disclosure; variables defined below; e.g. III and IV) and methods are provided for treating disorders associated with compromised vasculostasis. Invention methods and compns. are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like. Although the methods of preparation are not claimed, many example preps. are included. For example, III was prepared (75 %) from 2-(2-aminophenyl)indole and 4-hydroxyphenylacetic acid. Various expts. are described that show the use of the claimed compds. along with chemotherapeutic agents for cancer treatment. The claimed compds. also show inhibition of vascular leak induced by interleukin 2. Inhibition of VEGF-induced edema, reduction of myocardial infarction and inhibition of c-Src and Yes kinases were demonstrated for some of the claimed compds. For I: each R0 = -H, -COOH, -OR', -SO3H, wherein R' is -H or lower alkyl, or when x = 2, each R0 is taken together to form a 1,3-dioxolyl ring, or each R0 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted heterocyclic, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted alkylaryl, (un)substituted arylalkyl, (un)substituted arylalkenyl, (un)substituted arylalkynyl, halogen, amino, amido, nitro, or thioalkyl. R1 and R2 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted heterocyclic, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted alkylaryl, (un)substituted arylalkyl, (un)substituted arylalkenyl, (un)substituted arylalkynyl; G is NH, O, S, or (CR'')p, wherein R'' is -H, lower alkyl, or acetamido, and wherein p = 0-3; Ar is aryl or heteroaryl, and x and y = 1-4. For II: Z1-Z6 = C, -C:O, N, or NRa, wherein Ra is -H, (un)substituted alkyl, wherein said substituents are halogen, hydroxy, oxo, or amino; each X = halogen, -ORb, -NRb2, or -SRb, wherein Rb is -H

lower alkyl, $-(CH_2)_2NH\text{Et}$, $-(CH_2)_3\text{morpholin-1-yl}$, $-(CH_2)_3-(N\text{-methylpiperazin-1-yl})$, aryl, heteroaryl, $-(NH-NH-R_c)$, $-(N:N-NH-R_c)$, wherein R_c is H or lower alkyl. Each $Y = -OR_d$, $-NR_d2$, $-SR_d$, or $-OPO_3H_2$ wherein R_d is H, lower alkyl, aryl, heteroaryl, $-(CH_2)_2NH\text{Et}$, $-(CH_2)_3\text{morpholin-1-yl}$, or $(CH_2)_3-(N\text{-methylpiperazin-1-yl})$; or each $Y =$ (un)substituted alkyl, (un)substituted aryl, (un)substituted heteroaryl, or halogen, wherein said substituents = halogen, $-OR_e$, $-NRe_2$, $-SRe$, $-P(O)(OH)_2$, wherein Re is $-H$, lower alkyl, aryl, or heteroaryl; or each $Y = CH_2\text{glyciny1}$, $CH_2NH\text{ethoxy}$, $CH_2NHCH_2\text{alkyl}$, $CH_2NHCH_2t\text{-Bu}$, $CH_2NHCH_2\text{aryl}$, $CH_2NHCH_2\text{substituted aryl}$, $CH_2NHCH_2\text{heteroaryl}$, $CH_2NHCH_2\text{substituted heteroaryl}$; or when n is 2, each Y is taken together to form a fused aromatic or heteroarom. ring system; and m and $n = 1$ to 4, wherein when Z_1 , Z_3 , Z_5 , and Z_6 are each N, X is NH_2 , and $m = n = 2$, Y is not Ph or 4-hydroxyphenyl.

- ST indolylphenyl carboxamide prepn vasculostatic agent compn; pteridine prepn vasculostatic agent compn; quinoxaline prepn vasculostatic agent compn; quinazoline prepn vasculostatic agent compn; benzotriazine prepn vasculostatic agent compn; vasculostasis treatment fused nitrogen heterocycle prepn
- IT Respiratory distress syndrome
 - (acute; preparation of vasculostatic agents and methods of use)
- IT Respiratory distress syndrome
 - (adult; preparation of vasculostatic agents and methods of use)
- IT Alkylation
 - (agents, codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Antibiotics
 - (anthracycline, codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Antitumor agents
 - (antifolates, codrugs; preparation of vasculostatic agents and methods of use)
- IT Cytotoxic agents
 - (antimetabolites, codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Disease, animal
 - (arthropathy; preparation of vasculostatic agents and methods of use)
- IT Antibodies and Immunoglobulins
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (binding to HER2 protein, growth factors or growth factor receptors, or integrin receptors; codrugs; preparation of vasculostatic agents and methods of use)
- IT Antibiotics
 - (bleomycin- and mitomycin-type, codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Interleukin 2
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (codrug; preparation of vasculostatic agents and methods of use)
- IT Taxanes
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Intestine, neoplasm
 - (colon; preparation of vasculostatic agents and methods of use)
- IT Joint, anatomical
 - (disease; preparation of vasculostatic agents and methods of use)
- IT Heart, disease
 - (failure; preparation of vasculostatic agents and methods of use)
- IT Crosslinking agents
 - (for DNA, as codrugs for cancer; preparation of vasculostatic agents and methods of use)
- IT Heart, disease

(infarction; preparation of vasculostatic agents and methods of use)

IT Microtubule
(inhibitors, codrugs for cancer; preparation of vasculostatic agents and methods of use)

IT Reperfusion
(injury; preparation of vasculostatic agents and methods of use)

IT Capillary vessel, disease
(leakage syndrome; preparation of vasculostatic agents and methods of use)

IT Eye, disease
(macula, degeneration; preparation of vasculostatic agents and methods of use)

IT Angiogenesis inhibitors
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antitumor agents
Arthritis
Autoimmune disease
Bladder, neoplasm
Blood vessel, disease
Bone, neoplasm
Brain, neoplasm
Burn
Cardiovascular agents
Digestive tract, neoplasm
Diuretics
Drug delivery systems
Edema
Human
Immunomodulators
Inflammation
Ischemia
Kidney, neoplasm
Leukemia
Liver, neoplasm
Lung, neoplasm
Lymphoma
Mammary gland, neoplasm
Myoma
Neoplasm
Ovary, neoplasm
Packaging materials
Prostate gland, neoplasm
Skin, neoplasm
Transplant rejection
(preparation of vasculostatic agents and methods of use)

IT Injury
(reperfusion; preparation of vasculostatic agents and methods of use)

IT Eye, disease
(retinopathy; preparation of vasculostatic agents and methods of use)

IT Brain, disease
(stroke; preparation of vasculostatic agents and methods of use)

IT Alkaloids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vinca, codrugs for cancer; preparation of vasculostatic agents and methods of use)

IT Eye, disease
(vitreoretinal; preparation of vasculostatic agents and methods of use)

IT 180288-69-1, Trastuzumab 183319-69-9, OSI-774 216974-75-3, Bevacizumab
892553-42-3, Vitaxin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(codrug for cancer; preparation of vasculostatic agents and methods of use)

IT 50-76-0, Dactinomycin 59-05-2, Methotrexate 64-86-8, Colchicine 477-30-5, Demecolcine 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 33069-62-4, Taxol 33419-42-0, Etoposide 39472-31-6, Carminomycin 41575-94-4, Carboplatin 42077-25-8, Adriamycin-14-octanoate 56420-45-2, Epirubicin 58957-92-9, Idarubicin 59367-03-2, Adriamycin-14-benzoate 64161-91-7, Adriamycin-14-naphthaleneacetate 65271-80-9, Mitoxantrone 79466-09-4, 13-Deoxydaunorubicin 84325-15-5, 11-Deoxydaunorubicin 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(codrugs for cancer; preparation of vasculostatic agents and methods of use)

IT 24850-02-0P 677297-15-3P, N-[2-(1H-Indol-2-yl)phenyl]-2-(2-methoxyphenyl)acetamide 677297-25-5P, N-[2-(1H-Indol-2-yl)phenyl]phthalamic acid 677297-30-2P, 6,7-Bis(4-hydroxyphenyl)pteridin-4-ylamine 677297-48-2P, 4-(4-Aminopteridin-7-yl)phenol 677297-51-7P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine 677297-58-4P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine 677297-61-9P, 6,7-Bis(4-hydroxyphenyl)pteridin-4-ylamine sulfate 677297-63-1P, 6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diamine dihydrochloride 677297-75-5P 677297-77-7P 677297-99-3P, 3-(3-Aminobenzo[1,2,4]triazin-7-yl)phenol 677298-01-0P, N-(7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)phenylamine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of vasculostatic agents and methods of use)

IT 14892-98-9P, 6,7-Diphenylpteridine-2,4-diol 18181-93-6P, 6,7-Diphenylpteridine-2,4-diamine 24863-39-6P, 6,7-Diphenylpteridin-4-ol 32044-95-4P, 2,3-Diphenylquinoxalin-5-amine 73384-11-9P, 7-Phenylpteridin-4-amine 102554-55-2P, 2,3-Diphenylquinoxalin-5-ol 102704-20-1P, N-[2-(1H-Indol-2-yl)phenyl]-2-phenylacetamide 126988-00-9P, 3-Phenylquinoxalin-5-amine 128076-13-1P, (6-Phenylpteridin-4-yl)amine 278799-97-6P, 6-[(Benzylamino)methyl]-2,4-pteridinediamine 677297-11-9P, 2-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]acetamide 677297-12-0P, 4-Hydroxy-N-[2-(1H-indol-2-yl)phenyl]benzamide 677297-13-1P, 3,4-Dihydroxy-N-[2-(1H-indol-2-yl)phenyl]benzamide 677297-14-2P, 2-Hydroxy-N-[2-(1H-indol-2-yl)phenyl]benzamide 677297-16-4P, 2-(2-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]acetamide 677297-17-5P, 2-(3,4-Dihydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]acetamide 677297-18-6P, 2-(Benzodioxol-5-yl)-N-[2-(1H-indol-2-yl)phenyl]acetamide 677297-19-7P, N-[2-(1H-Indol-2-yl)phenyl]-3-phenylpropionamide 677297-20-0P, 3-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]propionamide 677297-21-1P, N-[2-(1H-Indol-2-yl)phenyl]-3-(2-methoxyphenyl)propionamide 677297-22-2P, 3-(3,4-Dihydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]propionamide 677297-23-3P, 2-(4-Hydroxyphenoxy)-N-[2-(1H-indol-2-yl)phenyl]acetamide 677297-24-4P, 2-Acetylmino-3-(4-hydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]propionamide 677297-26-6P, 2-[[2-(1H-Indol-2-yl)phenyl]carbamoyl]nicotinic acid 677297-27-7P, 3,4,5-Trihydroxy-N-[2-(1H-indol-2-yl)phenyl]benzamide 677297-28-8P, 2-(2-Phthalimidophenyl)-1H-indole 677297-29-9P, [6,7-Bis(4-hydroxyphenyl)pteridin-4-yl][3-(morpholin-4-yl)propyl]amine hydrochloride 677297-31-3P, Acetic acid 4-[7-(4-acetoxyphenyl)-4-aminopteridin-6-yl]phenyl ester 677297-32-4P, Acetic acid 4-[2-(4-acetoxyphenyl)-6-aminopyrido[2,3-b]pyrazin-3-yl]phenyl ester 677297-35-7P, (3,4-Dimethoxyphenyl)(6-phenylpteridin-4-yl)amine 677297-36-8P, (3-Chloro-4,6-dimethoxyphenyl)(6-phenylpteridin-4-yl)amine 677297-37-9P, (3-Hydroxy-4-methoxyphenyl)(6-phenylpteridin-4-yl)amine 677297-38-0P, (4-Hydroxyphenyl)(6-phenylpteridin-4-yl)amine 677297-39-1P, (2,5-Dimethyl-4-hydroxyphenyl)(6-phenylpteridin-4-yl)amine 677297-40-4P, 2-Hydroxy-5-(6-phenylpteridin-4-ylamino)benzenesulfonic acid

677297-41-5P, 2-[(Diethylamino)methyl]-4-(6-phenylpteridin-4-ylamino)phenol 677297-42-6P, 5-(6-Phenylpteridin-4-ylamino)quinolin-8-ol dihydrochloride 677297-44-8P, Benzyl(6-phenylpteridin-4-yl)amine 677297-45-9P, 4-[(6-Phenylpteridin-4-ylamino)methyl]benzene-1,2-diol 677297-46-0P, (Indan-2-yl)(6-phenylpteridin-4-yl)amine 677297-47-1P, [2-(3,4-Dimethoxyphenyl)ethyl](6-phenylpteridin-4-yl)amine 677297-49-3P, 4-(4-Benzylaminopteridin-7-yl)phenol 677297-50-6P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine monohydrochloride 677297-52-8P, 6-(Pyridin-2-yl)-7-(pyridin-3-yl)pteridin-4-amine 677297-53-9P, 6-(Pyridin-2-yl)-7-(pyridin-3-yl)pteridin-4-amine sulfate 677297-54-0P, 6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diol 677297-55-1P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine dihydrochloride 677297-56-2P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine methanesulfonate 677297-57-3P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine dihydrobromide 677297-59-5P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine hydrochloride 677297-60-8P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine methanesulfonate 677297-62-0P, 6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diamine 677297-64-2P, 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine hydrochloride 677297-65-3P, 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine 677297-66-4P, 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine methanesulfonate 677297-67-5P, 4-(2,4-Diaminopteridin-6-yl)phenol 677297-68-6P, (2,3-Diphenylpyrido[3,4-b]pyrazin-8-yl)amine hydrochloride 677297-69-7P, 2,3-Bis(4-hydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine hydrochloride 677297-70-0P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine hydrochloride 677297-71-1P, 2,3-Bis(3-hydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine hydrochloride 677297-72-2P, 2,3-Bis(3-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride 677297-73-3P, 2,3-Bis(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride 677297-76-6P 677297-78-8P 677297-79-9P, 4-(4-Aminopteridin-7-yl)benzene-1,2-diol 677297-80-2P, 4-(2,4-Diaminopteridin-7-yl)benzene-1,2-diol 677297-81-3P, 4-(2,4-Diaminopteridin-7-yl)phenol 677297-82-4P, 4-[2-(6-Phenylpteridin-4-ylamino)ethyl]benzene-1,2-diol 677297-83-5P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride 677297-84-6P, 2,3-Bis(3-hydroxyphenyl)quinoxalin-6-ylamine dihydrochloride 677297-85-7P, 2,3-Bis(4-hydroxyphenyl)quinoxalin-6-ylamine dihydrochloride 677297-86-8P, 2,3-Bis(3,4-dihydroxyphenyl)quinoxalin-6-ylamine dihydrochloride 677297-94-8P, [7-(2-Trifluoromethylphenyl)benzo[1,2,4]triazin-3-yl]amine 677297-98-2P, [7-(Naphthalen-1-yl)benzo[1,2,4]triazin-3-yl]amine 677298-00-9P, N-[7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-yl]phenylamine 677298-02-1P, (7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)[3-(4-methylpiperazin-1-yl)propyl]amine 677298-03-2P, N-[5-Methyl-7-(2,4,6-trimethylphenyl)benzo[1,2,4]triazin-3-yl]phenylamine 677298-04-3P, N-[7-(2-Fluoro-6-methoxyphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]phenylamine 677298-05-4P, N-[7-(2,6-Dimethoxyphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]phenylamine 677298-06-5P, N-[7-(2,6-Dimethylphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]phenylamine 677298-08-7P, 2-[(2,4-Diaminopteridin-6-ylmethyl)amino]-3-(4-hydroxyphenyl)propionic acid tert-butyl ester 677298-09-8P, 6-[[[(Pyridin-2-ylmethyl)amino]methyl]-2,4-pteridinediamine 677298-10-1P, 6-[[[(Naphthalen-1-ylmethyl)amino]methyl]-2,4-pteridinediamine 677298-11-2P, 6-[[[(Adamantan-1-ylmethyl)amino]methyl]-2,4-pteridinediamine 677298-12-3P, 6-[(3,4-Dimethoxybenzyl)amino]-2,4-pteridinediamine 677298-13-4P, 6-[(2,2-Dimethylpropylamino)methyl]-2,4-pteridinediamine 677298-14-5P, 6-[[[2-(3,4-Dimethoxyphenyl)ethyl]amino]methyl]-2,4-pteridinediamine 677298-15-6P, 6-[[[2-(3,4-Dihydroxyphenyl)ethyl]amino]methyl]-2,4-pteridinediamine 677298-16-7P, 4-[2-[Di(2,4-diaminopteridin-6-ylmethyl)amino]ethyl]benzene-1,2-diol 677298-17-8P, 6-[[[(3,4-Dihydroxybenzyl)amino]methyl]-2,4-pteridinediamine 677298-18-9P, 3-(4-tert-Butoxyphenyl)-2-[[[(2,4-diaminopteridin-6-

yl)methyl]amino]propionic acid tert-butyl ester 677298-19-0P,
 1-[[Bis(2,4-diaminopteridin-6-ylmethyl)amino]methyl]naphthalene
 677298-20-3P, 6-(2,6-Dimethylphenyl)-3H-quinazolin-4-one 677298-21-4P,
 6-(2,6-Dimethoxyphenyl)-3H-quinazolin-4-one 677298-22-5P,
 6-(2-Chloro-6-methoxyphenyl)-3H-quinazolin-4-one 677298-23-6P,
 6-(2,4,6-Trimethylphenyl)-3H-quinazolin-4-one 677298-24-7P,
 6-(Naphthalen-1-yl)-3H-quinazolin-4-one 677298-25-8P,
 6-(Naphthalen-2-yl)-3H-quinazolin-4-one 677298-26-9P,
 6-(4-Phenoxyphenyl)-3H-quinazolin-4-one 677298-28-1P,
 6-(2,6-Dimethylphenyl)-3-(3-hydroxypropionyl)-3H-quinazolin-4-one
 677298-29-2P, 6-(2-Chloro-6-methoxyphenyl)-3-(3-hydroxypropionyl)-3H-
 quinazolin-4-one 677298-32-7P, (6,7-Diphenylpteridin-4-yl)[3-(4-
 methylpiperazin-1-yl)propyl]amine 677298-33-8P 677298-34-9P,
 3-[(Benzimidazol-2-ylmethyl)amino]-1H-indolin-2-one 677298-35-0P,
 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine sulfate 677298-36-1P,
 4-(2,4-Diaminopteridin-6-yl)phenol sulfate 677298-37-2P,
 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diol 677298-38-3P,
 N-[2-(2,3-Dihydro-1H-indol-2-yl)phenyl]-2-hydroxybenzamide 677298-39-4P,
 3-[[2-(1H-Indol-2-yl)phenyl]carbonyl]pyridine-2-carboxylic acid
 677298-40-7P, 6-[[Naphthalen-2-ylmethyl)amino]methyl]pteridine-2,4-
 diamine 677298-42-9P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[3,4-b]pyrazin-8-
 ylamine 677298-46-3P, 3,4,5-Trihydroxy-N-(1H-indol-2-yl)benzamide
 677298-47-4P, 6,7-Bis(pyridin-2-yl)pteridin-4-ylamine 677298-48-5P,
 6,7-Bis(3-hydroxyphenyl)pteridin-2-amine 677298-49-6P,
 6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine hydrobromide 677298-50-9P,
 2-Phenylquinoxalin-5-amine 677298-51-0P, 6-(Pyridin-2-yl)-7-(pyridin-3-
 yl)pteridine-2,4-diol 677298-53-2P, 6-(Pyridin-3-yl)-7-(pyridin-2-
 yl)pteridin-4-amine 677298-54-3P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[2,3-
 b]pyrazin-6-ylamine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of vasculostatic agents and methods of use)

IT 677298-52-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(drug candidate; preparation of vasculostatic agents and methods of use)

IT 143180-75-0

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors, codrugs for cancer; preparation of vasculostatic agents and
 methods of use)

IT 372092-80-3, Protein kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors, codrugs; preparation of vasculostatic agents and methods of
 use)

IT 9026-43-1, Serine kinase 9031-44-1, Kinase 80449-02-1, Tyrosine kinase

141349-89-5, Src kinase 141349-91-9, Yes kinase 144697-17-6, c-Src
 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; preparation of vasculostatic agents and methods of use)

IT 51-61-6, 2-(3,4-Dihydroxyphenyl)ethylamine, reactions 62-31-7,

3-Hydroxytyramine hydrochloride 62-53-3, Aniline, reactions 69-72-7,

Salicylic acid, reactions 85-44-9, Phthalic anhydride 91-56-5,

Isatin 93-25-4, 2-Methoxyphenylacetic acid 99-50-3,

3,4-Dihydroxybenzoic acid 99-96-7, 4-Hydroxybenzoic acid, reactions

100-46-9, Benzylamine, reactions 102-32-9, 3,4-Dihydroxyphenylacetic

acid 103-82-2, Phenylacetic acid, reactions 118-31-0,

1-Aminomethylnaphthalene 123-00-2, N-(3-Aminopropyl)morpholine

134-81-6, Benzil 149-91-7, Gallic acid, reactions 156-38-7,

4-Hydroxyphenylacetic acid 501-52-0, Hydrocinnamic acid 501-97-3,

3-(4-Hydroxyphenyl)propionic acid 537-55-3, N-Acetyl-L-tyrosine

615-47-4, 1,2,4-Benzenetriamine dihydrochloride 635-85-8,
 2-(3,4-Dimethoxyphenyl)ethylamine hydrochloride 699-98-9,
 2,3-Pyridinedicarboxylic anhydride 814-68-6, Acryloyl chloride
 875-51-4, (4-Bromo-2-nitrophenyl)amine 1078-61-1, 3,4-
 Dihydroxyhydrocinnamic acid 1124-40-9, (3,4-Dihydroxybenzyl)amine
 hydrochloride 1423-27-4, 2-Trifluoromethylphenylboronic acid
 1878-84-8, (4-Hydroxyphenoxy)acetic acid 2861-28-1, 3,4-
 (Methylenedioxy)phenylacetic acid 3731-51-9, 2-(Aminomethyl)pyridine
 4572-03-6, 3-(4-Methylpiperazin-1-yl)propylamine 5122-94-1,
 (4-Biphenyl)boronic acid 5763-61-1, 3,4-Dimethoxybenzylamine
 5794-88-7, 2-Amino-5-Bromobenzoic acid 5813-64-9, 2,2-
 Dimethylpropylamine 5980-97-2, 2,4,6-Trimethylphenylboronic acid
 6309-15-5, 3,3',4,4'-Tetrahydroxybenzil 6342-77-4, 3-(2-
 Methoxyphenyl)propionic acid 7757-21-3 13922-41-3, (1-Naphthyl)boronic
 acid 16290-26-9, 3,4-Dihydroxybenzylamine hydrobromide 17601-94-4,
 2-Amino-3-bromo-5-nitrobenzonitrile 17768-41-1, 1-Aminomethyladamantane
 20284-90-6, 2,3,6-Triaminopyridine dihydrochloride 21454-19-3,
 Bis[4-(1,2-dioxo-2-phenylethyl)phenyl] ether 23112-96-1,
 2,6-Dimethoxyphenylboronic acid 24645-80-5, 4-Hydroxyphenylglyoxal
 32316-92-0, (2-Naphthyl)boronic acid 32566-01-1, 2-(2-Aminophenyl)indole
 33288-79-8, 4,4'-Dihydroxybenzil 42965-55-9, 5,6-Diamino-2,4-
 dihydroxypyrimidine sulfate 49647-58-7, 2,4,5,6-Tetraaminopyrimidine
 sulfate 49721-45-1, 4,5,6-Triaminopyrimidine sulfate 51067-38-0,
 4-Phenoxyphenylboronic acid 52853-40-4, 6-Bromomethyl-2,4-
 pteridinediamine hydrobromide 63192-57-4, 3,3'-Dihydroxybenzil
 76145-91-0, (2,4-Diaminopteridin-6-yl)methanol hydrobromide 77712-97-1,
 3,4,5-Triaminopyridine hydrochloride 77811-44-0, (4-Bromo-2-methyl-6-
 nitrophenyl)amine 78495-63-3, 2-Fluoro-6-methoxyphenylboronic acid
 87199-18-6, 3-Hydroxyphenylboronic acid 88878-78-8, 2-Amino-3-(4-
 hydroxyphenyl)propionic acid tert-butyl ester 94839-07-3,
 3,4-(Methylenedioxy)phenylboronic acid 95195-43-0, 2,3'-Pyridil
 98437-24-2, 2-Benzofuranboronic acid 100124-06-9, 4-Dibenzofuranboronic
 acid 100379-00-8, 2,6-Dimethylphenylboronic acid 123324-71-0,
 4-tert-Butylphenylboronic acid 385370-80-9, 2-Chloro-6-
 methoxyphenylboronic acid 545390-26-9, 2-Amino-3-(4-tert-
 butoxyphenyl)propionic acid tert-butyl ester hydrochloride 677297-33-5,
 2,3-Bis(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine 677297-34-6,
 N'-(3-Cyano-5-phenylpyrazin-2-yl)-N,N-dimethylformamidine
 RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of vasculostatic agents and methods of use)


IT 6298-38-0P, (7-Bromobenzo[1,2,4]triazin-3-yl)amine 1-oxide 32084-59-6P,
 6-Bromo-3H-quinazolin-4-one 59368-16-0P, 6-Bromomethyl-2,4-
 pteridinediamine 677297-74-4P 677297-87-9P 677297-88-0P,
 [7-(Benzodioxol-5-yl)benzo[1,2,4]triazin-3-yl]amine 1-oxide
 677297-89-1P, [7-(Benzodioxol-5-yl)benzo[1,2,4]triazin-3-yl]amine
 677297-90-4P, [7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-yl]amine
 677297-91-5P, [7-(4-Phenoxyphenyl)benzo[1,2,4]triazin-3-yl]amine
 677297-92-6P, [7-(2,6-Dimethoxyphenyl)benzo[1,2,4]triazin-3-yl]amine
 677297-93-7P, [7-(4-tert-Butylphenyl)benzo[1,2,4]triazin-3-yl]amine
 677297-95-9P, [7-(Biphenyl-4-yl)benzo[1,2,4]triazin-3-yl]amine
 677297-96-0P, [7-(Benzofuran-2-yl)benzo[1,2,4]triazin-3-yl]amine
 677297-97-1P, [7-(Dibenzofuran-4-yl)benzo[1,2,4]triazin-3-yl]amine
 677298-27-0P, 6-Bromo-3-(3-hydroxypropionyl)-3H-quinazolin-4-one
 677298-30-5P, 4-Amino-8-bromo-6-nitroquinazolin-2-ol 677298-31-6P,
 8-Bromo-4-[[3-(4-methylpiperazin-1-yl)propyl]amino]-6-nitroquinazolin-2-ol
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of vasculostatic agents and methods of use)

IT 677298-07-6P, [7-(Naphthalen-2-yl)benzo[1,2,4]triazin-3-yl]amine 1-oxide
 RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of vasculostatic agents and methods of use)

L32 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 1072-84-0, 4-Imidazolecarboxylic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyridinones as modulators of p38 MAP kinase for
 treatment of inflammatory conditions, ischemia, viral
 infections, autoimmune diseases, and other conditions)
 RN 1072-84-0 CAPLUS
 CN 1H-Imidazole-5-carboxylic acid (CA INDEX NAME)



ACCESSION NUMBER: 2003:656582 CAPLUS
 DOCUMENT NUMBER: 139:197371
 TITLE: Preparation of substituted pyridinones as modulators
 of p38 MAP kinase
 INVENTOR(S): Devadas, Balekudru; Walker, John; Selness, Shaun R.;
 Boehm, Terri L.; Durley, Richard C.; Devraj, Rajesh;
 Hickory, Brian S.; Rucker, Paul V.; Jerome, Kevin D.;
 Madsen, Heather M.; Alvira, Edgardo; Promo, Michele
 A.; Bleviss-Bal, Radhika M.; Marrufo, Laura D.;
 Hitchcock, Jeff; Owen, Thomas; Naing, Win; Xing, Li;
 Shieh, Huey S.; Sambandam, Aruna; Liu, Shuang; Scott,
 Ian L.; McGee, Kevin F.
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 1052 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068230	A1	20030821	WO 2003-US4634	20030214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2476012	A1	20030821	CA 2003-2476012	20030214
AU 2003217433	A1	20030904	AU 2003-217433	20030214
US 20040058964	A1	20040325	US 2003-367987	20030214
US 7067540	B2	20060627		
BR 2003007631	A	20041221	BR 2003-7631	20030214
EP 1490064	A1	20041229	EP 2003-713478	20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1646125	A	20050727	CN 2003-808042	20030214
JP 2005531501	T	20051020	JP 2003-567412	20030214
NZ 534395	A	20061027	NZ 2003-534395	20030214

IN 2004DN02150	A	20050401	IN 2004-DN2150	20040723
MX 2004PA07470	A	20041110	MX 2004-PA7470	20040802
ZA 2004006275	A	20051004	ZA 2004-6275	20040805
NO 2004003820	A	20041109	NO 2004-3820	20040913
US 20060211694	A1	20060921	US 2005-226556	20050914
US 20070088033	A1	20070419	US 2006-531492	20060913
JP 2007023053	A	20070201	JP 2006-263778	20060928
KR 2007017443	A	20070209	KR 2007-701895	20070125
AU 2007202607	A1	20070628	AU 2007-202607	20070607

PRIORITY APPLN. INFO.:

US 2002-357029P	P	20020214
US 2002-436915P	P	20021230
AU 2003-217433	A3	20030214
JP 2003-567412	A3	20030214
US 2003-367987	A1	20030214
WO 2003-US4634	W	20030214
KR 2004-712622	A3	20040813
US 2005-226556	A3	20050914

OTHER SOURCE(S): MARPAT 139:197371

AN 2003:656582 CAPLUS

DN 139:197371

ED Entered STN: 22 Aug 2003

TI Preparation of substituted pyridinones as modulators of p38 MAP kinase

IN Devadas, Balekudru; Walker, John; Selness, Shaun R.; Boehm, Terri L.; Durley, Richard C.; Devraj, Rajesh; Hickory, Brian S.; Rucker, Paul V.; Jerome, Kevin D.; Madsen, Heather M.; Alvira, Edgardo; Promo, Michele A.; Bleviss-Bal, Radhika M.; Marrufo, Laura D.; Hitchcock, Jeff; Owen, Thomas; Naing, Win; Xing, Li; Shieh, Huey S.; Sambandam, Aruna; Liu, Shuang; Scott, Ian L.; McGee, Kevin F.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 1052 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-4412

ICS A61P029-00; C07D213-69; C07D401-06; C07D409-06; C07D213-70; C07D213-64; C07D213-74; C07D405-06; C07D213-84; C07D401-10; C07D405-12; C07D401-12; C07D213-75; C07D401-14; C07D213-79; C07D401-04; C07D405-04; C07D413-10; C07D215-22

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068230	A1	20030821	WO 2003-US4634	20030214
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2476012	A1	20030821	CA 2003-2476012	20030214
AU 2003217433	A1	20030904	AU 2003-217433	20030214
US 20040058964	A1	20040325	US 2003-367987	20030214
US 7067540	B2	20060627		
BR 2003007631	A	20041221	BR 2003-7631	20030214
EP 1490064	A1	20041229	EP 2003-713478	20030214
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
CN	1646125	A	20050727
JP	2005531501	T	20051020
NZ	534395	A	20061027
IN	2004DN02150	A	20050401
MX	2004PA07470	A	20041110
ZA	2004006275	A	20051004
NO	2004003820	A	20041109
US	20060211694	A1	20060921
US	20070088033	A1	20070419
JP	2007023053	A	20070201
KR	2007017443	A	20070209
AU	2007202607	A1	20070628
PRAI	US 2002-357029P	P	20020214
	US 2002-436915P	P	20021230
	AU 2003-217433	A3	20030214
	JP 2003-567412	A3	20030214
	US 2003-367987	A1	20030214
	WO 2003-US4634	W	20030214
	KR 2004-712622	A3	20040813
	US 2005-226556	A3	20050914

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003068230	ICM	A61K031-4412
	ICS	A61P029-00; C07D213-69; C07D401-06; C07D409-06; C07D213-70; C07D213-64; C07D213-74; C07D405-06; C07D213-84; C07D401-10; C07D405-12; C07D401-12; C07D213-75; C07D401-14; C07D213-79; C07D401-04; C07D405-04; C07D413-10; C07D215-22
	IPCI	A61K0031-4412 [ICM, 7]; A61P0029-00 [ICS, 7]; C07D0213-69 [ICS, 7]; C07D0401-06 [ICS, 7]; C07D0409-06 [ICS, 7]; C07D0213-70 [ICS, 7]; C07D0213-64 [ICS, 7]; C07D0213-74 [ICS, 7]; C07D0405-06 [ICS, 7]; C07D0213-84 [ICS, 7]; C07D0401-10 [ICS, 7]; C07D0405-12 [ICS, 7]; C07D0401-12 [ICS, 7]; C07D0213-75 [ICS, 7]; C07D0401-14 [ICS, 7]; C07D0213-79 [ICS, 7]; C07D0401-04 [ICS, 7]; C07D0401-00 [ICS, 7, C*]; C07D0405-04 [ICS, 7]; C07D0413-10 [ICS, 7]; C07D0413-00 [ICS, 7, C*]; C07D0215-22 [ICS, 7]; C07D0215-00 [ICS, 7, C*]; C07D0405-14 [ICS, 7]; C07D0405-00 [ICS, 7, C*]; C07D0409-14 [ICS, 7]; C07D0409-00 [ICS, 7, C*]; C07D0213-85 [ICS, 7]; C07D0213-00 [ICS, 7, C*]
	IPCR	A61K0031-4412 [I, C*]; A61K0031-4412 [I, A]; A61K0031-4418 [I, C*]; A61K0031-4418 [I, A]; A61K0031-4427 [I, C*]; A61K0031-4439 [I, A]; A61K0031-444 [I, A]; A61K0031-4523 [I, C*]; A61K0031-4545 [I, A]; A61K0031-455 [I, C*]; A61K0031-455 [I, A]; A61K0031-472 [I, C*]; A61K0031-4725 [I, A]; A61K0031-496 [I, C*]; A61K0031-496 [I, A]; A61K0031-4965 [I, C*]; A61K0031-497 [I, A]; A61K0031-506 [I, C*]; A61K0031-506 [I, A]; A61K0031-5375 [I, C*]; A61K0031-5377 [I, A]; A61P0001-00 [I, C*]; A61P0001-04 [I, A]; A61P0001-16 [I, A]; A61P0003-00 [I, C*]; A61P0003-10 [I, A]; A61P0007-00 [I, C*]; A61P0007-02 [I, A]; A61P0009-00 [I, C*]; A61P0009-04 [I, A]; A61P0009-10 [I, A]; A61P0011-00 [I, C*]; A61P0011-00 [I, A]; A61P0011-06 [I, A]; A61P0013-00 [I, C*]; A61P0013-12 [I, A]; A61P0015-00 [I, C*]; A61P0015-08 [I, A]; A61P0017-00 [I, C*]; A61P0017-02 [I, A]; A61P0017-06 [I, A]; A61P0019-00 [I, C*]; A61P0019-02 [I, A]; A61P0019-06 [I, A];

A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A]; A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00 [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]; C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85; C07D215/22D; C07D401/04+213+211; C07D401/04+239B+213; C07D401/04+231+213; C07D401/06+213+211; C07D401/06+217+213; C07D401/06+213+209C; C07D401/06+231+213; C07D401/06+239B+213; C07D401/06+241B+213; C07D401/10+213+211; C07D401/10+233+213; C07D401/10+231+213; C07D401/12+213+207; C07D401/12+233+213; C07D401/14+239B+213+211; C07D405/04+307B+213; C07D405/06+307B+213; C07D405/06+317+213; C07D405/12+307B+213; C07D405/14+307B+307B+213; C07D409/06+333B+213; C07D409/14+333B+333B+213; C07D413/10+261+213

ECLA A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0401-04 [ICS,7]; C07D0405-04 [ICS,7]; C07D0401-06 [ICS,7]; C07D0405-06 [ICS,7]; C07D0409-06 [ICS,7]; C07D0401-10 [ICS,7]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*]; C07D0401-12 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C*]; C07D0213-64 [ICS,7]; C07D0213-69 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-74 [ICS,7]; C07D0213-75 [ICS,7]; C07D0213-79 [ICS,7]; C07D0213-84 [ICS,7]; C07D0213-85 [ICS,7]; C07D0213-00 [ICS,7,C*]

CA 2476012 IPCI A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C*]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A]; A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472 [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00 [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];

IPCR

A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00 [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*]; A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A]; A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00 [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]; C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85; C07D215/22D; C07D401/04+213+211; C07D401/04+231+213; C07D401/04+239B+213; C07D401/06+213+209C; C07D401/06+213+211; C07D401/06+217+213; C07D401/06+231+213; C07D401/06+239B+213; C07D401/06+241B+213; C07D401/10+213+211; C07D401/10+231+213; C07D401/10+233+213; C07D401/12+213+207; C07D401/12+233+213; C07D401/14+239B+213+211; C07D405/04+307B+213; C07D405/06+307B+213; C07D405/06+317+213; C07D405/12+307B+213; C07D405/14+307B+307B+213; C07D409/06+333B+213; C07D409/14+333B+333B+213; C07D413/10+261+213

AU 2003217433 ECLA A61K0031-4412 [ICM,7]; C07D0409-14 [ICS,7]; C07D0213-85 [ICS,7]; A61P0029-00 [ICS,7]; C07D0213-69 [ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0213-70 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-74 [ICS,7]; C07D0405-06 [ICS,7]; C07D0213-84 [ICS,7]; C07D0401-10 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-12 [ICS,7]; C07D0213-75 [ICS,7]; C07D0401-14 [ICS,7]; C07D0213-79 [ICS,7]; C07D0213-00 [ICS,7,C*]; C07D0401-04 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C*]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]

AU 2003217433 IPCI A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C*]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A]; A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472 [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497

AU 2003217433 IPCR

[I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
 A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
 [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
 A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
 [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
 A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
 [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
 A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
 [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
 A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
 [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
 A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
 [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
 A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
 A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
 A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
 [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
 A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
 [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
 A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
 C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
 C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
 [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
 C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
 C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
 C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
 A61K0031-44 [I,A]; C07D0213-02 [I,A]; C07D0213-00
 [I,C*]; C07D0401-02 [I,A]; C07D0401-00 [I,C*]
 IPCR A61P0029-00 [I,C*]; A61P0029-00 [I,A]; C07D0213-00
 [I,C*]; C07D0213-64 [I,A]; C07D0213-69 [I,A];
 C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75
 [I,A]; C07D0213-79 [I,A]; C07D0213-84 [I,A];
 C07D0213-85 [I,A]; C07D0215-00 [I,C*]; C07D0215-22
 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A];
 C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12
 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C*];
 C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12
 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*];
 C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00
 [I,C*]; C07D0413-10 [I,A]
 NCL 514/340.000; 514/344.000; 514/345.000; 546/268.100;
 546/288.000; 546/290.000; 514/348.000; 514/256.000;
 514/336.000; 544/333.000; 546/283.400; 546/296.000
 ECLA C07D213/64A; C07D401/14+239B+213+211;
 C07D405/04+307B+213; C07D405/06+307B+213;
 C07D405/06+317+213; C07D405/12+307B+213;
 C07D405/14+307B+307B+213; C07D409/06+333B+213;
 C07D409/14+333B+333B+213; C07D413/10+261+213;
 C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C;
 C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85;
 C07D215/22D; C07D401/04+213+211; C07D401/04+231+213;
 C07D401/04+239B+213; C07D401/06+213+209C;
 C07D401/06+217+213; C07D401/06+213+211;
 C07D401/06+239B+213; C07D401/06+231+213;

BR 2003007631 IPCI

C07D401/06+241B+213; C07D401/10+213+211;
C07D401/10+231+213; C07D401/10+233+213;
C07D401/12+213+207; C07D401/12+233+213
A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0213-69
[ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7];
C07D0409-00 [ICS,7,C*]; C07D0213-70 [ICS,7];
C07D0213-64 [ICS,7]; C07D0213-74 [ICS,7]; C07D0213-84
[ICS,7]; C07D0405-06 [ICS,7]; C07D0401-10 [ICS,7];
C07D0405-12 [ICS,7]; C07D0401-12 [ICS,7]; C07D0213-75
[ICS,7]; C07D0401-14 [ICS,7]; C07D0213-79 [ICS,7];
C07D0213-00 [ICS,7,C*]; C07D0401-04 [ICS,7];
C07D0401-00 [ICS,7,C*]; C07D0405-04 [ICS,7];
C07D0405-00 [ICS,7,C*]; C07D0413-10 [ICS,7];
C07D0413-00 [ICS,7,C*]

IPCR

A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
[I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
[I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*];
A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
[I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
[I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
[I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
[I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
[I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
[I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
[I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
[I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
[I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
[I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
[I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
[I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
[I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
[I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
[I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
[I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
[I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]

ECLA

C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
C07D213/85; C07D215/22D; C07D401/04+213+211;
C07D401/04+231+213; C07D401/04+239B+213;
C07D401/06+213+209C; C07D401/06+213+211;
C07D401/06+217+213; C07D401/06+231+213;
C07D401/06+239B+213; C07D401/06+241B+213;

EP 1490064

IPCI

IPCR

ECLA

C07D401/10+213+211; C07D401/10+231+213;
C07D401/10+233+213; C07D401/12+213+207;
C07D401/12+233+213; C07D401/14+239B+213+211;
C07D405/04+307B+213; C07D405/06+307B+213;
C07D405/06+317+213; C07D405/12+307B+213;
C07D405/14+307B+307B+213; C07D409/06+333B+213;
C07D409/14+333B+333B+213; C07D413/10+261+213
A61K0031-4412 [ICM, 7]; A61P0029-00 [ICS, 7]; C07D0213-69
[ICS, 7]; C07D0401-06 [ICS, 7]; C07D0409-06 [ICS, 7];
C07D0409-00 [ICS, 7, C*]; C07D0213-70 [ICS, 7];
C07D0213-64 [ICS, 7]; C07D0213-74 [ICS, 7]; C07D0405-06
[ICS, 7]; C07D0213-84 [ICS, 7]; C07D0401-10 [ICS, 7];
C07D0405-12 [ICS, 7]; C07D0401-12 [ICS, 7]; C07D0213-75
[ICS, 7]; C07D0401-14 [ICS, 7]; C07D0213-79 [ICS, 7];
C07D0213-00 [ICS, 7, C*]; C07D0401-04 [ICS, 7];
C07D0401-00 [ICS, 7, C*]; C07D0405-04 [ICS, 7];
C07D0413-10 [ICS, 7]; C07D0413-00 [ICS, 7, C*];
C07D0215-22 [ICS, 7]; C07D0215-00 [ICS, 7, C*];
C07D0405-14 [ICS, 7]; C07D0405-00 [ICS, 7, C*]
A61K0031-4412 [I, C*]; A61K0031-4412 [I, A];
A61K0031-4418 [I, C*]; A61K0031-4418 [I, A];
A61K0031-4427 [I, C*]; A61K0031-4439 [I, A]; A61K0031-444
[I, A]; A61K0031-4523 [I, C*]; A61K0031-4545 [I, A];
A61K0031-455 [I, C*]; A61K0031-455 [I, A]; A61K0031-472
[I, C*]; A61K0031-4725 [I, A]; A61K0031-496 [I, C*];
A61K0031-496 [I, A]; A61K0031-4965 [I, C*]; A61K0031-497
[I, A]; A61K0031-506 [I, C*]; A61K0031-506 [I, A];
A61K0031-5375 [I, C*]; A61K0031-5377 [I, A]; A61P0001-00
[I, C*]; A61P0001-04 [I, A]; A61P0001-16 [I, A];
A61P0003-00 [I, C*]; A61P0003-10 [I, A]; A61P0007-00
[I, C*]; A61P0007-02 [I, A]; A61P0009-00 [I, C*];
A61P0009-04 [I, A]; A61P0009-10 [I, A]; A61P0011-00
[I, C*]; A61P0011-00 [I, A]; A61P0011-06 [I, A];
A61P0013-00 [I, C*]; A61P0013-12 [I, A]; A61P0015-00
[I, C*]; A61P0015-08 [I, A]; A61P0017-00 [I, C*];
A61P0017-02 [I, A]; A61P0017-06 [I, A]; A61P0019-00
[I, C*]; A61P0019-02 [I, A]; A61P0019-06 [I, A];
A61P0019-08 [I, A]; A61P0019-10 [I, A]; A61P0025-00
[I, C*]; A61P0025-00 [I, A]; A61P0025-02 [I, A];
A61P0025-04 [I, A]; A61P0025-14 [I, A]; A61P0025-16
[I, A]; A61P0025-28 [I, A]; A61P0027-00 [I, C*];
A61P0027-02 [I, A]; A61P0029-00 [I, C*]; A61P0029-00
[I, A]; A61P0031-00 [I, C*]; A61P0031-04 [I, A];
A61P0031-12 [I, A]; A61P0031-18 [I, A]; A61P0033-00
[I, C*]; A61P0033-02 [I, A]; A61P0033-06 [I, A];
A61P0035-00 [I, C*]; A61P0035-00 [I, A]; A61P0037-00
[I, C*]; A61P0037-06 [I, A]; A61P0043-00 [I, C*];
A61P0043-00 [I, A]; C07D0213-00 [I, C*]; C07D0213-64
[I, A]; C07D0213-69 [I, A]; C07D0213-70 [I, A];
C07D0213-74 [I, A]; C07D0213-75 [I, A]; C07D0213-79
[I, A]; C07D0213-80 [I, A]; C07D0213-82 [I, A];
C07D0213-84 [I, A]; C07D0213-85 [I, A]; C07D0215-00
[I, C*]; C07D0215-22 [I, A]; C07D0401-00 [I, C*];
C07D0401-04 [I, A]; C07D0401-06 [I, A]; C07D0401-10
[I, A]; C07D0401-12 [I, A]; C07D0401-14 [I, A];
C07D0405-00 [I, C*]; C07D0405-04 [I, A]; C07D0405-06
[I, A]; C07D0405-12 [I, A]; C07D0405-14 [I, A];
C07D0409-00 [I, C*]; C07D0409-06 [I, A]; C07D0409-14
[I, A]; C07D0413-00 [I, C*]; C07D0413-10 [I, A]
C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;

CN 1646125

IPCI

IPCR

C07D213/85; C07D215/22D; C07D401/04+213+211;
C07D401/04+231+213; C07D401/04+239B+213;
C07D401/06+213+209C; C07D401/06+213+211;
C07D401/06+217+213; C07D401/06+231+213;
C07D401/06+239B+213; C07D401/06+241B+213;
C07D401/10+213+211; C07D401/10+231+213;
C07D401/10+233+213; C07D401/12+213+207;
C07D401/12+233+213; C07D401/14+239B+213+211;
C07D405/04+307B+213; C07D405/06+307B+213;
C07D405/06+317+213; C07D405/12+307B+213;
C07D405/14+307B+307B+213; C07D409/06+333B+213;
C07D409/14+333B+333B+213; C07D413/10+261+213
A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0213-69
[ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7];
C07D0213-70 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-74
[ICS,7]; C07D0405-06 [ICS,7]; C07D0213-84 [ICS,7];
C07D0401-10 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-12
[ICS,7]; C07D0213-75 [ICS,7]; C07D0401-14 [ICS,7];
C07D0213-79 [ICS,7]; C07D0401-04 [ICS,7]; C07D0401-00
[ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0413-10 [ICS,7];
C07D0413-00 [ICS,7,C*]; C07D0215-22 [ICS,7];
C07D0215-00 [ICS,7,C*]; C07D0405-14 [ICS,7];
C07D0405-00 [ICS,7,C*]; C07D0409-14 [ICS,7];
C07D0409-00 [ICS,7,C*]; C07D0213-85 [ICS,7];
C07D0213-00 [ICS,7,C*]
A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
[I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
[I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*];
A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
[I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
[I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
[I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
[I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
[I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
[I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
[I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
[I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
[I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
[I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
[I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
[I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
[I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
[I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
[I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];

C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
 ECLA C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85; C07D215/22D; C07D401/04+213+211; C07D401/04+231+213; C07D401/04+239B+213; C07D401/06+213+209C; C07D401/06+213+211; C07D401/06+217+213; C07D401/06+231+213; C07D401/06+239B+213; C07D401/06+241B+213; C07D401/10+213+211; C07D401/10+231+213; C07D401/10+233+213; C07D401/12+213+207; C07D401/12+233+213; C07D401/14+239B+213+211; C07D405/04+307B+213; C07D405/06+307B+213; C07D405/06+317+213; C07D405/12+307B+213; C07D405/14+307B+307B+213; C07D409/06+333B+213; C07D409/14+333B+333B+213; C07D413/10+261+213
 JP 2005531501 IPCI C07D0213-64 [ICM,7]; A61K0031-4412 [ICS,7]; A61K0031-4418 [ICS,7]; A61K0031-4439 [ICS,7]; A61K0031-444 [ICS,7]; A61K0031-4427 [ICS,7,C*]; A61K0031-4545 [ICS,7]; A61K0031-4523 [ICS,7,C*]; A61K0031-455 [ICS,7]; A61K0031-4725 [ICS,7]; A61K0031-472 [ICS,7,C*]; A61K0031-496 [ICS,7]; A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C*]; A61K0031-506 [ICS,7]; A61K0031-5377 [ICS,7]; A61K0031-5375 [ICS,7,C*]; A61P0001-04 [ICS,7]; A61P0001-16 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0003-10 [ICS,7]; A61P0003-00 [ICS,7,C*]; A61P0007-02 [ICS,7]; A61P0007-00 [ICS,7,C*]; A61P0009-04 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]; A61P0011-00 [ICS,7]; A61P0011-06 [ICS,7]; A61P0013-12 [ICS,7]; A61P0013-00 [ICS,7,C*]; A61P0015-08 [ICS,7]; A61P0015-00 [ICS,7,C*]; A61P0017-02 [ICS,7]; A61P0017-06 [ICS,7]; A61P0017-00 [ICS,7,C*]; A61P0019-02 [ICS,7]; A61P0019-06 [ICS,7]; A61P0019-08 [ICS,7]; A61P0019-10 [ICS,7]; A61P0019-00 [ICS,7,C*]; A61P0025-00 [ICS,7]; A61P0025-02 [ICS,7]; A61P0025-04 [ICS,7]; A61P0025-14 [ICS,7]; A61P0025-16 [ICS,7]; A61P0025-28 [ICS,7]; A61P0027-02 [ICS,7]; A61P0027-00 [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-12 [ICS,7]; A61P0031-18 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0033-02 [ICS,7]; A61P0033-06 [ICS,7]; A61P0033-00 [ICS,7,C*]; A61P0035-00 [ICS,7]; A61P0037-06 [ICS,7]; A61P0037-00 [ICS,7,C*]; A61P0043-00 [ICS,7]; C07D0213-69 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-74 [ICS,7]; C07D0213-75 [ICS,7]; C07D0213-79 [ICS,7]; C07D0213-80 [ICS,7]; C07D0213-82 [ICS,7]; C07D0213-85 [ICS,7]; C07D0213-00 [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C*]; C07D0401-04 [ICS,7]; C07D0401-06 [ICS,7]; C07D0401-10 [ICS,7]; C07D0401-12 [ICS,7]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0405-12 [ICS,7]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0409-06 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*]
 IPCR A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C*]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];

A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
 [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*];
 A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
 A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
 [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
 A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
 [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
 A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
 [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
 A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
 [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
 A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
 [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
 A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
 [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
 A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
 A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
 A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
 [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
 A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
 [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
 A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
 C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
 C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
 [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
 C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
 C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
 C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]

FTERM

4C031/EA15; 4C031/EA17; 4C055/AA03; 4C055/AA06;
 4C055/AA09; 4C055/AA10; 4C055/BA02; 4C055/BA42;
 4C055/CA01; 4C055/CA02; 4C055/CA39; 4C055/DA08;
 4C055/DA42; 4C055/DA47; 4C055/DA52; 4C055/DB01;
 4C055/DB04; 4C055/DB06; 4C055/DB08; 4C055/DB10;
 4C055/DB16; 4C055/FA03; 4C063/AA01; 4C063/AA03;
 4C063/BB01; 4C063/BB03; 4C063/BB04; 4C063/BB06;
 4C063/BB08; 4C063/BB09; 4C063/CC12; 4C063/CC15;
 4C063/CC22; 4C063/CC25; 4C063/CC29; 4C063/CC34;
 4C063/CC51; 4C063/CC71; 4C063/CC75; 4C063/CC92;
 4C063/DD03; 4C063/DD06; 4C063/DD10; 4C063/DD12;
 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03;
 4C086/BC17; 4C086/BC21; 4C086/BC30; 4C086/BC36;
 4C086/BC37; 4C086/BC38; 4C086/BC42; 4C086/BC47;
 4C086/BC48; 4C086/BC67; 4C086/BC73; 4C086/GA02;
 4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA09;
 4C086/GA12; 4C086/GA13; 4C086/MA01; 4C086/NA14;
 4C086/ZA02; 4C086/ZA08; 4C086/ZA33; 4C086/ZA36;
 4C086/ZA40; 4C086/ZA45; 4C086/ZA54; 4C086/ZA59;
 4C086/ZA66; 4C086/ZA68; 4C086/ZA75; 4C086/ZA81;
 4C086/ZA89; 4C086/ZA96; 4C086/ZA97; 4C086/ZB08;
 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB26;
 4C086/ZB33; 4C086/ZB35; 4C086/ZB38; 4C086/ZC10;
 4C086/ZC11; 4C086/ZC31; 4C086/ZC35; 4C086/ZC55

NZ 534395

IPCI

A61K0031-4412 [ICS,7]; A61K0029-00 [ICS,7]; C07D0213-64

[ICS,7]; C07D0213-69 [ICS,7]; C07D0213-70 [ICS,7];
 C07D0213-74 [ICS,7]; C07D0213-75 [ICS,7]; C07D0213-79
 [ICS,7]; C07D0213-84 [ICS,7]; C07D0213-85 [ICS,7];
 C07D0213-00 [ICS,7,C*]; C07D0215-22 [ICS,7];
 C07D0215-00 [ICS,7,C*]; C07D0401-04 [ICS,7];
 C07D0401-06 [ICS,7]; C07D0401-10 [ICS,7]; C07D0401-12
 [ICS,7]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*];
 C07D0405-04 [ICS,7]; C07D0405-06 [ICS,7]; C07D0405-12
 [ICS,7]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*];
 C07D0409-06 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00
 [ICS,7,C*]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*]
 IPCR A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
 A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
 A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
 A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
 [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*];
 A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
 A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
 [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
 A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
 [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
 A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
 [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
 A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
 [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
 A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
 [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
 A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
 [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
 A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
 A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
 A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
 [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
 A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
 [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
 A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
 C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
 C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
 [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
 C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
 C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
 C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
 ECLA C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
 C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
 C07D213/85; C07D215/22D; C07D401/04+213+211;
 C07D401/04+231+213; C07D401/04+239B+213;
 C07D401/06+213+209C; C07D401/06+213+211;
 C07D401/06+217+213; C07D401/06+231+213;
 C07D401/06+239B+213; C07D401/06+241B+213;
 C07D401/10+213+211; C07D401/10+231+213;
 C07D401/10+233+213; C07D401/12+213+207;
 C07D401/12+233+213; C07D401/14+239B+213+211;

			C07D405/04+307B+213; C07D405/06+307B+213; C07D405/06+317+213; C07D405/12+307B+213; C07D405/14+307B+307B+213; C07D409/06+333B+213; C07D409/14+333B+333B+213; C07D413/10+261+213
IN	2004DN02150	IPCI	A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0213-69 [ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-74 [ICS,7]; C07D0405-06 [ICS,7]; C07D0213-84 [ICS,7]; C07D0401-10 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-12 [ICS,7]; C07D0213-75 [ICS,7]; C07D0401-14 [ICS,7]; C07D0213-79 [ICS,7]; C07D0401-04 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C*]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0213-85 [ICS,7]; C07D0213-00 [ICS,7,C*]
MX	2004PA07470	IPCI	A61K0031-4412 [ICM,7]; A61P0029-00 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-69 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-74 [ICS,7]; C07D0213-75 [ICS,7]; C07D0213-79 [ICS,7]; C07D0213-84 [ICS,7]; C07D0213-85 [ICS,7]; C07D0213-00 [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00 [ICS,7,C*]; C07D0401-04 [ICS,7]; C07D0401-06 [ICS,7]; C07D0401-10 [ICS,7]; C07D0401-12 [ICS,7]; C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0405-06 [ICS,7]; C07D0405-12 [ICS,7]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0409-06 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00 [ICS,7,C*]; C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*]
ZA	2004006275	IPCI	A61K [ICM,7]; A61P [ICS,7]; C07D [ICS,7]
NO	2004003820	IPCI	C07D0213-64 [ICM,7]; C07D0213-00 [ICM,7,C*]
		IPCR	A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C*]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A]; A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472 [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00 [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*]; A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00 [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*]; A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A]; A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00 [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];

C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
 C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
 [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
 C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
 C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
 C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
 ECLA C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
 C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
 C07D213/85; C07D215/22D; C07D401/04+213+211;
 C07D401/04+231+213; C07D401/04+239B+213;
 C07D401/06+213+209C; C07D401/06+213+211;
 C07D401/06+217+213; C07D401/06+231+213;
 C07D401/06+239B+213; C07D401/06+241B+213;
 C07D401/10+213+211; C07D401/10+231+213;
 C07D401/10+233+213; C07D401/12+213+207;
 C07D401/12+233+213; C07D401/14+239B+213+211;
 C07D405/04+307B+213; C07D405/06+307B+213;
 C07D405/06+317+213; C07D405/12+307B+213;
 C07D405/14+307B+307B+213; C07D409/06+333B+213;
 C07D409/14+333B+333B+213; C07D413/10+261+213
 US 20060211694 IPCI A61K0031-53 [I,A]; A61K0031-506 [I,A]; A61K0031-498
 [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,C*];
 A61K0031-501 [I,A]; A61K0031-4439 [I,A]; A61K0031-4427
 [I,C*]; A61K0031-4747 [I,A]; A61K0031-4709 [I,A];
 A61K0031-4412 [I,A]
 IPCR A61K0031-53 [I,C]; A61K0031-53 [I,A]; A61K0031-4412
 [I,C]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C];
 A61K0031-4439 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709
 [I,A]; A61K0031-4747 [I,C]; A61K0031-4747 [I,A];
 A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-498
 [I,C]; A61K0031-498 [I,A]; A61K0031-501 [I,C];
 A61K0031-501 [I,A]; A61K0031-506 [I,C]; A61K0031-506
 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A];
 C07D0213-00 [I,C*]; C07D0213-64 [I,A]; C07D0213-69
 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A];
 C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-84
 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C*];
 C07D0215-22 [I,A]; C07D0401-00 [I,C*]; C07D0401-04
 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A];
 C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00
 [I,C*]; C07D0405-04 [I,A]; C07D0405-06 [I,A];
 C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00
 [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A];
 C07D0413-00 [I,C*]; C07D0413-10 [I,A]
 NCL 514/241.000; 514/252.030; 514/255.050; 514/256.000;
 514/307.000; 514/338.000; 514/340.000; 514/341.000;
 514/344.000; 514/345.000; 544/209.000; 544/238.000;
 544/333.000; 544/405.000; 546/015.000; 546/148.000;
 546/256.000; 546/272.700; 546/275.400; 546/276.400;
 546/284.400; 546/288.000; 546/290.000
 ECLA C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
 C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
 C07D213/85; C07D215/22D; C07D401/04+213+211;
 C07D401/04+231+213; C07D401/04+239B+213;
 C07D401/06+213+209C; C07D401/06+213+211;
 C07D401/06+217+213; C07D401/06+231+213;
 C07D401/06+239B+213; C07D401/06+241B+213;


C07D401/10+213+211; C07D401/10+231+213;
 C07D401/10+233+213; C07D401/12+213+207;
 C07D401/12+233+213; C07D401/14+239B+213+211;
 C07D405/04+307B+213; C07D405/06+307B+213;
 C07D405/06+317+213; C07D405/12+307B+213;
 C07D405/14+307B+307B+213; C07D409/06+333B+213;
 C07D409/14+333B+333B+213; C07D413/10+261+213
 US 20070088033 IPCI A61K0031-53 [I,A]; A61K0031-506 [I,A]; A61K0031-497
 [I,A]; A61K0031-4965 [I,C*]; A61K0031-4439 [I,A];
 A61K0031-4427 [I,C*]; A61K0031-4545 [I,A];
 A61K0031-4523 [I,C*]; A61K0031-4709 [I,A]; C07D0417-02
 [I,A]; C07D0417-00 [I,C*]; C07D0403-02 [I,A];
 C07D0403-00 [I,C*]; C07D0401-02 [I,A]; C07D0401-00
 [I,C*]
 IPCR A61K0031-53 [I,C]; A61K0031-53 [I,A]; A61K0031-4427
 [I,C]; A61K0031-4439 [I,A]; A61K0031-4523 [I,C];
 A61K0031-4545 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709
 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A];
 A61K0031-506 [I,C]; A61K0031-506 [I,A]; C07D0401-00
 [I,C]; C07D0401-02 [I,A]; C07D0403-00 [I,C];
 C07D0403-02 [I,A]; C07D0417-00 [I,C]; C07D0417-02 [I,A]
 NCL 514/241.000; 514/255.050; 514/256.000; 514/310.000;
 514/314.000; 514/318.000; 514/340.000; 514/341.000;
 544/209.000; 544/333.000; 544/405.000; 546/148.000;
 546/169.000; 546/194.000; 546/268.400; 546/269.700;
 546/272.700; 546/273.100; 546/275.100
 JP 2007023053 IPCI C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0401-06
 [I,A]; C07D0409-06 [I,A]; C07D0213-70 [I,A];
 C07D0213-74 [I,A]; C07D0405-04 [I,A]; C07D0401-10
 [I,A]; C07D0213-75 [I,A]; C07D0405-12 [I,A];
 C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0401-00
 [I,C*]; C07D0213-80 [I,A]; C07D0213-00 [I,C*];
 C07D0405-06 [I,A]; C07D0405-14 [I,A]; C07D0405-00
 [I,C*]; C07D0409-14 [I,A]; C07D0409-00 [I,C*];
 A61K0031-4412 [I,A]; A61K0031-4545 [I,A]; A61K0031-4535
 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4418 [I,A];
 A61K0031-4725 [I,A]; A61K0031-472 [I,C*]; A61K0031-4439
 [I,A]; A61K0031-443 [I,A]; A61K0031-5377 [I,A];
 A61K0031-5375 [I,C*]; A61K0031-497 [I,A]; A61K0031-4965
 [I,C*]; A61K0031-506 [I,A]; A61K0031-444 [I,A];
 A61K0031-4427 [I,A]; A61K0031-4436 [I,A]; A61P0043-00
 [I,A]; A61P0029-00 [I,A]; A61P0019-02 [I,A];
 A61P0019-06 [I,A]; A61P0037-02 [I,A]; A61P0025-00
 [I,A]; A61P0037-08 [I,A]; A61P0037-00 [I,C*];
 A61P0011-00 [I,A]; A61P0035-00 [I,A]; A61P0011-06
 [I,A]; A61P0009-10 [I,A]; A61P0007-02 [I,A];
 A61P0007-00 [I,C*]; A61P0009-04 [I,A]; A61P0009-12
 [I,A]; A61P0009-00 [I,C*]; A61P0013-12 [I,A];
 A61P0013-00 [I,C*]; A61P0017-02 [I,A]; A61P0001-16
 [I,A]; A61P0001-04 [I,A]; A61P0027-02 [I,A];
 A61P0027-06 [I,A]; A61P0027-00 [I,C*]; A61P0001-02
 [I,A]; A61P0001-00 [I,C*]; A61P0003-10 [I,A];
 A61P0003-00 [I,C*]; A61P0017-00 [I,A]; A61P0017-06
 [I,A]; A61P0031-04 [I,A]; A61P0031-12 [I,A];
 A61P0033-06 [I,A]; A61P0033-00 [I,C*]; A61P0031-18
 [I,A]; A61P0031-22 [I,A]; A61P0031-16 [I,A];
 A61P0031-00 [I,C*]; A61P0019-10 [I,A]; A61P0015-08
 [I,A]; A61P0015-00 [I,C*]; A61P0019-08 [I,A];
 A61P0019-00 [I,C*]; A61P0035-02 [I,A]; A61P0025-28
 [I,A]; A61P0025-16 [I,A]; A61P0025-14 [I,A];
 A61P0021-04 [I,A]; A61P0021-00 [I,C*]; A61P0025-02

[I,A]; C07D0413-10 [I,A]; C07D0413-00 [I,C*]
 IPCR C07D0213-00 [I,C]; C07D0213-64 [I,A]; A61K0031-4412
 [I,C]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C];
 A61K0031-4418 [I,A]; A61K0031-4427 [I,C]; A61K0031-4427
 [I,A]; A61K0031-443 [I,A]; A61K0031-4436 [I,A];
 A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523
 [I,C]; A61K0031-4535 [I,A]; A61K0031-4545 [I,A];
 A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
 [I,C]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*];
 A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497
 [I,A]; A61K0031-506 [I,C]; A61K0031-506 [I,A];
 A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61P0001-00
 [I,C]; A61P0001-02 [I,A]; A61P0001-04 [I,A];
 A61P0001-16 [I,A]; A61P0003-00 [I,C]; A61P0003-10
 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A];
 A61P0009-00 [I,C]; A61P0009-04 [I,A]; A61P0009-10
 [I,A]; A61P0009-12 [I,A]; A61P0011-00 [I,C];
 A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00
 [I,C]; A61P0013-12 [I,A]; A61P0015-00 [I,C];
 A61P0015-08 [I,A]; A61P0017-00 [I,C]; A61P0017-00
 [I,A]; A61P0017-02 [I,A]; A61P0017-06 [I,A];
 A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0019-06
 [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A];
 A61P0021-00 [I,C]; A61P0021-04 [I,A]; A61P0025-00
 [I,C]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
 A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C];
 A61P0027-02 [I,A]; A61P0027-06 [I,A]; A61P0029-00
 [I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C];
 A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16
 [I,A]; A61P0031-18 [I,A]; A61P0031-22 [I,A];
 A61P0033-00 [I,C]; A61P0033-02 [I,A]; A61P0033-06
 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A];
 A61P0035-02 [I,A]; A61P0037-00 [I,C]; A61P0037-02
 [I,A]; A61P0037-06 [I,A]; A61P0037-08 [I,A];
 A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D0213-69
 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A];
 C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80
 [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A];
 C07D0213-85 [I,A]; C07D0215-00 [I,C*]; C07D0215-22
 [I,A]; C07D0401-00 [I,C]; C07D0401-04 [I,A];
 C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12
 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C];
 C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12
 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C];
 C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00
 [I,C]; C07D0413-10 [I,A]
 ECLA C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
 C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
 C07D213/85; C07D215/22D; C07D401/04+213+211;
 C07D401/04+231+213; C07D401/04+239B+213;
 C07D401/06+213+209C; C07D401/06+213+211;
 C07D401/06+217+213; C07D401/06+231+213;
 C07D401/06+239B+213; C07D401/06+241B+213;
 C07D401/10+213+211; C07D401/10+231+213;
 C07D401/10+233+213; C07D401/12+213+207;
 C07D401/12+233+213; C07D401/14+239B+213+211;
 C07D405/04+307B+213; C07D405/06+307B+213;
 C07D405/06+317+213; C07D405/12+307B+213;
 C07D405/14+307B+307B+213; C07D409/06+333B+213;
 C07D409/14+333B+333B+213; C07D413/10+261+213


FTERM		4C055/AA01; 4C055/AA03; 4C055/AA04; 4C055/AA05; 4C055/AA06; 4C055/AA09; 4C055/AA10; 4C055/AA12; 4C055/AA13; 4C055/BA01; 4C055/BA02; 4C055/BA03; 4C055/BA05; 4C055/BA06; 4C055/BA16; 4C055/BA25; 4C055/BA27; 4C055/BA42; 4C055/BA50; 4C055/BB02; 4C055/BB08; 4C055/CA01; 4C055/CA02; 4C055/CA05; 4C055/CA06; 4C055/CA13; 4C055/CA25; 4C055/CA39; 4C055/CA57; 4C055/CA59; 4C055/DA01; 4C055/DA05; 4C055/DA06; 4C055/DA22; 4C055/DA25; 4C055/DA47; 4C055/DA53; 4C055/DB01; 4C055/DB02; 4C055/DB07; 4C055/EA01; 4C063/AA01; 4C063/AA03; 4C063/BB02; 4C063/BB05; 4C063/BB06; 4C063/BB07; 4C063/BB08; 4C063/BB09; 4C063/CC12; 4C063/CC15; 4C063/CC22; 4C063/CC25; 4C063/CC29; 4C063/CC34; 4C063/CC73; 4C063/CC75; 4C063/CC92; 4C063/DD03; 4C063/DD06; 4C063/DD10; 4C063/DD12; 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BC17; 4C086/BC21; 4C086/BC28; 4C086/BC30; 4C086/BC37; 4C086/BC38; 4C086/BC39; 4C086/BC42; 4C086/BC48; 4C086/BC50; 4C086/BC73; 4C086/GA02; 4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA01; 4C086/ZA02; 4C086/ZA07; 4C086/ZA08; 4C086/ZA15; 4C086/ZA16; 4C086/ZA18; 4C086/ZA20; 4C086/ZA33; 4C086/ZA34; 4C086/ZA36; 4C086/ZA37; 4C086/ZA40; 4C086/ZA45; 4C086/ZA53; 4C086/ZA59; 4C086/ZA67; 4C086/ZA68; 4C086/ZA75; 4C086/ZA81; 4C086/ZA89; 4C086/ZA94; 4C086/ZA96; 4C086/ZA97; 4C086/ZB05; 4C086/ZB07; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB26; 4C086/ZB27; 4C086/ZB33; 4C086/ZB35; 4C086/ZB38; 4C086/ZC02; 4C086/ZC54; 4C086/ZC55
KR 2007017443	IPCI	A61K0031-4412 [I,A]; A61P0029-00 [I,A]; C07D0401-06 [I,A]; C07D0401-00 [I,C*]
AU 2007202607	IPCI	A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C*]; A61K0031-4418 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A]; A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472 [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00 [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*]; A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00 [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*]; A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A]; A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00 [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];

A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]

OS MARPAT 139:197371
GI



I



II

AB Disclosed are title compds. I [wherein R¹ = H, halo, NO₂, CHO, CN, CO₂H, or (un)substituted (halo)alkyl, (aryl)alkoxy, aryl(alkyl), alkenyl, (aryl)alkynyl, (aryl)alkanoyl, alkoxyalkyl, or haloalkoxy; R² = H, OH, halo, NR⁸R⁹, CO₂R, or (un)substituted OSO₂-alkyl, OSO₂-aryl, arylalkoxy, aryloxy(alkyl), arylthio(alkoxy), arylalkynyl, alkoxy(alkoxy), alkyl, alkynyl, OCONH(CH₂)_n-aryl, OCON(alkyl)(CH₂)_n-aryl, dialkylamino, (hetero)aryl(alkyl), arylalkenyl, or heterocycloalkyl(alkyl); R³ = H, halo, alkenyl, NR⁶R⁷, NR⁶R⁷-alkyl, alkyl, or (un)substituted (aryl)alkoxycarbonyl, aryloxycarbonyl, arylalkyl, OCONH(CH₂)_n-aryl, arylalkoxy, OCON(alkyl)(CH₂)_n-aryl, aryloxy, arylthio, or (aryl)thioalkoxy; R⁴ = H or (un)substituted alkyl; R⁵ = H, aryl, aryl(thio)alkyl, NH₂, alkoxyalkyl, alkynyl, SO₂-alkyl, (hetero)cycloalkyl(alkyl), heteroaryl, or (un)substituted alkyl, alkoxy(alkyl), or alkenyl; R⁶ and R⁷ = independently H, OH, or (un)substituted (aryl)alkyl, alkoxy(alkyl), alkanoyl(alkyl), arylalkoxy, SO₂-alkyl, (aryl)alkoxycarbonyl, heteroarylalkyl, or arylalkanoyl; or NR⁶R⁷ = (un)substituted (thio)morpholinyl, pyrrolidinyl, piperidinyl, pyrrolidinyl, or piperazinyl; R⁸ = independently H or (un)substituted (aryl)alkyl or (aryl)alkanoyl; R⁹ = H or (un)substituted (aryl)alkyl, (aryl)alkanoyl, cycloalkyl(alkyl), alkenyl, heteroaryl, (alkyl)aminoalkyl, SO₂Ph, or aryl; R = independently H or (un)substituted alkyl; n = 0-6; and pharmaceutically acceptable salts thereof]. These compds. are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity, such as inflammation, ischemia, viral infections, and autoimmune diseases (no data). Pharmaceutical compns. containing I, methods of preparing them, and methods of treatment using the compds. are also disclosed. For example, reaction of 4-benzyloxy-2(1H)-pyridone with EtBr in the presence of K₂CO₃ in DMF gave II. The latter inhibited MKK6-activated human p38α kinase phosphorylation of a biotinylated substrate or human p38α-induced phosphorylation of EGFRP (epidermal growth factor receptor peptide) with an IC₅₀ in the range of 1 μM to 25 μM.

ST pyridone p38 MAP kinase inhibitor antiinflammatory antiviral antiischemic immunomodulator

IT AIDS (disease)
 (-related complex, cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lymphoma
 (B-cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
 (Crohn's disease; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, disease
 (Crohn's; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Nervous system, disease
 (Huntington's chorea; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma
 (adenocarcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Respiratory distress syndrome
 (adult; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Transplant rejection
 (allotransplant; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Nervous system, disease
 (amyotrophic lateral sclerosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Blood vessel, neoplasm
 (angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Bone
 (avascular necrosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Necrosis
 (avascular, bone; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Infection
 (bacterial; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Skin, neoplasm
 (basal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma
(basal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT AIDS (disease)
Human herpesvirus
Pneumonia
(cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart, disease
(cardiomyopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Edema
Ischemia
(cerebral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Uterus, neoplasm
(cervix; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
Lung, disease
(chronic pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm
(colon; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm
(colorectal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Transplant rejection
(corneal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Kidney, disease
(diabetic nephropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
(diabetic retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease
(edema; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Uterus, disease
(endometriosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(epidermal growth factor-binding; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart, disease
(failure; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Ulcer
(gastric; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
Stomach, disease
(gastritis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Transplant and Transplantation
(graft-vs.-host reaction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Blood vessel, neoplasm
(hemangioma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart, disease
(infarction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, disease
(inflammatory; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
Reperfusion
Spinal cord, disease
(injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, disease
(irritable bowel syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease
(ischemia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Rheumatoid arthritis
(juvenile; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Neoplasm
(metastasis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Pharynx
(nasopharynx, angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions,

ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lip
(neoplasm; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Glaucoma (disease)
(neovascular; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Angiogenesis
(neovascularization, eye; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Angiogenesis
(neovascularization, retinal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
(neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
Kidney, disease
(nephritis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
(neurogenic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Nerve, disease
(neuropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury
(ocular; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
(photophobia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
Lung, disease
(pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Alzheimer's disease
Analgesics
Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiartherosclerotics
Antiarthritics
Antiasthmatics

Antibacterial agents
Anticoagulants
Antidiabetic agents
Antimalarials
Antiparkinsonian agents
Antipyretics
Antirheumatic agents
Antitumor agents
Antiulcer agents
Antiviral agents
Arteriosclerosis
Arthritis
Asthma
Autoimmune disease
Bladder, neoplasm
Bone, neoplasm
Bone resorption
Bone resorption inhibitors
Brain, neoplasm
Burn
Cachexia
Carcinoma
Cardiovascular agents
Cardiovascular system, disease
Dermatitis
Diabetes insipidus
Diabetes mellitus
Digestive tract, disease
Digestive tract, neoplasm
Drug delivery systems
Eczema
Esophagus, neoplasm
Eye, disease
Fever and Hyperthermia
Gastrointestinal agents
Gout
Granulation tissue
Human
Immunomodulators
Inflammation
Influenza
 Ischemia
Keloid
Leukemia
Lip
Liver, disease
Liver, neoplasm
Lung, disease
Lung, neoplasm
Lymphoma
Malaria
Mammary gland, neoplasm
Meningitis
Mouth, neoplasm
Multiple sclerosis
Neoplasm
Nervous system agents
Osteoarthritis
Osteoporosis
Ovary, neoplasm
Pain

Pancreas, neoplasm
Parkinson's disease
Phosphorylation, biological
Prostate gland, neoplasm
Psoriasis
Reproduction disorders
Rheumatoid arthritis
Sepsis
Silicosis
Skin, disease
Skin, neoplasm
Solid phase synthesis
Stomach, neoplasm
Thrombosis

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Sarcoidosis

(pulmonary; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Kidney, neoplasm

(renal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma

(renal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart

Kidney

(reperfusion injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury

(reperfusion; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease

(retina, neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease

(retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease

(retrolental fibroplasia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lung, disease

(sarcoidosis; preparation of pyridinones as modulators of p38 MAP kinase for

treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Shock (circulatory collapse)
(septic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm
(small; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury
(spinal cord; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Spinal column, disease
(spondyloarthropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease
(stroke; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lupus erythematosus
(systemic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Shock (circulatory collapse)
(toxic shock syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease
(trauma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Stomach, disease
(ulcer; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
Intestine, disease
(ulcerative colitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
Inflammation
(uveitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Infection
(viral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Central nervous system, disease
(with inflammatory or apoptotic component; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 329-59-9P, Methyl 4-fluoro-3-nitrobenzoate 369-26-6P, Methyl

3-amino-4-fluorobenzoate 874-97-5P, 3-Hydroxymethylbenzonitrile
 3446-91-1P, 4-Bromomethyl-N,N-dimethylbenzenesulfonamide 3749-51-7P,
 4-Hydroxy-6-methyl-2(1H)-pyridone 13737-35-4P, (2-
 Bromomethylphenyl)acetic acid 13737-37-6P, Methyl (2-
 Bromomethylphenyl)acetate 19858-50-5P, [2-(Methylthio)pyrimidin-5-
 yl]methanol 21317-88-4P, 1-Allyl-4-hydroxy-6-methylpyridin-2(1H)-one
 21642-98-8P, 4-Methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile
 24812-90-6P, Methyl 3-amino-4-methoxybenzoate 26576-93-2P,
 3-Chloro-4-hydroxy-6-methyl-1H-pyridin-2-one 33524-79-7P,
 1-Benzyl-4-hydroxy-6-methylpyridin-2(1H)-one 38275-41-1P, Methyl
 2-(methylthio)pyrimidine-5-carboxylate 39204-47-2P, 2-
 Chloromethylpyrazine 41110-34-3P, Ethyl 5-methylpyrazine-2-carboxylate
 49668-89-5P 49668-90-8P, Methyl 6-(chloromethyl)nicotinate
 68432-92-8P, Methyl 3-cyanomethylbenzoate 76518-57-5P,
 Isoquinolin-5-ylmethanol 104317-94-4P, 3-Amino-4-chlorobenzyl alcohol
 119887-89-7P, 3-Acetyl-1-(2-chlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-
 one 121669-69-0P, 4-Methylpyrazole-1-carboxylic acid tert-butyl ester
 123226-36-8P, (3-Bromomethylphenyl)acetonitrile 135645-63-5P,
 4-(Bromomethyl)-2-(methylthio)pyrimidine 140215-42-5P, Ethyl
 (3-bromomethylphenyl)acetate 171670-20-5P, Methyl 3-bromomethyl-2-
 fluorobenzoate 177665-49-5P, (3-Hydroxymethylphenyl)acetonitrile
 185629-32-7P, Methyl 4-amino-3-fluorobenzoate 186551-69-9P,
 3-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester 186551-70-2P,
 3-Methylpyrazole-1-carboxylic acid tert-butyl ester 217661-27-3P,
 2-(Bromomethyl)-5-fluorobenzonitrile 220364-34-1P, [3-
 (Bromomethyl)benzyl]carbamic acid tert-butyl ester 220798-39-0P
 226070-69-5P, [3-(Hydroxymethyl)benzyl]carbamic acid tert-butyl ester
 227609-86-1P, (3-Amino-4-fluorophenyl)methanol 391957-11-2P,
 3-[(tert-Butyldimethylsilyloxy)methyl]benzylamine 530144-72-0P,
 4-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester 586373-04-8P,
 1-Benzyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl 4-bromobenzenesulfonate
 586373-18-4P, 1-Benzyl-3-bromo-4-hydroxypyridin-2(1H)-one 586373-21-9P,
 1-Benzyl-3-bromo-4-(phenylethynyl)pyridin-2(1H)-one 586373-24-2P,
 3-Acetyl-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
 586373-25-3P, 1-(2,6-Dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
 586373-26-4P, 4-(Benzyloxy)-1-(2,6-dichlorophenyl)-6-methylpyridin-2(1H)-
 one 586373-29-7P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl
 N-methyl-N-phenylcarbamate 586373-31-1P, 4-(Benzyloxy)-1-(3-
 fluorobenzyl)-3-iodopyridin-2(1H)-one 586373-32-2P, 4-(Benzyloxy)-1-(3-
 fluorobenzyl)-3-[(trimethylsilyl)ethynyl]pyridin-2(1H)-one 586373-34-4P,
 1-(3-Fluorobenzyl)-4-hydroxypyridin-2(1H)-one 586373-35-5P,
 4-(Benzylamino)-1-(3-fluorobenzyl)pyridin-2(1H)-one 586373-37-7P,
 4-[(4-Fluorobenzyl)oxy]pyridine-1-oxide 586373-38-8P,
 4-[(4-Fluorobenzyl)oxy]pyridine-2(1H)-one 586373-39-9P,
 3-Bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one 586373-51-5P,
 3-[(tert-Butyldimethylsilyloxy)methyl]benzonitrile 586373-57-1P,
 4-[(2,4-Difluorobenzyl)oxy]pyridine-1-oxide 586373-58-2P,
 4-[(2,4-Difluorobenzyl)oxy]pyridin-2(1H)-one 586373-59-3P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-60-6P,
 3-Bromo-1-(4-chloromethylbenzyl)-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-
 one 586373-67-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
 586373-68-4P, 3-Chloro-1-(4-chloromethylbenzyl)-4-[(2,4-
 difluorobenzyl)oxy]-1H-pyridin-2-one 586373-70-8P, 1-Chloromethyl-3-
 (methanesulfonyl)benzene 586373-73-1P, Methyl 4-[[3-chloro-4-[(2,4-
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586373-76-4P,
 5-Bromomethylisoquinoline hydrobromide 586373-79-7P,
 [5-(Carboxymethyl)indol-1-yl]carbamic acid tert-butyl ester
 586373-80-0P, [5-Hydroxymethylindol-1-yl]carbamic acid tert-butyl ester
 586373-81-1P, [5-Bromomethylindol-1-yl]carbamic acid tert-butyl ester
 586373-82-2P, [5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
 yl]methyl]indol-1-yl]carbamic acid tert-butyl ester 586373-93-5P,

4-[(2,4-Difluorobenzyl)oxy]-1-(2,4-difluorobenzyl)-1H-pyridin-2-one
 586374-02-9P, 3-Bromo-1-(3-bromomethyl-2-fluorobenzyl)-4-[(2,4-
 difluorobenzyl)oxy]-1H-pyridin-2-one 586374-04-1P, Methyl
 2-fluoro-3-methylbenzoate 586374-07-4P, 3-Bromo-1-(3-fluorobenzyl)-4-
 hydroxypyridin-2(1H)-one 586374-12-1P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-
 fluorobenzyl)-1H-pyridin-2-one 586374-29-0P, Methyl [2-[[3-bromo-4-[(2,4-
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetate
 586374-37-0P, 1-(3-Fluorobenzyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-
 carbonitrile 586374-38-1P, 1-(3-Fluorobenzyl)-4-hydroxy-2-oxo-1,2-
 dihydropyridine-3-carbonitrile 586374-40-5P, Methyl 1-cyclohexyl-4-
 hydroxy-2,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate
 586374-41-6P, 1-Cyclohexyl-4-hydroxy-2,5-dimethyl-6-oxo-1,6-
 dihydropyridine-3-carboxylic acid 586374-42-7P, 1-Cyclohexyl-4-hydroxy-
 3,6-dimethyl-1H-pyridin-2-one 586374-44-9P, 4-[[3-Chloro-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazole-1-
 carboxylic acid tert-butyl ester 586374-45-0P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-09-9P,
 4-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]benzonitrile 586375-14-6P,
 1-(4-Cyanophenyl)-4-hydroxy-2(1H)-pyridinone 586375-15-7P,
 4-[4-[(2,4-Difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]benzonitrile
 586375-16-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1(2H)-
 yl]benzoate 586375-18-0P, 4-Hydroxy-1-[3-(hydroxymethyl)phenyl]-6-
 methylpyridin-2(1H)-one 586375-19-1P, 1-[3-(Hydroxymethyl)phenyl]-4-
 [(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-21-5P, Methyl
 4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586375-22-6P,
 Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]benzoate 586375-29-3P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-2-oxo-2H-pyridin-1-yl]methyl]benzaldehyde 586375-31-7P,
 1-(4-Methoxybenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586375-35-1P,
 4-Hydroxy-4-methylpiperidine hydrochloride 586375-72-6P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
 586375-93-1P 586375-98-6P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-
 1-yl)benzoate 586376-00-3P, Methyl 3-[3-bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate
 586376-21-8P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
 oxo-2H-pyridin-1-yl]benzoate 586376-24-1P, 1-[3-(Chloromethyl)phenyl]-4-
 [(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-25-2P,
 1-[3-(Aminomethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
 2(1H)-one 586376-34-3P 586376-39-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-[3-
 [(dimethylamino)methyl]phenyl]-6-methylpyridin-2(1H)-one 586376-52-5P,
 3,4-Dibromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586376-56-9P,
 4-Azido-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586376-58-1P,
 4-Amino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one hydrochloride
 586376-62-7P, 1-(4-Bromo-2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-
 2(1H)-one 586376-74-1P, 4-[(2,4-Difluorobenzyl)oxy]-6-(hydroxymethyl)-1-
 (2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-80-9P,
 4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-yl)phenyl]-6-
 methylpyridin-2(1H)-one 586376-91-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-
 difluoro-4-hydroxyphenyl)-6-methylpyridin-2(1H)-one 586376-95-6P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-hydroxyphenyl)-6-
 methylpyridin-2(1H)-one 586376-99-0P, 1-(2,6-Difluorophenyl)-4-[[4-
 fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one
 586377-01-7P, 1-(2,6-Difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
 586377-08-4P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-
 methylbenzoate 586377-09-5P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoate 586377-10-8P,
 3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-
 methylbenzoic acid 586377-11-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
 6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-32-4P,
 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-
 methylbenzoic acid 586377-38-0P, tert-Butyl [4-[3-chloro-4-[(2,4-

difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]carbamate 586377-40-4P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl](methyl)carbamate 586377-41-5P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl](cyclopropylmethyl)carbamate 586377-43-7P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzamide 586377-45-9P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-hydroxybenzonitrile 586377-46-0P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-hydroxybenzonitrile potassium salt 586377-58-4P, 1-(3-Fluorobenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-59-5P, 3-Bromo-1-(3-fluorobenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-60-8P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586377-61-9P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-4-(phenylethynyl)pyridin-2(1H)-one 586377-66-4P, 1-(2,6-Dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-67-5P, 3-Bromo-1-(2,6-dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-72-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-76-6P, 4-Hydroxy-1-(2-methoxy-6-methylphenyl)-6-methylpyridin-2(1H)-one 586377-77-7P, 3-Bromo-4-hydroxy-1-(2-methoxy-6-methylphenyl)-6-methylpyridin-2(1H)-one 586377-79-9P, 3,5-Dichloro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzenesulfonamide 586377-81-3P, 3-Bromo-1-(2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-84-6P, 3,5-Difluoro-N,N-dimethylbenzene-1,2-diamine 586377-85-7P, 1-[2-(Dimethylamino)-4,6-difluorophenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586377-86-8P, 3-Bromo-1-[2-(dimethylamino)-4,6-difluorophenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586378-01-0P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586378-02-1P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one 586378-06-5P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-hydroxy-6-methylpyridin-2(1H)-one 586378-26-9P, 4-Hydroxy-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-27-0P, 3-Bromo-4-hydroxy-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-30-5P, Ethyl 5-(bromomethyl)pyrazine-2-carboxylate 586378-34-9P, 3-Bromo-1-[[5-(chloromethyl)pyrazin-2-yl]methyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586378-40-7P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylic acid 586378-50-9P, 1-(3-Fluorobenzyl)-4-hydroxy-3-iodopyridin-2(1H)-one 586378-55-4P, 4-Amino-1-(3-fluorobenzyl)pyridin-2(1H)-one 586378-56-5P, 4-Fluoro-N-[1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]benzamide 586378-58-7P, 3-Chloro-1-(2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586378-60-1P, 1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)amino]-6-methylpyridin-2(1H)-one 586378-64-5P, 3-Bromo-4-hydroxy-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586378-66-7P, 3-Bromo-4-hydroxy-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-68-9P, 3-Bromo-4-hydroxy-6-methyl-1-(pyridin-2-ylmethyl)pyridin-2(1H)-one 586378-69-0P, 586378-84-9P, 3-Bromo-6-methyl-2-oxo-1-[(pyridin-3-yl)methyl]-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586378-85-0P, 3-Bromo-4-[2-(4-fluorophenyl)ethynyl]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one 586378-88-3P, 3-Chloro-4-hydroxy-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-99-6P, 3-Chloro-4-hydroxy-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586379-10-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylic acid 586379-14-8P, 1-Allyl-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-16-0P, 1-Allyl-3-chloro-4-hydroxy-6-methylpyridin-2(1H)-one 586379-19-3P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-prop-2-ynylpyridin-2(1H)-one 586379-26-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carboxaldehyde 586379-27-3P, 4-[(2,4-

Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-one 586379-36-4P, Methyl 4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-3-methylbenzoate 586379-37-5P, Methyl 4-(3-bromo-4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-3-methylbenzoate 586379-43-3P, 1-(4-Bromo-2-methylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586379-44-4P, 1-(4-Bromo-2-methylphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-45-5P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(2-methyl-4-vinylphenyl)pyridin-2(1H)-one 586379-48-8P, Methyl 4-chloro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586379-49-9P, Methyl 4-chloro-3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586379-52-4P, 4-Hydroxy-1-[5-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-53-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-55-7P, 1-[2-Chloro-5-(hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586379-56-8P, 1-[2-Chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-58-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzaldehyde 586379-61-5P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methylbenzoate 586379-62-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-63-7P, 3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586379-64-8P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586379-70-6P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-73-9P, Methyl 3-chloro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586379-74-0P, Methyl 3-chloro-4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586379-77-3P, 4-[(2,4-Difluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-82-0P, 4-[(2,4-Difluorobenzyl)amino]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586379-86-4P, 4-[(2,4-Difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586379-89-7P, 3-[(4-Hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzonitrile 586379-90-0P, 3-[4-[(2,4-Difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-94-4P, 1-[2-Fluoro-5-(hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586379-95-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[2-fluoro-5-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586379-97-7P, Methyl 4-fluoro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586379-98-8P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586379-99-9P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586380-12-3P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586380-14-5P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methoxybenzoate 586380-15-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxybenzoate 586380-16-7P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxybenzoate 586380-20-3P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzamide 586380-49-6P 586380-51-0P, 4-[(2,4-Difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586380-53-2P 586380-54-3P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]nicotinic acid 586380-58-7P, 4-Hydroxy-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-one 586380-59-8P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-one 586380-65-6P, 4-(Benzyloxy)-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586380-83-8P 586380-84-9P 586380-85-0P 586380-88-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzoic acid 586380-90-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid

586381-05-7P, Methyl 3-fluoro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586381-06-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoate 586381-12-6P, 1-[4-(Aminomethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-13-7P, [2-[[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]amino]-2-oxoethyl] acetate 586381-16-0P, tert-Butyl [4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]carbamate 586381-33-1P, 4-Bromomethyl-N-(2-hydroxyethyl)benzenesulfonamide 586381-36-4P, 4-Bromomethyl-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide 586381-39-7P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazole-1-carboxylic acid tert-butyl ester 586381-41-1P, [5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]indol-1-yl]carbamic acid tert-butyl ester 586381-42-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-indol-5-ylmethyl)-1H-pyridin-2-one 586381-44-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-3,3-dibromo-1H-indol-2-one 586381-53-5P, 586381-55-7P, 4-Hydroxy-1-(1H-indazol-5-yl)-6-methylpyridin-2(1H)-one 586381-57-9P, 4-Hydroxy-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one 586381-59-1P, Methyl 3-[4-[(2-cyano-4-fluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-61-5P, Methyl 3-[4-[[2-(aminomethyl)-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate trifluoroacetate 586381-62-6P 586381-63-7P, 3-[4-[[4-Fluoro-2-[[(methoxycarbonyl) amino]methyl]benzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-64-8P, 3-[3-Bromo-4-[[4-fluoro-2-[[(methoxycarbonyl) amino]methyl]benzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-72-8P, Methyl 3-[4-[[2-[[(ethoxycarbonyl) amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-73-9P, 3-[4-[[2-[[(ethoxycarbonyl) amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-74-0P, 3-[3-Bromo-4-[[2-[[(ethoxycarbonyl) amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-76-2P, Methyl 3-[4-[[2-[[[(cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-77-3P, 3-[4-[[2-[[[(Cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-79-5P, Ethyl (5-fluoro-2-methylphenoxy)acetate 586381-80-8P, Ethyl [2-(bromomethyl)-5-fluorophenoxy]acetate 586381-81-9P, Ethyl [2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorophenoxy]acetate 586381-82-0P, [2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorophenoxy]acetic acid 586381-84-2P, 3-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-oxopropyl acetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586381-85-3P, Methyl 3-[6-[(acetyloxy)methyl]-4-hydroxy-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-86-4P, Methyl 3-[6-[(acetyloxy)methyl]-3-bromo-4-hydroxy-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-93-3P, (2E)-4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenic acid 586381-96-6P, 2-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-[(methylamino)carbonyl]benzoic acid 586382-03-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-methylpyridin-2(1H)-one 586382-08-3P, 1-[4-(Aminomethyl)benzyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-14-1P, [1-[3-(Aminocarbonyl)phenyl]-4-hydroxy-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate 586382-15-2P, [1-[3-(Aminocarbonyl)phenyl]-4-[(2,4-

difluorobenzyl)oxy]-6-oxo-1,6-dihydropyridin-2-yl)methyl acetate
 586382-17-4P, 5-(Chloromethyl)-2-(methylthio)pyrimidine 586382-19-6P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylthio)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate 586382-21-0P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate
 586382-26-5P, Ethyl 3-[3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylphenyl]-3-oxopropanoate 586382-30-1P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]quinolin-2(1H)-one 586382-31-2P,
 Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-yl]methyl]benzoate 586382-33-4P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoic acid 586382-35-6P,
 Methyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-furoate
 586382-36-7P, Methyl 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furoate 586382-37-8P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furoic acid
 586382-39-0P, Dimethyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)isophthalate 586382-40-3P, Dimethyl 5-(3-bromo-4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)isophthalate 586382-41-4P, Dimethyl
 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]isophthalate 586382-42-5P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]isophthalic acid 586382-48-1P, tert-Butyl
 [3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]carbamate 586382-50-5P, 2-[[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]amino]-2-oxoethyl acetate 586382-52-7P, 2-[[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]amino]-1,1-dimethyl-2-oxoethyl acetate 586382-54-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586375-79-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; hydrochloride)

IT 586379-66-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(methylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one
 586380-87-2P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzamide
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586414-48-4P 586414-49-5P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 108379-95-9P 571168-92-8P, 1-Benzyl-4-(benzyloxy)-3-iodopyridin-2(1H)-

one 586372-64-7P, 4-(Benzyloxy)-1-(4-methylbenzyl)pyridin-2(1H)-one
 586372-72-7P, 4-(Benzyloxy)-1-[(3-fluorophenyl)methyl]pyridin-2(1H)-one
 586372-73-8P, 4-(Benzyloxy)-3-bromo-1-[(3-fluorophenyl)methyl]pyridin-
 2(1H)-one 586372-76-1P, 4-(Benzyloxy)-3-bromopyridin-2(1H)-one
 586372-77-2P, 4-(Benzyloxy)-1-[4-(benzyloxy)benzyl]-3-bromopyridin-2(1H)-
 one 586372-81-8P, 4-(Benzyloxy)-1-[(4-cyanophenyl)methyl]pyridin-2(1H)-
 one 586372-82-9P 586372-87-4P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-
 2(1H)-one hydrobromide 586373-00-4P, 1-Benzyl-4-(benzyloxy)-6-
 methylpyridin-2(1H)-one 586373-03-7P, 1-Benzyl-4-[(3-chlorobenzyl)oxy]-6-
 methylpyridin-2(1H)-one 586373-06-0P, 1-Benzyl-4-[(2,6-
 dichlorobenzyl)oxy]pyridin-2(1H)-one 586373-14-0P, 1-Benzyl-4-
 (benzyloxy)-3-vinylpyridin-2(1H)-one 586373-20-8P, 1-Benzyl-3-bromo-2-
 oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586373-50-4P
 586373-55-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[2-
 (hydroxymethyl)benzyl]pyridin-2(1H)-one 586373-64-0P,
 [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
 yl]methyl]benzyl]carbamic acid tert-butyl ester 586373-75-3P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(isoquinolin-5-yl)methyl]-1H-
 pyridin-2-one trifluoroacetate 586373-78-6P, 3-Chloro-4-[(2,4-
 difluorobenzyl)oxy]-1-(1H-indol-5-ylmethyl)-1H-pyridin-2-one
 586373-84-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-
 indol-5-yl)methyl]pyridin-2(1H)-one 586373-95-7P, 2-[[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
 586373-97-9P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
 pyridin-1-yl]methyl]benzoate 586374-03-0P, Methyl 3-[[3-chloro-4-[(2,4-
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-fluorobenzoate
 586374-06-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-
 fluorobenzyl)pyridin-2(1H)-one 586374-28-9P, 2-[2-[[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide
 586374-30-3P, Ethyl [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
 pyridin-1-yl]methyl]phenyl]acetate 586374-34-7P, 4-[(2,4-
 Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-
 carbonitrile 586374-39-2P, 1-Cyclohexyl-4-[(2,4-difluorobenzyl)oxy]-3,6-
 dimethylpyridin-2(1H)-one 586374-46-1P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-
 2H-pyridin-1-yl]methyl]benzonitrile 586374-47-2P, 2-[[4-(Benzyloxy)-3-
 bromo-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586374-55-2P,
 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile
 586374-59-6P, 2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]methyl]benzonitrile 586374-61-0P, 3-[[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
 586374-62-1P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]methyl]benzonitrile 586374-63-2P, 4-[[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide
 586374-65-4P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
 oxo-2H-pyridin-1-yl]methyl]benzoate 586374-70-1P, 3-Bromo-1-[4-
 (bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
 586374-72-3P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-80-3P,
 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]methyl]benzoic acid 586375-08-8P, Methyl 4-[4-(benzyloxy)-3-bromo-2-
 oxo-2H-pyridin-1-yl]benzoate 586375-10-2P, 4-[4-(Benzyloxy)-3-bromo-2-
 oxo-2H-pyridin-1-yl]benzoic acid 586375-20-4P, Methyl
 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]benzoate 586375-23-7P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-2-oxo-2H-pyridin-1-yl]benzoic acid 586375-25-9P,
 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]methyl]benzoic acid 586375-26-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
 1-[4-(hydroxymethyl)benzyl]-6-methylpyridin-2(1H)-one 586375-30-6P,
 4-[(2,4-Difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-methylpyridin-2(1H)-one
 586375-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-
 methylpyridin-2(1H)-one 586375-66-8P, 3-Bromo-4-[(2,4-

difluorobenzyl)oxy]-6-methyl-1-[4-(1-pyrrolidinylcarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-71-5P, Methyl 4-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586375-97-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoic acid 586375-99-7P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-20-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoic acid 586376-23-0P, 1-[3-(Aminomethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-64-9P, 1-(4-Bromo-2,6-difluorophenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-66-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-70-7P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586377-36-8P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzonitrile 586377-37-9P, 1-[4-(Aminomethyl)-2,6-difluorophenyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one hydrochloride 586377-80-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586377-82-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586377-88-0P, 2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile 586377-90-4P, 4-[[2-(Aminomethyl)-4-fluorobenzyl]oxy]-3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586377-96-0P, 4-[[2-(Aminomethyl)-4-fluorobenzyl]oxy]-3-chloro-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586378-00-9P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-03-2P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586378-05-4P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-12-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylthio)pyrimidin-4-yl]methyl]pyridin-2(1H)-one 586378-13-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-4-yl]methyl]pyridin-2(1H)-one 586378-15-6P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-carbonitrile trifluoroacetate 586378-29-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586378-31-6P, Ethyl 5-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylate 586378-38-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one trifluoroacetate 586378-49-6P, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-iodopyridin-2(1H)-one 586379-02-4P, Ethyl 5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylate 586379-25-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-one 586379-30-8P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carboxaldehyde 586379-42-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2-methyl-4-vinylphenyl)pyridin-2(1H)-one 586379-51-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-72-8P, Methyl 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzoate 586379-96-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoic acid 586380-11-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoic acid 586380-13-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxybenzoic acid 586380-19-0P, 1-[5-(Aminomethyl)-2-fluorophenyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586380-26-9P, 2-[[[3-Chloro-1-(2,6-difluorophenyl)-6-

methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy)methyl]-5-fluorobenzonitrile
 586380-60-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
 methyl-5-vinylpyridin-2(1H)-one 586380-61-2P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxyethyl)-6-
 methylpyridin-2(1H)-one 586380-62-3P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(hydroxymethyl)-6-
 methylpyridin-2(1H)-one 586380-63-4P, 5-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-
 dihydropyridine-3-carboxaldehyde 586380-64-5P, 4-(Benzyloxy)-3-bromo-1-
 (2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586380-67-8P,
 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-
 1,6-dihydropyridine-3-carboxaldehyde oxime 586380-73-6P,
 4-(Allylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-
 one 586380-75-8P, Ethyl 3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
 oxo-2H-1,2'-bipyridine-5'-carboxylate 586380-82-7P 586381-04-6P,
 Methyl 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]-3-fluorobenzoate 586381-07-9P, 4-[[3-Chloro-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoic acid
 586381-08-0P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]methyl]benzamide 586381-15-9P, 1-(4-Aminobenzyl)-3-bromo-4-
 [(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-40-0P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(2,3-dihydro-1H-indol-5-
 yl)methyl]-1H-pyridin-2-one 586381-58-0P, Methyl [2-[[[3-bromo-6-methyl-
 1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-2-oxo-1,2-dihydropyridin-4-
 yl]oxy)methyl]-5-fluorobenzyl]carbamate 586381-78-4P,
 3-[3-Bromo-4-[[2-[[[(cyclopropylamino)carbonyl]amino]methyl]-4-
 fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid
 586381-89-7P 586381-94-4P, Methyl 5-[[3-bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoate
 586381-95-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]-4-(hydroxymethyl)-N-methylbenzamide 586382-02-7P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-
 methylpyridin-2(1H)-one 586382-04-9P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2,6-difluorophenyl]-6-
 methylpyridin-2(1H)-one 586382-05-0P, 4-[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-
 difluorobenzaldehyde 586382-16-3P 586382-46-9P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[4-(1-hydroxy-1-methylethyl)phenyl]-6-methylpyridin-
 2(1H)-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
 kinase for treatment of inflammatory conditions,
 ischemia, viral infections, autoimmune diseases, and other
 conditions)

IT 4241-21-8P, 2-Oxo-6-phenethyl-1,2-dihydropyridine-3-carbonitrile
 39883-43-7P, 6-Oxo-1,6-dihydro-[2,3']bipyridinyl-5-carbonitrile
 43083-13-2P, 2-Oxo-6-phenyl-1,2-dihydropyridine-3-carbonitrile
 53179-13-8P, 5-Methyl-1-phenyl-1H-pyridin-2-one 54923-34-1P,
 4-Benzyloxy-3-methyl-1H-pyridin-2-one 56304-43-9P, 6-Oxo-1,6-dihydro-
 [2,3']bipyridinyl-5-carboxylic acid 123100-43-6P, 1-(2-Bromobenzyl)-3-
 [(2-bromobenzyl)oxy]pyridin-2(1H)-one 242472-06-6P, 5-[[4-(3-
 Chlorophenyl)piperazin-1-yl]carbonyl]-1-(3,4-dichlorobenzyl)-1H-pyridin-2-
 one 242472-09-9P, N-Allyl-2-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-
 yl)carbonyl]hydrazinecarbothioamide 338774-98-4P, N-[5-Acetyl-1-(4-
 chlorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]-4-chlorobenzamide
 338782-59-5P, 1-(3,4-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
 carboxylic acid N-(2,4-difluorophenyl)amide 338978-39-5P 338981-04-7P,
 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid
 N-(3-dimethylaminopropyl)amide 338981-05-8P, 1-(2,6-Dichlorobenzyl)-6-

oxo-1,6-dihydropyridine-3-carboxylic acid N-(2-dimethylaminoethyl)amide
 339008-61-6P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
 carboxylic acid N-(2,4-difluorophenyl)amide 339008-62-7P,
 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid
 N-(4-chlorophenyl)amide 339008-63-8P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-
 dihydropyridine-3-carboxylic acid N-(3-trifluoromethylphenyl)amide
 339008-64-9P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
 carboxylic acid N-(4-trifluoromethoxyphenyl)amide 339008-65-0P,
 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid
 benzylamide 339008-68-3P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-
 dihydropyridine-3-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide
 339009-09-5P, 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
 carboxylic acid N-(2,4-difluorophenyl)amide 339023-89-1P,
 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic
 acid N-(3-trifluoromethylphenyl)amide 339023-98-2P, 5-Chloro-1-(2,6-
 dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid benzylamide
 339024-00-9P 400087-49-2P, Methyl 5-chloro-1-(4-chlorobenzyl)-6-oxo-1,6-
 dihydropyridine-3-carboxylate 477852-96-3P, 1-Benzyl-5-[5-[(3,4-
 dichlorobenzyl)sulfanyl]-[1,3,4]oxadiazol-2-yl]-1H-pyridin-2-one
 477858-09-6P, 1-(4-Chlorobenzyl)-5-[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-
 yl]-1H-pyridin-2-one 477864-11-2P, N'-[[1-Benzyl-6-oxo-1,6-
 dihydropyridin-3-yl]carbonyl]oxy]pyridine-4-carboximidamide
 478065-97-3P, 1-Benzyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid
 N-[2-(morpholin-4-yl)ethyl]amide 478066-00-1P, 1-(2,6-Dichlorobenzyl)-6-
 oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-trifluoromethylbenzyl)amide
 478247-73-3P, 3-Benzyl-4-hydroxy-1-(2-phenylethyl)pyridin-2(1H)-one
 565156-95-8P, 4-Bromo-2-(2,6-dichlorophenyl)-5-[[2-
 (hydroxymethyl)benzyl]oxy]pyridazin-3(2H)-one 565157-26-8P,
 4-Bromo-2-(2,6-dichlorophenyl)-5-[[2,4-difluorobenzyl]oxy]pyridazin-3(2H)-
 one 586372-66-9P, 4-(Benzyloxy)-3-bromo-1-(4-methylbenzyl)pyridin-2(1H)-
 one 586372-68-1P, 4-(Benzyloxy)-1-[(4-bromophenyl)methyl]pyridin-2(1H)-
 one 586372-69-2P, 4-(Benzyloxy)-3-bromo-1-[(4-bromophenyl)methyl]pyridin-
 2(1H)-one 586372-70-5P, 4-(Benzyloxy)-1-[(4-chlorophenyl)methyl]pyridin-
 2(1H)-one 586372-71-6P, 4-(Benzyloxy)-3-bromo-1-[(4-
 chlorophenyl)methyl]pyridin-2(1H)-one 586372-74-9P, 4-(Benzyloxy)-1-[(2-
 fluorophenyl)methyl]pyridin-2(1H)-one 586372-75-0P, 4-(Benzyloxy)-3-
 bromo-1-[(2-fluorophenyl)methyl]pyridin-2(1H)-one 586372-78-3P,
 4-(Benzyloxy)-1-[[4-(methoxycarbonyl)phenyl]methyl]pyridin-2(1H)-one
 586372-79-4P, 4-(Benzyloxy)-3-bromo-1-[[4-(methoxycarbonyl)phenyl]methyl]p
 yridin-2(1H)-one 586372-80-7P, 4-(Benzyloxy)-3-bromo-1-[(4-
 carboxyphenyl)methyl]pyridin-2(1H)-one 586372-83-0P,
 4-(Benzyloxy)-1-[(4-tert-butylphenyl)methyl]pyridin-2(1H)-one
 586372-84-1P, 4-(Benzyloxy)-3-bromo-1-[(4-tert-butylphenyl)methyl]pyridin-
 2(1H)-one 586372-85-2P, 4-(Benzyloxy)-3-bromo-1-ethylpyridin-2(1H)-one
 586372-86-3P, 3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one
 586372-88-5P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-2(1H)-one
 586372-89-6P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]-N'-
 hydroxybenzenecarboximidamide 586372-90-9P, 4-(Benzyloxy)-3-bromo-1-
 (piperidin-4-ylmethyl)pyridin-2(1H)-one hydrochloride 586372-91-0P,
 4-(Benzyloxy)-1-[4-(trifluoromethyl)benzyl]pyridin-2(1H)-one
 586372-92-1P, 4-(Benzyloxy)-3-bromo-1-[4-(trifluoromethyl)benzyl]pyridin-
 2(1H)-one 586372-93-2P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-
 ylmethyl)pyridin-2(1H)-one hydrochloride 586372-94-3P,
 4-(Benzyloxy)-3-bromo-1-[2-(thien-3-yl)ethyl]pyridin-2(1H)-one
 586372-95-4P, 4-(Benzyloxy)-3-bromo-1-[2-(thien-2-yl)ethyl]pyridin-2(1H)-
 one 586372-96-5P, 4-(Benzyloxy)-3-bromo-1-[3-
 (trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-97-6P,
 4-(Benzyloxy)-3-bromo-1-[2-(trifluoromethyl)benzyl]pyridin-2(1H)-one
 586372-98-7P, 4-(Benzyloxy)-1-[4-(trifluoromethoxy)benzyl]pyridin-2(1H)-
 one 586372-99-8P, 4-(Benzyloxy)-3-bromo-1-[4-
 (trifluoromethoxy)benzyl]pyridin-2(1H)-one 586373-01-5P,

1-Benzyl-4-(benzyloxy)-3-bromo-6-methylpyridin-2(1H)-one 586373-02-6P,
 1-Benzyl-4-(benzyloxy)-3,5-dibromo-6-methylpyridin-2(1H)-one
 586373-05-9P, 1-Benzyl-3-bromo-4-[(3-chlorobenzyl)oxy]-6-methylpyridin-
 2(1H)-one 586373-07-1P, 1-Benzyl-3-bromo-4-[(2,6-
 dichlorobenzyl)oxy]pyridin-2(1H)-one 586373-08-2P, 1-Benzyl-4-[(2-
 chlorobenzyl)oxy]pyridin-2(1H)-one 586373-09-3P, 1-Benzyl-3-bromo-4-[(2-
 chlorobenzyl)oxy]pyridin-2(1H)-one 586373-10-6P, 1-Benzyl-3-bromo-4-[(4-
 methylbenzyl)oxy]pyridin-2(1H)-one 586373-11-7P, 1-Benzyl-4-[(3-
 chlorobenzyl)oxy]pyridin-2(1H)-one 586373-12-8P,
 1-Benzyl-4-(benzylthio)-3-bromopyridin-2(1H)-one 586373-13-9P,
 1-Benzyl-3-bromo-4-[[2-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one
 586373-15-1P, 1-Benzyl-4-(benzyloxy)-3-ethylpyridin-2(1H)-one
 586373-16-2P, 3-Acetyl-4-(benzyloxy)-1-(2-chlorophenyl)-6-methylpyridin-
 2(1H)-one 586373-17-3P, 1-Benzyl-3-bromo-4-(2-phenylethyl)pyridin-2(1H)-
 one 586373-22-0P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-4-(2-
 phenylethyl)pyridin-2(1H)-one 586373-23-1P, 4-(Benzyloxy)-3-bromo-1-(2,6-
 dichlorophenyl)-6-methylpyridin-2(1H)-one 586373-27-5P,
 3-Bromo-1-(3-fluorobenzyl)-4-(2-phenylethyl)pyridin-2(1H)-one
 586373-28-6P, 1-Benzyl-3-bromo-2-oxo-1,2-dihydropyridin-4-yl
 N-methyl-N-phenylcarbamate 586373-30-0P, 4-(Benzyloxy)-3-ethynyl-1-(3-
 fluorobenzyl)pyridin-2(1H)-one 586373-33-3P, 4-(Benzylamino)-3-bromo-1-
 (3-fluorobenzyl)pyridin-2(1H)-one 586373-36-6P, 3-Bromo-1-
 (cyclopropylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
 586373-40-2P, 3-Bromo-1-[(pyridin-4-yl)methyl]-4-[(4-
 fluorobenzyl)oxy]pyridin-2(1H)-one 586373-41-3P, 3-Bromo-1-[(pyridin-3-
 yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-42-4P,
 3-Bromo-1-(4-tert-butylbenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
 586373-43-5P, 3-Bromo-1-(3-trifluoromethylbenzyl)-4-[(4-
 fluorobenzyl)oxy]pyridin-2(1H)-one 586373-44-6P, 3-Bromo-1-[(biphenyl-2-
 yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-45-7P,
 3-Bromo-1-(4-methoxybenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
 586373-46-8P 586373-47-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[4-
 (trifluoromethyl)benzyl]pyridin-2(1H)-one 586373-48-0P,
 3-Bromo-1-[(biphenyl-4-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
 586373-49-1P, 3-Bromo-1-(cyclohexylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-
 2(1H)-one 586373-52-6P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(4-
 fluorobenzyl)oxy]pyridin-2(1H)-one 586373-53-7P, 1-(3-Aminomethylbenzyl)-
 3-bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one trifluoroacetate
 (1:1.125) 586373-54-8P, Methyl 2-[[3-bromo-4-[(4-fluorobenzyl)oxy]-2-oxo-
 2H-pyridin-1-yl]methyl]benzoate 586373-56-0P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[4-[(dimethylamino)methyl]benzyl]-1H-pyridin-2-one
 586373-61-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-
 [(isopropylamino)methyl]benzyl]-1H-pyridin-2-one 586373-62-8P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(dimethylaminomethyl)benzyl]-1H-
 pyridin-2-one 586373-63-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-
 [(methylamino)methyl]benzyl]-1H-pyridin-2-one 586373-65-1P,
 1-[(3-Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-
 one 586373-66-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-
 [(isopropylamino)methyl]benzyl]-1H-pyridin-2-one 586373-69-5P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(methanesulfonyl)benzyl]-1H-
 pyridin-2-one 586373-71-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-
 (methanesulfonyl)benzyl]-1H-pyridin-2-one 586373-72-0P,
 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
 yl]methyl]benzamide 586373-77-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
 [(1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one
 586373-83-3P, 1-[(1-Acetyl-1H-indol-5-yl)methyl]-3-chloro-4-[(2,4-
 difluorobenzyl)oxy]pyridin-2(1H)-one 586373-85-5P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
 586373-86-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(pyridin-4-
 ylmethyl)pyridin-2(1H)-one 586373-87-7P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[(pyridin-2-yl)methyl]-1H-pyridine-2-one

586373-88-8P, 3-Bromo-1-(4-tert-butylbenzyl)-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-89-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-methoxybenzyl)pyridin-2(1H)-one 586373-90-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(benzodioxol-5-yl)methyl]pyridine-2(1H)-one 586373-91-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-fluorobenzyl)pyridin-2(1H)-one 586373-92-4P, 3-Bromo-1-(2,4-difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-94-6P, [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetonitrile 586373-96-8P, 1-[2-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-98-0P, Methyl 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586373-99-1P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-00-7P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-01-8P, 1-(3-Aminomethyl-2-fluorobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586374-05-2P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-fluorobenzamide 586374-08-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2,3,4-trifluorobenzyl)oxy]-1H-pyridin-2-one 586374-10-9P 586374-11-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(3-fluorobenzyl)-1H-pyridin-2-one 586374-13-2P, 3-Bromo-4-[(3-chlorobenzyl)oxy]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586374-14-3P, 3-Bromo-4-[(3,4-difluorobenzyl)oxy]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586374-15-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586374-16-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)oxy]pyridin-2(1H)-one 586374-18-7P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-methoxybenzyl)oxy]pyridin-2(1H)-one 586374-19-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-tert-butylbenzyl)oxy]-1H-pyridin-2-one 586374-20-1P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-methylbenzyl)oxy]pyridin-2(1H)-one 586374-21-2P, 3-Bromo-1-(3-fluorobenzyl)-4-[[4-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one 586374-22-3P 586374-23-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2-methylbenzyl)oxy]pyridin-2(1H)-one 586374-24-5P 586374-25-6P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-methoxybenzyl)oxy]pyridin-2(1H)-one 586374-27-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[[2-(hydroxymethyl)benzyl]oxy]pyridin-2(1H)-one 586374-31-4P, 2-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide 586374-32-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-3-methylpyridin-2(1H)-one 586374-33-6P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-3-iodo-1H-pyridin-2-one 586374-43-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-4-ylmethyl)-1H-pyridin-2-one 586374-48-3P, 1-[4-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-49-4P, 1-[3-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-50-7P, 1-[2-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-51-8P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-52-9P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-53-0P, 2-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-54-1P, Methyl 3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586374-56-3P, 2-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile 586374-57-4P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetic acid 586374-58-5P 586374-64-3P, Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586374-66-5P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-67-6P, 2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-68-7P, 1-[2-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-69-8P, 3-Bromo-1-[3-(bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-71-2P, 1-[4-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-73-4P,

1-[3-[(Morpholin-4-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-74-5P, 1-[3-[(Dimethylamino)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-75-6P, 1-[3-[(Isopropylamino)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-76-7P, 1-[3-[(Piperidin-1-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-77-8P, 1-[3-[[2-Hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-78-9P, 1-[3-[[Bis(2-hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-79-0P, 1-[3-[(Piperazin-1-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-81-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(acetylaminomethyl]benzyl]pyridin-2(1H)-one 586374-82-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methoxycarbonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-83-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methylsulfonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-84-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyacetylaminomethyl]benzyl]pyridin-2(1H)-one 586374-85-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(aminocarbonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-86-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(isopropylamino)methyl]benzyl]pyridin-2(1H)-one 586374-87-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(morpholin-4-yl)methyl]benzyl]pyridin-2(1H)-one 586374-88-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)methyl]benzyl]pyridin-2(1H)-one 586374-89-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(piperidin-1-yl)methyl]benzyl]pyridin-2(1H)-one 586374-90-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-hydroxyethyl)amino]methyl]benzyl]pyridin-2(1H)-one 586374-91-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[2-hydroxyethyl)amino]methyl]benzyl]pyridin-2(1H)-one 586374-92-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(piperazin-1-yl)methyl]benzyl]pyridin-2(1H)-one 586374-93-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(methoxycarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one 586374-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[acetylaminomethyl]benzyl]pyridin-2(1H)-one 586374-95-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(methylsulfonyl)amino]methyl]benzyl]pyridin-2(1H)-one 586374-96-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(aminocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one 586374-97-2P, 4-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzoyl]piperazine-1-carboxamide 586374-99-4P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl]-2-methoxyacetamide 586375-00-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[[[(methoxycarbonyl)methyl]carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586375-01-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[(1-hydroxy-1-methylethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586375-02-2P, 586375-03-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[[[(aminomethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-04-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[[[(hydroxymethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586375-05-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[[[(acetylaminomethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one 586375-06-6P, 1-[4-[(4-Acetylpiperazin-1-yl)carbonyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-07-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[4-[(methylsulfonyl)piperazin-1-yl]carbonyl]benzyl]pyridin-2(1H)-one

586375-11-3P, 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzamide
 586375-12-4P, 1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one
 586375-13-5P, Methyl 4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]benzoate
 586375-17-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one
 586375-24-8P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-(trifluoromethyl)pyridin-2(1H)-one
 586375-27-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1-hydroxy-1-methylethyl)benzyl]-6-methylpyridin-2(1H)-one
 586375-28-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(methylamino)methyl]benzyl]pyridin-2(1H)-one
 586375-33-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-hydroxybenzyl)-6-methylpyridin-2(1H)-one
 586375-34-0P 586375-36-2P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)benzamide
 586375-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-[(4-hydroxypiperidin-1-yl)carbonyl]benzyl]-6-methylpyridin-2(1H)-one
 586375-38-4P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzamide
 586375-39-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(piperazino)carbonyl]benzyl]pyridin-2(1H)-one
 586375-40-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-aminoethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
 586375-41-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-aminopropyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
 586375-42-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(hydroxyamino)carbonyl]benzyl]pyridin-2(1H)-one
 586375-43-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(methylamino)carbonyl]benzyl]pyridin-2(1H)-one
 586375-44-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one
 586375-45-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(morpholino)carbonyl]benzyl]pyridin-2(1H)-one
 586375-46-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
 586375-47-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(cyclopentylamino)carbonyl]benzyl]pyridin-2(1H)-one
 586375-48-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one
 586375-49-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(1-pyrrolidinyl)carbonyl]benzyl]pyridin-2(1H)-one
 586375-50-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-methylpiperazinyl)carbonyl]benzyl]pyridin-2(1H)-one
 586375-51-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[2-(dimethylamino)ethyl]amino]carbonyl]benzyl]pyridin-2(1H)-one
 586375-52-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-methoxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
 586375-53-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]benzyl]pyridin-2(1H)-one
 586375-54-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[N-(2-methoxyethyl)-N-methylamino]carbonyl]benzyl]pyridin-2(1H)-one
 586375-55-5P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)benzamide
 586375-56-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(piperazinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride
 586375-57-7P, N-(2-Aminoethyl)-4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide hydrochloride
 586375-58-8P, N-(3-Aminopropyl)-4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide hydrochloride
 586375-59-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(hydroxyamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
 586375-60-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(methylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
 586375-61-3P, 3-Bromo-4-[(2,4-

difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-62-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-63-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-64-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-65-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-67-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586375-68-0P, 4-(Benzyloxy)-3-bromo-1-[4-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586375-69-1P, 4-(Benzyloxy)-3-bromo-1-[4-(piperazin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-70-4P, 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586375-73-7P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-methylbenzamide 586375-74-8P 586375-75-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(2-aminoethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-76-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(3-aminopropyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586375-77-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(hydroxyamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-78-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-81-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-82-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[bis(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-83-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-84-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-85-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(1-pyrrolidinylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-86-2P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-methoxyacetamide 586375-87-3P 586375-88-4P 586375-89-5P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-acetoxyacetamide hydrochloride 586375-90-8P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-hydroxy-2-methylpropanamide 586375-91-9P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-1-hydroxycyclopropanecarboxamide 586375-92-0P, N'-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N,N-dimethylurea 586375-94-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(piperazinocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(methylamino)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-96-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(morpholinocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586376-01-4P, Ethyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-

6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-02-5P,
 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methylbenzamide 586376-03-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(piperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-04-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-aminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-05-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-aminopropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-06-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(hydroxyamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-07-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-08-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(morpholino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-09-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-10-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(piperidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-11-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-12-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(pyrrolidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-13-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-14-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-dimethylaminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-15-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-16-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[N-(2-dimethylaminoethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-17-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-18-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[N-(2-methoxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586376-19-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586376-22-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586376-26-3P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]methanesulfonamide 586376-27-4P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]acetamide 586376-28-5P 586376-29-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-methoxyacetamide 586376-30-9P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-acetoxyacetamide hydrochloride 586376-31-0P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-aminoacetamide hydrochloride 586376-32-1P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide hydrochloride 586376-33-2P, N'-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-N,N-dimethylurea 586376-35-4P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-N'-methylurea 586376-36-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(morpholinocarbonyl)amino]methyl]phenyl]pyridin-2(1H)-one 586376-37-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]urea 586376-38-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-[(dimethylamino)methyl]phenyl]-6-methylpyridin-2(1H)-one 586376-41-2P, N-[4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzyl]acetamide 586376-44-5P, N-[4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide 586376-45-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(morpholin-4-

yl)ethyl]pyridin-2(1H)-one 586376-47-8P, Ethyl 3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoate 586376-48-9P, Methyl 3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoate 586376-50-3P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,6-difluorobenzamide 586376-60-5P, 3-Bromo-1-(4-bromo-2,6-difluorophenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-68-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-72-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-76-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-78-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-yl)phenyl]-6-methylpyridin-2(1H)-one 586376-82-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2(1H)-one 586376-83-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2(1H)-one 586376-87-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586376-89-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586376-90-1P, 3-Bromo-1-(3,5-dibromo-2,6-difluoro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-93-4P, 2-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorophenoxy]acetamide 586376-97-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(2-hydroxyethoxy)phenyl]-6-methylpyridin-2(1H)-one 586376-98-9P, 3-Bromo-1-(2,6-difluorophenyl)-4-[[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one 586377-04-0P, 3-Chloro-1-(2,6-difluorophenyl)-4-[[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one 586377-06-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methyl-N-[2-(morpholin-4-yl)ethyl]benzamide 586377-13-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[2-methoxyethyl)amino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-15-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-17-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[2-hydroxyethyl)amino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-18-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-19-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[N-(2-hydroxyethyl)-N-methylamino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-21-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-yl)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-23-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholinocarbonyl)-2-methylphenyl]pyridin-2(1H)-one 586377-24-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[N-(2-methoxyethyl)-N-methylamino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-26-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(aminocarbonyl)-2-methylphenyl]pyridin-2(1H)-one 586377-28-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586377-30-2P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-2-methylbenzamide 586377-33-5P, 586377-34-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-2-methylbenzamide 586377-35-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzamide 586377-39-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(methylamino)methyl]phenyl]pyridin-2(1H)-one hydrochloride 586377-42-6P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluoro-N,N-dimethylbenzamide 586377-44-8P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-methoxybenzonitrile 586377-47-1P, N-[4-[3-Chloro-4-[(2,4-

difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]urea
 586377-48-2P, 2-[[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]amino]-1,1-dimethyl-2-oxoethyl acetate
 586377-49-3P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]acetamide 586377-50-6P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-methoxyacetamide 586377-51-7P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-furamide
 586377-52-8P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-1H-imidazole-4-carboxamide 586377-53-9P
 586377-54-0P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-3-hydroxy-3-methylbutanamide 586377-55-1P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-1-hydroxycyclopropanecarboxamide 586377-56-2P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-hydroxy-2-methylpropanamide 586377-57-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzonitrile 586377-62-0P, 3-Bromo-1-(3-fluorobenzyl)-4-(1-phenylethoxy)pyridin-2(1H)-one 586377-63-1P, 3-Bromo-1-(3-fluorobenzyl)-4-[(E)-2-(4-fluorophenyl)ethenyl]pyridin-2(1H)-one 586377-64-2P, 4-(Benzyloxy)-3-bromo-1-[(6-fluoropyridin-3-yl)methyl]pyridin-2(1H)-one 586377-65-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-methylpyridin-2(1H)-one 586377-68-6P, 3-Bromo-1-(2,6-dimethylphenyl)-4-[(4-fluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-69-7P, 3-Bromo-1-(2,6-dimethylphenyl)-6-methyl-4-[(2,4,6-trifluorobenzyl)oxy]pyridin-2(1H)-one 586377-70-0P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-methylpyridin-2(1H)-one 586377-71-1P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-fluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-73-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-74-4P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(2,6-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-75-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-methoxy-6-methylphenyl)-6-methylpyridin-2(1H)-one 586377-78-8P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-dichlorobenzenesulfonamide 586377-83-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586377-87-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,4-difluoro-6-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586377-91-5P, N-[2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]urea 586377-92-6P, Methyl [2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-93-7P, N-[2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]-2-hydroxyacetamide 586377-94-8P, Ethyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-97-1P, Isobutyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-98-2P, Cyclopropylmethyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586378-07-6P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586378-09-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-ylmethyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586378-11-2P 586378-17-8P 586378-19-0P, Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-carboxylate trifluoroacetate 586378-21-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2-hydroxypyrimidin-4-yl)methyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-23-6P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-

carboxamide trifluoroacetate 586378-24-7P, Methyl [4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidin-2-yl]methylcarbamate 586378-25-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-28-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyrazin-2-ylmethyl)pyridin-2(1H)-one 586378-33-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(dimethylamino)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-36-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[[2-hydroxyethyl](methyl)amino]methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586378-37-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one 586378-41-8P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)-N-methylpyrazine-2-carboxamide 586378-42-9P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2,3-dihydroxypropyl)pyrazine-2-carboxamide 586378-43-0P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)pyrazine-2-carboxamide 586378-44-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(methoxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586378-45-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(2-methoxyethoxy)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586378-46-3P, Carbamic acid [5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazin-2-yl]methyl ester 586378-48-5P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-methylpyridin-2(1H)-one 586378-51-0P, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-methylpyridin-2(1H)-one 586378-52-1P, 1-Benzyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586378-54-3P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-4-fluorobenzamide 586378-57-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586378-59-8P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)amino]-6-methylpyridin-2(1H)-one 586378-61-2P, 3-Bromo-1-(cyclopropylmethyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586378-63-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586378-65-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-67-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-2-ylmethyl)pyridin-2(1H)-one 586378-70-3P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-4-yl)methyl]pyridin-2(1H)-one 586378-71-4P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methyl]pyridin-2(1H)-one 586378-72-5P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methyl]pyridin-2(1H)-one 586378-73-6P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methyl]pyridin-2(1H)-one 586378-74-7P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methyl]pyridin-2(1H)-one 586378-75-8P, 3-Bromo-4-[(2-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methyl]pyridin-2(1H)-one 586378-76-9P, 3-Bromo-4-[(2,4,5-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methyl]pyridin-2(1H)-one 586378-77-0P, 3-Bromo-4-[(4-chloro-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one 586378-78-1P, 3-Bromo-4-[(2-chloro-4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methyl]pyridin-2(1H)-one 586378-79-2P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methyl]pyridin-2(1H)-one 586378-80-5P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methyl]pyridin-2(1H)-one 586378-81-6P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methyl]pyridin-2(1H)-one 586378-82-7P, 3-Bromo-4-[(2,4,5-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methyl]pyridin-2(1H)-one 586378-83-8P, 3-Bromo-4-[2-(4-fluorophenyl)ethyl]-6-methyl-1-(pyridin-3-yl)methyl]pyridin-2(1H)-one 586378-86-1P, 3-Bromo-4-[2-(4-fluorophenyl)ethyl]-6-methyl-1-(pyridin-4-yl)methyl]pyridin-2(1H)-one 586378-87-2P, 3-Chloro-4-[(2,4-

difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
 586378-91-8P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-
 4-[(2,4,6-trifluorobenzyl)oxy]pyridin-2(1H)-one trifluoroacetate
 586378-93-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-methyl-4-
 (methylamino)pyrimidin-5-yl)methyl]pyridin-2(1H)-one trifluoroacetate
 586378-95-2P 586378-97-4P 586378-98-5P, 3-Chloro-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-
 one 586379-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-
 [(methylamino)methyl]pyrazin-2-yl)methyl]pyridin-2(1H)-one
 trifluoroacetate 586379-03-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
 [[5-(hydroxymethyl)pyrazin-2-yl)methyl]-6-methylpyridin-2(1H)-one
 586379-04-6P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl)methyl]-N,N-dimethylpyrazine-2-carboxamide 586379-05-7P,
 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl)methyl]-N-methylpyrazine-2-carboxamide 586379-06-8P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(1-hydroxy-1-methylethyl)pyrazin-
 2-yl)methyl]-6-methylpyridin-2(1H)-one 586379-07-9P,
 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl)methyl]-N-(2-methoxyethyl)pyrazine-2-carboxamide 586379-08-0P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-(morpholin-4-
 ylcarbonyl)pyrazin-2-yl)methyl]pyridin-2(1H)-one 586379-09-1P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(4-hydroxypiperidin-1-
 yl)carbonyl]pyrazin-2-yl)methyl]-6-methylpyridin-2(1H)-one 586379-11-5P,
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl)methyl]-N-(3-hydroxy-2,2-dimethylpropyl)pyrazine-2-carboxamide
 586379-12-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl)methyl]-N-(2,2,2-trifluoroethyl)pyrazine-2-carboxamide
 586379-13-7P, 1-Allyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
 2(1H)-one 586379-15-9P, 1-Allyl-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
 methylpyridin-2(1H)-one 586379-17-1P, Methyl (2E)-4-[3-bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenate
 586379-18-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-prop-2-
 ynylpyridin-2(1H)-one 586379-21-7P, 4-[(2,4-Difluorobenzyl)oxy]-6-
 (hydroxymethyl)-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-23-9P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-
 ylmethyl)pyridin-2(1H)-one 586379-24-0P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-[(dimethylamino)methyl]-1-(pyridin-3-
 ylmethyl)pyridin-2(1H)-one 586379-29-5P, 3-Chloro-4-[(2,4-
 difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-
 one 586379-31-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
 difluorophenyl)-6-[(dimethylamino)methyl]pyridin-2(1H)-one 586379-32-0P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(morpholin-4-
 ylmethyl)pyridin-2(1H)-one 586379-33-1P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[[2-
 methoxyethyl)amino]methyl]pyridin-2(1H)-one 586379-34-2P,
 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-
 dihydropyridine-2-carboxylic acid 586379-35-3P, Methyl
 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-
 methylbenzoate 586379-38-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-1-(2-methyl-4-carboxyphenyl)pyridin-2(1H)-one 586379-39-7P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-
 (hydroxymethyl)phenyl]pyridin-2(1H)-one 586379-40-0P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-[[2-
 methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586379-41-1P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-
 [(methylamino)carbonyl]phenyl]pyridin-2(1H)-one 586379-46-6P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2-
 methylphenyl]-6-methylpyridin-2(1H)-one 586379-47-7P, Methyl
 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-
 chlorobenzoate 586379-50-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-2-oxo-2H-pyridin-1-yl]-4-chlorobenzoic acid 586379-54-6P,

3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-57-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(dimethylamino)methyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one hydrochloride 586379-59-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(isopropylamino)methyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one hydrochloride 586379-60-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-4-methylbenzamide 586379-65-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[[2-methoxyethyl]amino]carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-67-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(dimethylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-68-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(morpholinocarbonyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-69-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1-hydroxy-1-methylethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-71-7P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-76-2P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-78-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[[3-(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one 586379-79-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[[4-fluoro-2-(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one 586379-80-8P, 3-Bromo-4-[(4-chloro-2-fluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-81-9P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586379-83-1P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-85-3P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586379-87-5P, 3-Chloro-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586379-88-6P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-91-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-93-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586380-00-9P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-methylbenzamide 586380-01-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one 586380-02-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[2-hydroxyethyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-03-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(4-methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one 586380-04-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586380-05-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[2-methoxyethyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-06-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one 586380-07-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[3-hydroxypropyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-08-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[2,3-dihydroxypropyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-09-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[2-hydroxy-1,1-dimethylethyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-10-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(piperazinocarbonyl)phenyl]pyridin-2(1H)-one 586380-17-8P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxy-N-methylbenzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP

kinase for treatment of inflammatory conditions,
ischemia, viral infections, autoimmune diseases, and other
conditions)

IT 586380-18-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxy-N,N-dimethylbenzamide 586380-21-4P,
3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]benzamide 586380-22-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(acetylamino)methyl]phenyl]pyridin-2(1H)-one 586380-23-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(methoxyacetylamino)methyl]phenyl]pyridin-2(1H)-one 586380-24-7P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(methylsulfonylamino)methyl]phenyl]pyridin-2(1H)-one 586380-25-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(aminocarbonylamino)methyl]phenyl]pyridin-2(1H)-one 586380-27-0P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(methoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-28-1P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(trifluoromethyl)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-29-2P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(isopropoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-30-5P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(ethylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-31-6P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(tetrahydrofuran-3-yloxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-32-7P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(propoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-33-8P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(allyloxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-34-9P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(propargyloxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-35-0P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(tert-butoxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-36-1P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(tert-butyl)amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-37-2P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(propylsulfonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-38-3P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(ethylsulfonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-39-4P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(isopropylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-40-7P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(methoxymethyl)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-41-8P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(methylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-42-9P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[[N-methyl-N-(tert-butyl)amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-43-0P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(cyclopropylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-44-1P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[[[2,2,2-trifluoroethyl]amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-45-2P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[[[cyclopropylmethyl]amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-46-3P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[[[2,2-dimethylpropylamino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-47-4P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[[[dimethylamino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-48-5P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[[5-(1-hydroxy-1-methylethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586380-50-9P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-one

586380-52-1P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)-N-methylnicotinamide
586380-55-4P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)nicotinamide 586380-56-5P,
6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylnicotinamide 586380-57-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-one 586380-66-7P, Carbamic acid [5-bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-dihydropyridin-3-yl]methyl ester 586380-68-9P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-dihydropyridine-3-carbonitrile 586380-69-0P,
4-(Benzyloxy)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586380-70-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methyl-5-(oxiran-2-yl)pyridin-2(1H)-one 586380-71-4P,
4-(Benzylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586380-72-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methyl-5-((E)-2-phenylethenyl)pyridin-2(1H)-one 586380-74-7P, 4-(Allylamino)-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586380-76-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-5'-(1-hydroxy-1-methylethyl)-6-methyl-2H-1,2'-bipyridin-2-one 586380-77-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(furyl-2-ylmethyl)-6-methylpyridin-2(1H)-one 586380-78-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(thien-2-ylmethyl)pyridin-2(1H)-one 586380-79-2P, 3-Bromo-1-(2,6-difluorophenyl)-4-(furyl-2-ylmethoxy)-6-methylpyridin-2(1H)-one 586380-80-5P, 3-Bromo-1-[2-fluoro-6-(furyl-3-ylmethoxy)phenyl]-4-(furyl-3-ylmethoxy)-6-methylpyridin-2(1H)-one 586380-81-6P, 3-Bromo-1-[2-fluoro-6-(thien-3-ylmethoxy)phenyl]-6-methyl-4-(thien-3-ylmethoxy)pyridin-2(1H)-one 586380-86-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-(1-hydroxy-1-methylethyl)-N-methylbenzamide 586380-89-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzamide 586380-91-8P 586380-92-9P,
N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]propanamide 586380-93-0P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-N',N'-dimethylurea 586380-94-1P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-2-hydroxyacetamide 586380-95-2P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-2-hydroxy-2-methylpropanamide 586380-96-3P 586380-97-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzamide 586380-98-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-methylbenzamide 586380-99-6P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N,N-dimethylbenzamide 586381-00-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-[(4-methylpiperazin-1-yl)carbonyl]phenyl]-6-methylpyridin-2(1H)-one 586381-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586381-02-4P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one 586381-03-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[2-hydroxy-2-methylpropyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586381-09-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylbenzamide 586381-10-4P,
4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)benzamide 586381-11-5P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide 586381-14-8P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586381-17-1P, 1-(3-Aminobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-18-2P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide

586381-19-3P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]-2-hydroxyacetamide 586381-20-6P,
 N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]-2-acetoxyacetamide 586381-21-7P 586381-22-8P,
 N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide 586381-23-9P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-methylurea 586381-24-0P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-(2-hydroxy-2-methylpropyl)urea 586381-25-1P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]piperidine-1-carboxamide 586381-26-2P,
 N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]morpholine-4-carboxamide 586381-27-3P,
 N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]piperazine-1-carboxamide hydrochloride 586381-28-4P,
 N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-(2-hydroxyethyl)urea 586381-29-5P,
 N'-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N,N-dimethylurea 586381-30-8P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-4-hydroxypiperidine-1-carboxamide 586381-31-9P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylbenzenesulfonamide 586381-32-0P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzenesulfonamide 586381-35-3P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide 586381-38-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-3-ylmethyl)-1H-pyridin-2-one 586381-43-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydroindol-2-one 586381-45-5P,
 N-[[5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazin-2-yl]methyl]-N-methylmethanesulfonamide 586381-46-6P,
 Methyl [5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazin-2-yl]methyl(methyl)carbamate 586381-47-7P
 586381-48-8P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)pyrazine-2-carboxamide 586381-50-2P, 1-[(5-Aminopyrazin-2-yl)methyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate 586381-52-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(3-methyl-1,2,4-triazin-6-yl)methyl]pyridin-2(1H)-one trifluoroacetate 586381-54-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-yl)-6-methylpyridin-2(1H)-one 586381-56-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one 586381-65-9P, Methyl [2-[[[3-bromo-1-[5-[[2-hydroxyethyl]amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-66-0P, Methyl [2-[[[3-bromo-1-[5-[[2-hydroxy-2-methylpropyl]amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-67-1P, Methyl [2-[[[3-bromo-1-[5-[[2-methoxyethyl]amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-68-2P, O-Methyl [2-[[[1-[5-(aminocarbonyl)-2-methylphenyl]-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-69-3P, N-[2-[[[3-Chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]-N'-phenylurea 586381-70-6P, (Thien-3-yl)methyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-71-7P, Ethyl [2-[[[3-bromo-6-methyl-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-75-1P 586381-83-1P, Methyl 3-[6-[(acetyloxy)methyl]-3-bromo-4-

[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate
 586381-87-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-88-6P,
 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-4-methylbenzamide 586381-90-0P,
 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-4-methylbenzamide 586381-91-1P, [5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate 586381-92-2P, (2E)-4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methyl-2-butenamide 586381-97-7P 586381-98-8P 586381-99-9P 586382-00-5P 586382-01-6P,
 Carbamic acid 2-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-[(methylamino)carbonyl]benzyl ester 586382-06-1P,
 Carbamic acid 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl ester 586382-07-2P,
 N-[4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-hydroxyacetamide 586382-09-4P, N-[4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-1-hydroxycyclopropanecarboxamide 586382-10-7P, Carbamic acid 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl ester 586382-11-8P, (S)-2-[[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]amino]-1-methyl-2-oxoethyl acetate 586382-12-9P, 2-[[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]amino]-1,1-dimethyl-2-oxoethyl acetate 586382-13-0P, [1-[3-(Aminocarbonyl)phenyl]-5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate 586382-20-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-5-yl]methyl]pyridin-2(1H)-one 586382-22-1P, Ethyl [2-[[[3-bromo-1-[5-[[2-(2-hydroxyethyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586382-24-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1H-imidazol-2-yl)-2-methylphenyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586382-25-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(5-hydroxy-1H-pyrazol-3-yl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586382-27-6P 586382-28-7P 586382-29-8P, Methyl 4-[[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-yl]methyl]benzoate 586382-32-3P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furamide 586382-34-5P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furamide 586382-38-9P, 1-[3,5-Bis(hydroxymethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-43-6P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]isophthalamide 586382-44-7P, 1-[3,5-Bis(1-hydroxy-1-methylethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-45-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586382-47-0P, 1-(5-Amino-2-fluorophenyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586382-49-2P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-2-hydroxyacetamide 586382-51-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-2-hydroxy-2-methylpropanamide 586382-53-8P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluoro-N,N-dimethylbenzamide 586382-55-0P 586382-56-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-indol-5-yl]methyl]-6-methylpyridin-2(1H)-one 586382-57-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methoxyacetyl)-2,3-dihydro-1H-indol-5-yl]methyl]-6-methylpyridin-2(1H)-one 586382-58-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylindoline-1-carboxamide 586382-59-4P 586382-60-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methoxyacetyl)-

2,3-dihydro-1H-indol-5-yl)methyl]pyridin-2(1H)-one 586382-61-8P,
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-N,N-
 dimethylindoline-1-carboxamide 586382-62-9P, 1-Benzyl-4-(benzyloxy)-3-
 bromopyridin-2(1H)-one 586382-63-0P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-
 fluorobenzyl)oxy]pyridin-2(1H)-one 586382-64-1P, 4-(Benzyloxy)-3-bromo-1-
 (4-fluorobenzyl)pyridin-2(1H)-one 586382-65-2P, 4-(Benzyloxy)-3-bromo-1-
 [4-(methylthio)benzyl]pyridin-2(1H)-one 586382-66-3P,
 1-Benzyl-4-(benzyloxy)-3-chloropyridin-2(1H)-one 586382-67-4P,
 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-fluorobenzyl)pyridin-2(1H)-one
 586382-68-5P, 1-Benzyl-3-bromo-4-[(4-chlorobenzyl)oxy]pyridin-2(1H)-one
 586382-69-6P, 3-Bromo-1-(4-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-
 2(1H)-one 586382-70-9P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-[2-
 (phenylthio)ethyl]pyridin-2(1H)-one 586382-71-0P, 3-Bromo-4-[(4-
 chlorobenzyl)oxy]-1-(2-phenylethyl)pyridin-2(1H)-one 586382-72-1P
 586382-73-2P, 1-Benzyl-2-oxo-4-phenoxy-1,2-dihydropyridine-3-
 carboxaldehyde 586382-74-3P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-
 methoxybenzyl)pyridin-2(1H)-one 586382-75-4P, 3-Bromo-4-[(4-
 fluorobenzyl)oxy]-1-(3-phenylpropyl)pyridin-2(1H)-one 586382-76-5P,
 1-Benzyl-4-(benzyloxy)-3-(hydroxymethyl)pyridin-2(1H)-one 586382-77-6P,
 3-Bromo-1-(4-methylbenzyl)-4-[(4-methylbenzyl)oxy]pyridin-2(1H)-one
 586382-78-7P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-
 2(1H)-one 586382-79-8P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-
 fluorobenzyl)oxy]pyridin-2(1H)-one 586382-80-1P, 5-Bromo-1-(2-chloro-6-
 fluorobenzyl)-3-methylpyridin-2(1H)-one 586382-81-2P,
 1-Benzyl-4-(benzyloxy)-2-oxo-1,2-dihydropyridine-3-carboxaldehyde
 586382-82-3P, 1-Benzyl-4-chloro-2-oxo-1,2-dihydropyridine-3-carboxaldehyde
 586382-83-4P, 1-Benzyl-4-hydroxy-2-oxo-1,2-dihydropyridine-3-
 carboxaldehyde 586382-84-5P, 1-Benzyl-4-(benzyloxy)-3-methylpyridin-
 2(1H)-one 586382-85-6P, 4-(Benzyloxy)-1-(4-fluorobenzyl)pyridin-2(1H)-
 one 586382-86-7P, 1-Benzyl-4-(benzyloxy)-3,5-dibromopyridin-2(1H)-one
 586382-87-8P, 1-Benzyl-3-bromo-4-(3-phenylpropyl)pyridin-2(1H)-one
 586382-88-9P, 1-Benzyl-3-methyl-4-(2-phenylethyl)pyridin-2(1H)-one
 586382-89-0P, 1-Benzyl-3-methyl-4-(3-phenylpropyl)pyridin-2(1H)-one
 586382-90-3P, 1-Benzyl-4-(benzylthio)-3-methylpyridin-2(1H)-one
 586382-91-4P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate
 586382-92-5P, 6-(Benzyloxy)-1-methyl-2-oxo-1,2-dihydropyridine-3-
 carbonitrile 586382-93-6P, 3-Benzoyl-6-(benzyloxy)-1-methylpyridin-2(1H)-
 one 586382-94-7P, 3-Benzyl-6-(benzyloxy)-1-methylpyridin-2(1H)-one
 586382-95-8P, 1-Benzyl-4-(benzylthio)pyridin-2(1H)-one 586382-96-9P,
 4-Amino-1-benzylpyridin-2(1H)-one 586382-97-0P, 4-[(2,6-
 Dichlorobenzyl)oxy]pyridine-1-oxide 586382-98-1P, 3-Bromo-1-(3-
 fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one 586382-99-2P
 586383-00-8P, 1-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-3-chloro-4-[(2,4-
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-01-9P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-
 2,3-dihydro-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-02-0P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-2,3-
 dihydro-1H-indol-5-yl]pyridin-2(1H)-one 586383-03-1P
 , 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-2,3-dihydro-1H-
 indol-5-yl]-6-methylpyridin-2(1H)-one 586383-04-2P, 3-Chloro-4-[(2,4-
 difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-indol-
 5-yl]-6-methylpyridin-2(1H)-one 586383-05-3P, 5-[3-Chloro-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]indoline-1-carboxamide
 586383-06-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-
 (methylsulfonyl)-2,3-dihydro-1H-indol-5-yl]pyridin-2(1H)-one
 586383-07-5P, 1-(1-Acetyl-1H-indol-5-yl)-3-chloro-4-[(2,4-
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-08-6P
 586383-09-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-
 methylpropanoyl)-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-10-0P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
 indol-5-yl]pyridin-2(1H)-one 586383-11-1P, 3-Chloro-4-[(2,4-

difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-12-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-13-3P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-indole-1-carboxamide 586383-14-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-indol-5-yl]pyridin-2(1H)-one 586383-15-5P, 1-(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-16-6P, 586383-17-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one 586383-18-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-methylglycyl)-2,3-dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one 586383-20-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxypropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one 586383-21-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one 586383-22-4P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide 586383-23-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-2,3-dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one 586383-24-6P, 1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-25-7P, 586383-26-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-27-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]pyridin-2(1H)-one 586383-28-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-29-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-30-4P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586383-31-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]pyridin-2(1H)-one 586383-32-6P, 1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-33-7P, 586383-34-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-35-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one 586383-36-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-37-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-38-2P, 7-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586383-39-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one 586383-40-6P, 1-(1-Acetyl-1H-benzimidazol-5-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-41-7P, 586383-42-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-43-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-44-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-45-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-47-3P,

5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-benzimidazole-1-carboxamide 586383-48-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-49-5P, 3-Chloro-1-(1,3-diacetyl-2,3-dihydro-1H-benzimidazol-5-yl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-50-8P 586383-51-9P, 1-[3-Acetyl-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-52-0P, 1-[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-53-1P, 1-[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-54-2P, 1-[3-Acetyl-1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-55-3P, 3-Acetyl-5-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586383-56-4P 586383-57-5P 586383-58-6P 586383-59-7P 586383-60-0P
 586383-61-1P 586383-62-2P 586383-63-3P 586383-64-4P,
 1-[1-Acetyl-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
 586383-65-5P, 1-[1,3-Bis(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-66-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-67-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-68-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-69-9P,
 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586383-70-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-71-3P, 1-[1-Acetyl-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-72-4P 586383-73-5P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-74-6P, 1-[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
 586383-75-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-76-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one
 586383-77-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-78-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(N-methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-79-1P, 1-[1-Acetyl-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-80-4P 586383-81-5P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-

(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-82-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-83-7P, 1-[1,3-Bis(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-84-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-85-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-86-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-87-1P, 1-[1-Acetyl-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-88-2P, 586383-89-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-90-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-91-7P, 1-[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-92-8P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-93-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-94-0P, 3-Acetyl-6-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-95-1P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-96-2P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-97-3P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-98-4P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-99-5P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-benzimidazole-1,3(2H)-dicarboxamide 586384-00-1P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-01-2P, 1-[1-Acetyl-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-02-3P, 586384-03-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-04-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586384-05-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-06-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-07-8P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-08-9P, 1-[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-09-0P, 1-[3-Acetyl-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-10-3P, 1-(1-Acetyl-1H-pyrrol-3-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-

methypyridin-2(1H)-one 586384-11-4P 586384-12-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-
pyrrol-3-yl]-6-methypyridin-2(1H)-one 586384-13-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
pyrrol-3-yl]pyridin-2(1H)-one 586384-14-7P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrrol-3-yl]-6-
methypyridin-2(1H)-one 586384-15-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrrol-3-yl]-6-
methypyridin-2(1H)-one 586384-16-9P, 3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrrole-1-
carboxamide 586384-17-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[1-(methylsulfonyl)-1H-pyrrol-3-yl]pyridin-2(1H)-one 586384-18-1P,
1-(1-Acetyl-1H-imidazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methypyridin-2(1H)-one 586384-19-2P 586384-20-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-
imidazol-4-yl]-6-methypyridin-2(1H)-one 586384-21-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
imidazol-4-yl]pyridin-2(1H)-one 586384-22-7P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-imidazol-4-yl]-6-
methypyridin-2(1H)-one 586384-23-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-imidazol-4-yl]-6-
methypyridin-2(1H)-one 586384-24-9P, 4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-imidazole-1-
carboxamide 586384-25-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[1-(methylsulfonyl)-1H-imidazol-4-yl]pyridin-2(1H)-one 586384-26-1P,
1-(1-Acetyl-1H-pyrazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methypyridin-2(1H)-one 586384-27-2P 586384-28-3P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-
pyrazol-4-yl]-6-methypyridin-2(1H)-one 586384-29-4P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
pyrazol-4-yl]pyridin-2(1H)-one 586384-30-7P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrazol-4-yl]-6-
methypyridin-2(1H)-one 586384-31-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrazol-4-yl]-6-
methypyridin-2(1H)-one 586384-32-9P, 4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrazole-1-
carboxamide 586384-33-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridin-2(1H)-one 586384-34-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-isoquinolin-7-yl-6-methylpyridin-
2(1H)-one 586384-35-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
(isoquinolin-6-ylmethyl)pyridin-2(1H)-one 586384-36-3P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-
dihydro-2H-indol-2-one 586384-37-4P, 1-[(1-Acetyl-2,3-dihydro-1H-indol-5-
yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
586384-38-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-
methylpropanoyl)-2,3-dihydro-1H-indol-5-yl]methylpyridin-2(1H)-one
586384-39-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(N-methylglycyl)-
2,3-dihydro-1H-indol-5-yl]methylpyridin-2(1H)-one 586384-40-9P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-2,3-
dihydro-1H-indol-5-yl]methylpyridin-2(1H)-one 586384-41-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-
2,3-dihydro-1H-indol-5-yl]methylpyridin-2(1H)-one 586384-42-1P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]indoline-1-carboxamide 586384-43-2P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(methylsulfonyl)-2,3-dihydro-1H-indol-5-
yl]methylpyridin-2(1H)-one 586384-44-3P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-
one 586384-45-4P, 1-[(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)methyl]-3-
chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-46-5P
586384-47-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-
methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]methylpyridin-2(1H)-one

586384-48-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-49-8P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-50-1P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-51-2P,
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-isoindole-2-carboxamide 586384-52-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-53-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-54-5P, 1-[(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-55-6P 586384-56-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-57-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-58-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-59-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-60-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586384-61-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-62-5P, 1-[(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-63-6P 586384-64-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-65-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-66-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-67-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-68-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586384-69-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-70-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-71-6P, 1-[(1-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-72-7P 586384-73-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-74-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-75-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-76-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-77-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-78-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-79-4P, 1-[(3-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-80-7P, 3-Chloro-1-[(1,3-diacetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-81-8P 586384-82-9P, 1-[[3-Acetyl-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-

yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one
 586384-83-0P, 1-[[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one
 586384-84-1P, 1-[[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]
 pyridin-2(1H)-one 586384-85-2P, 1-[[3-Acetyl-1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-86-3P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-87-4P, 1-[[3-Acetyl-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-88-5P 586384-89-6P
 586384-90-9P 586384-91-0P 586384-92-1P 586384-93-2P 586384-94-3P
 586384-95-4P 586384-96-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-97-6P, 1-[[1-Acetyl-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-98-7P 586384-99-8P, 1-[[1,3-Bis(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-00-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-01-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-02-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-03-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-04-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-05-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-06-0P, 1-[[1-Acetyl-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-07-1P 586385-08-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-09-3P, 1-[[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-10-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one
 586385-11-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-12-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-13-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-14-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-15-1P, 1-[[1-Acetyl-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-16-2P 586385-17-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-18-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586385-19-5P, 1-[[1,3-Bis(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-

[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one 586385-20-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-21-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-22-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-23-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-24-2P, 1-[[1-Acetyl-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one 586385-25-3P 586385-26-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-27-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-28-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-29-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-30-0P, 1-[[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one 586385-31-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-32-2P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-33-3P, 3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-34-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-35-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-36-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-37-7P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-38-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1H-benzimidazole-1,3(2H)-dicarboxamide 586385-39-9P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-40-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-41-3P, 1-[[1-Acetyl-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-42-4P 586385-43-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-44-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-45-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-46-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-47-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-48-0P, 1-[[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one

586385-49-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-50-4P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-51-5P 586385-52-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-53-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-54-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-55-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-56-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-57-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-58-2P, 1-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-59-3P, 1,3-Diacetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-60-6P 586385-61-7P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-62-8P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-63-9P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-64-0P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-65-1P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-66-2P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-67-3P 586385-68-4P 586385-69-5P 586385-70-8P 586385-71-9P 586385-72-0P 586385-73-1P 586385-74-2P 586385-75-3P 586385-76-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-77-5P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-78-6P 586385-79-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-80-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586385-81-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-82-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-83-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-84-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-

yl)methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-85-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-86-6P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-87-7P 586385-88-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-89-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1,3-bis(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-90-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-91-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-92-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(N-methylglycyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-93-5P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(N-methylglycyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-94-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-95-7P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-96-8P 586385-97-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-98-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-99-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1,3-bis(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-00-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-01-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxypropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-02-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-03-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-04-1P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-05-2P 586386-06-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-07-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-08-5P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1,3-bis(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-09-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-10-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-11-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-12-1P, 3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-13-2P 586386-14-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-

oxo-2H-pyridin-1-yl)methyl]-3-(2-hydroxy-2-methylpropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-15-4P,
6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(N-methylglycyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-16-5P,
6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxypropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-17-6P,
6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-18-7P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-2-oxo-1H-benzimidazole-1,3(2H)-dicarboxamide 586386-19-8P,
6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(methysulfonyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-20-1P,
6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(methysulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-21-2P,
1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(methysulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-22-3P
586386-23-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(methysulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-24-5P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(N-methylglycyl)-3-(methysulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-25-6P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxypropanoyl)-3-(methysulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-26-7P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(methysulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-27-8P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(methysulfonyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-28-9P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1,3-bis(methysulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-30-3P,
3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-fluorophenyl)ethynyl]-6-methylpyridin-2(1H)-one 586386-31-4P,
3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzaldehyde 586386-32-5P,
4-[(2,4-Difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586386-33-6P,
4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586386-34-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(hydroxymethyl)-2-methoxyphenyl]-6-methylpyridin-2(1H)-one 586386-35-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-yl)carbonyl]phenyl]pyridin-2(1H)-one 586386-36-9P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-(dimethylamino)ethyl]benzamide 586386-37-0P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)benzamide 586386-38-1P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-(dimethylamino)ethyl]-N-methylbenzamide 586386-39-2P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-N-methylbenzamide 586386-40-5P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-N-methylbenzamide 586386-41-6P,
4-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-methylbenzoic acid 586386-42-7P,
Methyl [2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-3,5-difluorobenzyl]carbamate 586386-43-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-44-9P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(ethoxyamino)methyl]pyridin-2(1H)-one 586386-45-0P,
N-(3-Aminopropyl)-4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzamide hydrochloride 586386-46-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-

indazol-5-ylmethyl)pyridin-2(1H)-one 586386-47-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-methylpyridin-2(1H)-one hydrochloride 586386-48-3P, N-(2-Aminoethyl)-4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide hydrochloride 586386-49-4P, N-(2-Aminoethyl)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586386-50-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperazin-1-ylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586386-51-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(dimethylamino)methyl]pyridin-2(1H)-one 586386-52-9P 586386-53-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-isopropylbenzamide 586386-54-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholin-4-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-55-2P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-bis(2-hydroxyethyl)benzamide 586386-56-3P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-hydroxybenzamide 586386-57-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-hydroxymethylbenzyl)-6-methyl-1H-pyridin-2-one 586386-58-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(pyrrolidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-59-6P, 3-Bromo-1-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-60-9P, 3-Chloro-1-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-61-0P 586386-62-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)benzamide 586386-63-2P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzamide 586386-64-3P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylbenzamide 586386-65-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586386-66-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(pyrrolidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586386-67-6P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-isopropylbenzamide 586386-68-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586386-69-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-70-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-dimethylbenzamide 586386-71-2P, 4-(Benzylamino)-1-(3-fluorobenzyl)-6-methyl-3-nitropyridin-2(1H)-one 586386-72-3P, tert-Butyl 4-[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]piperazine-1-carboxylate 586386-73-4P, Ethyl [4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]acetate 586386-74-5P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]benzenesulfonamide 586386-75-6P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-1-phenylmethanesulfonamide 586386-76-7P, 3-Bromo-4-[(2,4-difluorophenyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586386-77-8P, 4-Anilino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586386-78-9P, Methyl 4-[[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]amino]benzoate 586386-79-0P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3,4,5-trimethoxyphenyl)amino]pyridin-2(1H)-one 586386-80-3P, 3-Bromo-1-(3-fluorobenzyl)-4-[4-(4-fluorophenyl)piperazin-1-yl]pyridin-2(1H)-one 586386-82-5P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-methylpiperazin-1-yl)pyridin-2(1H)-one trifluoroacetate 586386-83-6P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,5-difluorobenzamide 586386-84-7P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,4-difluorobenzamide 586386-85-8P, 3-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoic acid 586386-86-9P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-N'-(2,4-difluorophenyl)urea 586386-87-0P, 3-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide 586386-88-1P, 4-(Benzyloxy)-3-bromo-1-[3-

(morpholin-4-yl)-3-oxopropyl]pyridin-2(1H)-one 586386-89-2P,
N-(3-Aminopropyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide hydrochloride 586386-90-5P, 4-(Benzyloxy)-3-bromo-1-[3-oxo-3-(piperazin-1-yl)propyl]pyridin-2(1H)-one hydrochloride 586386-91-6P, 4-(Benzyloxy)-3-bromo-1-[2-(morpholin-4-yl)ethyl]pyridin-2(1H)-one 586386-92-7P, N-(2-Aminoethyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide hydrochloride 586386-93-8P, [3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]acetic acid 586386-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-one 586386-95-0P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-one 586386-96-1P, Methyl 3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridine-1-carboxylate 586386-97-2P, 1-Allyl-3-(2,4-difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-98-3P, 4-(Benzyloxy)-1-(2,2-diethoxyethyl)pyridin-2(1H)-one 586386-99-4P 586387-00-0P 586387-01-1P 586387-02-2P, 4-(Benzyloxy)-1-(2-oxopropyl)pyridin-2(1H)-one 586387-03-3P, 5-[[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]-5-methylimidazolidine-2,4-dione 586387-04-4P, Ethyl [4-(benzyloxy)-2-oxo-2H-pyridin-1-yl]acetate 586387-05-5P, 2-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]acetamide 586387-06-6P, 4-(Benzyloxy)-1-ethylpyridin-2(1H)-one 586387-07-7P, tert-Butyl 3-[[4-(benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-carboxylate 586387-08-8P, 1,3-Dibenzyl-4-hydroxy-6-methylpyridin-2(1H)-one 586387-09-9P, 1-Benzyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate 586387-10-2P, 1-Benzyl-4-(naphthyl-1-ylmethoxy)pyridin-2(1H)-one 586387-11-3P, 1-Benzyl-4-(benzylthio)-3,5-dibromopyridin-2(1H)-one 586387-12-4P, 1-Benzyl-3-[(benzylamino)methyl]-4-(benzyloxy)pyridin-2(1H)-one 586387-13-5P, 1-Benzyl-4-(benzyloxy)-3-[[2-cyclohexylethyl]amino]methyl]pyridin-2(1H)-one 586387-14-6P, 1-Benzyl-4-(benzylthio)-5-methylpyridin-2(1H)-one 586387-15-7P, 1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate 586387-16-8P, 1-Benzyl-3-bromo-6-methyl-4-[[2-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one 586387-17-9P, 1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl 4-bromobenzenesulfonate 586387-18-0P, 4-Phenoxy-1-[[2-(trimethylsilyl)ethoxy]methyl]pyridin-2(1H)-one 586387-19-1P, 1-Benzyl-4-phenoxy-pyridin-2(1H)-one 586387-20-4P 586387-21-5P, 3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one hydrochloride 586387-22-6P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-ylmethyl)pyridin-2(1H)-one 586387-23-7P, Benzyl (5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)acetate 586387-24-8P, Methyl (2E)-4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenate 586387-25-9P, tert-Butyl 4-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-carboxylate 586387-26-0P, 1-Benzyl-4-[(4-methylbenzyl)oxy]pyridin-2(1H)-one 586387-27-1P, 2-[[[3-Bromo-2-oxo-1-(pyridin-3-ylmethyl)-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile 586387-28-2P, tert-Butyl 3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-carboxylate 586387-29-3P, 4-Benzyloxy-3-bromo-1-(methanesulfonyl)-1H-pyridin-2-one 586387-30-6P, tert-Butyl 4-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]piperidine-1-carboxylate 586387-31-7P, 4-(Benzyloxy)-1-[4-(methylthio)benzyl]pyridin-2(1H)-one 586387-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2-methyl-4-methylaminopyrimidin-5-yl)methyl]-1H-pyridin-2-one 586387-33-9P, 4-(Benzyloxy)-1-[4-(methylsulfonyl)benzyl]pyridin-2(1H)-one 586387-34-0P, 4-Phenoxy-1H-pyridin-2-one 586387-35-1P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586387-36-2P, 1-(3-Fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one 586387-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylthio)pyrimidin-4-yl]pyridin-2(1H)-one 586387-38-4P, 4-(Benzyloxy)-3-bromo-1-piperidin-4-ylpyridin-2(1H)-one hydrochloride 586387-39-5P, 4-Benzyloxy-1-difluoromethyl-1H-pyridin-2-one

586387-40-8P, 4-Benzyloxy-3-bromo-1-(2-chlorophenyl)-6-methyl-1H-pyridin-2-one
 586387-41-9P, 3-Bromo-6-methyl-1-(pyridin-3-ylmethyl)-4-[(pyridin-3-ylmethyl)amino]-1H-pyridin-2-one
 586387-42-0P, 2-Chloro-N-[1-(2,6-dichlorobenzyl)-6-oxo-5-trifluoromethyl-1,6-dihydropyridin-3-yl]-4-fluorobenzamide
 586387-43-1P, N-[1-(2,6-Dichlorobenzyl)-6-oxo-5-trifluoromethyl-1,6-dihydropyridin-3-yl]-4-isopropoxybenzamide
 586387-44-2P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-methoxyphenyl)-1H-pyridin-2-one
 586387-45-3P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-isopropylphenyl)-1H-pyridin-2-one
 586387-46-4P, 3'-Bromo-1'-(3-fluorobenzyl)-6-methoxy-1'H-[3,4']bipyridinyl-2'-one
 586387-47-5P, 4-Benzo[1,3]dioxol-5-yl-3-bromo-1-(3-fluorobenzyl)-1H-pyridin-2-one
 586387-48-6P, 3-Bromo-1-(3-fluorobenzyl)-4-thiophen-3-yl-1H-pyridin-2-one
 586387-49-7P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-trifluoromethylphenyl)-1H-pyridin-2-one
 586387-50-0P, 3-Bromo-1-(3-fluorobenzyl)-4-naphthalen-2-yl-1H-pyridin-2-one
 586387-51-1P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-fluorophenyl)-1H-pyridin-2-one
 586387-52-2P, 1-Benzenesulfonyl-4-benzyloxy-3-bromo-1H-pyridin-2-one
 586387-53-3P, 4-[3-Amino-1-(2,4-difluorophenyl)propoxy]-3-bromo-6-methyl-1-[(pyridin-3-yl)methyl]-1H-pyridin-2-one
 586387-54-4P, 2-[[[1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile
 586387-55-5P, 1-(2-Chloro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1H-pyridin-2-one
 586387-56-6P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-vinyl-1H-pyridin-2-one
 586387-57-7P 586387-58-8P, 1-(2,6-Difluorophenyl)-4-methoxy-6-methyl-5-phenethyl-1H-pyridin-2-one
 586387-59-9P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-phenethyl-1H-pyridin-2-one
 586387-60-2P, 1-(1H-Indazol-5-yl)-4-(1H-indazol-5-ylamino)-6-methylpyridin-2(1H)-one
 586387-61-3P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-[2-(2,4-difluorophenyl)ethyl]-6-oxo-1,6-dihydropyridine-3-carboxaldehyde
 586387-62-4P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]pyrimidine-2-carbonitrile
 586387-63-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid
 586387-64-6P, 3-Bromo-4-[(5-carboxypyridin-2-yl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid
 586387-65-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6,6'-dimethyl-2-oxo-2H-[1,2']bipyridinyl-3'-carbonitrile
 586387-66-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid
 methylamide
 586387-67-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid
 N-(2-hydroxyethyl)amide
 586387-68-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid
 N-(2-methoxyethyl)amide
 586387-69-1P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-(4-methylbenzyl)-1H-pyridin-2-one
 586387-70-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxy-2-phenylethyl)-6-methylpyridin-2(1H)-one
 586387-71-5P, 3-Chloro-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
 586387-72-6P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
 trifluoroacetate
 586387-74-8P 586387-75-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methylbenzamide
 586387-76-0P
 , 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one
 586387-77-1P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide
 586387-78-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[2-(4-fluorophenyl)ethyl]-6-methylpyridin-2(1H)-one
 586387-79-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-isopropylbenzamide
 586387-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(pyrrolidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one
 586387-81-7P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-bis(2-hydroxyethyl)benzamide
 586387-83-9P, 4-(Benzyloxy)-1-(piperidin-3-ylmethyl)pyridin-2(1H)-one
 trifluoroacetate
 586387-84-0P,

3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-85-1P 586387-86-2P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-87-3P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)amino]pyridin-2(1H)-one 586387-88-4P
 586387-89-5P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide 586387-90-8P,
 1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
 586387-91-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-dimethylbenzamide 586387-92-0P, 4-(Allylamino)-3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586387-93-1P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-indol-5-yl)methyl]-1H-pyridin-2-one 586387-94-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxyacetyl)-2,3-dihydro-1H-indol-5-yl)methyl]-6-methyl-1H-pyridin-2-one 586387-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-3-ylmethyl)-1H-pyridin-2-one 586396-12-5P, 3-Chloro-1-[4-[[cyclopropylmethyl)amino]methyl]-2,6-difluorophenyl]-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one hydrochloride 586396-39-6P,
 N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl]-2-acetoxyacetamide 586396-68-1P 586397-52-6P
 586397-63-9P 586397-73-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 165245-96-5, p38 α MAP kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586374-26-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 56-37-1, Benzyltriethylammonium chloride 75-31-0, Isopropylamine, reactions 79-44-7, Dimethylcarbonyl chloride 86-95-3, 4-Hydroxy-1,2-dihydroquinolin-2-one 87-62-7, 2,6-Dimethylaniline 88-17-5, 2-(Trifluoromethyl)aniline 95-02-3, 4-Amino-5-aminomethyl-2-methylpyrimidine 96-33-3, Methyl acrylate 98-00-0, Furfuryl alcohol 98-58-8, 4-Bromobenzenesulfonyl chloride 98-79-3 99-27-4, Dimethyl 5-aminoisophthalate 100-82-3, 3-Fluorobenzylamine 103-64-0, β -Bromostyrene 103-71-9, Phenyl isocyanate, reactions 104-81-4, 4-Methylbenzyl bromide 105-36-2, Ethyl bromoacetate 106-96-7, Propargyl bromide 107-11-9, Allylamine 109-01-3, 1-Methylpiperazine 109-08-0, 2-Methylpyrazine 109-83-1, 2-(Methylamino)ethanol 109-85-3, 2-Methoxyethylamine 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl acrylate 315-14-0, 2,4,6-Trifluoronitrobenzene 315-31-1, 2-Fluoro-3-methylbenzoic acid 363-81-5, 2,4,6-Trifluoroaniline 402-23-3, 3-Trifluoromethylbenzyl bromide 403-43-0, 4-Fluorobenzoyl chloride 405-99-2, 4-Fluorostyrene 452-85-7, 5-Fluoro-2-methylphenol 453-71-4, 4-Fluoro-3-nitrobenzoic acid 455-87-8, 4-Amino-3-fluorobenzoic acid 456-41-7, 3-Fluorobenzyl bromide 459-46-1, 4-Fluorobenzyl bromide 459-56-3, 4-Fluorobenzyl alcohol 527-69-5, 2-Furoyl chloride 536-74-3, Phenylacetylene 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl

chloroformate 582-33-2, Ethyl 3-aminobenzoate 585-71-7,
 (1-Bromoethyl)benzene 594-61-6, 2-Hydroxyisobutyric acid 616-30-8,
 3-Amino-1,2-propanediol 617-88-9, 2-(Chloromethyl)furan 619-45-4,
 Methyl 4-aminobenzoate 625-45-6, Methoxyacetic acid 626-03-9,
 2,4-Dihydroxypyridine 626-15-3, α,α' -Dibromo-m-xylene
 674-82-8, Diketene 675-10-5, 4-Hydroxy-6-methyl-2H-pyran-2-one
 765-50-4, 2-(Chloromethyl)thiophene 766-98-3, 4-Fluorophenylacetylene
 867-44-7 873-63-2, 3-Chlorobenzyl alcohol 1011-65-0, Methyl
 indole-5-carboxylate 1071-46-1, Monoethyl malonate 1072-84-0,
 4-Imidazolecarboxylic acid 1117-71-1, Methyl 4-bromocrotonate
 1121-76-2, 4-Chloropyridine 1-oxide 1124-33-0, 4-Nitropyridine N-oxide
 1129-28-8, Methyl 3-bromomethylbenzoate 1194-02-1, 4-Fluorobenzonitrile
 1453-58-3, 3-Methyl-1H-pyrazole 1465-76-5, 1-tert-Butyl-4-oxopiperidine
 1877-77-6, 3-Aminobenzyl alcohol 2038-03-1, 4-(2-Aminoethyl)morpholine
 2144-37-8 2393-23-9, 4-Methoxybenzylamine 2417-72-3, Methyl
 4-(bromomethyl)benzoate 2486-74-0, 4-Amino-2-methylmethyl benzoate
 2840-26-8, 3-Amino-4-methoxybenzoic acid 2854-16-2, 3-Amino-2-methyl-2-
 propanol 3240-94-6, 4-(2-Chloroethyl)morpholine 3320-83-0,
 2-Chlorophenyl isocyanate 3544-24-9, 3-Aminobenzamide 3731-51-9,
 2-(Aminomethyl)pyridine 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1,
 4-(Aminomethyl)pyridine 3739-30-8, 2-Hydroxy-2-methylbutyric acid
 4285-42-1, N-Methyl-N-phenylcarbonyl chloride 4385-35-7,
 Isochroman-3-one 4412-91-3, 3-Furylmethanol 4518-10-9, Methyl
 3-aminobenzoate 4530-20-5, Boc-glycine 5345-27-7, 3-
 (Methylsulfonyl)benzoic acid 5382-16-1, 4-Hydroxypiperidine 5394-63-8,
 2,2,6-Trimethyl-4H-1,3-dioxin-4-one 5470-70-2, Methyl 6-methylnicotinate
 5509-65-9, 2,6-Difluoroaniline 5521-55-1, 5-Methylpyrazine-2-carboxylic
 acid 5571-03-9, Methyl 2-methyl-5-pyrimidinecarboxylate 6482-24-2,
 2-Methoxyethyl bromide 6723-30-4, [(Tetrahydro-2H-pyran-2-yl)oxy]amine
 7051-34-5, Cyclopropylmethyl bromide 7554-65-6, 4-Methyl-1H-pyrazole
 7693-46-1, 4-Nitrophenyl chloroformate 10406-24-3, 3-
 (Aminomethyl)benzonitrile 13737-36-5, 4-(Bromomethyl)phenylacetic acid
 13831-30-6, Acetoxyacetic acid 13831-31-7, Acetoxyacetyl chloride
 14001-63-9, 4-Methyl-2-methylthiopyrimidine 15781-71-2, 2-Methylmalonic
 acid bis(2,4,6-trichlorophenyl) ester 17201-43-3, α -Bromo-p-
 tolunitrile 17994-25-1, 1-Hydroxy-1-cyclopropanecarboxylic acid
 18063-02-0, 2,6-Difluorobenzoyl chloride 18583-89-6, Methyl
 3-amino-2-methylbenzoate 18595-18-1, Methyl 3-amino-4-methylbenzoate
 19335-11-6, 5-Aminoindazole 20274-69-5, 4-Fluoro-3-nitrobenzyl alcohol
 22115-41-9, α -Bromo-o-tolunitrile 22134-75-4 22600-30-2, Methyl
 2-amino-5-furoate 23063-36-7, α,α -Dichloro-p-xylene
 23915-07-3, 2,4-Difluorobenzyl bromide 24424-99-5, Di-tert-butyl
 dicarbonate 24964-64-5, 3-Cyanobenzaldehyde 25006-86-4,
 2,6-Bis(bromomethyl)fluorobenzene 30533-50-7, 1-Amino-2-methyl-2-
 propanol hydrochloride 36394-75-9, (S)-(-)-2-Acetoxypropionyl chloride
 38870-89-2, 2-Methoxyacetyl chloride 39920-37-1, 2,6-Dichlorophenyl
 isocyanate 40061-55-0, m-Tolylacetic acid ethyl ester 40635-66-3,
 2-Acetoxy-2-methylpropionyl chloride 40872-87-5, Methyl
 3-amino-4-chlorobenzoate 49608-01-7, Ethyl 6-chloronicotinate
 50628-37-0, 3,3-Dimethoxy-2-methoxycarbonylpropen-1-ol sodium salt
 53937-02-3, 4-Benzyloxy-2(1H)-pyridone 55912-20-4, 3-Nitro-4-
 chlorobenzyl alcohol 56456-47-4, 2,4-Difluorobenzyl alcohol
 57260-71-6, N-(tert-Butyloxycarbonyl)piperazine 57791-63-6,
 3-(Cyclohexylamino)-2-butenic acid methyl ester 60728-41-8,
 3-Amino-4-(methoxycarbonyl)benzoic acid 62558-08-1, 1,2-
 Bis(hydroxymethyl)-4-fluorobenzene 66176-39-4, 4-
 (Bromomethyl)benzenesulfonyl chloride 67567-26-4, 4-Bromo-2,6-
 difluoroaniline 71637-34-8, Thien-3-ylmethanol 72235-52-0,
 2,4-Difluorobenzylamine 77532-79-7, 5-Fluoro-2-methylbenzonitrile
 80278-67-7, Isoquinoline-5-carboxaldehyde 81863-45-8,
 3-Amino-4-methylbenzyl alcohol 84257-12-5, 5-(1-Hydroxy-3-oxobutylidene)-

2,2-dimethyl-1,3-dioxane-4,6-dione 105827-74-5, 5-Bromomethyl-2-fluoropyridine 114896-64-9, Methanesulfonic acid 2-(thiophen-3-yl)ethyl ester 120100-15-4, Methyl 3-amino-2-chlorobenzoate 132664-85-8, 5-Aminomethyl-2-methylpyrazine 134227-45-5, 3,4,5-Trifluorobenzonitrile 135394-68-2 161975-39-9, 4-(Methanesulfonyloxymethyl)-1-piperidine-1-carboxylic acid tert-butyl ester 162166-99-6, 3-[(Methanesulfonyloxy)methyl]piperidine-1-carboxylic acid tert-butyl ester 192369-91-8, 5-(Bromomethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole 586373-19-5, 1-Benzyl-4-hydroxypyridin-2(1H)-one 586374-17-6, 1-(3-Fluorobenzyl)-4-[(3-fluorobenzyl)oxy]-1H-pyridin-2-one 586374-35-8 586374-60-9, 3-Bromo-4-(2,4-difluorophenoxy)-6-methylpyridin-2(1H)-one 586374-98-3, 3-Bromo-4-(2,4-difluorophenoxy)-6-methyl-1-[4-(piperazin-1-ylcarbonyl)benzyl]pyridin-2(1H)-one 586376-42-3, 1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one hydrochloride 586376-54-7, 3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586376-85-4, 4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2(1H)-one 586378-53-2, 1-Benzyl-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one 586378-62-3, 3-Bromo-1-(cyclopropylmethyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586378-89-4, 4-Hydroxy-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-00-2, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[5-[(methylamino)methyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one 586379-20-6, 4-[(2,4-Difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-22-8, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 58804-19-6P 586378-47-4P 586381-34-2P 586381-37-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; CHEM BER 1956, V89, P876
- (2) Anon; COLLECT CZECH CHEM COMMUN 1993, V58(4), P947
- (3) Anon; JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1 1986, P1289
- (4) Anon; LIEBIGS ANN, RECL 1997, V8, P1777
- (5) Crich, J; WO 0031063 A 2000 CAPLUS
- (6) Dorn, C; US 3715358 A 1973
- (7) Graham, P; US 3654291 A 1972 CAPLUS
- (8) Margolin, S; WO 9710712 A 1997 CAPLUS
- (9) Merck & Co Inc; GB 1289187 A 1972 CAPLUS
- (10) Sandoz Ag; WO 8601815 A 1986 CAPLUS
- (11) Witzel, B; US 3644626 A 1972 CAPLUS

L32 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 84-11-7, Phenanthrene-9,10-dione

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutics for chemokine-mediated diseases)

RN 84-11-7 CAPLUS

CN 9,10-Phenanthrenedione (CA INDEX NAME)



ACCESSION NUMBER: 2002:449493 CAPLUS
 DOCUMENT NUMBER: 137:15782
 TITLE: Therapeutics for chemokine-mediated diseases
 INVENTOR(S): Saxena, Geeta; Tudan, Christopher R.; Salari, Hassan
 PATENT ASSIGNEE(S): Chemokine Therapeutics Corporation, Can.
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002045702	A2	20020613	WO 2001-CA1748	20011205
WO 2002045702	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2330350	A1	20020605	CA 2000-2330350	20001205
US 20030069265	A1	20030410	US 2001-767378	20010122
US 6706767	B2	20040316		
AU 2002015737	A5	20020618	AU 2002-15737	20011205
PRIORITY APPLN. INFO.:				
			CA 2000-2330350	A 20001205
			US 2001-767378	A 20010122
			WO 2001-CA1748	W 20011205

OTHER SOURCE(S): MARPAT 137:15782
 AN 2002:449493 CAPLUS
 DN 137:15782
 ED Entered STN: 14 Jun 2002
 TI Therapeutics for chemokine-mediated diseases
 IN Saxena, Geeta; Tudan, Christopher R.; Salari, Hassan
 PA Chemokine Therapeutics Corporation, Can.
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-00
 CC 1-7 (Pharmacology)
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002045702	A2	20020613	WO 2001-CA1748	20011205
WO 2002045702	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
 UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2330350	A1	20020605	CA 2000-2330350	20001205
US 20030069265	A1	20030410	US 2001-767378	20010122
US 6706767	B2	20040316		
AU 2002015737	A5	20020618	AU 2002-15737	20011205
PRAI CA 2000-2330350	A	20001205		
US 2001-767378	A	20010122		
WO 2001-CA1748	W	20011205		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002045702	ICM	A61K031-00
	IPCI	A61K0031-00 [ICM,7]
	IPCR	A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-01 [I,C*]; A61K0031-015 [I,A]; A61K0031-11 [I,C*]; A61K0031-11 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0025-00 [I,C*]; A61P0025-28 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-02 [I,A]; A61P0033-00 [I,C*]; A61P0033-06 [I,A]; A61P0037-00 [I,C*]; A61P0037-00 [I,A]
	ECLA	A61K031/00+A; A61K031/015; A61K031/11; A61K031/122; A61K031/473
CA 2330350	IPCI	A61K0031-122 [ICM,7]; A61K0031-015 [ICS,7]; A61K0031-01 [ICS,7,C*]; A61P0019-02 [ICS,7]; A61P0019-00 [ICS,7,C*]; A61P0001-04 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0011-06 [ICS,7]; A61P0011-00 [ICS,7,C*]; A61P0017-06 [ICS,7]; A61P0017-00 [ICS,7,C*]; A61P0037-06 [ICS,7]; A61P0037-00 [ICS,7,C*]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]; A61K0031-11 [ICS,7]; A61K0031-473 [ICS,7]; A61K0031-66 [ICS,7]; A61K0031-695 [ICS,7]
	IPCR	A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-01 [I,C*]; A61K0031-015 [I,A]; A61K0031-11 [I,C*]; A61K0031-11 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A]
	ECLA	A61K031/00+A; A61K031/015; A61K031/11; A61K031/122; A61K031/473
US 20030069265	IPCI	A61K0031-473 [ICM,7]; A61K0031-122 [ICS,7]; A61K0031-015 [ICS,7]; A61K0031-01 [ICS,7,C*]
	IPCR	A61K0031-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-01 [I,C*]; A61K0031-015 [I,A]; A61K0031-11 [I,A]; A61K0031-11 [I,C*]; A61K0031-122 [I,A]; A61K0031-122 [I,C*]; A61K0031-473 [I,A]; A61K0031-473 [I,C*]
	NCL	514/290.000; 514/680.000; 514/765.000
	ECLA	A61K031/00+A; A61K031/015; A61K031/11; A61K031/122; A61K031/473
AU 2002015737	IPCI	A61K0031-00 [ICM,7]
	IPCR	A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-01 [I,C*]; A61K0031-015 [I,A]; A61K0031-11 [I,C*];

A61K0031-11 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0025-00 [I,C*]; A61P0025-28 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-02 [I,A]; A61P0033-00 [I,C*]; A61P0033-06 [I,A]; A61P0037-00 [I,C*]; A61P0037-00 [I,A]

OS MARPAT 137:15782

AB The invention provides therapeutic and biol. uses of chemokine receptor-binding compds. (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as tricyclic phenanthrene derivs., including uses in the treatment of disease states mediated by chemokines or chemokine receptors. The relevant chemokines may be e.g. monocyte chemoattractant protein-1 (MCP-1) or interleukin-8 (IL-8), and the relevant chemokine receptors may be e.g. corresponding chemokine receptors (CCR-2, CCR-4, CXCR-1, and CXCR-2). The invention also provides corresponding pharmaceutical compns. and therapeutic methods. In one aspect, for example, the invention provides for the use of phenanthrene-9,10-dione in the treatment of multiple sclerosis.

ST chemokine mediated disease treatment chemokine receptor binding compd; tricyclic phenanthrene deriv chemokine mediated disease treatment; phenanthrenedione multiple sclerosis treatment

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR2; therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR4; therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR1; therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR2; therapeutics for chemokine-mediated diseases)

IT Inflammation

(Crohn's disease; therapeutics for chemokine-mediated diseases)

IT Intestine, disease

(Crohn's; therapeutics for chemokine-mediated diseases)

IT Sepsis

(Gram-neg.; therapeutics for chemokine-mediated diseases)

IT Neutrophil

(activation; therapeutics for chemokine-mediated diseases)

IT Inflammation

(acute; therapeutics for chemokine-mediated diseases)

IT Respiratory distress syndrome

(adult; therapeutics for chemokine-mediated diseases)

IT Transplant rejection

(allotransplant; therapeutics for chemokine-mediated diseases)

IT Antiarteriosclerotics

(antiatherosclerotics; therapeutics for chemokine-mediated diseases)

IT Dermatitis

(atopic; therapeutics for chemokine-mediated diseases)

IT Lung, disease

(chronic obstructive pulmonary disease; therapeutics for chemokine-mediated diseases)

IT Inflammation

Transplant rejection

(chronic; therapeutics for chemokine-mediated diseases)

IT Autoimmune disease
(exptl. autoimmune encephalomyelitis; therapeutics for chemokine-mediated diseases)

IT Encephalomyelitis
(exptl. autoimmune; therapeutics for chemokine-mediated diseases)

IT Lung, disease
(fibrosis, idiopathic; therapeutics for chemokine-mediated diseases)

IT Ischemia
(focal; therapeutics for chemokine-mediated diseases)

IT Inflammation
Kidney, disease
(glomerulonephritis; therapeutics for chemokine-mediated diseases)

IT Transplant and Transplantation
(graft-vs.-host reaction; therapeutics for chemokine-mediated diseases)

IT Intestine, disease
(inflammatory; therapeutics for chemokine-mediated diseases)

IT Reperfusion
(injury, cardiac and renal; therapeutics for chemokine-mediated diseases)

IT Lung, disease
(injury, mononuclear phagocyte-dependent; therapeutics for chemokine-mediated diseases)

IT Phagocyte
(mononuclear, mononuclear phagocyte-dependent lung injury; therapeutics for chemokine-mediated diseases)

IT Cell activation
(neutrophil; therapeutics for chemokine-mediated diseases)

IT Arthritis
(pseudogout, acute; therapeutics for chemokine-mediated diseases)

IT Fibrosis
(pulmonary, idiopathic; therapeutics for chemokine-mediated diseases)

IT Injury
(pulmonary, mononuclear phagocyte-dependent; therapeutics for chemokine-mediated diseases)

IT Heart, disease
Kidney, disease
(reperfusion injury; therapeutics for chemokine-mediated diseases)

IT Injury
(reperfusion, cardiac and renal; therapeutics for chemokine-mediated diseases)

IT Artery, disease
(restenosis; therapeutics for chemokine-mediated diseases)


IT Shock (circulatory collapse)
(septic; therapeutics for chemokine-mediated diseases)

IT Brain, disease
(stroke; therapeutics for chemokine-mediated diseases)

IT Multiple sclerosis
(therapeutic agents; therapeutics for chemokine-mediated diseases)

IT Alzheimer's disease
Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Anticoagulants
Antimalarials
Arthritis
Asthma

Atherosclerosis
 Cardiovascular agents
 Drug delivery systems
 Gastrointestinal agents
 Gout
 Inflammation
 Malaria
 Multiple sclerosis
 Neutrophil
 Psoriasis
 Rheumatoid arthritis
 Sarcoidosis
 Thrombosis
 (therapeutics for chemokine-mediated diseases)
 IT Chemokine receptors
 Chemokines
 Interleukin 8
 Monocyte chemoattractant protein-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (therapeutics for chemokine-mediated diseases)
 IT Shock (circulatory collapse)
 (toxic shock syndrome; therapeutics for chemokine-mediated diseases)
 IT Inflammation
 Intestine, disease
 (ulcerative colitis; therapeutics for chemokine-mediated diseases)
 IT Interleukin 8 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α ; therapeutics for chemokine-mediated diseases)
 IT Interleukin 8 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β ; therapeutics for chemokine-mediated diseases)
 IT 7440-70-2, Calcium, biological studies 169592-56-7, Caspase 3
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (therapeutics for chemokine-mediated diseases)
 IT 82-86-0, Acenaphthenequinone 83-32-9, Acenaphthene 84-11-7,
 Phenanthrene-9,10-dione 1015-89-0, 6(5H)-Phenanthridinone 4707-71-5,
 Phenanthrene-9-carboxaldehyde
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (therapeutics for chemokine-mediated diseases)
 L32 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
 IT 98-59-9, p-Toluenesulfonyl chloride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of novel multicyclic compds. and their amino acid derivs. as
 inhibitors of enzymes for treatment of diseases related to
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
 kinase)
 RN 98-59-9 CAPLUS
 CN Benzenesulfonyl chloride, 4-methyl- (CA INDEX NAME)



ACCESSION NUMBER: 2001:833276 CAPLUS

DOCUMENT NUMBER: 135:371989
 TITLE: Preparation of novel multicyclic compounds and their amino acid derivatives as inhibitors of enzymes such as poly(ADP-ribose) polymerase
 INVENTOR(S): Ator, Mark A.; Bihovsky, Ron; Chatterjee, Sankar; Dunn, Derek; Hudkins, Robert L.
 PATENT ASSIGNEE(S): Cephalon, Inc., USA
 SOURCE: PCT Int. Appl., 209 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085686	A2	20011115	WO 2001-US14996	20010509
WO 2001085686	A3	20020530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020028815	A1	20020307	US 2001-850858	20010508
US 7122679	B2	20061017		
CA 2409758	A1	20011115	CA 2001-2409758	20010509
EP 1294725	A2	20030326	EP 2001-935215	20010509
EP 1294725	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010993	A	20030624	BR 2001-10993	20010509
HU 2003002385	A2	20031229	HU 2003-2385	20010509
HU 2003002385	A3	20070328		
JP 2004501097	T	20040115	JP 2001-582287	20010509
NZ 522539	A	20040528	NZ 2001-522539	20010509
AT 315039	T	20060215	AT 2001-935215	20010509
ES 2256238	T3	20060716	ES 2001-935215	20010509
EP 1754707	A2	20070221	EP 2005-76862	20010509
EP 1754707	A3	20070228		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
MX 2002PA10977	A	20030714	MX 2002-PA10977	20021107
ZA 2002009065	A	20040209	ZA 2002-9065	20021107
NO 2002005376	A	20030108	NO 2002-5376	20021108
NO 324256	B1	20070917		
IN 2002CN01380	A	20050311	IN 2002-CN1380	20021108
KR 832602	B1	20080527	KR 2002-715062	20021109
BG 107355	A	20030731	BG 2002-107355	20021205
HK 1051369	A1	20060504	HK 2003-103639	20030522
PRIORITY APPLN. INFO.:			US 2000-202947P	P 20000509
			US 2001-850858	A 20010508
			EP 2001-935215	A3 20010509
			WO 2001-US14996	W 20010509
OTHER SOURCE(S):		MARPAT 135:371989		
AN 2001:833276		CAPLUS		
DN 135:371989				
ED Entered STN: 16 Nov 2001				

TI Preparation of novel multicyclic compounds and their amino acid
 derivatives as inhibitors of enzymes such as poly(ADP-ribose) polymerase
 IN Ator, Mark A.; Bihovsky, Ron; Chatterjee, Sankar; Dunn, Derek; Hudkins,
 Robert L.
 PA Cephalon, Inc., USA
 SO PCT Int. Appl., 209 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D209-00
 CC 34-2 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 1, 7, 28

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085686	A2	20011115	WO 2001-US14996	20010509
	WO 2001085686	A3	20020530		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,				
	HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,				
	RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,				
	YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 20020028815	A1	20020307	US 2001-850858	20010508
	US 7122679	B2	20061017		
	CA 2409758	A1	20011115	CA 2001-2409758	20010509
	EP 1294725	A2	20030326	EP 2001-935215	20010509
	EP 1294725	B1	20060104		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001010993	A	20030624	BR 2001-10993	20010509
	HU 2003002385	A2	20031229	HU 2003-2385	20010509
	HU 2003002385	A3	20070328		
	JP 2004501097	T	20040115	JP 2001-582287	20010509
	NZ 522539	A	20040528	NZ 2001-522539	20010509
	AT 315039	T	20060215	AT 2001-935215	20010509
	ES 2256238	T3	20060716	ES 2001-935215	20010509
	EP 1754707	A2	20070221	EP 2005-76862	20010509
	EP 1754707	A3	20070228		
	R:				
	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,				
	NL, PT, SE, TR				
	MX 2002PA10977	A	20030714	MX 2002-PA10977	20021107
	ZA 2002009065	A	20040209	ZA 2002-9065	20021107
	NO 2002005376	A	20030108	NO 2002-5376	20021108
	NO 324256	B1	20070917		
	IN 2002CN01380	A	20050311	IN 2002-CN1380	20021108
	KR 832602	B1	20080527	KR 2002-715062	20021109
	BG 107355	A	20030731	BG 2002-107355	20021205
	HK 1051369	A1	20060504	HK 2003-103639	20030522
PRAI	US 2000-202947P	P	20000509		
	US 2001-850858	A	20010508		
	EP 2001-935215	A3	20010509		
	WO 2001-US14996	W	20010509		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001085686	ICM	C07D209-00
	IPCI	C07D0209-00 [ICM, 7]

	IPCR	A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]	
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00	
	US 20020028815	IPCI	C07D0209-56 [I,A]; C07D0209-00 [I,C*]; A61K0031-46 [I,A]
	IPCR	A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]	
	NCL	514/249.000; 514/290.000; 514/373.000; 514/411.000; 544/234.000; 546/079.000; 548/207.000; 548/427.000; 548/418.000; 548/416.000; 548/417.000; 548/420.000	
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00	
	CA 2409758	IPCI	C07D0487-04 [ICM, 7]; C07D0487-00 [ICM, 7,C*]; C07D0209-00 [ICS, 7]; C07D0221-00 [ICS, 7]; C07D0223-00

		[ICS,7]; C07D0243-00 [ICS,7]; C07D0307-00 [ICS,7]; C07D0519-00 [ICS,7]; A61P0043-00 [ICS,7]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; C07D0491-14 [ICS,7]; C07D0491-00 [ICS,7,C*]; A61K0031-395 [ICS,7]
IPCR		A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
ECLA		C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
EP 1294725	IPCI	C07D0487-00 [I,C]; A61K0031-395 [I,C]; A61P0043-00 [I,C]; C07D0471-00 [I,C]; C07D0491-00 [I,C]; C07D0519-00 [I,C]; C07D0487-04 [I,A]; A61K0031-395 [I,A]; A61P0043-00 [I,A]; C07D0471-14 [I,A]; C07D0491-14 [I,A]; C07D0519-00 [I,A]
	IPCR	C07D0487-00 [I,C]; C07D0487-04 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A]; A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D0471-00 [I,C]; C07D0471-14 [I,A]; C07D0491-00 [I,C]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C]; C07D0519-00 [I,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A;

		C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
BR 2001010993	IPCI	C07D0209-00 [ICM, 7]
	IPCR	A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
HU 2003002385	IPCI	C07D0487-04 [ICM, 7]; C07D0487-00 [ICM, 7,C*]
	IPCR	A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
JP 2004501097	IPCI	C07D0487-04 [ICM, 7]; C07D0487-00 [ICM, 7,C*]; A61K0031-407 [ICS, 7]; A61K0031-41 [ICS, 7]; A61K0031-4178 [ICS, 7]; A61K0031-4164 [ICS, 7,C*]; A61K0031-4196 [ICS, 7]; A61K0031-427 [ICS, 7]; A61K0031-4412 [ICS, 7]; A61K0031-4439 [ICS, 7];

A61K0031-4427 [ICS,7,C*]; A61K0031-4453 [ICS,7];
 A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C*];
 A61K0031-501 [ICS,7]; A61K0031-5377 [ICS,7];
 A61K0031-5375 [ICS,7,C*]; A61P0003-10 [ICS,7];
 A61P0003-00 [ICS,7,C*]; A61P0009-10 [ICS,7];
 A61P0009-00 [ICS,7,C*]; A61P0015-00 [ICS,7];
 A61P0017-06 [ICS,7]; A61P0017-00 [ICS,7,C*];
 A61P0025-14 [ICS,7]; A61P0025-16 [ICS,7]; A61P0025-28
 [ICS,7]; A61P0025-00 [ICS,7,C*]; A61P0027-02 [ICS,7];
 A61P0027-00 [ICS,7,C*]; A61P0029-00 [ICS,7];
 A61P0035-00 [ICS,7]; A61P0043-00 [ICS,7]
 IPCR A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41
 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*];
 A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
 A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
 A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
 A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
 A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*];
 A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
 A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
 A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
 A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
 A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14
 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
 C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14
 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A];
 C07D0519-00 [I,C*]; C07D0519-00 [I,A]
 ECLA C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
 C07D487/04+235A+209A; C07D487/04+237A+209A;
 C07D487/04+239A+209A; C07D491/04+307A+209A;
 C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
 C07D519/00+487/00+487/00
 FTERM 4C050/AA01; 4C050/AA07; 4C050/AA08; 4C050/BB04;
 4C050/CC04; 4C050/DD10; 4C050/EE02; 4C050/FF01;
 4C050/FF02; 4C050/FF05; 4C050/FF10; 4C050/GG03;
 4C050/HH03; 4C050/HH04; 4C086/AA01; 4C086/AA02;
 4C086/AA03; 4C086/CB03; 4C086/NA14; 4C086/ZA02;
 4C086/ZA15; 4C086/ZA16; 4C086/ZA33; 4C086/ZA36;
 4C086/ZA81; 4C086/ZA89; 4C086/ZB11; 4C086/ZB15;
 4C086/ZB21; 4C086/ZB26; 4C086/ZC02; 4C086/ZC35
 NZ 522539 IPCI C07D0487-04 [ICM,7]; C07D0487-00 [ICM,7,C*];
 C07D0519-00 [ICS,7]; C07D0491-14 [ICS,7]; C07D0491-00
 [ICS,7,C*]; C07D0471-14 [ICS,7]; C07D0471-00
 [ICS,7,C*]; A61K0031-395 [ICS,7]; A61P0043-00 [ICS,7]
 IPCR A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41
 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*];
 A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
 A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
 A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
 A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
 A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*];
 A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];

A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]

AT 315039 ECLA C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00

IPCI C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]; A61K0031-395 [ICS,7]; A61P0043-00 [ICS,7]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; C07D0491-14 [ICS,7]; C07D0491-00 [ICS,7,C*]; C07D0519-00 [ICS,7]

IPCR A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]



ECLA C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00

ES 2256238 IPCI C07D0487-04 [ICS,4]; C07D0487-00 [ICS,4,C*]; A61K0031-395 [ICS,4]; C07D0471-14 [ICS,4]; C07D0471-00 [ICS,4,C*]; C07D0491-14 [ICS,4]; C07D0491-00 [ICS,4,C*]; C07D0519-00 [ICS,4]; A61P0043-00 [ICS,4]

IPCR A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10

		[I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
EP 1754707	IPCI	C07D0487-04 [I,A]; C07D0487-00 [I,C*]; A61K0031-395 [I,A]; A61P0043-00 [I,A]; C07D0519-00 [I,A]; C07D0491-04 [I,A]; C07D0491-00 [I,C*]; C07D0495-04 [I,A]; C07D0495-00 [I,C*]; C07D0209-00 [N,A]; C07D0243-00 [N,A]; C07D0223-00 [N,A]; C07D0307-00 [N,A]; C07D0221-00 [N,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
MX 2002PA10977	IPCI	C07D0209-00 [ICM,6]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
ZA 2002009065	IPCI	C07D [ICM,7]
NO 2002005376	IPCI	C07D0209-00 [ICM,7]
	IPCR	A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C*]; C07D0519-00 [I,A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A;

		C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
IN 2002CN01380	IPCI	C07D0209-00 [ICM, 7]
KR 832602	IPCI	C07D0487-04 [I, A]; C07D0487-00 [I, C*]
BG 107355	IPCI	C07D0487-04 [ICM, 7]; C07D0487-00 [ICM, 7, C*]; A61K0031-395 [ICS, 7]; A61P0043-00 [ICS, 7]; C07D0519-00 [ICS, 7]; C07D0491-14 [ICS, 7]; C07D0491-00 [ICS, 7, C*]; C07D0471-14 [ICS, 7]; C07D0471-00 [ICS, 7, C*]
	IPCR	C07D0487-00 [I, C*]; C07D0487-04 [I, A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
HK 1051369	IPCI	C07D [ICS, 7]; A61K [ICS, 7]; A61P [ICS, 7]
	IPCR	A61K0031-407 [I, C*]; A61K0031-407 [I, A]; A61K0031-41 [I, C*]; A61K0031-41 [I, A]; A61K0031-4164 [I, C*]; A61K0031-4178 [I, A]; A61K0031-4196 [I, C*]; A61K0031-4196 [I, A]; A61K0031-427 [I, C*]; A61K0031-427 [I, A]; A61K0031-4412 [I, C*]; A61K0031-4412 [I, A]; A61K0031-4427 [I, C*]; A61K0031-4439 [I, A]; A61K0031-4453 [I, C*]; A61K0031-4453 [I, A]; A61K0031-4965 [I, C*]; A61K0031-497 [I, A]; A61K0031-501 [I, C*]; A61K0031-501 [I, A]; A61K0031-5375 [I, C*]; A61K0031-5377 [I, A]; A61P0003-00 [I, C*]; A61P0003-10 [I, A]; A61P0009-00 [I, C*]; A61P0009-10 [I, A]; A61P0015-00 [I, C*]; A61P0015-00 [I, A]; A61P0017-00 [I, C*]; A61P0017-06 [I, A]; A61P0025-00 [I, C*]; A61P0025-14 [I, A]; A61P0025-16 [I, A]; A61P0025-28 [I, A]; A61P0027-00 [I, C*]; A61P0027-02 [I, A]; A61P0029-00 [I, C*]; A61P0029-00 [I, A]; A61P0035-00 [I, C*]; A61P0035-00 [I, A]; A61P0043-00 [I, C*]; A61P0043-00 [I, A]; C07D0471-00 [I, C*]; C07D0471-14 [I, A]; C07D0487-00 [I, C*]; C07D0487-04 [I, A]; C07D0491-00 [I, C*]; C07D0491-04 [I, A]; C07D0491-14 [I, A]; C07D0495-00 [I, C*]; C07D0495-04 [I, A]; C07D0519-00 [I, C*]; C07D0519-00 [I, A]
	ECLA	C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00
OS	MARPAT 135:371989	
GI		



AB The title compds. such as penta[a]pyrrolo[3,4-c]carbazole, hexano[a]pyrrolo[3,4-c]carbazole, pyrrolo[3,4-c]carbazole, and

furano[a-3,2]pyrrolo[3,4-c]carbazole derivs. [I; A, B = CO, CH(OR₃), CH(SR₃), CH₂, CHR₃, CHR₃CHR₄, CR₃R₄, COR₃, N:CR₃, SO, SO₂ (wherein R₃, R₄ = H, optionally substituted lower alkyl or aryl); Y and Z, together with the carbon to which they are attached, form an (un)substituted mono- or bicyclic aryl or bicyclic heteroaryl, or C₃-5 heteroaryl; E, F = lower alkyl or E and F, together with the carbon to which they are attached, form an (un)substituted C₄-7 cycloalkyl, C₃-6 heterocycloalkyl or heteroaryl, or an (un)substituted heterocycloalkyl endocyclically comprising at least one group G (wherein G = O, S, SO, SO₂, NR₂, NR₂CO, NR₂CONR₃, NR₂SO₂, NR₃SO₂; R₂ = H, optionally substituted lower alkyl or alkanoyl, CHO, acetyl, lower alkylsulfonyl, arylsulfonyl, an optionally protected amino acid)] are prepared These compds. are effective in the treatment of diseases or disease states related to the activity of enzymes such as poly(ADP-ribose) polymerase (PARP), vascular endothelial growth factor receptor kinase (VEGFR2 kinase), and MLK3 kinase (a member of the mixed lineage kinase family), including, for example, traumatic central nervous system injuries, neurodegenerative diseases (in particular Parkinson's, Huntington's, or Alzheimer's disease), inflammation, cerebral or cardiac ischemia, endotoxic shock, diabetes, or cellular proliferative disorders (in particular cancer, solid tumors, diabetic retinopathy, intraocular neovascular syndromes, macular degeneration, rheumatoid arthritis, psoriasis, or endometriosis). They also suppress the formation of blood vessels (angiogenesis) and prevent neuronal degradation associated with traumatic central nervous system injuries. Thus, 2H-1,3,4,5,6,7-hexahydrocyclopenta[a]pyrrolo[3,4-c]carbazole-1,3-dione (II; R = H) (preparation given) was treated with NaH in DMF at room

temperature for

30 min and condensed with a stirred mixture of Boc-Lys(Boc)-OH dicyclohexylamine salt, TBTU, N-Methylmorpholine, and DMF at room temperature for 1 h, followed by treatment of the product with 4 N HCl in dioxane to give II (R = H-Lys). II (R = H-Lys) showed IC₅₀ of $\mu\text{g/mL}$ against of 22 nM against PARP.

ST clopentapyrrolocarbazole prepn inhibitor poly ADP ribose polymerase; PARP inhibitor multicyclic compd prepn; pyrrolocarbazole prepn inhibitor VEGFR2 kinase; furanopyrrolocarbazole prepn inhibitor VEGFR2 kinase; neurodegenerative disease treatment multicyclic compd prepn; inflammation treatment multicyclic compd prepn; ischemia treatment multicyclic compd prepn; MLK3 kinase inhibitor multicyclic compd prepn

IT Nervous system

(Huntington's chorea; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Amides, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Nervous system

(central, injury; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Nervous system

(degeneration; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,

and MLK3 kinase)

IT Eye, disease
(diabetic retinopathy; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Cell proliferation
(disorders; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Uterus, disease
(endometriosis; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Eye, disease
(intraocular neovascular syndromes; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Brain, disease
Heart, disease
(ischemia; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Eye, disease
(macula, degeneration; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Heterocyclic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nitrogen, aromatic; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Alzheimer's disease
Angiogenesis inhibitors
Anti-inflammatory agents
Antidiabetic agents
Antitumor agents
Parkinson's disease
Psoriasis
Rheumatoid arthritis
(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Amino acids, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Shock (circulatory collapse)
(septic; preparation of novel multicyclic compds. and their amino acid
derivs. as inhibitors of enzymes for treatment of diseases
related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,
and MLK3 kinase)

IT	374069-00-8P	374069-03-1P	374069-12-2P	374069-14-4P	374069-19-9P
	374069-21-3P	374069-22-4P	374069-23-5P	374069-25-7P	374069-26-8P
	374069-31-5P	374069-33-7P	374069-35-9P	374069-36-0P	374069-43-9P
	374069-44-0P	374069-53-1P	374069-62-2P	374069-75-7P	374070-30-1P
	374070-33-4P	374070-38-9P	374070-39-0P	374070-57-2P	374070-59-4P
	374070-64-1P	374070-73-2P	374070-77-6P	374070-79-8P	374070-80-1P
	374070-83-4P	374070-95-8P	374070-96-9P	374071-01-9P	374071-12-2P
	374071-16-6P	374071-28-0P			

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)

(preparation of novel multicyclic compds. and their amino acid derivs. as
inhibitors of enzymes for treatment of diseases related to
enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
kinase)

IT	154114-97-3P	374068-99-2P	374069-01-9P	374069-02-0P	374069-04-2P
	374069-05-3P	374069-06-4P	374069-07-5P	374069-08-6P	374069-09-7P
	374069-10-0P	374069-11-1P	374069-13-3P	374069-15-5P	374069-16-6P
	374069-17-7P	374069-18-8P	374069-20-2P	374069-24-6P	374069-27-9P
	374069-28-0P	374069-29-1P	374069-30-4P	374069-32-6P	374069-34-8P
	374069-37-1P	374069-38-2P	374069-39-3P	374069-40-6P	374069-41-7P
	374069-42-8P	374069-45-1P	374069-46-2P	374069-47-3P	374069-48-4P
	374069-49-5P	374069-50-8P	374069-51-9P	374069-52-0P	374069-54-2P
	374069-55-3P	374069-56-4P	374069-57-5P	374069-58-6P	374069-59-7P
	374069-60-0P	374069-61-1P	374069-63-3P	374069-64-4P	374069-65-5P
	374069-66-6P	374069-67-7P	374069-68-8P	374069-69-9P	374069-70-2P
	374069-71-3P	374069-72-4P	374069-73-5P	374069-74-6P	374069-76-8P
	374069-77-9P	374069-78-0P	374069-79-1P	374069-80-4P	374069-81-5P
	374069-82-6P	374069-83-7P	374069-84-8P	374069-85-9P	374069-87-1P
	374069-88-2P	374069-89-3P	374069-90-6P	374069-91-7P	374069-92-8P
	374069-93-9P	374069-94-0P	374069-95-1P	374069-96-2P	374069-97-3P
	374069-98-4P	374069-99-5P	374070-00-5P	374070-01-6P	374070-02-7P
	374070-03-8P	374070-04-9P	374070-05-0P	374070-06-1P	374070-07-2P
	374070-08-3P	374070-09-4P	374070-10-7P	374070-11-8P	374070-12-9P
	374070-13-0P	374070-14-1P	374070-15-2P	374070-16-3P	374070-17-4P
	374070-18-5P	374070-19-6P	374070-20-9P	374070-21-0P	374070-22-1P
	374070-23-2P	374070-24-3P	374070-25-4P	374070-26-5P	374070-27-6P
	374070-28-7P	374070-29-8P	374070-31-2P	374070-32-3P	374070-34-5P
	374070-35-6P	374070-36-7P	374070-37-8P	374070-40-3P	374070-41-4P
	374070-42-5P	374070-43-6P	374070-44-7P	374070-45-8P	374070-46-9P
	374070-47-0P	374070-48-1P	374070-49-2P	374070-50-5P	374070-51-6P
	374070-52-7P	374070-53-8P	374070-54-9P	374070-55-0P	374070-56-1P
	374070-58-3P	374070-60-7P	374070-62-9P	374070-63-0P	374070-65-2P
	374070-66-3P	374070-67-4P	374070-68-5P	374070-69-6P	374070-70-9P
	374070-71-0P	374070-72-1P	374070-74-3P	374070-75-4P	374070-76-5P
	374070-78-7P	374070-81-2P	374070-82-3P	374070-84-5P	374070-85-6P
	374070-86-7P	374070-87-8P	374070-88-9P	374070-89-0P	374070-90-3P
	374070-91-4P	374070-92-5P	374070-93-6P	374070-94-7P	374070-97-0P
	374070-98-1P	374070-99-2P	374071-00-8P	374071-02-0P	374071-03-1P
	374071-04-2P	374071-05-3P	374071-06-4P	374071-07-5P	374071-08-6P
	374071-09-7P	374071-10-0P	374071-11-1P	374071-13-3P	374071-14-4P
	374071-15-5P	374071-17-7P	374071-18-8P	374071-19-9P	374071-20-2P
	374071-21-3P	374071-22-4P	374071-23-5P	374071-24-6P	374071-25-7P
	374071-26-8P	374071-27-9P	374071-29-1P	374071-30-4P	374071-31-5P
	374071-32-6P	374071-33-7P	374071-34-8P	374071-35-9P	374071-36-0P

374071-37-1P	374071-38-2P	374071-39-3P	374071-40-6P	374071-41-7P
374071-42-8P	374071-43-9P	374071-44-0P	374071-45-1P	374071-46-2P
374071-47-3P	374071-48-4P	374071-49-5P	374071-50-8P	374071-51-9P
374071-52-0P	374071-53-1P	374071-54-2P	374071-55-3P	374071-56-4P
374071-57-5P	374071-58-6P	374072-29-4P	374553-23-8P	374553-24-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT 9055-67-8, Poly(ADP-ribose) polymerase 150977-45-0, VEGFR2 kinase
153190-46-6, MLK3 kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT 50-00-0, Formaldehyde, reactions 60-34-4 62-55-5, Thioacetamide 62-56-6, Thiourea, reactions 64-19-7, Acetic acid, reactions 68-12-2, DMF, reactions 74-88-4, Methyl iodide, reactions 75-36-5, Acetyl chloride 79-03-8, Propionyl chloride 79-09-4, Propionic acid, reactions 79-30-1, Isobutyryl chloride 79-37-8, Oxalyl chloride 95-15-8, Benzothiophene 98-09-9, Phenylsulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 100-39-0, Benzyl bromide 105-36-2, Ethyl bromoacetate 107-13-1, Acrylonitrile, reactions 107-92-6, Butyric acid, reactions 108-00-9, N,N-Dimethylethylenediamine 108-12-3, Isovaleryl chloride 108-30-5, Succinic anhydride, reactions 108-55-4, Glutaric anhydride 109-01-3, N-Methylpiperazine 109-86-4, 2-Methoxyethanol 109-89-7, Diethylamine, reactions 109-90-0, Ethyl isocyanate 109-97-7, Pyrrole 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 120-72-9, Indole, reactions 120-92-3, Cyclopentanone 123-75-1, Pyrrolidine, reactions 124-63-0, Methanesulfonyl chloride 140-88-5, Ethyl acrylate 141-43-5, Ethanolamine, reactions 141-75-3, Butyryl chloride 271-89-6, Benzofuran 288-88-0, 1H-1,2,4-Triazole 399-52-0, 5-Fluorindole 541-59-3, Maleimide 544-92-3, Copper(I) cyanide 557-21-1, Zinc cyanide 591-08-2, N-Acetylthiourea 594-27-4, Tetramethyltin 598-21-0, Bromoacetyl bromide 598-52-7, N-Methylthiourea 614-96-0, 5-Methylindole 623-91-6, Diethyl fumarate 630-08-0, Carbon monoxide, reactions 638-29-9, Valeryl chloride 690-76-6, 2-(tert-Butoxycarbonyl)thioacetamide 762-42-5, Dimethyl acetylenedicarboxylate 933-67-5, 7-Methylindole 999-97-3, Hexamethyldisilazane 1121-92-2 1462-37-9, Benzyl 2-bromoethyl ether 1501-27-5, Glutaric acid monomethyl ester 2038-03-1, 4-(2-Aminoethyl)morpholine 2114-02-5 2133-40-6, L-Proline methyl ester hydrochloride 2812-46-6 3303-84-2, N-tert-Butoxycarbonyl- β -alanine 3878-55-5, Succinic acid monomethyl ester 4023-34-1, Cyclopropanecarbonyl chloride 4377-33-7, 2-Picolyl chloride 4524-93-0, Cyclopentanecarbonyl chloride 4530-20-5, N-tert-Butoxycarbonyl-glycine 4744-50-7, Furo[3,4-b]pyrazine-5,7-dione 5070-13-3, Bis(4-nitrophenyl) carbonate 5332-06-9, 4-Bromobutyronitrile 5332-26-3 5437-45-6, Benzyl bromoacetate 5699-40-1, N-Acetylguanidine 6940-76-7, 1-Chloro-3-iodopropane 6971-44-4, 4-(N-Methylaminomethyl)pyridine 7148-07-4, 1-(Cyclopenten-1-yl)pyrrolidine 7531-52-4, L-Prolinamide 13154-24-0, Triisopropylsilyl chloride 15098-69-8 16503-22-3, N-Methylhistamine dihydrochloride 18107-18-1, Trimethylsilyldiazomethane 19099-93-5, Benzyl 4-oxo-1-piperidinecarboxylate 21035-59-6, 2-(N-Methylaminomethyl)pyridine 24424-99-5, Di-tert-butyl dicarbonate 40594-97-6 49548-40-5

53300-47-3, 2-(Methanesulfonyl)thioacetamide 53654-35-6, 2-Vinylindole
 54663-78-4, 2-(Tributylstannyl)thiophene 57260-71-6 57260-73-8,
 N-tert-Butoxycarbonylethylenediamine 57294-38-9, 4-(tert-
 Butoxycarbonylamino)butyric acid 76822-35-0 86864-60-0,
 (2-Bromoethoxy)-tert-butyldimethylsilane 89031-84-5,
 (3-Bromopropoxy)-tert-butyldimethylsilane 98518-10-6 118486-97-8,
 2-(Tributylstannyl)-1-methylpyrrole 124252-41-1, 4-
 (Tributylstannyl)pyridine 133565-49-8 136088-69-2 138585-09-8,
 p-(tert-Butyldimethylsilyloxy)benzyl chloride 155440-58-7,
 3-(Furan-3-yl)indole 175277-31-3, 2-(tert-Butanesulfonyl)thioacetamide
 175334-72-2, 5-Isoxazolecarbothioamide 374071-64-4, 5-
 (Triisopropylsilyloxy)-2-(1-hydroxycyclopentyl)indole 374071-66-6,
 5-Methoxy-2-(1-hydroxycyclopentyl)indole 374071-67-7,
 5-(2-Ethoxyethoxy)-2-(1-hydroxycyclopentyl)indole 374071-68-8,
 5-[2-(Diethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-69-9,
 5-[2-(Dimethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-70-2,
 5-[2-Morpholinoethoxy]-2-(1-hydroxycyclopentyl)indole 374071-71-3,
 2-(tert-Butoxycarbonyloxy)thioacetamide 374071-77-9,
 2-(2-Buten-2-yl)indole 374071-87-1 374071-90-6, 2-(3-Hepten-3-
 yl)indole 374071-91-7, 3-(Cyclohexen-1-yl)-1-methylindole 374071-92-8,
 2-(2,3-Dihydrofuran-4-yl)indole 374071-93-9 374071-94-0 374071-96-2,
 6-Methoxy-2-(1-hydroxycyclopentyl)indole 374071-97-3,
 4-Methoxy-2-(1-hydroxycyclopentyl)indole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of novel multicyclic compds. and their amino acid derivs. as
 inhibitors of enzymes for treatment of diseases related to
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
 kinase)

IT 90971-74-7P, 3-(Cyclopenten-1-yl)-1-(triisopropylsilyl)pyrrole
 118959-02-7P, 2-(Cyclopenten-1-yl)benzofuran 374071-59-7P,
 2-(1-Hydroxycyclopentyl)indole 374071-60-0P, 2-(1-Cyclopentenyl)indole
 374071-61-1P 374071-62-2P 374071-63-3P 374071-65-5P 374071-72-4P
 374071-73-5P 374071-74-6P 374071-75-7P 374071-76-8P 374071-78-0P
 374071-79-1P, 2-(Cyclopenten-1-yl)pyrrole 374071-80-4P,
 3-(Cyclopenten-1-yl)pyrrole 374071-81-5P, 2-(Cyclopenten-1-yl)-1-
 (triisopropylsilyl)pyrrole 374071-82-6P 374071-83-7P 374071-84-8P
 374071-85-9P, 1,6,7,8-Tetrahydrocyclopenta[g]indole-4,5-dicarboxylic acid
 374071-86-0P 374071-88-2P 374071-89-3P 374071-95-1P 374071-98-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of novel multicyclic compds. and their amino acid derivs. as
 inhibitors of enzymes for treatment of diseases related to
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
 kinase)

L32 ANSWER 19 OF 19 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights
 reserved on STN

ACCESSION NUMBER: 1999036418 EMBASE

TITLE: Angiogenesis: Possibilities for therapeutic interventions.

AUTHOR: Wynendaele, W.; Van Oosterom, A.T.; Pawinski, A.; De
 Bruijn, E.A., Dr. (correspondence)

CORPORATE SOURCE: Laboratory of Experimental Oncology, Herestraat 49, B-3000
 Leuven, Belgium.

AUTHOR: De Bruijn, E.A., Dr. (correspondence); Maes, R.A.

CORPORATE SOURCE: Laboratory of Human Toxicology, Department of
 Pharmaceuticals, University of Utrecht, Sorbonnelaan 16, 3508
 TB Utrecht, Netherlands.

AUTHOR: De Bruijn, E.A., Dr. (correspondence)

CORPORATE SOURCE: Patent Technology Lille France, P.O. Box 192, NL-4500 AD
 Oostburg, Netherlands.

SOURCE: Pharmacy World and Science, (1998) Vol. 20, No. 6, pp.

225-235.
 Refs: 131
 ISSN: 0928-1231 CODEN: PWSCED
 COUNTRY: Netherlands
 DOCUMENT TYPE: Journal; General Review; (Review)
 FILE SEGMENT: 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 18 Feb 1999
 Last Updated on STN: 18 Feb 1999

AN 1999036418 EMBASE
 TI Angiogenesis: Possibilities for therapeutic interventions.
 AU Wynendaele, W.; Van Oosterom, A.T.; Pawinski, A.; De Bruijn, E.A., Dr.
 (correspondence)
 CS Laboratory of Experimental Oncology, Herestraat 49, B-3000 Leuven, Belgium
 .
 AU De Bruijn, E.A., Dr. (correspondence); Maes, R.A.
 CS Laboratory of Human Toxicology, Department of Pharmaceutics, University of
 Utrecht, Sorbonnelaan 16, 3508 TB Utrecht, Netherlands.
 AU De Bruijn, E.A., Dr. (correspondence)
 CS Patent Technology Lille France, P.O. Box 192, NL-4500 AD Oostburg,
 Netherlands.
 SO Pharmacy World and Science, (1998) Vol. 20, No. 6, pp. 225-235.
 Refs: 131
 ISSN: 0928-1231 CODEN: PWSCED
 CY Netherlands
 DT Journal; General Review; (Review)
 FS 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 LA English
 SL English
 ED Entered STN: 18 Feb 1999
 Last Updated on STN: 18 Feb 1999

AB Vascular proliferation normally occurs only during embryonic development,
 the female reproductive cycle and wound healing. Various pathological
 conditions such as diabetic retinopathy are characterized by persistent,
 uncontrolled angiogenesis. At the other hand, impaired development of new
 blood vessels has been found to be related with myocardial infarction. A
 series of anti-angiogenic drugs are currently included in experimental
 cancer treatment, whereas the failure of ulcers to heal may be
 limited by increased angiogenesis upon administration of growth factors.
 In the present review control mechanisms of the vasculature are summarized
 and therapeutic approaches discussed.

CT Medical Descriptors:
 *angiogenesis
 cancer
 cardiovascular disease
 diabetic retinopathy
 embryo development
 endothelium
 heart infarction
 ischemia
 ovary cycle
 review
 ulcer healing
 wound healing

CT Drug Descriptors:
 acidic fibroblast growth factor
 alpha interferon
 *angiogenesis inhibitor

angiogenic factor
 angiogenin
 angiostatin
 basic fibroblast growth factor
 genistein
 granulocyte colony stimulating factor
 *growth factor
 herbimycin a
 hyaluronic acid
 *interleukin 2
 interleukin 8
 lavendustin a
 oleanolic acid
 platelet derived endothelial cell growth factor
 prolactin
 proliferin
 roquinimex
 scatter factor
 *sialic acid derivative
 suramin
 thrombocyte factor 4
 thrombospondin 1
 tissue inhibitor of metalloproteinase 1
 tissue inhibitor of metalloproteinase 2
 tissue inhibitor of metalloproteinase 3
 transforming growth factor alpha
 transforming growth factor beta
 ursolic acid
 vasculotropin

RN (acidic fibroblast growth factor) 106096-92-8; (angiogenin) 97950-81-7;
 (angiostatin) 172642-30-7, 86090-08-6; (basic fibroblast growth factor)
 106096-93-9; (genistein) 446-72-0; (herbimycin A) 70563-58-5; (hyaluronic
 acid) 31799-91-4, 9004-61-9, 9067-32-7; (interleukin 2) 85898-30-2;
 (interleukin 8) 114308-91-7; (lavendustin A) 125697-92-9; (oleanolic acid)
 508-02-1; (prolactin) 12585-34-1, 50647-00-2, 9002-62-4; (proliferin)
 92769-12-5; (roquinimex) 84088-42-6; (scatter factor) 67256-21-7,
 72980-71-3; (suramin) 129-46-4, 145-63-1; (thrombocyte factor 4)
 37270-94-3, 69670-74-2; (thrombospondin 1) 343987-56-4; (tissue inhibitor
 of metalloproteinase 1) 140208-24-8; (tissue inhibitor of
 metalloproteinase 2) 124861-55-8; (tissue inhibitor of metalloproteinase
 3) 145809-21-8, 164781-40-2; (ursolic acid) 77-52-1; (vasculotropin)
 127464-60-2

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3
 SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162
 L3 22 S L2 AND DIONE
 L4 0 S L2 AND PHENANTHROLINEDIONE
 L5 2 S L2 AND PHENANTHROLINE
 L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON
11 JUN 2008

L7 224329 S L2
L8 13877 S L3
L9 406 S L5
L10 224329 S L7 OR L8 OR L9
L11 3300 S 10 AND ANTIANGIOGENIC
L12 56 S L11 AND ISCHEMIA
L13 28 S L11 AND ("HEART DISEASE")
L14 2 S L13 AND L12
L15 7 S (L3 OR L5) AND ANTIANGIOGENIC
L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"
L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

L18 STR 27318-90-7
L19 1 S L18 FAM SAM
SET SMA OFF
SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON
11 JUN 2008

L20 1303 S ("1,4-NAPHTHALENEDIONE?")
L21 129 S L20 AND (TREAT OR TREATMENT OR TREATING)
L22 0 S L21 AND ("HEART ATTACK")
L23 0 S L21 AND ("MYOCARDIAL INFARCTION")
L24 4 S L21 AND ISCHEMIA
L25 1 S L16 AND ("MYOCARDIAL INFARCTION")
L26 0 S L16 AND ("ANGIOGENESIS INHIBITOR?")
L27 552 S L2 AND ("ANGIOGENESIS INHIBITOR?")
L28 24 S L3 AND ("ANGIOGENESIS INHIBITOR?")
L29 2 S L5 AND ("ANGIOGENESIS INHIBITOR?")
L30 53 S (L27 OR L28 OR L29) AND HEART
L31 24 S L30 AND ISCHEMIA
L32 19 S L31 AND (TREAT OR TREATING OR TREATMENT)

=> s l32 and ("5,6-dione")
L33 0 L32 AND ("5,6-DIONE")

=> s l32 and ("1,10-phenanthrene")
L34 0 L32 AND ("1,10-PHENANTHRENE")

=> s l32 and dione
L35 5 L32 AND DIONE

=> dup rem l32 l35
PROCESSING COMPLETED FOR L32
PROCESSING COMPLETED FOR L35
L36 19 DUP REM L32 L35 (5 DUPLICATES REMOVED)
ANSWERS '1-18' FROM FILE CAPLUS
ANSWER '19' FROM FILE EMBASE

=> d scan l35

L35 5 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
IC ICM C07D277-46
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of thiazole derivatives as modulators of the phosphoinositide

3-kinases (PI3Ks)

ST thiazole prepn phosphoinositide 3 kinase PI3K gamma modulator

IT Nervous system, disease
(Huntington's chorea, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Sarcoma
(Kaposi's, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle, disease
(atrophy, treating or preventing skeletal muscle atrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Infection
(bacterial, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle
(cardiac, treating or preventing cardiac myocyte dysfunction; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Hypertrophy
(cardiac, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Lung, disease
(chronic obstructive pulmonary disease, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Nervous system, disease
(degeneration, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Kidney, disease
(fibrosis, treating or preventing progressive renal fibrosis; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Inflammation
Kidney, disease
(glomerulonephritis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Kidney, disease
(glomerulosclerosis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle, disease
(hypertrophy, treating or preventing skeletal muscle atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Heart, disease
(hypertrophy, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Brain, disease
(infection, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Intestine, disease
(inflammatory, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Lung, disease
Reperfusion

(injury, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Neoplasm
(metastasis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Hypertrophy
(muscular, treating or preventing skeletal muscle atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Heart
(myocardium, treating or preventing cardiac myocyte dysfunction; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Inflammation
Lung, disease
(pneumonitis, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Allergy inhibitors
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Antibacterial agents
Anticoagulants
Antihypertensives
Antirheumatic agents
Antitumor agents
Antiviral agents
Cardiovascular agents
Human
Immunosuppressants
Platelet aggregation inhibitors
(preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Injury
(pulmonary, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Fibrosis
(renal, treating or preventing progressive renal fibrosis; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Injury
(reperfusion, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Brain, disease
(stroke, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Lupus erythematosus
(systemic, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Central nervous system, disease
(trauma, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Leukocyte
(treating or preventing leukocyte recruitment in cancer tissue; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Allergy
Alzheimer's disease
Anaphylaxis

Angiogenesis
 Asthma
 Atherosclerosis
 Autoimmune disease
 Cardiovascular system, disease
 Encephalitis
 Fibrosis
 Hypertension
 Inflammation
 Ischemia
 Kidney, disease
 Melanoma
 Meningitis
 Multiple sclerosis
 Neoplasm
 Platelet aggregation
 Psoriasis
 Rheumatoid arthritis
 Sepsis
 Thrombosis
 Transplant and Transplantation
 Transplant rejection
 Vasoconstriction

(treating or preventing; preparation of thiazole derivs. as
 modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Infection
 (viral, treating or preventing; preparation of thiazole derivs. as
 modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 115926-52-8
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of thiazole derivs. as modulators of the phosphoinositide
 3-kinases (PI3Ks))

IT 860619-22-3P 860619-39-2P 860619-58-5P 860619-75-6P 860620-37-7P
 860620-38-8P 860620-39-9P 860620-40-2P 860620-42-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of thiazole derivs. as modulators of the phosphoinositide
 3-kinases (PI3Ks))

IT 32558-17-1P 307343-36-8P 315704-54-2P 315705-71-6P 315705-72-7P
 315705-74-9P 315705-75-0P 315705-76-1P 315705-77-2P 315705-78-3P
 315705-79-4P 315705-80-7P 315705-81-8P 315705-82-9P 315705-83-0P
 315705-86-3P 315705-87-4P 315705-90-9P 315705-91-0P 315705-92-1P
 315705-94-3P 315705-95-4P 333746-52-4P 333746-55-7P 333746-64-8P
 333746-84-2P 412919-76-7P 421580-61-2P 428836-20-8P 443747-65-7P
 472980-88-4P 860619-23-4P 860619-24-5P 860619-25-6P 860619-26-7P
 860619-27-8P 860619-28-9P 860619-29-0P 860619-30-3P 860619-31-4P
 860619-32-5P 860619-33-6P 860619-34-7P 860619-35-8P 860619-36-9P
 860619-37-0P 860619-38-1P 860619-40-5P 860619-41-6P 860619-42-7P
 860619-43-8P 860619-44-9P 860619-45-0P 860619-46-1P 860619-47-2P
 860619-48-3P 860619-49-4P 860619-50-7P 860619-51-8P 860619-52-9P
 860619-53-0P 860619-54-1P 860619-55-2P 860619-56-3P 860619-57-4P
 860619-59-6P 860619-60-9P 860619-61-0P 860619-62-1P 860619-63-2P
 860619-64-3P 860619-65-4P 860619-66-5P 860619-67-6P 860619-68-7P
 860619-69-8P 860619-70-1P 860619-71-2P 860619-72-3P 860619-73-4P
 860619-74-5P 860619-76-7P 860619-77-8P 860619-78-9P 860619-79-0P
 860619-80-3P 860619-81-4P 860619-82-5P 860619-83-6P 860619-84-7P
 860619-85-8P 860619-86-9P 860619-87-0P 860619-88-1P 860619-89-2P
 860619-90-5P 860619-91-6P 860619-92-7P 860619-93-8P 860619-94-9P
 860619-95-0P 860619-96-1P 860619-98-3P 860620-00-4P 860620-02-6P
 860620-03-7P 860620-04-8P 860620-05-9P 860620-06-0P 860620-07-1P

860620-08-2P	860620-09-3P	860620-10-6P	860620-11-7P	860620-12-8P
860620-13-9P	860620-14-0P	860620-15-1P	860620-16-2P	860620-17-3P
860620-18-4P	860620-19-5P	860620-20-8P	860620-21-9P	860620-22-0P
860620-23-1P	860620-24-2P	860620-25-3P	860620-26-4P	860620-27-5P
860620-28-6P	860620-29-7P	860620-30-0P	860620-31-1P	860620-32-2P
860620-33-3P	860620-34-4P	860620-35-5P	860620-36-6P	860620-41-3P
860620-43-5P	860620-44-6P	860620-45-7P	860620-46-8P	860620-47-9P
860620-48-0P	860620-49-1P	860620-50-4P	860620-51-5P	860620-52-6P
860620-53-7P	860620-70-8P	860620-75-3P	860620-76-4P	860620-77-5P
860620-78-6P	860620-83-3P	860620-84-4P	860620-86-6P	860620-87-7P
860620-88-8P	860620-89-9P	860621-18-7P	860621-19-8P	860621-20-1P
860621-21-2P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 79-19-6, Thiosemicarbazide 103-85-5, N-Phenylthiourea 107-95-9, β -Alanine 109-57-9, N-Allylthiourea 109-94-4, Ethyl formate 121-92-6, 3-Nitrobenzoic acid 123-54-6, 2,4-Pentanedione, reactions 367-57-7, 1,1,1-Trifluoropentane-2,4-dione 621-83-0, N-Benzylthiourea 709-72-8 1516-33-2, N-Isobutylthiourea 1516-37-6, N-(2-Methoxyphenyl)thiourea 1520-26-9 1520-27-0, N-(4-Hydroxyphenyl)thiourea 2237-30-1, 3-Aminobenzonitrile 2293-07-4, N-(4-Methoxyphenyl)thiourea 2295-31-0, 2,4-Thiazolidinedione 3394-05-6, N-(3-Hydroxyphenyl)thiourea 3460-55-7, N-(4-Cyanophenyl)thiourea 3696-22-8, N-(4-Nitrophenyl)thiourea 3696-23-9, N-(4-Chlorophenyl)thiourea 4947-89-1, N-(3-Chlorophenyl)thiourea 5055-72-1, N-Cyclohexylthiourea 5100-34-5, Ethyl 3-isocyanatopropionate 5344-82-1, N-(2-Chlorophenyl)thiourea 5657-42-1 6814-99-9, N-(sec-Butyl)thiourea 6815-00-5, N-(2-Phenylethyl)thiourea 7204-48-0, N-(tert-Butyl)thiourea 7366-56-5 14294-09-8, 1-Piperidinecarbothioamide 14294-10-1, 4-Morpholinecarbothioamide 14294-11-2, N-Pyridin-2-ylthiourea 20602-45-3 25343-29-7, N-(2,2-Dimethylpropyl)thiourea 25433-09-4 29146-81-4 30162-37-9, N-Pyridin-3-ylthiourea 30162-39-1 30381-21-6, N-(2-Cyanoethyl)thiourea 30748-47-1, 5-Acetyl-2-amino-4-methylthiazole 33860-28-5, 4-Methylpiperazine-1-carbothioamide 37014-08-7 37182-75-5 40398-36-5, 1-Pyrrolidinecarbothioamide 51039-84-0 52992-37-7 55130-40-0 56541-14-1, N-Cyclopropylthiourea 61451-94-3, N-(2,3-Dihydro-1H-inden-2-yl)thiourea 63467-61-8, N-(2,2-Diethoxyethyl)thiourea 66892-01-1 66892-25-9, N-(Tetrahydrofuran-2-ylmethyl)thiourea 72806-58-7 73161-70-3, N-(Pyridin-3-ylmethyl)thiourea 73434-75-0, N-(2-Hydroxy-2-phenylethyl)thiourea 74764-61-7 86114-63-8 99115-47-6 102353-42-4, N-(2-Methoxyethyl)thiourea 102936-57-2, N-Cyclopentylthiourea 111538-46-6, N-(3-(Morpholin-4-yl)propyl)thiourea 122641-10-5, N-(2-(Morpholin-4-yl)ethyl)thiourea 125117-97-7, N-(6-Chloropyridin-3-yl)thiourea 140899-50-9 171874-49-0, N-[2-(2-Hydroxyethyl)phenyl]thiourea 179927-28-7 196809-80-0 206761-87-7, N-(2-(Piperidin-1-yl)ethyl)thiourea 227932-43-6 237385-80-7, N-[3-(Hydroxymethyl)phenyl]thiourea 282715-65-5, N-(Pyridin-4-ylmethyl)thiourea 342626-46-4 420130-44-5, N-(6-Methoxypyridin-3-yl)thiourea 473706-96-6 473706-97-7 500865-55-4 572889-33-9, N-Cyclobutylthiourea 618913-44-3, N-(Cyclopropylmethyl)thiourea 659741-74-9 659741-75-0 763887-70-3 850164-09-9, N-(3-Cyanophenyl)thiourea 859786-81-5 860615-45-8, N-(Benzofuran-5-yl)thiourea 860617-18-1, N-(2-Chloropyridin-4-yl)thiourea 860620-65-1 860620-66-2 860620-67-3 860620-68-4, 3-Hydroxypyrrolidine-1-carbothioamide 860620-69-5, N-(2-Fluoropyridin-3-yl)thiourea 860620-71-9, N-(3,3-Diethoxypropyl)thiourea 860620-72-0,

N-(2-Chloropyridin-3-yl)thiourea 860620-73-1, N-[3-(1,3-Oxazol-5-yl)phenyl]thiourea 860620-74-2, N-[3-(1H-Tetrazol-5-yl)phenyl]thiourea 860620-79-7, N-[3-(5-Hydroxy-1,3,4-oxadiazol-2-yl)phenyl]thiourea 860620-80-0, N-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]thiourea 860620-91-3 860620-92-4, N-[4-(2-Hydroxyethyl)phenyl]thiourea 860620-93-5, N-[3-[(2-Hydroxyethyl)sulfonyl]phenyl]thiourea 860620-94-6 860620-95-7 860620-96-8 860620-97-9 860620-98-0 860620-99-1 860621-00-7 860621-01-8 860621-02-9 860621-03-0 860621-04-1 860621-05-2, N-(4-Hydroxybutyl)thiourea 860621-06-3 860621-07-4 860621-08-5 860621-09-6 860621-10-9 860621-11-0 860621-12-1 860621-13-2 860621-14-3 860621-15-4 860621-16-5 860621-17-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 618-95-1P, Methyl 3-nitrobenzoate 926-59-0P 3043-28-5P, 3-Bromo-2,4-pentanedione 4138-35-6P, Methyl 3-aminopropanoate 14062-34-1P 32519-72-5P 32519-75-8P 39884-12-3P 53159-71-0P, 1-(2-Amino-1,3-thiazol-5-yl)ethanone 83725-80-8P, 5-(3-Nitrophenyl)-1,3,4-oxadiazol-2-ol 87005-15-0P 94284-63-6P, Ethyl 5-acetyl-2-amino-1,3-thiazole-4-carboxylate 115082-05-8P 167405-28-9P, 1-[2-Amino-4-(trifluoromethyl)-1,3-thiazol-5-yl]ethanone 191399-17-4P, 1-(2-Amino-4-methyl-1,3-oxazol-5-yl)ethanone 299441-33-1P, 5-(3-Aminophenyl)-1,3,4-thiadiazol-2-amine 440087-89-8P 696629-98-8P 860615-87-8P 860620-54-8P 860620-55-9P, N-(5-Acetyl-4-methyl-1,3-oxazol-2-yl)acetamide 860620-56-0P 860620-57-1P, N-(5-Acetyl-1,3-thiazol-2-yl)acetamide 860620-58-2P 860620-59-3P, N-[5-Acetyl-4-(trifluoromethyl)-1,3-thiazol-2-yl]acetamide 860620-60-6P 860620-61-7P, Ethyl 5-acetyl-2-(acetylamino)-1,3-thiazole-4-carboxylate 860620-62-8P 860620-63-9P 860620-64-0P, N-[3-(5-Amino-[1,3,4]thiadiazol-2-yl)phenyl]-2,2,2-trifluoroacetamide 860620-81-1P 860620-82-2P 860620-85-5P 860620-90-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L35 5 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K031-00

CC 1-7 (Pharmacology)

TI Therapeutics for chemokine-mediated diseases

ST chemokine mediated disease treatment chemokine receptor binding compd; tricyclic phenanthrene deriv chemokine mediated disease treatment; phenanthrenedione multiple sclerosis treatment

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR2; therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR4; therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR1; therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR2; therapeutics for chemokine-mediated diseases)

IT Inflammation

(Crohn's disease; therapeutics for chemokine-mediated diseases)

IT Intestine, disease

(Crohn's; therapeutics for chemokine-mediated diseases)

IT Sepsis
(Gram-neg.; therapeutics for chemokine-mediated diseases)

IT Neutrophil
(activation; therapeutics for chemokine-mediated diseases)

IT Inflammation
(acute; therapeutics for chemokine-mediated diseases)

IT Respiratory distress syndrome
(adult; therapeutics for chemokine-mediated diseases)

IT Transplant rejection
(allotransplant; therapeutics for chemokine-mediated diseases)

IT Antiarteriosclerotics
(antiatherosclerotics; therapeutics for chemokine-mediated diseases)

IT Dermatitis
(atopic; therapeutics for chemokine-mediated diseases)

IT Lung, disease
(chronic obstructive pulmonary disease; therapeutics for chemokine-mediated diseases)

IT Inflammation
Transplant rejection
(chronic; therapeutics for chemokine-mediated diseases)

IT Autoimmune disease
(exptl. autoimmune encephalomyelitis; therapeutics for chemokine-mediated diseases)

IT Encephalomyelitis
(exptl. autoimmune; therapeutics for chemokine-mediated diseases)

IT Lung, disease
(fibrosis, idiopathic; therapeutics for chemokine-mediated diseases)

IT Ischemia
(focal; therapeutics for chemokine-mediated diseases)

IT Inflammation
Kidney, disease
(glomerulonephritis; therapeutics for chemokine-mediated diseases)

IT Transplant and Transplantation
(graft-vs.-host reaction; therapeutics for chemokine-mediated diseases)

IT Intestine, disease
(inflammatory; therapeutics for chemokine-mediated diseases)

IT Reperfusion
(injury, cardiac and renal; therapeutics for chemokine-mediated diseases)

IT Lung, disease
(injury, mononuclear phagocyte-dependent; therapeutics for chemokine-mediated diseases)

IT Phagocyte
(mononuclear, mononuclear phagocyte-dependent lung injury; therapeutics for chemokine-mediated diseases)

IT Cell activation
(neutrophil; therapeutics for chemokine-mediated diseases)

IT Arthritis
(pseudogout, acute; therapeutics for chemokine-mediated diseases)

IT Fibrosis
(pulmonary, idiopathic; therapeutics for chemokine-mediated diseases)

IT Injury
(pulmonary, mononuclear phagocyte-dependent; therapeutics for chemokine-mediated diseases)

IT Heart, disease
Kidney, disease
(reperfusion injury; therapeutics for chemokine-mediated diseases)

IT Injury
(reperfusion, cardiac and renal; therapeutics for chemokine-mediated diseases)

IT Artery, disease

(restenosis; therapeutics for chemokine-mediated diseases)

IT Shock (circulatory collapse)
(septic; therapeutics for chemokine-mediated diseases)

IT Brain, disease
(stroke; therapeutics for chemokine-mediated diseases)

IT Multiple sclerosis
(therapeutic agents; therapeutics for chemokine-mediated diseases)

IT Alzheimer's disease

Angiogenesis

Angiogenesis inhibitors

Anti-Alzheimer's agents

Anti-inflammatory agents

Anti-ischemic agents

Antiarthritics

Antiasthmatics

Anticoagulants

Antimalarials

Arthritis

Asthma

Atherosclerosis

Cardiovascular agents

Drug delivery systems

Gastrointestinal agents

Gout

Inflammation

Malaria

Multiple sclerosis

Neutrophil

Psoriasis

Rheumatoid arthritis

Sarcoidosis

Thrombosis
(therapeutics for chemokine-mediated diseases)

IT Chemokine receptors

Chemokines

Interleukin 8

Monocyte chemoattractant protein-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(therapeutics for chemokine-mediated diseases)

IT Shock (circulatory collapse)
(toxic shock syndrome; therapeutics for chemokine-mediated diseases)

IT Inflammation

Intestine, disease
(ulcerative colitis; therapeutics for chemokine-mediated diseases)

IT Interleukin 8 receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α ; therapeutics for chemokine-mediated diseases)

IT Interleukin 8 receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β ; therapeutics for chemokine-mediated diseases)

IT 7440-70-2, Calcium, biological studies 169592-56-7, Caspase 3

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(therapeutics for chemokine-mediated diseases)

IT 82-86-0, Acenaphthenequinone 83-32-9, Acenaphthene 84-11-7,
Phenanthrene-9,10-dione 1015-89-0, 6(5H)-Phenanthridinone
4707-71-5, Phenanthrene-9-carboxaldehyde

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(therapeutics for chemokine-mediated diseases)

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

TI Preparation of pyrazine derivatives, particularly N-[3-(oxyphenylamino)quinoxalin-2-yl]sulfonamides, as PI3K inhibitors

ST pyrazine quinoxaline oxyphenylamino sulfonamide prepn phosphoinositide kinase PIK3K inhibitor; pyridopyrazine pyrazine quinoxaline prepn PIK3K inhibitor

IT Nervous system, disease
 (Huntington's chorea; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Sarcoma
 (Kaposi's; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease
 (airway inflammation; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Antiarteriosclerotics
 (antiatherosclerotics; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Muscle, disease
 (atrophy, skeletal; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection
 (bacterial, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection
 (bacterial, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection
 (bacterial; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease
 (chronic obstructive pulmonary disease; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Nervous system, disease
 (degeneration; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Erythrocyte
 (disease, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Sperm motility
 (diseases; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Blood vessel, disease
 (endothelium injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung
 (epithelium, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Blood, disease
 (erythrocyte, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Kidney, disease
 (fibrosis, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation
 Kidney, disease
 (glomerulonephritis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Muscle, disease

(hypertrophy; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Brain, disease
(infection; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease
Reperfusion
(injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Neoplasm
(metastasis, invasion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Hypertrophy
(muscular; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation
Pancreas, disease
(pancreatitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Skin, disease
(passive cutaneous anaphylaxis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation
Lung, disease
(pneumonitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Allergy
Allergy inhibitors
Alzheimer's disease
Anaphylaxis
Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Antibacterial agents
Antifibrotic agents
Antihypertensives
Antirheumatic agents
Antitumor agents
Antiviral agents
Asthma
Atherosclerosis
Autoimmune disease
B cell (lymphocyte)
Bone marrow
Cardiac hypertrophy
Cardiovascular agents
Cardiovascular system, disease
Central nervous system agents
Encephalitis
Fibrosis
Glomerulosclerosis
Heart, disease
Human
Hypertension
Immunomodulators
Immunosuppressants
Inflammation
Inflammatory bowel disease

Ischemia
 Kidney, disease
 Mast cell
 Melanoma
 Meningitis
 Multiple organ failure
 Multiple sclerosis
 Neoplasm
 Neuroprotective agents
 Pharmaceutical carriers
 Pharmaceutical excipients
 Platelet activation
 Platelet aggregation
 Platelet aggregation inhibitors
 Prophylaxis
 Psoriasis
 Rheumatoid arthritis
 Sepsis
 Stroke
 Thrombolytics
 Thrombosis
 Transplant and Transplantation
 Transplant rejection
 Vasoconstriction
 Vasodilators

(preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

- IT Epithelium
 - (pulmonary, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Injury
 - (pulmonary; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Leukocyte
 - (recruitment in cancer tissue; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Fibrosis
 - (renal, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Injury
 - (reperfusion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Lupus erythematosus
 - (systemic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Central nervous system, disease
 - (trauma; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Injury
 - (vascular endothelial; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Endothelium
 - (vascular, disease, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Infection
 - (viral, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Infection
 - (viral, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)
- IT Infection

(viral; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 328039-48-1P, 4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 331723-61-6P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 371958-49-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 372090-78-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 372091-52-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide 424804-76-2P, 4-Chloro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 432007-91-5P, 4-Bromo-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 577998-70-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 585560-01-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide 713083-87-5P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714245-33-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 714257-01-9P, 4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714282-93-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 714916-66-2P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 714917-87-0P, 4-Fluoro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714932-70-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 714932-98-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methoxybenzenesulfonamide 843630-52-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928139-93-9P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928139-97-3P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928140-00-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(hydroxymethyl)pyridine-3-sulfonamide 928140-31-2P, Methyl 3-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylate 928140-32-3P, Methyl 3-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylate 928140-36-7P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-38-9P, Methyl 3-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-39-0P, Methyl 3-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-43-6P, 4-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-50-5P, Methyl 4-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-51-6P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-52-7P, Methyl 4-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoate 928140-53-8P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoate 928140-71-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928140-73-2P, 4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-75-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-77-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-79-8P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide 928140-83-4P, 4-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-85-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(trifluoromethyl)Benzenesulfonamide 928140-87-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide 928140-90-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-

iodobenzenesulfonamide 928140-92-5P, 4,5-Dichloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 928140-95-8P, 4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-96-9P, Methyl 3-[4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]propanoate 928140-98-1P, 5-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928141-00-8P, 5-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide 928141-04-2P, 5-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 928141-06-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide 928141-11-1P, N-[7-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-13-3P, Methyl 5-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-carboxylate 928141-14-4P, 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928141-15-5P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 928141-18-8P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-20-2P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-22-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-24-6P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-26-8P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide 928141-28-0P, 6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-30-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(dimethylamino)pyridine-3-sulfonamide 928141-32-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide 928141-35-9P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-4-cyanobenzenesulfonamide 928141-37-1P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-39-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxypyridine-3-sulfonamide 928141-42-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-47-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluoro-2-methylbenzenesulfonamide 928141-51-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-53-1P, 4-Cyano-N-[3-[(5-methoxy-2-methylphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-56-4P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-58-6P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide 928141-59-7P, Methyl 5-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]pyridine-2-carboxylate 928141-62-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide 928141-75-7P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]pyridine-2-carboxylic acid 928141-78-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide 928141-81-5P, 4-(Aminomethyl)-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-84-8P, 3-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-88-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-yl)methyl]benzenesulfonamide 928141-90-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide 928141-91-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide 928141-93-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(dimethylamino)methyl]benzenesul

fonamide 928141-95-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(dimethylamino)methyl]benzenesulfonamide 928142-00-1P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-(dimethylamino)propyl]benzamide 928142-02-3P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-(dimethylamino)propyl]benzamide 928142-07-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide 928142-12-5P, 5-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 714244-38-9P, 3-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714924-49-9P, 3-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-02-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylsulfonylbenzenesulfonamide 928140-03-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide 928140-04-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(morpholin-4-yl)pyridine-3-sulfonamide 928140-07-2P, N-[3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]acetamide 928140-08-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-(methylsulfonyl)benzenesulfonamide 928140-09-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-(methylsulfonyl)benzenesulfonamide 928140-10-7P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,3-dihydro-1,4-benzodioxine-6-sulfonamide 928140-11-8P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(pyrrolidin-1-yl)sulfonyl]benzenesulfonamide 928140-12-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide 928140-13-0P, 2-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-14-1P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-15-2P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methoxybenzenesulfonamide 928140-16-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928140-17-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-fluorobenzenesulfonamide 928140-18-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-fluorobenzenesulfonamide 928140-19-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(methylsulfonyl)benzenesulfonamide 928140-20-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(pyrrolidin-1-yl)sulfonyl]benzenesulfonamide 928140-21-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-(methylsulfonyl)benzenesulfonamide 928140-22-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,1,3-benzothiadiazole-4-sulfonamide 928140-23-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928140-24-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,1,3-benzoxadiazole-4-sulfonamide 928140-25-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-2-yl)methanesulfonamide 928140-26-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-2-yl)methanesulfonamide 928140-27-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-3-yl)methanesulfonamide 928140-29-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-3-yl)methanesulfonamide 928140-30-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-1,2-dimethyl-1H-imidazole-5-sulfonamide 928140-33-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide 928140-34-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide 928140-35-6P,

2-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-37-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methoxybenzenesulfonamide 928140-40-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-fluorobenzenesulfonamide 928140-41-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-fluorobenzenesulfonamide 928140-42-5P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-44-7P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-45-8P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-sulfonamide 928140-46-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-sulfonamide 928140-47-0P, N-[3-[[5-Methoxy-2-(1H-pyrrol-1-yl)phenyl]amino]quinoxalin-2-yl]benzenesulfonamide 928140-48-1P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-49-2P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-55-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-56-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide potassium salt 928140-59-4P, 4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-60-7P, 4-Fluoro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-61-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928140-62-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methoxybenzenesulfonamide potassium salt 928140-63-0P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide potassium salt 928140-64-1P, 4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-65-2P, 4-Chloro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-66-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-67-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928140-68-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-69-6P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-70-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928140-72-1P, 4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-74-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-76-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-78-7P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt 928140-80-1P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-81-2P, 4-Bromo-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-82-3P, 4-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-84-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(trifluoromethyl)Benzenesulfonamide potassium salt 928140-86-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide potassium salt 928140-88-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide potassium salt 928140-91-4P, 4,5-Dichloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928140-93-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-94-7P, 4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928140-97-0P, 5-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-

sulfonamide potassium salt 928140-99-2P, 5-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-sulfonamide potassium salt 928141-01-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide potassium salt 928141-02-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide potassium salt 928141-03-1P, 5-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928141-05-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide potassium salt 928141-07-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide 928141-08-6P, N-[2-[(2,5-Dimethoxyphenyl)amino]pyrido[3,4-b]pyrazin-3-yl]benzenesulfonamide 928141-09-7P, N-[7-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt 928141-12-2P 928141-16-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium salt 928141-17-7P, 2-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-19-9P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-21-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-23-5P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-25-7P, 3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide potassium salt 928141-27-9P, 6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-29-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(dimethylamino)pyridine-3-sulfonamide potassium salt 928141-31-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide hydrochloride 928141-33-7P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-34-8P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-4-cyanobenzenesulfonamide potassium salt 928141-36-0P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide potassium salt 928141-38-2P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxypyridine-3-sulfonamide potassium salt 928141-40-6P 928141-41-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-44-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluoro-2-methylbenzenesulfonamide potassium salt 928141-49-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-55-3P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-57-5P, N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide potassium salt 928141-60-0P, N-[3-[(2-Bromo-5-methoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide 928141-61-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide potassium salt 928141-63-3P, 3-[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]sulfamoyl]benzoic acid 928141-65-5P, 4-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid 928141-66-6P, 4-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoic acid 928141-67-7P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoic acid 928141-68-8P, 3-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylic acid 928141-69-9P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-carboxylic acid 928141-70-2P, 3-[4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-

yl]amino)sulfonyl]phenyl]propanoic acid 928141-71-3P,
5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-4-
methylthiophene-2-carboxylic acid 928141-72-4P, 5-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-4-methylthiophene-2-
carboxylic acid 928141-73-5P, 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinox-
alin-2-yl]amino)sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium
salt 928141-74-6P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino)sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium salt
928141-76-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
[(morpholin-4-yl)methyl]benzenesulfonamide 928141-77-9P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-
yl)methyl]benzenesulfonamide dihydrochloride 928141-80-4P
928141-82-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
(hydroxymethyl)benzenesulfonamide 928141-83-7P, 3-(Aminomethyl)-N-[3-
[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
hydrochloride 928141-85-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
2-yl]-4-(hydroxymethyl)benzenesulfonamide 928141-87-1P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-
yl)methyl]benzenesulfonamide hydrochloride 928141-89-3P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-
yl)methyl]benzenesulfonamide dihydrochloride 928141-92-8P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
[(dimethylamino)methyl]benzenesulfonamide hydrochloride 928141-94-0P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
[(dimethylamino)methyl]benzenesulfonamide hydrochloride 928141-96-2P,
4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino)sulfonyl]benzamide sodium salt 928141-97-3P,
4-[[[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-
yl]amino)sulfonyl]benzamide sodium salt 928141-98-4P,
4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-N-(3-
methoxypropyl)benzamide 928141-99-5P, 4-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-N-[3-
(dimethylamino)propyl]benzamide hydrochloride 928142-01-2P
928142-03-4P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino)sulfonyl]-N,N-dimethylpyridine-2-carboxamide 928142-04-5P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-
yl)carbonyl]benzenesulfonamide potassium salt 928142-05-6P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(morpholin-4-
yl)carbonyl]pyridine-3-sulfonamide 928142-06-7P, N-[3-[(3,5-
Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide
potassium salt 928142-08-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
2-yl]-6-[(4-methylpiperazin-1-yl)methyl]pyridine-3-sulfonamide
928142-09-0P 928142-14-7P, N-[6-Chloro-3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928142-15-8P,
N-[3-[[[2,3-Dihydro-1,4-benzodioxin-5-yl)methyl]amino]quinoxalin-2-
yl]benzenesulfonamide 928142-16-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]-6-
nitroquinoxalin-2-yl]benzenesulfonamide 928142-17-0P,
5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-1-
methyl-1H-pyrrole-2-carboxylic acid 928142-18-1P, 5-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]-1-methyl-1H-pyrrole-
2-carboxylic acid 928142-19-2P, 4-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino)sulfonyl]benzamide
928142-20-5P, 4-[[[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-
yl]amino)sulfonyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful
in treatment and prophylaxis of diseases)

IT 98-10-2P, Benzenesulfonamide 636-76-0P, 3-(Aminosulfonyl)benzoic acid
825-86-5P, 4-Iodobenzenesulfonamide 1565-17-9P, 4-

Acetylbenzenesulfonamide 1899-94-1P, 3-Methylbenzenesulfonamide
 2067-84-7P, 1,4-Dihydropyrido[2,3-b]pyrazine-2,3-dione
 2922-45-4P, 3-Pyridinesulfonamide 4029-41-8P, N-(3-Chloroquinoxalin-2-
 yl)-4-methylbenzenesulfonamide 4029-43-0P, 4-Bromo-N-(3-chloroquinoxalin-
 2-yl)benzenesulfonamide 6339-87-3P, 2-Thiophenesulfonamide 6684-39-5P,
 6-Chloropyridine-3-sulfonyl chloride 22808-73-7P, Methyl
 4-(aminosulfonyl)benzoate 24243-71-8P, 1-Propanesulfonamide
 25710-18-3P, 2,3-Dichloropyrido[2,3-b]pyrazine 32947-34-5P, Methyl
 5-(aminosulfonyl)pyridine-2-carboxylate 34082-13-8P,
 6-Methylpyridine-3-sulfonamide 34117-90-3P, 3-Chloroquinoxalin-2-amine
 35251-84-4P, 1,4-Dihydropyrido[3,4-b]pyrazine-2,3-dione
 35251-99-1P, 2,3-Dichloropyrido[3,4-b]pyrazine 40741-46-6P,
 6-Chloropyridine-3-sulfonamide 53595-65-6P, 5-Bromothiophene-2-
 sulfonamide 59777-67-2P, Methyl 3-(aminosulfonyl)benzoate 63555-50-0P,
 Methyl 3-(chlorosulfonyl)benzoate 69156-30-5P, 2-Chloro-4-
 fluorobenzenesulfonamide 88398-46-3P, 5-Chloro-1,3-dimethyl-1H-pyrazole-
 4-sulfonamide 165058-49-1P, N-(3-Methoxyphenyl)quinoxaline-2,3-diamine
 166271-34-7P, N-(3-Chloro-2-quinoxaliny)benzenesulfonamide
 199590-78-8P, 6-(Dimethylamino)pyridine-3-sulfonamide 256353-34-1P,
 4,5-Dichlorothiophene-2-sulfonamide 478264-00-5P, 6-Methylpyridine-3-
 sulfonyl chloride 488744-02-1P, N-(3-Chloroquinoxalin-2-yl)-4-
 fluorobenzenesulfonamide 522628-95-1P, 4-Chloro-N-(3-chloroquinoxalin-2-
 yl)benzenesulfonamide 565172-05-6P, N-(3-Chloroquinoxalin-2-yl)-3-
 methylbenzenesulfonamide 743444-94-2P, 3-Chloro-N-(3-chloroquinoxalin-2-
 yl)benzenesulfonamide 847985-15-3P, 2-Chloro-N-(3-chloroquinoxalin-2-
 yl)benzenesulfonamide 848052-87-9P, N-(3-Chloroquinoxalin-2-yl)thiophene-
 2-sulfonamide 856955-32-3P, 6-Methoxypyridine-3-sulfonamide
 859491-30-8P, 5-[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-
 2-sulfonamide 883057-32-7P, 5-(Aminosulfonyl)-1-methyl-1H-pyrrole-2-
 carboxylic acid methyl ester 928139-26-8P, N-(3,5-
 Dimethoxyphenyl)quinoxaline-2,3-diamine 928139-27-9P,
 N-(2,5-Dimethoxyphenyl)quinoxaline-2,3-diamine 928139-28-0P, Methyl
 3-[4-(aminosulfonyl)phenyl]propanoate 928139-29-1P, Methyl
 5-(aminosulfonyl)-4-methylthiophene-2-carboxylate 928139-30-4P,
 3-Cyano-4-fluorobenzenesulfonamide 928139-31-5P, 6-Cyanopyridine-3-
 sulfonyl chloride 928139-32-6P, 6-Cyanopyridine-3-sulfonamide
 928139-33-7P, 3-[(Morpholin-4-yl)carbonyl]benzenesulfonamide
 928139-34-8P, 6-[(3-Methoxypropyl)amino]pyridine-3-sulfonamide
 928139-35-9P, N-(3-Chloroquinoxalin-2-yl)-3-fluorobenzenesulfonamide
 928139-36-0P, N-(3-Chloroquinoxalin-2-yl)propane-1-sulfonamide
 928139-37-1P, Methyl 4-[[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]butanoate
 928139-39-3P, Methyl 4-[[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]benzoate
 928139-44-0P, N-(3-Chloroquinoxalin-2-yl)-4-methoxybenzenesulfonamide
 928139-48-4P, N-(3-Chloroquinoxalin-2-yl)pyridine-3-sulfonamide
 928139-50-8P, N-(3-Chloroquinoxalin-2-yl)-4-cyanobenzenesulfonamide
 928139-52-0P, N-(3-Chloroquinoxalin-2-yl)methanesulfonamide
 928139-54-2P, N-(3-Chloroquinoxalin-2-yl)-4-(trifluoromethyl)benzenesulfon
 amide 928139-56-4P, N-(3-Chloroquinoxalin-2-yl)-4-iodobenzenesulfonamide
 928139-58-6P, 4,5-Dichloro-N-(3-chloroquinoxalin-2-yl)thiophene-2-
 sulfonamide 928139-60-0P, 5-Chloro-N-(3-chloroquinoxalin-2-yl)-1,3-
 dimethyl-1H-pyrazole-4-sulfonamide 928139-62-2P, 4-Acetyl-N-(3-
 chloroquinoxalin-2-yl)benzenesulfonamide 928139-63-3P, Methyl
 3-[4-[[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]phenyl]propanoate
 928139-64-4P, 5-Bromo-N-(3-chloroquinoxalin-2-yl)thiophene-2-sulfonamide
 928139-66-6P, N-(3,6-Dichloroquinoxalin-2-yl)benzenesulfonamide
 928139-67-7P, Methyl 5-[[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]-4-
 methylthiophene-2-carboxylate 928139-70-2P, 5-[[[(3-Chloroquinoxalin-2-
 yl)amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester
 928139-72-4P, 2-Chloro-N-(3-chloroquinoxalin-2-yl)-4-
 fluorobenzenesulfonamide 928139-74-6P, N-(3-Chloroquinoxalin-2-yl)-5-
 [(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-2-sulfonamide

928139-76-8P, N-(3-Chloroquinoxalin-2-yl)-3-cyano-4-fluorobenzenesulfonamide 928139-78-0P, 6-Chloro-N-(3-chloroquinoxalin-2-yl)pyridine-3-sulfonamide 928139-79-1P, N-(3-Chloroquinoxalin-2-yl)-6-(dimethylamino)pyridine-3-sulfonamide 928139-81-5P, N-(3-Chloroquinoxalin-2-yl)-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide 928139-83-7P, N-(3-Chloroquinoxalin-2-yl)-6-methoxypyridine-3-sulfonamide 928139-85-9P, N-(3-Chloroquinoxalin-2-yl)-6-methylpyridine-3-sulfonamide 928139-87-1P, Methyl 5-[[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]pyridine-2-carboxylate 928139-88-2P, N-(3-Chloroquinoxalin-2-yl)-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide 928139-89-3P, N-(3-Chloroquinoxalin-2-yl)-1-methyl-1H-imidazole-4-sulfonamide 928139-90-6P, N-(2-Chloropyrido[3,4-b]pyrazin-3-yl)benzenesulfonamide 928139-91-7P, N-(3-Chloropyrido[2,3-b]pyrazin-2-yl)benzenesulfonamide 928139-92-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide 928139-94-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-yl)carbonyl]benzenesulfonamide 928139-95-1P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-dimethylbenzamide 928139-96-2P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-dimethylbenzamide 928139-98-4P, 6-(Chloromethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928140-01-6P, Methyl 5-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-carboxylate 928142-21-6P, N-(5-Methoxy-2-methylphenyl)quinoxaline-2,3-diamine 928142-22-7P, N-[5-Methoxy-2-(pyrrol-1-yl)phenyl]quinoxaline-2,3-diamine 928142-23-8P, N-(5-Methoxy-2-chlorophenyl)quinoxaline-2,3-diamine 928142-24-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 115926-52-8, Phosphoinositide 3-kinase 148640-14-6, Akt kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 928142-13-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT 54-96-6, 3,4-Diaminopyridine 70-55-3, p-Toluenesulfonamide 98-09-9, Benzenesulfonyl chloride 98-61-3, Pipsyl chloride 98-64-6, 4-Chlorobenzenesulfonamide 102-56-7, 2,5-Dimethoxyaniline 109-01-3, 1-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 138-41-0, 4-(Aminosulfonyl)benzoic acid 402-46-0, 4-Fluorobenzenesulfonamide 452-58-4, 2,3-Diaminopyridine 536-90-3, m-Anisidine 701-34-8, 4-Bromobenzenesulfonamide 830-43-3, 4-(Trifluoromethyl)benzenesulfonamide 1129-26-6, 4-Methoxybenzenesulfonamide 1524-40-9, 3-Fluorobenzenesulfonamide 1788-10-9, 4-Acetylbenzenesulfonyl chloride 1899-93-0, m-Toluenesulfonyl chloride 2213-63-0, 2,3-Dichloroquinoxaline 2401-24-3, 2-Chloro-5-methoxyaniline 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2958-87-4, 2,3,6-Trichloroquinoxaline 3119-02-6, 4-Cyanobenzenesulfonamide 3430-14-6, 3-Amino-6-methylpyridine 4025-64-3, 3-(Chlorosulfonyl)benzoic acid 4808-69-9, 6-Methylpyridine-3-sulfonic acid 5332-73-0, 3-Methoxypropylamine 5335-40-0, 3-(Methylsulfonyl)benzenesulfonyl chloride 5350-93-6, 5-Amino-2-chloropyridine 6961-82-6, 2-Chlorobenzenesulfonamide 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1, 1-Propanesulfonyl chloride 10272-07-8, 3,5-Dimethoxyaniline

16133-25-8, 3-Pyridinesulfonyl chloride 16629-19-9, 2-Thiophenesulfonyl chloride 17260-71-8, 3-Chlorobenzenesulfonamide 23905-46-6, 3-Acetylaminobenzenesulfonyl chloride 50868-72-9, 5-Methoxy-2-methylaniline 51175-71-4, 3-Thiophenesulfonyl chloride 55338-73-3, 5-Amino-2-cyanopyridine 55854-46-1, 5-Bromothiophene-2-sulfonyl chloride 56542-67-7, 3-Cyanobenzenesulfonyl chloride 59194-26-2, 5-Methoxy-2-(1H-pyrrol-1-yl)aniline 59337-92-7, Methyl 3-(chlorosulfonyl)thiophene-2-carboxylate 59557-92-5, 2-Bromo-5-methoxyaniline 63758-12-3 69360-26-5, 2-Cyanobenzenesulfonyl chloride 73713-79-8 82964-91-8, 4-(Methylsulfonyl)benzenesulfonyl chloride 85958-57-2, 2-Chloro-4-fluorobenzenesulfonyl chloride 88398-93-0, 5-Chloro-1,3-dimethylpyrazole-4-sulfonyl chloride 89265-35-0, 2-(Methylsulfonyl)benzenesulfonyl chloride 111124-90-4, 1-Methyl-1H-imidazole-4-sulfonamide 114322-14-4, 2,1,3-Benzoxadiazole-4-sulfonyl chloride 126714-85-0, 2,3-Dichlorothiophene-5-sulfonyl chloride 137049-00-4, 1-Methylimidazole-4-sulfonyl chloride 165669-32-9, 4-[(Pyrrolidin-1-yl)sulfonyl]benzenesulfonyl chloride 175476-51-4, Methyl 4-(aminosulfonyl)butanoate 306936-62-9, 5-(Aminosulfonyl)-1-methyl-1H-pyrrole-2-carboxylic acid 312300-42-8, 6-Methoxypyridine-3-sulfonyl chloride 332361-07-6, 5-[(1,3-Dioxo-1,3-dihydroisoindol-2-yl)methyl]thiophene-2-sulfonyl chloride 337508-68-6 351003-23-1, 4-Fluoro-3-cyanobenzenesulfonyl chloride 374537-95-8, Methyl 3-(4-chlorosulfonylphenyl)propionate 423768-46-1, Methyl 5-(chlorosulfonyl)-4-methyl-2-thiophenecarboxylate 847744-22-3, N-(3-Chloroquinoxalin-2-yl)-4-fluoro-2-methylbenzenesulfonamide 849351-92-4, 1,2-Dimethyl-1H-imidazole-5-sulfonyl chloride 878682-97-4, 3-Methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonyl chloride 882564-09-2 928140-28-7 928141-10-0, N-(3,7-Dichloroquinoxalin-2-yl)benzenesulfonamide 928142-10-3, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-2-sulfonamide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

- L35 5 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
- IC ICM A61K031-4412
- ICS A61P029-00; C07D213-69; C07D401-06; C07D409-06; C07D213-70; C07D213-64; C07D213-74; C07D405-06; C07D213-84; C07D401-10; C07D405-12; C07D401-12; C07D213-75; C07D401-14; C07D213-79; C07D401-04; C07D405-04; C07D413-10; C07D215-22
- CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
 Section cross-reference(s): 1, 63
- TI Preparation of substituted pyridinones as modulators of p38 MAP kinase
- ST pyridone p38 MAP kinase inhibitor antiinflammatory antiviral antiischemic immunomodulator
- IT AIDS (disease)
 (-related complex, cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Lymphoma
 (B-cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Inflammation
 (Crohn's disease; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)
- IT Intestine, disease
 (Crohn's; preparation of pyridinones as modulators of p38 MAP kinase for

treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Nervous system, disease
(Huntington's chorea; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma
(adenocarcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Respiratory distress syndrome
(adult; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Transplant rejection
(allotransplant; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Nervous system, disease
(amyotrophic lateral sclerosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Blood vessel, neoplasm
(angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Bone
(avascular necrosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Necrosis
(avascular, bone; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Infection
(bacterial; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Skin, neoplasm
(basal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma
(basal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT AIDS (disease)
Human herpesvirus
Pneumonia
(cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart, disease
(cardiomyopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Edema

Ischemia
(cerebral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Uterus, neoplasm
(cervix; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
Lung, disease
(chronic pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm
(colon; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm
(colorectal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Transplant rejection
(corneal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Kidney, disease
(diabetic nephropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
(diabetic retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease
(edema; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Uterus, disease
(endometriosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(epidermal growth factor-binding; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart, disease
(failure; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Ulcer
(gastric; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
Stomach, disease
(gastritis; preparation of pyridinones as modulators of p38 MAP kinase for

treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Transplant and Transplantation
(graft-vs.-host reaction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Blood vessel, neoplasm
(hemangioma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart, disease
(infarction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, disease
(inflammatory; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
Reperfusion
Spinal cord, disease
(injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, disease
(irritable bowel syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease
(ischemia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Rheumatoid arthritis
(juvenile; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Neoplasm
(metastasis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Pharynx
(nasopharynx, angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lip
(neoplasm; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Glaucoma (disease)
(neovascular; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Angiogenesis
(neovascularization, eye; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Angiogenesis
(neovascularization, retinal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
(neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
Kidney, disease
(nephritis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
(neurogenic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Nerve, disease
(neuropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury
(ocular; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
(photophobia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
Lung, disease
(pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Alzheimer's disease
Analgesics
Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiartherosclerotics
Antiarthritics
Antiasthmatics
Antibacterial agents
Anticoagulants
Antidiabetic agents
Antimalarials
Antiparkinsonian agents
Antipyretics
Antirheumatic agents
Antitumor agents
Antiulcer agents
Antiviral agents
Arteriosclerosis
Arthritis
Asthma
Autoimmune disease
Bladder, neoplasm

Bone, neoplasm
Bone resorption
Bone resorption inhibitors
Brain, neoplasm
Burn
Cachexia
Carcinoma
Cardiovascular agents
Cardiovascular system, disease
Dermatitis
Diabetes insipidus
Diabetes mellitus
Digestive tract, disease
Digestive tract, neoplasm
Drug delivery systems
Eczema
Esophagus, neoplasm
Eye, disease
Fever and Hyperthermia
Gastrointestinal agents
Gout
Granulation tissue
Human
Immunomodulators
Inflammation
Influenza
 Ischemia
Keloid
Leukemia
Lip
Liver, disease
Liver, neoplasm
Lung, disease
Lung, neoplasm
Lymphoma
Malaria
Mammary gland, neoplasm
Meningitis
Mouth, neoplasm
Multiple sclerosis
Neoplasm
Nervous system agents
Osteoarthritis
Osteoporosis
Ovary, neoplasm
Pain
Pancreas, neoplasm
Parkinson's disease
Phosphorylation, biological
Prostate gland, neoplasm
Psoriasis
Reproduction disorders
Rheumatoid arthritis
Sepsis
Silicosis
Skin, disease
Skin, neoplasm
Solid phase synthesis
Stomach, neoplasm
Thrombosis
 (preparation of pyridinones as modulators of p38 MAP kinase for

treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Sarcoidosis
 (pulmonary; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Kidney, neoplasm
 (renal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma
 (renal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart
 Kidney
 (reperfusion injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury
 (reperfusion; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
 (retina, neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
 (retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
 (retrolental fibroplasia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lung, disease
 (sarcoidosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Shock (circulatory collapse)
 (septic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm
 (small; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Injury
 (spinal cord; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Spinal column, disease

(spondyloarthropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease
(stroke; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Lupus erythematosus
(systemic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Shock (circulatory collapse)
(toxic shock syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease
(trauma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Stomach, disease
(ulcer; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation
Intestine, disease
(ulcerative colitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease
Inflammation
(uveitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Infection
(viral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Central nervous system, disease
(with inflammatory or apoptotic component; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 329-59-9P, Methyl 4-fluoro-3-nitrobenzoate 369-26-6P, Methyl 3-amino-4-fluorobenzoate 874-97-5P, 3-Hydroxymethylbenzonitrile 3446-91-1P, 4-Bromomethyl-N,N-dimethylbenzenesulfonamide 3749-51-7P, 4-Hydroxy-6-methyl-2(1H)-pyridone 13737-35-4P, (2-Bromomethylphenyl)acetic acid 13737-37-6P, Methyl (2-Bromomethylphenyl)acetate 19858-50-5P, [2-(Methylthio)pyrimidin-5-yl]methanol 21317-88-4P, 1-Allyl-4-hydroxy-6-methylpyridin-2(1H)-one 21642-98-8P, 4-Methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 24812-90-6P, Methyl 3-amino-4-methoxybenzoate 26576-93-2P, 3-Chloro-4-hydroxy-6-methyl-1H-pyridin-2-one 33524-79-7P, 1-Benzyl-4-hydroxy-6-methylpyridin-2(1H)-one 38275-41-1P, Methyl 2-(methylthio)pyrimidine-5-carboxylate 39204-47-2P, 2-Chloromethylpyrazine 41110-34-3P, Ethyl 5-methylpyrazine-2-carboxylate 49668-89-5P 49668-90-8P, Methyl 6-(chloromethyl)nicotinate 68432-92-8P, Methyl 3-cyanomethylbenzoate 76518-57-5P, Isoquinolin-5-ylmethanol 104317-94-4P, 3-Amino-4-chlorobenzyl alcohol

119887-89-7P, 3-Acetyl-1-(2-chlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 121669-69-0P, 4-Methylpyrazole-1-carboxylic acid tert-butyl ester 123226-36-8P, (3-Bromomethylphenyl)acetonitrile 135645-63-5P, 4-(Bromomethyl)-2-(methylthio)pyrimidine 140215-42-5P, Ethyl (3-bromomethylphenyl)acetate 171670-20-5P, Methyl 3-bromomethyl-2-fluorobenzoate 177665-49-5P, (3-Hydroxymethylphenyl)acetonitrile 185629-32-7P, Methyl 4-amino-3-fluorobenzoate 186551-69-9P, 3-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester 186551-70-2P, 3-Methylpyrazole-1-carboxylic acid tert-butyl ester 217661-27-3P, 2-(Bromomethyl)-5-fluorobenzonitrile 220364-34-1P, [3-(Bromomethyl)benzyl]carbamic acid tert-butyl ester 220798-39-0P 226070-69-5P, [3-(Hydroxymethyl)benzyl]carbamic acid tert-butyl ester 227609-86-1P, (3-Amino-4-fluorophenyl)methanol 391957-11-2P, 3-[(tert-Butyldimethylsilyloxy)methyl]benzylamine 530144-72-0P, 4-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester 586373-04-8P, 1-Benzyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl 4-bromobenzenesulfonate 586373-18-4P, 1-Benzyl-3-bromo-4-hydroxypyridin-2(1H)-one 586373-21-9P, 1-Benzyl-3-bromo-4-(phenylethynyl)pyridin-2(1H)-one 586373-24-2P, 3-Acetyl-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586373-25-3P, 1-(2,6-Dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586373-26-4P, 4-(Benzyloxy)-1-(2,6-dichlorophenyl)-6-methylpyridin-2(1H)-one 586373-29-7P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl N-methyl-N-phenylcarbamate 586373-31-1P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-iodopyridin-2(1H)-one 586373-32-2P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-[(trimethylsilyl)ethynyl]pyridin-2(1H)-one 586373-34-4P, 1-(3-Fluorobenzyl)-4-hydroxypyridin-2(1H)-one 586373-35-5P, 4-(Benzylamino)-1-(3-fluorobenzyl)pyridin-2(1H)-one 586373-37-7P, 4-[(4-Fluorobenzyl)oxy]pyridine-1-oxide 586373-38-8P, 4-[(4-Fluorobenzyl)oxy]pyridine-2(1H)-one 586373-39-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one 586373-51-5P, 3-[(tert-Butyldimethylsilyloxy)methyl]benzonitrile 586373-57-1P, 4-[(2,4-Difluorobenzyl)oxy]pyridine-1-oxide 586373-58-2P, 4-[(2,4-Difluorobenzyl)oxy]pyridin-2(1H)-one 586373-59-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-60-6P, 3-Bromo-1-(4-chloromethylbenzyl)-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586373-67-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-68-4P, 3-Chloro-1-(4-chloromethylbenzyl)-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586373-70-8P, 1-Chloromethyl-3-(methanesulfonyl)benzene 586373-73-1P, Methyl 4-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586373-76-4P, 5-Bromomethylisoquinoline hydrobromide 586373-79-7P, [5-(Carboxymethyl)indol-1-yl]carbamic acid tert-butyl ester 586373-80-0P, [5-Hydroxymethylindol-1-yl]carbamic acid tert-butyl ester 586373-81-1P, [5-Bromomethylindol-1-yl]carbamic acid tert-butyl ester 586373-82-2P, [5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]indol-1-yl]carbamic acid tert-butyl ester 586373-93-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,4-difluorobenzyl)-1H-pyridin-2-one 586374-02-9P, 3-Bromo-1-(3-bromomethyl-2-fluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586374-04-1P, Methyl 2-fluoro-3-methylbenzoate 586374-07-4P, 3-Bromo-1-(3-fluorobenzyl)-4-hydroxypyridin-2(1H)-one 586374-12-1P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-1H-pyridin-2-one 586374-29-0P, Methyl [2-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetate 586374-37-0P, 1-(3-Fluorobenzyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 586374-38-1P, 1-(3-Fluorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 586374-40-5P, Methyl 1-cyclohexyl-4-hydroxy-2,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate 586374-41-6P, 1-Cyclohexyl-4-hydroxy-2,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 586374-42-7P, 1-Cyclohexyl-4-hydroxy-3,6-dimethyl-1H-pyridin-2-one 586374-44-9P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazole-1-

carboxylic acid tert-butyl ester 586374-45-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-09-9P, 4-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]benzonitrile 586375-14-6P, 1-(4-Cyanophenyl)-4-hydroxy-2(1H)-pyridinone 586375-15-7P, 4-[4-[(2,4-Difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]benzonitrile 586375-16-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1(2H)-yl]benzoate 586375-18-0P, 4-Hydroxy-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586375-19-1P, 1-[3-(Hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-21-5P, Methyl 4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586375-22-6P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586375-29-3P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzaldehyde 586375-31-7P, 1-(4-Methoxybenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586375-35-1P, 4-Hydroxy-4-methylpiperidine hydrochloride 586375-72-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-93-1P 586375-98-6P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586376-00-3P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-21-8P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-24-1P, 1-[3-(Chloromethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-25-2P, 1-[3-(Aminomethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-34-3P 586376-39-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-[3-[(dimethylamino)methyl]phenyl]-6-methylpyridin-2(1H)-one 586376-52-5P, 3,4-Dibromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586376-56-9P, 4-Azido-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586376-58-1P, 4-Amino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one hydrochloride 586376-62-7P, 1-(4-Bromo-2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586376-74-1P, 4-[(2,4-Difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-80-9P, 4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-yl)phenyl]-6-methylpyridin-2(1H)-one 586376-91-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluoro-4-hydroxyphenyl)-6-methylpyridin-2(1H)-one 586376-95-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-hydroxyphenyl)-6-methylpyridin-2(1H)-one 586376-99-0P, 1-(2,6-Difluorophenyl)-4-[[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one 586377-01-7P, 1-(2,6-Difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-08-4P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-methylbenzoate 586377-09-5P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoate 586377-10-8P, 3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-11-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-32-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-38-0P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]carbamate 586377-40-4P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl] (methyl)carbamate 586377-41-5P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl] (cyclopropylmethyl)carbamate 586377-43-7P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzamide 586377-45-9P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-hydroxybenzonitrile 586377-46-0P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-hydroxybenzonitrile potassium salt 586377-58-4P, 1-(3-Fluorobenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-59-5P, 3-Bromo-1-(3-fluorobenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-60-8P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586377-61-9P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-4-(phenylethynyl)pyridin-2(1H)-one 586377-66-4P,

1-(2,6-Dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-67-5P,
 3-Bromo-1-(2,6-dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
 586377-72-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-
 2(1H)-one 586377-76-6P, 4-Hydroxy-1-(2-methoxy-6-methylphenyl)-6-
 methylpyridin-2(1H)-one 586377-77-7P, 3-Bromo-4-hydroxy-1-(2-methoxy-6-
 methylphenyl)-6-methylpyridin-2(1H)-one 586377-79-9P,
 3,5-Dichloro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-
 yl)benzenesulfonamide 586377-81-3P, 3-Bromo-1-(2,6-difluorophenyl)-4-
 hydroxy-6-methylpyridin-2(1H)-one 586377-84-6P, 3,5-Difluoro-N,N-
 dimethylbenzene-1,2-diamine 586377-85-7P, 1-[2-(Dimethylamino)-4,6-
 difluorophenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586377-86-8P,
 3-Bromo-1-[2-(dimethylamino)-4,6-difluorophenyl]-4-hydroxy-6-methylpyridin-
 2(1H)-one 586378-01-0P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4-
 hydroxy-6-methylpyridin-2(1H)-one 586378-02-1P, 1-[(4-Amino-2-
 methylpyrimidin-5-yl)methyl]-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one
 586378-06-5P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-
 hydroxy-6-methylpyridin-2(1H)-one 586378-26-9P, 4-Hydroxy-6-methyl-1-[(5-
 methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-27-0P,
 3-Bromo-4-hydroxy-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-
 one 586378-30-5P, Ethyl 5-(bromomethyl)pyrazine-2-carboxylate
 586378-34-9P, 3-Bromo-1-[[5-(chloromethyl)pyrazin-2-yl]methyl]-4-[(2,4-
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586378-40-7P,
 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]methyl]pyrazine-2-carboxylic acid 586378-50-9P, 1-(3-Fluorobenzyl)-4-
 hydroxy-3-iodopyridin-2(1H)-one 586378-55-4P, 4-Amino-1-(3-
 fluorobenzyl)pyridin-2(1H)-one 586378-56-5P, 4-Fluoro-N-[1-(3-
 fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]benzamide 586378-58-7P,
 3-Chloro-1-(2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
 586378-60-1P, 1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)amino]-6-methylpyridin-
 2(1H)-one 586378-64-5P, 3-Bromo-4-hydroxy-6-methyl-1-(pyridin-4-
 ylmethyl)pyridin-2(1H)-one 586378-66-7P, 3-Bromo-4-hydroxy-6-methyl-1-
 (pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-68-9P, 3-Bromo-4-hydroxy-6-
 methyl-1-(pyridin-2-ylmethyl)pyridin-2(1H)-one 586378-69-0P
 586378-84-9P, 3-Bromo-6-methyl-2-oxo-1-[(pyridin-3-yl)methyl]-1,2-
 dihydropyridin-4-yl trifluoromethanesulfonate 586378-85-0P,
 3-Bromo-4-[2-(4-fluorophenyl)ethynyl]-6-methyl-1-[(pyridin-3-
 yl)methyl]pyridin-2(1H)-one 586378-88-3P, 3-Chloro-4-hydroxy-6-methyl-1-
 (pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-99-6P, 3-Chloro-4-hydroxy-6-
 methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586379-10-4P,
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]methyl]pyrazine-2-carboxylic acid 586379-14-8P, 1-Allyl-4-[(2,4-
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-16-0P,
 1-Allyl-3-chloro-4-hydroxy-6-methylpyridin-2(1H)-one 586379-19-3P,
 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-prop-2-ynylpyridin-2(1H)-one
 586379-26-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-
 dihydropyridine-2-carboxaldehyde 586379-27-3P, 4-[(2,4-
 Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-
 one 586379-36-4P, Methyl 4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-3-
 methylbenzoate 586379-37-5P, Methyl 4-(3-bromo-4-hydroxy-6-methyl-2-oxo-
 2H-pyridin-1-yl)-3-methylbenzoate 586379-43-3P, 1-(4-Bromo-2-
 methylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586379-44-4P,
 1-(4-Bromo-2-methylphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
 2(1H)-one 586379-45-5P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(2-methyl-
 4-vinylphenyl)pyridin-2(1H)-one 586379-48-8P, Methyl
 4-chloro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate
 586379-49-9P, Methyl 4-chloro-3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
 oxo-2H-pyridin-1-yl]benzoate 586379-52-4P, 4-Hydroxy-1-[5-
 (hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-53-5P,
 4-[(2,4-Difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-
 methylpyridin-2(1H)-one 586379-55-7P, 1-[2-Chloro-5-
 (hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586379-56-8P,

1-[2-Chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-58-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzaldehyde 586379-61-5P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methylbenzoate 586379-62-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-63-7P, 3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586379-64-8P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586379-70-6P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-73-9P, Methyl 3-chloro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586379-74-0P, Methyl 3-chloro-4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586379-77-3P, 4-[(2,4-Difluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-82-0P, 4-[(2,4-Difluorobenzyl)amino]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586379-86-4P, 4-[(2,4-Difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586379-89-7P, 3-[(4-Hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzonitrile 586379-90-0P, 3-[[4-[(2,4-Difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-94-4P, 1-[2-Fluoro-5-(hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586379-95-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[2-fluoro-5-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586379-97-7P, Methyl 4-fluoro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586379-98-8P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586379-99-9P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586380-12-3P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate 586380-14-5P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methoxybenzoate 586380-15-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxybenzoate 586380-16-7P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxybenzoate 586380-20-3P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzamide 586380-49-6P 586380-51-0P, 4-[(2,4-Difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586380-53-2P 586380-54-3P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]nicotinic acid 586380-58-7P, 4-Hydroxy-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-one 586380-59-8P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-one 586380-65-6P, 4-(Benzyloxy)-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586380-83-8P 586380-84-9P 586380-85-0P 586380-88-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzoic acid 586380-90-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-05-7P, Methyl 3-fluoro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate 586381-06-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoate 586381-12-6P, 1-[4-(Aminomethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-13-7P, [2-[[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]amino]-2-oxoethyl] acetate 586381-16-0P, tert-Butyl [4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]carbamate 586381-33-1P, 4-Bromomethyl-N-(2-hydroxyethyl)benzenesulfonamide 586381-36-4P, 4-Bromomethyl-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide 586381-39-7P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazole-1-carboxylic acid tert-butyl ester 586381-41-1P, [5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]indol-1-yl]carbamic acid tert-butyl ester 586381-42-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-indol-5-

ylmethyl)-1H-pyridin-2-one 586381-44-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-3,3-dibromo-1H-indol-2-one 586381-53-5P 586381-55-7P, 4-Hydroxy-1-(1H-indazol-5-yl)-6-methylpyridin-2(1H)-one 586381-57-9P, 4-Hydroxy-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one 586381-59-1P, Methyl 3-[4-[(2-cyano-4-fluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-61-5P, Methyl 3-[4-[[2-(aminomethyl)-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate trifluoroacetate 586381-62-6P 586381-63-7P, 3-[4-[[4-Fluoro-2-[[methoxycarbonyl]amino]methyl]benzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-64-8P, 3-[3-Bromo-4-[[4-fluoro-2-[[methoxycarbonyl]amino]methyl]benzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-72-8P, Methyl 3-[4-[[2-[[ethoxycarbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-73-9P, 3-[4-[[2-[[ethoxycarbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-74-0P, 3-[3-Bromo-4-[[2-[[ethoxycarbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-76-2P, Methyl 3-[4-[[2-[[[(cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-77-3P, 3-[4-[[2-[[[(Cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-79-5P, Ethyl (5-fluoro-2-methylphenoxy)acetate 586381-80-8P, Ethyl [2-(bromomethyl)-5-fluorophenoxy]acetate 586381-81-9P, Ethyl [2-[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorophenoxy]acetate 586381-82-0P, [2-[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorophenoxy]acetic acid 586381-84-2P, 3-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-oxopropyl acetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586381-85-3P, Methyl 3-[6-[(acetyloxy)methyl]-4-hydroxy-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-86-4P, Methyl 3-[6-[(acetyloxy)methyl]-3-bromo-4-hydroxy-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-93-3P, (2E)-4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenic acid 586381-96-6P, 2-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-[(methylamino)carbonyl]benzoic acid 586382-03-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-methylpyridin-2(1H)-one 586382-08-3P, 1-[4-(Aminomethyl)benzyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-14-1P, [1-[3-(Aminocarbonyl)phenyl]-4-hydroxy-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate 586382-15-2P, [1-[3-(Aminocarbonyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate 586382-17-4P, 5-(Chloromethyl)-2-(methylthio)pyrimidine 586382-19-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylthio)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate 586382-21-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate 586382-26-5P, Ethyl 3-[3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylphenyl]-3-oxopropanoate 586382-30-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]quinolin-2(1H)-one 586382-31-2P, Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-yl]methyl]benzoate 586382-33-4P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoic acid 586382-35-6P, Methyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-furoate 586382-36-7P, Methyl 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furoate 586382-37-8P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furoic acid

586382-39-0P, Dimethyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)isophthalate 586382-40-3P, Dimethyl 5-(3-bromo-4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)isophthalate 586382-41-4P, Dimethyl 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]isophthalate 586382-42-5P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]isophthalic acid 586382-48-1P, tert-Butyl [3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]carbamate 586382-50-5P, 2-[[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]amino]-2-oxoethyl acetate 586382-52-7P, 2-[[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]amino]-1,1-dimethyl-2-oxoethyl acetate 586382-54-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586375-79-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; hydrochloride)

IT 586379-66-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(methylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586380-87-2P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzamide
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586414-48-4P 586414-49-5P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 108379-95-9P 571168-92-8P, 1-Benzyl-4-(benzyloxy)-3-iodopyridin-2(1H)-one 586372-64-7P, 4-(Benzyloxy)-1-(4-methylbenzyl)pyridin-2(1H)-one 586372-72-7P, 4-(Benzyloxy)-1-[(3-fluorophenyl)methyl]pyridin-2(1H)-one 586372-73-8P, 4-(Benzyloxy)-3-bromo-1-[(3-fluorophenyl)methyl]pyridin-2(1H)-one 586372-76-1P, 4-(Benzyloxy)-3-bromopyridin-2(1H)-one 586372-77-2P, 4-(Benzyloxy)-1-[4-(benzyloxy)benzyl]-3-bromopyridin-2(1H)-one 586372-81-8P, 4-(Benzyloxy)-1-[(4-cyanophenyl)methyl]pyridin-2(1H)-one 586372-82-9P 586372-87-4P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-2(1H)-one hydrobromide 586373-00-4P, 1-Benzyl-4-(benzyloxy)-6-methylpyridin-2(1H)-one 586373-03-7P, 1-Benzyl-4-[(3-chlorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586373-06-0P, 1-Benzyl-4-[(2,6-dichlorobenzyl)oxy]pyridin-2(1H)-one 586373-14-0P, 1-Benzyl-4-(benzyloxy)-3-vinylpyridin-2(1H)-one 586373-20-8P, 1-Benzyl-3-bromo-2-oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate 586373-50-4P 586373-55-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[2-(hydroxymethyl)benzyl]pyridin-2(1H)-one 586373-64-0P, [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-

yl)methyl]benzyl]carbamic acid tert-butyl ester 586373-75-3P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(isoquinolin-5-yl)methyl]-1H-
 pyridin-2-one trifluoroacetate 586373-78-6P, 3-Chloro-4-[(2,4-
 difluorobenzyl)oxy]-1-(1H-indol-5-ylmethyl)-1H-pyridin-2-one
 586373-84-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-
 indol-5-yl)methyl]pyridin-2(1H)-one 586373-95-7P, 2-[[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
 586373-97-9P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
 pyridin-1-yl]methyl]benzoate 586374-03-0P, Methyl 3-[[3-chloro-4-[(2,4-
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-fluorobenzoate
 586374-06-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-
 fluorobenzyl)pyridin-2(1H)-one 586374-28-9P, 2-[2-[[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide
 586374-30-3P, Ethyl [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
 pyridin-1-yl]methyl]phenyl]acetate 586374-34-7P, 4-[(2,4-
 Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-
 carbonitrile 586374-39-2P, 1-Cyclohexyl-4-[(2,4-difluorobenzyl)oxy]-3,6-
 dimethylpyridin-2(1H)-one 586374-46-1P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-
 2H-pyridin-1-yl]methyl]benzonitrile 586374-47-2P, 2-[[4-(Benzyloxy)-3-
 bromo-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586374-55-2P,
 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile
 586374-59-6P, 2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]methyl]benzonitrile 586374-61-0P, 3-[[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
 586374-62-1P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]methyl]benzonitrile 586374-63-2P, 4-[[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide
 586374-65-4P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
 oxo-2H-pyridin-1-yl]methyl]benzoate 586374-70-1P, 3-Bromo-1-[4-
 (bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
 586374-72-3P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-80-3P,
 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]methyl]benzoic acid 586375-08-8P, Methyl 4-[4-(benzyloxy)-3-bromo-2-
 oxo-2H-pyridin-1-yl]benzoate 586375-10-2P, 4-[4-(Benzyloxy)-3-bromo-2-
 oxo-2H-pyridin-1-yl]benzoic acid 586375-20-4P, Methyl
 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]benzoate 586375-23-7P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-2-oxo-2H-pyridin-1-yl]benzoic acid 586375-25-9P,
 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]methyl]benzoic acid 586375-26-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
 1-[4-(hydroxymethyl)benzyl]-6-methylpyridin-2(1H)-one 586375-30-6P,
 4-[(2,4-Difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-methylpyridin-2(1H)-one
 586375-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-
 methylpyridin-2(1H)-one 586375-66-8P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-1-[4-(1-pyrrolidinylcarbonyl)phenyl]pyridin-
 2(1H)-one hydrochloride 586375-71-5P, Methyl 4-[[3-chloro-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoate
 586375-97-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]benzoic acid 586375-99-7P, Methyl 3-[4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate
 586376-20-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]benzoic acid 586376-23-0P, 1-[3-(Aminomethyl)phenyl]-3-
 bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
 586376-64-9P, 1-(4-Bromo-2,6-difluorophenyl)-4-[(2,4-difluorobenzyl)oxy]-6-
 methylpyridin-2(1H)-one 586376-66-1P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one
 586376-70-7P, 4-[[2,4-Difluorobenzyl)oxy]-6-methyl-1-(2,4,6-
 trifluorophenyl)pyridin-2(1H)-one 586377-36-8P, 4-[3-Chloro-4-[(2,4-
 difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzonitrile
 586377-37-9P, 1-[4-(Aminomethyl)-2,6-difluorophenyl]-3-chloro-4-[(2,4-

difluorobenzyl)oxy]pyridin-2(1H)-one hydrochloride 586377-80-2P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-
2(1H)-one 586377-82-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586377-88-0P,
2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-5-fluorobenzonitrile 586377-90-4P, 4-[[2-(Aminomethyl)-4-
fluorobenzyl]oxy]-3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one
trifluoroacetate 586377-96-0P, 4-[[2-(Aminomethyl)-4-fluorobenzyl]oxy]-3-
chloro-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate
586378-00-9P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate
586378-03-2P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride
586378-05-4P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate
586378-12-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-
(methylthio)pyrimidin-4-yl]methyl]pyridin-2(1H)-one 586378-13-4P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-
(methylsulfonyl)pyrimidin-4-yl]methyl]pyridin-2(1H)-one 586378-15-6P,
4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]pyrimidine-2-carbonitrile trifluoroacetate 586378-29-2P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyrazin-2-
yl]methyl]-6-methylpyridin-2(1H)-one 586378-31-6P, Ethyl
5-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]pyrazine-2-carboxylate 586378-38-3P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-
yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one trifluoroacetate
586378-49-6P, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-iodopyridin-
2(1H)-one 586379-02-4P, Ethyl 5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylate 586379-25-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
(hydroxymethyl)pyridin-2(1H)-one 586379-30-8P, 5-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-
carboxaldehyde 586379-42-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-1-(2-methyl-4-vinylphenyl)pyridin-2(1H)-one 586379-51-3P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-
methylpyridin-2(1H)-one 586379-72-8P, Methyl 4-[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzoate
586379-96-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-fluorobenzoic acid 586380-11-2P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoic acid
586380-13-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-methoxybenzoic acid 586380-19-0P, 1-[5-(Aminomethyl)-2-
fluorophenyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-
one hydrochloride 586380-26-9P, 2-[[[3-Chloro-1-(2,6-difluorophenyl)-6-
methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile
586380-60-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
methyl-5-vinylpyridin-2(1H)-one 586380-61-2P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxyethyl)-6-
methylpyridin-2(1H)-one 586380-62-3P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(hydroxymethyl)-6-
methylpyridin-2(1H)-one 586380-63-4P, 5-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-
dihydropyridine-3-carboxaldehyde 586380-64-5P, 4-(Benzyloxy)-3-bromo-1-
(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586380-67-8P,
5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-
1,6-dihydropyridine-3-carboxaldehyde oxime 586380-73-6P,
4-(Allylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-
one 586380-75-8P, Ethyl 3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-1,2'-bipyridine-5'-carboxylate 586380-82-7P 586381-04-6P,
Methyl 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-

yl]-3-fluorobenzoate 586381-07-9P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoic acid 586381-08-0P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586381-15-9P, 1-(4-Aminobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-40-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(2,3-dihydro-1H-indol-5-yl)methyl]-1H-pyridin-2-one 586381-58-0P, Methyl [2-[[[3-bromo-6-methyl-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-78-4P, 3-[3-Bromo-4-[[2-[[[(cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-89-7P 586381-94-4P, Methyl 5-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoate 586381-95-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-(hydroxymethyl)-N-methylbenzamide 586382-02-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-methylpyridin-2(1H)-one 586382-04-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586382-05-0P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzaldehyde 586382-16-3P 586382-46-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1-hydroxy-1-methylethyl)phenyl]-6-methylpyridin-2(1H)-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 4241-21-8P, 2-Oxo-6-phenethyl-1,2-dihydropyridine-3-carbonitrile 39883-43-7P, 6-Oxo-1,6-dihydro-[2,3']bipyridinyl-5-carbonitrile 43083-13-2P, 2-Oxo-6-phenyl-1,2-dihydropyridine-3-carbonitrile 53179-13-8P, 5-Methyl-1-phenyl-1H-pyridin-2-one 54923-34-1P, 4-Benzyloxy-3-methyl-1H-pyridin-2-one 56304-43-9P, 6-Oxo-1,6-dihydro-[2,3']bipyridinyl-5-carboxylic acid 123100-43-6P, 1-(2-Bromobenzyl)-3-[(2-bromobenzyl)oxy]pyridin-2(1H)-one 242472-06-6P, 5-[[4-(3-Chlorophenyl)piperazin-1-yl]carbonyl]-1-(3,4-dichlorobenzyl)-1H-pyridin-2-one 242472-09-9P, N-Allyl-2-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)carbonyl]hydrazinecarbothioamide 338774-98-4P, N-[5-Acetyl-1-(4-chlorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]-4-chlorobenzamide 338782-59-5P, 1-(3,4-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(2,4-difluorophenyl)amide 338978-39-5P 338981-04-7P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-dimethylaminopropyl)amide 338981-05-8P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(2-dimethylaminoethyl)amide 339008-61-6P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(2,4-difluorophenyl)amide 339008-62-7P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(4-chlorophenyl)amide 339008-63-8P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-trifluoromethylphenyl)amide 339008-64-9P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(4-trifluoromethoxyphenyl)amide 339008-65-0P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid benzylamide 339008-68-3P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide 339009-09-5P, 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(2,4-difluorophenyl)amide 339023-89-1P, 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-trifluoromethylphenyl)amide 339023-98-2P, 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid benzylamide

339024-00-9P 400087-49-2P, Methyl 5-chloro-1-(4-chlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylate 477852-96-3P, 1-Benzyl-5-[5-[(3,4-dichlorobenzyl)sulfanyl]-[1,3,4]oxadiazol-2-yl]-1H-pyridin-2-one 477858-09-6P, 1-(4-Chlorobenzyl)-5-[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-yl]-1H-pyridin-2-one 477864-11-2P, N'-[[1-Benzyl-6-oxo-1,6-dihydropyridin-3-yl]carbonyl]oxy]pyridine-4-carboximidamide 478065-97-3P, 1-Benzyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide 478066-00-1P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-trifluoromethylbenzyl)amide 478247-73-3P, 3-Benzyl-4-hydroxy-1-(2-phenylethyl)pyridin-2(1H)-one 565156-95-8P, 4-Bromo-2-(2,6-dichlorophenyl)-5-[[2-(hydroxymethyl)benzyl]oxy]pyridazin-3(2H)-one 565157-26-8P, 4-Bromo-2-(2,6-dichlorophenyl)-5-[[2,4-difluorobenzyl]oxy]pyridazin-3(2H)-one 586372-66-9P, 4-(Benzyloxy)-3-bromo-1-(4-methylbenzyl)pyridin-2(1H)-one 586372-68-1P, 4-(Benzyloxy)-1-[(4-bromophenyl)methyl]pyridin-2(1H)-one 586372-69-2P, 4-(Benzyloxy)-3-bromo-1-[(4-bromophenyl)methyl]pyridin-2(1H)-one 586372-70-5P, 4-(Benzyloxy)-1-[(4-chlorophenyl)methyl]pyridin-2(1H)-one 586372-71-6P, 4-(Benzyloxy)-3-bromo-1-[(4-chlorophenyl)methyl]pyridin-2(1H)-one 586372-74-9P, 4-(Benzyloxy)-1-[(2-fluorophenyl)methyl]pyridin-2(1H)-one 586372-75-0P, 4-(Benzyloxy)-3-bromo-1-[(2-fluorophenyl)methyl]pyridin-2(1H)-one 586372-78-3P, 4-(Benzyloxy)-1-[[4-(methoxycarbonyl)phenyl]methyl]pyridin-2(1H)-one 586372-79-4P, 4-(Benzyloxy)-3-bromo-1-[[4-(methoxycarbonyl)phenyl]methyl]pyridin-2(1H)-one 586372-80-7P, 4-(Benzyloxy)-3-bromo-1-[(4-carboxyphenyl)methyl]pyridin-2(1H)-one 586372-83-0P, 4-(Benzyloxy)-1-[(4-tert-butylphenyl)methyl]pyridin-2(1H)-one 586372-84-1P, 4-(Benzyloxy)-3-bromo-1-[(4-tert-butylphenyl)methyl]pyridin-2(1H)-one 586372-85-2P, 4-(Benzyloxy)-3-bromo-1-ethylpyridin-2(1H)-one 586372-86-3P, 3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one 586372-88-5P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-2(1H)-one 586372-89-6P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]-N'-hydroxybenzenecarboximidamide 586372-90-9P, 4-(Benzyloxy)-3-bromo-1-(piperidin-4-ylmethyl)pyridin-2(1H)-one hydrochloride 586372-91-0P, 4-(Benzyloxy)-1-[4-(trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-92-1P, 4-(Benzyloxy)-3-bromo-1-[4-(trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-93-2P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-ylmethyl)pyridin-2(1H)-one hydrochloride 586372-94-3P, 4-(Benzyloxy)-3-bromo-1-[2-(thien-3-yl)ethyl]pyridin-2(1H)-one 586372-95-4P, 4-(Benzyloxy)-3-bromo-1-[2-(thien-2-yl)ethyl]pyridin-2(1H)-one 586372-96-5P, 4-(Benzyloxy)-3-bromo-1-[3-(trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-97-6P, 4-(Benzyloxy)-3-bromo-1-[2-(trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-98-7P, 4-(Benzyloxy)-1-[4-(trifluoromethoxy)benzyl]pyridin-2(1H)-one 586372-99-8P, 4-(Benzyloxy)-3-bromo-1-[4-(trifluoromethoxy)benzyl]pyridin-2(1H)-one 586373-01-5P, 1-Benzyl-4-(benzyloxy)-3-bromo-6-methylpyridin-2(1H)-one 586373-02-6P, 1-Benzyl-4-(benzyloxy)-3,5-dibromo-6-methylpyridin-2(1H)-one 586373-05-9P, 1-Benzyl-3-bromo-4-[(3-chlorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586373-07-1P, 1-Benzyl-3-bromo-4-[(2,6-dichlorobenzyl)oxy]pyridin-2(1H)-one 586373-08-2P, 1-Benzyl-4-[(2-chlorobenzyl)oxy]pyridin-2(1H)-one 586373-09-3P, 1-Benzyl-3-bromo-4-[(2-chlorobenzyl)oxy]pyridin-2(1H)-one 586373-10-6P, 1-Benzyl-3-bromo-4-[(4-methylbenzyl)oxy]pyridin-2(1H)-one 586373-11-7P, 1-Benzyl-4-[(3-chlorobenzyl)oxy]pyridin-2(1H)-one 586373-12-8P, 1-Benzyl-4-(benzylthio)-3-bromopyridin-2(1H)-one 586373-13-9P, 1-Benzyl-3-bromo-4-[[2-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one 586373-15-1P, 1-Benzyl-4-(benzyloxy)-3-ethylpyridin-2(1H)-one 586373-16-2P, 3-Acetyl-4-(benzyloxy)-1-(2-chlorophenyl)-6-methylpyridin-2(1H)-one 586373-17-3P, 1-Benzyl-3-bromo-4-(2-phenylethyl)pyridin-2(1H)-one 586373-22-0P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-4-(2-phenylethyl)pyridin-2(1H)-one 586373-23-1P, 4-(Benzyloxy)-3-bromo-1-(2,6-dichlorophenyl)-6-

methypyridin-2(1H)-one 586373-27-5P, 3-Bromo-1-(3-fluorobenzyl)-4-(2-phenylethyl)pyridin-2(1H)-one 586373-28-6P, 1-Benzyl-3-bromo-2-oxo-1,2-dihydropyridin-4-yl N-methyl-N-phenylcarbamate 586373-30-0P, 4-(Benzyloxy)-3-ethynyl-1-(3-fluorobenzyl)pyridin-2(1H)-one 586373-33-3P, 4-(Benzylamino)-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586373-36-6P, 3-Bromo-1-(cyclopropylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-40-2P, 3-Bromo-1-[(pyridin-4-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-41-3P, 3-Bromo-1-[(pyridin-3-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-42-4P, 3-Bromo-1-(4-tert-butylbenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-43-5P, 3-Bromo-1-(3-trifluoromethylbenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-44-6P, 3-Bromo-1-[(biphenyl-2-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-45-7P, 3-Bromo-1-(4-methoxybenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-46-8P 586373-47-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[4-(trifluoromethyl)benzyl]pyridin-2(1H)-one 586373-48-0P, 3-Bromo-1-[(biphenyl-4-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-49-1P, 3-Bromo-1-(cyclohexylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-52-6P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-53-7P, 1-(3-Aminomethylbenzyl)-3-bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one trifluoroacetate (1:1.125) 586373-54-8P, Methyl 2-[[3-bromo-4-[(4-fluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586373-56-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-[(dimethylamino)methyl]benzyl]-1H-pyridin-2-one 586373-61-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-[(isopropylamino)methyl]benzyl]-1H-pyridin-2-one 586373-62-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(dimethylaminomethyl)benzyl]-1H-pyridin-2-one 586373-63-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(methylamino)methyl]benzyl]-1H-pyridin-2-one 586373-65-1P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586373-66-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-[(isopropylamino)methyl]benzyl]-1H-pyridin-2-one 586373-69-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(methanesulfonyl)benzyl]-1H-pyridin-2-one 586373-71-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-(methanesulfonyl)benzyl]-1H-pyridin-2-one 586373-72-0P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586373-77-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586373-83-3P, 1-[(1-Acetyl-1H-indol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-85-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586373-86-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586373-87-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(pyridin-2-yl)methyl]-1H-pyridine-2-one 586373-88-8P, 3-Bromo-1-(4-tert-butylbenzyl)-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-89-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-methoxybenzyl)pyridin-2(1H)-one 586373-90-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(benzodioxol-5-yl)methyl]pyridine-2(1H)-one 586373-91-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-fluorobenzyl)pyridin-2(1H)-one 586373-92-4P, 3-Bromo-1-(2,4-difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-94-6P, [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetonitrile 586373-96-8P, 1-[2-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-98-0P, Methyl 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586373-99-1P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-00-7P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-01-8P, 1-(3-Aminomethyl-2-fluorobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586374-05-2P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-

fluorobenzamide 586374-08-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2,3,4-trifluorobenzyl)oxy]-1H-pyridin-2-one 586374-10-9P 586374-11-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(3-fluorobenzyl)-1H-pyridin-2-one 586374-13-2P, 3-Bromo-4-[(3-chlorobenzyl)oxy]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586374-14-3P, 3-Bromo-4-[(3,4-difluorobenzyl)oxy]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586374-15-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586374-16-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)oxy]pyridin-2(1H)-one 586374-18-7P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-methoxybenzyl)oxy]pyridin-2(1H)-one 586374-19-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-tert-butylbenzyl)oxy]-1H-pyridin-2-one 586374-20-1P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-methylbenzyl)oxy]pyridin-2(1H)-one 586374-21-2P, 3-Bromo-1-(3-fluorobenzyl)-4-[[4-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one 586374-22-3P 586374-23-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2-methylbenzyl)oxy]pyridin-2(1H)-one 586374-24-5P 586374-25-6P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-methoxybenzyl)oxy]pyridin-2(1H)-one 586374-27-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[[2-(hydroxymethyl)benzyl]oxy]pyridin-2(1H)-one 586374-31-4P, 2-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide 586374-32-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-3-methylpyridin-2(1H)-one 586374-33-6P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-3-iodo-1H-pyridin-2-one 586374-43-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-4-ylmethyl)-1H-pyridin-2-one 586374-48-3P, 1-[4-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-49-4P, 1-[3-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-50-7P, 1-[2-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586374-51-8P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-52-9P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-53-0P, 2-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586374-54-1P, Methyl 3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586374-56-3P, 2-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile 586374-57-4P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetic acid 586374-58-5P 586374-64-3P, Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoate 586374-66-5P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-67-6P, 2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-68-7P, 1-[2-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-69-8P, 3-Bromo-1-[3-(bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-71-2P, 1-[4-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-73-4P, 1-[3-[(Morpholin-4-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-74-5P, 1-[3-[(Dimethylamino)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-75-6P, 1-[3-[(Isopropylamino)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-76-7P, 1-[3-[(Piperidin-1-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-77-8P, 1-[3-[[2-(Hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-78-9P, 1-[3-[[Bis(2-hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-79-0P, 1-[3-[(Piperazin-1-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-81-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(acetylaminomethyl)benzyl]pyridin-2(1H)-one 586374-82-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methoxycarbonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-83-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-

[(methylsulfonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-84-7P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-
 hydroxyacetyl amino)methyl]benzyl]pyridin-2(1H)-one 586374-85-8P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
 [(aminocarbonylamino)methyl]benzyl]pyridin-2(1H)-one 586374-86-9P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
 [(isopropylamino)methyl]benzyl]pyridin-2(1H)-one 586374-87-0P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(morpholin-4-
 yl)methyl]benzyl]pyridin-2(1H)-one 586374-88-1P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)methyl]benzyl]pyridin-
 2(1H)-one 586374-89-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
 [4-[(piperidin-1-yl)methyl]benzyl]pyridin-2(1H)-one 586374-90-5P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-
 hydroxyethyl)amino)methyl]benzyl]pyridin-2(1H)-one 586374-91-6P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[2-
 hydroxyethyl)amino)methyl]benzyl]pyridin-2(1H)-one 586374-92-7P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(piperazin-1-
 yl)methyl]benzyl]pyridin-2(1H)-one 586374-93-8P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-1-[4-[[[(methoxycarbonyl)amino)methyl]benzyl]p
 yridin-2(1H)-one 586374-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-1-[4-[(acetyl amino)methyl]benzyl]pyridin-2(1H)-one 586374-95-0P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
 [[(methylsulfonyl)amino)methyl]benzyl]pyridin-2(1H)-one 586374-96-1P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
 [[(aminocarbonyl)amino)methyl]benzyl]pyridin-2(1H)-one 586374-97-2P,
 4-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl)methyl]benzoyl]piperazine-1-carboxamide 586374-99-4P,
 N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl)methyl]benzyl]-2-methoxyacetamide 586375-00-0P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-1-[4-[[[(methoxycarbonyl)methyl]carbonyl]ami
 no)methyl]benzyl]pyridin-2(1H)-one 586375-01-1P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-1-[4-[[[(1-hydroxy-1-
 methylethyl)carbonyl]amino)methyl]benzyl]pyridin-2(1H)-one 586375-02-2P
 586375-03-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
 [[[(aminomethyl)carbonyl]amino)methyl]benzyl]pyridin-2(1H)-one
 hydrochloride 586375-04-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
 1-[4-[[[(hydroxymethyl)carbonyl]amino)methyl]benzyl]pyridin-2(1H)-one
 586375-05-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
 [[[(acetyl amino)methyl]carbonyl]amino)methyl]benzyl]pyridin-2(1H)-one
 586375-06-6P, 1-[4-[(4-Acetylpiperazin-1-yl)carbonyl]benzyl]-3-bromo-4-
 [(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-07-7P
 , 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[4-
 (methylsulfonyl)piperazin-1-yl]carbonyl]benzyl]pyridin-2(1H)-one
 586375-11-3P, 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzamide
 586375-12-4P, 1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-
 one 586375-13-5P, Methyl 4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-
 2H-pyridin-1-yl]benzoate 586375-17-9P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one
 586375-24-8P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-(trifluoromethyl)pyridin-
 2(1H)-one 586375-27-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1-
 hydroxy-1-methylethyl)benzyl]-6-methylpyridin-2(1H)-one 586375-28-2P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
 [(methylamino)methyl]benzyl]pyridin-2(1H)-one 586375-33-9P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-hydroxybenzyl)-6-methylpyridin-
 2(1H)-one 586375-34-0P 586375-36-2P, 4-[[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-hydroxy-2-
 methylpropyl)benzamide 586375-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
 1-[4-[(4-hydroxypiperidin-1-yl)carbonyl]benzyl]-6-methylpyridin-2(1H)-one
 586375-38-4P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl)methyl]-N-(2-hydroxyethyl)benzamide 586375-39-5P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-

[(piperazino)carbonyl]benzyl]pyridin-2(1H)-one 586375-40-8P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-aminoethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-41-9P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-aminopropyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-42-0P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(hydroxyamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-43-1P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(methylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-44-2P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-45-3P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(morpholino)carbonyl]benzyl]pyridin-2(1H)-one 586375-46-4P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-47-5P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(cyclopentylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-48-6P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one 586375-49-7P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(1-pyrrolidinylcarbonyl)benzyl]pyridin-2(1H)-one 586375-50-0P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-methylpiperazinyl)carbonyl]benzyl]pyridin-2(1H)-one 586375-51-1P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[[2-(dimethylamino)ethyl]amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-52-2P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-methoxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one 586375-53-3P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]benzyl]pyridin-2(1H)-one 586375-54-4P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[N-(2-methoxyethyl)-N-methylamino]carbonyl]benzyl]pyridin-2(1H)-one 586375-55-5P,
 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)benzamide 586375-56-6P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperazinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-57-7P,
 N-(2-Aminoethyl)-4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide hydrochloride 586375-58-8P,
 N-(3-Aminopropyl)-4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide hydrochloride 586375-59-9P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(hydroxyamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-60-2P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(methylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-61-3P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-62-4P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-63-5P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-64-6P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-65-7P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride 586375-67-9P,
 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586375-68-0P,
 4-(Benzyloxy)-3-bromo-1-[4-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586375-69-1P,
 4-(Benzyloxy)-3-bromo-1-[4-(piperazin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one hydrochloride 586375-70-4P,
 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586375-73-7P,
 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-methylbenzamide 586375-74-8P 586375-75-9P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[2-(2-aminoethyl)amino]carbonyl]benzyl]py

ridin-2(1H)-one hydrochloride 586375-76-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(3-aminopropyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586375-77-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(hydroxyamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
586375-78-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
586375-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-81-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
586375-82-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[bis(2-hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
586375-83-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-84-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
586375-85-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(1-pyrrolidinylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride
586375-86-2P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-methoxyacetamide 586375-87-3P
586375-88-4P 586375-89-5P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-acetoxyacetamide hydrochloride 586375-90-8P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-hydroxy-2-methylpropanamide
586375-91-9P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-1-hydroxycyclopropanecarboxamide
586375-92-0P, N'-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N,N-dimethylurea 586375-94-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(piperazinocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride
586375-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(methylamino)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586375-96-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(morpholinocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride 586376-01-4P, Ethyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate 586376-02-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methylbenzamide 586376-03-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(piperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-04-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(2-aminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-05-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(3-aminopropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-06-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(hydroxyamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-07-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-08-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(morpholino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-09-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[[(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-10-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(piperidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride

586376-11-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
 [(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
 586376-12-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
 [(pyrrolidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
 586376-13-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-
 methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
 586376-14-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-
 dimethylaminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
 586376-15-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-
 methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
 586376-16-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[N-(2-
 dimethylaminoethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
 hydrochloride 586376-17-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
 1-[3-[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
 hydrochloride 586376-18-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
 1-[3-[N-(2-methoxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
 hydrochloride 586376-19-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-2-oxo-2H-pyridin-1-yl]benzamide 586376-22-9P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-
 methylpyridin-2(1H)-one 586376-26-3P, N-[3-[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]benzyl]methanesulfonamide 586376-27-4P, N-[3-[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]acetamide
 586376-28-5P 586376-29-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-methoxyacetamide 586376-30-9P,
 N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]benzyl]-2-acetoxyacetamide hydrochloride 586376-31-0P,
 N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]benzyl]-2-aminoacetamide hydrochloride 586376-32-1P,
 N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]benzyl]-2-hydroxyacetamide hydrochloride 586376-33-2P,
 N'-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]benzyl]-N,N-dimethylurea 586376-35-4P, N-[3-[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-N'-methylurea
 586376-36-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
 [(morpholinocarbonyl)amino]methyl]phenyl]pyridin-2(1H)-one
 586376-37-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]benzyl]urea 586376-38-7P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[3-[(dimethylamino)methyl]phenyl]-6-methylpyridin-
 2(1H)-one 586376-41-2P, N-[4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
 yl]benzyl]acetamide 586376-44-5P, N-[4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-
 pyridin-1-yl]benzyl]-2-hydroxyacetamide 586376-45-6P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(morpholin-4-
 yl)ethyl]pyridin-2(1H)-one 586376-47-8P, Ethyl 3-[4-(benzyloxy)-3-bromo-
 2-oxo-2H-pyridin-1-yl]propanoate 586376-48-9P, Methyl
 3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoate 586376-50-3P,
 N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,6-
 difluorobenzamide 586376-60-5P, 3-Bromo-1-(4-bromo-2,6-difluorophenyl)-4-
 [(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-68-3P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2,4,6-
 trifluorophenyl)pyridin-2(1H)-one 586376-72-9P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-
 2(1H)-one 586376-76-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
 (hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one 586376-78-5P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-
 yl)phenyl]-6-methylpyridin-2(1H)-one 586376-82-1P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-
 methylpyridin-2(1H)-one 586376-83-2P, 3-Chloro-4-[(2,4-
 difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-
 methylpyridin-2(1H)-one 586376-87-6P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-difluorophenyl]-6-

methylpyridin-2(1H)-one 586376-89-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586376-90-1P, 3-Bromo-1-(3,5-dibromo-2,6-difluoro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-93-4P, 2-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorophenoxy]acetamide 586376-97-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(2-hydroxyethoxy)phenyl]-6-methylpyridin-2(1H)-one 586376-98-9P, 3-Bromo-1-(2,6-difluorophenyl)-4-[[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one 586377-04-0P, 3-Chloro-1-(2,6-difluorophenyl)-4-[[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one 586377-06-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methyl-N-[2-(morpholin-4-yl)ethyl]benzamide 586377-13-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-methoxyethyl)amino]carbonyl]-2-methylphenylpyridin-2(1H)-one 586377-15-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(dimethylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-17-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-hydroxyethyl)amino]carbonyl]-2-methylphenylpyridin-2(1H)-one 586377-18-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(methylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-19-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[N-(2-hydroxyethyl)-N-methylamino]carbonyl]-2-methylphenylpyridin-2(1H)-one 586377-21-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-yl)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-23-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholinocarbonyl)-2-methylphenyl]pyridin-2(1H)-one 586377-24-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[N-(2-methoxyethyl)-N-methylamino]carbonyl]-2-methylphenylpyridin-2(1H)-one 586377-26-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(aminocarbonyl)-2-methylphenyl]pyridin-2(1H)-one 586377-28-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586377-30-2P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-2-methylbenzamide 586377-33-5P 586377-34-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-2-methylbenzamide 586377-35-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzamide 586377-39-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(methylamino)methyl]phenyl]pyridin-2(1H)-one hydrochloride 586377-42-6P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluoro-N,N-dimethylbenzamide 586377-44-8P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-methoxybenzonitrile 586377-47-1P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]urea 586377-48-2P, 2-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]amino]-1,1-dimethyl-2-oxoethyl acetate 586377-49-3P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]acetamide 586377-50-6P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-methoxyacetamide 586377-51-7P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-furamide 586377-52-8P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-1H-imidazole-4-carboxamide 586377-53-9P 586377-54-0P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-3-hydroxy-3-methylbutanamide 586377-55-1P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-1-hydroxycyclopropanecarboxamide 586377-56-2P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-hydroxy-2-methylpropanamide 586377-57-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzonitrile 586377-62-0P, 3-Bromo-1-(3-fluorobenzyl)-4-(1-

phenylethoxy)pyridin-2(1H)-one 586377-63-1P, 3-Bromo-1-(3-fluorobenzyl)-
 4-[(E)-2-(4-fluorophenyl)ethenyl]pyridin-2(1H)-one 586377-64-2P,
 4-(Benzyloxy)-3-bromo-1-[(6-fluoropyridin-3-yl)methyl]pyridin-2(1H)-one
 586377-65-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-
 methylpyridin-2(1H)-one 586377-68-6P, 3-Bromo-1-(2,6-dimethylphenyl)-4-
 [(4-fluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-69-7P,
 3-Bromo-1-(2,6-dimethylphenyl)-6-methyl-4-[(2,4,6-
 trifluorobenzyl)oxy]pyridin-2(1H)-one 586377-70-0P, 3-Bromo-4-[(2,6-
 difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-methylpyridin-2(1H)-one
 586377-71-1P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-fluorobenzyl)oxy]-6-
 methylpyridin-2(1H)-one 586377-73-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-
 [(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-74-4P,
 3-Bromo-1-(2,6-dichlorophenyl)-4-[(2,6-difluorobenzyl)oxy]-6-methylpyridin-
 2(1H)-one 586377-75-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-methoxy-
 6-methylphenyl)-6-methylpyridin-2(1H)-one 586377-78-8P,
 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-
 dichlorobenzenesulfonamide 586377-83-5P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-
 methylpyridin-2(1H)-one 586377-87-9P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[2,4-difluoro-6-[(2-hydroxyethyl)(methyl)amino]phenyl]-
 6-methylpyridin-2(1H)-one 586377-91-5P, N-[2-[[[3-Bromo-1-(2,6-
 difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
 fluorobenzyl]urea 586377-92-6P, Methyl [2-[[[3-bromo-1-(2,6-
 difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
 fluorobenzyl]carbamate 586377-93-7P, N-[2-[[[3-Bromo-1-(2,6-
 difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
 fluorobenzyl]-2-hydroxyacetamide 586377-94-8P, Ethyl
 [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
 yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-97-1P, Isobutyl
 [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
 yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-98-2P, Cyclopropylmethyl
 [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
 yl]oxy]methyl]-5-fluorobenzyl]carbamate 586378-07-6P,
 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-
 difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride
 586378-09-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-
 ylmethyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586378-11-2P
 586378-17-8P 586378-19-0P, Methyl 4-[[3-bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-
 carboxylate trifluoroacetate 586378-21-4P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-1-[(2-hydroxypyrimidin-4-yl)methyl]-6-methylpyridin-
 2(1H)-one trifluoroacetate 586378-23-6P, 4-[[3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-
 carboxamide trifluoroacetate 586378-24-7P, Methyl [4-[[3-bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidin-2-
 yl]methylcarbamate 586378-25-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-28-1P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyrazin-2-ylmethyl)pyridin-
 2(1H)-one 586378-33-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-
 [(dimethylamino)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
 trifluoroacetate 586378-36-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-
 [(2-hydroxyethyl)(methyl)amino]methyl]pyrazin-2-yl]methyl]-6-
 methylpyridin-2(1H)-one trifluoroacetate 586378-37-2P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-
 yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one 586378-41-8P,
 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]methyl]-N-(2-hydroxyethyl)-N-methylpyrazine-2-carboxamide
 586378-42-9P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]methyl]-N-(2,3-dihydroxypropyl)pyrazine-2-carboxamide
 586378-43-0P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]methyl]-N-(2-hydroxyethyl)pyrazine-2-carboxamide

586378-44-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(methoxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
 586378-45-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(2-methoxyethoxy)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
 586378-46-3P, Carbamic acid [5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazin-2-yl]methyl ester
 586378-48-5P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-methylpyridin-2(1H)-one
 586378-51-0P, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-methylpyridin-2(1H)-one
 586378-52-1P, 1-Benzyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
 586378-54-3P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-4-fluorobenzamide
 586378-57-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one
 586378-59-8P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)amino]-6-methylpyridin-2(1H)-one
 586378-61-2P, 3-Bromo-1-(cyclopropylmethyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
 586378-63-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one
 586378-65-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
 586378-67-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-2-ylmethyl)pyridin-2(1H)-one
 586378-70-3P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one
 586378-71-4P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one
 586378-72-5P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one
 586378-73-6P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one
 586378-74-7P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one
 586378-75-8P, 3-Bromo-4-[(2-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one
 586378-76-9P, 3-Bromo-4-[(2,4,5-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one
 586378-77-0P, 3-Bromo-4-[(4-chloro-2-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one
 586378-78-1P, 3-Bromo-4-[(2-chloro-4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one
 586378-79-2P, 3-Bromo-4-[(2,6-difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one
 586378-80-5P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methylpyridin-2(1H)-one
 586378-81-6P, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methylpyridin-2(1H)-one
 586378-82-7P, 3-Bromo-4-[(2,4,5-trifluorobenzyl)oxy]-6-methyl-1-(pyridin-2-yl)methylpyridin-2(1H)-one
 586378-83-8P, 3-Bromo-4-[2-(4-fluorophenyl)ethyl]-6-methyl-1-(pyridin-3-yl)methylpyridin-2(1H)-one
 586378-86-1P, 3-Bromo-4-[2-(4-fluorophenyl)ethyl]-6-methyl-1-(pyridin-4-yl)methylpyridin-2(1H)-one
 586378-87-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
 586378-91-8P
 , 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-4-[(2,4,6-trifluorobenzyl)oxy]pyridin-2(1H)-one trifluoroacetate
 586378-93-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-methyl-4-(methylamino)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate
 586378-95-2P
 586378-97-4P
 586378-98-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one
 586379-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(methylamino)methyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one trifluoroacetate
 586379-03-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
 586379-04-6P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylpyrazine-2-carboxamide
 586379-05-7P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-methylpyrazine-2-carboxamide
 586379-06-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(1-hydroxy-1-methylethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
 586379-07-9P,

5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-methoxyethyl)pyrazine-2-carboxamide 586379-08-0P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-(morpholin-4-ylcarbonyl)pyrazin-2-yl]methyl]pyridin-2(1H)-one 586379-09-1P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(4-hydroxypiperidin-1-yl)carbonyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one 586379-11-5P,
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(3-hydroxy-2,2-dimethylpropyl)pyrazine-2-carboxamide
 586379-12-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2,2,2-trifluoroethyl)pyrazine-2-carboxamide
 586379-13-7P, 1-Allyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-15-9P, 1-Allyl-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-17-1P, Methyl (2E)-4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenate
 586379-18-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-prop-2-ynylpyridin-2(1H)-one 586379-21-7P, 4-[(2,4-Difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-23-9P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-24-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-[(dimethylamino)methyl]-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-29-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-one 586379-31-9P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(dimethylamino)methyl]pyridin-2(1H)-one 586379-32-0P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(morpholin-4-ylmethyl)pyridin-2(1H)-one 586379-33-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[[2-methoxyethyl]amino]methyl]pyridin-2(1H)-one 586379-34-2P,
 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carboxylic acid 586379-35-3P, Methyl 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-methylbenzoate 586379-38-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2-methyl-4-carboxyphenyl)pyridin-2(1H)-one 586379-39-7P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-(hydroxymethyl)phenyl]pyridin-2(1H)-one 586379-40-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-[[2-methoxyethyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586379-41-1P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-[(methylamino)carbonyl]phenyl]pyridin-2(1H)-one 586379-46-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-47-7P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-chlorobenzoate 586379-50-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-chlorobenzoic acid 586379-54-6P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-57-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(dimethylamino)methyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one hydrochloride 586379-59-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(isopropylamino)methyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one hydrochloride 586379-60-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-4-methylbenzamide 586379-65-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[[2-methoxyethyl]amino]carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-67-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(dimethylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-68-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(morpholinocarbonyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-69-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1-hydroxy-1-methylethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-71-7P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-76-2P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-

1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-78-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[[3-(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one 586379-79-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[[4-fluoro-2-(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one 586379-80-8P, 3-Bromo-4-[(4-chloro-2-fluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-81-9P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-6-methyl-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 586379-83-1P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-85-3P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate 586379-87-5P, 3-Chloro-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586379-88-6P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-91-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-93-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586380-00-9P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-methylbenzamide 586380-01-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one 586380-02-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-03-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(4-methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one 586380-04-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586380-05-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2-methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-06-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one 586380-07-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(3-hydroxypropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-08-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2,3-dihydroxypropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-09-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2-hydroxy-1,1-dimethylethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-10-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(piperazinocarbonyl)phenyl]pyridin-2(1H)-one 586380-17-8P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxy-N-methylbenzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586380-18-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methoxy-N,N-dimethylbenzamide 586380-21-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]benzamide 586380-22-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(acetylaminomethyl]phenyl]pyridin-2(1H)-one 586380-23-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(methoxyacetylaminomethyl]phenyl]pyridin-2(1H)-one 586380-24-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(methylsulfonylamino)methyl]phenyl]pyridin-2(1H)-one 586380-25-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(aminocarbonylamino)methyl]phenyl]pyridin-2(1H)-one 586380-27-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[(methoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one

586380-28-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[trifluoromethyl]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-29-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[(isopropoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-30-5P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[ethylamino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-31-6P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[tetrahydrofuran-3-yloxy]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-
 one 586380-32-7P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-
 2-[[propoxycarbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-33-8P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[allyloxy]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-34-9P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[propargyloxy]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-35-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[tert-butoxy]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-36-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[[tert-butyl]amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-37-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[(propylsulfonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-38-3P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [(ethylsulfonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-39-4P,
 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[isopropylamino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-40-7P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[methoxymethyl]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-41-8P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[methylamino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
 586380-42-9P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
 [[[[N-methyl-N-(tert-butyl)amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-
 2(1H)-one 586380-43-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-
 fluoro-2-[[[(cyclopropylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-
 2(1H)-one 586380-44-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-
 fluoro-2-[[[[2,2,2-trifluoroethyl]amino]carbonyl]amino]methyl]benzyl]oxy]
 pyridin-2(1H)-one 586380-45-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-
 4-[[4-fluoro-2-[[[[cyclopropylmethyl]amino]carbonyl]amino]methyl]benzyl]o
 xy]pyridin-2(1H)-one 586380-46-3P, 3-Chloro-1-(2,6-difluorophenyl)-6-
 methyl-4-[[4-fluoro-2-[[[(2,2-dimethylpropylamino)carbonyl]amino]methyl]be
 nzyl]oxy]pyridin-2(1H)-one 586380-47-4P, 3-Chloro-1-(2,6-difluorophenyl)-
 6-methyl-4-[[4-fluoro-2-[[[(dimethylamino)carbonyl]amino]methyl]benzyl]oxy
]pyridin-2(1H)-one 586380-48-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-
 [[5-(1-hydroxy-1-methylethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-
 one 586380-50-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-
 (hydroxymethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-one
 586380-52-1P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]methyl]-N-(2-hydroxyethyl)-N-methylnicotinamide
 586380-55-4P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
 pyridin-1-yl]methyl]-N-(2-hydroxyethyl)nicotinamide 586380-56-5P,
 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
 yl]methyl]-N,N-dimethylnicotinamide 586380-57-6P, 3-Bromo-4-[(2,4-
 difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-
 one 586380-66-7P, Carbamic acid [5-bromo-4-[(2,4-difluorobenzyl)oxy]-1-
 (2,6-difluorophenyl)-2-methyl-6-oxo-1,6-dihydropyridin-3-yl]methyl ester
 586380-68-9P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-
 methyl-6-oxo-1,6-dihydropyridine-3-carbonitrile 586380-69-0P,
 4-(Benzyloxy)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-
 one 586380-70-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
 difluorophenyl)-6-methyl-5-(oxiran-2-yl)pyridin-2(1H)-one 586380-71-4P,
 4-(Benzylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-
 2(1H)-one 586380-72-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
 difluorophenyl)-6-methyl-5-((E)-2-phenylethenyl)pyridin-2(1H)-one

586380-74-7P, 4-(Allylamino)-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586380-76-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-5'-(1-hydroxy-1-methylethyl)-6-methyl-2H-1,2'-bipyridin-2-one 586380-77-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(furyl-2-ylmethyl)-6-methylpyridin-2(1H)-one 586380-78-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(thien-2-ylmethyl)pyridin-2(1H)-one 586380-79-2P, 3-Bromo-1-(2,6-difluorophenyl)-4-(furyl-2-ylmethoxy)-6-methylpyridin-2(1H)-one 586380-80-5P, 3-Bromo-1-[2-fluoro-6-(furyl-3-ylmethoxy)phenyl]-4-(furyl-3-ylmethoxy)-6-methylpyridin-2(1H)-one 586380-81-6P, 3-Bromo-1-[2-fluoro-6-(thien-3-ylmethoxy)phenyl]-6-methyl-4-(thien-3-ylmethoxy)pyridin-2(1H)-one 586380-86-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-(1-hydroxy-1-methylethyl)-N-methylbenzamide 586380-89-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzamide 586380-91-8P 586380-92-9P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]propanamide 586380-93-0P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-N',N'-dimethylurea 586380-94-1P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-2-hydroxyacetamide 586380-95-2P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-2-hydroxy-2-methylpropanamide 586380-96-3P 586380-97-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzamide 586380-98-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-methylbenzamide 586380-99-6P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N,N-dimethylbenzamide 586381-00-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-[(4-methylpiperazin-1-yl)carbonyl]phenyl]-6-methylpyridin-2(1H)-one 586381-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586381-02-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one 586381-03-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[2-hydroxy-2-methylpropyl]amino]carbonyl]phenyl]pyridin-2(1H)-one 586381-09-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylbenzamide 586381-10-4P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)benzamide 586381-11-5P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide 586381-14-8P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide 586381-17-1P, 1-(3-Aminobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-18-2P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide 586381-19-3P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]-2-hydroxyacetamide 586381-20-6P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]-2-acetoxyacetamide 586381-21-7P 586381-22-8P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide 586381-23-9P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-methylurea 586381-24-0P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-(2-hydroxy-2-methylpropyl)urea 586381-25-1P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]piperidine-1-carboxamide 586381-26-2P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]morpholine-4-carboxamide 586381-27-3P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]piperazine-1-carboxamide hydrochloride 586381-28-4P, N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-

yl)methyl]benzyl]-N'-(2-hydroxyethyl)urea 586381-29-5P,
 N'-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl]-N,N-dimethylurea 586381-30-8P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl]-4-hydroxypiperidine-1-carboxamide 586381-31-9P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N,N-dimethylbenzenesulfonamide 586381-32-0P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-hydroxyethyl)benzenesulfonamide 586381-35-3P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide 586381-38-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-3-ylmethyl)-1H-pyridin-2-one 586381-43-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-1,3-dihydroindol-2-one 586381-45-5P, N-[5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]pyrazin-2-yl)methyl]-N-methylmethanesulfonamide 586381-46-6P, Methyl [5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]pyrazin-2-yl)methyl(methyl)carbamate 586381-47-7P 586381-48-8P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-hydroxy-2-methylpropyl)pyrazine-2-carboxamide 586381-50-2P, 1-[(5-Aminopyrazin-2-yl)methyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate 586381-52-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(3-methyl-1,2,4-triazin-6-yl)methyl]pyridin-2(1H)-one trifluoroacetate 586381-54-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-yl)-6-methylpyridin-2(1H)-one 586381-56-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one 586381-65-9P, Methyl [2-[[[3-bromo-1-[5-[[2-hydroxyethyl]amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-66-0P, Methyl [2-[[[3-bromo-1-[5-[[2-hydroxy-2-methylpropyl]amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-67-1P, Methyl [2-[[[3-bromo-1-[5-[[2-methoxyethyl]amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-68-2P, O-Methyl [2-[[[1-[5-(aminocarbonyl)-2-methylphenyl]-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-69-3P, N-[2-[[[3-Chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]-N'-phenylurea 586381-70-6P, (Thien-3-yl)methyl [2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-71-7P, Ethyl [2-[[[3-bromo-6-methyl-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-75-1P 586381-83-1P, Methyl 3-[6-[(acetyloxy)methyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-87-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-88-6P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-4-methylbenzamide 586381-90-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-1-yl]-4-methylbenzamide 586381-91-1P, [5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-6-oxo-1,6-dihydropyridin-2-yl)methyl acetate 586381-92-2P, (2E)-4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methyl-2-butenamide 586381-97-7P 586381-98-8P 586381-99-9P 586382-00-5P 586382-01-6P, Carbamic acid 2-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-[(methylamino)carbonyl]benzyl ester 586382-06-1P, Carbamic acid 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl ester 586382-07-2P, N-[4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl]-2-hydroxyacetamide 586382-09-4P, N-[4-[[3-Chloro-4-

[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl]-1-hydroxycyclopropanecarboxamide 586382-10-7P, Carbamic acid
 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzyl ester 586382-11-8P, (S)-2-[[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]phenyl]amino]-1-methyl-2-oxoethyl acetate 586382-12-9P, 2-[[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]phenyl]amino]-1,1-dimethyl-2-oxoethyl acetate 586382-13-0P, [1-[3-(Aminocarbonyl)phenyl]-5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxo-1,6-dihydropyridin-2-yl)methyl acetate 586382-20-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-5-yl)methyl]pyridin-2(1H)-one 586382-22-1P, Ethyl [2-[[[3-bromo-1-[5-[(2-hydroxyethyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy)methyl]-5-fluorobenzyl]carbamate 586382-24-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1H-imidazol-2-yl)-2-methylphenyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586382-25-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(5-hydroxy-1H-pyrazol-3-yl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586382-27-6P 586382-28-7P 586382-29-8P, Methyl 4-[[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-yl)methyl]benzoate 586382-32-3P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-2-furamide 586382-34-5P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furamide 586382-38-9P, 1-[3,5-Bis(hydroxymethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-43-6P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]isophthalamide 586382-44-7P, 1-[3,5-Bis(1-hydroxy-1-methylethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-45-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586382-47-0P, 1-(5-Amino-2-fluorophenyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride 586382-49-2P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-2-hydroxyacetamide 586382-51-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-2-hydroxy-2-methylpropanamide 586382-53-8P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluoro-N,N-dimethylbenzamide 586382-55-0P 586382-56-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-indol-5-yl)methyl]-6-methylpyridin-2(1H)-one 586382-57-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methoxyacetyl)-2,3-dihydro-1H-indol-5-yl)methyl]-6-methylpyridin-2(1H)-one 586382-58-3P
 , 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N,N-dimethylindoline-1-carboxamide 586382-59-4P 586382-60-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methoxyacetyl)-2,3-dihydro-1H-indol-5-yl)methyl]pyridin-2(1H)-one 586382-61-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-N,N-dimethylindoline-1-carboxamide 586382-62-9P, 1-Benzyl-4-(benzyloxy)-3-bromopyridin-2(1H)-one 586382-63-0P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586382-64-1P, 4-(Benzyloxy)-3-bromo-1-(4-fluorobenzyl)pyridin-2(1H)-one 586382-65-2P, 4-(Benzyloxy)-3-bromo-1-[4-(methylthio)benzyl]pyridin-2(1H)-one 586382-66-3P, 1-Benzyl-4-(benzyloxy)-3-chloropyridin-2(1H)-one 586382-67-4P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-fluorobenzyl)pyridin-2(1H)-one 586382-68-5P, 1-Benzyl-3-bromo-4-[(4-chlorobenzyl)oxy]pyridin-2(1H)-one 586382-69-6P, 3-Bromo-1-(4-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-2(1H)-one 586382-70-9P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-[2-(phenylthio)ethyl]pyridin-2(1H)-one 586382-71-0P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(2-phenylethyl)pyridin-2(1H)-one 586382-72-1P 586382-73-2P, 1-Benzyl-2-oxo-4-phenoxy-1,2-dihydropyridine-3-carboxaldehyde 586382-74-3P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-methoxybenzyl)pyridin-2(1H)-one 586382-75-4P, 3-Bromo-4-[(4-

fluorobenzyl)oxy]-1-(3-phenylpropyl)pyridin-2(1H)-one 586382-76-5P,
1-Benzyl-4-(benzyloxy)-3-(hydroxymethyl)pyridin-2(1H)-one 586382-77-6P,
3-Bromo-1-(4-methylbenzyl)-4-[(4-methylbenzyl)oxy]pyridin-2(1H)-one
586382-78-7P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-
2(1H)-one 586382-79-8P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-
fluorobenzyl)oxy]pyridin-2(1H)-one 586382-80-1P, 5-Bromo-1-(2-chloro-6-
fluorobenzyl)-3-methylpyridin-2(1H)-one 586382-81-2P,
1-Benzyl-4-(benzyloxy)-2-oxo-1,2-dihydropyridine-3-carboxaldehyde
586382-82-3P, 1-Benzyl-4-chloro-2-oxo-1,2-dihydropyridine-3-carboxaldehyde
586382-83-4P, 1-Benzyl-4-hydroxy-2-oxo-1,2-dihydropyridine-3-
carboxaldehyde 586382-84-5P, 1-Benzyl-4-(benzyloxy)-3-methylpyridin-
2(1H)-one 586382-85-6P, 4-(Benzyloxy)-1-(4-fluorobenzyl)pyridin-2(1H)-
one 586382-86-7P, 1-Benzyl-4-(benzyloxy)-3,5-dibromopyridin-2(1H)-one
586382-87-8P, 1-Benzyl-3-bromo-4-(3-phenylpropyl)pyridin-2(1H)-one
586382-88-9P, 1-Benzyl-3-methyl-4-(2-phenylethyl)pyridin-2(1H)-one
586382-89-0P, 1-Benzyl-3-methyl-4-(3-phenylpropyl)pyridin-2(1H)-one
586382-90-3P, 1-Benzyl-4-(benzylthio)-3-methylpyridin-2(1H)-one
586382-91-4P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate
586382-92-5P, 6-(Benzyloxy)-1-methyl-2-oxo-1,2-dihydropyridine-3-
carbonitrile 586382-93-6P, 3-Benzoyl-6-(benzyloxy)-1-methylpyridin-2(1H)-
one 586382-94-7P, 3-Benzyl-6-(benzyloxy)-1-methylpyridin-2(1H)-one
586382-95-8P, 1-Benzyl-4-(benzylthio)pyridin-2(1H)-one 586382-96-9P,
4-Amino-1-benzylpyridin-2(1H)-one 586382-97-0P, 4-[(2,6-
Dichlorobenzyl)oxy]pyridine-1-oxide 586382-98-1P, 3-Bromo-1-(3-
fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one 586382-99-2P
586383-00-8P, 1-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-3-chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-01-9P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-
2,3-dihydro-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-02-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-2,3-
dihydro-1H-indol-5-yl]pyridin-2(1H)-one 586383-03-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-2,3-dihydro-
1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-04-2P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-2,3-
dihydro-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-05-3P,
5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]indoline-1-carboxamide 586383-06-4P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-2,3-dihydro-1H-indol-5-
yl]pyridin-2(1H)-one 586383-07-5P, 1-(1-Acetyl-1H-indol-5-yl)-3-chloro-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-08-6P
586383-09-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-
methylpropanoyl)-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-10-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
indol-5-yl]pyridin-2(1H)-one 586383-11-1P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-indol-5-yl]-6-
methylpyridin-2(1H)-one 586383-12-2P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-indol-5-yl]-6-
methylpyridin-2(1H)-one 586383-13-3P, 5-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-indole-1-
carboxamide 586383-14-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[1-(methylsulfonyl)-1H-indol-5-yl]pyridin-2(1H)-one 586383-15-5P,
1-(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)-3-chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-16-6P
586383-17-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-
methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one
586383-18-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-
methylglycyl)-2,3-dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one
586383-20-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-
hydroxypropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one
586383-21-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-
methylbutanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one

586383-22-4P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide 586383-23-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methanesulfonyl)-2,3-dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one 586383-24-6P, 1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-25-7P 586383-26-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-27-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]pyridin-2(1H)-one 586383-28-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-29-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-one 586383-30-4P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586383-31-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methanesulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]pyridin-2(1H)-one 586383-32-6P, 1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-33-7P 586383-34-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-35-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one 586383-36-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-37-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-one 586383-38-2P, 7-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586383-39-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methanesulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one 586383-40-6P, 1-(1-Acetyl-1H-benzimidazol-5-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-41-7P 586383-42-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-43-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-44-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-45-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-47-3P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-benzimidazole-1-carboxamide 586383-48-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methanesulfonyl)-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-49-5P, 3-Chloro-1-(1,3-diacetyl-2,3-dihydro-1H-benzimidazol-5-yl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-50-8P 586383-51-9P, 1-[3-Acetyl-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-52-0P, 1-[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-53-1P, 1-[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-54-2P, 1-[3-Acetyl-1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-55-3P, 3-Acetyl-5-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586383-56-4P 586383-57-5P 586383-58-6P 586383-59-7P 586383-60-0P
586383-61-1P 586383-62-2P 586383-63-3P 586383-64-4P,
1-[1-Acetyl-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
586383-65-5P, 1-[1,3-Bis(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-66-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-67-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-68-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-69-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-70-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-71-3P, 1-[1-Acetyl-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-72-4P 586383-73-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-74-6P, 1-[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-75-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-76-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-77-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-78-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(N-methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586383-79-1P, 1-[1-Acetyl-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-80-4P 586383-81-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-82-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-83-7P, 1-[1,3-Bis(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-84-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-85-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-86-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-87-1P, 1-[1-Acetyl-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-88-2P 586383-89-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-

benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-90-6P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-91-7P, 1-[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-92-8P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-93-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-94-0P, 3-Acetyl-6-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-95-1P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-96-2P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-97-3P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-98-4P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-99-5P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-benzimidazole-1,3(2H)-dicarboxamide 586384-00-1P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-01-2P, 1-[1-Acetyl-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-02-3P 586384-03-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-04-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586384-05-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-06-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586384-07-8P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-08-9P, 1-[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-09-0P, 1-[3-Acetyl-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-10-3P, 1-(1-Acetyl-1H-pyrrol-3-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-11-4P 586384-12-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-pyrrol-3-yl]-6-methylpyridin-2(1H)-one 586384-13-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-pyrrol-3-yl]pyridin-2(1H)-one 586384-14-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrrol-3-yl]-6-methylpyridin-2(1H)-one 586384-15-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrrol-3-yl]-6-methylpyridin-2(1H)-one 586384-16-9P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrrole-1-carboxamide 586384-17-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-pyrrol-3-yl]pyridin-2(1H)-one 586384-18-1P, 1-(1-Acetyl-1H-imidazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-19-2P 586384-20-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-imidazol-4-yl]-6-methylpyridin-2(1H)-one 586384-21-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-

imidazol-4-yl]pyridin-2(1H)-one 586384-22-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-imidazol-4-yl]-6-methylpyridin-2(1H)-one 586384-23-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-imidazol-4-yl]-6-methylpyridin-2(1H)-one 586384-24-9P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-imidazole-1-carboxamide 586384-25-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-imidazol-4-yl] pyridin-2(1H)-one 586384-26-1P, 1-(1-Acetyl-1H-pyrazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-27-2P 586384-28-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-pyrazol-4-yl]-6-methylpyridin-2(1H)-one 586384-29-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-pyrazol-4-yl]pyridin-2(1H)-one 586384-30-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrazol-4-yl]-6-methylpyridin-2(1H)-one 586384-31-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrazol-4-yl]-6-methylpyridin-2(1H)-one 586384-32-9P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrazole-1-carboxamide 586384-33-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridin-2(1H)-one 586384-34-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-isoquinolin-7-yl-6-methylpyridin-2(1H)-one 586384-35-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(isoquinolin-6-ylmethyl)pyridin-2(1H)-one 586384-36-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-indol-2-one 586384-37-4P, 1-[(1-Acetyl-2,3-dihydro-1H-indol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-38-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-39-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-40-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-41-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-42-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]indoline-1-carboxamide 586384-43-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methylsulfonyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-44-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-one 586384-45-4P, 1-[(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-46-5P 586384-47-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-48-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-49-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-50-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-51-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-isoindole-2-carboxamide 586384-52-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-53-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-54-5P, 1-[(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-55-6P 586384-56-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-57-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-

yl)methyl]pyridin-2(1H)-one 586384-58-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-59-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-60-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586384-61-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-2(1H)-one 586384-62-5P, 1-[[2-Acetyl-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-63-6P 586384-64-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586384-65-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586384-66-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586384-67-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586384-68-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide 586384-69-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one 586384-70-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-71-6P, 1-[(1-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-72-7P 586384-73-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-74-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-75-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-76-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-77-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-78-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-79-4P, 1-[(3-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-80-7P, 3-Chloro-1-[(1,3-diacetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-81-8P 586384-82-9P, 1-[[3-Acetyl-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-83-0P, 1-[[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-84-1P, 1-[[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-85-2P, 1-[[3-Acetyl-1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-86-3P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586384-87-4P, 1-[[3-Acetyl-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-88-5P 586384-89-6P 586384-90-9P 586384-91-0P 586384-92-1P 586384-93-2P 586384-94-3P 586384-95-4P 586384-96-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-97-6P, 1-[[1-Acetyl-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]

pyridin-2(1H)-one 586384-98-7P 586384-99-8P, 1-[[1,3-Bis(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-00-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-01-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-02-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-03-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-04-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-05-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-06-0P, 1-[[1-Acetyl-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-07-1P 586385-08-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-09-3P, 1-[[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-10-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-11-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-12-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-13-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-14-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-15-1P, 1-[[1-Acetyl-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-16-2P 586385-17-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-18-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-19-5P, 1-[[1,3-Bis(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-20-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-21-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-22-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-23-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-24-2P, 1-[[1-Acetyl-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-25-3P 586385-26-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-27-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-28-6P, 3-Chloro-4-[(2,4-

difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-29-7P,
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586385-30-0P, 1-[[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]
 pyridin-2(1H)-one 586385-31-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-32-2P,
 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-33-3P,
 3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-34-4P,
 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586385-35-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586385-36-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586385-37-7P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586385-38-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1H-benzimidazole-1,3(2H)-dicarboxamide
 586385-39-9P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586385-40-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
 586385-41-3P, 1-[[1-Acetyl-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586385-42-4P 586385-43-5P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
 586385-44-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
 586385-45-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
 586385-46-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
 586385-47-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586385-48-0P, 1-[[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
 586385-49-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-50-4P,
 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-51-5P
 586385-52-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586385-53-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
 586385-54-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586385-55-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586385-56-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586385-57-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
 586385-58-2P, 1-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-59-3P,

1,3-Diacetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-60-6P
 586385-61-7P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-62-8P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-63-9P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-64-0P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-65-1P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-66-2P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methanesulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-67-3P 586385-68-4P 586385-69-5P 586385-70-8P 586385-71-9P 586385-72-0P 586385-73-1P 586385-74-2P 586385-75-3P 586385-76-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-77-5P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-78-6P 586385-79-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-80-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 586385-81-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-82-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-83-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-84-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(methanesulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-85-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-86-6P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-87-7P 586385-88-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-89-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-90-2P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-91-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-92-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-93-5P,

5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-1-(methanolsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
 586385-94-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586385-95-7P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586385-96-8P 586385-97-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586385-98-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
 586385-99-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-00-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-01-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586386-02-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-1-(methanolsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-03-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-04-1P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-05-2P 586386-06-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-07-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-08-5P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-09-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586386-10-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1-(methanolsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-11-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586386-12-1P, 3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586386-13-2P 586386-14-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586386-15-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586386-16-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586386-17-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586386-18-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-1H-benzimidazole-1,3(2H)-dicarboxamide
 586386-19-8P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methanolsulfonyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
 586386-20-1P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methanolsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-21-2P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methanolsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-22-3P 586386-23-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-one

oxo-2H-pyridin-1-yl)methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-24-5P,
 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(N-methylglycyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-25-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-26-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
 586386-27-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-3-(methylsulfonyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-28-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl)methyl]-1,3-bis(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-30-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-fluorophenyl)ethynyl]-6-methylpyridin-2(1H)-one 586386-31-4P,
 3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzaldehyde 586386-32-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-difluorophenyl]-6-methylpyridin-2(1H)-one 586386-33-6P,
 4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-hydroxyethyl)(methyl)amino]phenyl]-6-methylpyridin-2(1H)-one 586386-34-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(hydroxymethyl)-2-methoxyphenyl]-6-methylpyridin-2(1H)-one 586386-35-8P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-yl)carbonyl]phenyl]pyridin-2(1H)-one 586386-36-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-(dimethylamino)ethyl]benzamide 586386-37-0P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)benzamide 586386-38-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-(dimethylamino)ethyl]-N-methylbenzamide 586386-39-2P,
 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-N-methylbenzamide 586386-40-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-N-methylbenzamide 586386-41-6P, 4-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-methylbenzoic acid 586386-42-7P, Methyl
 [2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-3,5-difluorobenzyl]carbamate 586386-43-8P,
 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-44-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(ethoxyamino)methyl]pyridin-2(1H)-one 586386-45-0P, N-(3-Aminopropyl)-4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzamide
 hydrochloride 586386-46-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-ylmethyl)pyridin-2(1H)-one 586386-47-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-methylpyridin-2(1H)-one hydrochloride 586386-48-3P, N-(2-Aminoethyl)-4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl)methyl]benzamide hydrochloride 586386-49-4P, N-(2-Aminoethyl)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide
 586386-50-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperazin-1-ylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586386-51-8P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(dimethylamino)methyl]pyridin-2(1H)-one 586386-52-9P 586386-53-0P,
 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-isopropylbenzamide 586386-54-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholin-4-ylcarbonyl)benzyl]-1H-pyridin-2-one
 586386-55-2P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-bis(2-hydroxyethyl)benzamide 586386-56-3P,
 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-hydroxybenzamide 586386-57-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-hydroxymethylbenzyl)-6-methyl-1H-pyridin-2-one

586386-58-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(pyrrolidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-59-6P, 3-Bromo-1-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-60-9P, 3-Chloro-1-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-61-0P 586386-62-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)benzamide 586386-63-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzamide 586386-64-3P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-dimethylbenzamide 586386-65-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586386-66-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(pyrrolidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586386-67-6P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-isopropylbenzamide 586386-68-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586386-69-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-70-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-dimethylbenzamide 586386-71-2P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-6-methyl-3-nitropyridin-2(1H)-one 586386-72-3P, tert-Butyl 4-[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]piperazine-1-carboxylate 586386-73-4P, Ethyl [4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]acetate 586386-74-5P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]benzenesulfonamide 586386-75-6P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-1-phenylmethanesulfonamide 586386-76-7P, 3-Bromo-4-[(2,4-difluorophenyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one 586386-77-8P, 4-Anilino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586386-78-9P, Methyl 4-[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]amino]benzoate 586386-79-0P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3,4,5-trimethoxyphenyl)amino]pyridin-2(1H)-one 586386-80-3P, 3-Bromo-1-(3-fluorobenzyl)-4-[4-(4-fluorophenyl)piperazin-1-yl]pyridin-2(1H)-one 586386-82-5P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-methylpiperazin-1-yl)pyridin-2(1H)-one trifluoroacetate 586386-83-6P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,5-difluorobenzamide 586386-84-7P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,4-difluorobenzamide 586386-85-8P, 3-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoic acid 586386-86-9P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-N'-(2,4-difluorophenyl)urea 586386-87-0P, 3-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide 586386-88-1P, 4-(Benzyloxy)-3-bromo-1-[3-(morpholin-4-yl)-3-oxopropyl]pyridin-2(1H)-one 586386-89-2P, N-(3-Aminopropyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide hydrochloride 586386-90-5P, 4-(Benzyloxy)-3-bromo-1-[3-oxo-3-(piperazin-1-yl)propyl]pyridin-2(1H)-one hydrochloride 586386-91-6P, 4-(Benzyloxy)-3-bromo-1-[2-(morpholin-4-yl)ethyl]pyridin-2(1H)-one 586386-92-7P, N-(2-Aminoethyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanamide hydrochloride 586386-93-8P, [3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]acetic acid 586386-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-one 586386-95-0P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-one 586386-96-1P, Methyl 3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridine-1-carboxylate 586386-97-2P, 1-Allyl-3-(2,4-difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586386-98-3P, 4-(Benzyloxy)-1-(2,2-diethoxyethyl)pyridin-2(1H)-one 586386-99-4P 586387-00-0P 586387-01-1P 586387-02-2P, 4-(Benzyloxy)-1-(2-oxopropyl)pyridin-2(1H)-one 586387-03-3P, 5-[[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]-5-

methylimidazolidine-2,4-dione 586387-04-4P, Ethyl
 [4-(benzyloxy)-2-oxo-2H-pyridin-1-yl]acetate 586387-05-5P,
 2-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]acetamide 586387-06-6P,
 4-(Benzyloxy)-1-ethylpyridin-2(1H)-one 586387-07-7P, tert-Butyl
 3-[[4-(benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-carboxylate
 586387-08-8P, 1,3-Dibenzyl-4-hydroxy-6-methylpyridin-2(1H)-one
 586387-09-9P, 1-Benzyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl
 methanesulfonate 586387-10-2P, 1-Benzyl-4-(naphthyl-1-ylmethoxy)pyridin-
 2(1H)-one 586387-11-3P, 1-Benzyl-4-(benzylthio)-3,5-dibromopyridin-2(1H)-
 one 586387-12-4P, 1-Benzyl-3-[(benzylamino)methyl]-4-(benzyloxy)pyridin-
 2(1H)-one 586387-13-5P, 1-Benzyl-4-(benzyloxy)-3-[[2-(
 cyclohexylethyl)amino]methyl]pyridin-2(1H)-one 586387-14-6P,
 1-Benzyl-4-(benzylthio)-5-methylpyridin-2(1H)-one 586387-15-7P,
 1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate
 586387-16-8P, 1-Benzyl-3-bromo-6-methyl-4-[[2-(
 (trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one 586387-17-9P,
 1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl
 4-bromobenzenesulfonate 586387-18-0P, 4-Phenoxy-1-[[2-(
 (trimethylsilyl)ethoxy)methyl]pyridin-2(1H)-one 586387-19-1P,
 1-Benzyl-4-phenoxy-pyridin-2(1H)-one 586387-20-4P 586387-21-5P,
 3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one hydrochloride
 586387-22-6P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-ylmethyl)pyridin-2(1H)-
 one 586387-23-7P, Benzyl (5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-
 yl)acetate 586387-24-8P, Methyl (2E)-4-[4-[(2,4-difluorobenzyl)oxy]-6-
 methyl-2-oxo-2H-pyridin-1-yl]-2-butenate 586387-25-9P, tert-Butyl
 4-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-
 carboxylate 586387-26-0P, 1-Benzyl-4-[(4-methylbenzyl)oxy]pyridin-2(1H)-
 one 586387-27-1P, 2-[[[3-Bromo-2-oxo-1-(pyridin-3-ylmethyl)-1,2-
 dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile 586387-28-2P,
 tert-Butyl 3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
 yl]methyl]piperidine-1-carboxylate 586387-29-3P, 4-Benzyloxy-3-bromo-1-(
 methanesulfonyl)-1H-pyridin-2-one 586387-30-6P, tert-Butyl
 4-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]piperidine-1-carboxylate
 586387-31-7P, 4-(Benzyloxy)-1-[4-(methylthio)benzyl]pyridin-2(1H)-one
 586387-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2-methyl-4-
 methylaminopyrimidin-5-yl)methyl]-1H-pyridin-2-one 586387-33-9P,
 4-(Benzyloxy)-1-[4-(methylsulfonyl)benzyl]pyridin-2(1H)-one
 586387-34-0P, 4-Phenoxy-1H-pyridin-2-one 586387-35-1P,
 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-
 one 586387-36-2P, 1-(3-Fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one
 586387-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(
 methylthio)pyrimidin-4-yl]pyridin-2(1H)-one 586387-38-4P,
 4-(Benzyloxy)-3-bromo-1-piperidin-4-ylpyridin-2(1H)-one hydrochloride
 586387-39-5P
 , 4-Benzyloxy-1-difluoromethyl-1H-pyridin-2-one 586387-40-8P,
 4-Benzyloxy-3-bromo-1-(2-chlorophenyl)-6-methyl-1H-pyridin-2-one
 586387-41-9P, 3-Bromo-6-methyl-1-(pyridin-3-ylmethyl)-4-[(pyridin-3-
 ylmethyl)amino]-1H-pyridin-2-one 586387-42-0P, 2-Chloro-N-[1-(2,6-
 dichlorobenzyl)-6-oxo-5-trifluoromethyl-1,6-dihydropyridin-3-yl]-4-
 fluorobenzamide 586387-43-1P, N-[1-(2,6-Dichlorobenzyl)-6-oxo-5-
 trifluoromethyl-1,6-dihydropyridin-3-yl]-4-isopropoxybenzamide
 586387-44-2P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-methoxyphenyl)-1H-pyridin-2-
 one 586387-45-3P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-isopropylphenyl)-1H-
 pyridin-2-one 586387-46-4P, 3'-Bromo-1'-(3-fluorobenzyl)-6-methoxy-1'H-
 [3,4']bipyridinyl-2'-one 586387-47-5P, 4-Benzo[1,3]dioxol-5-yl-3-bromo-1-
 (3-fluorobenzyl)-1H-pyridin-2-one 586387-48-6P, 3-Bromo-1-(3-
 fluorobenzyl)-4-thiophen-3-yl-1H-pyridin-2-one 586387-49-7P,
 3-Bromo-1-(3-fluorobenzyl)-4-(3-trifluoromethylphenyl)-1H-pyridin-2-one
 586387-50-0P, 3-Bromo-1-(3-fluorobenzyl)-4-naphthalen-2-yl-1H-pyridin-2-
 one 586387-51-1P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-fluorophenyl)-1H-
 pyridin-2-one 586387-52-2P, 1-Benzenesulfonyl-4-benzyloxy-3-bromo-1H-

pyridin-2-one 586387-53-3P, 4-[3-Amino-1-(2,4-difluorophenyl)propoxy]-3-bromo-6-methyl-1-[(pyridin-3-yl)methyl]-1H-pyridin-2-one 586387-54-4P, 2-[[[1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile 586387-55-5P, 1-(2-Chloro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1H-pyridin-2-one 586387-56-6P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-vinyl-1H-pyridin-2-one 586387-57-7P 586387-58-8P, 1-(2,6-Difluorophenyl)-4-methoxy-6-methyl-5-phenethyl-1H-pyridin-2-one 586387-59-9P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-phenethyl-1H-pyridin-2-one 586387-60-2P, 1-(1H-Indazol-5-yl)-4-(1H-indazol-5-ylamino)-6-methylpyridin-2(1H)-one 586387-61-3P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-[2-(2,4-difluorophenyl)ethyl]-6-oxo-1,6-dihydropyridine-3-carboxaldehyde 586387-62-4P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]pyrimidine-2-carbonitrile 586387-63-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid 586387-64-6P, 3-Bromo-4-[(5-carboxypyridin-2-yl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid 586387-65-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6,6'-dimethyl-2-oxo-2H-[1,2']bipyridinyl-3'-carbonitrile 586387-66-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid methylamide 586387-67-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid N-(2-hydroxyethyl)amide 586387-68-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid N-(2-methoxyethyl)amide 586387-69-1P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-(4-methylbenzyl)-1H-pyridin-2-one 586387-70-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxy-2-phenylethyl)-6-methylpyridin-2(1H)-one 586387-71-5P, 3-Chloro-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586387-72-6P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile trifluoroacetate 586387-74-8P 586387-75-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methylbenzamide 586387-76-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-77-1P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide 586387-78-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[2-(4-fluorophenyl)ethyl]-6-methylpyridin-2(1H)-one 586387-79-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-isopropylbenzamide 586387-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(pyrrolidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-81-7P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-bis(2-hydroxyethyl)benzamide 586387-83-9P, 4-(Benzyloxy)-1-(piperidin-3-ylmethyl)pyridin-2(1H)-one trifluoroacetate 586387-84-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-85-1P 586387-86-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-87-3P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)amino]pyridin-2(1H)-one 586387-88-4P 586387-89-5P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide 586387-90-8P, 1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586387-91-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-dimethylbenzamide 586387-92-0P, 4-(Allylamino)-3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586387-93-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-indol-5-yl)methyl]-1H-pyridin-2-one 586387-94-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxyacetyl)-2,3-dihydro-1H-indol-5-yl]methyl]-6-methyl-1H-pyridin-2-one 586387-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-3-ylmethyl)-1H-pyridin-2-one 586396-12-5P, 3-Chloro-1-[4-[[[cyclopropylmethyl]amino]methyl]-2,6-difluorophenyl]-4-[(2,4-

difluorobenzyl)oxy] pyridin-2(1H)-one hydrochloride 586396-39-6P,
N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-acetoxyacetamide 586396-68-1P 586397-52-6P
586397-63-9P 586397-73-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
kinase for treatment of inflammatory conditions,
ischemia, viral infections, autoimmune diseases, and other
conditions)

IT 165245-96-5, p38 α MAP kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyridinones as modulators of p38 MAP kinase for
treatment of inflammatory conditions, ischemia, viral
infections, autoimmune diseases, and other conditions)

IT 586374-26-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyridinones as modulators of p38 MAP kinase for
treatment of inflammatory conditions, ischemia, viral
infections, autoimmune diseases, and other conditions)

IT 56-37-1, Benzyltriethylammonium chloride 75-31-0, Isopropylamine,
reactions 79-44-7, Dimethylcarbamyl chloride 86-95-3,
4-Hydroxy-1,2-dihydroquinolin-2-one 87-62-7, 2,6-Dimethylaniline
88-17-5, 2-(Trifluoromethyl)aniline 95-02-3, 4-Amino-5-aminomethyl-2-
methylpyrimidine 96-33-3, Methyl acrylate 98-00-0, Furfuryl alcohol
98-58-8, 4-Bromobenzenesulfonyl chloride 98-79-3 99-27-4, Dimethyl
5-aminoisophthalate 100-82-3, 3-Fluorobenzylamine 103-64-0,
 β -Bromostyrene 103-71-9, Phenyl isocyanate, reactions 104-81-4,
4-Methylbenzyl bromide 105-36-2, Ethyl bromoacetate 106-96-7,
Propargyl bromide 107-11-9, Allylamine 109-01-3, 1-Methylpiperazine
109-08-0, 2-Methylpyrazine 109-83-1, 2-(Methylamino)ethanol 109-85-3,
2-Methoxyethylamine 110-89-4, Piperidine, reactions 110-91-8,
Morpholine, reactions 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl
acrylate 315-14-0, 2,4,6-Trifluoronitrobenzene 315-31-1,
2-Fluoro-3-methylbenzoic acid 363-81-5, 2,4,6-Trifluoroaniline
402-23-3, 3-Trifluoromethylbenzyl bromide 403-43-0, 4-Fluorobenzoyl
chloride 405-99-2, 4-Fluorostyrene 452-85-7, 5-Fluoro-2-methylphenol
453-71-4, 4-Fluoro-3-nitrobenzoic acid 455-87-8, 4-Amino-3-fluorobenzoic
acid 456-41-7, 3-Fluorobenzyl bromide 459-46-1, 4-Fluorobenzyl bromide
459-56-3, 4-Fluorobenzyl alcohol 527-69-5, 2-Furoyl chloride 536-74-3,
Phenylacetylene 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl
chloroformate 582-33-2, Ethyl 3-aminobenzoate 585-71-7,
(1-Bromoethyl)benzene 594-61-6, 2-Hydroxyisobutyric acid 616-30-8,
3-Amino-1,2-propanediol 617-88-9, 2-(Chloromethyl)furan 619-45-4,
Methyl 4-aminobenzoate 625-45-6, Methoxyacetic acid 626-03-9,
2,4-Dihydroxypyridine 626-15-3, α,α' -Dibromo-m-xylene
674-82-8, Diketene 675-10-5, 4-Hydroxy-6-methyl-2H-pyran-2-one
765-50-4, 2-(Chloromethyl)thiophene 766-98-3, 4-Fluorophenylacetylene
867-44-7 873-63-2, 3-Chlorobenzyl alcohol 1011-65-0, Methyl
indole-5-carboxylate 1071-46-1, Monoethyl malonate 1072-84-0,
4-Imidazolecarboxylic acid 1117-71-1, Methyl 4-bromocrotonate
1121-76-2, 4-Chloropyridine 1-oxide 1124-33-0, 4-Nitropyridine N-oxide
1129-28-8, Methyl 3-bromomethylbenzoate 1194-02-1, 4-Fluorobenzonitrile
1453-58-3, 3-Methyl-1H-pyrazole 1465-76-5, 1-tert-Butyl-4-oxopiperidine
1877-77-6, 3-Aminobenzyl alcohol 2038-03-1, 4-(2-Aminoethyl)morpholine
2144-37-8 2393-23-9, 4-Methoxybenzylamine 2417-72-3, Methyl
4-(bromomethyl)benzoate 2486-74-0, 4-Amino-2-methylmethyl benzoate
2840-26-8, 3-Amino-4-methoxybenzoic acid 2854-16-2, 3-Amino-2-methyl-2-

propanol 3240-94-6, 4-(2-Chloroethyl)morpholine 3320-83-0,
 2-Chlorophenyl isocyanate 3544-24-9, 3-Aminobenzamide 3731-51-9,
 2-(Aminomethyl)pyridine 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1,
 4-(Aminomethyl)pyridine 3739-30-8, 2-Hydroxy-2-methylbutyric acid
 4285-42-1, N-Methyl-N-phenylcarbonyl chloride 4385-35-7,
 Isochroman-3-one 4412-91-3, 3-Furylmethanol 4518-10-9, Methyl
 3-aminobenzoate 4530-20-5, Boc-glycine 5345-27-7,
 3-(Methylsulfonyl)benzoic acid 5382-16-1, 4-Hydroxypiperidine
 5394-63-8, 2,2,6-Trimethyl-4H-1,3-dioxin-4-one 5470-70-2, Methyl
 6-methylnicotinate 5509-65-9, 2,6-Difluoroaniline 5521-55-1,
 5-Methylpyrazine-2-carboxylic acid 5571-03-9, Methyl
 2-methyl-5-pyrimidinecarboxylate 6482-24-2, 2-Methoxyethyl bromide
 6723-30-4, [(Tetrahydro-2H-pyran-2-yl)oxy]amine 7051-34-5,
 Cyclopropylmethyl bromide 7554-65-6, 4-Methyl-1H-pyrazole 7693-46-1,
 4-Nitrophenyl chloroformate 10406-24-3, 3-(Aminomethyl)benzonitrile
 13737-36-5, 4-(Bromomethyl)phenylacetic acid 13831-30-6, Acetoxyacetic
 acid 13831-31-7, Acetoxyacetyl chloride 14001-63-9,
 4-Methyl-2-methylthiopyrimidine 15781-71-2, 2-Methylmalonic acid
 bis(2,4,6-trichlorophenyl) ester 17201-43-3, α -Bromo-p-tolunitrile
 17994-25-1, 1-Hydroxy-1-cyclopropanecarboxylic acid 18063-02-0,
 2,6-Difluorobenzoyl chloride 18583-89-6, Methyl 3-amino-2-methylbenzoate
 18595-18-1, Methyl 3-amino-4-methylbenzoate 19335-11-6, 5-Aminoindazole
 20274-69-5, 4-Fluoro-3-nitrobenzyl alcohol 22115-41-9,
 α -Bromo-o-tolunitrile 22134-75-4 22600-30-2, Methyl
 2-amino-5-furoate 23063-36-7, α,α -Dichloro-p-xylene
 23915-07-3, 2,4-Difluorobenzyl bromide 24424-99-5, Di-tert-butyl
 dicarbonate 24964-64-5, 3-Cyanobenzaldehyde 25006-86-4,
 2,6-Bis(bromomethyl)fluorobenzene 30533-50-7, 1-Amino-2-methyl-2-
 propanol hydrochloride 36394-75-9, (S)-(-)-2-Acetoxypropionyl chloride
 38870-89-2, 2-Methoxyacetyl chloride 39920-37-1, 2,6-Dichlorophenyl
 isocyanate 40061-55-0, m-Tolylacetic acid ethyl ester 40635-66-3,
 2-Acetoxy-2-methylpropionyl chloride 40872-87-5, Methyl
 3-amino-4-chlorobenzoate 49608-01-7, Ethyl 6-chloronicotinate
 50628-37-0, 3,3-Dimethoxy-2-methoxycarbonylpropen-1-ol sodium salt
 53937-02-3, 4-Benzyloxy-2(1H)-pyridone 55912-20-4, 3-Nitro-4-
 chlorobenzyl alcohol 56456-47-4, 2,4-Difluorobenzyl alcohol
 57260-71-6, N-(tert-Butyloxycarbonyl)piperazine 57791-63-6,
 3-(Cyclohexylamino)-2-butenic acid methyl ester 60728-41-8,
 3-Amino-4-(methoxycarbonyl)benzoic acid 62558-08-1, 1,2-
 Bis(hydroxymethyl)-4-fluorobenzene 66176-39-4, 4-
 (Bromomethyl)benzenesulfonyl chloride 67567-26-4, 4-Bromo-2,6-
 difluoroaniline 71637-34-8, Thien-3-ylmethanol 72235-52-0,
 2,4-Difluorobenzylamine 77532-79-7, 5-Fluoro-2-methylbenzonitrile
 80278-67-7, Isoquinoline-5-carboxaldehyde 81863-45-8,
 3-Amino-4-methylbenzyl alcohol 84257-12-5, 5-(1-Hydroxy-3-oxobutylidene)-
 2,2-dimethyl-1,3-dioxane-4,6-dione 105827-74-5,
 5-Bromomethyl-2-fluoropyridine 114896-64-9, Methanesulfonic acid
 2-(thiophen-3-yl)ethyl ester 120100-15-4, Methyl 3-amino-2-
 chlorobenzoate 132664-85-8, 5-Aminomethyl-2-methylpyrazine
 134227-45-5, 3,4,5-Trifluorobenzonitrile 135394-68-2 161975-39-9,
 4-(Methanesulfonyloxymethyl)-1-piperidine-1-carboxylic acid tert-butyl
 ester 162166-99-6, 3-[(Methanesulfonyloxy)methyl]piperidine-1-carboxylic
 acid tert-butyl ester 192369-91-8, 5-(Bromomethyl)-1-(tetrahydro-2H-
 pyran-2-yl)-1H-indazole 586373-19-5, 1-Benzyl-4-hydroxypyridin-2(1H)-one
 586374-17-6, 1-(3-Fluorobenzyl)-4-[(3-fluorobenzyl)oxy]-1H-pyridin-2-one
 586374-35-8 586374-60-9, 3-Bromo-4-(2,4-difluorophenoxy)-6-methylpyridin-
 2(1H)-one 586374-98-3, 3-Bromo-4-(2,4-difluorophenoxy)-6-methyl-1-[4-
 (piperazin-1-ylcarbonyl)benzyl]pyridin-2(1H)-one 586376-42-3,
 1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one
 hydrochloride 586376-54-7, 3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-
 dihydropyridin-4-yl trifluoromethanesulfonate 586376-85-4,

4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2(1H)-one 586378-53-2, 1-Benzyl-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one 586378-62-3, 3-Bromo-1-(cyclopropylmethyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586378-89-4, 4-Hydroxy-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-00-2, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(methylamino)methyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one 586379-20-6, 4-[(2,4-Difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-22-8, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT 58804-19-6P 586378-47-4P 586381-34-2P 586381-37-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

L35 5 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM C07D209-00

CC 34-2 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 7, 28

TI Preparation of novel multicyclic compounds and their amino acid

derivatives as inhibitors of enzymes such as poly(ADP-ribose) polymerase

ST clopentapyrrolocarbazole prepn inhibitor poly ADP ribose polymerase; PARP

inhibitor multicyclic compd prepn; pyrrolocarbazole prepn inhibitor VEGFR2

kinase; furanopyrrolocarbazole prepn inhibitor VEGFR2 kinase;

neurodegenerative disease treatment multicyclic compd prepn;

inflammation treatment multicyclic compd prepn; ischemia

treatment multicyclic compd prepn; MLK3 kinase inhibitor

multicyclic compd prepn

IT Nervous system

(Huntington's chorea; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Amides, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Nervous system

(central, injury; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Nervous system

(degeneration; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Eye, disease

(diabetic retinopathy; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Cell proliferation
 (disorders; preparation of novel multicyclic compds. and their amino acid
 derivs. as inhibitors of enzymes for treatment of diseases
 related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,
 and MLK3 kinase)

IT Uterus, disease
 (endometriosis; preparation of novel multicyclic compds. and their amino
 acid derivs. as inhibitors of enzymes for treatment of
 diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2
 kinase, and MLK3 kinase)

IT Eye, disease
 (intraocular neovascular syndromes; preparation of novel multicyclic compds.
 and their amino acid derivs. as inhibitors of enzymes for
 treatment of diseases related to enzymes such as
 poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Brain, disease
 Heart, disease
 (ischemia; preparation of novel multicyclic compds. and their
 amino acid derivs. as inhibitors of enzymes for treatment of
 diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2
 kinase, and MLK3 kinase)

IT Eye, disease
 (macula, degeneration; preparation of novel multicyclic compds. and their
 amino acid derivs. as inhibitors of enzymes for treatment of
 diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2
 kinase, and MLK3 kinase)

IT Heterocyclic compounds
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (nitrogen, aromatic; preparation of novel multicyclic compds. and their
 amino
 acid derivs. as inhibitors of enzymes for treatment of
 diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2
 kinase, and MLK3 kinase)

IT Alzheimer's disease
 Angiogenesis inhibitors
 Anti-inflammatory agents
 Antidiabetic agents
 Antitumor agents
 Parkinson's disease
 Psoriasis
 Rheumatoid arthritis
 (preparation of novel multicyclic compds. and their amino acid derivs. as
 inhibitors of enzymes for treatment of diseases related to
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
 kinase)

IT Amino acids, preparation
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel multicyclic compds. and their amino acid derivs. as
 inhibitors of enzymes for treatment of diseases related to
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
 kinase)

IT Shock (circulatory collapse)
 (septic; preparation of novel multicyclic compds. and their amino acid
 derivs. as inhibitors of enzymes for treatment of diseases
 related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,
 and MLK3 kinase)

IT 374069-00-8P 374069-03-1P 374069-12-2P 374069-14-4P 374069-19-9P

374069-21-3P	374069-22-4P	374069-23-5P	374069-25-7P	374069-26-8P
374069-31-5P	374069-33-7P	374069-35-9P	374069-36-0P	374069-43-9P
374069-44-0P	374069-53-1P	374069-62-2P	374069-75-7P	374070-30-1P
374070-33-4P	374070-38-9P	374070-39-0P	374070-57-2P	374070-59-4P
374070-64-1P	374070-73-2P	374070-77-6P	374070-79-8P	374070-80-1P
374070-83-4P	374070-95-8P	374070-96-9P	374071-01-9P	374071-12-2P
374071-16-6P	374071-28-0P			

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT	154114-97-3P	374068-99-2P	374069-01-9P	374069-02-0P	374069-04-2P
	374069-05-3P	374069-06-4P	374069-07-5P	374069-08-6P	374069-09-7P
	374069-10-0P	374069-11-1P	374069-13-3P	374069-15-5P	374069-16-6P
	374069-17-7P	374069-18-8P	374069-20-2P	374069-24-6P	374069-27-9P
	374069-28-0P	374069-29-1P	374069-30-4P	374069-32-6P	374069-34-8P
	374069-37-1P	374069-38-2P	374069-39-3P	374069-40-6P	374069-41-7P
	374069-42-8P	374069-45-1P	374069-46-2P	374069-47-3P	374069-48-4P
	374069-49-5P	374069-50-8P	374069-51-9P	374069-52-0P	374069-54-2P
	374069-55-3P	374069-56-4P	374069-57-5P	374069-58-6P	374069-59-7P
	374069-60-0P	374069-61-1P	374069-63-3P	374069-64-4P	374069-65-5P
	374069-66-6P	374069-67-7P	374069-68-8P	374069-69-9P	374069-70-2P
	374069-71-3P	374069-72-4P	374069-73-5P	374069-74-6P	374069-76-8P
	374069-77-9P	374069-78-0P	374069-79-1P	374069-80-4P	374069-81-5P
	374069-82-6P	374069-83-7P	374069-84-8P	374069-85-9P	374069-87-1P
	374069-88-2P	374069-89-3P	374069-90-6P	374069-91-7P	374069-92-8P
	374069-93-9P	374069-94-0P	374069-95-1P	374069-96-2P	374069-97-3P
	374069-98-4P	374069-99-5P	374070-00-5P	374070-01-6P	374070-02-7P
	374070-03-8P	374070-04-9P	374070-05-0P	374070-06-1P	374070-07-2P
	374070-08-3P	374070-09-4P	374070-10-7P	374070-11-8P	374070-12-9P
	374070-13-0P	374070-14-1P	374070-15-2P	374070-16-3P	374070-17-4P
	374070-18-5P	374070-19-6P	374070-20-9P	374070-21-0P	374070-22-1P
	374070-23-2P	374070-24-3P	374070-25-4P	374070-26-5P	374070-27-6P
	374070-28-7P	374070-29-8P	374070-31-2P	374070-32-3P	374070-34-5P
	374070-35-6P	374070-36-7P	374070-37-8P	374070-40-3P	374070-41-4P
	374070-42-5P	374070-43-6P	374070-44-7P	374070-45-8P	374070-46-9P
	374070-47-0P	374070-48-1P	374070-49-2P	374070-50-5P	374070-51-6P
	374070-52-7P	374070-53-8P	374070-54-9P	374070-55-0P	374070-56-1P
	374070-58-3P	374070-60-7P	374070-62-9P	374070-63-0P	374070-65-2P
	374070-66-3P	374070-67-4P	374070-68-5P	374070-69-6P	374070-70-9P
	374070-71-0P	374070-72-1P	374070-74-3P	374070-75-4P	374070-76-5P
	374070-78-7P	374070-81-2P	374070-82-3P	374070-84-5P	374070-85-6P
	374070-86-7P	374070-87-8P	374070-88-9P	374070-89-0P	374070-90-3P
	374070-91-4P	374070-92-5P	374070-93-6P	374070-94-7P	374070-97-0P
	374070-98-1P	374070-99-2P	374071-00-8P	374071-02-0P	374071-03-1P
	374071-04-2P	374071-05-3P	374071-06-4P	374071-07-5P	374071-08-6P
	374071-09-7P	374071-10-0P	374071-11-1P	374071-13-3P	374071-14-4P
	374071-15-5P	374071-17-7P	374071-18-8P	374071-19-9P	374071-20-2P
	374071-21-3P	374071-22-4P	374071-23-5P	374071-24-6P	374071-25-7P
	374071-26-8P	374071-27-9P	374071-29-1P	374071-30-4P	374071-31-5P
	374071-32-6P	374071-33-7P	374071-34-8P	374071-35-9P	374071-36-0P
	374071-37-1P	374071-38-2P	374071-39-3P	374071-40-6P	374071-41-7P
	374071-42-8P	374071-43-9P	374071-44-0P	374071-45-1P	374071-46-2P
	374071-47-3P	374071-48-4P	374071-49-5P	374071-50-8P	374071-51-9P
	374071-52-0P	374071-53-1P	374071-54-2P	374071-55-3P	374071-56-4P
	374071-57-5P	374071-58-6P	374072-29-4P	374553-23-8P	374553-24-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT 9055-67-8, Poly(ADP-ribose) polymerase 150977-45-0, VEGFR2 kinase
153190-46-6, MLK3 kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT 50-00-0, Formaldehyde, reactions 60-34-4 62-55-5, Thioacetamide 62-56-6, Thiourea, reactions 64-19-7, Acetic acid, reactions 68-12-2, DMF, reactions 74-88-4, Methyl iodide, reactions 75-36-5, Acetyl chloride 79-03-8, Propionyl chloride 79-09-4, Propionic acid, reactions 79-30-1, Isobutyryl chloride 79-37-8, Oxalyl chloride 95-15-8, Benzothiophene 98-09-9, Phenylsulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 100-39-0, Benzyl bromide 105-36-2, Ethyl bromoacetate 107-13-1, Acrylonitrile, reactions 107-92-6, Butyric acid, reactions 108-00-9, N,N-Dimethylethylenediamine 108-12-3, Isovaleryl chloride 108-30-5, Succinic anhydride, reactions 108-55-4, Glutaric anhydride 109-01-3, N-Methylpiperazine 109-86-4, 2-Methoxyethanol 109-89-7, Diethylamine, reactions 109-90-0, Ethyl isocyanate 109-97-7, Pyrrole 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 120-72-9, Indole, reactions 120-92-3, Cyclopentanone 123-75-1, Pyrrolidine, reactions 124-63-0, Methanesulfonyl chloride 140-88-5, Ethyl acrylate 141-43-5, Ethanolamine, reactions 141-75-3, Butyryl chloride 271-89-6, Benzofuran 288-88-0, 1H-1,2,4-Triazole 399-52-0, 5-Fluoroindole 541-59-3, Maleimide 544-92-3, Copper(I) cyanide 557-21-1, Zinc cyanide 591-08-2, N-Acetylthiourea 594-27-4, Tetramethyltin 598-21-0, Bromoacetyl bromide 598-52-7, N-Methylthiourea 614-96-0, 5-Methylindole 623-91-6, Diethyl fumarate 630-08-0, Carbon monoxide, reactions 638-29-9, Valeryl chloride 690-76-6, 2-(tert-Butoxycarbonyl)thioacetamide 762-42-5, Dimethyl acetylenedicarboxylate 933-67-5, 7-Methylindole 999-97-3, Hexamethyldisilazane 1121-92-2 1462-37-9, Benzyl 2-bromoethyl ether 1501-27-5, Glutaric acid monomethyl ester 2038-03-1, 4-(2-Aminoethyl)morpholine 2114-02-5 2133-40-6, L-Proline methyl ester hydrochloride 2812-46-6 3303-84-2, N-tert-Butoxycarbonyl- β -alanine 3878-55-5, Succinic acid monomethyl ester 4023-34-1, Cyclopropanecarbonyl chloride 4377-33-7, 2-Picolyl chloride 4524-93-0, Cyclopentanecarbonyl chloride 4530-20-5, N-tert-Butoxycarbonyl-glycine 4744-50-7, Furo[3,4-b]pyrazine-5,7-dione 5070-13-3, Bis(4-nitrophenyl) carbonate 5332-06-9, 4-Bromobutyronitrile 5332-26-3 5437-45-6, Benzyl bromoacetate 5699-40-1, N-Acetylguanidine 6940-76-7, 1-Chloro-3-iodopropane 6971-44-4, 4-(N-Methylaminomethyl)pyridine 7148-07-4, 1-(Cyclopenten-1-yl)pyrrolidine 7531-52-4, L-Prolinamide 13154-24-0, Triisopropylsilyl chloride 15098-69-8 16503-22-3, N-Methylhistamine dihydrochloride 18107-18-1, Trimethylsilyldiazomethane 19099-93-5, Benzyl 4-oxo-1-piperidinecarboxylate 21035-59-6, 2-(N-Methylaminomethyl)pyridine 24424-99-5, Di-tert-butyl dicarbonate 40594-97-6 49548-40-5 53300-47-3, 2-(Methanesulfonyl)thioacetamide 53654-35-6, 2-Vinylindole 54663-78-4, 2-(Tributylstannyl)thiophene 57260-71-6 57260-73-8, N-tert-Butoxycarbonylethylenediamine 57294-38-9, 4-(tert-Butoxycarbonylamino)butyric acid 76822-35-0 86864-60-0, (2-Bromoethoxy)-tert-butyl dimethylsilane 89031-84-5, (3-Bromopropoxy)-tert-butyl dimethylsilane 98518-10-6 118486-97-8,

2-(Tributylstannyl)-1-methylpyrrole 124252-41-1, 4-
 (Tributylstannyl)pyridine 133565-49-8 136088-69-2 138585-09-8,
 p-(tert-Butyldimethylsilyloxy)benzyl chloride 155440-58-7,
 3-(Furan-3-yl)indole 175277-31-3, 2-(tert-Butanesulfonyl)thioacetamide
 175334-72-2, 5-Isoxazolecarbothioamide 374071-64-4, 5-
 (Triisopropylsilyloxy)-2-(1-hydroxycyclopentyl)indole 374071-66-6,
 5-Methoxy-2-(1-hydroxycyclopentyl)indole 374071-67-7,
 5-(2-Ethoxyethoxy)-2-(1-hydroxycyclopentyl)indole 374071-68-8,
 5-[2-(Diethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-69-9,
 5-[2-(Dimethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-70-2,
 5-[2-Morpholinoethoxy]-2-(1-hydroxycyclopentyl)indole 374071-71-3,
 2-(tert-Butoxycarbonyloxy)thioacetamide 374071-77-9,
 2-(2-Buten-2-yl)indole 374071-87-1 374071-90-6, 2-(3-Hepten-3-
 yl)indole 374071-91-7, 3-(Cyclohexen-1-yl)-1-methylindole 374071-92-8,
 2-(2,3-Dihydrofuran-4-yl)indole 374071-93-9 374071-94-0 374071-96-2,
 6-Methoxy-2-(1-hydroxycyclopentyl)indole 374071-97-3,
 4-Methoxy-2-(1-hydroxycyclopentyl)indole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of novel multicyclic compds. and their amino acid derivs. as
 inhibitors of enzymes for treatment of diseases related to
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
 kinase)

IT 90971-74-7P, 3-(Cyclopenten-1-yl)-1-(triisopropylsilyl)pyrrole
 118959-02-7P, 2-(Cyclopenten-1-yl)benzofuran 374071-59-7P,
 2-(1-Hydroxycyclopentyl)indole 374071-60-0P, 2-(1-Cyclopentenyl)indole
 374071-61-1P 374071-62-2P 374071-63-3P 374071-65-5P 374071-72-4P
 374071-73-5P 374071-74-6P 374071-75-7P 374071-76-8P 374071-78-0P
 374071-79-1P, 2-(Cyclopenten-1-yl)pyrrole 374071-80-4P,
 3-(Cyclopenten-1-yl)pyrrole 374071-81-5P, 2-(Cyclopenten-1-yl)-1-
 (triisopropylsilyl)pyrrole 374071-82-6P 374071-83-7P 374071-84-8P
 374071-85-9P, 1,6,7,8-Tetrahydrocyclopenta[g]indole-4,5-dicarboxylic acid
 374071-86-0P 374071-88-2P 374071-89-3P 374071-95-1P 374071-98-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of novel multicyclic compds. and their amino acid derivs. as
 inhibitors of enzymes for treatment of diseases related to
 enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
 kinase)

ALL ANSWERS HAVE BEEN SCANNED

=> s (method? or procedure? or assay?) and (identifying or screening) and
 ("angiogenesis inhibitor?")

L37 1075 (METHOD? OR PROCEDURE? OR ASSAY?) AND (IDENTIFYING OR SCREENING)
 AND ("ANGIOGENESIS INHIBITOR?")

=> s L37 and phenanthrene

L38 0 L37 AND PHENANTHRENE

=> s L37 and phenanthroline

L39 3 L37 AND PHENANTHROLINE

=> d L39 1-3 hitstr ibib all

L39 ANSWER 1 OF 3 MEDLINE on STN

ACCESSION NUMBER: 2005611849 MEDLINE

DOCUMENT NUMBER: PubMed ID: 16236503

TITLE: C8c-C15 monoseco-analogues of the phenanthroquinolizidine
 alkaloids julandine and cryptopleurine exhibiting potent
 anti-angiogenic properties.

AUTHOR: Banwell Martin G; Bezos Anna; Burns Christopher;
 Kruszelnicki Irma; Parish Christopher R; Su Stephen; Sydnes
 Magne O
 CORPORATE SOURCE: Research School of Chemistry, The Australian National
 University, Canberra ACT 0200, Australia..
 mgb@rsc.anu.edu.au
 SOURCE: Bioorganic & medicinal chemistry letters, (2006 Jan 1) Vol.
 16, No. 1, pp. 181-5. Electronic Publication: 2005-10-19.
 Journal code: 9107377. ISSN: 0960-894X.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200603
 ENTRY DATE: Entered STN: 22 Nov 2005
 Last Updated on STN: 22 Mar 2006
 Entered Medline: 21 Mar 2006
 AN 2005611849 MEDLINE
 DN PubMed ID: 16236503
 TI C8c-C15 monoseco-analogues of the phenanthroquinolizidine alkaloids
 julandine and cryptopleurine exhibiting potent anti-angiogenic properties.
 AU Banwell Martin G; Bezos Anna; Burns Christopher; Kruszelnicki Irma; Parish
 Christopher R; Su Stephen; Sydnes Magne O
 CS Research School of Chemistry, The Australian National University, Canberra
 ACT 0200, Australia.. mgb@rsc.anu.edu.au
 SO Bioorganic & medicinal chemistry letters, (2006 Jan 1) Vol. 16, No. 1, pp.
 181-5. Electronic Publication: 2005-10-19.
 Journal code: 9107377. ISSN: 0960-894X.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200603
 ED Entered STN: 22 Nov 2005
 Last Updated on STN: 22 Mar 2006
 Entered Medline: 21 Mar 2006
 AB Four enantiomerically pure monoseco-analogues, 5, 7, 9, and 11, of the
 phenanthroquinolizidine alkaloid julandine (1) and four of congener
 cryptopleurine (2), viz. compounds 6, 8, 10, and 12, have been prepared
 and subjected to preliminary biological evaluation. These analogues show
 dramatically reduced cytotoxicity compared with the parent system 2 but
 they are, nevertheless, potent anti-angiogenic agents.
 CT *Alkaloids: CH, chemistry
 Alkaloids: PD, pharmacology
 Angiogenesis Inhibitors: PD, pharmacology
 Animals
 Aorta: DE, drug effects
 Cell Line, Tumor
 Drug Screening Assays, Antitumor: MT, methods
 Humans
 Inhibitory Concentration 50
 Mice
 Models, Chemical
 *Phenanthrolines: CH, chemistry
 Phenanthrolines: PD, pharmacology
 *Quinolizines: CH, chemistry
 Quinolizines: PD, pharmacology
 Rats
 Stereoisomerism

Stilbenes: PD, pharmacology
RN 117048-59-6 (combretastatin A-4); 482-22-4 (cryptopleurine)
CN 0 (Alkaloids); 0 (Angiogenesis Inhibitors); 0 (Phenanthrolines); 0 (Quinolizines); 0 (Stilbenes); 0 (julandine)

L39 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:332055 CAPLUS
DOCUMENT NUMBER: 136:350543
TITLE: Metalloprotease inhibitors for treatment of angiogenesis
INVENTOR(S): Pan, Duoia; Rubin, Gerald M.; Zhang, Hongbing
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034289	A1	20020502	WO 2001-US45612	20011025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6436629	B1	20020820	US 2000-697854	20001027
CA 2426043	A1	20020502	CA 2001-2426043	20011025
AU 2002020098	A	20020506	AU 2002-20098	20011025
EP 1333856	A1	20030813	EP 2001-988593	20011025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004522702	T	20040729	JP 2002-537340	20011025
AU 2002220098	B2	20050127	AU 2002-220098	20011025
US 20020132778	A1	20020919	US 2002-68591	20020206
US 6872750	B2	20050329		
US 20050171024	A1	20050804	US 2005-85949	20050321
PRIORITY APPLN. INFO.:			US 2000-697854	A 20001027
			WO 2001-US45612	W 20011025
			US 2002-68591	A3 20020206

AN 2002:332055 CAPLUS
DN 136:350543
ED Entered STN: 03 May 2002
TI Metalloprotease inhibitors for treatment of angiogenesis
IN Pan, Duoia; Rubin, Gerald M.; Zhang, Hongbing
PA The Regents of the University of California, USA
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K039-00
ICS A61K039-395; A61K049-00; C12Q001-00; G01N033-53; G01N033-48
CC 1-6 (Pharmacology)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 2002034289	A1	20020502	WO 2001-US45612	20011025
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 6436629	B1	20020820	US 2000-697854	20001027
	CA 2426043	A1	20020502	CA 2001-2426043	20011025
	AU 2002020098	A	20020506	AU 2002-20098	20011025
	EP 1333856	A1	20030813	EP 2001-988593	20011025
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004522702	T	20040729	JP 2002-537340	20011025
	AU 2002220098	B2	20050127	AU 2002-220098	20011025
	US 20020132778	A1	20020919	US 2002-68591	20020206
	US 6872750	B2	20050329		
	US 20050171024	A1	20050804	US 2005-85949	20050321
PRAI	US 2000-697854	A	20001027		
	WO 2001-US45612	W	20011025		
	US 2002-68591	A3	20020206		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002034289	ICM	A61K039-00
	ICS	A61K039-395; A61K049-00; C12Q001-00; G01N033-53; G01N033-48
	IPCI	A61K0039-00 [ICM, 7]; A61K0039-395 [ICS, 7]; A61K0049-00 [ICS, 7]; C12Q0001-00 [ICS, 7]; G01N0033-53 [ICS, 7]; G01N0033-48 [ICS, 7]
	IPCR	G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	ECLA	A61K031/198; A61K031/381; A61K031/405; A61K038/48N; C07K016/18; C12Q001/37; G01N033/573; K61K; M07K; S01N; S01N; S01N
US 6436629	IPCI	C12Q0001-00 [ICM, 7]; C12N0005-00 [ICS, 7]; A61K0049-00 [ICS, 7]
	IPCR	G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]

		[I,A]
	NCL	435/004.000; 424/009.100; 424/009.200; 435/375.000
	ECLA	A61K031/198; A61K031/381; A61K031/405; A61K038/48N; C07K016/18; C12Q001/37; G01N033/573
CA 2426043	IPCI	A61K0039-00 [ICM,7]; A61K0049-00 [ICS,7]; C12Q0001-00 [ICS,7]; A61K0039-395 [ICS,7]; G01N0033-48 [ICS,7]; G01N0033-53 [ICS,7]
	IPCR	G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
AU 2002020098	IPCI	A61K0039-00 [ICM,7]; A61K0039-395 [ICS,7]; A61K0049-00 [ICS,7]; C12Q0001-00 [ICS,7]; G01N0033-53 [ICS,7]; G01N0033-48 [ICS,7]
	IPCR	G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
EP 1333856	IPCI	A61K0039-00 [ICM,7]; A61K0039-395 [ICS,7]; A61K0049-00 [ICS,7]; C12Q0001-00 [ICS,7]; G01N0033-53 [ICS,7]; G01N0033-48 [ICS,7]
	IPCR	G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*]; G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	ECLA	A61K031/198; A61K031/381; A61K031/405; A61K038/48N; C07K016/18; C12Q001/37; G01N033/573; K61K; M07K; S01N; S01N; S01N
JP 2004522702	IPCI	A61K0045-00 [ICM,7]; A61K0031-198 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0039-395 [ICS,7]; A61P0035-00 [ICS,7]; A61P0043-00 [ICS,7]; G01N0033-48 [ICS,7]; G01N0033-53 [ICS,7]; G01N0033-574 [ICS,7]
	IPCR	A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,A]; A61K0031-381 [I,C*]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; C12Q0001-37 [I,A]; C12Q0001-37 [I,C*]; G01N0033-573

[I,A]; G01N0033-573 [I,C*]

FTERM 2G045/AA29; 2G045/BB20; 2G045/BB50; 2G045/CB01;
2G045/CB02; 2G045/FA16; 4C084/AA17; 4C084/ZB26;
4C085/AA13; 4C085/CC03; 4C085/CC04; 4C085/CC22;
4C085/DD23; 4C085/EE03; 4C206/FA53; 4C206/MA04;
4C206/ZB26; 4C206/ZC78

AU 2002220098 IPCI A61K0039-00 [ICS,7]; G01N0033-48 [ICS,7]; G01N0033-53
[ICS,7]; C12Q0001-00 [ICS,7]; A61K0049-00 [ICS,7];
A61K0039-395 [ICS,7]

IPCR G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185
[I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*];
A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405
[I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00
[I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*];
A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
[I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53
[I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*];
G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574
[I,A]

ECLA A61K031/198; A61K031/381; A61K031/405; A61K038/48N;
C07K016/18; C12Q001/37; G01N033/573; K61K; M07K; S01N;
S01N; S01N

US 20020132778 IPCI A61K0038-05 [ICM,7]; A61K0039-395 [ICS,7]; A61K0031-19
[ICS,7]; A61K0031-185 [ICS,7,C*]

IPCR G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185
[I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*];
A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405
[I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00
[I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*];
A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
[I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53
[I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*];
G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574
[I,A]

NCL 514/019.000; 514/575.000

ECLA A61K031/198; A61K031/381; A61K031/405; A61K038/48N;
C07K016/18; C12Q001/37; G01N033/573

US 20050171024 IPCI A61K0038-04 [ICM,7]; A61K0031-405 [ICS,7]; A61K0031-403
[ICS,7,C*]; A61K0031-19 [ICS,7]; A61K0031-185
[ICS,7,C*]

IPCR A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381
[I,C*]; A61K0031-381 [I,A]; A61K0031-403 [I,C*];
A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48
[I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-573
[I,C*]; G01N0033-573 [I,A]

NCL 514/019.000; 514/419.000; 514/575.000

ECLA A61K031/198; A61K031/381; A61K031/405; A61K038/48N;
C07K016/18; C12Q001/37; G01N033/573

AB The invention provides methods and compns. relating to Kuz
involvement in angiogenesis. In various embodiments, the invention
provides methods for modulating angiogenesis by specifically
modulating the activity of Kuz in a vertebrate animal predetd. to have a
pathogenic angiogenesis; and subsequently detecting a resultant angiogenic
modulation in the animal. Methods are provided for
identifying a modulator of angiogenesis by (a) contacting an
angiogenic assay system comprising a predetd. amount of Kuz with a

candidate agent, under conditions whereby but for the presence of the agent, the system provides a reference angiogenesis; and (b) detecting an agent-biased angiogenesis of the system.

- ST angiogenesis antitumor metalloprotease inhibitor Kuz protein
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Kuz mutant fused to Fc region of; metalloprotease inhibitors for treatment of angiogenesis)
- IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Kuz-specific; metalloprotease inhibitors for treatment of angiogenesis)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Kuzbanian (Kuz); metalloprotease inhibitors for treatment of angiogenesis)
- IT Carboxylic acids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carboxylates; metalloprotease inhibitors for treatment of angiogenesis)
- IT Hydroxamic acids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxamates; metalloprotease inhibitors for treatment of angiogenesis)
- IT Angiogenesis inhibitors
Antitumor agents
Chelating agents
(metalloprotease inhibitors for treatment of angiogenesis)
- IT Flavanols
Thiols, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metalloprotease inhibitors for treatment of angiogenesis)
- IT 81669-70-7, Metalloprotease 151769-16-3, TACE
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; metalloprotease inhibitors for treatment of angiogenesis)
- IT 60-00-4, EDTA, biological studies 66-71-7, 1,10-Phenanthroline 120-80-9D, o-Hydroxyphenol, derivs. 130370-60-4, Batimastat 142880-36-2, GM6001 421553-77-7, IC 3 421567-09-1, GW 9471
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metalloprotease inhibitors for treatment of angiogenesis)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Fambrough; Proc Natl Acad Sci 1996, V93, P13233 CAPLUS
(2) Pan; Cell 1997, V90, P271 CAPLUS
(3) Wen; Development 1997, V124, P4759 CAPLUS

L39 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:194336 CAPLUS

DOCUMENT NUMBER: 130:232477

TITLE: Methods using NGR receptor binding for identifying molecules that home to angiogenic vasculature in tumors

INVENTOR(S): Ruoslahti, Erkki; Pasqualini, Renata

PATENT ASSIGNEE(S): The Burnham Institute, USA

SOURCE: PCT Int. Appl., 180 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913329	A1	19990318	WO 1998-US18895	19980908
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6576239	B1	20030610	US 1997-926914	19970910
US 6180084	B1	20010130	US 1998-139802	19980825
AU 9894773	A	19990329	AU 1998-94773	19980908
EP 1015884	A1	20000705	EP 1998-948140	19980908
R: CH, DE, FR, GB, IT, LI				
JP 2001516055	T	20010925	JP 2000-511062	19980908
US 6491894	B1	20021210	US 2000-659786	20000911
US 20030113320	A1	20030619	US 2002-264374	20021003
US 20040096441	A9	20040520		
US 20030152578	A1	20030814	US 2003-375992	20030227
US 20040131623	A9	20040708		

PRIORITY APPLN. INFO.:
 US 1997-926914 A 19970910
 US 1998-139802 A 19980825
 US 1996-60947P P 19960910
 US 1996-710067 A 19960910
 WO 1998-US18895 W 19980908
 US 2000-659786 A3 20000911

AN 1999:194336 CAPLUS
 DN 130:232477
 ED Entered STN: 25 Mar 1999
 TI Methods using NGR receptor binding for identifying molecules that home to angiogenic vasculature in tumors
 IN Ruoslahti, Erkki; Pasqualini, Renata
 PA The Burnham Institute, USA
 SO PCT Int. Appl., 180 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM G01N033-50
 ICS G01N033-574
 CC 1-6 (Pharmacology)
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913329	A1	19990318	WO 1998-US18895	19980908
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6576239	B1	20030610	US 1997-926914	19970910
US 6180084	B1	20010130	US 1998-139802	19980825
AU 9894773	A	19990329	AU 1998-94773	19980908
EP 1015884	A1	20000705	EP 1998-948140	19980908
R: CH, DE, FR, GB, IT, LI				
JP 2001516055	T	20010925	JP 2000-511062	19980908
US 6491894	B1	20021210	US 2000-659786	20000911
US 20030113320	A1	20030619	US 2002-264374	20021003
US 20040096441	A9	20040520		
US 20030152578	A1	20030814	US 2003-375992	20030227
US 20040131623	A9	20040708		
PRAI US 1997-926914	A	19970910		

US 1998-139802	A	19980825
US 1996-60947P	P	19960910
US 1996-710067	A	19960910
WO 1998-US18895	W	19980908
US 2000-659786	A3	20000911

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9913329	ICM	G01N033-50
	ICS	G01N033-574
	IPCI	G01N0033-50 [ICM,6]; G01N0033-574 [ICS,6]
	IPCR	G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00 [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A]; G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
US 6576239	ECLA	G01N033/50D2B; G01N033/574V4
	IPCI	A61K0039-00 [ICM,7]
	IPCR	A61K0047-48 [I,C*]; A61K0047-48 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	NCL	424/185.100; 424/001.570; 514/002.000; 514/008.000; 530/300.000; 530/324.000; 530/328.000
US 6180084	ECLA	A61K047/48R2
	IPCI	A61K0049-00 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-566 [ICS,7]
	IPCR	G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	NCL	424/009.100; 424/009.200; 435/007.800; 436/501.000
AU 9894773	ECLA	G01N033/50D2B; G01N033/574V4
	IPCI	G01N0033-50 [ICM,6]; G01N0033-574 [ICS,6]
	IPCR	G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00 [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A]; G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
EP 1015884	IPCI	G01N0033-50 [ICM,6]; G01N0033-574 [ICS,6]
	IPCR	G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00 [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A]; G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	ECLA	G01N033/50D2B; G01N033/574V4; S01N; S01N

JP 2001516055	IPCI	G01N0033-566 [ICM,7]; A61K0031-122 [ICS,7]; A61K0031-198 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0031-704 [ICS,7]; A61K0031-7028 [ICS,7,C*]; A61K0045-00 [ICS,7]; A61K0047-48 [ICS,7]; A61K0051-00 [ICS,7]; A61P0035-00 [ICS,7]; A61P0043-00 [ICS,7]; C07K0007-00 [ICS,7]; G01N0033-15 [ICS,7]; G01N0033-50 [ICS,7]; G01N0033-574 [ICS,7]
	IPCR	G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00 [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A]; G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
US 6491894	IPCI	A61K0049-00 [ICM,7]
	IPCR	G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	NCL	424/009.100; 424/009.200; 424/093.200; 435/007.230; 435/007.800; 436/501.000; 514/002.000; 530/300.000
	ECLA	G01N033/50D2B; G01N033/574V4
US 20030113320	IPCI	A61K0039-395 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]; C07K0014-705 [ICS,7]; C07K0014-435 [ICS,7,C*]
	IPCR	G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	NCL	424/143.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
	ECLA	G01N033/50D2B; G01N033/574V4
US 20030152578	IPCI	G01N0033-574 [ICM,7]; A61K0039-395 [ICS,7]
	IPCR	A61K0047-48 [I,C*]; A61K0047-48 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
	NCL	424/178.100; 435/007.230
	ECLA	A61K047/48R2; G01N033/50D2B; G01N033/574V4
AB	A method is disclosed for identifying a tumor homing	
	mol. that homes to angiogenic vasculature by contacting a substantially	
	purified NGR receptor with one or more mols. and determining specific binding	
of	a mol. to the NGR receptor, where the presence of specific binding	
	identifies the mol. as a tumor homing mol. that homes to angiogenic	
	vasculature. The invention also provides a method of directing	
	a moiety to angiogenic vasculature in a subject by administering to the	
	subject a conjugate including a moiety linked to a tumor homing mol. that	
	exhibits specific binding to an NGR receptor, whereby the moiety is	
	directed to angiogenic vasculature. In addition, the invention provides a	
	method of imaging the angiogenic vasculature of a tumor in a	
	subject by administering to the subject a conjugate having a detectable	
	moiety linked to a tumor homing mol. that exhibits specific binding to an	
	NGR receptor and detecting the conjugate.	
ST	NGR receptor tumor homing mol identification; angiogenic vasculature tumor	
	homing NGR receptor; imaging conjugate angiogenic vasculature tumor	
IT	Antitumor agents	
	Antitumor agents	
	(Hodgkin's disease inhibitors; methods using NGR receptor	
	binding for identifying mols. that home to angiogenic	
	vasculature in tumors, and therapeutic and imaging methods)	
IT	Sarcoma	

(Kaposi's; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Peptides, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (NGR-containing; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Leukemia
 (acute myelogenous; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Mammary gland
 (carcinoma, inhibitors; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Ovary, neoplasm
 (carcinoma; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Mammary gland
 (carcinoma; tumor homing peptide identification by in vivo panning against a breast tumor)

IT Blood vessel
 (endothelium; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Hodgkin's disease
 Hodgkin's disease
 (inhibitors; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Antitumor agents
 (mammary gland carcinoma; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Angiogenesis
 Angiogenesis inhibitors
 Blood vessel
 Drug screening
 Drug targeting
 Hodgkin's disease
 Imaging agents
 Immobilization, biochemical
 Melanoma
 Neoplasm
 Peptide library
 Phage display library
 Scintigraphic agents
 (methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT RGD peptides
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Receptors

RL: BPR (Biological process); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); PROC (Process)

(methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Proliferation inhibition

(proliferation inhibitors, tumor homing mol. conjugates; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Antitumor agents

Cytotoxic agents

Drugs

(tumor homing mol. conjugates; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT Radionuclides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tumor homing mol. conjugates; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 9031-94-1, Aminopeptidase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(CD13-like, inhibitors; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 189023-66-3 205117-84-6 221230-70-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 221230-69-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 221230-66-6P 221230-67-7P 221230-68-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 149635-29-0D, conjugates 189023-64-1D, conjugates 205117-83-5D, conjugates 221230-65-5D, conjugates

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 66-71-7, o-Phenanthroline 13434-13-4, Actinonin 23214-92-8D, Doxorubicin, tumor homing mol. conjugates 58970-76-6, Bestatin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
 (methods using NGR receptor binding for identifying
 mols. that home to angiogenic vasculature in tumors, and therapeutic
 and imaging methods)

IT 162901-68-0 168179-57-5
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
 (Properties); BIOL (Biological study); PROC (Process)
 (methods using NGR receptor binding for identifying
 mols. that home to angiogenic vasculature in tumors, and therapeutic
 and imaging methods)

IT 9054-63-1P, Aminopeptidase N
 RL: BPR (Biological process); BSU (Biological study, unclassified); PUR
 (Purification or recovery); BIOL (Biological study); PREP (Preparation);
 PROC (Process)
 (methods using NGR receptor binding for identifying
 mols. that home to angiogenic vasculature in tumors, and therapeutic
 and imaging methods)

IT 152880-65-4
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (methods using NGR receptor binding for identifying
 mols. that home to angiogenic vasculature in tumors, and therapeutic
 and imaging methods)

IT 14133-76-7D, Technetium-99, tumor homing mol. conjugates, biological
 studies 14333-33-6D, Carbon-11, tumor homing mol. conjugates, biological
 studies 14762-74-4D, Carbon-13, tumor homing mol. conjugates, biological
 studies 15750-15-9D, Indium-111, tumor homing mol. conjugates,
 biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods using NGR receptor binding for identifying
 mols. that home to angiogenic vasculature in tumors, and therapeutic
 and imaging methods)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Burnham Inst; WO 9810795 A 1998 CAPLUS
 (2) Erkki, R; US 5536814 A 1996 CAPLUS
 (3) Jolla Cancer Res Found; WO 9514714 A 1995 CAPLUS
 (4) Jolla Cancer Res Found; WO 9710507 A 1997 CAPLUS
 (5) Koivunen, E; BIO/TECHNOLOGY 1995, V13(3), P265 CAPLUS
 (6) Koivunen, E; JOURNAL OF BIOLOGICAL CHEMISTRY 1993, V268(27), P20205 CAPLUS

=> SET SMA OFF

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L39 3

L39 WAS CREATED DURING MULTIFILE PROCESSING AND CANNOT BE USED WHEN CREATING E#S
 Enter SET SMARTSELECT ON before using SELECT to create an L-number of
 terms extracted from an L-number that contains answers or terms from
 more than one file. SET SMARTSELECT ON must be entered before you
 execute the SELECT command.

=> SET SMA ON

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L39 3

SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

L40 SEL L39 3 1 : 1 TERM

=>

=>

=> SET SMA LOGIN

=> FIL CAPLUS

SET COMMAND COMPLETED

=> S L40

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	237.04	442.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-16.00	-23.20

FILE 'CAPLUS' ENTERED AT 10:49:25 ON 11 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jun 2008 VOL 148 ISS 24
FILE LAST UPDATED: 10 Jun 2008 (20080610/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> D L39 BIB,ABS

L41 1 L40

=> DEL L40 Y

YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, CAPLUS' - CONTINUE? (Y)/N:
YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, CAPLUS' - CONTINUE? (Y)/N:n

=>

=> FIL MEDLINE CAPLUS EMBASE BIOSIS SCISEARCH

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.00	447.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-23.20

FILE 'MEDLINE' ENTERED AT 10:52:54 ON 11 JUN 2008

FILE 'CAPLUS' ENTERED AT 10:52:54 ON 11 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:52:54 ON 11 JUN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:52:54 ON 11 JUN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 10:52:54 ON 11 JUN 2008
Copyright (c) 2008 The Thomson Corporation

=>

=>

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008
E US2007-599748/APPS
E US2006-599748/APPS

L1 1 S E3
SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162
L3 22 S L2 AND DIONE
L4 0 S L2 AND PHENANTHROLINEDIONE
L5 2 S L2 AND PHENANTHROLINE
L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008

L7 224329 S L2
L8 13877 S L3
L9 406 S L5
L10 224329 S L7 OR L8 OR L9
L11 3300 S 10 AND ANTIANGIOGENIC
L12 56 S L11 AND ISCHEMIA
L13 28 S L11 AND ("HEART DISEASE")
L14 2 S L13 AND L12
L15 7 S (L3 OR L5) AND ANTIANGIOGENIC
L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"
L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

L18 STR 27318-90-7
L19 1 S L18 FAM SAM
SET SMA OFF
SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON 11 JUN 2008

L20 1303 S ("1,4-NAPHTHALENEDIONE?")
L21 129 S L20 AND (TREAT OR TREATMENT OR TREATING)
L22 0 S L21 AND ("HEART ATTACK")
L23 0 S L21 AND ("MYOCARDIAL INFARCTION")
L24 4 S L21 AND ISCHEMIA
L25 1 S L16 AND ("MYOCARDIAL INFARCTION")
L26 0 S L16 AND ("ANGIOGENESIS INHIBITOR?")
L27 552 S L2 AND ("ANGIOGENESIS INHIBITOR?")
L28 24 S L3 AND ("ANGIOGENESIS INHIBITOR?")
L29 2 S L5 AND ("ANGIOGENESIS INHIBITOR?")
L30 53 S (L27 OR L28 OR L29) AND HEART
L31 24 S L30 AND ISCHEMIA
L32 19 S L31 AND (TREAT OR TREATING OR TREATMENT)
L33 0 S L32 AND ("5,6-DIONE")
L34 0 S L32 AND ("1,10-PHENANTHRENE")
L35 5 S L32 AND DIONE
L36 19 DUP REM L32 L35 (5 DUPLICATES REMOVED)
L37 1075 S (METHOD? OR PROCEDURE? OR ASSAY?) AND (IDENTIFYING OR SCREENI
L38 0 S L37 AND PHENANTHRENE
L39 3 S L37 AND PHENANTHROLINE
SET SMA OFF
SET SMA ON
L40 SEL L39 3 1 : 1 TERM
SET SMA LOGIN

FILE 'CAPLUS' ENTERED AT 10:49:25 ON 11 JUN 2008

L41 1 S L40

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:52:54 ON 11 JUN 2008

=>
=>